token,score
test_predictions_source.txtGlioblastomas,0.01956827302647296
are,0.008083561230101679
deadly,0.007320203581991887
cancers,0.007650754377407641
that,0.0076593101579609
display,0.007083954105268846
a,0.005952267982868908
functional,0.004196585795283125
cellular,0.004992305050805509
hierarchy,0.0059007260342512245
maintained,0.005341235272619916
by,0.006605161517088709
self-renewing,0.005666118770985005
glioblastoma,0.0045454837945411
stem,0.003998974048492845
cells,0.003579421507197551
(GSCs).,0.0028850871155723093
GSCs,0.00612770887846667
are,0.0019282404541108502
regulated,0.002876762317817799
by,0.002881247400301088
molecular,0.002386429879759362
pathways,0.0024561968105764566
distinct,0.00216960965557172
from,0.003085391615891232
the,0.003189223777667512
bulk,0.0023427522907684658
tumor,0.003360646068763824
that,0.0022163902446617457
may,0.001766601343185427
be,0.0016902985976360962
useful,0.0017013726349830959
therapeutic,0.0020108018661479385
targets.,0.0012953916699351556
We,0.506814998393741
determined,0.5450142647834798
that,0.5872116755098846
A20,0.48296112430116317
"(TNFAIP3),",0.6059484302554394
a,0.6726316329225771
regulator,0.5861294252936031
of,0.6590289146582572
cell,0.6596026904247033
survival,0.6023313446168411
and,0.6053756495392961
the,0.6177902434323115
NF-kappaB,0.6370430499802978
"pathway,",0.6796204821964092
is,0.5779644934192493
overexpressed,0.5325634445726641
in,0.6309884525696943
GSCs,0.6220696597878569
relative,0.5973084711490603
to,0.5970405094336888
non-stem,0.6097886102360908
glioblastoma,0.555316506061565
cells,0.6379042744457212
at,0.5584803452751363
both,0.5615316333689453
the,0.5207448310038966
mRNA,0.5433714980286736
and,0.4698313455079716
protein,0.4654002212858399
levels.,0.5157803374288872
To,0.01674391435988032
determine,0.00985656928246599
the,0.011942808701260871
functional,0.013690691367272807
significance,0.014270298439492885
of,0.02557989427439168
A20,0.08247251293572593
in,0.03309129122861097
"GSCs,",0.028812240369028547
we,0.05185874122926899
targeted,0.04017728174789755
A20,0.08738305449846026
expression,0.07360044302937784
with,0.6147063248413247
lentiviral-mediated,0.4623588675505126
delivery,0.5224415396733864
of,0.6368624382024722
short,0.48481367986172175
hairpin,0.3402988186897803
RNA,0.3505660993743047
(shRNA).,0.2751137715487646
Inhibiting,0.8343627383275893
A20,0.6967897209191057
expression,0.7600250575328121
decreased,0.8252255391615264
GSC,0.7782238456276248
growth,0.8023483140874589
and,0.865926133553487
survival,0.8174832400194137
through,0.8530369155267379
mechanisms,0.8589822986333994
associated,0.8598993000781822
with,0.8401762835582539
decreased,0.8651465022200978
cell-cycle,0.8401834067382209
progression,0.8366194861538603
and,0.8715969709176251
decreased,0.8768191547087701
phosphorylation,0.8505154970771086
of,0.836149860955383
p65/RelA.,0.7037733527616218
Elevated,0.54928702033722
levels,0.5805547607521939
of,0.6050441313533836
A20,0.5396221347157345
in,0.6437853393869388
GSCs,0.5696495524776812
contributed,0.5994825806879632
to,0.6091526413366308
apoptotic,0.6586526042621687
resistance:,0.5974611554647601
GSCs,0.6886394789849477
were,0.7551853906999647
less,0.8034072554058246
susceptible,0.7569434041114302
to,0.7785380442432585
TNFalpha-induced,0.7269394655013243
cell,0.7861553327085076
death,0.7719654015866096
than,0.8379406716011817
matched,0.7132347740807463
non-stem,0.7458768674171781
glioma,0.7023419022478793
"cells,",0.7566468192211825
but,0.7863155058679249
A20,0.7122325934888093
knockdown,0.7365799235348066
sensitized,0.7878269987360025
GSCs,0.7342536059460648
to,0.7657499811713454
TNFalpha-mediated,0.7344937503467235
apoptosis.,0.8138437736653938
The,0.5502263288539464
decreased,0.5407947148221687
survival,0.5413749037482436
of,0.5460450966947559
GSCs,0.5574772353194467
upon,0.5576565355731269
A20,0.5083047643784339
knockdown,0.25705121897431976
contributed,0.2890265748843027
to,0.33192405967176225
the,0.2809903859339841
reduced,0.20514652686883864
ability,0.17164021238204377
of,0.17026509520769104
these,0.23887756887385206
cells,0.22431400222325332
to,0.15989944613246193
self-renew,0.128419413200571
in,0.15422826202555473
primary,0.12712662817188258
and,0.19418856925055603
secondary,0.09321945096741166
neurosphere,0.11726135872998918
formation,0.10163695835755711
assays.,0.084178158805012
The,0.5025192211476053
tumorigenic,0.49075052899002375
potential,0.5256600292791234
of,0.5471597248793005
GSCs,0.4962267046010622
was,0.5591694022206797
decreased,0.5075116078409716
with,0.5864912178666168
A20,0.5289171891945762
"targeting,",0.5427555549556417
resulting,0.6472206235964045
in,0.6704792181959037
increased,0.6415970246283941
survival,0.6029923003464065
of,0.6178403532763014
mice,0.6062585369053364
bearing,0.5868694983353226
human,0.5714122789370091
glioma,0.5483747774706427
xenografts.,0.5344768801617754
In,0.012751828935873285
silico,0.006770765789171292
analysis,0.007960400080550418
of,0.00664777068059828
a,0.007576638888515415
glioma,0.005354263324489311
patient,0.006521952509482648
genomic,0.0038835356777648595
database,0.004680742749024379
indicates,0.012784520588925995
that,0.010761222662022521
A20,0.011255449977217218
overexpression,0.004831100500204915
and,0.0071054501124077525
amplification,0.004140988106418899
is,0.005440713391212228
inversely,0.0033823587140681902
correlated,0.006160516838809211
with,0.009032968996469857
survival.,0.005614258112568025
Together,0.00818216536099991
these,0.011387414753503876
data,0.007863798062370904
indicate,0.013440309960866204
that,0.015447448476484122
A20,0.016980533472040368
contributes,0.014679423157415506
to,0.019401250841085384
glioma,0.009616304947384642
maintenance,0.012210496217932496
through,0.028772924872043904
effects,0.011685173482128119
on,0.018818200699108726
the,0.015096445945034526
glioma,0.010806983504423405
stem,0.01034622625461046
cell,0.01711321101133973
subpopulation.,0.01362153703608709
Although,0.47325566917361206
inactivating,0.4458381416938626
mutations,0.4209184773289148
in,0.48933683267256073
A20,0.3700734589641117
in,0.5165883792631729
lymphoma,0.5988102187096271
suggest,0.5639699457390696
A20,0.5101079532072869
can,0.5036628194973558
act,0.5871906862872278
as,0.5611215496638119
a,0.5631595943679103
tumor,0.4500796238335645
"suppressor,",0.5752265714260498
similar,0.521402175586747
point,0.41189450274657136
mutations,0.4039610568763775
have,0.2946391200489669
not,0.33574752733972607
been,0.23412828906554448
identified,0.27133439269904164
through,0.30497139270272927
glioma,0.42335276749503625
genomic,0.35543109175245685
sequencing:,0.31094347298642655
in,0.5016116062247762
"fact,",0.5605343028424796
our,0.4411563987441659
data,0.43411733076369136
suggest,0.4941356189201043
A20,0.5580204790416022
may,0.5468471778713119
function,0.7111140505540158
as,0.7349466053641749
a,0.7708062108627495
tumor,0.706362154877426
enhancer,0.8274194734253119
in,0.786455111464343
glioma,0.7683102595113732
through,0.8006922494069733
promotion,0.7650388343771213
of,0.7560836217544669
GSC,0.7138947539665011
survival.,0.7109994517839898
A20,0.04618989086779636
anticancer,0.007640975041341469
therapies,0.009450420342601367
should,0.00910128678374615
therefore,0.008756434201181993
be,0.004636363432620734
viewed,0.0043873233090512016
with,0.006056066701291355
caution,0.00664080279793791
as,0.012983533037764294
effects,0.004296291402359173
will,0.005976952086698676
likely,0.004039567937393659
differ,0.004658511545886395
depending,0.004302016920398754
on,0.004882227372427682
the,0.0052841753770183535
tumor,0.004964822740435803
type.,0.004038295255471854
Podocytes,0.012391502643754089
are,0.0030494806747987497
critical,0.003944522427369879
in,0.005110857712487014
the,0.004135693996978768
maintenance,0.003810017483773705
of,0.005230203409057959
a,0.004594738072732167
healthy,0.005359902566924419
glomerular,0.004106772707202668
filter;,0.005749732577850447
"however,",0.002898352050548184
they,0.00233054697381846
have,0.002126982795940415
been,0.0022501305642887506
difficult,0.0017430525482715967
to,0.0021749521977310385
study,0.0031157133972759005
in,0.003194498113322995
the,0.0033412613568271593
intact,0.003085354215520903
kidney,0.005007433765315708
because,0.0022216865221296738
of,0.0018859569917538607
technical,0.002320126869977506
limitations.,0.0012217401120904884
Here,0.045834456300390854
we,0.051054655136934086
report,0.03946832650241133
the,0.02617751696333138
development,0.017959879938804865
of,0.019362015899671167
serial,0.00930557623035118
multiphoton,0.008666517345695929
microscopy,0.009938954497862527
(MPM),0.006793757982070867
of,0.012487482653767925
the,0.013292818275724138
same,0.019943026673238638
glomeruli,0.01067695446254845
over,0.02249948433878379
several,0.01381750393450343
days,0.015385503677484844
to,0.01343075654678665
visualize,0.010864611585819786
the,0.010164479907167455
motility,0.006127258772630973
of,0.0114662022734618
podocytes,0.014689521978111185
and,0.009522080909572132
parietal,0.011552131282571598
epithelial,0.007945443899059022
cells,0.009217043965946805
(PECs),0.006843280072017764
in,0.01782637926215858
vivo.,0.015469951645265835
In,0.5637046807079505
podocin-GFP,0.5014989368416393
"mice,",0.5426436373131039
podocytes,0.4762021095289021
formed,0.4065715749360884
sporadic,0.3878472469463138
multicellular,0.3653715318179315
clusters,0.4217675511713851
after,0.4648266661590844
unilateral,0.4509988890243457
ureteral,0.4930293680725302
ligation,0.33836489633906774
and,0.29777881975021564
migrated,0.2903595538481014
into,0.3183651110771985
the,0.29882636939963925
parietal,0.2822387442773177
Bowman's,0.24690931692168405
capsule.,0.2579820400529659
The,0.2382008544508984
tracking,0.21871312874073304
of,0.19567092025133287
single,0.1363693439597109
cells,0.19586819876026842
in,0.25336591860766455
podocin-confetti,0.22314378067823826
mice,0.2421670838653665
featuring,0.21740435372485584
cell-specific,0.19678025348278538
expression,0.23778031075489137
of,0.20883089789111586
"CFP,",0.2549373936336838
"GFP,",0.2332195489128171
YFP,0.24622920157615966
or,0.19370298762168994
RFP,0.1966851189722527
revealed,0.2501946298464047
the,0.18596430198821873
simultaneous,0.17329344035336494
migration,0.17601073996762304
of,0.15987443451048558
multiple,0.1477483934661699
podocytes.,0.19600030227522347
In,0.4065943189474444
phosphoenolpyruvate,0.2833299628010033
carboxykinase,0.2665102604444478
(PEPCK)-GFP,0.24854857999547877
"mice,",0.3745274229629626
serial,0.3054206990034973
MPM,0.3384673820110023
found,0.3849596208153214
PEC-to-podocyte,0.3138066646791362
migration,0.37364384110964044
and,0.35318051874481393
nanotubule,0.29468003744746263
connections.,0.31872519303488356
Our,0.18993858339045613
data,0.11600166354591525
support,0.13633718241797316
a,0.13794667740657962
highly,0.12841245506943072
dynamic,0.08251385503655574
rather,0.13271520835105693
than,0.15519778254374017
a,0.08908715346393327
static,0.08422646999106082
nature,0.07791012772010567
of,0.058823918380691655
the,0.06598643941714154
glomerular,0.06175142924653739
environment,0.08004297040719523
and,0.0503223769798254
cellular,0.07896360004076391
composition.,0.043926980196147575
Future,0.04129797648360757
application,0.029190603058270818
of,0.038139784497585226
this,0.06910168612503144
new,0.03820065369366349
approach,0.0613620788802939
should,0.05028424914236138
advance,0.02081024382557187
our,0.04434089242675643
understanding,0.019998731055469104
of,0.01941064460051143
the,0.023752951031732743
mechanisms,0.02687759519997901
of,0.030496257756457562
glomerular,0.07655537858455182
injury,0.09283366682610741
and,0.031853263632765284
regeneration.,0.07451465260152665
T,0.030588560280455233
cell,0.03505092631944765
activation,0.029623012923153995
is,0.017210651733427302
predicated,0.022381818072705912
on,0.02412483672298337
the,0.019241154994681663
interaction,0.022705112227433856
between,0.01366873294094181
the,0.023351161036383135
T,0.024658420891412798
cell,0.043811990013652
receptor,0.04258675751588248
and,0.013139313226469374
peptide-major,0.017432535886374077
histocompatibility,0.01660300618036354
(pMHC),0.011219485643411978
ligands.,0.006113142151567215
The,0.0025492629103799442
factors,0.0027622223331704534
that,0.0027429472286788375
determine,0.0030302009006796765
the,0.0027854795759298086
stimulatory,0.0030547206462323514
potency,0.004355949965813693
of,0.004635868337358311
a,0.004396312717695587
pMHC,0.004936941622136898
molecule,0.011692486040473855
remain,0.002534113737750061
unclear.,0.0028410206019979
We,0.2833685183890565
describe,0.19288342996381705
results,0.21746251864572963
showing,0.2425977356305982
that,0.34353323805258024
a,0.3020434907499162
peptide,0.29337404116493937
exhibiting,0.19517298894453466
many,0.20273102780664978
hallmarks,0.11423259529558359
of,0.2755257724380837
a,0.2622072073564035
weak,0.19819143534177017
agonist,0.24868724989877466
stimulates,0.34837273108388767
T,0.26674092792897386
cells,0.3600348519485036
to,0.2824872968699181
proliferate,0.3110280088842275
more,0.32991626449666617
than,0.2954601743590221
the,0.19649111463716526
wild-type,0.12129209487833835
agonist,0.21565308758523669
ligand.,0.1425409534683026
An,0.30911450206400815
in,0.2754224404894466
silico,0.26892776311287137
approach,0.2780028830239012
suggested,0.4014233286002547
that,0.42661493426046293
the,0.32390099507601205
inability,0.3171320270358043
to,0.28575734930994895
form,0.27485819742725587
the,0.26108794796097445
central,0.2937487152681818
supramolecular,0.32573131022963725
activation,0.33937183898754114
cluster,0.30255870935396195
(cSMAC),0.26923663116262564
could,0.3445947266449991
underlie,0.3170089045436157
the,0.3378050413403785
increased,0.3867704189765849
proliferation.,0.6693135389819603
This,0.6090997182152298
conclusion,0.6134799270421992
was,0.6123078096281775
supported,0.43393896137062626
by,0.6100281297868766
experiments,0.695833012978334
that,0.6680935654403143
showed,0.692287955996917
that,0.7470388893565816
enhancing,0.8574789772947654
cSMAC,0.8140113345581658
formation,0.8279681881182812
reduced,0.8578458673312658
stimulatory,0.871959259983166
capacity,0.8225849338276949
of,0.8566570252362944
the,0.8196511706661205
weak,0.7527526011454305
peptide.,0.8075792124250292
Our,0.1290245218823433
studies,0.07631133975053143
highlight,0.06845546110042014
the,0.05807419054136785
fact,0.08347006987337813
that,0.09059368216908781
a,0.07816852714041375
complex,0.05211658666126381
interplay,0.04727146317709213
of,0.0454782108717933
factors,0.04764406194424585
determines,0.04019634555675344
the,0.03321839982853039
quality,0.042870055871760106
of,0.04770760399549387
a,0.05010614358846879
T,0.07282917139373773
cell,0.12103062036441854
antigen.,0.066059573692884
Genetically,0.010772674091298845
identical,0.00562110507837874
cells,0.009698165819503723
sharing,0.005967600555990599
an,0.006905517048719449
environment,0.008548445847842725
can,0.008792440712513658
display,0.0087767108070804
markedly,0.007547748351660214
different,0.004756301293570339
phenotypes.,0.004584632072297797
It,0.0029805324896096277
is,0.002411886657423175
often,0.002563130601161347
unclear,0.0024640663734664782
how,0.0020786715609275447
much,0.002237561815530367
of,0.0029909499071063277
this,0.0033475474432423124
variation,0.003024347891655119
derives,0.002742310778767203
from,0.003073613828230984
"chance,",0.0028198225309400767
external,0.002056835119562834
"signals,",0.0032104656643513136
or,0.002557614174118106
attempts,0.004142124841137081
by,0.0024884263140425547
individual,0.002537822732233914
cells,0.0032285461384452224
to,0.0031214050992661095
exert,0.0033008522998342936
autonomous,0.003090891451037225
phenotypic,0.00229759046913288
programs.,0.004128474122004977
By,0.12475763888944137
observing,0.06341156166896819
thousands,0.03738564301363632
of,0.039094938629927106
cells,0.04319311229256428
for,0.03592874445739083
hundreds,0.025751286196197768
of,0.031912618661522126
consecutive,0.02405789924791233
generations,0.012362172682842901
under,0.016670889589266144
constant,0.01716189358577238
"conditions,",0.023005352597815783
we,0.09368886324249136
dissect,0.045981873067252974
the,0.04360951762172746
stochastic,0.025320985870896876
decision,0.06138814765800907
between,0.03474226023004739
a,0.04584066592975241
"solitary,",0.045977736774439705
motile,0.0363195942397278
state,0.07122064081834169
and,0.03695059082831387
a,0.05492874400880209
"chained,",0.05601045424061663
sessile,0.058681068819582065
state,0.07922936749437569
in,0.07112840427088676
Bacillus,0.05142530317656442
subtilis.,0.05050019853065892
We,0.46140468777769844
show,0.4831717622590174
that,0.5472421148262175
the,0.38260481193588625
motile,0.3798029398275401
state,0.43405799685765506
is,0.49735137503740684
"'memoryless',",0.5263711142946411
exhibiting,0.5833360005506232
no,0.51265172624994
autonomous,0.4718556683790484
control,0.4043670195368076
over,0.3727188793144773
the,0.3298629925157589
time,0.3964666399896925
spent,0.3041075407418789
in,0.28966196441702347
the,0.2649222576384069
state.,0.2984907382473737
In,0.43074922528802373
"contrast,",0.5264582601171671
the,0.18062304739743912
time,0.10902413477568956
spent,0.08464480325733395
as,0.08944498498723143
connected,0.06653216156297954
chains,0.07118350911396086
of,0.05875632601758327
cells,0.08832279936304648
is,0.10420168654159781
tightly,0.09307461867240964
"controlled,",0.08118180818720284
enforcing,0.07081945724252539
coordination,0.09875461415602549
among,0.06452262440934714
related,0.06269130032388241
cells,0.0797680639381554
in,0.07671696273578787
the,0.07701571174394078
multicellular,0.0727704511369242
state.,0.07523510295254798
We,0.3640845544022018
show,0.40390391090832395
that,0.33483579043869915
the,0.15654152261138898
three-protein,0.0878544447093582
regulatory,0.12721627562497498
circuit,0.11711417327449723
governing,0.08864426270982
the,0.09200650547011803
decision,0.1039581752085589
is,0.19948794919420512
"modular,",0.1343573681873596
as,0.3128693829455534
initiation,0.11461868237458002
and,0.13204538264509855
maintenance,0.10431408822737082
of,0.10267550834973031
chaining,0.09421220676402177
are,0.16619465759783913
genetically,0.20061910750085993
separable,0.16939180034101461
functions.,0.12563645026589945
As,0.35747798191728075
stimulation,0.3079960918821388
of,0.2726809045930108
the,0.26739792592415623
same,0.26242360559859274
initiating,0.3729453771194763
pathway,0.3639469027914866
triggers,0.31956825881501655
biofilm,0.31401045927620963
"formation,",0.3012125593833197
we,0.36801219191891954
argue,0.34252054457607445
that,0.38203154411729257
autonomous,0.27658589741496237
timing,0.24235981159672124
allows,0.3730809575312633
a,0.3589035598792414
trial,0.3266271794854694
commitment,0.2859976565711927
to,0.2572177825809576
multicellularity,0.21628470456291915
that,0.26354595282182436
external,0.23059077513897708
signals,0.2401529748863151
could,0.2835169546253239
extend.,0.24665672368065006
OBJECTIVE,0.0010063698730449148
To,0.0006478749152778325
determine,0.0006142932087111427
whether,0.0005651746738794728
higher,0.0007098389904060527
past,0.0005240712016652651
exposure,0.0005108065982747127
to,0.0008675096823224383
particulate,0.0006927390513709987
air,0.0007411793145538774
pollution,0.0005864070168180999
is,0.0006015332871733982
associated,0.0005116138973488357
with,0.0006558407007697594
prevalent,0.0005938478057121942
high,0.00066297758823025
symptoms,0.0004898926055501148
of,0.0007774489908927969
anxiety.,0.0006349479276550631
DESIGN,0.0010345618518546847
Observational,0.0022360490464937584
cohort,0.001281365017081863
study.,0.001148151055025799
SETTING,0.0016703884234918914
Nurses',0.0012309646055107242
Health,0.0009472805377796022
Study.,0.001075555577000195
PARTICIPANTS,0.0021643692857670456
"71,271",0.0012404586172436048
women,0.0015400273758293735
enrolled,0.0013455076361343255
in,0.0024213871630417174
the,0.0021336566726024944
Nurses',0.0015392899415332248
Health,0.0012744710385183035
Study,0.0016751523137548306
residing,0.0014041290910045928
throughout,0.001224498029439877
the,0.001700722411435288
contiguous,0.0014720493237059744
United,0.0016628188542375584
States,0.001639567870438083
who,0.0016002194793979369
had,0.0014678069672756802
valid,0.0013561547610829285
estimates,0.001318286167447309
on,0.0014061999339110304
exposure,0.001136431459453011
to,0.0021544199321449522
particulate,0.0016728608502989133
matter,0.002121980460472645
for,0.0014220647386160433
at,0.0028144095268101198
least,0.0022399999297563625
one,0.002004917902386938
exposure,0.0011073722140355667
period,0.0014391433129453454
of,0.002325950944270333
interest,0.0014597904166462827
and,0.0016072592840278115
data,0.0011213465625188673
on,0.001221612400634265
anxiety,0.0010862089777404656
symptoms.,0.0008330770723410135
MAIN,0.003156967888449665
OUTCOME,0.004374999625852853
MEASURES,0.00526212629838976
Meaningfully,0.0077639351496487765
high,0.00489200878782338
symptoms,0.005281298835663029
of,0.014050538482885433
"anxiety,",0.0033924648571822154
defined,0.0024332428241703925
as,0.004813113558484684
a,0.0037096991076461306
score,0.0014515072358459754
of,0.0020800231473799813
6,0.0015400578044013813
points,0.0013992837510709505
or,0.0016834910282560753
greater,0.0017538904431551698
on,0.0016257582810671157
the,0.0017250021254764734
phobic,0.0011244775427310598
anxiety,0.00139228717000217
subscale,0.0013886052644460501
of,0.0015293977801193082
the,0.0016284085451350036
Crown-Crisp,0.002046153811068199
"index,",0.0012040859630977078
administered,0.0011443038381152456
in,0.0017757447872704469
2004.,0.0012936113124795534
RESULTS,0.0028709693492468126
The,0.001798684959390536
"71,271",0.0010564925746606511
eligible,0.0014701763225306865
women,0.001378202071934987
were,0.001437637579224731
aged,0.001139370594071336
between,0.0010683803100374185
57,0.0012573171859461064
and,0.002103600157350675
85,0.0016568362116276434
years,0.001116258805661929
(mean,0.001611778966899262
70,0.0014230736795237565
years),0.00124009062639955
at,0.0015686779614354262
the,0.0018661581064046634
time,0.0013387477055124457
of,0.0022116436794172903
assessment,0.0013182616842877153
of,0.001622520153562868
anxiety,0.00144072779469459
"symptoms,",0.0010461759199623852
with,0.0024792193841381145
a,0.0018110301746395133
prevalence,0.0012231967907875181
of,0.001826892290938097
high,0.0017398631804775944
anxiety,0.0021368509581296395
symptoms,0.0014690315611590914
of,0.0027935037656574603
15%.,0.0018627000205624579
Exposure,0.10505254991104115
to,0.08423364688442443
particulate,0.08343168334490525
matter,0.11299192841985821
was,0.07507933313493247
characterized,0.05683964382350058
using,0.10582525724932894
estimated,0.11265219351249009
average,0.10450061379982704
exposure,0.10921774813719476
to,0.12502568740384373
particulate,0.1167029996468819
matter,0.1481723920177297
<2.5,0.11862491878441564
μm,0.10161224203050925
in,0.10037081524808028
diameter,0.09112743746929665
(PM2.5),0.11903442547527032
and,0.1494573451602492
2.5,0.26668578007235405
to,0.19894258604964887
10,0.19777488948320138
μm,0.12203694705120806
in,0.1148443730715288
diameter,0.10486277669061679
(PM2.5-10),0.11163054454241086
in,0.07841956027275312
the,0.026051809153895964
one,0.02531331115531295
"month,",0.016235641534470078
three,0.016916741051115007
"months,",0.010177539902109374
six,0.01221300836374916
"months,",0.007595949402517112
one,0.017475316022383128
"year,",0.0074006265636923675
and,0.013314989059695451
15,0.013599926273729999
years,0.009389709027637227
prior,0.01398645921011206
to,0.016139166268226413
assessment,0.01955541010095483
of,0.01722321411953489
anxiety,0.02139130076265038
"symptoms,",0.017539461890998864
and,0.018733216131348276
residential,0.019715994436128106
distance,0.018814384389716724
to,0.020684973902594054
the,0.017960222654845495
nearest,0.015282411813429724
major,0.019037673311863998
road,0.022315426280389412
two,0.01515861691467263
years,0.008264487757616977
prior,0.010853172277372158
to,0.014140759169854305
assessment.,0.013689606462701693
Significantly,0.9026688662249055
increased,0.9169224367546377
odds,0.9353971939885207
of,0.9238445710130361
high,0.9179358403580679
anxiety,0.901880349469765
symptoms,0.9146033432387823
were,0.9059373247139333
observed,0.9283527860090044
with,0.9244418756094839
higher,0.9256010648156693
exposure,0.9236446851033423
to,0.9236929539769945
PM2.5,0.8905544546845794
for,0.9358509362128198
multiple,0.9234308835264612
averaging,0.9264138652045711
periods,0.9335171958229844
(for,0.9220372558594774
"example,",0.9194394037487653
odds,0.9392372124576837
ratio,0.9215921039784153
per,0.9257992051923136
10,0.909682131711015
µg/m(3),0.9157384402508837
increase,0.9153865719394054
in,0.9259869177608642
prior,0.928277185155049
one,0.9072761948401904
month,0.9327590933965515
average,0.9297674959690323
PM2.5:,0.8944010550513422
"1.12,",0.8903751552526151
95%,0.939850457750316
confidence,0.9302434438928533
interval,0.9187492879044921
1.06,0.9184742189679039
to,0.9043452255578925
1.19;,0.8799263110629184
in,0.9133947551835921
prior,0.9068333476586378
12,0.8656098315020972
month,0.9192212746331335
average,0.8989245594441662
PM2.5:,0.8881622508440038
"1.15,",0.8392295917929957
1.06,0.3234419560706975
to,0.23185990273775386
1.26).,0.2050764504656057
Models,0.17555932108904806
including,0.1210410705134382
multiple,0.11397100233052412
exposure,0.11848161764203914
windows,0.11338548565267678
suggested,0.18478439915800413
short,0.17390912853931095
term,0.1151378571898441
averaging,0.11849531405557133
periods,0.14247904166956896
were,0.1132206422549157
more,0.14580395477788322
relevant,0.09122144524500976
than,0.14526134428112306
long,0.1539413673779102
term,0.09995671926864805
averaging,0.10961308161873277
periods.,0.11743192388985589
There,0.05665483355382022
was,0.05840453259909349
no,0.04888030258353388
association,0.049718668942016146
between,0.024986057851899224
anxiety,0.050029302069544195
and,0.01773335036017925
exposure,0.03372800945742404
to,0.05318599757735811
PM2.5-10.,0.06274347181975569
Residential,0.03437535626067124
proximity,0.03884802308536405
to,0.032381745696740336
major,0.02436888669145395
roads,0.02482361707401187
was,0.054636356388598026
not,0.04809386244704275
related,0.032944604908828
to,0.029403133466923772
anxiety,0.0267282268416423
symptoms,0.030245347884470287
in,0.054597553721282686
a,0.04213032079506893
dose,0.04570341742655919
dependent,0.03178131720968118
manner.,0.06159681583143243
CONCLUSIONS,0.7204420652934236
Exposure,0.6049088246121422
to,0.5467241509262697
fine,0.380695262547721
particulate,0.333224973852333
matter,0.48525380293848563
(PM2.5),0.5203171254537134
was,0.6377137622153012
associated,0.683461240420734
with,0.6775193445750332
high,0.6172563736513179
symptoms,0.620362648362491
of,0.7130582891854356
"anxiety,",0.502291965077395
with,0.5688291092498048
more,0.6577720365896257
recent,0.5271082975618483
exposures,0.408220634240687
potentially,0.49207701990115044
more,0.6025121827361283
relevant,0.4680461585207069
than,0.5904081884628506
more,0.5719085498739693
distant,0.37785581499726717
exposures.,0.3611014690870548
Research,0.1438882747028617
evaluating,0.059279661946749586
whether,0.04674355171378658
reductions,0.13218333936797838
in,0.08476923043915702
exposure,0.18801187828726915
to,0.15000847815094775
ambient,0.1732359368571347
PM2.5,0.5919704304280543
would,0.5910170885581914
reduce,0.6486706386714367
the,0.5538199177123893
population,0.5733696580755198
level,0.5179870595252277
burden,0.5341783656512591
of,0.48613512662036384
clinically,0.5210684728001851
relevant,0.42473659927464386
symptoms,0.4640093043604832
of,0.4328036561429943
anxiety,0.43967240767014376
is,0.4003738098262043
warranted.,0.3931776250492525
Chaperone-mediated,0.2915835590661155
autophagy,0.2264108045513549
"(CMA),",0.22806074676203208
a,0.3183416608711471
selective,0.28459094877770197
mechanism,0.2598072117036638
for,0.30456002350976125
degradation,0.2917134239901483
of,0.2817766945226713
cytosolic,0.2572503019942556
proteins,0.24682405274028754
in,0.2908173849949031
"lysosomes,",0.21833150884921246
contributes,0.25984108457504596
to,0.29007231621156393
the,0.2699801671426284
removal,0.2161692055056039
of,0.21833739866770854
altered,0.23574901492881636
proteins,0.20621023428301635
as,0.2371329234943403
part,0.21778600272960677
of,0.21446019523176557
the,0.21431121824204577
cellular,0.20037996083777368
quality-control,0.16547700650226219
systems.,0.21433003197037032
We,0.43541530509584253
have,0.40598042407808294
previously,0.4435405748973527
found,0.5214916063017233
that,0.6186630662233708
CMA,0.6146771147754108
activity,0.6771526361727912
declines,0.5242982915235918
in,0.5860259709837822
aged,0.4923142698250728
organisms,0.5280150338922917
and,0.5386918717148376
have,0.3561033865982214
proposed,0.4085206481176945
that,0.5106735231087584
this,0.6237027741667936
failure,0.5622806777795483
in,0.6431122941278496
cellular,0.6773270291567922
clearance,0.6258578841982219
could,0.5449296883893183
contribute,0.588882105943911
to,0.6176202622641462
the,0.6689487116428884
accumulation,0.6111248294117373
of,0.6125817447121746
altered,0.5604615076988784
"proteins,",0.5549093090337273
the,0.6571716875856054
abnormal,0.5395203457113005
cellular,0.5846416807534437
homeostasis,0.6120490037667632
"and,",0.6197984950070214
"eventually,",0.5207348553388581
the,0.6051989686652265
functional,0.4786561533348722
loss,0.4640032960320551
characteristic,0.4255604490877063
of,0.3876328708234076
aged,0.35471420713051344
organisms.,0.34996791435608476
To,0.06403425313650749
determine,0.032892006346176055
whether,0.027940211741206658
these,0.08312635859204731
negative,0.05371877901785517
features,0.07143391419308598
of,0.11666980636171059
aging,0.12973662104162095
can,0.04298163558078274
be,0.03942622823585803
prevented,0.06168333596058733
by,0.14307003163553253
maintaining,0.12124161281750886
efficient,0.10102226607157105
autophagic,0.10912495990588911
activity,0.18693640386441499
until,0.055035435671685576
late,0.15696690812925188
in,0.0561177709306324
"life,",0.04844983381063684
in,0.06336336461091735
this,0.06748432393921668
work,0.0592293782226851
we,0.08798473878610269
have,0.07088449181301575
corrected,0.057517462192122296
the,0.05923085287304289
CMA,0.10461378043002403
defect,0.08977228811622275
in,0.05654292642201416
aged,0.043735172101035315
rodents.,0.041824768333479784
We,0.07264990880473939
have,0.05924427244357004
generated,0.04229837622526611
a,0.061645212577980155
double,0.06361909219932287
transgenic,0.05340575238333532
mouse,0.0643314476025785
model,0.06782578218290566
in,0.09181532395889777
which,0.06219848254383024
the,0.06499008159710193
amount,0.09562104857910371
of,0.09007382248841453
the,0.09308637252855194
lysosomal,0.1237872778832282
receptor,0.15166897730935824
for,0.11031440179909849
"CMA,",0.14031562028844094
previously,0.2159864115891936
shown,0.15427420976138767
to,0.11527347286038399
decrease,0.08783903700509488
in,0.12873161850412942
abundance,0.09475833119541742
with,0.19346313778475577
"age,",0.09643286467042012
can,0.06248678291309988
be,0.04291586293309915
modulated.,0.04513680423159811
We,0.015395077753980862
have,0.009520857736157191
analyzed,0.005315406040624585
in,0.006741249733093349
this,0.007232977800735255
model,0.006310373218874514
the,0.006405007694082108
consequences,0.0068899183577926125
of,0.018892151976092227
preventing,0.009796352378669137
the,0.010914325020609026
age-dependent,0.009099059480981631
decrease,0.016632041776723946
in,0.011260291960241224
receptor,0.017221963125084463
abundance,0.01772567520013353
in,0.013267559163343918
aged,0.008567052159808203
rodents,0.013368152602230827
at,0.009384625295716275
the,0.007679690917192625
cellular,0.011184483932234505
and,0.009891668359568999
organ,0.010059573176509445
levels.,0.00872966555682321
We,0.786968455280662
show,0.7624559195984836
here,0.6845809929518561
that,0.8018151522606215
CMA,0.6925417041598791
activity,0.7386502214588172
is,0.7059029797542734
maintained,0.6630955551938144
until,0.6698786707682548
advanced,0.7228837470559238
ages,0.7284602833934036
if,0.7056851536878843
the,0.6846997555841378
decrease,0.6390353511581457
in,0.6722784507174449
the,0.7386496518895107
receptor,0.6822577589137383
abundance,0.7276944680945395
is,0.6442428182059611
prevented,0.6719504843339847
and,0.7924198737750476
that,0.7700465211691722
preservation,0.7075483712626313
of,0.7514197188874144
autophagic,0.7654287353274234
activity,0.7078224227325206
is,0.8896841064660663
associated,0.9159367656856722
with,0.9128662290058452
lower,0.9051934897942259
intracellular,0.8997886511047816
accumulation,0.8415399241742135
of,0.8778572248035375
damaged,0.8030464277166781
"proteins,",0.802461473087645
better,0.8893218240444345
ability,0.8631912322428356
to,0.8531872026794117
handle,0.7887723721350016
protein,0.7796249279212014
damage,0.8007127278619476
and,0.9044757291672575
improved,0.8851244005960981
organ,0.829688586267071
function.,0.8392263749452114
BACKGROUND,0.21580141976420464
Endothelium-dependent,0.40461087682408053
modulation,0.41291014839053836
of,0.454007606883326
coronary,0.49133836990089735
tone,0.35972392268073683
is,0.31833638373160356
impaired,0.31683761208762806
in,0.4064919832639838
the,0.41495940009741666
collateral-dependent,0.4747320953406945
coronary,0.45536777662620687
microcirculation.,0.455521847962972
We,0.011755112297928555
used,0.0062353056686354465
a,0.005226309820475816
porcine,0.00484647895282857
model,0.00526747912441315
of,0.007071330903933034
chronic,0.004199206997854144
coronary,0.006935028093483902
occlusion,0.008736170992160917
and,0.007447003356046712
collateral,0.006958897100136819
development,0.021808075610089902
to,0.0031178490730761933
evaluate,0.0034107651980044592
the,0.003928301464590538
hypothesis,0.005096307773736849
that,0.01233124732079031
exercise,0.016183102122967915
training,0.01550017282142526
enhances,0.021134724150113884
endothelium-mediated,0.017811324360981314
relaxation,0.04810940779693543
and,0.10743658495195157
increases,0.01202751395402453
endothelial,0.018804536801923934
nitric,0.009751558947081842
oxide,0.008769367160084227
synthase,0.016741510333785608
(ecNOS),0.01228106717891801
mRNA,0.01398216574228178
levels,0.018674986984769246
of,0.0198130900136547
collateral-dependent,0.01396645931257823
microvasculature.,0.012388095168110787
METHODS,0.18637522736290923
AND,0.09504471469519922
RESULTS,0.1684673767376329
Adult,0.17603394305872386
female,0.1277482147976241
miniature,0.1723226156092053
swine,0.2429621027905524
were,0.07791287681236551
subjected,0.049255776097941864
to,0.1098231925998998
"chronic,",0.10815114819509355
progressive,0.11744739329508763
ameroid,0.10402536520845442
occlusion,0.10986699070589816
of,0.21233556729950995
the,0.14130823899632436
proximal,0.10627079189086959
left,0.11422391093285401
circumflex,0.0956116884705246
coronary,0.0881955137237085
artery,0.12360174967700056
(LCx);,0.05023058058642515
after,0.022230814167142256
2,0.024353609323297394
"months,",0.01464709093203773
animals,0.012217834208094133
were,0.01725318797629925
randomly,0.009241655549098423
exposed,0.01519291164483386
to,0.014764181872738407
16-week,0.007701169400906921
exercise-training,0.011826969279293975
(EX,0.008502718174109575
group;,0.013791981653965849
treadmill,0.007806936015239016
running),0.017362242402251163
or,0.010449152993412132
sedentary,0.009796010097332738
(SED,0.007067386343687615
group;,0.012864901276883814
cage,0.010940425621390965
confinement),0.012713071743043104
protocols.,0.01523254454299278
After,0.08646683684053007
completion,0.03910420076260633
of,0.04183963324715401
EX,0.03158951773893401
or,0.0218978058655862
SED,0.030116092767247978
"programs,",0.04075054803483719
coronary,0.10065634010769267
arterioles,0.0840617381965573
(,0.04461467642654193
approximately,0.037398270823631355
100,0.054721734806178514
microm,0.05777344136592133
in,0.03044652310092694
diameter),0.021098452064901314
were,0.04101873622011059
isolated,0.06041500927858622
from,0.09128623558508166
collateral-dependent,0.14478818788148162
LCx,0.12405011079013614
(distal,0.1181611461523836
to,0.2028388002728334
occlusion),0.16384982873566378
and,0.09853103500973959
nonoccluded,0.14851950644275644
left,0.1801526048020521
anterior,0.18007560492847413
descending,0.18763385208152003
coronary,0.30546037561265627
artery,0.009112866274060267
(LAD),0.0019211236505175908
regions,0.006143468744684872
of,0.005834384938400488
each,0.004389437919477802
heart.,0.0022786842509951405
Arterioles,0.000800231534031074
were,0.0009103420526915287
studied,0.0006997818408409288
by,0.0007236791607136255
in,0.0009452499664211688
vitro,0.0015212412638968902
videomicroscopy,0.0006917415627596772
or,0.0008459105248003927
frozen,0.0007299502911800056
for,0.0007496407174078421
ecNOS,0.000924859763304307
mRNA,0.000878938478198674
analysis,0.0006467983400727419
(RT-PCR,0.000638974435212867
techniques).,0.0006817533367837504
Relaxation,0.29565236572605275
to,0.3702065028448338
the,0.365892340715457
endothelium-dependent,0.3887742276292742
vasodilator,0.35031463495426607
bradykinin,0.34961649002891243
was,0.3077870837781583
decreased,0.2615749071701878
(P<0.05),0.25934782705483417
in,0.23383187994127527
arterioles,0.18533987888887227
isolated,0.2047772005523748
from,0.21611655179663222
collateral-dependent,0.26026672821645996
LCx,0.27368623098739053
versus,0.24725609617142752
nonoccluded,0.21699128561949116
LAD,0.2719728732421838
regions,0.3208558941578557
of,0.1935636393559697
SED,0.2058976152236517
animals.,0.2859271525885877
Bradykinin-mediated,0.3508329422072129
"relaxation,",0.314070389860024
"however,",0.301158326679203
was,0.3075503421083959
not,0.26860596890866806
different,0.23767996195651844
in,0.2811230559910572
LCx,0.32243408102540005
versus,0.2786905030997563
LAD,0.3332291852423619
arterioles,0.29509840707237267
isolated,0.27094550659123584
from,0.28466314803926723
EX,0.3343207705571066
animals.,0.33852182211529497
Nitroprusside-induced,0.1685163538931294
relaxation,0.1912401837860595
was,0.21003759689282514
unaffected,0.15960572763435082
by,0.14212749544942402
either,0.10206216384584067
chronic,0.15230014278115908
occlusion,0.11478775064061353
or,0.12707382430547876
exercise.,0.18235495812078542
"Importantly,",0.2630410500218225
ecNOS,0.28588039300828566
mRNA,0.30663805886660683
expression,0.2964407761762688
was,0.30200442620795986
significantly,0.3022101786353674
decreased,0.2704639800805086
in,0.2843880513537067
arterioles,0.1598896380606162
isolated,0.2470419068996059
from,0.24274909149513949
LCx,0.27215404713648306
versus,0.2981685638059773
LAD,0.2848417395832637
regions,0.28468809084084296
of,0.22950705934148483
SED,0.20877996905981747
animals.,0.28918210248880355
After,0.08017099151104203
"training,",0.08030364991002595
ecNOS,0.0844620245122772
mRNA,0.0745741529130872
expression,0.07569510359333607
was,0.06964336933954664
not,0.05933380464115831
different,0.03461209452824497
between,0.027686846840900666
LAD,0.06466511022487427
and,0.03505701505747373
LCx,0.062413244748683205
arterioles.,0.03354660186154748
CONCLUSIONS,0.7378778175806622
These,0.6228096601004198
data,0.6423211406102918
indicate,0.6531554601959882
that,0.7341520546143111
exercise,0.7014934607486372
training,0.70701999106795
enhances,0.7682125464099591
bradykinin-mediated,0.78918075333135
relaxation,0.7436822960505451
of,0.7124105171155194
collateral-dependent,0.8090761837733542
LCx,0.725074711855385
arterioles,0.748910819494041
isolated,0.6922234563078815
after,0.688966894803649
chronic,0.7501365424042962
coronary,0.8096730195467926
"occlusion,",0.7543171110823508
most,0.6923975165073714
likely,0.6846625535662384
because,0.7229136502202961
of,0.6636968859520165
effects,0.7729363845771352
on,0.8934184790714321
ecNOS,0.8648116038912883
mRNA,0.8779622674346768
expression,0.8196799101827855
and,0.8925338040000032
increased,0.8730921955212427
production,0.831537432682865
of,0.8572487433240552
NO.,0.7660818485478056
An,0.009473979907309532
adoption,0.014230246411400894
study,0.005477437805447514
of,0.004215866199942581
genetic,0.004103506408356895
effects,0.004703706791271633
on,0.00516260154367346
obesity,0.01261145154599323
in,0.009889081481906547
adulthood,0.008685409189131646
was,0.004950287163922417
carried,0.0028412158072969205
out,0.002594089636446534
in,0.007742799510570453
which,0.01250641468668239
adoptees,0.02394219786804639
separated,0.022160631036870732
from,0.02943262669377087
their,0.020675314355491085
natural,0.025407281277592286
parents,0.03825678240379718
very,0.015371326757076531
early,0.029275847782829975
in,0.037042605735555616
life,0.015924504188489726
were,0.014711110319258416
compared,0.01067149342361944
with,0.017879804138913262
their,0.014871820477146724
biological,0.014031101315035682
full,0.036665250953715034
and,0.01974250316689028
half,0.01705781701861923
siblings,0.016026951446818587
reared,0.016142763149188596
by,0.014815813264607514
their,0.011402877224249928
natural,0.010401877207976168
parents.,0.014830826642527828
The,0.0029620034588561913
adoptees,0.005230365911268208
represented,0.0023621343224568955
four,0.0019729403096651805
groups,0.0020251313982254326
who,0.00241985861460793
by,0.0018280038987888627
sampling,0.001959771018070826
from,0.001489163516240529
a,0.001579651196534838
larger,0.0015803424782769677
population,0.0016410163828550503
were,0.0022361453267269195
categorised,0.0012559709467369602
as,0.002067612901438492
either,0.0016626700447144043
"thin,",0.0017005524063520244
medium,0.0020409254669402593
"weight,",0.002809016234101959
"overweight,",0.0021462628164224057
or,0.0026020607447686276
obese.,0.0018339683273748508
Weight,0.005093773416912105
and,0.005860609394384584
height,0.004586262259892023
were,0.005944104280464905
obtained,0.0035008774335169852
for,0.004651486937911162
115,0.0032360970942761514
full,0.0036876085043046096
siblings,0.003335475232877916
of,0.004036582033677998
57,0.0027001892507956156
adoptees,0.0034733112637030834
and,0.004672946183039877
for,0.00470634840193894
850,0.0028205117885116405
half,0.0027641209795929854
siblings,0.003344449021066423
of,0.0037374268303835404
341,0.002256048184204546
adoptees.,0.004452726641929868
In,0.2855325387480478
full,0.16435251876487406
siblings,0.2029119946457969
body,0.2562289501619241
mass,0.255615008647837
index,0.2263506619224509
(kg/m2),0.13542803459983702
significantly,0.16311273739827997
increased,0.1793340791766322
with,0.2256354141381201
weight,0.17787191821749385
of,0.1963957847067716
the,0.1590214114533248
adoptees.,0.13111843474220913
Body,0.24947061751428937
mass,0.26520748949197015
index,0.2469302370422326
of,0.24559910836039342
the,0.372213527873612
half,0.19564950475776516
siblings,0.24012009638182868
showed,0.31835195660114185
a,0.32320322085852793
steady,0.25773572450791093
but,0.1901125793639016
weaker,0.22585838562487962
increase,0.2229559714778401
across,0.19959717641378222
the,0.1994858075594226
four,0.126397396951551
weight,0.2078177578431115
groups,0.1253089476414676
of,0.13241686432146044
adoptees.,0.1808102775961839
There,0.259829053932661
were,0.23654767715597808
no,0.21591133751472333
significant,0.17035455791692697
interactions,0.19495663233284027
with,0.10879299277370597
sex,0.1507601154162784
of,0.11713744070777708
the,0.15286189699204328
"adoptees,",0.18399562523142884
sex,0.14457129879220035
of,0.11728980424250458
the,0.1302425464299526
"siblings,",0.15086246407530104
or,0.10120014408770325
(for,0.17001979098757417
the,0.1309086681363251
half,0.14999791453240915
siblings),0.15060042434400756
sex,0.12841258849174111
of,0.11117083519516617
the,0.11064712681394927
common,0.1259219185384752
parent.,0.15109964707151732
In,0.2737993379064705
contrast,0.25738821051165134
with,0.23538668947446625
the,0.23719747918791917
findings,0.25272379276868817
in,0.2097692962954441
half,0.17003073397066484
siblings,0.2205561394536559
and,0.23775032889647763
(previously),0.2176864290742034
the,0.22991823402243328
natural,0.2291071966927912
parents,0.21430646105313778
there,0.3085357129329205
was,0.24206075845431926
a,0.24251017417986026
"striking,",0.1877240502341174
significant,0.22656317677156262
increase,0.20436336611364955
in,0.20801281809675862
body,0.23737636594264308
mass,0.2589245097637592
index,0.23160354382173567
between,0.2296197208203407
full,0.24366259372719187
siblings,0.17043300115534374
of,0.17775484633318933
overweight,0.2208402783970349
and,0.19840632601831318
obese,0.17466660734921988
adoptees.,0.22526218958592598
The,0.12116743427739203
degree,0.11190352542045406
of,0.10599293791909921
fatness,0.19398377665326663
in,0.14914537608289294
adults,0.20423006065649021
living,0.18227692415011235
in,0.15530173282647564
the,0.12641222606316938
same,0.10252277866568014
environment,0.16966882792253207
appears,0.13070776712448845
to,0.07412153066491224
be,0.08683352522154963
influenced,0.1221151046765999
by,0.15803393227568263
genetic,0.13524687272276031
factors,0.13328108149674972
independent,0.1289521650913337
of,0.12154806729060498
"sex,",0.13241572078665648
which,0.17729924735026395
may,0.12088113784177391
include,0.1313052943850933
polygenic,0.1559311075898558
as,0.20033379378744134
well,0.17043551248698746
as,0.11257529632959229
major,0.1442638030618913
gene,0.149008710425419
effects,0.1389929468105519
on,0.18309158910067963
obesity.,0.6413654646842541
"Currently,",0.0020900701827044612
major,0.0018109638016582537
concerns,0.0015494455181655664
about,0.0015201946755238097
the,0.001216695059783621
safety,0.0010486925338457635
and,0.0011585088938854437
efficacy,0.00101717077003794
of,0.0015777477845516769
RNA,0.0020058841635845308
interference,0.003068122034801813
(RNAi)-based,0.0014294295511161946
bone,0.002823870633254106
anabolic,0.0014241518238594178
strategies,0.0019699305633140885
still,0.0014521466697989395
exist,0.0016931913140907499
because,0.0023028130076748025
of,0.0022210730012928526
the,0.0020021853044364353
lack,0.001809432725599748
of,0.0020437691818590642
direct,0.002220070911092213
osteoblast-specific,0.0020770584243846044
delivery,0.002944492780425729
systems,0.0024441011136076512
for,0.0023005594909362996
osteogenic,0.002220822040207893
siRNAs.,0.004696144058585179
Here,0.2911071304760815
we,0.23038665151233073
screened,0.23586730463726288
the,0.23671952719718087
aptamer,0.28679303438156883
CH6,0.26596358386068336
by,0.2295773219416941
"cell-SELEX,",0.24274217244193905
specifically,0.37070742909946586
targeting,0.36426369832239924
both,0.399979285645862
rat,0.29452974450468533
and,0.37129228633370537
human,0.3427590972588067
"osteoblasts,",0.39461733050281944
and,0.2232731806783691
then,0.24754031408012034
we,0.1817284790674444
developed,0.21310451028022062
CH6,0.208491712273428
aptamer–functionalized,0.19788505677993473
lipid,0.15234700504897075
nanoparticles,0.11985057458070975
(LNPs),0.08315531930108687
encapsulating,0.16714209561650972
osteogenic,0.20335703963401164
pleckstrin,0.1933033137794817
homology,0.24813588328518937
domain-containing,0.21199030285719173
family,0.19683040617394673
O,0.17941190192676082
member,0.20132674566354036
1,0.1419660025171373
(Plekho1),0.2861322308906504
siRNA,0.32681042510523195
(CH6-LNPs-siRNA).,0.2877966290448165
Our,0.8166856936175693
results,0.7636639564724728
showed,0.8702669389091889
that,0.9391544309775748
CH6,0.8954847267897549
facilitated,0.9526686976447719
in,0.9487896221023273
vitro,0.9193329835044536
osteoblast-selective,0.9638511776714702
uptake,0.9607221038881919
of,0.9530287316051915
Plekho1,0.944944827471208
"siRNA,",0.937629921940877
mainly,0.9587567242042273
via,0.9659277158429083
"macropinocytosis,",0.9443987846841905
and,0.9546674047811478
boosted,0.9580860812587458
in,0.961991849119484
vivo,0.9625966477186225
osteoblast-specific,0.9636529373203206
Plekho1,0.93717451368509
gene,0.9536946133079854
"silencing,",0.940547466247541
which,0.9491475623227464
promoted,0.9442132648530654
bone,0.9081738007752759
"formation,",0.9177709427676493
improved,0.944087646472853
bone,0.8890337652313345
"microarchitecture,",0.9177728949696552
increased,0.9388805032099052
bone,0.8709992012937654
mass,0.8714554323510333
and,0.9431467488911115
enhanced,0.9309738700372785
mechanical,0.8140437825248015
properties,0.8561357258220437
in,0.8806391018056595
both,0.8850406838960273
osteopenic,0.8860586317357003
and,0.8585872706031765
healthy,0.87531463868188
rodents.,0.7914131268265596
These,0.43977775508766637
results,0.42979400608380874
indicate,0.4552305663002234
that,0.36180535478393966
osteoblast-specific,0.4653235733252574
aptamer-functionalized,0.44531175820801655
LNPs,0.3955243995574508
could,0.43122003705004064
act,0.5321845298046703
as,0.6244896537915934
a,0.6296855523583521
new,0.5486657906292574
RNAi-based,0.4300936413904944
bone,0.4549602985219183
anabolic,0.5509506930754083
"strategy,",0.5728736582412753
advancing,0.5721087456827489
the,0.5092489896809689
targeted,0.5528531610090381
delivery,0.4962361495380299
selectivity,0.5138440719750818
of,0.4578422032444648
osteogenic,0.5219604356709814
siRNAs,0.4504201893629241
from,0.4029479022109592
the,0.4221226458265263
tissue,0.491195683601758
level,0.49082832110339325
to,0.3676733289828203
the,0.388907513586819
cellular,0.4439031394074239
level.,0.45382939392838756
The,0.002289596078350253
interest,0.0019235846982990593
in,0.0014909687374412386
brown,0.0025541757631791008
adipose,0.003979391477394577
tissue,0.0036355894463675803
(BAT),0.0016902728495181503
as,0.0012182333363423069
a,0.0012331914226046097
target,0.0010435410616829155
to,0.0012087618382468075
combat,0.0013919298750012484
metabolic,0.00161091980015957
disease,0.001353462237636143
has,0.00173931003870746
recently,0.001810563029414291
been,0.0014634980753498693
renewed,0.0014343381493677945
with,0.0022001319464898
the,0.0021559637631900943
discovery,0.0019008088224613054
of,0.0016605715061041055
functional,0.0020214466589233795
BAT,0.002718717987624604
in,0.0018577680218251084
humans.,0.0013612385323549154
In,0.6257950580801124
"rodents,",0.4392180730563672
BAT,0.4983210254237129
can,0.5754853951039948
be,0.6165756394970543
activated,0.6599401917873429
by,0.7092170957171552
bile,0.6301966812810929
"acids,",0.5920415649367011
which,0.6494517757095272
activate,0.7120489337414455
type,0.6550300404647302
2,0.6282585008603231
iodothyronine,0.6300379232324437
deiodinase,0.666519308129332
(D2),0.6323980756220153
in,0.7637117757080918
BAT,0.5940688122594193
via,0.7470936490408252
the,0.622744092592837
G-coupled,0.6222469358385517
protein,0.570256576247045
receptor,0.650117697078773
"TGR5,",0.6402648371982698
resulting,0.7245632674428216
in,0.7268016608656994
increased,0.7188781726661094
oxygen,0.5990465404922369
consumption,0.6711422991723514
and,0.756333160696905
energy,0.6739680783777812
expenditure.,0.6533125648655694
Here,0.032018974347741376
we,0.032203324913173036
examined,0.012007203471666046
the,0.006250948038495842
effects,0.006896796343523791
of,0.012309195452617354
oral,0.011836976707564291
supplementation,0.006531605413355084
of,0.011987395605562412
the,0.010903782721623546
bile,0.006948490452087978
acid,0.010496960815629106
chenodeoxycholic,0.009671529387885467
acid,0.016390560607551306
(CDCA),0.009810159880732803
on,0.009599265000473488
human,0.007612444420920134
BAT,0.014862964859886628
activity.,0.010332015865141419
Treatment,0.057526871937185066
of,0.07590258440570813
12,0.05259502166894174
healthy,0.052145998239733066
female,0.07465780262454413
subjects,0.6383240265899315
with,0.5746343273880747
CDCA,0.5229301721792299
for,0.5921141288332314
2,0.5360632266291754
days,0.5765785939784657
resulted,0.5919892624579962
in,0.6087163224383703
increased,0.5832221936168717
BAT,0.44566626176016527
activity.,0.5308734199284122
Whole-body,0.4114348555248173
energy,0.33786770322946286
expenditure,0.32362527081082415
was,0.3627695857098982
also,0.3761982618347418
increased,0.3263372099885898
upon,0.34491658541053793
CDCA,0.33222855869401224
treatment.,0.37634622905694465
In,0.7674102521798146
vitro,0.7289090076572228
treatment,0.7318020479401817
of,0.7643379817775903
primary,0.7703632822387239
human,0.8067253490830438
brown,0.6627234477425614
adipocytes,0.7631262610113452
derived,0.7521202853993653
with,0.7368186556638214
CDCA,0.7502227173461093
or,0.7329175494187439
specific,0.7682014871420828
TGR5,0.7427089524164839
agonists,0.7694988673082899
increased,0.756265768510106
mitochondrial,0.7561172787841014
uncoupling,0.8060417200316468
and,0.7657578074044419
D2,0.7310249496752476
"expression,",0.7518662740096284
an,0.6490649914085024
effect,0.6927641790835247
that,0.5824855487401337
was,0.5684800730457803
absent,0.5542532378335069
in,0.5766572335549498
human,0.5496824278938793
primary,0.6149355562354512
white,0.5837751304810014
adipocytes.,0.630457067945737
These,0.1977929527300116
findings,0.21345105783108248
identify,0.12983194960352076
bile,0.12931871759618732
acids,0.11006331130616558
as,0.07185085335539826
a,0.08422880092629023
target,0.07592191846347505
to,0.08412629517138791
activate,0.1381703789379525
BAT,0.1563857602566825
in,0.09696395139957915
humans.,0.08050325142317097
CONTEXT,0.002108468456380806
Many,0.0008569186420555942
observational,0.0005926366673853721
studies,0.0006825523192478729
have,0.0007274331650899165
shown,0.000904761147001994
that,0.0014097710013433417
physical,0.0006588058888937955
activity,0.0007350276701803194
reduces,0.0009278211337586647
the,0.0008854363212421014
risk,0.0006011180588456549
of,0.0010209128827926629
cognitive,0.0006516601556021777
decline;,0.0007850171105283773
"however,",0.0007731625763041707
evidence,0.0006734292264666343
from,0.0005996442957724879
randomized,0.0005061747104415106
trials,0.0005378047534854079
is,0.0006361333087568421
lacking.,0.0006021582454660634
OBJECTIVE,0.000901923153557157
To,0.000641045282669793
determine,0.000665757672758499
whether,0.0007383448091584582
physical,0.0006251591307432494
activity,0.0006194354630404404
reduces,0.0007644631967549007
the,0.0006288691225378539
rate,0.0006333508319917481
of,0.0007820167633743479
cognitive,0.0006977575722274412
decline,0.0007448011306426878
among,0.0008098463968679629
older,0.0005917657480000628
adults,0.0006226769439387222
at,0.0006476968021445817
risk.,0.0005126376718704568
DESIGN,0.0008635514463876077
AND,0.0007005355062305301
SETTING,0.0008588162918559459
Randomized,0.0008584098837070447
controlled,0.0005992178059138381
trial,0.0007208287521269565
of,0.0008980129415031899
a,0.0009356661523491259
24-week,0.0010619069355457976
physical,0.0006387677185231288
activity,0.000693606587997045
intervention,0.0008435356387990217
conducted,0.0008462132472011831
between,0.0012660364636806903
2004,0.0009616965651154693
and,0.0012592023634200222
2007,0.0007972836184198165
in,0.0010602339924885306
metropolitan,0.0007022500311678902
"Perth,",0.0007431113154089344
Western,0.0008273160564792319
Australia.,0.0006790836463690638
Assessors,0.00070664141015658
of,0.0008233543154188066
cognitive,0.0005644074298418089
function,0.00071956674580517
were,0.001029906939223966
blinded,0.0008230311378820617
to,0.001018938905186186
group,0.0006575079434707679
membership.,0.000671580495902439
PARTICIPANTS,0.008034317267310197
We,0.01452303898486905
recruited,0.005574655806203748
volunteers,0.004035042956727284
who,0.005981459659199326
reported,0.01268172761327606
memory,0.00428070065984337
problems,0.005837605236034118
but,0.010560466714148066
did,0.010220388501083436
not,0.007438163674983442
meet,0.003573344978394503
criteria,0.0019331691860734635
for,0.0036369119199805055
dementia.,0.0024949494801079705
Three,0.012990785321531704
hundred,0.005121953698222082
eleven,0.00180853553190168
individuals,0.0018037278012062545
aged,0.0015570523326498785
50,0.0020107210099704455
years,0.0020327913514913286
or,0.003222338820660108
older,0.002253816737500109
were,0.002065094726093684
screened,0.0012592950171383926
for,0.001549730292019696
"eligibility,",0.001756667688267688
89,0.0018140237904447894
were,0.0020751063380832525
not,0.0017281889774627029
"eligible,",0.0014763394213080643
and,0.0028960110210342963
52,0.001513797963797107
refused,0.001690310667201173
to,0.002734427383519342
participate.,0.0018175024003998683
A,0.0020987855186331717
total,0.0016944959389528498
of,0.002513022886205742
170,0.001353348164593961
participants,0.0011372680397217616
were,0.0017139662721116838
randomized,0.001411820237515685
and,0.002739868726577022
138,0.0016057002421336322
participants,0.0010391466996606499
completed,0.0012791006622337089
the,0.0018120424479039139
18-month,0.0017583835149685804
assessment.,0.0011518564716922195
INTERVENTION,0.0025799407595907807
Participants,0.002274060976216056
were,0.002728635421749091
randomly,0.001826743605865726
allocated,0.0014409809519267593
to,0.002136840282253563
an,0.0021171354278500852
education,0.0016348828297928315
and,0.0019215703394885452
usual,0.00229348041242983
care,0.0015666583371038154
group,0.0016581760192671737
or,0.002185006040361446
to,0.0020618372505058096
a,0.0023913163218941473
24-week,0.0025640005500217906
home-based,0.0026412144341597093
program,0.0020826734535293718
of,0.0036642464433893104
physical,0.0017605321176790514
activity.,0.002255970905000414
MAIN,0.0027383148164331073
OUTCOME,0.00429821641111092
MEASURE,0.003692170645067142
Change,0.00241451024161991
in,0.0026831310030758317
Alzheimer,0.0019371224216889614
Disease,0.0016364740551139622
Assessment,0.0017453307395441863
Scale-Cognitive,0.0028683857782723795
Subscale,0.0023959956109160154
(ADAS-Cog),0.0029628534350382802
scores,0.0023379437202188397
(possible,0.0026951956037213226
"range,",0.0023176601809311993
0-70),0.002647396640184614
over,0.00416527794185814
18,0.0024734818753384433
months.,0.0027873113257712045
RESULTS,0.0680880925396415
In,0.11504777671653832
an,0.15263060869109227
intent-to-treat,0.7938560242530138
"analysis,",0.8449923279681295
participants,0.8033237333637957
in,0.814164269167876
the,0.8168485702199278
intervention,0.7848946225752315
group,0.84113422709547
improved,0.8236794164591551
0.26,0.8004261903508787
points,0.809332400369976
(95%,0.8089337900342165
confidence,0.8306550821138803
"interval,",0.8520769619492535
-0.89,0.8121795446663143
to,0.8004796719439387
0.54),0.7837346224685927
and,0.8206256440444756
those,0.8085129048300831
in,0.8355615004375903
the,0.8503549301454505
usual,0.8312739557896233
care,0.81968420934957
group,0.8618344190243757
deteriorated,0.8191127956231008
1.04,0.8270716616490735
points,0.8111530825351473
(95%,0.7875452907746574
confidence,0.8384608910256587
"interval,",0.8506049492584237
0.32,0.8088557849458884
to,0.7566815209570498
1.82),0.7883388671246105
on,0.8249306319158113
the,0.8123246787186966
ADAS-Cog,0.7971588240024878
at,0.8073715505040818
the,0.8192791292111595
end,0.7960715126262533
of,0.8193669577523469
the,0.8063409758490063
intervention.,0.7909688825389771
The,0.028902140557291737
absolute,0.015270551069871503
difference,0.018250754996301164
of,0.015663110185475247
the,0.013959122909953733
outcome,0.019622715402039317
measure,0.0188137682171749
between,0.017110724812907027
the,0.01592800728982112
intervention,0.04276873701883266
and,0.021176930076730605
control,0.01383934007098505
groups,0.01961856265137685
was,0.03403525156080216
-1.3,0.051492229811789726
points,0.019138557097323577
(95%,0.03813269615741546
confidence,0.024292607312125986
"interval,-2.38",0.02650533012019166
to,0.04283691406263907
-0.22),0.07547836867934879
at,0.018542492015226144
the,0.017274120430227562
end,0.019524163024825344
of,0.019272363604722245
the,0.019737585187776796
intervention.,0.035390596424301056
At,0.24788713221105493
18,0.12449800917440856
"months,",0.12570244612949713
participants,0.19784455804491774
in,0.2059414933106121
the,0.1596044724430249
intervention,0.18335932486894282
group,0.2653577606540587
improved,0.7110838788421397
0.73,0.6742854329284638
points,0.6842530785941322
(95%,0.7022274183061492
confidence,0.7345022297213881
"interval,",0.7499373409648639
-1.27,0.7112001012864729
to,0.7074892959278487
0.03),0.6584643338420825
on,0.7259438327619503
the,0.7019209666856959
"ADAS-Cog,",0.6973270865110479
and,0.7191829953338902
those,0.6740085900943583
in,0.6689702336058724
the,0.6918165970184441
usual,0.7141216330351267
care,0.7348052058419468
group,0.7426890308155614
improved,0.6914818477795928
0.04,0.6392291372019941
points,0.6491865545075767
(95%,0.645170497432218
confidence,0.6979095563870877
"interval,",0.7192212013566335
-0.46,0.68713802346033
to,0.6522794775001463
0.88).,0.6085869120627528
Word,0.02228385309256747
list,0.02999600841505542
delayed,0.04940681281395326
recall,0.04400988696202645
and,0.039868384781411276
Clinical,0.01828673997677737
Dementia,0.025491408018111346
Rating,0.017210244433645383
sum,0.027189659516061605
of,0.025595543137045464
boxes,0.02254643351976307
improved,0.054611400042672474
modestly,0.06196830453537345
as,0.15493730466765235
"well,",0.1394606176132481
whereas,0.11155513727876787
word,0.01563706765542528
list,0.01977230658597615
total,0.027416791675438933
immediate,0.02227974202193832
"recall,",0.027846262578968814
digit,0.011309852879987056
symbol,0.013059615884463298
"coding,",0.02458480542715602
verbal,0.016135350650175347
"fluency,",0.008618568361700017
Beck,0.027880713155575533
depression,0.013479728851569539
"score,",0.015419317314306676
and,0.016471461862522435
Medical,0.01234529482142727
Outcomes,0.00777441499480667
36-Item,0.012701989306159725
Short-Form,0.016533291316491894
physical,0.016048408170563164
and,0.018990051958233303
mental,0.01295370111123066
component,0.015012833483503277
summaries,0.010551626537935038
did,0.04584141155622833
not,0.06727310118326009
change,0.026549329919966693
significantly.,0.033444482779429914
CONCLUSIONS,0.8682754508402984
In,0.8927808589120191
this,0.8455227133862717
study,0.8551909609040551
of,0.8596442334814695
adults,0.7852332116943799
with,0.8530508209929519
subjective,0.8751386841105934
memory,0.7884927155940303
"impairment,",0.8637645665512178
a,0.9015945260731469
6-month,0.8734274877969881
program,0.9073932926834438
of,0.9313714923259255
physical,0.9121160799400857
activity,0.9020407316610912
provided,0.909860918884521
a,0.9114612211957719
modest,0.9066443133510715
improvement,0.9067373815115154
in,0.9216311168549375
cognition,0.9260199015618943
over,0.9043851056814661
an,0.8873161885101215
18-month,0.8736130345323334
follow-up,0.901729425786356
period.,0.8894083355454975
TRIAL,0.013413837264628133
REGISTRATION,0.020390236904383675
anzctr.org.au,0.02319605467303968
Identifier:,0.015606021567910033
ACTRN12605000136606.,0.012401187491566936
BACKGROUND,0.25263441453861546
Artemisinin,0.4037837973495455
derivatives,0.5584107955093647
used,0.4847736197867779
in,0.4334030156223162
recently,0.4303657244508011
introduced,0.379976700633689
combination,0.3910328225883071
therapies,0.24751711675023472
(ACTs),0.3615454426137013
for,0.5515441759990812
Plasmodium,0.612391920718791
falciparum,0.6775138424034903
malaria,0.7089364227503695
significantly,0.7434820844641257
lower,0.7692037788998297
patient,0.6095517942166367
infectiousness,0.4894073689632336
and,0.7741039378629745
have,0.5651505831572925
the,0.6888306760200407
potential,0.48364579419001585
to,0.62040240220427
reduce,0.6244673560358999
population-level,0.44891335820542216
transmission,0.5168788371493143
of,0.5000362806021531
the,0.5389646833409354
parasite.,0.358287787159608
With,0.006039181385218042
the,0.0058720902690146595
increased,0.0033430053400161286
interest,0.0024956396509080913
in,0.001972301011832175
malaria,0.002695689105442217
"elimination,",0.0014450175605835694
understanding,0.0017403030037750325
the,0.001262763776793682
impact,0.001289122910014071
on,0.0020951340281075118
transmission,0.001307317607434943
of,0.0018122727455992349
ACT,0.0030746528514508744
and,0.0018957066391179463
other,0.0012497204027755327
antimalarial,0.001432286964854926
drugs,0.0014994896222167635
with,0.0012722921631071564
different,0.001403506093111062
pharmacodynamics,0.0012508737752009622
becomes,0.0015677558963630258
a,0.001553736672147287
key,0.001671562908148029
issue.,0.001661162119904532
This,0.002250218349588084
study,0.002839558676169992
estimates,0.0023329435518837406
the,0.002181731622782087
reduction,0.0017430214346682406
in,0.0027394029822905013
transmission,0.001761734651644393
that,0.002208914216602067
may,0.0022399045496077742
be,0.001761493995427167
achieved,0.0013451062818538345
by,0.003256240730566324
introducing,0.0018391125343717324
different,0.0019680920731894257
types,0.0015039852369322791
of,0.002061196669655841
treatment,0.001582824250255532
for,0.0023047956872873777
symptomatic,0.0025050480006283283
P.,0.005553083784718939
falciparum,0.006351387802360887
malaria,0.003752211930846541
in,0.002611657458779013
endemic,0.001406782928722367
areas.,0.0018269905514450868
METHODS,0.04866063756234312
AND,0.03138748151246262
FINDINGS,0.06626496667430487
We,0.01984298392292362
developed,0.01152159296408848
a,0.009142440431281802
mathematical,0.006664636569502084
model,0.005324713253126332
to,0.007560462365493919
predict,0.006021149848471794
the,0.005171362922278422
potential,0.00844407772949471
impact,0.009981362395963216
on,0.008262852317138624
transmission,0.017701251434615907
outcomes,0.014058579866285779
of,0.024912019159039362
introducing,0.03436611787165233
ACT,0.04230850878605923
as,0.04277485254925978
first-line,0.022494317349518317
treatment,0.04064938123719247
for,0.02365145854277627
uncomplicated,0.012563522952314115
malaria,0.030638831187825285
in,0.020633243941455656
six,0.013238276177608753
areas,0.03014716073938822
of,0.02207217409932678
varying,0.010795045358538759
transmission,0.031509582950720864
intensity,0.031111962444738885
in,0.018839677734361248
Tanzania.,0.020611933342079572
We,0.010850166539587442
also,0.00819309464489098
estimated,0.007348620897400945
the,0.006426540567760725
impact,0.008622083099045082
that,0.007069165058105246
could,0.009280103310941147
be,0.007249388685048156
achieved,0.010574202178010923
by,0.015744625090882116
antimalarials,0.014282021193003414
with,0.010095126881966319
different,0.00803151029616283
"efficacy,",0.019697262501621078
prophylactic,0.009583999651928106
"time,",0.033405687674604195
and,0.009441151458825358
gametocytocidal,0.01733242961792384
effects.,0.01332786883815197
Rates,0.0020969647176581566
of,0.003822878034142764
"treatment,",0.002866757144922799
asymptomatic,0.001992444209903643
"infection,",0.004671372902020747
and,0.002956893943949377
symptomatic,0.001496966181200848
infection,0.0056526899934464985
in,0.002590335580974154
the,0.0021443575511393485
six,0.0021855669847742347
study,0.0019910745620515097
areas,0.00180159517669548
were,0.003310547364666248
estimated,0.0014216097806059006
using,0.0026035994490371532
the,0.001986967471499308
model,0.0023535234286969965
together,0.0030048415265976217
with,0.0022447751755325872
data,0.0027900495944921284
from,0.0031643136133402095
a,0.0027827629818623655
cross-sectional,0.0027631439011100065
survey,0.004348405063228037
of,0.0038636627322535086
"5,667",0.0021112604106300966
individuals,0.0026119754513164455
conducted,0.002051928582022942
prior,0.0022207903418730436
to,0.002242172923411856
policy,0.003467619383436568
change,0.004979997361331731
from,0.06096707939161659
sulfadoxine-pyrimethamine,0.04512942170552925
to,0.0283704484425103
ACT.,0.04537357083217538
The,0.0013938875026962886
effects,0.0012869508867549653
of,0.0023001687987643927
ACT,0.00819926363299361
and,0.0012842151573581883
other,0.0011482787521759853
drug,0.001103875199634289
types,0.0011101849829357473
on,0.0014114780996487908
gametocytaemia,0.001892921244719688
and,0.00113447183210097
infectiousness,0.00075257108582684
to,0.001211859531673228
mosquitoes,0.0009294533590511746
were,0.0007975571726715276
independently,0.0006920330080976411
estimated,0.0007796284896188973
from,0.0008722804672463481
clinical,0.0007634208895964863
trial,0.0006419845516261475
data.,0.0007241814034672406
Predicted,0.0062075929955600455
percentage,0.008548160935872602
reductions,0.0050108833830961675
in,0.007773385135917595
prevalence,0.004579669974211036
of,0.0072205438711904005
infection,0.0036082099095820657
and,0.007073648117365133
incidence,0.005190110470389606
of,0.006819483554658728
clinical,0.0035195824196850634
episodes,0.004259501702974493
achieved,0.003732342631120343
by,0.005303873076686127
ACT,0.010015140118654814
were,0.00731281991456244
highest,0.00391067091491306
in,0.005366908064989192
the,0.005564848187086156
areas,0.004610423344223213
with,0.00602073748542904
low,0.0034385335024603517
initial,0.00652441385836999
transmission.,0.003963101101631476
A,0.533407441186425
53%,0.5716439362575296
reduction,0.42252176043853834
in,0.4181335786160865
prevalence,0.4596393827667876
of,0.46204373433341484
infection,0.37176483044849845
was,0.4228721225789804
seen,0.4534123037143566
if,0.46696511618640674
100%,0.4716937577403129
of,0.44082105870576427
current,0.40096638451376604
treatment,0.43137599499357865
was,0.3674941079186358
switched,0.3431331695569388
to,0.3668006741995449
ACT,0.38490214287589614
in,0.4636144113311076
the,0.46573168452847896
area,0.35445156807676637
where,0.4844939677195399
baseline,0.4954286257485952
slide-prevalence,0.43540695866143314
of,0.537226131628708
parasitaemia,0.5331025662546856
was,0.424777653918256
lowest,0.37939864933800954
"(3.7%),",0.4099761378177027
compared,0.6005168724580712
to,0.5591761194299915
an,0.5532436888517783
11%,0.5675866301009201
reduction,0.5189312306696714
in,0.0653724074164886
the,0.03565858622013002
highest-transmission,0.01701744503329474
setting,0.027930189656716464
(baseline,0.033336643589073095
slide,0.01917672697921631
prevalence,0.029979710554999532
=,0.059774405200093195
57.1%).,0.02241025687329214
Estimated,0.00978293364975678
percentage,0.010533148112515857
reductions,0.010445811888509978
in,0.013154463983256566
incidence,0.013980157529282656
of,0.016841905561652458
clinical,0.009774659455685683
episodes,0.014835570179739226
were,0.012620346449427538
similar.,0.00818582104307398
The,0.007853865605712083
absolute,0.0040617344142008195
size,0.005494491023378802
of,0.004608267290807902
the,0.006065991555512702
public,0.004859861333318193
health,0.004902399356386525
"impact,",0.007473908652857916
"however,",0.008276340117286736
was,0.012051658814930897
greater,0.005302443110161821
in,0.010038958212068683
the,0.00803443602696375
highest-transmission,0.004322210521770938
"area,",0.005304807729930484
with,0.01093123996248373
54,0.00707726105800091
clinical,0.005144015074352312
episodes,0.007176176969061596
per,0.004498086228324563
100,0.004860048131023509
persons,0.00656783081639247
per,0.004592505396811988
year,0.003541136080747265
averted,0.004728313105956871
compared,0.01732198237420943
to,0.007170953791374718
five,0.007214171789830382
per,0.00661360206839563
100,0.006624385901244683
persons,0.006900816279652726
per,0.004967255550394792
year,0.004008040767128715
in,0.008875989295710419
the,0.007700621009799369
lowest-transmission,0.0042570441366817655
area.,0.004443668803697607
High,0.03157949420987857
coverage,0.04922408816923341
was,0.029457018966881323
important.,0.03080597325088516
Reducing,0.26479334363659707
presumptive,0.15836954175389162
treatment,0.13441039560709153
through,0.29621617209022566
improved,0.3497418267644299
diagnosis,0.12059132264615374
substantially,0.36655586976725757
reduced,0.32904914629470056
the,0.2453671019151083
number,0.15852972337231638
of,0.13321435580505475
treatment,0.08947158136765285
courses,0.12526327559495423
required,0.10000201346906124
per,0.11914081806170583
clinical,0.06993207875815861
episode,0.06236022127560763
averted,0.12637358660448048
in,0.21650943136148043
the,0.21923928781409033
lower-transmission,0.18557062818635753
settings,0.18299135664355562
although,0.41132975879642597
there,0.25201415624288737
was,0.2602996988554373
some,0.3383057285197525
loss,0.1450367636884497
of,0.15592977395121577
overall,0.13801023387997935
impact,0.152038481247125
on,0.0981334179540069
transmission.,0.07599096252648249
An,0.7341679569039578
efficacious,0.7814010757266134
antimalarial,0.7218081889241912
regimen,0.6708947599087662
with,0.7603353012506626
no,0.7590069563414374
specific,0.6781319977603287
gametocytocidal,0.7357276126956974
properties,0.6830829221259813
but,0.7736783484309897
a,0.7973345041759676
long,0.7610694936631334
prophylactic,0.6839666616810065
time,0.701239193259303
was,0.6837961698417497
estimated,0.6181718200815612
to,0.6903598482344036
be,0.7548915186248814
more,0.7914394559408412
effective,0.7869329491828558
at,0.7720061938279827
reducing,0.7407332769101578
transmission,0.6558905318639534
than,0.7991600778810466
a,0.7035372198407862
short-acting,0.725070161151707
ACT,0.6702045826948531
in,0.6639057725910441
the,0.6491587770530819
highest-transmission,0.7002268183953682
setting.,0.6507790544880054
CONCLUSIONS,0.5239978876185183
Our,0.09465741101826804
results,0.0520005309175576
suggest,0.07326762982555408
that,0.05624882363768775
ACTs,0.04590362074648429
have,0.03439704719772367
the,0.04773368274936026
potential,0.04067477595844575
for,0.06930561976142768
transmission,0.03165588035085423
reductions,0.03801482463219746
approaching,0.07225610674457124
those,0.06480033193790817
achieved,0.04559656680956243
by,0.04044251773756552
insecticide-treated,0.02718304818130934
nets,0.04249692341456518
in,0.04297887494964015
lower-transmission,0.0346426153659296
settings.,0.03978341364486671
ACT,0.08366547864214854
partner,0.06705470590952739
drugs,0.0744676424818329
and,0.05043136426161821
nonartemisinin,0.05307068305487276
regimens,0.05794165769192091
with,0.04885582313155008
longer,0.10324486116593092
prophylactic,0.026904313274421
times,0.05453266167384942
could,0.0220978221914581
result,0.027441494850873625
in,0.02606324802847178
a,0.018713037993825406
larger,0.019834131391862322
impact,0.021903561651584875
in,0.03161432543320105
higher-transmission,0.022887605924427873
"settings,",0.020670598451080848
although,0.01954265367985465
their,0.011747024778291794
long,0.007139996421575753
term,0.006006978680719531
benefit,0.013985048731642975
must,0.005157856305956934
be,0.003376818586514318
evaluated,0.005732371395063934
in,0.02482478871446845
relation,0.13441291984232173
to,0.11260083826350688
the,0.12100114473766012
risk,0.16531100332282425
of,0.1812068618748567
development,0.2682599468072721
of,0.2181370006788981
parasite,0.22341329593356998
resistance.,0.21179076396024962
Research,0.008716347717853021
on,0.004938108321835634
the,0.005171429157640941
human,0.006691294614179223
microbiome,0.0043078788880905345
has,0.004890128910518159
established,0.005756768370487749
that,0.006566003229197171
commensal,0.0035914348283170136
and,0.003795301135303175
pathogenic,0.0023035876831315723
bacteria,0.006689241215427257
can,0.0036831289695066728
influence,0.004944267322067223
"obesity,",0.006402779177529147
"cancer,",0.003284624789263972
and,0.003249557126340013
autoimmunity,0.002388797990744505
through,0.0033526166633301145
mechanisms,0.0025000974060986163
mostly,0.002186992606575541
unknown.,0.0023103236117748382
We,0.6461273625768122
found,0.7148440640534371
that,0.7290366084135478
a,0.6257456839992255
component,0.5744032963484123
of,0.675023711117879
bacterial,0.49130688019594715
"biofilms,",0.5283047470555081
the,0.5473089337836025
amyloid,0.5511219456050742
protein,0.5909454350744962
"curli,",0.5491534711895039
irreversibly,0.64989859095634
formed,0.5894498198628678
fibers,0.6107771007050836
with,0.574676792712283
bacterial,0.5303931643055305
DNA,0.6098232119607779
during,0.7010343356345967
biofilm,0.6053480436316913
formation.,0.6251538605544964
This,0.6554480263337317
interaction,0.5969285099715221
accelerated,0.7487193395087028
amyloid,0.6841818352097081
polymerization,0.6623977990420628
and,0.754436389431854
created,0.7296227528294128
potent,0.7203594775596478
immunogenic,0.7112629959542174
complexes,0.6714629043106755
that,0.7198470080343625
activated,0.7341045651608145
immune,0.5735690749514347
"cells,",0.605542020095148
including,0.6496127139839347
dendritic,0.636314705631276
"cells,",0.6539862394849711
to,0.6540884903515717
produce,0.6079428350712379
cytokines,0.5678608333947988
such,0.4011954803507718
as,0.36690504081467296
type,0.33355044835753067
I,0.40831101274563486
"interferons,",0.46625400143161544
which,0.31764783322268303
are,0.247722779525757
pathogenic,0.24097756229567835
in,0.2905357709702769
systemic,0.4132202258542972
lupus,0.39918813854119095
erythematosus,0.40555269284363166
(SLE).,0.33895444506175676
When,0.5506517429302528
given,0.3857030654483748
"systemically,",0.3520352615681307
curli-DNA,0.3864434293067639
composites,0.5207496474133371
triggered,0.7262918608945217
immune,0.7007425037338716
activation,0.7367371207296823
and,0.7681896473735494
production,0.7226322405989665
of,0.7542081305352925
autoantibodies,0.6600099062386521
in,0.6814112185217233
lupus-prone,0.5131005810133861
and,0.5646204110493372
wild-type,0.47888964703825143
mice.,0.5789149133257283
We,0.6741331277764017
also,0.7927017267018643
found,0.8216427342034582
that,0.846829393007221
the,0.8320097911412595
infection,0.7350649450975345
of,0.8017408984048704
lupus-prone,0.7508712432539809
mice,0.7410322785468599
with,0.8034456577942014
curli-producing,0.6442920237030672
bacteria,0.7052383222741532
triggered,0.8108377245569154
higher,0.8310885166585492
autoantibody,0.7967393501346899
titers,0.853090767930444
compared,0.8107698804412458
to,0.7920711799292182
curli-deficient,0.6265320351732127
bacteria.,0.6854772827789719
These,0.048908303645359925
data,0.034715996843783466
provide,0.032494694006000004
a,0.022193228725920024
mechanism,0.018179846631437183
by,0.012479188498379257
which,0.024981771688471054
the,0.03174522341538317
microbiome,0.020279504456451644
and,0.02423645626473471
biofilm-producing,0.015573224927111924
enteric,0.01601254431288579
infections,0.021990245335140008
may,0.019462548131701642
contribute,0.01778731163309902
to,0.020936686242950912
the,0.011383840147291354
progression,0.009107616904876452
of,0.01356436945325406
SLE,0.03724630626387636
and,0.05049561443398289
point,0.022532327435222536
to,0.014470520602341755
a,0.008348355793706803
potential,0.009118301741883853
molecular,0.010146279807227801
target,0.009131822490547272
for,0.007733139435113505
treatment,0.009482552886310771
of,0.027616883581119647
autoimmunity.,0.46687156521590334
The,0.05127271966685646
TLX1,0.07538854376565557
and,0.06531500007249674
TLX3,0.07420701056383525
transcription,0.043790356217702095
factor,0.05310615358173232
oncogenes,0.026610702564627935
have,0.01514822545481471
a,0.013889053004453596
key,0.015520359833013501
role,0.015649109389048114
in,0.014460463101354718
the,0.013932265082953038
pathogenesis,0.008305933854325988
of,0.01602698340584726
T,0.019298558341832008
cell,0.026694058581946054
acute,0.010644222115732559
lymphoblastic,0.015988240645696837
leukemia,0.02683767075781054
(T-ALL).,0.01242686889664462
Here,0.07266401312806083
we,0.04822031752289782
used,0.03569421358530637
reverse,0.017071421937547862
engineering,0.023590563646269987
of,0.020723525646859742
global,0.022611344183029944
transcriptional,0.02388379912354495
networks,0.026798814411101712
to,0.01984682609165248
decipher,0.01581108830592706
the,0.02678897911875823
oncogenic,0.03134741134287666
regulatory,0.027258697243647552
circuit,0.02946842805455463
controlled,0.020951017825093135
by,0.02743449639128073
TLX1,0.023177748651617758
and,0.024420636109851443
TLX3.,0.023479351562860334
This,0.045801586243752336
systems,0.01493852449336039
biology,0.018771348383589816
analysis,0.022863850863874238
defined,0.02799585630498705
T,0.02936120141955623
cell,0.06077968246714542
leukemia,0.0269932721122115
homeobox,0.04621290502855568
1,0.029221637808167285
(TLX1),0.023106064687477546
and,0.03254090231779219
TLX3,0.029425500082853353
as,0.052740147749426196
master,0.031963883560735956
regulators,0.03702051738384673
of,0.06416639210962755
an,0.06056260180416565
oncogenic,0.0429663635194988
transcriptional,0.054756424829656924
circuit,0.06116850135957545
governing,0.049396097894272115
T-ALL.,0.03606221802318483
"Notably,",0.08889319854339428
a,0.1352179523599649
network,0.13856302173468102
structure,0.63667274307203
analysis,0.6377162392260772
of,0.6316016271984728
this,0.6247599419221131
hierarchical,0.5988157996103437
network,0.5743616021554916
identified,0.6947187958292779
RUNX1,0.6448822721117352
as,0.7307558692841797
a,0.7540161021412216
key,0.7431165256778641
mediator,0.7263093614098184
of,0.7487858603554497
the,0.752728305829921
T-ALL,0.6488320642017774
induced,0.7151462944439683
by,0.7657082061172981
TLX1,0.6748765643264065
and,0.7599896974634528
TLX3,0.6547621411280374
and,0.7571294279917794
predicted,0.7337700721166096
a,0.7527460726302566
tumor-suppressor,0.7033740127962727
role,0.7060531487510663
for,0.7551680011462215
RUNX1,0.7021981592385742
in,0.7510661921660087
T,0.6842367302131879
cell,0.7414870468857306
transformation.,0.7299471447138851
Consistent,0.2954350559769012
with,0.22177762545326526
these,0.29962714195244516
"results,",0.26045338714199695
we,0.29893776991499776
identified,0.2791007430509531
recurrent,0.21209628440283468
somatic,0.22852562025978207
loss-of-function,0.15502048380677144
mutations,0.21086475797007068
in,0.22404554279734387
RUNX1,0.29819094728621026
in,0.2183017766777538
human,0.19069878211866476
T-ALL.,0.2496295987185914
"Overall,",0.505454548306972
these,0.41369393480009664
results,0.4432104152207117
place,0.4607087397183129
TLX1,0.4507218560955385
and,0.5230583675791683
TLX3,0.431899755097907
at,0.4831699449814615
the,0.5022622825799682
top,0.4031429792211907
of,0.4937441018863891
an,0.5082462477202205
oncogenic,0.5353391046807051
transcriptional,0.5148688362077253
network,0.49214050654604147
controlling,0.5384000954225717
leukemia,0.512154318869129
"development,",0.5993571788548726
show,0.37688547682076146
the,0.3261211004281159
power,0.243105025318751
of,0.30937213934971125
network,0.2971603601789361
analyses,0.45935978924640997
to,0.5016032923940819
identify,0.5151289159271978
key,0.5223636180566552
elements,0.4526794781669823
in,0.5077319062765059
the,0.5393092986924019
regulatory,0.5493403626609632
circuits,0.5324963008335022
governing,0.5297435108618567
human,0.5717124922756903
cancer,0.4466791318773196
and,0.5852202548517736
identify,0.5971560224776016
RUNX1,0.5956695313000229
as,0.6492468740870871
a,0.6563231542346936
tumor-suppressor,0.6017163908743924
gene,0.6182258423048471
in,0.6743812360776332
T-ALL.,0.586910868370254
BACKGROUND,0.0680740436042365
LDL,0.17148321843404743
cholesterol,0.07980945519863263
has,0.033604689726788345
a,0.05032748744905171
causal,0.05272887506488353
role,0.05453343611206721
in,0.037415170094492106
the,0.03686295174665601
development,0.040816097792041026
of,0.03153041646031129
cardiovascular,0.043073612729851524
disease.,0.03417724398790514
Improved,0.0030675802475372254
understanding,0.0014061848683182452
of,0.0011426669444185439
the,0.0011195184925902445
biological,0.0010787962144610595
mechanisms,0.0011395467057749198
that,0.0018791962873045927
underlie,0.001192335457272656
the,0.0011771214232568965
metabolism,0.0017223593009886944
and,0.001677419361788818
regulation,0.0014352088516901014
of,0.0020833192080204396
LDL,0.011568390014210757
cholesterol,0.005486268719596873
might,0.002582216074200263
help,0.002304491434339231
to,0.001735675930910447
identify,0.0012222187850235136
novel,0.0010292267124665721
therapeutic,0.0011936695655312994
targets.,0.0008747912220980531
We,0.003683151716771852
therefore,0.0017881221992675704
did,0.0013982117565656716
a,0.0008836124982021567
genome-wide,0.0009631196566304933
association,0.0011580212228241226
study,0.001227420570691105
of,0.001109504638851172
LDL-cholesterol,0.0031876370339923594
concentrations.,0.0012397578746585005
METHODS,0.009235719625454991
We,0.019768561712775932
used,0.006236359102779422
genome-wide,0.0035137306647340617
association,0.004581747466903261
data,0.0070438682075351965
from,0.005667291552025119
up,0.0027230991324743315
to,0.003203077087503023
"11,685",0.0034407122889465796
participants,0.004701070002960882
with,0.00377319380585292
measures,0.004369885826940231
of,0.00461651296578784
circulating,0.004954521494888949
LDL-cholesterol,0.012709959920328185
concentrations,0.008333707265671503
across,0.004724450552434156
five,0.002877786982666621
"studies,",0.008447380126052981
including,0.005141233948953276
data,0.00771654009424941
for,0.008623489391796146
293,0.004225981381824402
461,0.011512304867031729
autosomal,0.005511932903903145
single,0.018291500133977314
nucleotide,0.11693246171027516
polymorphisms,0.028196491065174634
(SNPs),0.021611652334359667
with,0.03162575060172575
a,0.03199052226982825
minor,0.0424205366250036
allele,0.029443471341263884
frequency,0.0524080464096331
of,0.04891398221505936
5%,0.06999128485361888
or,0.033353154703987246
more,0.04488944284555111
that,0.03225415564320232
passed,0.02342675056844171
our,0.013473932828304544
quality,0.00967707547228558
control,0.007673670171665092
criteria.,0.014468966831038928
We,0.00815788821986809
also,0.004845869548959647
used,0.006172917982403335
data,0.0037443122515717383
from,0.0027385492142930064
a,0.003524812415681465
second,0.0034204195000664683
genome-wide,0.00195968614782192
array,0.0027402166206739885
in,0.004873589205115717
up,0.0029202324561435566
to,0.002428945576601301
4337,0.0017346901428333863
participants,0.0027700822354515217
from,0.0021805957601692847
three,0.002663048343391026
of,0.0028220974501788672
these,0.00408445648928837
five,0.002332369835548877
"studies,",0.003931918112795687
with,0.0028912954377008173
data,0.0025199693182109263
for,0.002510409542773963
"290,140",0.0014200358139558056
SNPs.,0.0022262766388835664
We,0.007809599533348156
did,0.0035663373112730483
replication,0.0014258158866044968
studies,0.0018368542179923047
in,0.0015705857772407058
two,0.002011843717845547
independent,0.0012793888190820624
populations,0.0014392320554765126
consisting,0.0015036111329277087
of,0.0020025512148567444
up,0.0011190767982734366
to,0.0013184559926292627
4979,0.001066550603330597
participants.,0.0012632088706497353
Statistical,0.00298161668552301
"approaches,",0.0023027116726188086
including,0.0018482113726914025
meta-analysis,0.0011689171956563978
and,0.0013941493690962775
linkage,0.0014194483485570487
disequilibrium,0.0009036663379421262
"plots,",0.001227605598286619
were,0.0035930366209483023
used,0.0019005473955653006
to,0.0022244682447262287
refine,0.0016186776526009253
association,0.007583752147214136
signals;,0.0034864653635266656
we,0.005449339407226302
analysed,0.002721209175939739
pooled,0.0025698649820007744
data,0.006031875428571523
from,0.005066849422493173
all,0.00482930578959067
seven,0.005705337757818494
populations,0.005801368529983386
to,0.002307619749571757
determine,0.001743130127270497
the,0.0021403382057556585
effect,0.005020875996447114
of,0.006035914930944657
each,0.004935914544367866
SNP,0.009764414056974249
on,0.005670901416312637
variations,0.00549220119140343
in,0.009952406538763616
circulating,0.15469570982649541
LDL-cholesterol,0.2268865497508016
concentrations.,0.2045338078784872
FINDINGS,0.11541177100155846
In,0.3147759430552577
our,0.28001157082090306
initial,0.331495381765224
"scan,",0.2194905314867412
we,0.32790534633840074
found,0.363385701897769
two,0.276958956786712
SNPs,0.20990934621888913
(rs599839,0.276482009606864
[p=1.7x10(-15)],0.3394360057140227
and,0.3435200180363115
rs4970834,0.24741468626406823
[p=3.0x10(-11)]),0.35955814963476496
that,0.25703403663583424
showed,0.27142727675957445
genome-wide,0.15967828648370647
statistical,0.1772371011662469
association,0.16574583512200455
with,0.1898455897082973
LDL,0.27536688838332124
cholesterol,0.2505671192435205
at,0.19287433185575606
chromosomal,0.14823333227245655
locus,0.1156740014839848
1p13.3.,0.19710472528528059
The,0.1413438986875403
second,0.1401472949189028
genome,0.05702323848238188
screen,0.07443168829831184
found,0.12005169320131184
a,0.08462775914391404
third,0.07333500248897963
statistically,0.09375395920439045
associated,0.060752215990170166
SNP,0.09839302083884705
at,0.06712186987483147
the,0.040163658228475015
same,0.06565754514656545
locus,0.04853701172747716
(rs646776,0.11167089901471088
[p=4.3x10(-9)]).,0.2935829631265125
Meta-analysis,0.09920313863755488
of,0.0904136483945657
data,0.08694310460347193
from,0.06651655654070782
all,0.08841130816895208
studies,0.1128872489795713
showed,0.15636309084705974
an,0.10387327349126191
association,0.09577494799222959
of,0.07975520154425529
SNPs,0.09613418130183712
rs599839,0.09107127891535301
(combined,0.10204074739013162
p=1.2x10(-33)),0.13936356938143243
and,0.09308294082843602
rs646776,0.11414357770234711
(p=4.8x10(-20)),0.11486941172496402
with,0.07220672861578704
LDL-cholesterol,0.24309158483722718
concentrations.,0.13403727087349965
SNPs,0.5368281916419814
rs599839,0.4594147376554677
and,0.5722564249114691
rs646776,0.44328162187116205
both,0.5580525816110786
explained,0.57656371123677
around,0.5877854348465652
1%,0.5888017512501905
of,0.5835509169989267
the,0.5288607858344269
variation,0.4900986403540265
in,0.48868848447702934
circulating,0.5550747352520302
LDL-cholesterol,0.5708130929256265
concentrations,0.6050669242338281
and,0.6814871560413253
were,0.58374112256468
associated,0.6434834836615427
with,0.6130412627066496
about,0.6250635699941225
15%,0.6471025539738599
of,0.6726226357795122
an,0.6258712653865434
SD,0.6442365682612902
change,0.5733241012963486
in,0.606195635506308
LDL,0.6146388438035792
cholesterol,0.0657817976483426
per,0.02725381089777803
"allele,",0.01913913222792529
assuming,0.039166640654228854
an,0.03171741300023345
SD,0.025352673559522882
of,0.031718082985890086
1,0.03244786421123895
mmol/L.,0.0263621079592798
INTERPRETATION,0.12668725187080684
We,0.27692501211284193
found,0.38242822913399466
evidence,0.36143026390821104
for,0.3435353753225185
a,0.3230449195612719
novel,0.23920864546665352
locus,0.2099801632215638
for,0.33394775529335374
LDL,0.27441238651934624
cholesterol,0.29764728187949163
on,0.3079079344707156
chromosome,0.22739629932472222
1p13.3.,0.23550967181822596
These,0.0894883012159942
results,0.08549776965765012
potentially,0.0444873321795167
provide,0.034725581640061745
insight,0.04051656853869099
into,0.036725109201762696
the,0.03743090842242867
biological,0.0344642778114068
mechanisms,0.03255934183485154
that,0.04089548832011286
underlie,0.01740305707999169
the,0.024193028034776107
regulation,0.05114823512270689
of,0.04889322298108248
LDL,0.11750795966333624
cholesterol,0.10958536527019186
and,0.10591868908905686
might,0.03954088435760894
help,0.0365319418676176
in,0.032997037468359025
the,0.027081901265758136
discovery,0.022460363634607183
of,0.02850421743629132
novel,0.020335580571183485
therapeutic,0.017433812115579633
targets,0.013406806121839919
for,0.01593349607167721
cardiovascular,0.02234962693421372
disease.,0.021534168170016403
Methyl-CpG,0.07677338190524785
binding,0.07640120594201487
protein,0.0580155234180263
1,0.09096495473785109
(MBD1),0.08845286043088423
regulates,0.050727122198311304
gene,0.03530725659314156
expression,0.042533163479766434
via,0.05423344972870184
a,0.04281013198291572
DNA,0.04594056787214611
methylation-mediated,0.0214478267297654
epigenetic,0.01630206694444773
mechanism.,0.04259346555940071
We,0.03999149921334603
have,0.04597154606999066
previously,0.04384486213089267
demonstrated,0.07286366347759668
that,0.06755544633677049
MBD1,0.06499670285006111
deficiency,0.045999216930946614
impairs,0.04756172327068293
adult,0.0337757002690214
neural,0.024485615941607745
stem/progenitor,0.012913706235787999
cell,0.03387512769936654
(aNSC),0.02955598091763614
differentiation,0.07433735682004969
and,0.03697741444814276
"neurogenesis,",0.0184066801602318
but,0.005619259669632565
the,0.003528603765122614
underlying,0.003950341967453372
mechanism,0.005780572457644515
was,0.006175489859401755
unclear.,0.003735411310653512
"Here,",0.6649264023055612
we,0.6848748602100277
show,0.6716364485056353
that,0.7201862157504639
MBD1,0.5171664171438285
regulates,0.6295494493684234
the,0.634080245958657
expression,0.6185775733926917
of,0.6131203455597428
several,0.5411755658726033
microRNAs,0.5535996565416045
in,0.6307180277180332
aNSCs,0.5056762082067107
"and,",0.6547768406245148
"specifically,",0.6774722001139474
that,0.6444215116606578
miR-184,0.5522604720588643
is,0.5265598288354109
directly,0.5020531002524665
repressed,0.5251806811475191
by,0.5443765998060986
MBD1.,0.5217512777904979
High,0.4881442548301656
levels,0.4844885148383709
of,0.4526601674034613
miR-184,0.5060998006204024
promoted,0.45854225744379423
proliferation,0.7096747351540217
but,0.8120450048503641
inhibited,0.8187875267952703
differentiation,0.6952833001383488
of,0.7419870377557772
"aNSCs,",0.6818086158830093
whereas,0.7998892941979328
inhibition,0.7794481026516227
of,0.7085187392196421
miR-184,0.6060921937023984
rescued,0.6619842163639262
the,0.623011539876176
phenotypes,0.5990761600342961
associated,0.5726046260121801
with,0.5631900632797902
MBD1,0.5385504854999563
deficiency.,0.586134120845172
We,0.7316194948740645
further,0.7803245705821276
found,0.8344656396966168
that,0.8632549775488783
miR-184,0.7497836267686036
regulates,0.8148199645465594
the,0.8196315126120371
expression,0.8113778084013616
of,0.8302487630207093
Numblike,0.7328144654268203
"(Numbl),",0.7994175864538969
a,0.840272600793314
known,0.779642131761778
regulator,0.7918619214074106
of,0.8170351705762957
brain,0.7977883048648677
"development,",0.8211056097286895
by,0.887116451766544
binding,0.8021958209505554
to,0.7569848479653651
the,0.7929445368494512
3'-UTR,0.7459146169550334
of,0.742164482275311
Numbl,0.6569887243669245
mRNA,0.7942356431876915
and,0.8245253461728067
affecting,0.8116483857177748
its,0.7338697491304944
translation.,0.7504839358874813
Expression,0.18806379614806032
of,0.15662120688158934
exogenous,0.13198254780157082
Numbl,0.19500770559446437
could,0.17760274754098945
rescue,0.1937640538514363
the,0.18779756192729427
aNSC,0.3029093679961767
defects,0.21800170935002217
that,0.18503987447147047
result,0.19582602208747824
from,0.2825799927447392
either,0.2473943489629079
miR-184,0.3102334691406964
overexpression,0.27137756168239463
or,0.2839846754571658
MBD1,0.30458306678696695
deficiency.,0.30546321134733545
"Therefore,",0.49300678697270106
"MBD1,",0.4905827752442662
"miR-184,",0.4690407890036441
and,0.44238838170211214
Numbl,0.44976413820952305
form,0.365001517019304
a,0.3978245456034078
regulatory,0.4119045176705847
network,0.42872064758147316
that,0.382280939230105
helps,0.3960516243348749
control,0.3215361524937271
the,0.34515071040681405
balance,0.36572021567765406
between,0.3152627359582785
proliferation,0.3442679241447473
and,0.2654761861394928
differentiation,0.3654399131256395
of,0.34212204696819676
aNSCs.,0.45431511780144285
OBJECTIVE,0.0010364463340929418
To,0.0007826230369283311
assess,0.0007336789432441745
the,0.0007620525993057205
effect,0.000645674167707481
of,0.0007858525797169649
25-hydroxyvitamin,0.000884827400647438
D,0.0009770478119685171
(25-OHD),0.0009542579093499344
levels,0.0007044465809651557
on,0.0007737457693533527
pregnancy,0.000615174688470452
outcomes,0.0004332062374952525
and,0.0007569231932512739
birth,0.0005388864311083023
variables.,0.0005599984205328684
DESIGN,0.0007648342710574853
Systematic,0.0014344979720024645
review,0.0012562260799316204
and,0.0013358571682708603
meta-analysis.,0.0008079309787068988
DATA,0.0011705724147391208
SOURCES,0.002065450978390611
Medline,0.002532080010052702
(1966,0.0031617374048409615
to,0.0017813223602163694
August,0.0013366048362551974
"2012),",0.0018945737765330834
PubMed,0.0019177519137507486
(2008,0.0034196068940439174
to,0.00217045889300197
August,0.0022037594599579567
"2012),",0.0026642403470660695
Embase,0.0023577318590226053
(1980,0.0035262036414599024
to,0.0019779981325084993
August,0.002278662027352719
"2012),",0.0026215974146427032
CINAHL,0.0020610627907948114
(1981,0.0029370350961167666
to,0.0017289134640479016
August,0.001751288464243124
"2012),",0.00204300781415244
the,0.0016131280905682867
Cochrane,0.0010454971604023167
database,0.00153911882802933
of,0.002445458231597724
systematic,0.0011086887228545848
"reviews,",0.0009664646577383595
and,0.0015757165015322094
the,0.0012973863760944464
Cochrane,0.0008528170934488135
database,0.0014053752461748697
of,0.0017961658261576364
registered,0.0010071717347970095
clinical,0.0006813848784568442
trials.,0.0007525746716733251
STUDY,0.033848931543661885
SELECTION,0.039905924905029214
Studies,0.03760383786685948
reporting,0.031162882331283285
on,0.013350235470327846
the,0.010781312209885905
association,0.01845832526203139
between,0.022279614780157303
serum,0.023679897758763977
25-OHD,0.04817693909759336
levels,0.022009777110993407
during,0.042271018313135685
pregnancy,0.028958879474175945
and,0.0023087381491736104
the,0.0016776573358674312
outcomes,0.0012656132782236013
of,0.0012969959602625932
interest,0.0019109356551266895
"(pre-eclampsia,",0.0031619891450759244
gestational,0.002992578459260898
"diabetes,",0.006182120494542255
bacterial,0.004018585798122073
"vaginosis,",0.004198978699083509
caesarean,0.00394074542930235
"section,",0.01246234361637069
small,0.003302767541584785
for,0.006765239691501535
gestational,0.004101079074565161
age,0.004021186981878101
"infants,",0.005632136782699406
birth,0.005158152373823687
"weight,",0.0026188801773453785
birth,0.00607891083503725
"length,",0.005109172897753983
and,0.0016512421138927776
head,0.0023062999981225524
circumference).,0.002026736114896314
DATA,0.0011648789670207034
EXTRACTION,0.0029796413341014677
Two,0.0010877814033089996
authors,0.0008851851540388363
independently,0.000832139500332616
extracted,0.0009175678513447615
data,0.0006092810062044334
from,0.0008324160804778631
original,0.0010397084161270984
research,0.00087131002086249
"articles,",0.0007534214090838919
including,0.0007244240258425903
key,0.0007587174140218148
indicators,0.0006961699373670727
of,0.0009519699677629632
study,0.0008324166753728404
quality.,0.0007898341954120418
We,0.0009251376030580982
pooled,0.0007994245914909393
the,0.0008137614171381794
most,0.0007113503182567508
adjusted,0.0006368208960572744
odds,0.0006463868458032392
ratios,0.0007771127146376548
and,0.0009346232492482204
weighted,0.0006211624939949338
mean,0.0006516766140738551
differences.,0.0007285161013251627
Associations,0.0006181732026294412
were,0.0007416256663207982
tested,0.0005300735724779813
in,0.000833214811893224
subgroups,0.000648772553149967
representing,0.0006667785607570477
different,0.0006511205169050048
patient,0.0005030398800251704
characteristics,0.0004946935269658911
and,0.0007486359050578903
study,0.0005237258895129889
quality.,0.0005438296746632704
RESULTS,0.005157650781181339
3357,0.0015390561766574417
studies,0.0011093339574315209
were,0.0008605721681462939
identified,0.0005365229515988617
and,0.0015476082870375491
reviewed,0.0005498029526701144
for,0.0008194482292155143
eligibility.,0.0006651810094553797
31,0.0013963032481362817
eligible,0.005106098021155414
studies,0.008167369542487353
were,0.0038425392728573147
included,0.002337191985466231
in,0.003245965114756144
the,0.0043004607878572056
final,0.00470668345380693
analysis.,0.00481176160470503
Insufficient,0.08273994536003858
serum,0.1850459686757928
levels,0.11355449812706175
of,0.2130098814241389
25-OHD,0.2128550876083282
were,0.1602353679619613
associated,0.1668283696877222
with,0.1859266427395064
gestational,0.1133557626977536
diabetes,0.2057064920831983
(pooled,0.23912494129967285
odds,0.2815255206041277
ratio,0.2564142852696798
"1.49,",0.274638094410071
95%,0.23959122849619718
confidence,0.34990333922202965
interval,0.30183358865686727
1.18,0.30099771858411856
to,0.27976897787611155
"1.89),",0.30957602858920896
pre-eclampsia,0.20817908626157922
"(1.79,",0.219602241320291
1.25,0.2814210657139962
to,0.25177628202247226
"2.58),",0.2949912256014644
and,0.22827516519840327
small,0.1882937594184089
for,0.22839419206593656
gestational,0.12071626277308439
age,0.1357032056083619
infants,0.2106067460359891
"(1.85,",0.2279923688848761
1.52,0.2823573398455133
to,0.23666332541770047
2.26).,0.3455415282145746
Pregnant,0.8636900396995465
women,0.8111788017072322
with,0.8597412856041644
low,0.8563190520839677
serum,0.8705877799301334
25-OHD,0.743430517691939
levels,0.8593540799046896
had,0.8990173130535742
an,0.8985553149443793
increased,0.8985763774493917
risk,0.8923085425438831
of,0.9165182468601395
bacterial,0.8902209630012189
vaginosis,0.887989236655177
and,0.9140280626960596
low,0.9063955168453051
birthweight,0.8547659985840169
infants,0.8445338538832324
but,0.9189891757839617
not,0.9182811759271743
delivery,0.813680921810206
by,0.9134159373877625
caesarean,0.489215318404414
section.,0.5117735515792998
CONCLUSION,0.7349596210799968
Vitamin,0.607185555999783
D,0.7121928763111096
insufficiency,0.6876552486388637
is,0.5845828963320603
associated,0.6630247920785964
with,0.6409539473227429
an,0.6606340241258536
increased,0.6663806558189422
risk,0.6259228971737372
of,0.6650201019017973
gestational,0.5824859591472951
"diabetes,",0.5668896807439666
"pre-eclampsia,",0.6356834691177058
and,0.6261423438717747
small,0.6535382936839217
for,0.5393650663390296
gestational,0.4760840999055845
age,0.5200043109492908
infants.,0.5592808991201919
Pregnant,0.8705521777482368
women,0.8001543462519769
with,0.8598632561630737
low,0.8738367883935364
25-OHD,0.7818187902587633
levels,0.8598059174957929
had,0.8820087486122105
an,0.8872325297823547
increased,0.8818823842575897
risk,0.8886884775522031
of,0.909244077928167
bacterial,0.8542223594541826
vaginosis,0.872089574391788
and,0.9019703596893288
lower,0.8908284430475606
birth,0.8447683605108177
weight,0.8441717827598391
"infants,",0.8007638647832147
but,0.8981982224866935
not,0.8823423344681085
delivery,0.7858632721363239
by,0.8364757349946582
caesarean,0.8089017838010377
section.,0.7387830357691041
Lysine,0.1979444302610727
acetylation,0.10853512102555511
is,0.09140878199162879
a,0.11770000917638271
reversible,0.11032846575811538
posttranslational,0.1316837741824408
"modifcation,",0.12015389925240237
an,0.09665042388137568
epigenetic,0.07111754395404543
"phenomenon,",0.10338828168378579
referred,0.09021609352807791
to,0.07049784446453328
as,0.09322360265560356
transfer,0.1346294317156276
of,0.11477622558905477
an,0.14357937865609885
acetyl,0.11440677777499843
group,0.17903038448391556
from,0.2237654834513081
acetyl,0.11510216732665297
CoA,0.21310664425492232
to,0.16810845768874905
lysine,0.1636973690696774
e-,0.2220638575911897
amino,0.08792743760878682
group,0.1810878265671339
of,0.09599793582648992
targeted,0.08476658535899954
"protein,",0.09228115617001038
which,0.05163429782718129
is,0.03255385247066606
modulated,0.026913702700933594
by,0.02856043297603633
acetyltransferases,0.03335859737794359
(histone/,0.03260370631234631
lysine,0.16408153229374023
(K),0.07907989820476777
"acetyltransferases,",0.06476389522614606
HATs/KATs),0.12611136099673115
and,0.04034598346523515
deacetylases,0.05344776031055841
(histone/lysine,0.04307919492652901
(K),0.11260474533321457
"deacetylases,",0.11654769518511475
HDACs/KDACs).,0.12074350172224227
Lysine,0.3157955686763251
acetylation,0.2108061271836687
regulates,0.25285015216187523
various,0.18613865415061176
metabolic,0.22914228047066204
"processes,",0.18012332193090855
such,0.11889261951391254
as,0.13101213824926902
fatty,0.1620408585608073
acid,0.16347694254475695
"oxidation,",0.1826101668176153
Krebs,0.22323908668881964
"cycle,",0.24853829928359153
oxidative,0.19195750707443188
"phosphorylation,",0.1729880719744716
angiogenesis,0.18304938030076603
and,0.11112027674735439
so,0.13638499185585484
on.,0.12091787421345385
Thus,0.029903429525439642
disorders,0.021118497670330492
of,0.026551209333715367
lysine,0.06629448763009953
acetylation,0.0386695885887675
may,0.014591646687149466
be,0.012384901500018508
correlated,0.021918803493145587
with,0.019429261532272066
"obesity,",0.029336594154203317
diabetes,0.021685600022823326
and,0.01832348503805325
cardiovascular,0.021015865513742786
"disease,",0.014822921165281253
which,0.019474695588449612
are,0.013742242942545746
termed,0.016400974691275907
as,0.01628387585580518
the,0.02448748108504105
metabolic,0.021840189202835095
complication.,0.021052499856284896
With,0.06024883848530657
accumulating,0.028471564507561435
studies,0.036128683254087975
on,0.022380819076049694
proteomic,0.032157138518386544
"acetylation,",0.023293079239325474
lysine,0.05757938234431104
acetylation,0.03655134844545409
also,0.027778683055937125
involves,0.037362140376059685
in,0.038508211089310046
cell,0.03261521370587329
immune,0.018199745925794233
status,0.037343142791491306
and,0.0242818753394446
degenerative,0.01887197368707314
"diseases,",0.017894077860423935
for,0.018510357265601036
"example,",0.021078513629215583
Alzheimer’s,0.02143488049696006
disease,0.022684803282846194
and,0.04680275545695073
Huntington’s,0.03667174843335572
disease.,0.024623524568003
This,0.05332362322378976
review,0.030080485379284295
primarily,0.04572981616339787
summarizes,0.02116512673436975
the,0.027206436050108508
current,0.02948204480006947
studies,0.029552640531032806
of,0.031283979310487146
lysine,0.07127955212077268
acetylation,0.39905345167003137
in,0.39745376346197914
metabolism,0.43239785648466333
modulation,0.38626020977029885
and,0.31230931593027367
in,0.3423830930633591
metabolism-related,0.383260456795766
"diseases,",0.26019503531552096
such,0.21034506489304128
as,0.19277854549666962
cardiovascular,0.32519259776353865
disease,0.32498697800998844
and,0.2860323951457618
fat,0.37532920394305563
metabolism,0.4181617136226831
disorder.,0.3684602127838748
Local,0.052717705858945585
translation,0.09160995541045643
mediates,0.08454318960889512
axonal,0.05194227181197473
responses,0.05924348180574581
to,0.07136480377678463
Semaphorin3A,0.05526188188585823
(Sema3A),0.0785152083809886
and,0.05650476354983949
other,0.05146391763133572
guidance,0.042883235294927845
cues.,0.054778203026815867
"However,",0.016046209655869167
only,0.01614831525167205
a,0.013831638595004298
subset,0.013229241035688824
of,0.015682843528516916
the,0.01408075513295277
axonal,0.00937499297864809
proteome,0.016757385142314986
is,0.015973997038991005
locally,0.012667704759298563
"synthesized,",0.014928593664587675
whereas,0.020925143382384378
most,0.01314675344219133
proteins,0.008767075332529586
are,0.011230361482836087
trafficked,0.012533492965981824
from,0.017475735624422353
the,0.017410747976781906
soma.,0.012981545699112532
The,0.003225715418618099
reason,0.004570244454672694
why,0.003821870329976965
only,0.003743262940287023
specific,0.003029114212076021
proteins,0.003924096325068956
are,0.003532031621191424
locally,0.004975122871839504
synthesized,0.004017032569551296
is,0.002388995155003797
unknown.,0.00295972514535971
Here,0.4326516018959666
we,0.5142616937563317
show,0.39138376517486967
that,0.41174204090573563
local,0.21194328482832844
protein,0.24411672571721213
synthesis,0.22780497827780788
and,0.1148710904299523
degradation,0.10957534469116703
are,0.07834208393116567
linked,0.0963798721540004
events,0.13383190712225895
in,0.145500107838225
growth,0.28475345207577013
cones.,0.20096239954302736
We,0.6677692462089853
find,0.6698826448411566
that,0.7507286817671297
growth,0.6027552160814195
cones,0.5983053152451782
exhibit,0.6204175621420728
high,0.5923114121367759
levels,0.5638657060498856
of,0.5674271676319625
ubiquitination,0.5231864256544645
and,0.701995749610706
that,0.7576373208813197
local,0.6228927489938019
signalling,0.699760981296876
pathways,0.6872901283700862
trigger,0.6949131168406626
the,0.6863219320279811
ubiquitination,0.6793640357738173
and,0.6953249965358665
degradation,0.6012887253758608
of,0.6689559121084451
"RhoA,",0.6551793313815282
a,0.3710257655283769
mediator,0.34173119337364105
of,0.35109238920461106
Sema3A-induced,0.2468839095827335
growth,0.3191779670911153
cone,0.3326182231150802
collapse.,0.31414702144248985
Inhibition,0.24670413017216647
of,0.2571348648331592
RhoA,0.24339699075247295
degradation,0.2579674298733734
is,0.1804980732035226
sufficient,0.21087628322047278
to,0.21390734182261859
remove,0.20972085664715978
the,0.2364884793117775
protein-synthesis,0.23212010900408264
requirement,0.3317153245392919
for,0.27250233536792906
Sema3A-induced,0.22743360194424742
growth,0.27997857442591173
cone,0.27309689991462527
collapse.,0.30700337946398526
In,0.6684967523720732
addition,0.6747773834129402
to,0.6087184661349022
"RhoA,",0.5240902098425066
we,0.6679668087925593
find,0.6803689109387987
that,0.6929668129795837
locally,0.5543324129715351
translated,0.5700071853341886
proteins,0.5677572095672325
are,0.5935113960299754
the,0.5967876717208987
main,0.6201716895043603
targets,0.6206259786713028
of,0.6636858502318881
the,0.658516438307978
ubiquitin-proteasome,0.6618795647536491
system,0.6677417010892043
in,0.6499985150109712
growth,0.615272839532042
cones.,0.6264280658770173
"Thus,",0.6241013368113707
local,0.5262717835208092
protein,0.4903818574874778
degradation,0.5475493875111561
is,0.5167602846371634
a,0.5514953980167822
major,0.5265307429571451
feature,0.5578967210391359
of,0.5316996683544682
growth,0.527423710661154
cones,0.5292718941230855
and,0.6055302805581704
creates,0.5044317318893619
a,0.5746404782880454
requirement,0.5898996074967168
for,0.5488199937766094
local,0.49950882808272207
translation,0.5189384408585235
to,0.4882215449348357
replenish,0.5643061389352207
proteins,0.5284462732739056
needed,0.49879780457123446
to,0.4732397278572011
maintain,0.5211130815202926
growth,0.49237809516553616
cone,0.519048136495015
responses.,0.5661917547522388
BACKGROUND,0.0901220513203182
Alcohol,0.062284573253783476
has,0.024252130243565224
been,0.0243782980272347
reported,0.027766046136772537
to,0.0238602292235492
be,0.031214470465821643
a,0.03778986506798247
common,0.03262758288711233
and,0.04888517437360274
modifiable,0.01628221651464217
risk,0.02060022903405689
factor,0.019979586584056182
for,0.03221409733537055
hypertension.,0.03632947573485015
"However,",0.003119710366793519
observational,0.0016088202201775682
studies,0.0019011480977145932
are,0.0023605094585813224
subject,0.001999798520031511
to,0.0026338576291156466
confounding,0.0025001485404519716
by,0.0019948421699574133
other,0.0013811259042952803
behavioural,0.0011446786021657182
and,0.0033471489485529748
sociodemographic,0.0016495462443521449
"factors,",0.0013162455807551065
while,0.00452195983429607
clinical,0.0012065104127901424
trials,0.001419334128586485
are,0.0021599460994993955
difficult,0.001363622445819264
to,0.0012212880909270572
implement,0.0013467553843200656
and,0.006113812879212047
have,0.002166971135349207
limited,0.001805501541997808
follow-up,0.0011910587125601056
time.,0.0018194178237526573
Mendelian,0.0038027958252299155
randomization,0.0024149254774479974
can,0.005019338572515249
provide,0.0050436323240237325
robust,0.004594122016645987
evidence,0.0028933300063823894
on,0.0038538384172633047
the,0.003015485570012807
nature,0.0023898999322885684
of,0.0028430421986162927
this,0.00506486545541333
association,0.00270008010671076
by,0.006437916498270859
use,0.0053661661300016695
of,0.003416910421483745
a,0.0030688236561265724
common,0.003602134316978969
polymorphism,0.0031462260429102927
in,0.0035779107602771734
aldehyde,0.00275459358825107
dehydrogenase,0.003024790754051241
2,0.005601797483589023
(ALDH2),0.0032817232267201
as,0.0025040479290997695
a,0.0022900813971236836
surrogate,0.0030447953046378413
for,0.002979877202350493
measuring,0.003110463754349435
alcohol,0.005325281521140103
consumption.,0.003417545363643686
ALDH2,0.25584304750422937
encodes,0.2168084240313589
a,0.23627592500216751
major,0.21683284198535044
enzyme,0.16717905091271815
involved,0.23728054646998126
in,0.2821951136008091
alcohol,0.22706782075495666
metabolism.,0.307709948952572
Individuals,0.3575704798394688
homozygous,0.3320678273221117
for,0.24383807170171082
the,0.200374455133239
null,0.28054447995690546
variant,0.22306889965422855
(*2*2),0.22387611434454954
experience,0.44251252089779397
adverse,0.4060952608093558
symptoms,0.3635000595715543
when,0.5055099272855664
drinking,0.44722678508664576
alcohol,0.3779178442073651
and,0.5591252586432597
consequently,0.5193313243930099
drink,0.44621775858903445
considerably,0.4707873934149779
less,0.565371717163014
alcohol,0.4319736614604491
than,0.4656494971603674
wild-type,0.3474696025588218
homozygotes,0.3895684666390158
(*1*1),0.3120476827457715
or,0.3248937566493486
heterozygotes.,0.35310416894494817
We,0.023393353946780028
hypothesise,0.015439696048913414
that,0.016982308522522204
this,0.02329609796676445
polymorphism,0.019247481862763975
may,0.01673994642715456
influence,0.015242923162500432
the,0.011738868076972577
risk,0.015207278251225828
of,0.01739408586816527
hypertension,0.016074195049648986
by,0.03817956125205039
affecting,0.018968766183012093
alcohol,0.01529821750034751
drinking,0.018522177361354534
behaviour.,0.019898505211990783
METHODS,0.07920369468850501
AND,0.03875093573709777
FINDINGS,0.1148597701902667
We,0.05017917072313565
carried,0.02263006220619022
out,0.010870239579497901
fixed,0.008527728438061747
effect,0.018358149847037396
meta-analyses,0.008938626445247757
of,0.014957314920993808
the,0.02076725497199979
ALDH2,0.04139277355000306
genotype,0.020683653029031763
with,0.023471273464537253
blood,0.02058559878531049
pressure,0.02638076669215663
(five,0.02068744200827791
"studies,",0.04069125507482486
n,0.02072003980814035
=,0.03416520493830963
"7,658)",0.027460249727964618
and,0.01506841165934537
hypertension,0.02270062903688134
(three,0.027928519648797452
"studies,",0.006870867361081809
n,0.0035804948040401483
=,0.006228600638035376
"4,219)",0.005869730257283106
using,0.0033294997142018965
studies,0.0019220422872966013
identified,0.0011317404376142174
via,0.002944049742344367
systematic,0.001765370703895717
review.,0.001790288327731576
In,0.7949950555996743
"males,",0.8203172501902708
we,0.8283976741471603
obtained,0.7973776794110472
an,0.8049816275245039
overall,0.8517206723122336
odds,0.8650073138185927
ratio,0.8098671746555384
of,0.8092158002198375
2.42,0.8650606325581368
(95%,0.8128125669181238
confidence,0.8497848153471603
interval,0.8357522616408543
[CI],0.7705498101012698
"1.66-3.55,",0.8317213108400561
p,0.8591122088115585
=,0.8535063704904851
4.8,0.8590494458233306
x,0.8078027462085263
10(-6)),0.8131788312709751
for,0.829601353942659
hypertension,0.8308528456357355
comparing,0.8355688791230081
*1*1,0.8358593108382133
with,0.7816190090470355
*2*2,0.8351191132255472
homozygotes,0.8031707999404921
and,0.8316318120951994
an,0.7908214944671043
odds,0.8081273594034867
ratio,0.7744996783880035
of,0.7869780880512622
1.72,0.7524092395985474
(95%,0.7415532849978258
CI,0.7911768326148216
"1.17-2.52,",0.7694656956811934
p,0.7788123909148656
=,0.7716330125251099
0.006),0.6615725744913643
comparing,0.8159658278034639
heterozygotes,0.7616236775720825
(surrogate,0.7286033567956455
for,0.669427868120454
moderate,0.8008028884503819
drinkers),0.6803856382278818
with,0.7625301354420392
*2*2,0.40834942234928195
homozygotes.,0.4242865182414465
Systolic,0.7067880730905667
blood,0.7751014899964528
pressure,0.7278310523522364
was,0.7079969461441832
7.44,0.6002186143587452
mmHg,0.5776156983224762
(95%,0.7219716515613982
CI,0.7162565325891039
"5.39-9.49,",0.7709443667121195
p,0.7667362719885135
=,0.7877354070712609
1.1,0.7661607625316038
x,0.7616245541047911
10(-12)),0.7283070550748602
greater,0.8200718536013325
among,0.7365783333324484
*1*1,0.7402315121946994
than,0.7926946941089736
among,0.7225151462432937
*2*2,0.7036804898319198
"homozygotes,",0.7102537001754963
and,0.7800466662039591
4.24,0.7447612338063576
mmHg,0.644287707074052
(95%,0.6881941981038652
CI,0.6942525650668657
"2.18-6.31,",0.7270991369995434
p,0.6528997883157758
=,0.6826901006587888
0.00005),0.5406907218306849
greater,0.7903186161315101
among,0.7248638332922743
heterozygotes,0.6241370631651039
than,0.7133084325012615
among,0.6468398373960015
*2*2,0.5903777908474936
homozygotes.,0.6004816214824906
CONCLUSIONS,0.7418634218399105
These,0.3963439251984359
findings,0.3810974467699472
support,0.3228230134015223
the,0.351385606793684
hypothesis,0.41306926534481714
that,0.4402734224307314
alcohol,0.4097156614598035
intake,0.4715669340174938
has,0.27132316216313124
a,0.37970016077050245
marked,0.3619234340436496
effect,0.42087674960372734
on,0.6703315751520147
blood,0.6961358715876369
pressure,0.636879069263768
and,0.624192691512224
the,0.596190827329924
risk,0.6483937728255702
of,0.7394134181864384
hypertension.,0.7086829336574374
An,0.003934343823106899
analysis,0.0015531963944726054
of,0.0012297507926959765
the,0.0013558606365032002
genetic,0.001013041750540814
factors,0.0011294068918460574
in,0.0016569994872040266
obesity,0.0038092800466938653
has,0.0012777369094608309
been,0.0013953424948944435
carried,0.0012511517080135224
out,0.0009866113010564836
on,0.0014269365319456969
a,0.0013563081443955314
sample,0.001352049247323128
of,0.001453330537228902
nuclear,0.0012650097902252274
families,0.001508143858343011
from,0.0015033355368021246
Aosta,0.0032172625605857604
(N.,0.002071193365329834
Italy).,0.003272358799369735
The,0.0024279544466602188
families,0.0023484084629671166
consisted,0.002505003915230749
of,0.0020567861822378152
the,0.0022433530632630966
parents,0.0033989244767611763
and,0.0032242569272060632
sibs,0.002433596446926206
of,0.0021933205160573573
all,0.003339573035394892
elementary,0.0036998965681608307
school,0.0029416502334277633
children,0.002309691164389822
considered,0.0014566957866995042
to,0.0015143782724669809
be,0.0023853499590698398
obese,0.0030796219085318347
during,0.0028998069318436157
a,0.001813548105629795
preliminary,0.0019590725797836096
screening,0.00258376580757474
and,0.0019472829389467574
a,0.001598971337621048
similar,0.0016194750304709088
sample,0.0017060602768938702
of,0.0017210348990552105
non-obese,0.0018697253793220764
children,0.0015540965915558209
and,0.0012258234187057875
their,0.0012199882256242061
nuclear,0.0012255516891274251
families.,0.0012538027609232778
The,0.0011090280647409667
numbers,0.0008747493379102557
of,0.0010310786479230682
such,0.0008792959472356139
families,0.0009077687088842448
were,0.0014025080006469497
67,0.0010903689068057392
and,0.0017394197422404929
"112,",0.0011507548300670057
respectively.,0.0009837440748773204
Several,0.002573426656750315
tests,0.001305321949191864
were,0.002878399355950891
applied,0.0011522493471640145
in,0.0014337369247943218
order,0.0012319017845513597
to,0.0012060485107597255
examine,0.001210497911567803
the,0.0011885888511235546
genetic,0.000894744993487374
contribution,0.0016621362603825005
to,0.0024924870697330573
"obesity,",0.0030833982929452585
and,0.0018027832325141794
in,0.0012940004026856303
particular,0.001492675931540731
to,0.0011284978784291296
investigate,0.0011374018412906904
the,0.0008117011848737546
presence,0.0010422740284396477
of,0.0016144591267867625
a,0.0013089519199362104
dominant,0.001818319649483472
major,0.001909586031913419
gene.,0.0022387075803261087
Our,0.004922073873288839
conclusions,0.0027699439308786714
are,0.0061069091884307465
that,0.003824175729493352
genetic,0.001832429176050009
factors,0.0022890624006681386
are,0.002793182993459194
certainly,0.002040826406644342
present.,0.0016925708003188002
Several,0.15406978977172256
analyses,0.19846179697748512
suggest,0.21173720737753765
the,0.12097261335970327
presence,0.09026819900372775
of,0.17478720148348825
a,0.20812839245642203
dominant,0.5908444876250576
major,0.5995949850855112
gene,0.5826735367709481
with,0.5322038393199765
weak,0.4913879093919923
effect.,0.5535013985067173
Granulomas,0.005915891576563261
are,0.001766045600181483
the,0.0016047633262625633
pathological,0.0008896780789898957
hallmark,0.000882751619044356
of,0.0019581246306504835
tuberculosis,0.0021955433844796962
(TB).,0.0014981647769410054
"However,",0.0009977686454299454
their,0.0016298045404751443
function,0.0014172979590078485
and,0.0015929093671975666
mechanisms,0.0009971749365446938
of,0.001415525528003531
formation,0.001270435814344976
remain,0.0013570064995608352
poorly,0.00107316266322385
understood.,0.0012209853825341174
To,0.002127379057075751
understand,0.001655493938331082
the,0.0011886395172286048
role,0.0013150351425595802
of,0.002201890218460847
granulomas,0.002316278501510405
in,0.002169836258530874
"TB,",0.002139381115478852
we,0.0034171612989010477
analyzed,0.0022429224431635393
the,0.0019590315577575085
proteomes,0.0016376991866283218
of,0.0028255105739555175
granulomas,0.0024185087661124497
from,0.0014822805759385149
subjects,0.001354514482286161
with,0.0012816933571985272
tuberculosis,0.0015544410528068016
in,0.0016802436819678475
an,0.0019337005733275107
unbiased,0.00151899077627455
manner.,0.0019896206366553457
Using,0.0036727254206062997
laser-capture,0.001957222314098118
"microdissection,",0.002490141971181652
mass,0.0016049661764954268
spectrometry,0.002152237585119898
and,0.0022930849196261694
confocal,0.001923089949045866
"microscopy,",0.002124322720449226
we,0.004929508602409722
generated,0.0029294924794753346
detailed,0.0026697493389225
molecular,0.0025229657633676376
maps,0.0021812318535426507
of,0.002567483902109259
human,0.0029292947087181573
granulomas.,0.002733695406018676
We,0.6082949728054139
found,0.7144901808630986
that,0.745982068876275
the,0.5587145431687255
centers,0.5415095117169018
of,0.5846150449209746
granulomas,0.571777627794139
have,0.6061686895178817
a,0.6518583460719527
pro-inflammatory,0.6844403731259301
environment,0.6300131442698038
that,0.7086634844887123
is,0.6624564050626637
characterized,0.6793629970854964
by,0.7033208840764187
the,0.6666806409212879
presence,0.6441197774681401
of,0.6590112882659405
antimicrobial,0.6732487788741488
"peptides,",0.45463377512923336
reactive,0.44843626406618114
oxygen,0.36882514102297514
species,0.5031936038211988
and,0.42924688330391425
pro-inflammatory,0.5180038992787871
eicosanoids.,0.5213035773367023
"Conversely,",0.3975577029315978
the,0.3527594118243076
tissue,0.36973471472530534
surrounding,0.31092457897695847
the,0.363334347323479
caseum,0.29378980784848646
has,0.3311970636411489
a,0.3665499567493523
comparatively,0.37773769136121255
anti-inflammatory,0.33456674935575287
signature.,0.32502978211185707
These,0.02474782336491663
findings,0.02128787584574051
are,0.01543729333851798
consistent,0.009588413711270487
across,0.013592292260870192
a,0.007960848199265486
set,0.007996368481666984
of,0.007445479137147433
six,0.009922243219003627
human,0.012946981117153237
subjects,0.012813690493079125
and,0.012485242519190884
in,0.016531938412329982
rabbits.,0.014611436931823847
Although,0.5849259540760188
the,0.2823406305245271
balance,0.3721724068090705
between,0.20215908396692286
systemic,0.3498872561442575
pro-,0.3656615279490278
and,0.32416947015253095
anti-inflammatory,0.3260562502011572
signals,0.3427618834609601
is,0.3426838067672945
crucial,0.3566849368322762
to,0.32086980396645093
TB,0.4065128757656677
disease,0.38526354423825976
"outcome,",0.3583006520416085
here,0.531488759497508
we,0.6201898093460771
find,0.5686682130989773
that,0.5531696946803986
these,0.33999574476105254
signals,0.38478363210966704
are,0.37398697911778794
physically,0.34723299585570666
segregated,0.3493043161461687
within,0.3234553180769429
each,0.3007264701092516
granuloma.,0.38657726256460373
From,0.1345028128701764
the,0.08611884049502927
protein,0.05607640106149418
and,0.04624652393136992
lipid,0.05907153086093326
snapshots,0.03487349959828889
of,0.04085371221843652
human,0.0727404420112892
and,0.040647335811948494
rabbit,0.05890542678387862
lesions,0.06934334517652141
analyzed,0.03948901198344872
"here,",0.06342820855898552
we,0.13274314723230032
hypothesize,0.21683351508872206
that,0.19089969441305643
the,0.107099394891386
pathologic,0.1560836901328415
response,0.1546886328267643
to,0.15583832422091778
TB,0.28300896298165734
is,0.121418849822501
shaped,0.11041617276046943
by,0.1402386193560583
the,0.11963579094578868
precise,0.12268046607628358
anatomical,0.12319290368217196
localization,0.19772186070317904
of,0.1404953571383439
these,0.20684111218878967
inflammatory,0.31962172405526135
pathways,0.2519475795799945
during,0.24266523371331844
the,0.20522417002508428
development,0.3070086738175721
of,0.23857966206698797
the,0.2814910050876437
granuloma.,0.35918709209559035
Importance,0.0017666951052400278
Although,0.0036296136327030664
non–vitamin,0.003025479619811647
K,0.004288294529524128
antagonist,0.0035493219229687082
oral,0.0027497813766230125
anticoagulants,0.0019384144371410593
(NOACs),0.002226900599666927
are,0.002112786951440746
increasingly,0.0025671603234148506
used,0.002603553014677199
to,0.0013974013953566482
prevent,0.0014069644732093026
thromboembolic,0.002464331273959759
"disease,",0.0011804340943240867
there,0.0008890903873187167
are,0.0009544115736083202
limited,0.0008794021479131095
data,0.0008201649687467535
on,0.0007373229797551949
NOAC-related,0.0008513635464471464
intracerebral,0.001046579897290937
hemorrhage,0.0013441563849065686
(ICH).,0.000744116518469736
Objective,0.0009030515601525258
To,0.0007297352002956475
assess,0.0006687383495901087
the,0.000689747438359361
association,0.0007798227905271083
between,0.0009079992419258555
preceding,0.0009622907160845857
oral,0.0005879097600141872
anticoagulant,0.0008959105229054444
use,0.0008619059035767658
"(warfarin,",0.0011720990590826752
"NOACs,",0.0007184310307500105
and,0.0011844675123239942
no,0.0009221120841835954
oral,0.0005753455239302064
anticoagulants,0.0008380103311976983
[OACs]),0.0010541721556933344
and,0.0011025880329421334
in-hospital,0.0006962616663618433
mortality,0.0005532854635243205
among,0.0007793044528379174
patients,0.000478006021863483
with,0.0007641946126394431
ICH.,0.0006132968055635827
"Design,",0.002198040915799286
"Setting,",0.0016610862059871809
and,0.0031999666979062127
Participants,0.002610126418297723
Retrospective,0.005514123707394186
cohort,0.007608018515733347
study,0.007117697378471954
of,0.007323516859923324
141,0.003264042401780279
311,0.003899977243620795
patients,0.0031272305445300772
with,0.003931767780880609
ICH,0.001441903052852422
admitted,0.0006682511273256595
from,0.0007339238709778486
October,0.000517928760160769
2013,0.0005524722097611026
to,0.0005731970280639471
December,0.00046279654510432785
2016,0.0005577701573261275
to,0.0007503473904606202
1662,0.0006352563259190155
Get,0.0005592620532334072
With,0.0009910423964986296
The,0.0008865464422683264
Guidelines–Stroke,0.0005787697228653363
hospitals.,0.0005372675452651065
Exposures,0.0006052151955042604
Anticoagulation,0.0007784392198382648
therapy,0.0006211974240825629
before,0.000834442173871696
"ICH,",0.0006093334167784065
defined,0.0004823987767174378
as,0.000659339325179384
any,0.0006904374978114781
use,0.0010555913995525408
of,0.0008243572074526526
OACs,0.0004965102901854856
within,0.0006677445315549248
7,0.0009353639873967984
days,0.0006536439034743934
prior,0.001020649821751085
to,0.0009361465635324897
hospital,0.0005768411039509991
arrival.,0.0006353156620813099
Main,0.0006670653762329497
Outcomes,0.0006596026691050501
and,0.000875654565728305
Measures,0.000581439859293416
In-hospital,0.0008317145984449195
mortality.,0.0009267840968291331
Results,0.04887323681236766
Among,0.2242721526540587
141,0.06165155000390384
311,0.07994817864323442
patients,0.10287859947986844
with,0.0939937223674469
ICH,0.03074556650990719
(mean,0.11760571637629647
[SD],0.05827160650673591
"age,",0.05792169102988058
68.3,0.05494551063761668
[15.3],0.09846240055923874
years;,0.06064864601602728
48.1%,0.09634943114213812
"women),",0.16299376050242023
15,0.11303622022290687
036,0.07742981027108167
(10.6%),0.20822362768898864
were,0.14309952028807124
taking,0.09018330172752487
warfarin,0.09808487039929085
and,0.167745322692338
4918,0.09696172286736247
(3.5%),0.20865328733033353
were,0.12428822978408371
taking,0.08254777649324635
NOACs,0.07393895708748378
preceding,0.10759421196584164
"ICH,",0.07015626342345062
and,0.06853070492588526
39,0.02913232456345752
585,0.04659677791966265
(28.0%),0.06306560732062741
and,0.05300250159259547
5783,0.04907262438837846
(4.1%),0.056941289796929834
were,0.05805493721170972
taking,0.05580737251327315
concomitant,0.04182538461813505
single,0.04191316717230908
and,0.05716115380001932
dual,0.037628427667545344
antiplatelet,0.03906059575485762
"agents,",0.04626294761908175
respectively.,0.04093765166352615
Patients,0.02828019812676761
with,0.030730202243922557
prior,0.04381700923294896
use,0.039472362428950414
of,0.0362310310170681
warfarin,0.02958006851635968
or,0.030077264910489572
NOACs,0.027601275278909057
were,0.03250097214981275
older,0.03665735272289684
and,0.09967311949300627
had,0.04511480389747365
higher,0.05191163699841952
prevalence,0.033767718112410784
of,0.04954593692270657
atrial,0.031443484399820865
fibrillation,0.04560802260500017
and,0.08235587874204212
prior,0.059217250196523324
stroke.,0.03241604495055882
Acute,0.015943429944551172
ICH,0.009958448206182404
stroke,0.013034287968058302
severity,0.00908794824198421
(measured,0.010198651913715445
by,0.006270253155274562
the,0.00665853415983858
National,0.0059513736758577155
Institutes,0.0038794888330615303
of,0.00513330742235555
Health,0.00444354645491466
Stroke,0.0067803621522580975
Scale),0.0080589433947854
was,0.014412679813060403
not,0.03388171003612921
significantly,0.016666211893054395
different,0.014774775410617717
across,0.02691954772902315
the,0.02835396358675312
3,0.03364125853267312
groups,0.022818159242203023
"(median,",0.047480932332519925
9,0.02228544266284071
[interquartile,0.04464222972713596
"range,",0.032453714366658906
2-21],0.0401071110003189
for,0.05819772237091456
"warfarin,",0.052547129799262765
8,0.03920823953553291
[2-20],0.04185553583816677
for,0.06479191621648671
"NOACs,",0.3050450698809527
and,0.34656761735238845
8,0.2711498800578979
[2-19],0.35550054623159544
for,0.3616036708735668
no,0.3317084999704701
OACs).,0.28693559482139497
The,0.5308754972088187
unadjusted,0.4929835634153607
in-hospital,0.5396218848376931
mortality,0.5356079654373744
rates,0.5497894394873165
were,0.5150520680598248
32.6%,0.5866535890776505
for,0.5378862769099467
"warfarin,",0.5082390933823949
26.5%,0.618767674019762
for,0.5205015678115972
"NOACs,",0.46710155596641767
and,0.5829400031834396
22.5%,0.5949311556675079
for,0.5211021310216754
no,0.5040577457700192
OACs.,0.4630189138415945
Compared,0.8255833704893276
with,0.7602455304036356
patients,0.8037067039440378
without,0.7459415415318833
prior,0.7748229978050624
use,0.7079188892906899
of,0.7455544308598606
"OACs,",0.6785097716431217
the,0.7211312918285997
risk,0.7624672060128532
of,0.8069168722870136
in-hospital,0.7681267849826657
mortality,0.749821208653757
was,0.691224545820275
higher,0.7442511916872393
among,0.762796427483691
patients,0.8061330436244172
with,0.7866165917247361
prior,0.8009584268195926
use,0.7679999996614
of,0.8044291723323248
warfarin,0.7194005972653311
(adjusted,0.7692641624032956
risk,0.8049820392368869
difference,0.802019484925221
"[ARD],",0.759529588801972
9.0%,0.8125288491417886
[97.5%,0.7733532550602757
"CI,",0.7943601722982409
7.9%,0.8282631388989647
to,0.7712088028273651
10.1%];,0.7876886758782806
adjusted,0.7811697760154012
odds,0.7958371392197171
ratio,0.6699650041803881
"[AOR],",0.650778444913712
1.62,0.6613607013584064
[97.5%,0.655934742672877
"CI,",0.6797947984993288
1.53,0.6982137497267379
to,0.6508980572253145
1.71]),0.634810113556517
and,0.674383736005689
higher,0.6675188978697622
among,0.6867412299577211
patients,0.7130110903668874
with,0.6795692262455836
prior,0.7353750440333299
use,0.7501574833590708
of,0.7753338549961825
NOACs,0.7073913890091504
"(ARD,",0.6925622576288322
3.3%,0.8003434928688281
[97.5%,0.7357537684189918
"CI,",0.7348263909688658
1.7%,0.7899975292014204
to,0.7484677159888332
4.8%];,0.8133578203180112
"AOR,",0.7065203068129654
1.21,0.7687190940829872
[97.5%,0.7310564281909258
"CI,",0.7300933954575571
1.11-1.32]).,0.7706268568315805
Compared,0.900219869009364
with,0.8445158535166858
patients,0.8683870078750978
with,0.8632332205353475
prior,0.8403031577037668
use,0.815261980777038
of,0.83828643596355
"warfarin,",0.7746554563121221
patients,0.8720305741042278
with,0.861208498379768
prior,0.8418691274123546
use,0.8205385041152647
of,0.8467687312705514
NOACs,0.7687452891083344
had,0.8741446021999075
a,0.8679843031487942
lower,0.8529505741569232
risk,0.8581134019963643
of,0.8927898448174288
in-hospital,0.8630841221532166
mortality,0.8142351420321121
"(ARD,",0.8470766766986284
−5.7%,0.8702726521536538
[97.5%,0.5435436797797266
"CI,",0.570939074017699
−7.3%,0.5895192708351292
to,0.5773348327612727
−4.2%];,0.6062119813602798
"AOR,",0.530915621260983
0.75,0.5511450736344008
[97.5%,0.5790558544058234
"CI,",0.5737943362964799
0.69,0.5474282402412
to,0.5623988380355098
0.81]).,0.5188071789426473
The,0.3276607571001783
difference,0.3720033015255351
in,0.3390251047306102
mortality,0.3830831640026319
between,0.3072332202167325
NOAC-treated,0.33851887244384127
patients,0.39943334146864656
and,0.27235608580205317
warfarin-treated,0.33351974930564315
patients,0.41131149816636536
was,0.27427341163101426
numerically,0.36925736209288806
greater,0.31271236325302243
among,0.36622954794144535
patients,0.4617290043359681
with,0.44018861899578116
prior,0.46083856118236716
use,0.42546881539932146
of,0.4408801258140959
dual,0.40859289323804876
antiplatelet,0.4206270152729184
agents,0.4347628079040228
(32.7%,0.4569986677866414
vs,0.4336762299752535
47.1%;,0.518148191172889
"ARD,",0.5228363400093254
−15.0%,0.4918184561441927
[95.5%,0.5747927141167851
"CI,",0.5813149307092467
−26.3%,0.5843485969948042
to,0.5647203286238935
−3.8%];,0.5788412033026179
"AOR,",0.5409631361833278
0.50,0.5066206373627087
[97.5%,0.6315570047199002
"CI,",0.6379601209523763
0.29,0.6042365293450415
to,0.6303768015454116
0.86]),0.5231725242898134
than,0.7201585886721504
among,0.673326981293279
those,0.6907869642427891
taking,0.6755676871694987
these,0.6291627778644794
agents,0.6548523813975534
without,0.6664994849118565
prior,0.6595273677074796
antiplatelet,0.6607006229630419
therapy,0.6783435533421287
(26.4%,0.6237124580500253
vs,0.6305182196133374
31.7%;,0.6520249619304082
"ARD,",0.6831152180831983
−5.0%,0.7158753679279012
[97.5%,0.6332466559616815
"CI,",0.6516824793133263
−6.8%,0.7078063297995222
to,0.6453458454866946
−3.2%];,0.6804867503454056
"AOR,",0.5473923652096017
0.77,0.5560059158296726
[97.5%,0.5393644665826807
"CI,",0.5498321944784342
0.70,0.5056217764406954
to,0.5486092278511394
"0.85]),",0.44140302464440545
although,0.4536264350204035
the,0.14917213154425313
interaction,0.21849689451882565
P,0.13347265231162356
value,0.20547441422044407
(.07),0.14574236561365
was,0.07140467067455268
not,0.042662568498109316
statistically,0.11814241581694981
significant.,0.036615211605154616
Conclusions,0.2243860580842867
and,0.16061658302784473
Relevance,0.22696431966868919
Among,0.3242143469658437
patients,0.31633929500271435
with,0.3083481115324497
"ICH,",0.3277754325727849
prior,0.31791678069118223
use,0.3144079208299522
of,0.33310761193375155
NOACs,0.534834880897453
or,0.6430518074192207
warfarin,0.596014312293077
was,0.6735286150095615
associated,0.7136667073775673
with,0.6955817211093015
higher,0.6747898489200416
in-hospital,0.6684607636945328
mortality,0.6057487861040719
compared,0.688419969689084
with,0.5711107793479944
no,0.6086780049298804
OACs.,0.5242782745718386
Prior,0.8324516811749555
use,0.781833705248721
of,0.7983664080424597
"NOACs,",0.6856324015751061
compared,0.8639264667013095
with,0.8170595298616852
prior,0.8164467732951134
use,0.7654429685151745
of,0.810592190484644
"warfarin,",0.7623915567724914
was,0.8305146806219257
associated,0.8539341805493041
with,0.8524373498007952
lower,0.7996498297351498
risk,0.7963983673965506
of,0.8563582235210919
in-hospital,0.7862766101274051
mortality.,0.7510576780311717
Viral,0.0035212275696250754
replication,0.003993506082191597
usually,0.0028766918769273773
requires,0.004116904824041568
that,0.0043770459820788666
innate,0.0026877987681478664
intracellular,0.0024451715112491796
lines,0.0020306063357569465
of,0.0020507630573172566
defence,0.0030830809753393676
be,0.0033448320941092797
"overcome,",0.002051153444244836
a,0.002262162133173372
task,0.0017818892631286808
usually,0.0013501470847336375
accomplished,0.0015098394178640964
by,0.0018069643611421987
specialized,0.002231466429434885
viral,0.002506719646269103
gene,0.0018671780299681134
products.,0.001478426850680159
The,0.19668201120298381
virion,0.14118750035448413
infectivity,0.12225542368266783
factor,0.19973292802023102
(Vif),0.10602445247898669
protein,0.18570065759646137
of,0.22023549277436774
human,0.1790600936113127
immunodeficiency,0.12100620378348033
virus,0.129151727246284
(HIV),0.07275182829313002
is,0.18858902579061385
required,0.24632326827753323
during,0.3226186868830534
the,0.29583403812994863
late,0.32208257865256146
stages,0.30415834561769123
of,0.3140705953102902
viral,0.21522279976251052
production,0.29524394503882473
to,0.25040928975688664
counter,0.2405580907340346
the,0.3354584782352968
antiviral,0.276676085421804
activity,0.29783083972003277
of,0.3456938584305764
APOBEC3G,0.26000322112050367
(apolipoprotein,0.29294245177651546
B,0.2882005317167194
mRNA-editing,0.3254619617419047
"enzyme,",0.3221476085447814
catalytic,0.2641305208186826
polypeptide-like,0.2850208358012363
3G;,0.2741916277267434
also,0.18926529246002158
known,0.21664664272450537
as,0.23422575488953085
"CEM15),",0.3308854106452207
a,0.2976589824706155
protein,0.28417609895006685
expressed,0.3296766869503136
notably,0.2728477447649117
in,0.34849018764823037
human,0.24046240974521366
T,0.2867197983337678
lymphocytes.,0.29230918970993575
When,0.30013467764331414
produced,0.261714956339193
in,0.24573228490198404
the,0.22794972527764032
presence,0.26584653777010037
of,0.27523077614708064
"APOBEC3G,",0.03765940482060202
vif-defective,0.04279459095933747
virus,0.03168749361577473
is,0.022873973462727393
non-infectious.,0.019094144271969014
APOBEC3G,0.28028055417429937
is,0.28623907740457794
closely,0.2741362477399609
related,0.25595657779474107
to,0.32698453512814796
"APOBEC1,",0.37438141596193664
the,0.465649755309516
central,0.4709554621610541
component,0.3891788279464407
of,0.4486343724360914
an,0.4458153863211518
RNA-editing,0.36454553535996786
complex,0.39720926458218475
that,0.4600132145591812
deaminates,0.5010282429341038
a,0.44214334365721664
cytosine,0.4628645800402871
residue,0.427394355863947
in,0.4743400464237582
apoB,0.44650581487020113
messenger,0.39271570230528857
RNA.,0.3175780124467249
APOBEC,0.014622130328158517
family,0.006085325929011619
members,0.006673767410272804
also,0.006680492773021217
have,0.0068077136594979016
potent,0.005663294608748752
DNA,0.00414274939078824
mutator,0.004379869855226334
activity,0.008698562986722303
through,0.007898163874257982
dC,0.008866589412435988
deamination;,0.004501982524649392
"however,",0.0031004219667327246
whether,0.0024681062591857595
the,0.002810328178059888
editing,0.0030535097884484518
potential,0.0031577730665625623
of,0.005023170499064641
APOBEC3G,0.00938425958502337
has,0.0017740462486897132
any,0.002593942824393886
relevance,0.002454558190205092
to,0.0026135001158036604
HIV,0.004440330728748329
inhibition,0.002596231690398476
is,0.002085887351163244
unknown.,0.0026080268854366943
"Here,",0.6089617714776359
we,0.671710353499439
demonstrate,0.5765019923961279
that,0.6470102413016215
it,0.4896565142218383
"does,",0.5187142424381542
as,0.6013716658659959
APOBEC3G,0.5073411851270226
exerts,0.5950130566015814
its,0.5546482577349411
antiviral,0.5758106424021466
effect,0.6079198484424957
during,0.6301120580470606
reverse,0.5910469727500287
transcription,0.5869517061218765
to,0.6018518713554406
trigger,0.6407129600958901
G-to-A,0.5853904432262096
hypermutation,0.548337863319131
in,0.5690401475998953
the,0.52837233337393
nascent,0.45855756028020045
retroviral,0.45858699059672486
DNA.,0.5185115140682311
We,0.5987269487361859
also,0.5342701879057987
find,0.6351506957627596
that,0.6557986141101422
APOBEC3G,0.5555226799010374
can,0.5205601352336436
act,0.5682298413353812
on,0.5259100768704358
a,0.5170125121553523
broad,0.42382587593902576
range,0.37608135012553967
of,0.4410253318748293
retroviruses,0.5118176358648764
in,0.5104879019459946
addition,0.5482377600523445
to,0.46935636411807796
"HIV,",0.3587207552835184
suggesting,0.4727607064987677
that,0.4137102691386682
hypermutation,0.4069247730944997
by,0.48787805716365346
editing,0.3808164013458619
is,0.2841644229321066
a,0.31107456073501416
general,0.2624883213418488
innate,0.3246020164424303
defence,0.3089941464670748
mechanism,0.3255315798877902
against,0.24156599264666642
this,0.2802467178657934
important,0.26579328453427437
group,0.21751834116397967
of,0.23158786639344914
pathogens.,0.2505243485674104
Stem,0.0976906187769309
cells,0.08834074625854378
are,0.044739367229133166
proposed,0.07315086701843229
to,0.06874777559433363
segregate,0.14486618051238281
chromosomes,0.10931528886779102
asymmetrically,0.13596345622410988
during,0.14039954786236092
self-renewing,0.16406607338573997
divisions,0.10391417650861577
so,0.2451884811046541
that,0.3069659463478753
older,0.30114599556748434
(‘immortal’),0.21859624661011257
DNA,0.2650400886544606
strands,0.26942086867860043
are,0.3717803629445105
retained,0.37083377326177586
in,0.2851638030925551
daughter,0.2982821314405867
stem,0.22180622033088684
cells,0.26105110113051627
whereas,0.41099276219911496
newly,0.29054405794147264
synthesized,0.2532026389287382
strands,0.23111244414549212
segregate,0.31045154363020006
to,0.27956838490971725
differentiating,0.2385405652818653
cells.,0.19184449982657173
Stem,0.08724906620310034
cells,0.09258512242209428
are,0.04674968722349059
also,0.0425918273425652
proposed,0.05796586185715154
to,0.049853774361777424
retain,0.10393950455916884
DNA,0.0841183688866701
"labels,",0.09727635037167157
such,0.05661158897964646
as,0.07844597007363487
5-bromo-2-deoxyuridine,0.1510668818035093
"(BrdU),",0.06128950346337664
either,0.09860461769195732
because,0.1624170728117066
they,0.14752593100725975
segregate,0.1647725875457081
chromosomes,0.1384339989608333
asymmetrically,0.19905680123401687
or,0.10965417594298835
because,0.2001329842700751
they,0.1381794358279964
divide,0.1586499975727393
slowly.,0.19424542300468142
"However,",0.016945718104321834
the,0.013980926598535136
purity,0.020187523396949215
of,0.01622613180974284
stem,0.023780712269432285
cells,0.025859514634876977
among,0.020352646434531337
BrdU-label-retaining,0.05973486223566559
cells,0.03311590198269721
has,0.008504211711276135
not,0.010322412547086613
been,0.006415476395493895
documented,0.0127239390959472
in,0.01698849874591738
any,0.045638517293826064
"tissue,",0.005001030379729382
and,0.0035322338567191996
the,0.002506437086866337
‘immortal,0.008133107429448042
strand,0.0028778239266457127
hypothesis’,0.00268123683436491
has,0.001448134648736526
not,0.001544212347864125
been,0.001338782131496759
tested,0.0011804965013263995
in,0.0012203633354975422
a,0.0019930274248334172
system,0.0013272355399876288
with,0.001314660395434491
definitive,0.0013567994104722776
stem,0.0012415833482577016
cell,0.00146775699837819
markers.,0.0012806567477677583
Here,0.0024368468505700422
we,0.002809600655067392
tested,0.001579730163391787
these,0.0020391217678267237
hypotheses,0.0014067179535393924
in,0.0014622853980917245
haematopoietic,0.0013931386833081092
stem,0.0013530356407651435
cells,0.0014031472593722038
"(HSCs),",0.0012842255541769575
which,0.001374388829674946
can,0.001228033343708975
be,0.0013311466294368937
highly,0.0012053714887331937
purified,0.001235232823217507
using,0.001179011715322804
well,0.0012651122092703672
characterized,0.0013236586184248017
markers.,0.0012378354495956514
We,0.2547156280705788
administered,0.23344415575918037
BrdU,0.23783396700367648
to,0.2572610247082365
newborn,0.28060313266821935
"mice,",0.2358656287678965
mice,0.24735727858733497
treated,0.20395745012003527
with,0.21629261556952345
cyclophosphamide,0.30202639573354206
and,0.27353729305986885
granulocyte,0.28125748119049143
colony-stimulating,0.3527136054688672
"factor,",0.3086256296545213
and,0.1704971926027963
normal,0.2392545055351141
adult,0.2850716715060452
mice,0.2515605124858181
for,0.18899373342544784
4,0.20644517317839167
to,0.22004630768807337
10,0.1637003148178112
"days,",0.20204696361075186
followed,0.19321996437724417
by,0.19534705398517868
70,0.18744650175018637
days,0.20253253461133766
without,0.1956308579322028
BrdU.,0.2673894781856644
In,0.3513672506620872
each,0.2780153014965641
"case,",0.2661038962925461
less,0.34920885233723825
than,0.3291396094067716
6%,0.30508516772814503
of,0.3804195400098081
HSCs,0.22978010922746403
retained,0.6287539653365007
BrdU,0.6037262746952875
and,0.6748212404960567
less,0.6288269294435295
than,0.598182650032787
0.5%,0.5762209878203381
of,0.6121182123638176
all,0.5735314150383358
BrdU-retaining,0.5906062416116284
haematopoietic,0.5957343874235548
cells,0.6182868576089162
were,0.6534358246241493
"HSCs,",0.5758795986360636
revealing,0.6537464036129034
that,0.6009051433085963
BrdU,0.5558515023535356
has,0.5654308329387503
poor,0.5424431580875284
specificity,0.5106486657738878
and,0.6898324115069134
poor,0.5363073716878237
sensitivity,0.5097585168172699
as,0.6002842239649955
an,0.5798484166477639
HSC,0.47891979165114845
marker.,0.546089094275582
Sequential,0.04512460852772592
administration,0.04876217402707165
of,0.05348118754545727
5-chloro-2-deoxyuridine,0.10326018157618395
and,0.04397624025487194
5-iodo-2-deoxyuridine,0.07616145950397976
indicated,0.04719717674866812
that,0.04448954160664909
all,0.02993393179990519
HSCs,0.04009158341091357
segregate,0.03997940016123248
their,0.03162943451847411
chromosomes,0.029428390704183783
randomly.,0.025907413211988545
Division,0.018511513817671153
of,0.010713775768225822
individual,0.008746736037469243
HSCs,0.02084681936322469
in,0.012609248823853244
culture,0.014310404388524862
revealed,0.022918490171022203
no,0.015025767350891728
asymmetric,0.011486555741562082
segregation,0.013445141361855045
of,0.010326992575972431
the,0.012352834974300205
label.,0.011601583638840703
"Thus,",0.04166975066738381
HSCs,0.04759475057839388
cannot,0.020331489034011063
be,0.014281907073557719
identified,0.017320775058003154
on,0.020895500086251975
the,0.019941225677126653
basis,0.032276213445993046
of,0.658897590151898
BrdU-label,0.5836234283850703
retention,0.5764946373174373
and,0.6899579402947525
do,0.6383092061698357
not,0.6882755311971271
retain,0.5601418613591947
older,0.5726893513235083
DNA,0.5145653019937639
strands,0.5359122815953458
during,0.6546917855919919
"division,",0.4769137480542515
indicating,0.4982281315271677
that,0.4815897259183431
these,0.4410669094709361
are,0.3446486863524577
not,0.3997219365174957
general,0.3042619537993477
properties,0.3444433256575436
of,0.3349575664820864
stem,0.4337480885820368
cells.,0.3823210331625096
In,0.028696951936597655
the,0.011145915958272148
mammalian,0.011139836928074782
model,0.010232981081325192
of,0.007483725474354724
sex,0.008954064199178475
"determination,",0.012646018930308308
embryos,0.018034684978348148
are,0.017962928865259995
considered,0.02135199717167469
to,0.01932825386130772
be,0.026971448311290433
sexually,0.02234842618178527
indifferent,0.027936433626789835
until,0.016999292152295033
the,0.01925562519335425
transient,0.008837268920997277
action,0.01703540935873787
of,0.01570045864991058
a,0.011871895228260515
sex-determining,0.004952940836262831
gene,0.021879220745450883
initiates,0.013333344112604414
gonadal,0.004249034260608302
differentiation.,0.012959555338126554
Although,0.002032531153639322
this,0.0020171767303335617
model,0.0018994649818211183
is,0.0020316787307487674
thought,0.001438164424117981
to,0.0015271785064361306
apply,0.0018288188976273046
to,0.0021528654240848396
all,0.001906253557922824
"vertebrates,",0.0020259830078686084
this,0.001669707496583412
has,0.0015192634512640924
yet,0.0014979811107617039
to,0.001162609506301399
be,0.001680558854898064
established.,0.0013835225278671511
Here,0.18539002115650605
we,0.15355815953061078
have,0.08116893353309226
examined,0.07814380867543583
three,0.09063464013050343
lateral,0.08580947449345341
gynandromorph,0.12601264431094303
chickens,0.12220830491065984
(a,0.14762097562496118
"rare,",0.07803277558347634
naturally,0.07544753745334185
occurring,0.07451665853501693
phenomenon,0.1215765373833771
in,0.13979518103946043
which,0.12015774305007834
one,0.1779914966837978
side,0.17029972367686047
of,0.16097693075812602
the,0.12269980935480457
animal,0.11706631352417021
appears,0.1807189998722984
male,0.16343536005058162
and,0.2234437269605269
the,0.1529991826222024
other,0.2023079350150733
female),0.1361692559031084
to,0.0427754578028034
investigate,0.04432036274629772
the,0.04250856670836935
sex-determining,0.07620403785537413
mechanism,0.06226315325599383
in,0.06117084267253064
birds.,0.1089664521340491
These,0.23904949190460284
studies,0.2317713005038918
demonstrated,0.3517340116348741
that,0.28022694685761085
gynandromorph,0.3046008935692239
birds,0.29184208645362586
are,0.2817035520561179
genuine,0.3302905266281149
male:female,0.4319195214315963
"chimaeras,",0.4447110798548602
and,0.43181719452819806
indicated,0.43270473672860016
that,0.41716879941309665
male,0.45457810512767144
and,0.413410629736839
female,0.41742896491930037
avian,0.45024596431906017
somatic,0.46560048298852363
cells,0.4111794171522194
may,0.311363722448806
have,0.33056624249875427
an,0.3263650556633735
inherent,0.3074137251608645
sex,0.2535288786627958
identity.,0.28891656199219234
To,0.06801605355112837
test,0.041151953147839156
this,0.06167393240040674
"hypothesis,",0.051758326952400915
we,0.1150680287025333
transplanted,0.12881736103210784
presumptive,0.11358064186200817
mesoderm,0.14420125408784132
between,0.1227451785086688
embryos,0.1567389950677426
of,0.12718261345812606
reciprocal,0.17192561224702493
sexes,0.14807095613157192
to,0.12418961582686068
generate,0.1373561964579794
embryos,0.12824820852532048
containing,0.11632162124321287
male:female,0.13464125812728542
chimaeric,0.13174929747139932
gonads.,0.13934605510083878
In,0.08365196268697048
contrast,0.15230863083185076
to,0.13581717663365112
the,0.10474786305165251
outcome,0.10452764698755566
for,0.11585782992473287
mammalian,0.07557368006327043
mixed-sex,0.07115544752049666
"chimaeras,",0.13569295028419523
in,0.14518085230637537
chicken,0.11215280080175152
mixed-sex,0.07011634138617831
chimaeras,0.1423394655585087
the,0.12158514382717331
donor,0.11008638030252986
cells,0.12617964703598997
were,0.1224233249533026
excluded,0.09615821025052165
from,0.1001535664039264
the,0.09496676157371244
functional,0.09356107262728093
structures,0.09363626123505386
of,0.10341445795910564
the,0.108722259544368
host,0.14206305279114126
gonad.,0.1133737358554058
In,0.3790779497406493
an,0.3520374140200392
example,0.2840475938151031
where,0.40311626754612806
female,0.32121237128896896
tissue,0.35499663003563847
was,0.3062557831606697
transplanted,0.30659023450685163
into,0.37197550399793405
a,0.28460776273242633
male,0.29500770023481804
"host,",0.3335219497079589
donor,0.5777647690404307
cells,0.6474870137822084
contributing,0.6569759838336532
to,0.6942710114239581
the,0.6914312686313504
developing,0.6569875691987445
testis,0.6103604089290237
retained,0.6667906795715315
a,0.6887371747455784
female,0.5967806975179378
identity,0.6255768732003868
and,0.6740174824824343
expressed,0.6541228315262347
a,0.6667233222083544
marker,0.5923082519158034
of,0.634658003669008
female,0.5563071919256317
function.,0.5923416483995428
Our,0.6860158157772226
study,0.6630337610487714
demonstrates,0.6602142679286794
that,0.7682209042974195
avian,0.7576858084491197
somatic,0.7372125016942483
cells,0.6882432461811313
possess,0.7426184542218207
an,0.7575636329763608
inherent,0.7031631817675296
sex,0.6601001288122593
identity,0.6638745371149092
and,0.7763759584418608
"that,",0.7661029805976549
in,0.7390724827992625
"birds,",0.6718880849816847
sexual,0.6682776460148275
differentiation,0.6840236895736329
is,0.6670882431107081
substantively,0.6328743340145372
cell,0.6513083815623163
autonomous.,0.633232972147294
The,0.01716820243616562
bacterial,0.02062987653572092
type,0.012136371965783623
VI,0.010680563940629039
secretion,0.015134971011735613
system,0.020757977020913688
(T6SS),0.014060661982225399
is,0.011950367806770928
a,0.013835227753870801
large,0.012278985059101433
"multicomponent,",0.009710892767598364
dynamic,0.009274914054009459
macromolecular,0.010808232458660855
machine,0.016221283883658132
that,0.017116872785255435
has,0.006783363684677133
an,0.007778957183470775
important,0.011418995604192104
role,0.009951441054403471
in,0.009129598567777491
the,0.013243799265153632
ecology,0.00918961616473362
of,0.010309253725170732
many,0.009325462563152535
Gram-negative,0.00653841611109568
bacteria.,0.011369338421460049
T6SS,0.053807010946342916
is,0.05046382810758733
responsible,0.06719195787483317
for,0.0944421460410524
translocation,0.0682632620036647
of,0.0677497577057005
a,0.04190480982823636
wide,0.031791079794749426
range,0.03612820170951437
of,0.056592294976639645
toxic,0.03879961476434274
effector,0.05666601595578791
"molecules,",0.07210647846969698
allowing,0.11107412279055026
predatory,0.055594880893226076
cells,0.08363025358242039
to,0.09816577553810732
kill,0.07054399333869336
both,0.18509293880305677
prokaryotic,0.10169075193074693
as,0.15082802342071244
well,0.12546969045376222
as,0.0772006800895194
eukaryotic,0.07930093496217552
prey,0.047179591096752266
cells.,0.07267231947387766
The,0.23946658700722917
T6SS,0.24976259540391685
organelle,0.21712162046618289
is,0.24963583990721516
functionally,0.18231924338458905
analogous,0.18976901668174428
to,0.24155471217892785
contractile,0.260654140461805
tails,0.2297108260940872
of,0.2254161787326698
bacteriophages,0.22360296269761668
and,0.3637036676502546
is,0.19365151304815267
thought,0.20632427253742663
to,0.23684177819430538
attack,0.27706173742847545
cells,0.2572881374511888
by,0.40300043157848103
initially,0.42498938485569704
penetrating,0.3467675798615347
them,0.2899125049389783
with,0.3497769497146323
a,0.3178186427096524
trimeric,0.32606377162172234
protein,0.3154577804806707
complex,0.3477151191494413
called,0.2670400294224177
the,0.3197474216883346
VgrG,0.07048799085058345
spike.,0.04407180965113072
Neither,0.007171272914985032
the,0.005320660095492982
exact,0.005405436050205798
protein,0.008403078452085681
composition,0.009338478080172925
of,0.008341077642878269
the,0.014491277671300531
T6SS,0.03652374825247693
organelle,0.009849005317861767
nor,0.007179661752144089
the,0.004866611337441223
mechanisms,0.008542347555325257
of,0.007977093371419134
effector,0.010336641572955961
selection,0.010782514998009956
and,0.008497949843211755
delivery,0.010615131586016183
are,0.0039505849465124015
known.,0.004641312874951828
Here,0.6375209271258853
we,0.715399057579708
report,0.7398327697761148
that,0.8021005528878526
proteins,0.6324648675505646
from,0.6630931483825765
the,0.6634616713893434
PAAR,0.6336666520356039
(proline-alanine-alanine-arginine),0.6414527036565438
repeat,0.6675546270873325
superfamily,0.6183313739842712
form,0.6786226949708523
a,0.6881145483386067
sharp,0.6250664161513636
conical,0.6521557777962349
extension,0.6297815421466256
on,0.6641640071668057
the,0.6719998910092063
VgrG,0.7055469176056851
"spike,",0.6576984714554206
which,0.7122543198827274
is,0.7126687602485317
further,0.7104350965163373
involved,0.7081467528519427
in,0.7562314551082927
attaching,0.6540198841066561
effector,0.6203707199829713
domains,0.6469525047854701
to,0.5809664794170228
the,0.5924410780608474
spike.,0.5494779480340647
The,0.14084734461005533
crystal,0.054434784910401796
structures,0.05460402723397905
of,0.07877760596415784
two,0.10538256715860204
PAAR-repeat,0.14491867261362038
proteins,0.10638975035942645
bound,0.08790248408322018
to,0.11015182681436023
VgrG-like,0.2537764876551538
partners,0.09194654058385691
show,0.13939884659678095
that,0.17796503499750835
these,0.11431685742826297
proteins,0.10082865817751548
sharpen,0.10901645185791196
the,0.07445191826302837
tip,0.08634976888373695
of,0.10601018827917683
the,0.09460144257455004
T6SS,0.1465334083069984
spike,0.13065559406742772
complex.,0.10054152947683002
We,0.5660038342799172
demonstrate,0.4904081390216498
that,0.5155840761081111
PAAR,0.31970836077230685
proteins,0.3104801451070823
are,0.29748272912705354
essential,0.36059075478153724
for,0.38129261174191115
T6SS-mediated,0.33132928280297086
secretion,0.3290649507635279
and,0.3570014629675037
target,0.24333883654861885
cell,0.34120717952571367
killing,0.31930181994797735
by,0.32306248414321137
Vibrio,0.4032244188647054
cholerae,0.3798025958467913
and,0.38064951129691454
Acinetobacter,0.27589057048393023
baylyi.,0.3067215143536013
Our,0.2658199103014572
results,0.20254117010611644
indicate,0.2508668740837526
a,0.18488510854119425
new,0.14632734420160964
model,0.14638080391691494
of,0.16318584844884734
the,0.1378856183040087
T6SS,0.16111888577134229
organelle,0.13207383057854707
in,0.20594908642341286
which,0.18188804820788965
the,0.16721225276709487
VgrG-PAAR,0.30634508282996914
spike,0.2325269254871013
complex,0.20862508229105672
is,0.1350578730324252
decorated,0.16121308427944728
with,0.17415153717904663
multiple,0.16075239482099793
effectors,0.2152638622532648
that,0.16341521573291928
are,0.14322544662747044
delivered,0.2203972541665283
simultaneously,0.18222845255300057
into,0.3078181972494536
target,0.16102666430780752
cells,0.2572424096256363
in,0.26581026131769103
a,0.20617186445524033
single,0.12787295732096243
contraction-driven,0.19454853258703259
translocation,0.2249450824468087
event.,0.28805509999814916
Improved,0.004325167553353612
sequencing,0.0017563737980136969
technologies,0.0020536888585396687
offer,0.002905611638715375
unprecedented,0.0019846752941536875
opportunities,0.0014109049186756544
for,0.0022805507242089104
investigating,0.0014309900666102182
the,0.0009913809481673938
role,0.000893266858819089
of,0.0012253135739004157
rare,0.0013537555203169394
genetic,0.0010925870132342836
variation,0.0013499336484664548
in,0.0016665251698533227
common,0.0013249381836902296
disease.,0.0012134330217737571
"However,",0.001574928263204632
there,0.0020017084822910526
are,0.0017613057697976517
considerable,0.0016919448756353066
challenges,0.0010279153443064272
with,0.0017826828903625437
respect,0.0016219270412691656
to,0.0013302844938931785
study,0.0010281484414393575
"design,",0.000949175735408411
data,0.0009165394259586789
analysis,0.001011903291628566
and,0.0012584326114184288
replication.,0.0007930730668081079
Using,0.020090479725152457
pooled,0.0040859037351553724
next-generation,0.0070141961789762074
sequencing,0.007106385384519942
of,0.007769515180412687
507,0.004884082210456033
genes,0.011147766063224134
implicated,0.012044632191037546
in,0.013326301298715502
the,0.005927964793780484
repair,0.009600069703083318
of,0.008878579980795802
DNA,0.00565453023225519
in,0.008201565342642034
"1,150",0.0035408694040588843
"samples,",0.00619296667982236
an,0.010713871794511692
analytical,0.006914628518718551
strategy,0.007758432510888066
focused,0.0065885200431096795
on,0.006325105725137617
protein-truncating,0.011417948692176026
variants,0.006745007112238734
(PTVs),0.0027170578130601584
and,0.007407994792061161
a,0.010496854330961395
large-scale,0.007037431014450146
sequencing,0.009048617370340028
case–control,0.006204180159092071
replication,0.01037968765872562
experiment,0.01487403868682007
in,0.01298473689079798
"13,642",0.00739850243162826
"individuals,",0.017316713401037798
here,0.10440805826922
we,0.2340149154715166
show,0.31949973951480165
that,0.3646903585132232
rare,0.0776353848723745
PTVs,0.07257742703561958
in,0.40014155315162625
the,0.3002903829449152
p53-inducible,0.17651932040071028
protein,0.2645134584170925
phosphatase,0.042588726076166296
PPM1D,0.0524626744188901
are,0.02938360510131959
associated,0.03300242401399284
with,0.03533090761832153
predisposition,0.016483497614298685
to,0.026347220187338923
breast,0.02775214103972348
cancer,0.01801228267834449
and,0.028538159253871005
ovarian,0.017788592536630978
cancer.,0.02075553217608133
PPM1D,0.16600667047872616
PTV,0.16045499196477725
mutations,0.11557621444632835
were,0.10598990495833337
present,0.1047267423243547
in,0.10802803460382987
25,0.06294687442152085
out,0.09859273014561919
of,0.09479283825114032
"7,781",0.05581319573508035
cases,0.10926415950526198
versus,0.09337251800011144
1,0.05989927282150782
out,0.08763873496699962
of,0.07853629444122108
"5,861",0.05503258389662725
controls,0.10682107218101412
(P,0.07902683538137721
=,0.143670329246597
1.12,0.05873552933355383
×,0.08317516181766023
"10−5),",0.050487098891309895
including,0.07967496375690744
18,0.07036439972011412
mutations,0.08584425917124083
in,0.08770761207897
"6,912",0.04931337224713127
individuals,0.11490476600342588
with,0.08588474669549669
breast,0.1333945242683649
cancer,0.10268391075557236
(P,0.09563197661478688
=,0.1821730642688121
2.42,0.10748226213924056
×,0.11090769364578677
10−4),0.05936943730989363
and,0.08630409113175525
12,0.04882803881542432
mutations,0.08319613611903451
in,0.08713367617337177
"1,121",0.042645024782060725
individuals,0.08654166986565973
with,0.08384914109077929
ovarian,0.08419922032505306
cancer,0.09143768628781503
(P,0.08396986969870428
=,0.1640942534576981
3.10,0.10468396467676185
×,0.1241858816717161
10−9).,0.07017742634464595
"Notably,",0.11416291949362253
all,0.11079211352720701
of,0.11731065162903749
the,0.14102801907993756
identified,0.11085957825762356
PPM1D,0.20083675554701078
PTVs,0.2057476516505247
were,0.12379810709371052
mosaic,0.08217695600574415
in,0.2030089941329523
lymphocyte,0.2542557399714028
DNA,0.17372388417984208
and,0.22086582755618625
clustered,0.16325513459519986
within,0.17983911519318166
a,0.19700168392973147
370-base-pair,0.19117598241964698
region,0.1899988709400516
in,0.2029642890825679
the,0.16183221563388306
final,0.1599259503793612
exon,0.18119807592721976
of,0.1605494389285476
the,0.15241316646822398
"gene,",0.1853755111337639
carboxy-terminal,0.17249837363683787
to,0.1886084540624673
the,0.16008136401128167
phosphatase,0.2046825567996994
catalytic,0.12588132825826173
domain.,0.18726859375302404
Functional,0.5152174682731001
studies,0.6052698073716033
demonstrate,0.6318613252004645
that,0.6978251590023473
the,0.5606131384828582
mutations,0.5663383021187316
result,0.7441022571074098
in,0.7988748088318302
enhanced,0.795409716858874
suppression,0.7925338954904839
of,0.8073505440905888
p53,0.7107121628393864
in,0.7905638650300402
response,0.7060881126795653
to,0.6927732307343787
ionizing,0.663633276775499
radiation,0.6369963527128087
"exposure,",0.6474129705191795
suggesting,0.5456585734354685
that,0.5257241882078633
the,0.4876483816569775
mutant,0.48045754417887937
alleles,0.38738659416554
encode,0.35912388284762886
hyperactive,0.4987512692083411
PPM1D,0.49582600126983234
isoforms.,0.42908901745517664
"Thus,",0.5409328547377767
although,0.5423209404694019
the,0.2875098189956931
mutations,0.36475517417463094
cause,0.4154674977721913
premature,0.481447192015612
protein,0.3140236325589299
"truncation,",0.358945506877703
they,0.2961363294349303
do,0.32977687454777277
not,0.47583161395912044
result,0.4123980788600861
in,0.5024651797039508
the,0.3810480535248678
simple,0.3755852550959464
loss-of-function,0.31285839189914655
effect,0.38039289980781194
typically,0.22858350567389454
associated,0.3026785306120341
with,0.23502346369206184
this,0.2420892848659116
class,0.17999289478062397
of,0.25530873748453947
"variant,",0.26470117988852526
but,0.5271179734074544
instead,0.47609100473456456
probably,0.3301485222953548
have,0.3521640657584161
a,0.373662903325786
gain-of-function,0.24326946115492212
effect.,0.2032981339488699
Our,0.08330604108096692
results,0.06959931711219194
have,0.023468210727337496
implications,0.01427092728171857
for,0.018866749816559256
the,0.021089285279765283
detection,0.025419664193853598
and,0.017549715261972434
management,0.01341870031121049
of,0.01878660589252515
breast,0.036728782553208425
and,0.029148469093548696
ovarian,0.03068226783766953
cancer,0.02997075385587969
risk.,0.022007829585054026
More,0.04407951438817788
"generally,",0.047246450797340786
these,0.05539321752684635
data,0.05023266213278399
provide,0.04186815877900263
new,0.032169581003103985
insights,0.030720978733814273
into,0.029447113205018128
the,0.02194437970868925
role,0.01987167981245825
of,0.02891918236642017
rare,0.041830673557448496
and,0.04056443968613591
of,0.031559445451062776
mosaic,0.041892602163530704
genetic,0.03607328392800473
variants,0.04134981670856626
in,0.026057217883002148
common,0.02333507733706696
"conditions,",0.023768355897959333
and,0.027278921732532824
the,0.018487941966700408
use,0.020689487711578015
of,0.018227957013820476
sequencing,0.02358152317860289
in,0.017190932767743538
their,0.023037314916773837
identification.,0.025157259937520455
The,0.13693967949304325
functional,0.078819790987851
heart,0.11638330183358406
is,0.07909136731584504
comprised,0.09156598817682085
of,0.10841363994305822
distinct,0.06994664134760346
mesoderm-derived,0.09496504541457595
lineages,0.1242513795008111
including,0.13605068517070204
"cardiomyocytes,",0.17302174860228353
endothelial,0.2339932538552149
cells,0.2102546099266207
and,0.11451507777517284
vascular,0.14783823250685937
smooth,0.1466629358185763
muscle,0.15138158073774907
cells.,0.15275802704214267
Studies,0.33061092529816
in,0.18310101691274908
the,0.202152710171992
mouse,0.24471860159570746
embryo,0.2934008923046116
and,0.19041831678792936
the,0.12079556468988291
mouse,0.2278561074031979
embryonic,0.26160509497265916
stem,0.13335509588508782
cell,0.22526093612919426
differentiation,0.24803655511698652
model,0.19472783004322006
have,0.25838384586636104
provided,0.2192067734444539
evidence,0.3755985514014711
indicating,0.3644646485741194
that,0.4398894751303123
these,0.33742012810814237
three,0.292781779251549
lineages,0.41685410308622745
develop,0.4176916047041431
from,0.4936290516037392
a,0.4504111134292901
common,0.4229790327193934
Flk-1+,0.4985921122089566
(kinase,0.44942733702716575
insert,0.4790947285341704
domain,0.5093301375984065
protein,0.47078948081022
"receptor,",0.48174974461226283
also,0.32306974800956423
known,0.34597530097430546
as,0.3924927063965073
Kdr),0.44818141072899714
cardiovascular,0.5369591530110275
progenitor,0.5084739892566488
that,0.4503000857670698
represents,0.4325893822552925
one,0.4917174061730149
of,0.5229620934101542
the,0.4463690306195781
earliest,0.48415631118916835
stages,0.49327252056101617
in,0.4503488184839969
mesoderm,0.38986488972079336
specification,0.4675772886245408
to,0.3890032805186539
the,0.3430683713733829
cardiovascular,0.38399343384882706
lineages.,0.3743111745501193
To,0.06711274886596451
determine,0.02519964498114729
whether,0.019730122856529225
a,0.03836597436481342
comparable,0.05189569253017384
progenitor,0.08862219209328569
is,0.024006611892774393
present,0.07095753401869206
during,0.07492654916463523
human,0.07955382439889754
"cardiogenesis,",0.012871223283244013
we,0.013171097663989316
analysed,0.00346797943677065
the,0.006368870363499096
development,0.0053948741215502725
of,0.004884038177445146
the,0.006525010406960714
cardiovascular,0.006787761568622253
lineages,0.0039890495425426815
in,0.005295299027642976
human,0.005342432388326265
embryonic,0.005550619641567956
stem,0.003358770801677164
cell,0.005717372713483079
differentiation,0.0059125246506809715
cultures.,0.0037937590903842967
Here,0.5718434321269442
we,0.6659801075431578
show,0.6724426137569491
that,0.715175914379286
after,0.7125191206217648
induction,0.6005877198009515
with,0.6007351588192095
combinations,0.6208028543810237
of,0.5724893267435553
activin,0.5674532874472278
"A,",0.6478859886008338
bone,0.5633840884569088
morphogenetic,0.5864570758985667
protein,0.6008210765936088
4,0.5381746509078751
"(BMP4),",0.5255703293623695
basic,0.5924786446641133
fibroblast,0.6251739875697636
growth,0.6549769722312414
factor,0.6000441383464477
"(bFGF,",0.584157655014421
also,0.325605119147855
known,0.44286144296346797
as,0.38546217202343336
"FGF2),",0.5650495246029954
vascular,0.5661355911545582
endothelial,0.6401870685069572
growth,0.6498496649356658
factor,0.6186404615059137
"(VEGF,",0.5487432678966034
also,0.22304334420055116
known,0.30486816353827556
as,0.31862597095961626
VEGFA),0.5541745900864706
and,0.54327851597741
dickkopf,0.5174500599095289
homolog,0.6030264382122669
1,0.5661860231785005
(DKK1),0.5726349210311149
in,0.6364470449565853
serum-free,0.5509668187029384
"media,",0.5731216897559926
human,0.6513586394305853
embryonic-stem-cell-derived,0.36131065663690454
embryoid,0.35148404798333693
bodies,0.33936849483534726
generate,0.3323215525602523
a,0.317053700381189
KDRlow/C-KIT(CD117)neg,0.2638220443117221
population,0.39592602777275865
that,0.3239654529943534
displays,0.33530450106993603
"cardiac,",0.35713677893785917
endothelial,0.4653349950624516
and,0.3690992601939625
vascular,0.3296849524509157
smooth,0.3797221638278881
muscle,0.3363829823680472
potential,0.36089221735923566
in,0.4511863821625935
vitro,0.37339307317069875
"and,",0.29905830888440715
after,0.324606635805524
"transplantation,",0.31764079877684565
in,0.3918697487192089
vivo.,0.32149501954455223
When,0.0933946915056014
plated,0.05419288207111092
in,0.08403124285856078
monolayer,0.04109664835021078
"cultures,",0.0640539323845621
these,0.14915722908848256
KDRlow/C-KITneg,0.13219728808930187
cells,0.11000066512811438
differentiate,0.06772597675108596
to,0.059119925132003405
generate,0.06894641075648052
populations,0.07163201544462999
consisting,0.05530059971163622
of,0.05911120598530888
greater,0.05621869628014128
than,0.05221494977446757
50%,0.045678020527592296
contracting,0.06416192540876996
cardiomyocytes.,0.04426147044986544
Populations,0.11396489923412523
derived,0.09183696628192249
from,0.11206745269378961
the,0.107645994089994
KDRlow/C-KITneg,0.1670547432862051
fraction,0.14238167431449666
give,0.0983649999160186
rise,0.10498899154118996
to,0.10710781969342048
colonies,0.10515413446537478
that,0.07803682371809995
contain,0.0653472618132807
all,0.08879815328938581
three,0.09843675296772886
lineages,0.08035077379298322
when,0.15897420405154297
plated,0.20007733451463006
in,0.21555786885560868
methylcellulose,0.11725853301663237
cultures.,0.18953249927488441
Results,0.07215659945808671
from,0.05814711797764468
limiting,0.061088857661268176
dilution,0.03478830327638579
studies,0.08625610982236188
and,0.06426899112742814
cell-mixing,0.07474278343318974
experiments,0.07799546803872444
support,0.043078148212030036
the,0.050483515911716424
interpretation,0.08346332143493804
that,0.10674117482392059
these,0.1373432937382446
colonies,0.13108628487287358
are,0.09689931122883123
"clones,",0.09858895860622212
indicating,0.10805006819588246
that,0.11479549715555286
they,0.14190678133886325
develop,0.18671545561612996
from,0.20254390425535898
a,0.16322304071209665
cardiovascular,0.14954114266836255
colony-forming,0.2044451661483096
cell.,0.2122826226938319
"Together,",0.19281140100751873
these,0.2066806032399149
findings,0.19504296412770003
identify,0.18889814469480082
a,0.22316783566917628
human,0.19104688291109562
cardiovascular,0.18599927333709146
progenitor,0.253404589911168
that,0.19678952860080323
defines,0.18340522675836943
one,0.2587715851730567
of,0.2568684155761996
the,0.2289320606488515
earliest,0.22691637457573086
stages,0.19841479143482452
of,0.20419817789297437
human,0.1754939978424002
cardiac,0.16954082195076775
development.,0.21763328006641502
Brain-derived,0.11046400247325833
neurotrophic,0.1027031562066803
factor,0.08794628245428616
(BDNF),0.055798943360310514
and,0.07589652253726294
its,0.05387584030648061
receptor,0.09919355156064899
TrkB,0.12420642720124024
are,0.054009137377921
crucial,0.07636458861736517
for,0.07053911614847126
many,0.04829692720855438
forms,0.03576997442552636
of,0.03733102125535943
neuronal,0.05000399430213594
"plasticity,",0.04647227540209006
including,0.04068879815516402
structural,0.04067934871443048
long-term,0.03915812681545209
potentiation,0.04215120432469428
"(sLTP),",0.028779541589473448
which,0.046489684254716244
is,0.03517477610319601
a,0.04040917177810068
correlate,0.02990506874053881
of,0.0368455435436426
an,0.03642067178757161
animal’s,0.03805746118137828
learning.,0.04688985938692611
"However,",0.004434947208400194
it,0.0036395885657189166
is,0.0037996611701119707
unknown,0.004022076064163406
whether,0.004443355555322901
BDNF,0.01159988734994664
release,0.017750493705027667
and,0.010074657364339937
TrkB,0.02464657710055653
activation,0.012541060981841533
occur,0.0062664408461882105
during,0.009857102139973742
"sLTP,",0.011823840538723155
and,0.004360733867378645
if,0.002766186001678834
"so,",0.003911743745059879
when,0.005449941579345523
and,0.004862937486606628
where.,0.004423035196097172
"Here,",0.2077331361468909
using,0.12011694750043794
a,0.09893179199784091
fluorescence,0.07641603742734515
resonance,0.08645335353582946
energy,0.0721479644224356
transfer-based,0.08749895251832916
sensor,0.08394987328894299
for,0.11265293828716917
TrkB,0.12294692166045151
and,0.08919619988763733
two-photon,0.07307833665935352
fluorescence,0.07149942212513294
lifetime,0.1019943014115452
imaging,0.09234570842933218
"microscopy,",0.07073388281128808
we,0.15745252108770033
monitor,0.09947144189084973
TrkB,0.16338006575067565
activity,0.1477417663687944
in,0.0772376987850712
single,0.08849666121675225
dendritic,0.3213650402077027
spines,0.26270136511994235
of,0.3213976689467146
CA1,0.26967251587267643
pyramidal,0.2106320209814245
neurons,0.27100247859316123
in,0.2856004304640059
cultured,0.23165198093881018
murine,0.2060122664311122
hippocampal,0.24618240958264587
slices.,0.21397730775836485
In,0.7553505773622867
response,0.7172102377793266
to,0.7054973588396408
sLTP,0.6180663476993151
"induction,",0.6823435431695086
we,0.7212328605061562
find,0.7587198503973928
fast,0.7741902172747612
(onset,0.7229182647657565
<,0.615416636917345
1,0.6391628629023226
min),0.6959634014856111
and,0.7152833962869084
sustained,0.7531124886113505
(>20,0.7081535897309537
min),0.7243727697228171
activation,0.741154198255413
of,0.7689593069284877
TrkB,0.7384057392762698
in,0.7886815310995798
the,0.7865258550960649
stimulated,0.8075540826490207
spine,0.7631660216626622
that,0.7604594748985479
depends,0.7350927619567325
on,0.6557206452322655
NMDAR,0.6839706041465433
(N-methyl-d-aspartate,0.6689102264202257
receptor),0.6654017936306987
and,0.708461108720694
CaMKII,0.6284096735263173
signalling,0.6953173886345847
and,0.5661959363010909
on,0.5994332916783455
postsynaptically,0.629373788516747
synthesized,0.5788720552240573
BDNF.,0.5976765916292484
We,0.20495051115866628
confirm,0.17299282169378954
the,0.11975390682892004
presence,0.11428672872246187
of,0.1335197642441003
postsynaptic,0.17029761818698644
BDNF,0.15218614194526983
using,0.174007823079813
electron,0.1324827926330673
microscopy,0.1434063560445349
to,0.14897689331615893
localize,0.15077056292572122
endogenous,0.15519598513667637
BDNF,0.15638694766340128
to,0.5024834946451686
dendrites,0.46652233727839937
and,0.4617772659360544
spines,0.4208408924029346
of,0.473618435161491
hippocampal,0.4976476455442591
CA1,0.47204874326899326
pyramidal,0.40735831271142187
neurons.,0.4565583029591034
Consistent,0.3703714202582573
with,0.3982596542992793
these,0.4076811465760222
"findings,",0.4173174898019504
we,0.5146219228336382
also,0.49312711585454866
show,0.5318695846493707
"rapid,",0.5522449460546376
"glutamate-uncaging-evoked,",0.5714847168967764
time-locked,0.5641078123789746
BDNF,0.5836728015376241
release,0.5399062331332898
from,0.5460468548942334
single,0.46650994377153926
dendritic,0.5541884621513712
spines,0.5530890798624085
using,0.5272324411987465
BDNF,0.5399302964196878
fused,0.5300138098983934
to,0.4802592795984908
superecliptic,0.49730721298095676
pHluorin.,0.459012761171529
We,0.5868095496202584
demonstrate,0.5455602327510837
that,0.549812290557752
this,0.502410136122902
postsynaptic,0.5076715215442671
BDNF–TrkB,0.476399968675564
signalling,0.4777878747309571
pathway,0.4708031356859306
is,0.4771940942447491
necessary,0.46803754059368785
for,0.4987071185316636
both,0.44732657832975736
structural,0.4031482391583277
and,0.4428894716715791
functional,0.41021418832443873
LTP.,0.4530106765716282
"Together,",0.28731728922457533
these,0.30202829305851975
findings,0.3061448469027355
reveal,0.29139964905295423
a,0.24491251080077012
"spine-autonomous,",0.20766135273794836
autocrine,0.3105090223927135
signalling,0.3100088714285439
mechanism,0.2995294442215202
involving,0.32994070561575334
NMDAR–CaMKII-dependent,0.6122262866860639
BDNF,0.6939518573608281
release,0.7487579807710599
from,0.8136291381538823
stimulated,0.7871865336839438
dendritic,0.7346372487366636
spines,0.6995634992894876
and,0.7588793019046374
subsequent,0.7659347152198406
TrkB,0.6590195791541811
activation,0.7393820063186565
on,0.7090896525797892
these,0.5153617171307409
same,0.49273371284591577
spines,0.5299249440702541
that,0.5848741161512745
is,0.38091713151252427
crucial,0.446959293890873
for,0.3364952119596595
structural,0.3067599639019275
and,0.32422726278907216
functional,0.2977234339266188
plasticity.,0.32579162986815
CONTEXT,0.15427221112480494
Recent,0.1582522032243239
animal,0.24534693323344384
studies,0.15516315809551312
have,0.15104476893172145
found,0.30821021134674176
that,0.3627653677234529
3-hydroxy-3-methylglutaryl,0.228290159957675
coenzyme,0.2335197124659174
A,0.22665610593137273
(HMG-CoA),0.351967742382272
lipid-lowering,0.3267615043888252
drugs,0.3214202760956463
(statins),0.3939101791989472
substantially,0.5955444903323017
increase,0.46046002440589956
bone,0.28878020404322563
"formation,",0.41177405504449
but,0.10466913355550772
whether,0.024224579051701018
statin,0.16785101205912112
use,0.17727792152002997
in,0.1126570554791603
humans,0.18271241337916203
results,0.1609501649649319
in,0.16607188113778448
clinically,0.06816810732413785
meaningful,0.10015903496714856
bone,0.06859632907208807
formation,0.1967023913111249
or,0.054917476126314785
a,0.13399428584074619
reduction,0.20154881421578863
in,0.14087565691685922
the,0.06851980112223383
risk,0.10982441046403393
of,0.12170656841411139
osteoporotic,0.0898455574467889
fractures,0.10047027161179208
is,0.004062937272661278
not,0.003295233019142341
known.,0.004333964317379173
OBJECTIVE,0.0018773645805129503
To,0.0015901104858521155
determine,0.001095690229260754
whether,0.0009264256554907655
the,0.0011908465744710245
use,0.001262046242586459
of,0.0021775589709543903
statins,0.0012110131342297373
is,0.000881092818350628
associated,0.0009529423194416667
with,0.0011713819330867099
reduced,0.0011537765761913557
hip,0.0012873459460409989
fracture,0.0012011125102513289
risk.,0.0008187131967561703
DESIGN,0.0012825655751511253
Case-control,0.001314823492811159
study.,0.001847289271478136
SETTING,0.010936681582907027
AND,0.003843312333079354
PATIENTS,0.004431883897787471
A,0.005980205248470712
total,0.00759351270712618
of,0.004317792585586959
6110,0.0017013155381723794
New,0.0033293035094106973
Jersey,0.0033852878184196123
residents,0.0021144468936610604
aged,0.0019292937832688078
65,0.0024744838936537534
years,0.0033315653103756847
or,0.0047479085241919575
older,0.0032407439336577274
and,0.0030698873330874
enrolled,0.0020645690588709034
in,0.002294446792072642
Medicare,0.002230231515447742
and,0.0018277929197469509
either,0.0019534596116312156
Medicaid,0.002556808405075344
or,0.0017201200496586829
the,0.001975944771717438
Pharmacy,0.0017854903484144226
Assistance,0.00203899465641117
for,0.002349473375027761
the,0.0027551215180943883
Aged,0.0018735575902343207
and,0.0026555096448444304
Disabled,0.0019599958020568467
program.,0.0020346591736271403
Case,0.0034289928206296407
patients,0.004190224951263303
(n=1222),0.003729040844263844
underwent,0.003604354741905485
surgical,0.00417852004047346
repair,0.004869460673606716
of,0.005850848019885832
a,0.004291703206380144
hip,0.002708490648306023
fracture,0.003339206432008146
in,0.0039056135232004977
1994.,0.004072137783581684
Control,0.0014221845954954181
patients,0.001482218470465749
(n=4888),0.0018078655095503174
were,0.002005423640419769
identified,0.0012201968317720124
at,0.0019353563992112464
a,0.0024657336097775578
ratio,0.0016930047331568969
of,0.0034404098245258232
4:1,0.0034928419304675893
and,0.002790620791733038
frequency-matched,0.0013357906937719731
to,0.0018616648172445354
case,0.0012604866286958934
patients,0.0012894173130819245
for,0.0023428932785207195
age,0.0015418827824511397
and,0.0033165882832188937
sex.,0.001300376447664
MAIN,0.003737368239890326
OUTCOME,0.006774287647422694
MEASURE,0.006873153514902913
Adjusted,0.008172317212203593
odds,0.0041245677417323275
ratio,0.006320030884253095
(OR),0.008851677629659889
of,0.009568667963575228
hip,0.0051119040302440725
fracture,0.0038862999017749826
by,0.014168927275281634
statin,0.007168637173026603
use,0.0053750684389521275
in,0.006625892229042232
the,0.00824296357858862
180,0.0072531525338595795
days,0.008586676852439443
and,0.008861231454847808
3,0.015158067010911635
years,0.005912385921509774
prior,0.004115292254289205
to,0.008231569301099698
the,0.006183455089026301
index,0.004258224724479079
date,0.0032779843814763378
(the,0.006467704681503796
earliest,0.0026162914183999364
date,0.001834205335127301
of,0.0033961530701292417
admission,0.002512244274244563
for,0.0022409480901939235
"surgery),",0.002042594188341681
adjusted,0.003501438079183006
for,0.0018637854734670073
demographic,0.0016438022046234102
and,0.0026116034287289223
clinical,0.0010751353060213828
characteristics,0.0013243493294099295
and,0.002176899087792215
health,0.0010225995881429375
care,0.0014082248757607348
utilization.,0.0015684718497203948
RESULTS,0.9365549563090154
Use,0.9495928123001428
of,0.9467580862890322
statins,0.9413205971215418
in,0.9307058902051714
either,0.9371047311675598
the,0.9379169351411593
prior,0.9488526674040696
180,0.9124706897757966
days,0.9461371011363185
(adjusted,0.9253265526193571
"OR,",0.9438002251991634
0.50;,0.9307769022137767
95%,0.958021714511138
confidence,0.9459133492241911
interval,0.9349695871273538
"[CI],",0.90923063468226
0.33-0.76),0.9200256343594769
or,0.8902898074416299
prior,0.9321296149750271
3,0.9474970146040016
years,0.9402591382411933
(adjusted,0.8999057756847192
"OR,",0.9391207845138763
0.57;,0.9186196797907212
95%,0.9632827128891348
"CI,",0.9046788808678567
0.40-0.82),0.9241797019960977
was,0.9580112812364934
associated,0.9544721052628651
with,0.9496324549819105
a,0.9418957667365846
significant,0.938942853749099
reduction,0.9466463103162728
in,0.9490178359102647
the,0.9480090706054161
risk,0.9470847358076364
of,0.9552674439407459
hip,0.9450565939656788
"fracture,",0.9281261045254046
even,0.9426628398252989
after,0.9320054948821118
controlling,0.9499099789728044
for,0.918527921385988
variables,0.9272175428231834
such,0.8428540757324073
as,0.8789520933492356
"race,",0.8675293595531084
insurance,0.8732264205852683
"status,",0.8684991110189606
psychoactive,0.9348887313445313
"medications,",0.9039268588519289
estrogen,0.8946829309016775
and,0.4507967940082878
thiazide,0.33907644951362736
"use,",0.3930714346972492
ischemic,0.2509043567035941
heart,0.39048388102231896
"disease,",0.3709091369341083
"cancer,",0.277589153101243
and,0.3193409257669815
diabetes,0.3411549786341564
mellitus.,0.33618422697029954
No,0.16816931628786622
significant,0.1489285586645991
relationship,0.16273097744350218
was,0.15383792905046598
observed,0.14691269074378238
between,0.07911193912145281
use,0.21788722426377458
of,0.15924192947670227
nonstatin,0.21426577717801434
lipid-lowering,0.22203794164681256
agents,0.21065527133620535
and,0.06732569022468213
hip,0.25895154225507955
fracture,0.2103175680378513
risk.,0.1845845969005692
Clear,0.3843703951986922
relationships,0.38320970294326334
were,0.43553558792655184
observed,0.45519586544819834
between,0.24980678733843006
the,0.348043937245862
degree,0.4641233737841125
of,0.4932154376514562
reduction,0.46856213935797586
in,0.4833798604482374
hip,0.5294563356521651
fracture,0.5015517153320298
risk,0.5594432970861143
and,0.21005110655594414
the,0.30921362140983155
extent,0.45702214515684886
of,0.47383828964970476
statin,0.3806878181201655
use;,0.43740659718025005
there,0.36449952728429635
was,0.36867326181340115
no,0.338884166479084
evidence,0.3259893603234977
of,0.33586115375857345
such,0.3023636665546361
relationships,0.2865983115146775
with,0.23995557611852686
nonstatin,0.3191069053085458
lipid-lowering,0.3512077559144856
agents.,0.3243028694724234
After,0.7827151356078411
adjusting,0.7519457737895823
for,0.6854913604986
extent,0.7086707141804245
of,0.7047447626016794
statin,0.6495759398149314
use,0.6670109141511935
in,0.6785361972609381
the,0.7108504685811434
prior,0.6823266799404016
3,0.68499384605776
"years,",0.6816151954710552
current,0.7856128169142154
use,0.703642500961898
(on,0.7549042509965892
the,0.7044920296716594
index,0.6543551737871591
date),0.631217924180675
was,0.8065906315617168
associated,0.8223713249388303
with,0.8082259722863566
a,0.8237375458464502
71%,0.8247090607680176
reduction,0.7744872851049038
in,0.8103736902596765
risk,0.8066435621577395
(adjusted,0.7811512161307143
"OR,",0.7497632017120553
0.29;,0.7057284491475545
95%,0.3796628893234378
"CI,",0.39139878629288594
0.10-0.81).,0.2673683916885567
The,0.005952600913600947
relationship,0.006270033294572481
between,0.005584395877525279
statin,0.008681013242824007
use,0.011130808504634732
and,0.005556032444425845
hip,0.02545295947603032
fracture,0.014720800080695803
risk,0.0045672528767531535
persisted,0.00622420587685905
after,0.006457928373409798
controlling,0.004925310733143722
for,0.0034927996083875495
variables,0.003032569340633638
such,0.0032918057949843007
as,0.003613901636161976
the,0.0029583380395079577
number,0.003647141616879793
of,0.003433962198847257
"medications,",0.003079470392822212
the,0.003904899387036171
Charlson,0.006494660024112092
comorbidity,0.0030365797872013286
index,0.004113840502554973
"score,",0.005200255113799076
and,0.0044930563472859245
hospitalization,0.002383103720989668
or,0.003096532797909336
nursing,0.0033453384216270182
home,0.004041648054157442
stay,0.0032250171307631583
in,0.002878470522836592
the,0.0031640925201337996
last,0.0032105274661023155
180,0.004248168845823784
"days,",0.0026309644258581282
as,0.004172721409833991
well,0.004555273611343221
as,0.003906733216620347
after,0.005199312888790485
excluding,0.0038185531318223487
patients,0.004106693724061583
who,0.004537742410094368
were,0.004070393832324018
in,0.005266742118413208
a,0.003375943305598088
nursing,0.0039984157125390754
home,0.004358571980676821
prior,0.0047582948115248175
to,0.003753774599209897
their,0.003954299969318547
index,0.0041129224303670985
date,0.002720568699991413
or,0.0039930822038937155
who,0.004438861755267921
died,0.003969457875854019
in,0.008217600048421885
the,0.0038046279733109823
year,0.002223369948456626
after,0.005010926176523174
their,0.00569490056847742
index,0.006624831487783827
date.,0.0035833811977629393
Use,0.18546373697589832
of,0.1655992081350343
nonstatin,0.16018686651962477
lipid-lowering,0.2003616200714853
agents,0.10402964294157137
was,0.054404745234573414
not,0.0350794311985981
observed,0.044540534435975596
to,0.037587404372377196
be,0.04869284829253377
associated,0.09244960651707962
with,0.09830282415987049
reduction,0.11214940003124158
in,0.11342849740907555
hip,0.16771786447583414
fracture,0.17305066654113058
risk,0.1411199099272952
in,0.052374998389122
any,0.03322938908828901
of,0.0181459200664673
these,0.03167839075122084
alternative,0.02171627854795443
models,0.0603071197909355
or,0.015115483431453034
analyses.,0.061325129224336354
CONCLUSIONS,0.7034075076756743
These,0.5736379832840657
findings,0.5813978629386792
support,0.49546779067036345
an,0.5787301696166672
association,0.530189715247163
between,0.5936062759791998
statin,0.6419045107866969
use,0.6460960506761697
by,0.6317910972396559
elderly,0.6303548417517197
patients,0.5880192661697052
and,0.5730273102723142
reduction,0.5967838726676336
in,0.6147274064674875
the,0.5957770162095932
risk,0.6217071315741338
of,0.6694193142443572
hip,0.6356720187560638
fracture.,0.5867236294657455
Controlled,0.0029377606018358557
trials,0.0027734853783535508
are,0.0045400552572189634
needed,0.0032140727502200776
to,0.0030377803415960955
exclude,0.0025489113140787223
the,0.0023189649054083
possibility,0.002814654435000448
of,0.003429471916556953
unmeasured,0.00244527270283692
confounders.,0.0022490255112422356
JAMA.,0.04922841216976928
2000;283:3211-3216,0.025221320780156476
Efforts,0.0023721890642622164
to,0.0015285799126485504
develop,0.0013361778189449234
drugs,0.0010853377965818127
for,0.0013363353094691258
Alzheimer's,0.0011566897235603636
disease,0.0012281795656098851
(AD),0.0011553083032727527
have,0.002049029172057233
shown,0.0020759038443467965
promise,0.001232071937229621
in,0.0013783198778289072
animal,0.0009540354127689964
"studies,",0.0014283416360517003
only,0.0017027021949730578
to,0.0015295925748608585
fail,0.0012510015630153538
in,0.001395805674307298
human,0.0010632722582815564
"trials,",0.0011779590284303656
suggesting,0.0018433782032960164
a,0.0013901010848786876
pressing,0.0011668663253068666
need,0.0011453019357958473
to,0.0010066544321534116
study,0.0012256141436621
AD,0.0012587101235624792
in,0.0010450612428584505
human,0.000961850051453106
model,0.0010754572173490948
systems.,0.0009027891642435448
Using,0.8915303869659836
human,0.8790280077877185
neurons,0.8475205099002653
derived,0.841971246563685
from,0.8438407584053593
induced,0.8913208665672109
pluripotent,0.8007874470230553
stem,0.81142671636771
cells,0.8614210478902121
that,0.8448091256583821
expressed,0.8547971842135461
apolipoprotein,0.8574018200930097
E4,0.8060806311179338
"(ApoE4),",0.790617122496313
a,0.8471864454988716
variant,0.8337363049989185
of,0.8551898758345355
the,0.831182628150795
APOE,0.7549312031101815
gene,0.8074641952261201
product,0.8490723550775904
and,0.8545816420472614
the,0.8647985025237324
major,0.8140040069934295
genetic,0.820038149064336
risk,0.8102820891091803
factor,0.8356228721952248
for,0.797089846660322
"AD,",0.7769084147748597
we,0.8465559698809241
demonstrated,0.8601337298384995
that,0.8976770677283894
ApoE4-expressing,0.9086274283713316
neurons,0.8989383576336472
had,0.9178122628656524
higher,0.9164839728447522
levels,0.9170833709134201
of,0.9299768629193877
tau,0.8758807269807157
"phosphorylation,",0.8935462503020317
unrelated,0.9092029555297424
to,0.8851671751033796
their,0.9104622366112567
increased,0.9157429013547871
production,0.8757700154362068
of,0.876532008323375
amyloid-β,0.871482872174644
(Aβ),0.42819971961333786
"peptides,",0.4454112844120444
and,0.5464620869075983
that,0.5903713007923636
they,0.4725453869905843
displayed,0.5396423622771197
GABAergic,0.5119430500258422
neuron,0.5042015945596001
degeneration.,0.49919506138811637
ApoE4,0.6063340978529662
increased,0.6054835783656733
Aβ,0.6329201723609446
production,0.6205229873922515
in,0.6314851452979967
"human,",0.5533410016631868
but,0.6603206343695459
not,0.6357836515024109
in,0.6425149537845496
"mouse,",0.5088521364249708
neurons.,0.6313661752829801
Converting,0.38442888007955245
ApoE4,0.5073202795673752
to,0.3991838097240677
ApoE3,0.49569001665937146
by,0.5434000291789953
gene,0.3765560903641946
editing,0.4034820020189674
rescued,0.4404603526052821
these,0.30459732690333197
"phenotypes,",0.25593461936938594
indicating,0.13151677815378213
the,0.11735052858044236
specific,0.08988772707301824
effects,0.12026919631059521
of,0.12829152969419516
ApoE4.,0.17273409954913432
Neurons,0.11555185810855058
that,0.11295395218323195
lacked,0.16824490545315132
APOE,0.20447658793644322
behaved,0.13098598773421108
similarly,0.13962772945733
to,0.1698008808678796
those,0.1539577793143039
expressing,0.2091853681553043
"ApoE3,",0.23195520770255507
and,0.210283451844312
the,0.16701109739318032
introduction,0.17870165143056135
of,0.19734002611691034
ApoE4,0.22447198755006378
expression,0.185722695809923
recapitulated,0.130297517407186
the,0.11346164840033626
pathological,0.0752629671043322
"phenotypes,",0.08590961200498932
suggesting,0.14556138967436016
a,0.10010666476787934
gain,0.09369147480556377
of,0.09956465505652444
toxic,0.05799957735565868
effects,0.08408929634276566
from,0.16783470323121782
ApoE4.,0.4633510014086823
Treatment,0.6422996615195178
of,0.7186960367566337
ApoE4-expressing,0.6983392281627877
neurons,0.6617696074747269
with,0.6654146526340035
a,0.6845675753825897
small-molecule,0.6672819016338652
structure,0.5668616942383369
corrector,0.6045884622631746
ameliorated,0.7500021494799429
the,0.6030545931706435
detrimental,0.5155675239576868
"effects,",0.5829665081412372
thus,0.5790744636683419
showing,0.5932366665187878
that,0.5127697158076232
correcting,0.5215340145855638
the,0.40733348278458165
pathogenic,0.4564858828051019
conformation,0.3794720335776795
of,0.5338343287878521
ApoE4,0.5412275202714023
is,0.3670644702533781
a,0.3329352399019126
viable,0.2731474627459109
therapeutic,0.3616803802902211
approach,0.33499704357131393
for,0.3268857099840333
ApoE4-related,0.5312273019486513
AD.,0.45195490787332354
BACKGROUND,0.020047675561420144
Human,0.005590806313909138
immunodeficiency,0.0031244356528229936
virus,0.0034228714854426783
(HIV),0.0034153081619840557
infection,0.0044032316816402526
is,0.005195585119804181
the,0.006195144643766192
strongest,0.006285504603558933
risk,0.0034220282146815045
factor,0.00352152038122494
for,0.006155062756822916
developing,0.006166378978002863
tuberculosis,0.0036878712993100265
and,0.010790671010443035
has,0.004356745196054471
fuelled,0.0035356870664724586
its,0.005223662836201119
"resurgence,",0.004581238606462466
especially,0.004400826309338761
in,0.006260270593811745
sub-Saharan,0.0032832872095128157
Africa.,0.00486726029035291
In,0.0027857093896785927
"2010,",0.0019613856501068403
there,0.002517964877797418
were,0.0031362353818696247
an,0.002469365673260997
estimated,0.0024680786708072646
1.1,0.0018444102797669504
million,0.0018418394973989624
incident,0.0016241701127953998
cases,0.0018436769722555498
of,0.0021038689334930295
tuberculosis,0.0016343536724132835
among,0.0021450535198268106
the,0.0020748999745097262
34,0.0016138993049970329
million,0.001387041699683743
people,0.0019264068749151337
living,0.0018276637342712636
with,0.0018737189963349153
HIV,0.001624551348410399
worldwide.,0.002073648408632943
Antiretroviral,0.0018338993695347632
therapy,0.00137932836628457
has,0.0016503159857138925
substantial,0.0016468345875606735
potential,0.0010558295087456486
to,0.0014623202111256639
prevent,0.001311598796952498
HIV-associated,0.0010581684410540188
tuberculosis.,0.0011333449624401646
We,0.0018382194619489815
conducted,0.0011553143561208244
a,0.0011382941633158049
systematic,0.0008171041661936399
review,0.0010221727210063087
of,0.001343139998307926
studies,0.0008714281279357835
that,0.001123019808706956
analysed,0.0011737448026890168
the,0.0011878398672327832
impact,0.0008736435705293403
of,0.0010687144545168468
antiretroviral,0.0008394205024955649
therapy,0.0007598345784533459
on,0.0012239820315507607
the,0.0011084648404263158
incidence,0.0006457603245918844
of,0.0011169416907307681
tuberculosis,0.0006619215101010771
in,0.0010787517669028862
adults,0.0007808396649447927
with,0.0007054817063123519
HIV,0.0007282408788227724
infection.,0.0006396164743809493
METHODS,0.07496563284324839
AND,0.027434890803782398
FINDINGS,0.11491847871364057
"PubMed,",0.0006054800178427933
"Embase,",0.0006728710920243539
African,0.0004407530742884198
Index,0.0006345262787430891
"Medicus,",0.000670720194650632
"LILACS,",0.00047374445993500497
and,0.0007190594780473768
clinical,0.0003863689231610515
trial,0.0004216332649505075
registries,0.0005552292974443249
were,0.0005344002733494085
systematically,0.00044858598704492923
searched.,0.0004752779175071721
Randomised,0.0007251964367045908
controlled,0.0005678726437887766
"trials,",0.0005691441262345067
prospective,0.0006656698012329888
cohort,0.0009101761814610886
"studies,",0.0005204378939317626
and,0.0009116581664575444
retrospective,0.000500951469539649
cohort,0.0007592785042504619
studies,0.0005554120386002838
were,0.0007341309257118784
included,0.000538951154288293
if,0.0006601996671020319
they,0.0007354785554657318
compared,0.0006093686984554004
tuberculosis,0.00063092467839147
incidence,0.0006246432097836522
by,0.0007099720992701224
antiretroviral,0.0005788632331168326
therapy,0.0006064988446359914
status,0.0006625659106961735
in,0.0008185526973332233
HIV-infected,0.0005678553237962765
adults,0.0006005193626116222
for,0.0007171443437083382
a,0.000878432155327956
median,0.0006132753245831992
of,0.0011320361424564092
over,0.0007572947599378286
6,0.0009644920123808746
mo,0.0009369628238636145
in,0.0008299827537622899
developing,0.0005989909729208312
countries.,0.0005715524787708276
For,0.042649390595283596
the,0.02530692072038296
meta-analyses,0.023892746904744574
there,0.018331961255126344
were,0.020475486779120165
four,0.018321818987321915
categories,0.019484108259984586
based,0.012366982472394783
on,0.020422311765730186
CD4,0.08136191924674252
counts,0.0337087020496278
at,0.029285284229449895
antiretroviral,0.027645325070094037
therapy,0.05859833900517268
initiation:,0.04247177945200539
(1),0.04718998308362525
less,0.0809066629226579
than,0.066741810986633
200,0.1126155976020225
"cells/µl,",0.08378383020979065
(2),0.0440295970488882
200,0.12201750217497001
to,0.07820837688982958
350,0.11861240580630704
"cells/µl,",0.10995806281226085
(3),0.014442951162332811
greater,0.011220850505462721
than,0.013040129038228643
350,0.006242911205161427
"cells/µl,",0.015427697041352233
and,0.014487371041534518
(4),0.013441388024274173
any,0.00937857404610029
CD4,0.006317233065368306
count.,0.006949684924219767
Eleven,0.0018446850707615114
studies,0.003156881604709659
met,0.001840403243846548
the,0.0027529580394817354
inclusion,0.0019062018459544625
criteria.,0.0018514725278397657
Antiretroviral,0.9259528170165106
therapy,0.9186593552009729
is,0.9157506272954246
strongly,0.9080586149747426
associated,0.9297893045997733
with,0.9200422893542926
a,0.9260358005078805
reduction,0.9361817474335018
in,0.9336330138014427
the,0.9374568711348925
incidence,0.9396131214431499
of,0.9438320152221066
tuberculosis,0.9112641856663445
in,0.935859065637267
all,0.9243047295960901
baseline,0.9337011733866879
CD4,0.9270955288410054
count,0.925693226185158
categories:,0.9295519300081001
(1),0.9503341237014976
less,0.933589693654894
than,0.9444634052041111
200,0.9246448868394553
cells/µl,0.9138139602526412
(hazard,0.921837683209463
ratio,0.9211548707675441
[HR],0.9297278788469711
"0.16,",0.9331583543677929
95%,0.9519464142664165
confidence,0.9312604206779236
interval,0.9275137045848854
[CI],0.9157727438420649
0.07,0.9207241978101427
to,0.8955590816614055
"0.36),",0.9044688179058519
(2),0.9295553023142611
200,0.8735673279903866
to,0.9041539233997973
350,0.852558686266332
cells/µl,0.8747167838314017
(HR,0.8988990923043253
"0.34,",0.8317161468782901
95%,0.9304365002216143
CI,0.8784137994283094
0.19,0.8473200938381679
to,0.8873643929951344
"0.60),",0.8367455493456808
(3),0.9106533227819887
greater,0.94571181166105
than,0.9421504512651074
350,0.4175475436576471
cells/µl,0.43118420486055503
(HR,0.40742677575527214
"0.43,",0.37083494490389957
95%,0.5554118471954507
CI,0.5269986387236285
0.30,0.4469406853567282
to,0.5219060711526612
"0.63),",0.42301743513991064
and,0.403469019046361
(4),0.4577408017424097
any,0.41681322809565347
CD4,0.4185543615104695
count,0.43349088931783175
(HR,0.2895406995012076
"0.35,",0.3249678913434919
95%,0.19404483086608593
CI,0.43180598521694186
0.28,0.3492854310449112
to,0.38844256252283377
0.44).,0.2727385128723608
There,0.035425505568308556
was,0.03396488549859819
no,0.02400439705719149
evidence,0.017369915580748508
of,0.017582433839658736
hazard,0.01196441365476849
ratio,0.015316987654132948
modification,0.01537913564873426
with,0.017163118173230393
respect,0.013871492754984371
to,0.013048180079112398
baseline,0.00982333033574701
CD4,0.017799145211644114
count,0.011539631149254591
category,0.01311283927861794
(p,0.024671127887533638
=,0.03569670841488844
0.20).,0.02815989659658066
CONCLUSIONS,0.7023608174160079
Antiretroviral,0.42748659965287006
therapy,0.39539808593998876
is,0.29666730699311994
strongly,0.31967087737619504
associated,0.4347970613715251
with,0.4319378809314895
a,0.4589203620757512
reduction,0.38805203453636455
in,0.39232146453936445
the,0.3406003132060469
incidence,0.3727047400789692
of,0.37932741067617254
tuberculosis,0.25702872101980245
across,0.2972208150641402
all,0.24773284878883645
CD4,0.35719779420518055
count,0.26332140346451965
strata.,0.19352489076180918
Earlier,0.20383247642173088
initiation,0.1816501397176571
of,0.1663749036241377
antiretroviral,0.16225245681952746
therapy,0.1530414387311355
may,0.0974399234807348
be,0.09984416084863908
a,0.13048614875810277
key,0.13052884094352343
component,0.12494044496910424
of,0.13157981989214612
global,0.15980626910898071
and,0.02335938099752049
national,0.018314997663721057
strategies,0.012254728062766404
to,0.01083142263177255
control,0.010745249661908075
the,0.01293324708039901
HIV-associated,0.010382342736335034
tuberculosis,0.013620265348871112
syndemic.,0.00871135563367437
REVIEW,0.02238285102367886
REGISTRATION,0.053479449639699354
International,0.009335679494244534
Prospective,0.005688738263470652
Register,0.00797436564318883
of,0.008721280801950964
Systematic,0.005066963605235374
Reviews,0.012405746450129306
CRD42011001209,0.012006377616593084
Please,0.014917669028947977
see,0.011353366936952502
later,0.01194275243375828
in,0.014892649539506144
the,0.01175925370793136
article,0.008448164982901971
for,0.012346065203119025
the,0.008039374169069975
Editors',0.005153131296762832
Summary.,0.01089801933311229
Somatic,0.026181701872784978
mutations,0.015118461615492462
that,0.015550161473625708
activate,0.019326825862861767
phosphoinositide,0.029165574150783018
3-kinase,0.04991043045569916
(PI3K),0.01575284977841114
have,0.006924192918494927
been,0.005279238856819159
identified,0.007666008901845495
in,0.010363472973100363
the,0.01316675374948273
p110-alpha,0.053644879580458806
catalytic,0.012333367234286075
subunit,0.0182578626669062
(encoded,0.008830067026089253
by,0.014567727206225517
PIK3CA).,0.026998241435666964
They,0.010134089390858579
are,0.008596674557481313
most,0.006227749179725961
frequently,0.008144855740420863
observed,0.011196601075745648
in,0.012115072355636258
two,0.009311338894124988
hotspots:,0.007418445434913148
the,0.009775628729269546
helical,0.013641983374646848
domain,0.010413968657538875
(E545K,0.01228018512726591
and,0.02622987667124234
E542K),0.021817379954579337
and,0.009666559318843929
the,0.00979839012275909
kinase,0.01292945676706697
domain,0.011309367681502404
(H1047R).,0.013371714339623753
Although,0.0099711402321303
the,0.015466843589182369
p110-alpha,0.06266131216907435
mutants,0.014543443145446403
are,0.0077714637076132876
transforming,0.00501126853702979
in,0.008211267870633318
"vitro,",0.01233578669850962
their,0.008139287438784986
oncogenic,0.006376581878176046
potential,0.0047113319541297214
has,0.0028728817429677705
not,0.0028318549630295454
been,0.002366766777087828
assessed,0.0025516447327337205
in,0.003872815662078196
genetically,0.0027259267998936947
engineered,0.0030372922660209176
mouse,0.006969891810131903
models.,0.0039220448020170235
"Furthermore,",0.009159416934761914
clinical,0.01187814227840135
trials,0.014317360823218286
with,0.025686753073488233
PI3K,0.0026370869600793657
inhibitors,0.0011782241463092976
have,0.0010580845217003489
recently,0.0007854419380899514
been,0.000876748047726842
"initiated,",0.0008381399009454286
and,0.001339155455183893
it,0.0009172750216196713
is,0.0010868069772508025
unknown,0.0009063489557989195
if,0.0008870572267081565
their,0.0009278617994867834
efficacy,0.0009654868004383154
will,0.0009096577305223234
be,0.000898097868063959
restricted,0.0007224391896838326
to,0.0010280047082898678
"specific,",0.0007864539556551321
genetically,0.0006087311846743686
defined,0.0008832943044261152
malignancies.,0.0009322992820848486
In,0.00473990726194494
this,0.004520068099087819
"study,",0.0033507530274882935
we,0.006498057673996865
engineered,0.0037083123884438718
a,0.003320984129988067
mouse,0.0027221844113353563
model,0.0025877528116293913
of,0.0037482738176651694
lung,0.0035308880747356567
adenocarcinomas,0.0032050294663565114
initiated,0.003435134859474426
and,0.005462857666361897
maintained,0.003406698516293815
by,0.004882794987318475
expression,0.004383391582327022
of,0.0045238018944296415
p110-alpha,0.0046688571920816
H1047R.,0.003969212798071078
Treatment,0.07267513129787227
of,0.06714392328482768
these,0.09407574996924617
tumors,0.08497674155838936
with,0.09690124116325459
"NVP-BEZ235,",0.11962215007993451
a,0.14007446362683307
dual,0.09632249035885475
pan-PI3K,0.09270294775171568
and,0.16354651566864267
mammalian,0.06928506913807182
target,0.111733022284585
of,0.16570020541027086
rapamycin,0.14871754001963378
(mTOR),0.09435683726165617
inhibitor,0.10291241469073678
in,0.07303433211907603
clinical,0.04641575923585528
"development,",0.10474436409493343
led,0.09542064012888445
to,0.09614963193702245
marked,0.08005745108939483
tumor,0.06176572780768884
regression,0.0461617906735568
as,0.08117028492867213
shown,0.0488438536019886
by,0.059449600808082266
positron,0.045485124996585365
emission,0.07659240019275321
tomography-computed,0.024408917865880952
"tomography,",0.00965914202674169
magnetic,0.01268610468472344
resonance,0.011022728634405263
imaging,0.02192610618219538
and,0.022309049904994098
microscopic,0.012698330159974236
examination.,0.02381291084807548
In,0.33002471934466004
"contrast,",0.300845082645724
mouse,0.416522759583133
lung,0.30011591648058866
cancers,0.35632708483300235
driven,0.303928345866329
by,0.44959151326077174
mutant,0.3327814637523292
Kras,0.2565004382597443
did,0.3717805230388354
not,0.3460705835678679
substantially,0.3448833952223906
respond,0.29468813955905343
to,0.3569869393048193
single-agent,0.2498235708054768
NVP-BEZ235.,0.33111324466859404
"However,",0.5856719118220437
when,0.6006437223089592
NVP-BEZ235,0.599235532224132
was,0.5661103220140469
combined,0.5602719505965992
with,0.5235602547256859
a,0.539068557530753
mitogen-activated,0.6451494940482256
protein,0.5875074142656178
kinase,0.5255297753883849
kinase,0.5447290052367231
(MEK),0.4806979412814653
"inhibitor,",0.5626714019163989
"ARRY-142886,",0.5932962611625959
there,0.6904828008154077
was,0.6659110556216292
marked,0.6414152990454068
synergy,0.6256986734213262
in,0.6826528876371311
shrinking,0.6041171421519922
these,0.558130710363842
Kras-mutant,0.48433681736719536
cancers.,0.5320090959481337
These,0.391975010822954
in,0.398970499428708
vivo,0.46994451741321397
studies,0.39622553152820017
suggest,0.38244440049242556
that,0.30545033210911393
inhibitors,0.3032817170594674
of,0.40285726583148984
the,0.3182707661378541
PI3K-mTOR,0.37967259381445795
pathway,0.46387548093567416
may,0.644202182440531
be,0.6737989508183855
active,0.7102572941710311
in,0.7316188394766829
cancers,0.570689662803288
with,0.6445535594135172
PIK3CA,0.6803831171744997
mutations,0.6858281730518827
"and,",0.7888165606352182
when,0.6719924122617442
combined,0.6244684672670628
with,0.6134489263175419
MEK,0.6776399241912502
"inhibitors,",0.6218888156617376
may,0.725029143299833
effectively,0.7015220669531052
treat,0.7215273705174527
KRAS,0.6431359847946205
mutated,0.729067591724993
lung,0.6429793541755626
cancers.,0.6253228560732387
In,0.030945318694986193
this,0.01705248913152093
"study,",0.01350538160462332
we,0.027080864760778714
describe,0.01150814363994269
the,0.007596679124484939
3D,0.007274460863768064
chromosome,0.00960476551124882
regulatory,0.007882661748515318
landscape,0.007556196970167758
of,0.00936643668266686
human,0.009833523187785551
naive,0.013354843296371053
and,0.007380631544554345
primed,0.004410539407267299
embryonic,0.008423184955007981
stem,0.007046478418471177
cells.,0.00942649580745623
To,0.011048156861065405
devise,0.004283884669705803
this,0.008604714791557116
"map,",0.005843666063714889
we,0.013827800008253637
identified,0.011924279916930137
transcriptional,0.013398495832595768
enhancers,0.01453160799198407
and,0.013928148464770319
insulators,0.013614376113361188
in,0.026279482926867277
these,0.014382366213132863
cells,0.016580927364305966
and,0.009153756074508976
placed,0.008341848761597017
them,0.00887468060288831
within,0.004150294662666949
the,0.005397749468514385
context,0.0062539996922256385
of,0.009400366437390454
cohesin-associated,0.014893321133026723
CTCF-CTCF,0.018692666880347528
loops,0.017645806536827607
using,0.006231746281381302
cohesin,0.014617830065751541
ChIA-PET,0.009662321805439807
data.,0.00819024912133021
The,0.16627510568970122
CTCF-CTCF,0.15560866163910547
loops,0.14628956206200597
we,0.17104374767417968
identified,0.1496868591919702
form,0.12599692981886637
a,0.12786900229079345
chromosomal,0.11513226445388203
framework,0.1291811666091603
of,0.1311504826351455
insulated,0.13232984949237603
"neighborhoods,",0.12498337610486339
which,0.14020682869323609
in,0.13084581138546145
turn,0.14901598909344058
form,0.1054804626424576
topologically,0.058831739705977514
associating,0.09770742229437256
domains,0.11764048923908159
(TADs),0.07002562124830174
that,0.1230852831936799
are,0.06903026678558169
largely,0.10651693204787545
preserved,0.10182851356224376
during,0.1303362250221934
the,0.10074122448215617
transition,0.12218943748524032
between,0.08122463335774505
the,0.13972013157048999
naive,0.1509045024982469
and,0.11343372427381267
primed,0.06905063249280617
states.,0.10884808554352762
Regulatory,0.06079444445621091
changes,0.06459810933719039
in,0.05674574186437885
enhancer-promoter,0.08614645589391931
interactions,0.0746208461903892
occur,0.05108788003725667
within,0.05126041022058376
insulated,0.04484965500120787
neighborhoods,0.06414109178965739
during,0.06512233566697444
cell,0.11169540996828592
state,0.07007939238881858
transition.,0.058042265752933316
The,0.18729022181701632
CTCF,0.1723421098791194
anchor,0.18655191162268706
regions,0.17769050214091153
we,0.17604708447514594
identified,0.19930824521529503
are,0.13626166792425765
conserved,0.13939722342327077
across,0.1054851474900715
"species,",0.11858445514210161
influence,0.17567849276892195
gene,0.16517555013486648
"expression,",0.21161965244862294
and,0.24101282154194087
are,0.1884915336649355
a,0.20774407421634963
frequent,0.1878230102908961
site,0.15408172242712656
of,0.12417373336840658
mutations,0.1265185877285254
in,0.1503442792077583
cancer,0.11812547626941723
"cells,",0.13647794160140259
underscoring,0.10583838827242668
their,0.06171980380560949
functional,0.07048791665063034
importance,0.07924935450449079
in,0.063969117449655
cellular,0.1012227216961024
regulation.,0.08446396036254246
These,0.09168697601317591
3D,0.060100547543739134
regulatory,0.03430795723535946
maps,0.046669354148035844
of,0.038857055452374036
human,0.04635687893075392
pluripotent,0.028008452006727684
cells,0.03947643943286546
therefore,0.045282995833883524
provide,0.03159374830710145
a,0.03185139982596124
foundation,0.03060445719522361
for,0.03272476004307403
future,0.02856465686741074
interrogation,0.03317622526207039
of,0.027892130458730797
the,0.02438718818927375
relationships,0.025113298229495925
between,0.018538867211453557
chromosome,0.029469089483494772
structure,0.02527711260911635
and,0.01884384730955408
gene,0.02003055130785792
control,0.02210888647439838
in,0.02737374323976565
development,0.02914735586441076
and,0.02092741970319349
disease.,0.01477665482338652
One,0.014529050933646115
hypothesis,0.015829309432691865
that,0.009973943760580474
couples,0.010785755303189391
infection,0.011896135006854847
with,0.00929355001268446
autoimmune,0.00541653613589553
disease,0.007599733567960259
is,0.009566851481268467
molecular,0.01302019751397859
mimicry.,0.020741927125398574
Molecular,0.09834732395789035
mimicry,0.11332227335405629
is,0.08751782858004029
characterized,0.12212741195966932
by,0.12539736670163731
an,0.1130845982209306
immune,0.10592818360586792
response,0.14868733597026737
to,0.13380341521521738
an,0.10841856027013319
environmental,0.11327662051866665
agent,0.1453931753503336
that,0.12917284577265972
cross-reacts,0.20891545481586202
with,0.13624902714586098
a,0.09577476216442839
host,0.10016831816527225
"antigen,",0.09705864099426634
resulting,0.12052876491201088
in,0.12227909128683212
disease.,0.028208880302816697
This,0.005165706594132169
hypothesis,0.005520668590670673
has,0.004781260835816348
been,0.004181973878693517
implicated,0.005517148595303057
in,0.005481039172304924
the,0.006726242586952656
pathogenesis,0.003855239973434079
of,0.00600727763829142
"diabetes,",0.00420161336035264
lupus,0.007029734729073147
and,0.006193453867128381
multiple,0.003689418664157004
sclerosis,0.004039372261742315
(MS).,0.0035802413341887566
There,0.005952215787780051
is,0.004158271220858309
limited,0.0038784791600731255
direct,0.003438055595633767
evidence,0.004982612506899835
linking,0.0036548049163519767
causative,0.003037623657927637
agents,0.0026254634581584805
with,0.003285097051816999
pathogenic,0.0023928217621484427
immune,0.00224155055856699
reactions,0.0032052183708976218
in,0.0029604484982174344
these,0.0037267111423018137
diseases.,0.0026127991818273313
Our,0.009059687382992463
study,0.006664096784143562
establishes,0.0037916790852530764
a,0.0030217710830560043
clear,0.0030612390318690546
link,0.003896989534388953
between,0.0034707960585628503
viral,0.004187895677786721
"infection,",0.003695463608038624
autoimmunity,0.0024288265734873347
and,0.003657943892558609
neurological,0.003178076435653788
disease,0.002985295249265101
in,0.0039007988698640758
humans.,0.004047202811749551
As,0.05577963368542937
a,0.0382097956200135
model,0.0423152039238505
for,0.050554820730186516
molecular,0.03260564649974335
"mimicry,",0.04398273103988533
we,0.10995052635703685
studied,0.07705209810641904
patients,0.0897265501310878
with,0.05234939735031564
human,0.02217423313336601
T-lymphotropic,0.028515116426087825
virus,0.019312892492257216
type,0.016730881737959048
1,0.025042084792201498
(HTLV-1)-associated,0.02074894534014147
myelopathy/tropical,0.023674168672308614
spastic,0.024217425588044125
paraparesis,0.025331965034762895
"(HAM/TSP),",0.01602706424367021
a,0.022267665009160487
disease,0.020818249377799716
that,0.017891069732156872
can,0.01189855102065047
be,0.00841869171643028
indistinguishable,0.010395238228907663
from,0.016776631024536606
MS,0.019982611887409803
(refs.,0.017611837724029553
"5,6,7).",0.02322222598395985
HAM/TSP,0.015898052717416497
patients,0.02182265193373146
develop,0.025268890032231518
antibodies,0.012718127065373855
to,0.021771285450662047
neurons.,0.020630249862484087
We,0.01069343488329137
hypothesized,0.002329644110986411
these,0.005168630835890787
antibodies,0.005236649043235577
would,0.00588917554557784
identify,0.005414161783372288
a,0.0037073655930474664
central,0.00363177760115193
nervous,0.004694703372349534
system,0.007519221570257113
(CNS),0.004355926183520088
autoantigen.,0.0034040566728783866
Immunoglobulin,0.07271227284824408
G,0.09966974443538468
isolated,0.06418302309511022
from,0.12770219515239656
HAM/TSP,0.08681259017928614
patients,0.12049111359569674
identified,0.0894150713680842
heterogeneous,0.056001460558128456
nuclear,0.09069850963860931
ribonuclear,0.08698092269968835
protein-A1,0.04763427258287557
(hnRNP-A1),0.06902757782461293
as,0.07059571540967037
the,0.07772916587765905
autoantigen.,0.054354509578767134
Antibodies,0.015212826113346876
to,0.023465498030788557
hnRNP-A1,0.032753412511448816
cross-reacted,0.017020061510217094
with,0.01429863179334902
"HTLV-1-tax,",0.017037186053441445
the,0.018611473775057674
immune,0.014468405881791447
response,0.02388921910385776
to,0.01229817978285602
which,0.02021030914233081
is,0.015268461047066216
associated,0.02014083455021504
with,0.01586922961903149
HAM/TSP,0.014745505744368826
(refs.,0.017231119643641456
"5,9).",0.01938171086772888
Immunoglobulin,0.032248552321014284
G,0.03264629951022219
specifically,0.018938006486045912
stained,0.02627039112204627
human,0.022863065213561892
Betz,0.05649147612270186
"cells,",0.03228467789263893
whose,0.015104161668707716
axons,0.018595328932798583
are,0.010139108343505327
preferentially,0.009983603190617779
damaged.,0.01178060134145937
Infusion,0.12370567443824093
of,0.1330194899553413
autoantibodies,0.08045928714472539
in,0.13339012830403718
brain,0.09408083500808215
sections,0.11284566942712314
inhibited,0.11007662319404696
neuronal,0.08579166152952801
"firing,",0.12801784315232115
indicative,0.07775842318232266
of,0.07621969875566156
their,0.053523831197124325
pathogenic,0.033824375549405636
nature.,0.039621167323014204
These,0.06300711913264505
data,0.05017010924990215
demonstrate,0.045920628369480465
the,0.03213716531939761
importance,0.04108764837475713
of,0.4654090311281463
molecular,0.4513165666242195
mimicry,0.4161306852420126
between,0.39258378852553083
an,0.4408413548577851
infecting,0.43159323086737145
agent,0.4682871656092054
and,0.387130723213297
hnRNP-A1,0.40681369208790713
in,0.439576213055288
autoimmune,0.43827514964766656
disease,0.41959765111825376
of,0.48198633265975993
the,0.5271820269680204
CNS.,0.5643249646099475
Antigen-specific,0.06536347106730628
CD8+,0.07173244277216682
T-cell,0.04351987691541846
"tolerance,",0.04128400817135389
induced,0.029930681541283383
by,0.030450316814509323
myeloid-derived,0.02015212079714877
suppressor,0.022784322639657805
cells,0.046819765984997826
"(MDSCs),",0.01715039992134382
is,0.016008726220392986
one,0.012362565665334202
of,0.013322602626703655
the,0.014208907719886865
main,0.013283383912300746
mechanisms,0.012060388133488498
of,0.021348270941834436
tumor,0.03146780691569997
escape.,0.027282075612678005
Using,0.29293357218076876
in,0.15489817094414834
vivo,0.24797538262934066
"models,",0.24326118792120882
we,0.5906296192085528
show,0.5209992260010357
here,0.5171977461168182
that,0.6295614535090923
MDSCs,0.4525580148698399
directly,0.6834120762353764
disrupt,0.6501658821998119
the,0.6981495109336826
binding,0.6652420176156693
of,0.6529101773551984
specific,0.5763325302587557
peptide–major,0.6726676202255607
histocompatibility,0.5156589595069172
complex,0.5319360152322591
(pMHC),0.4587428126490983
dimers,0.5146151658156529
to,0.5856035096086929
CD8-expressing,0.6619972266816374
T,0.6165747816984685
cells,0.6914412576616777
through,0.7350006858290734
nitration,0.6891922765888528
of,0.6228559257217338
tyrosines,0.6676626231631334
in,0.633013877292634
a,0.6425966891288344
T-cell,0.614096040206224
receptor,0.5911040874314617
(TCR)-CD8,0.43569832799944064
complex.,0.6117212510802742
This,0.6217332612572161
process,0.5892305463205924
makes,0.6086971461054743
CD8-expressing,0.6659429528878489
T,0.6496164788096144
cells,0.6945254771807573
unable,0.6440153090543179
to,0.6269392393046616
bind,0.5931579755591232
pMHC,0.55473954681875
and,0.6440640230619039
to,0.6520236754965507
respond,0.08611977870520805
to,0.10785736224178262
the,0.08585723537774732
specific,0.06551173032053076
"peptide,",0.07299636947642806
although,0.10928807953954674
they,0.1216283367487799
retain,0.08471589013665674
their,0.10793399398516744
ability,0.11354701659630054
to,0.09639184330040952
respond,0.05625495598987325
to,0.0782834871948051
nonspecific,0.06836619281739742
stimulation.,0.06721004165710136
Nitration,0.4227164726313565
of,0.5072579426346763
TCR-CD8,0.4286561978696009
is,0.5863583215190645
induced,0.6131147785312648
by,0.6406663211518712
MDSCs,0.6112742689439902
through,0.660422145722503
hyperproduction,0.6260481964814762
of,0.6383914788811729
reactive,0.5823515533039941
oxygen,0.5638192431541822
species,0.6359178537090682
and,0.672917198323465
peroxynitrite,0.6289662885340388
during,0.662299699102061
direct,0.5839833651721011
cell-cell,0.6054225136980219
contact.,0.600473063285127
Molecular,0.01970996349276882
modeling,0.017944256385859506
suggests,0.025847511443926593
specific,0.01595423641484719
sites,0.01422364258317548
of,0.020219118289193587
nitration,0.01991688942352308
that,0.016082432517884916
might,0.011970326711812682
affect,0.016323646607289296
the,0.014238402545139315
conformational,0.013414484097880859
flexibility,0.01739691206365807
of,0.016871409122776765
TCR-CD8,0.031986410117077806
and,0.01283829920638944
its,0.011778780669903408
interaction,0.014010590554217864
with,0.017959226062819904
pMHC.,0.016320714364557103
These,0.09417431454484405
data,0.11052325846724173
identify,0.12825665184178187
a,0.13088409460953898
previously,0.09598585324230938
unknown,0.09461325169539792
mechanism,0.12648333826850439
of,0.09870776551042987
T-cell,0.16604300797265056
tolerance,0.15602268804026356
in,0.12292007765326249
cancer,0.13315437295149585
that,0.14826662903571444
is,0.10607750189476364
also,0.14171014494602385
pertinent,0.1311520923359841
to,0.14364815534701147
many,0.14031951009014762
pathological,0.08031046462390282
conditions,0.14148387591036077
associated,0.1358586673590673
with,0.13751778914693139
accumulation,0.1078906034239164
of,0.2042623152675963
MDSCs.,0.32056901477493577
Neutrophils,0.014383927720758652
rapidly,0.009923868819993955
undergo,0.006909699088437695
polarization,0.005198072469343878
and,0.011257246405938474
directional,0.005769145029436303
movement,0.007856201206105261
to,0.010966401759401383
infiltrate,0.005139824441114574
the,0.005277210965754061
sites,0.005228113656573399
of,0.005955222684360002
infection,0.005463373232564629
and,0.006233160932889258
inflammation.,0.0061649034287095195
"Here,",0.6929746375399038
we,0.7480032754770403
show,0.7389631560633445
that,0.8222706992860845
an,0.7105371092835575
inhibitory,0.6539420250479664
MHC,0.6583029764076547
I,0.6799164242512247
"receptor,",0.6991645394764129
"Ly49Q,",0.6678115534366933
was,0.7882677269308387
crucial,0.7391252329844396
for,0.8022816186994768
the,0.7919125980289237
swift,0.7328999776843894
polarization,0.6673415659330563
of,0.613658131998102
and,0.7519459294367428
tissue,0.6826627076082199
infiltration,0.6699280450894212
by,0.6629365010514895
neutrophils.,0.6967549633895657
During,0.7554419162856914
the,0.7176290180920866
steady,0.6792315432347306
"state,",0.714418528631248
Ly49Q,0.6649680002236824
inhibited,0.8036718809598373
neutrophil,0.8102577333875302
adhesion,0.7792062297891493
by,0.8412885323697536
preventing,0.7717386528872014
focal-complex,0.7184370977438749
"formation,",0.7490649016319645
likely,0.7325250499743564
by,0.8412966817445304
inhibiting,0.8221409290914495
Src,0.7163607467656383
and,0.7558642849198828
PI3,0.7508032953881055
kinases.,0.7219779507509833
"However,",0.6600546846211717
in,0.5466919457189432
the,0.5506960688228433
presence,0.45655640631198013
of,0.44623015194756466
inflammatory,0.5379575034375402
"stimuli,",0.4857970362501349
Ly49Q,0.19143046945718334
mediated,0.24400067202081996
rapid,0.2820349927115518
neutrophil,0.24497857591604721
polarization,0.2018735449461412
and,0.3015710387802004
tissue,0.21390246587785927
infiltration,0.18314195982809064
in,0.21235700106899086
an,0.24135437172931132
ITIM-domain-dependent,0.09119811543838616
manner.,0.2890792571176844
These,0.009402071668611404
opposite,0.005706272409899501
functions,0.007050135996341069
appeared,0.005334012641058059
to,0.003569188590961995
be,0.0034562815594950946
mediated,0.0042059189161853736
by,0.004636594495086734
distinct,0.004242483465195083
use,0.006143864712837713
of,0.006308537604322016
effector,0.006444196592730875
phosphatase,0.005238748401825046
SHP-1,0.019970429373433532
and,0.007343949215154655
SHP-2.,0.013799796013316091
Ly49Q-dependent,0.2162317678420358
polarization,0.11723364091014078
and,0.21011686400817395
migration,0.151654690400711
were,0.18250621279338816
affected,0.1786826427806339
by,0.2225458941557225
Ly49Q,0.2668021023616597
regulation,0.2224787241448813
of,0.18441172914810774
membrane,0.1689420179036972
raft,0.17606427322877943
functions.,0.163665164460604
We,0.650473799319642
propose,0.6468014530308853
that,0.7219697223048677
Ly49Q,0.6290500425089565
is,0.6574165190166894
pivotal,0.7048302211072871
in,0.7797550336483268
switching,0.753653576452068
neutrophils,0.7159346903199347
to,0.7853100882765609
their,0.7217592403616513
polarized,0.6898322712213915
morphology,0.6389409454696149
and,0.8267914563106147
rapid,0.8074150595650975
migration,0.6990719467030434
upon,0.8074270246350446
"inflammation,",0.6467973339859696
through,0.8197721573294496
its,0.7694248490185039
spatiotemporal,0.757075219384685
regulation,0.7544299626499795
of,0.7201805583410924
membrane,0.6695437597876909
rafts,0.6954934731350214
and,0.7667024448466112
raft-associated,0.5019285322456781
signaling,0.4976011102684103
molecules.,0.42186849311858
BACKGROUND,0.04079456474646484
Although,0.005881772558434555
unstable,0.004855418347032939
coronary,0.005358876926435713
artery,0.0029832238608769037
disease,0.004301319450474357
is,0.0030599979596141985
the,0.0033480502025915954
most,0.002084284991080324
common,0.002340634035953565
reason,0.0027081602935925576
for,0.002964132730653108
admission,0.0021069360062447736
to,0.002853441697559975
a,0.0024542353833427438
coronary,0.0027943002098829352
care,0.0018631890170115167
"unit,",0.0022059850127377615
the,0.001837864278649214
long-term,0.0014618614417583854
prognosis,0.0015899458429248425
of,0.0017209529768999485
patients,0.0011162518938495239
with,0.0015007752646108965
this,0.0021120928870799758
diagnosis,0.0018319800638573413
is,0.0014307451340220224
unknown.,0.0015504435625466593
This,0.0031733901980581223
is,0.002718373461873076
particularly,0.0026104988518025796
true,0.003247414872300138
for,0.002651849170760725
patients,0.0023039022295370444
with,0.0028785457974133946
diabetes,0.0026740994719645686
"mellitus,",0.0033565520060585673
who,0.0031900477701993345
are,0.0030236556892123696
known,0.002699822030554385
to,0.002538195740214216
have,0.0033434835849021224
a,0.0030788168377643976
high,0.003234286489240191
morbidity,0.002733808505228617
and,0.007360510722732631
mortality,0.002057537987711324
after,0.0036986013539740377
an,0.0034509725043229385
acute,0.002465765277046846
myocardial,0.004348268810678119
infarction.,0.0029005673986570936
METHODS,0.01829593176858833
AND,0.002873995216460938
RESULTS,0.018689192553172973
Prospectively,0.001780970097676745
collected,0.0021031427661325542
data,0.0018503303826522771
from,0.0017193149418288356
6,0.0013443884346984215
different,0.0012892306555891775
countries,0.0011183071150473612
in,0.0013232480193316452
the,0.0014161093492781678
Organization,0.0014103598397443725
to,0.002513113132317427
Assess,0.002066051095022945
Strategies,0.00159532121979312
for,0.0017715143403914584
Ischemic,0.0022263735585272564
Syndromes,0.0019374538739886833
(OASIS),0.00244174683853631
registry,0.0013566598612137696
were,0.0022904752834108756
analyzed,0.000903356422195601
to,0.0026018998707353184
determine,0.0013089232466134285
the,0.0013820930062577838
2-year,0.0016469043631417222
prognosis,0.0009946228565231997
of,0.001647372876755466
diabetic,0.0011467779089579565
and,0.0019387027448939736
nondiabetic,0.001075555577000195
patients,0.001342133326870894
who,0.0014936442196457956
were,0.0012921385731452623
hospitalized,0.0010538601227218069
with,0.0017493684454078864
unstable,0.002466818738130191
angina,0.002690899540466803
or,0.002754432478393544
non-Q-wave,0.0036661078792151716
myocardial,0.005622601834148984
infarction.,0.002617203634966629
"Overall,",0.00609786996562382
1718,0.00511628438777734
of,0.01057521995300046
8013,0.004779377949721879
registry,0.005742318736874114
patients,0.004411734100184663
(21%),0.006803348044978223
had,0.007912563860117051
diabetes.,0.004329953770650646
Diabetic,0.14520687737206536
patients,0.1659030903650263
had,0.24793955423262118
a,0.26593991602680345
higher,0.3085948651975798
rate,0.25893742817187154
of,0.3535016647340252
coronary,0.2733788980215379
bypass,0.22266142865534364
surgery,0.32465025682120285
than,0.33834148146358095
nondiabetic,0.1743964179433054
patients,0.23705467815323192
(23%,0.22728244936864575
versus,0.23409629652836844
"20%,",0.24815392054079932
P:<0.001),0.30080818730485936
but,0.26543449135976094
had,0.2030596288592771
similar,0.2237660011016586
rates,0.22607756578975244
of,0.25178328313172643
catheterization,0.16455533278035048
and,0.22765520267873493
angioplasty.,0.17768842935429166
Diabetes,0.3238473896610319
independently,0.2969829643426904
predicted,0.33613650237844056
mortality,0.32033687649300085
(relative,0.4017352184267332
risk,0.3585578999681122
"[RR],",0.3280908386260985
1.57;,0.3423211203559427
95%,0.7861791052459458
"CI,",0.7477082498650505
1.38,0.7751446221091294
to,0.7171173850521423
1.81;,0.6637825979458376
"P:<0.001),",0.7839973429162522
as,0.7956118802868098
well,0.8437541921665437
as,0.8360305121405548
cardiovascular,0.830847593428879
"death,",0.8043709241386581
new,0.8694494025798508
myocardial,0.8367080757579984
"infarction,",0.8274956450677884
"stroke,",0.7892561499777777
and,0.8168510224567475
new,0.8604875920690876
congestive,0.8339274749893786
heart,0.7857631717883663
failure.,0.8143074000438164
"Moreover,",0.6603500459043867
compared,0.5511153940363379
with,0.4109842031497086
their,0.4132592765004138
nondiabetic,0.4885814017627723
"counterparts,",0.38928750453010025
women,0.4108573252391613
had,0.4821779564036077
a,0.4370227813725153
significantly,0.4192341309719656
higher,0.42894479825650955
risk,0.4851638206478765
than,0.4557695919481352
men,0.40785292542423995
"(RR,",0.3363045442246643
1.98;,0.42236083727983714
95%,0.515233497057595
"CI,",0.5646712051923014
1.60,0.523943131383339
to,0.48857737182170574
2.44;,0.4976798546322787
and,0.4203657347499087
"RR,",0.5283859458282221
1.28;,0.4908117856917076
95%,0.4600566399778381
"CI,",0.5728307096129988
1.06,0.5043611240056328
to,0.4488072701993828
"1.56,",0.3887435988901623
respectively).,0.41007926368342495
"Interestingly,",0.2930941545522393
diabetic,0.29890092729447926
patients,0.2773159250030615
without,0.37506903209928205
prior,0.3889095844148797
cardiovascular,0.2618488903192085
disease,0.3146043213810822
had,0.1158275679526976
the,0.08393109105665228
same,0.06690204754751387
event,0.050760903554941235
rates,0.04427148660714303
for,0.04722336040864065
all,0.05197256542170224
outcomes,0.05748393880205488
as,0.06316578200527986
nondiabetic,0.059845173468844846
patients,0.059073459027581
with,0.054604039541726164
previous,0.082184877626977
vascular,0.05356706293787678
disease.,0.0526966892823533
CONCLUSIONS,0.6118753073831463
Hospitalization,0.09509205977119978
for,0.10906755479517403
unstable,0.14297689975477867
angina,0.1561874720806459
or,0.16595582683841928
non-Q-wave,0.18137134454250892
myocardial,0.17137388474711665
infarction,0.15487993730858068
predicts,0.1095773103595066
a,0.10239889906136271
high,0.07950803484508412
2-year,0.09479621387828632
morbidity,0.04919814057533816
and,0.10019026135554288
mortality;,0.05183255265914073
this,0.07720060365653733
is,0.0526334195304635
especially,0.05091008724674676
evident,0.06327529694071628
for,0.062119670039573874
patients,0.04249286353265813
with,0.036963590795958276
diabetes.,0.03917207823889735
Diabetic,0.06686684165321181
patients,0.0878249496424692
with,0.10370974832974375
no,0.09503472328924954
previous,0.08756247278206285
cardiovascular,0.051584561948203114
disease,0.047194437458259825
have,0.09450070774767724
the,0.06609347959438595
same,0.06519508038022899
long-term,0.05329967781113249
morbidity,0.049442657180873824
and,0.07176629682221082
mortality,0.04982763075822526
as,0.08120722508836062
nondiabetic,0.07397980443830798
patients,0.07351401089881492
with,0.10280083323697752
established,0.09944581667820937
cardiovascular,0.05492889871756291
disease,0.05551140764515765
after,0.09891194285637761
hospitalization,0.06537685780714822
for,0.1062233726127172
unstable,0.10355622214646266
coronary,0.1578847449560646
artery,0.10854241080719422
disease.,0.07979419705558224
CONTEXT,0.03857786771046161
Insomnia,0.00834119399641752
is,0.0044940386223937265
a,0.0051932171989689
common,0.007397170123479341
condition,0.00366577435349505
in,0.014097580691238856
older,0.00482351132270462
adults,0.005072590575036044
and,0.008109331348283334
is,0.0035666177615748676
associated,0.003100570088440934
with,0.0033258796934778636
a,0.0036862142509826073
number,0.004001450463314902
of,0.003234621624859701
adverse,0.0014152522393520715
"medical,",0.0016476214978335235
"social,",0.0029059597919320014
and,0.0030921802917651346
psychological,0.0010781551135641476
consequences.,0.0012967029166333901
Previous,0.0020238712670180925
research,0.0016779792134841898
has,0.0014433407414500981
suggested,0.0021731740293652827
beneficial,0.0010646745799407812
outcomes,0.0009416036921660452
of,0.0014095414410501914
both,0.002316676883148844
psychological,0.0008714299961902212
and,0.002137297867541202
pharmacological,0.00086328530003761
"treatments,",0.0010865926843292345
but,0.001524754812023615
blinded,0.00177034853994802
placebo-controlled,0.0011677669969986687
trials,0.0010683637709428733
comparing,0.0008118570540778248
the,0.001008723554869275
effects,0.00076428892499492
of,0.0010332021046997187
these,0.0011017315419828623
treatments,0.0010800960219248307
are,0.0015936853463252908
lacking.,0.0011025050583709397
OBJECTIVE,0.001542099355180394
To,0.0014414640634712902
examine,0.0011755874051886765
short-,0.0011123554017623575
and,0.0014569326685705212
long-term,0.001236795391715532
clinical,0.0006403281154435155
efficacy,0.0006680023174296031
of,0.0013718276999602561
cognitive,0.000825248861611525
behavioral,0.0008270193006656808
therapy,0.0009447180815022273
(CBT),0.0012270751434871555
and,0.0013264141481004888
pharmacological,0.0006794884191949179
treatment,0.0007853178893970087
in,0.0011215460666407274
older,0.0010250854259611464
adults,0.001115129823190822
experiencing,0.0009129992335340089
chronic,0.0009749602287687645
primary,0.00132554276449931
insomnia.,0.001427106743167345
"DESIGN,",0.0012955829201600627
"SETTING,",0.002502265585418986
AND,0.0012445878105229841
PARTICIPANTS,0.0016233402870127992
A,0.001984562903174953
"randomized,",0.0016203742367796457
"double-blinded,",0.0018825845862957692
placebo-controlled,0.0017565222001861222
trial,0.0013490510103328812
of,0.001962667663558479
46,0.0016632328996150775
adults,0.0019257679621520283
(mean,0.0018029930463118492
"age,",0.0027076052851263306
60.8,0.002878819539693638
y;,0.0021273628610517957
22,0.0019211762236736592
women),0.0013614589400589693
with,0.0015294290912480186
chronic,0.0016985027528902451
primary,0.0015819040502555641
insomnia,0.0014474228894726976
conducted,0.001600920128809404
between,0.002090210417555065
January,0.0018323035879813697
2004,0.002151618630834745
and,0.0024776885956860773
December,0.0020817985594169344
2005,0.001935815603880444
in,0.0020428372016050456
a,0.002606096356706236
single,0.0023695690854561623
Norwegian,0.0009601742532944817
university-based,0.0016595342887723448
outpatient,0.0015744353457022198
clinic,0.001434735348258376
for,0.0015093916340664594
adults,0.0019840218153685456
and,0.002055971546486805
elderly,0.001664174582740797
patients.,0.0013022501315977904
INTERVENTION,0.01270539527990209
CBT,0.00961171476132511
(sleep,0.012965662369935183
"hygiene,",0.007792769149876371
sleep,0.010184675778252517
"restriction,",0.010157952535220997
stimulus,0.009104250191559244
"control,",0.006630794855828472
cognitive,0.007973388715306106
"therapy,",0.01551882442057345
and,0.003647476919346438
relaxation;,0.012169451166372934
n,0.007421953895447121
=,0.01067684617166705
"18),",0.006575544908213091
sleep,0.018828557417833222
medication,0.01299017087707543
(7.5-mg,0.015056069201938306
zopiclone,0.010837161409794233
each,0.013930604536552881
night;,0.007340887360441921
n,0.010580592316983129
=,0.01207882993985965
"16),",0.0018326511565306663
or,0.0009791578185564926
placebo,0.0006637025529035937
medication,0.0009106309358510038
(n,0.0009481324680384674
=,0.0012856179579061858
12).,0.0010413599185098378
All,0.0010816304983919678
treatment,0.0010654040909006683
duration,0.001841594931074872
was,0.0017127575606389344
6,0.0013495721051888466
"weeks,",0.000942382729488694
and,0.0020288807686494608
the,0.0011854255082800272
2,0.0012727724327816765
active,0.0010046907666480037
treatments,0.0008427762078247893
were,0.0010481646621666187
followed,0.0006871782499873535
up,0.0010818188217373357
at,0.0011440828529275604
6,0.001084484101504364
months.,0.0009411810108275093
MAIN,0.001477325966966756
OUTCOME,0.0016736936388011144
MEASURES,0.0014957080096245153
Ambulant,0.0018155462140380398
clinical,0.0008717758997885191
polysomnographic,0.0016611387918217162
data,0.001176483033504593
and,0.0018839321979450972
sleep,0.0012115750254647955
diaries,0.001618022392911687
were,0.0015045754003399198
used,0.0012183110844478594
to,0.0014241291069739977
determine,0.0011146943713855099
total,0.0009336998186811686
wake,0.0012270526444069685
"time,",0.0009878519100201323
total,0.0007913616665045222
sleep,0.001314607807882207
"time,",0.0009948166601615206
sleep,0.0011493057668160729
"efficiency,",0.0009210434669136061
and,0.0013237821696785272
slow-wave,0.001094947826368588
sleep,0.0011145767754339904
(only,0.00134909437369276
assessed,0.0009157114946714486
using,0.001406728335970546
polysomnography),0.0014010812392607826
on,0.0011039632725780425
all,0.0010437911227918464
3,0.0014710225205049818
assessment,0.0007922206794884739
points.,0.0008731906304838317
RESULTS,0.7683322006777463
CBT,0.706968391680024
resulted,0.8061150833516774
in,0.8291268907250986
improved,0.7931413542126322
short-,0.8210271654344953
and,0.7796709869928151
long-term,0.8069675902176268
outcomes,0.7921498878764979
compared,0.8179626489532428
with,0.8166364401232168
zopiclone,0.798579500858465
on,0.8397809047623702
3,0.7892704160036581
out,0.841129941977565
of,0.8244030875923244
4,0.7113357074827654
outcome,0.7483415552717909
measures.,0.7649939174842542
For,0.6896556112994594
most,0.6610526699244809
"outcomes,",0.08382874964834512
zopiclone,0.10376964525995185
did,0.09952759230830306
not,0.05058023214544431
differ,0.03140990879465408
from,0.05145276909607613
placebo.,0.061763696809126335
Participants,0.7951368956538245
receiving,0.7674073158200719
CBT,0.6568857996467891
improved,0.8310464248433228
their,0.8376533694778835
sleep,0.8035777706684348
efficiency,0.8126609809694428
from,0.8659005829155062
81.4%,0.8847910197692301
at,0.8644019311456129
pretreatment,0.8698151451231265
to,0.8773494963904219
90.1%,0.8774758711103893
at,0.8555273606201903
6-month,0.8464252915161452
follow-up,0.847809082180142
compared,0.8693522320571824
with,0.839473775418244
a,0.821078869183156
decrease,0.800293465744439
from,0.8341553223072653
82.3%,0.8575729105104049
to,0.8251528509224838
81.9%,0.8519172087535892
in,0.8247768723831707
the,0.8413848626796054
zopiclone,0.7632670967368822
group.,0.8689694166614153
Participants,0.7004376708933521
in,0.6680416569138947
the,0.7266185149225085
CBT,0.6215271694317643
group,0.7748753646649824
spent,0.7411313565219435
much,0.7186053848146732
more,0.7674951347864315
time,0.733043388693858
in,0.7555189970427336
slow-wave,0.7117288562718135
sleep,0.6934647856035372
(stages,0.66834848539119
3,0.7232255476278525
and,0.6706641780757321
4),0.6037227881526648
compared,0.7844414457914047
with,0.7286393446204548
those,0.7011795877772011
in,0.6231325520754302
other,0.6192579581826251
"groups,",0.6508511941230146
and,0.7676032930366036
spent,0.7091673529858785
less,0.740856461107443
time,0.6665834935552162
awake,0.652783553859679
during,0.6517252457979213
the,0.7268046788206538
night.,0.5501784114595795
Total,0.2346666210713925
sleep,0.3150649460351415
time,0.3224937174650935
was,0.22595625999021465
similar,0.19923013010469856
in,0.24124918966973027
all,0.23843537444915616
3,0.25268834174001376
groups;,0.22701201566483228
at,0.518137793626043
6,0.4346694086681026
"months,",0.42050316370508706
patients,0.5298474174949407
receiving,0.4717785278570972
CBT,0.40256036871936635
had,0.5158958190607655
better,0.5792023933122769
sleep,0.5147073740133964
efficiency,0.45925165454158823
using,0.48701190016086443
polysomnography,0.4701144820897587
than,0.5558208788259181
those,0.4743808151511478
taking,0.47484389502774904
zopiclone.,0.4833141387534254
CONCLUSION,0.8059582219579878
These,0.8093786702060766
results,0.8446955851956578
suggest,0.8083054664727357
that,0.8607496903685087
interventions,0.904724586281588
based,0.9235362197393545
on,0.8984007452363988
CBT,0.8884559091771209
are,0.8691457558684463
superior,0.8623824579909054
to,0.875485682935796
zopiclone,0.9113673124643075
treatment,0.9185875737306952
both,0.9006229366292585
in,0.9106530899978775
short-,0.9283230859490087
and,0.8805225561260663
long-term,0.9144288756959348
management,0.8806618303529251
of,0.8927964854035809
insomnia,0.884589871979065
in,0.8259849548866586
older,0.8550566045468119
adults.,0.8008466025899676
TRIAL,0.008222885099166405
REGISTRATION,0.012716911691301703
clinicaltrials.gov,0.005909809510288668
Identifier:,0.01029864336031571
NCT00295386.,0.004911749017143378
Adenosine,0.13575706552166739
deaminases,0.20465186339260155
acting,0.16403158731806358
on,0.1611210689970636
RNA,0.06269279237757383
(ADARs),0.10027827043505974
are,0.09657353045761616
involved,0.13826073591941368
in,0.1354515553697286
RNA,0.07395601851725
editing,0.13956508760225428
that,0.1367091846164098
converts,0.15466394333960945
adenosine,0.126786341183719
residues,0.1779390951601713
to,0.1846054111809045
inosine,0.13552762710934402
specifically,0.12758296855180187
in,0.15197430460181707
double-stranded,0.07150213666696771
RNAs.,0.06276978665433684
In,0.16573849182478867
this,0.11874275754656653
"study,",0.09931205241441905
we,0.18351565092061659
investigated,0.07300843809220005
the,0.03705349728489691
interaction,0.05071797853721841
of,0.04119574444136858
the,0.038005256801187624
RNA,0.054288427031997204
editing,0.07963807477152614
mechanism,0.04800696087701387
with,0.04096222596572086
the,0.041430588732037206
RNA,0.04121827159928299
interference,0.060276551148912526
(RNAi),0.03285681903612288
machinery,0.05545297289707348
and,0.1447340675565705
found,0.293225761775723
that,0.2347619508052941
ADAR1,0.15917109488317352
forms,0.17848215552154992
a,0.1739545946541197
complex,0.1294343151416714
with,0.15071449371804654
Dicer,0.10177858406055341
through,0.18665471203317302
direct,0.1289186603124203
protein-protein,0.10262503534080926
interaction.,0.14266125025739262
Most,0.6800863564135011
"importantly,",0.7222672060819729
ADAR1,0.7035581795882742
increases,0.7890911023824099
the,0.7673807703811996
maximum,0.771616107083322
rate,0.7270883860241177
(Vmax),0.669656822362062
of,0.7474053099039324
pre-microRNA,0.6917045194176383
(miRNA),0.6211133076992402
cleavage,0.6623865890892304
by,0.7074662781495759
Dicer,0.6694974557070933
and,0.8547851027538942
facilitates,0.8076156660711997
loading,0.6646459529144353
of,0.6892690434989119
miRNA,0.6258746359501738
onto,0.6761944264009057
RNA-induced,0.5700072035954865
silencing,0.6351811999937694
"complexes,",0.01253993021552424
identifying,0.014734661168120982
a,0.010092339658099296
new,0.01031092260756344
role,0.008961203274027107
of,0.012544096539055917
ADAR1,0.021590169358923994
in,0.011172977674806992
miRNA,0.012443619554961023
processing,0.013573339834302783
and,0.01275260935045745
RNAi,0.008479901260229874
mechanisms.,0.007684496343886444
ADAR1,0.031443077787027575
differentiates,0.015026577184580791
its,0.015861784382631625
functions,0.018252735129318683
in,0.01697935352256238
RNA,0.013733914931963383
editing,0.018527986131998877
and,0.016944629890017597
RNAi,0.012806394124865053
by,0.013172575908755564
the,0.01682174813848195
formation,0.016456775668075952
of,0.015505760341985803
either,0.014857992837321012
ADAR1/ADAR1,0.03551585132214137
homodimer,0.022360736231575827
or,0.0174638636858569
Dicer/ADAR1,0.03810380928652873
heterodimer,0.017384946102791433
"complexes,",0.016363171340427966
respectively.,0.011833248729780593
As,0.3538518628901166
"expected,",0.3301019138422149
the,0.35200768896143414
expression,0.3934783607841864
of,0.40332350379350496
miRNAs,0.317174218142016
is,0.2889202968546404
globally,0.3221643861124817
inhibited,0.3451609626274389
in,0.47971873273258814
ADAR1(-/-),0.40138372006949335
mouse,0.35033972106023453
"embryos,",0.39918106189383856
"which,",0.6267289474774126
in,0.5580503306283705
"turn,",0.6058965619711112
alters,0.4926748376245766
the,0.48555962100866973
expression,0.5434867721086692
of,0.5032031191038265
their,0.2560345291156471
target,0.29094479093412057
genes,0.46082598402675723
and,0.5515369547788003
might,0.3921343329200777
contribute,0.5231606369676671
to,0.5110206130658265
their,0.34587188224674636
embryonic,0.4193163256218744
lethal,0.38280419160048396
phenotype.,0.4791196574147872
Gliomas,0.011328986620695612
arising,0.0037382800471463763
in,0.004613501095739536
the,0.004355504327797963
brainstem,0.0020008399189286176
and,0.004281821707329223
thalamus,0.0020521170412850414
are,0.0030630629940878993
devastating,0.0025578599080439786
tumors,0.0021956342681327488
that,0.0016607466126920694
are,0.0012536122972361585
difficult,0.0010454931763244503
to,0.0013842727772600553
surgically,0.0011421753261198053
resect.,0.0011524935900035433
To,0.0015735368706029894
determine,0.0010392432269662993
the,0.0008388835669583696
genetic,0.0009041309800153879
and,0.0013521303730448344
epigenetic,0.0008385249349993953
landscape,0.000911643182672353
of,0.0012109978502720718
these,0.0019096569214036112
"tumors,",0.0014101540205316593
we,0.0022504656655719453
performed,0.0017808175145544866
exomic,0.0013836612126752758
sequencing,0.0012749970609630186
of,0.001594062852817241
14,0.0012083462644299362
brainstem,0.0014879232279025993
gliomas,0.0016542421294187149
(BSGs),0.0012411860594881135
and,0.0016339211355031777
12,0.0011118995829167628
thalamic,0.0011754897058622279
gliomas.,0.0023536740205355603
We,0.0029607067806954493
also,0.0019108228849276643
performed,0.0024761587500697017
targeted,0.0014076087764634821
mutational,0.0013463296162958866
analysis,0.0017877183890710252
of,0.0016638090134454698
an,0.0013153254335568339
additional,0.0016147077851679315
24,0.0013633916252484887
such,0.0013337106630634408
tumors,0.0019295123234358185
and,0.0018757698830637155
genome-wide,0.0010104683569894671
methylation,0.0011121702442347674
profiling,0.0011437355209676723
of,0.0016611387918217162
45,0.001492632934753586
gliomas.,0.0033651840724166714
This,0.14051413683886302
study,0.15656584237318402
led,0.24027348683491492
to,0.31793894749760604
the,0.24540157060209633
discovery,0.3366987819219607
of,0.37466450217655756
tumor-specific,0.2979846243102953
mutations,0.3344151711935527
in,0.4071090105913975
"PPM1D,",0.4304918682861236
encoding,0.42004498605971363
wild-type,0.3360088941028486
p53-induced,0.45681366488382896
protein,0.43161807971217747
phosphatase,0.051527646577657134
1D,0.07234979575954033
"(WIP1),",0.07234866765942245
in,0.09092310864558305
37.5%,0.035879907880861296
of,0.05310194556835905
the,0.05981210902299713
BSGs,0.034948072108928405
that,0.048093032913569346
harbored,0.031935464079747546
hallmark,0.025862448705806486
H3F3A,0.024784046728827017
mutations,0.04305815718829776
encoding,0.0371127210126932
p.,0.03134694439714885
Lys27Met,0.02814850656557744
substitutions.,0.0344906592742814
PPM1D,0.367717812565574
mutations,0.5536767700734189
were,0.4804181797794857
mutually,0.37970081093151514
exclusive,0.39846109998644186
with,0.4581715948166274
TP53,0.453267190953067
mutations,0.6346091809874074
in,0.4875453737502856
BSG,0.41275008526027007
and,0.7054257674418433
attenuated,0.6968531539049786
p53,0.5101457019150742
activation,0.6463888548606643
in,0.602422115147526
vitro.,0.5690436873213409
PPM1D,0.6002540165596838
mutations,0.6858994531136069
were,0.7455254946994295
truncating,0.7452256421973456
alterations,0.7312716935474554
in,0.7340024247325169
exon,0.6783884916804451
6,0.6977675102500399
that,0.7346512211296267
enhanced,0.7590984119178662
the,0.7475391328241854
ability,0.775725700817433
of,0.7293861320042403
PPM1D,0.6362816762000603
to,0.7524389686219095
suppress,0.7316382376399269
the,0.7717520084101019
activation,0.7616070554956723
of,0.7634141509573628
the,0.696890007701583
DNA,0.6286265962386849
damage,0.631455548206311
response,0.6467297444938734
checkpoint,0.626152487457281
protein,0.6363066604726694
CHK2.,0.5402849906561755
These,0.2244437550797833
results,0.24846457259979254
define,0.09996392650356739
PPM1D,0.3228754649241639
as,0.09084191007580475
a,0.11473347117966419
frequent,0.11248718603223055
target,0.09798988886198552
of,0.1625923895569185
somatic,0.3707112285875205
mutation,0.29501875180300646
and,0.20368660883080936
as,0.15906637385811845
a,0.17072767629662264
potential,0.09237026141408135
therapeutic,0.11328090128721031
target,0.15102112264546813
in,0.2755393479916437
brainstem,0.2855150536098981
gliomas.,0.3389483617607066
Angiotensin,0.006213951635261263
converting,0.0036742297967552
enzyme,0.0022148590898432943
(ACE),0.001836754116630395
inhibitors,0.0022580857655356175
are,0.0020642925230980416
now,0.0019778207021223246
one,0.0017033049299303227
of,0.0017888641026131405
the,0.002033808763553026
most,0.0015620165780894364
frequently,0.0015404497634034175
used,0.001578501735134203
classes,0.0013313922864782671
of,0.0017633248971628637
antihypertensive,0.0016097905385612215
drugs.,0.002094403893145221
Beyond,0.00215542014316874
their,0.0022761575625367676
utility,0.002917568617236646
in,0.002311002407334101
the,0.0023648771585384437
management,0.002026877896112713
of,0.0020771933400989344
"hypertension,",0.0020937721451487114
their,0.0019397271600683382
use,0.002549417506821557
has,0.002280460130897454
been,0.0018060511963287774
extended,0.0021230020092524236
to,0.0021210724364120245
the,0.002219942050846369
long-term,0.0017789790668376086
management,0.0018236760879574226
of,0.002108685175166584
patients,0.0019124368587420206
with,0.0020021047940436626
congestive,0.001776875228838451
heart,0.0022220670851132852
failure,0.002059879345749673
"(CHF),",0.001471147198113788
as,0.0017476917645660626
well,0.002598046193283439
as,0.002453017504535239
diabetic,0.00160855829988263
and,0.002431791251045261
nondiabetic,0.002301331220378984
nephropathies.,0.0018664499005467308
Although,0.9118802617975591
ACE,0.753696715451676
inhibitor,0.7960000921068106
therapy,0.8496377814461811
usually,0.8925984817060814
improves,0.9096328787714675
renal,0.8699883118926336
blood,0.8806777218246021
flow,0.8688001795453723
(RBF),0.8551039346015582
and,0.9254388611134905
sodium,0.8625039552115917
excretion,0.9043658376440596
rates,0.8790974131890575
in,0.893353185612348
CHF,0.8286671370940115
and,0.9216681066941217
reduces,0.9048599736912885
the,0.8981521432096842
rate,0.8970300559475703
of,0.9153525504928659
progressive,0.9028513810438369
renal,0.885861159365645
injury,0.8472666876562444
in,0.8985410845564891
chronic,0.8866669697865741
renal,0.8611609572271856
"disease,",0.8464930353584296
its,0.841066737549479
use,0.46572694504695367
can,0.34212420015738776
also,0.36179698873582095
be,0.36124991925459266
associated,0.38021831085781377
with,0.38595183959017104
a,0.3680513638686563
syndrome,0.2892006708715755
of,0.4408369550433
“functional,0.48173546973192
renal,0.44269252413497845
insufficiency”,0.4173011093170593
and/or,0.4625549132507998
hyperkalemia.,0.35471555096998075
This,0.04728597182679642
form,0.037699288365414994
of,0.034602424449347566
acute,0.01994195723977177
renal,0.02243641169469678
failure,0.027512544529536
(ARF),0.01787202280442234
most,0.0305292262088313
commonly,0.026229304249617648
develops,0.03627779761101733
shortly,0.04512804499427429
after,0.04314946382337118
initiation,0.03259803679168079
of,0.03393887642290717
ACE,0.043148080800756744
inhibitor,0.026116977099113436
therapy,0.032011652174658164
but,0.04301302944076669
can,0.025698689549692393
be,0.017733902715537493
observed,0.03278253145829334
after,0.03775116690445288
months,0.01550636451699544
or,0.024736167787938676
years,0.014675233853566625
of,0.03166417647254846
"therapy,",0.028311070388108407
even,0.025082549169161587
in,0.03903610073866024
the,0.036602888591299856
absence,0.039349640558808664
of,0.03936858924872922
prior,0.038135529592555895
ill,0.016131698632875464
effects.,0.03647156964305534
ARF,0.40333185207351546
is,0.3659218972026049
most,0.3495159151079026
likely,0.3822167057152293
to,0.2683890604821954
occur,0.4314331235566555
when,0.5122439965213951
renal,0.536407613534928
perfusion,0.5548660137490176
pressure,0.5344980068059961
cannot,0.5192065918542438
be,0.5044092212540547
sustained,0.5388836142758457
because,0.5604292349905997
of,0.5386979001644481
substantial,0.5810909591428399
decreases,0.5294684147292643
in,0.5693070025971462
mean,0.5998741185054203
arterial,0.47416535518556363
pressure,0.5508499902879482
(MAP),0.38528519093024444
or,0.4889011354696802
when,0.4952209333663605
glomerular,0.5137612618555784
filtration,0.4380910260911722
rate,0.6039503288885267
(GFR),0.42467073114898396
is,0.5045672800336627
highly,0.5182934868475184
angiotensin,0.434811749466716
II,0.5020897872129438
(Ang,0.4755613233783287
II),0.5169207485560499
dependent.,0.09197445278953888
Conditions,0.027548385465958385
that,0.030926617170721992
predict,0.04581035009207875
an,0.03277966265920217
adverse,0.021479193481120037
hemodynamic,0.028334068006141272
effect,0.025867963353503772
of,0.05509809202373219
ACE,0.10350576435795471
inhibitors,0.06533463778815395
in,0.047623533526352214
patients,0.0467968632490239
with,0.06260968017647488
CHF,0.09136461460169794
are,0.05598972732629773
preexisting,0.08618571114391699
hypotension,0.05282742272247615
and,0.12694021544582548
low,0.08854846677333168
cardiac,0.19564580905267365
filling,0.11130833855744653
pressures.,0.07978900656784858
The,0.3485293326512002
GFR,0.3588309891941401
is,0.31652884341806137
especially,0.25584115807141855
dependent,0.2773838998849353
on,0.28350188671648724
Ang,0.4345744185685686
II,0.49348116352869514
during,0.43123800915107513
extracellular,0.4111784606521822
fluid,0.4614359536112626
(ECF),0.3336763133217259
volume,0.4865866010533715
"depletion,",0.42608462149118953
high-grade,0.4443234501514564
bilateral,0.4889554096069058
renal,0.46837905978638866
artery,0.5390618305763
"stenosis,",0.4274626014957492
or,0.29739285649384306
stenosis,0.421093171715325
of,0.4108555398349997
a,0.31299859395830004
dominant,0.4642914281907938
or,0.2268571929088453
single,0.3401354894058614
"kidney,",0.4473758046691573
as,0.2777410380208777
in,0.31563526366148803
a,0.26174952555896425
renal,0.40018454339839815
transplant,0.371790582065323
recipient.,0.39811367002619713
Understanding,0.027680454934834692
the,0.019847832549597655
pathophysiological,0.016970077907810004
mechanisms,0.0232612011573444
and,0.015735562690221933
the,0.018083772968722787
common,0.017430851404336846
risk,0.027803864098163482
factors,0.021105844454183245
for,0.05245025504884804
ACE,0.09538573832314903
inhibitor–induced,0.06398215963677976
functional,0.045494871679163454
ARF,0.128087709149283
is,0.03357087424798107
"critical,",0.22124721377834414
because,0.2186273109929237
preventive,0.1334044604261687
strategies,0.1551558761210468
for,0.16066369466358668
ARF,0.1724569174776471
"exist,",0.15459974081212852
and,0.19508297269121846
if,0.15162991524248548
effectively,0.15537187545860684
"used,",0.11420825640958264
they,0.1441122809668009
may,0.13562549255264947
permit,0.18185148229783882
use,0.1520767304369056
of,0.14135135707030785
these,0.1520687756151482
compounds,0.1723105356492333
in,0.1511928910851889
a,0.14088674509613133
less,0.19041619422962672
restricted,0.11521373163177219
fashion.,0.14317036489434565
Under,0.08535718753621041
normal,0.07286663513836894
physiological,0.059504849576154734
"conditions,",0.07241439653012655
renal,0.16510970150918503
autoregulation,0.08311282190294741
adjusts,0.12743416837266439
renal,0.13001749290811523
vascular,0.10036596608754596
"resistance,",0.09708422942931005
so,0.1290380863502999
that,0.14179807656104937
RBF,0.11342833557143266
and,0.12935059918006514
GFR,0.12074808319524354
remain,0.10371910105368527
constant,0.09518242930313667
over,0.08263367487634445
a,0.05867679540746819
wide,0.044225579327497565
range,0.04292347260367195
of,0.05838968564261443
MAPs.1,0.07308497457564991
The,0.030506928437517074
intrinsic,0.027917191400329253
renal,0.03799977432161726
autoregulation,0.016302518106375518
mechanism,0.02901048752280725
is,0.019932984600192175
adjusted,0.014644192181472804
by,0.02909820578247716
Ang,0.026039833979017348
II,0.03284234383388999
and,0.019167184240544415
the,0.014403768668346369
sympathetic,0.027403393336703923
nervous,0.022763037562327452
system.,0.024691499343399086
When,0.25465183323956153
renal,0.2728006633902027
perfusion,0.2817857778276749
pressure,0.26855170359725195
falls,0.2034291804412433
(as,0.20579750711450767
in,0.20489927367869748
…,0.2689217397908873
CONTEXT,0.02639029690399396
Exogenous,0.010729777145573414
estrogen,0.003827998714565274
use,0.011254815855150669
may,0.0075021050517145435
lower,0.009040170408245968
risk,0.004059404945348503
of,0.005198396725527168
dementia,0.004087195241392108
in,0.01064390074227722
postmenopausal,0.010274601027232268
women.,0.006440029019103661
A,0.0010292549032865949
relationship,0.0009694431930694592
between,0.001049584075799011
long-term,0.0011263102141919926
exposure,0.0009259828716086362
to,0.001226497018676329
endogenous,0.000954194950513575
estrogens,0.000909554162408787
and,0.001051861587653963
incident,0.000790641824464561
dementia,0.0011066651271842622
has,0.0009758377255451029
been,0.0008962661350359278
hypothesized,0.0009170205104566364
but,0.0013414934004876253
not,0.0010043976714167163
studied.,0.0009016222110810102
OBJECTIVE,0.001764982524083099
To,0.0012457732354608706
determine,0.0009626932880461541
whether,0.001117772990487937
a,0.0013788325653917347
longer,0.0013341165629711
reproductive,0.0013120982585978845
"period,",0.0011542803291297251
as,0.001306699237533131
an,0.0011484190439832124
indicator,0.0010395145414042928
of,0.0015540388804774028
longer,0.0013974093802007373
exposure,0.0009248886230299987
to,0.0016829645908720417
endogenous,0.0011402188393435442
"estrogens,",0.0010414700456521625
is,0.0009660752370033943
associated,0.0010102739135184867
with,0.001304255074399757
lower,0.0012967192808670915
risk,0.0007817759125761926
of,0.0016494802832014788
dementia,0.0012626940195266962
and,0.0016374988321761167
Alzheimer,0.0010304302885008809
disease,0.0012346643838306547
(AD),0.0013204330326988978
in,0.0011354589300796461
women,0.0009259056763420973
who,0.0013179544278614267
have,0.0010305696968076136
natural,0.0010036902882615607
menopause.,0.0015031143805537242
DESIGN,0.005789413038790166
AND,0.005181827522412861
SETTING,0.013126145333437898
The,0.012367439673235826
Rotterdam,0.00856133329850741
"Study,",0.0059712675312175055
a,0.005143046389822515
population-based,0.004269332926783638
prospective,0.0008332606639672626
cohort,0.0006892969783618757
study,0.0008149277254999233
conducted,0.0006983581312622909
in,0.0008705589935517308
the,0.0007816420144646447
Netherlands.,0.0005932731681517607
PARTICIPANTS,0.0023627884020047253
A,0.0008255245299955464
total,0.0008256466635810716
of,0.0013135433618285824
3601,0.000977467261079894
women,0.0010375392291700012
aged,0.0010601602616984532
55,0.0008685313455163936
years,0.0010818767937913133
or,0.0021334917031187385
older,0.0013000396129899798
who,0.0013324096298092082
did,0.0017124917909388643
not,0.0012407575793149386
have,0.001169990509373182
dementia,0.0010593924530252368
at,0.0008157749846502339
baseline,0.0007917090075657646
(1990-1993),0.0009542960957923376
and,0.0021880537128986487
had,0.0009743415533137041
information,0.0006434111345775526
on,0.0006313586777397527
age,0.000610568181681245
at,0.000732662344545865
"menarche,",0.0009575069324011308
age,0.0005931872254088419
at,0.000872144793229046
"menopause,",0.0011590271311470695
and,0.0006885668792104922
type,0.0006185151638653287
of,0.0005898357292132962
menopause.,0.0008792756302231648
Participants,0.0008216835143644584
were,0.0009404114779804797
reexamined,0.0007585332469321527
in,0.001073808470864626
1993-1994,0.001100972202178622
and,0.0013720328329665308
1997-1999,0.0010863996497983666
and,0.0011018149832107188
were,0.0009054085749730012
continuously,0.0008181791655366319
monitored,0.0007292610765557749
for,0.0008475968270674284
development,0.0006507760461687091
of,0.0007331998135265981
dementia.,0.0007735843108047591
MAIN,0.0021781801893050326
OUTCOME,0.002978484928305382
MEASURES,0.003629129955818639
Incidence,0.002791006963237158
of,0.0027464620913061934
"dementia,",0.0019605639393355714
based,0.00340473777366161
on,0.0037031049145333545
Diagnostic,0.002644479800640117
and,0.006116029842841379
Statistical,0.002189503871606367
Manual,0.0022823171972853103
of,0.002379421650662263
Mental,0.002009246074080675
"Disorders,",0.003117185175755703
Revised,0.003021029201632938
Third,0.0051192330096456636
Edition,0.001162616981692432
"criteria,",0.0008043166007516728
and,0.0015391646274268687
"AD,",0.000731323530102727
based,0.0007857653425442411
on,0.0008961440242199811
National,0.0008251735701966437
Institute,0.0007570171499420372
of,0.0019368306614327552
Neurological,0.0010842878258763833
Disorders,0.0010678842484407017
and,0.0010901305459074357
Stroke/Alzheimer's,0.000906877619705443
Disease,0.0009045333745003192
and,0.001206347520455427
Related,0.0012311806565108144
Disorders,0.0010889242209483538
Association,0.0008565316984118154
"criteria,",0.0006242203680111627
compared,0.0006995933011111949
by,0.0012630356263119936
quartiles,0.0008339113998732199
of,0.0009578091712800544
reproductive,0.0007300744711000525
period,0.0007813005756196449
among,0.000914742233952453
women,0.0008324567326119197
with,0.0007538638128401245
natural,0.0007483766216402748
menopause.,0.0010367270427247986
RESULTS,0.019033437197247947
During,0.015478614600517474
21,0.00455137893276164
046,0.003520389425987038
person-years,0.008993740029341607
of,0.007182337220348653
follow-up,0.005852701061944701
(median,0.009300750713350328
"follow-up,",0.0047513797607131505
6.3,0.0036737550317313085
"years),",0.003645319217748169
199,0.0075161690056539015
women,0.009454306806558309
developed,0.011852171074913273
"dementia,",0.0033577230544465948
including,0.004926032919975501
159,0.005045409335007534
who,0.006014156320328079
developed,0.008787795856809852
AD.,0.005791513055452953
After,0.09162656335877578
adjusting,0.0810316915599434
for,0.06087998564728189
"age,",0.06358771788196031
dementia,0.059241116595319034
was,0.07217216807382865
not,0.06014057988651756
clearly,0.060999443528297344
associated,0.066831318406263
with,0.06882970024884923
length,0.046800447414209426
of,0.03862011894994692
reproductive,0.07530384724806245
period.,0.06633177976207562
"However,",0.13945744876070537
after,0.208662238539399
adjusting,0.19765869498468733
for,0.1870028091451621
multiple,0.14358254491936281
"covariates,",0.1486294621700438
women,0.17565893423879794
with,0.20313719539157515
natural,0.269260250217635
menopause,0.689995750294971
and,0.7830972332270263
more,0.783200047142329
reproductive,0.6656965002991474
years,0.7623668513883335
had,0.7812039633829119
an,0.7814756545753481
increased,0.7645478281218616
risk,0.7441956982217699
of,0.7818233807378634
dementia,0.6493941288404956
(adjusted,0.6689861320813472
rate,0.49798079560181935
ratio,0.4567605082851028
[RR],0.45249776064114416
for,0.5561902761353299
women,0.5673172886299747
with,0.5455671822941086
>39,0.5636012577160444
reproductive,0.4618108704616829
years,0.4914995431992071
[highest,0.46183192896231257
quartile],0.4050032815087536
compared,0.6773808376767827
with,0.521020315867038
<34,0.5157938160484136
reproductive,0.4685085953698738
years,0.49449967802582445
[lowest,0.44928832418590176
"quartile],",0.407517726008633
1.78;,0.5529959953405695
95%,0.6663257209007732
confidence,0.5885894643703183
interval,0.5859867041470532
"[CI],",0.4689251754906172
1.12-2.84).,0.6276464203133509
The,0.2310712608303433
adjusted,0.24936669258987537
RR,0.24164602001573718
per,0.29659300216130174
year,0.21426377524284904
of,0.22229552902067715
increase,0.2827188475070636
was,0.27975718998291677
1.04,0.3178414067985952
(95%,0.2993596812951107
"CI,",0.4496904101791769
1.01-1.08).,0.4045749040216695
For,0.5120301791659041
risk,0.5637267143789102
of,0.6167479722710434
"AD,",0.5696961476373918
the,0.4231641613888383
adjusted,0.44745437885554
RRs,0.44563861904835705
were,0.45823182934816326
1.51,0.5353862269366695
(95%,0.4996473938811232
"CI,",0.5838915578780549
0.91-2.50),0.38879444219294135
and,0.39220862372450604
1.03,0.3895274258075077
(95%,0.353307470700688
"CI,",0.5023872819929298
"1.00-1.07),",0.4204592523076817
respectively.,0.3138695714053926
Risk,0.7601789912723473
of,0.8213902017674972
dementia,0.7397433471993126
associated,0.8134430412021516
with,0.8083758226951541
a,0.8055794496760211
longer,0.8250573415542087
reproductive,0.7716931643834856
period,0.7679720463377305
was,0.7164060940286315
most,0.6776419879022366
pronounced,0.7128765055877735
in,0.7689847417222027
APOE,0.752750698624923
epsilon4,0.8310908511289594
carriers,0.7739112438945529
(adjusted,0.7803720569836043
RR,0.7612747825735563
for,0.7481732363582492
>39,0.7541944013931894
reproductive,0.7630247295382245
years,0.7924619511325937
compared,0.8297412454402304
with,0.7545536637915659
<34,0.7580680166125573
reproductive,0.7566700418802951
"years,",0.7947821831945383
4.20,0.8370042472284717
[95%,0.7369034562681193
"CI,",0.7680532234272056
1.97-8.92],0.7669992140524512
for,0.777415415165808
dementia,0.7772833624975718
and,0.751424177803307
3.42,0.8141325138823841
[95%,0.6966469330793121
"CI,",0.7413604177059011
1.51-7.75],0.7202985987207671
for,0.7129652774655911
"AD),",0.768640422363262
whereas,0.7691478822975296
in,0.7393997454243053
"noncarriers,",0.7963287721693545
no,0.6127876469784598
clear,0.48507395132715947
association,0.5995805230225898
with,0.6373478538062831
dementia,0.33941351695375654
or,0.23897512116277206
AD,0.2921868825680857
was,0.2734120691433651
observed.,0.27210765456046626
CONCLUSION,0.7342811690134259
Our,0.3871804718108005
findings,0.338376315506274
do,0.22110534485141844
not,0.25645696443239896
support,0.15658259252894374
the,0.17985378868529386
hypothesis,0.20717794336327613
that,0.3503707344891337
a,0.6042431287158114
longer,0.6018554527706916
reproductive,0.5114495218737096
period,0.603100323012613
reduces,0.4950122699638185
risk,0.48456463581126324
of,0.49045387441711913
dementia,0.4482981820843027
in,0.47422739069667497
women,0.400268729454412
who,0.4567182987315093
have,0.4618633155843818
natural,0.4963309305873191
menopause.,0.4380667291436157
Antibiotics,0.11132967214404267
can,0.04563160692423031
have,0.04101628381756193
significant,0.05686890103364051
and,0.0883626575503668
long-lasting,0.032454545373516025
effects,0.05474825625309782
on,0.05835873801165299
the,0.07535333567176834
gastrointestinal,0.05856818815116372
tract,0.04572936358052359
"microbiota,",0.042262129548328656
reducing,0.054945696341552816
colonization,0.059674724108380206
resistance,0.04048934639967058
against,0.03304708589909747
pathogens,0.027113699862385612
including,0.03577089132052345
Clostridium,0.07904529605752166
difficile.,0.04754027853364584
Here,0.6219448800237632
we,0.6189873222506872
show,0.6288052056887717
that,0.7084057123706511
antibiotic,0.47624938297832575
treatment,0.5064348988133603
induces,0.5638587654535061
substantial,0.5388445753684927
changes,0.4782533109846349
in,0.5382196439379447
the,0.5449195114167015
gut,0.5020618005206394
microbial,0.5018644786632765
community,0.5046569025425288
and,0.539598820545982
in,0.5490703197191236
the,0.5323577555118546
metabolome,0.49195319559854317
of,0.5764811351446932
mice,0.5165772491760103
susceptible,0.3829280495123523
to,0.5036128521753557
C.,0.45485739388886526
difficile,0.4571161190632749
infection.,0.4710837759092516
Levels,0.3137805464716569
of,0.3282520236148097
secondary,0.37758737294181915
bile,0.3964223226815708
"acids,",0.3141137735842949
"glucose,",0.3382320335124145
free,0.35460766910522423
fatty,0.2646295375890608
acids,0.3141230773987751
and,0.3496267430868427
dipeptides,0.3380321885889693
"decrease,",0.2999630163948904
whereas,0.3286229072763934
those,0.21928409129808427
of,0.271874987220868
primary,0.27950140811397384
bile,0.3220440312122216
acids,0.28386525552853475
and,0.28306457758099085
sugar,0.2652914417891596
alcohols,0.22997547511560806
"increase,",0.2829802390229506
reflecting,0.26723757043098983
the,0.2729733396286336
modified,0.2586446339006742
metabolic,0.2509249927777922
activity,0.22881550809957907
of,0.18840490749713298
the,0.26266134708369304
altered,0.2624791654417826
gut,0.33319010840622126
microbiome.,0.2600589022525052
In,0.4268151369950893
vitro,0.4174176771540682
and,0.717891607351331
ex,0.6048299214961285
vivo,0.6004260636032676
analyses,0.6011126762693955
demonstrate,0.6582845609968883
that,0.7819713469773463
C.,0.663148489586346
difficile,0.6156616173875151
can,0.7482340200966755
exploit,0.6907636522489952
specific,0.6950499268038658
metabolites,0.6985036162995529
that,0.7218874684995267
become,0.7277386566024514
more,0.8010516338306545
abundant,0.7200327382483924
in,0.7957858545502229
the,0.8326981701492115
mouse,0.7772810202131843
gut,0.7059324603295215
after,0.7865503831742594
"antibiotics,",0.7993087803029872
including,0.7204708096218891
the,0.7839989730570915
primary,0.7655901665984919
bile,0.7635557617071341
acid,0.7360873834403979
taurocholate,0.7406191920194026
for,0.7547306960902681
"germination,",0.828244587448604
and,0.7939566890977153
carbon,0.7927422733132564
sources,0.7902526571801419
such,0.6979299452323144
as,0.7029146383318569
"mannitol,",0.692173198615029
"fructose,",0.7068483614722343
"sorbitol,",0.6896794412958366
raffinose,0.6484815027684623
and,0.6796227436271063
stachyose,0.6653832345637618
for,0.7140524384747352
growth.,0.803219963199622
Our,0.4523483341166049
results,0.3826786838563465
indicate,0.4617477480894984
that,0.5121553725032585
antibiotic-mediated,0.3985204695638906
alteration,0.3003725461021208
of,0.3704854075947046
the,0.3748758419000335
gut,0.3946935371495305
microbiome,0.4109448336592784
converts,0.42087977415615124
the,0.3952392242754224
global,0.33063829708341086
metabolic,0.3627564736799859
profile,0.34517791918683416
to,0.43245308914124836
one,0.3962130975114697
that,0.38161330201884097
favours,0.3820575489009339
C.,0.43074922894185297
difficile,0.413149118761206
germination,0.3844420537214356
and,0.4229830037571235
growth.,0.3857367687670122
The,0.03195989642793937
canonical,0.01890405198923558
role,0.017727234050278023
of,0.026521394300852902
messenger,0.026452499962109393
RNA,0.022941563155010794
(mRNA),0.02648724963474143
is,0.01476542003005121
to,0.01713941585267655
deliver,0.02751969632883107
protein-coding,0.021124822131243056
information,0.028723133677233587
to,0.017084140691586848
sites,0.014640621560226268
of,0.007505860580210109
protein,0.017542765340632156
synthesis.,0.02134477693397513
"However,",0.04085688873813084
given,0.0754825031222053
that,0.08642616673983661
microRNAs,0.07557430468326742
bind,0.09153463852830238
to,0.10216376190276447
"RNAs,",0.06596675182735462
we,0.06447497841471685
hypothesized,0.023665722184473836
that,0.07606676642126825
RNAs,0.07958641623347985
could,0.07187684580329601
possess,0.09228888532073846
a,0.10714770576413302
regulatory,0.09500646638796353
role,0.14358843784183678
that,0.09668328190337648
relies,0.10931158052899927
on,0.13117510542074928
their,0.07832257304438986
ability,0.12960895895683855
to,0.11856764761271973
compete,0.1429574586045177
for,0.11635412181288897
microRNA,0.12514034814227992
"binding,",0.1484925536806326
independently,0.15272808287460948
of,0.11889442404568361
their,0.06008762639291592
protein-coding,0.05318525320386782
function.,0.13266131383467808
As,0.030874376723653976
a,0.01963558729043946
model,0.01803663576527087
for,0.01603142255995378
the,0.012304978678912023
protein-coding-independent,0.01756539024543795
role,0.014215765410674189
of,0.021654771935233512
"RNAs,",0.014207358260063014
we,0.04787186445671874
describe,0.025450928096595094
the,0.015622424286711595
functional,0.015621390370843697
relationship,0.01962553636995559
between,0.014814487431503395
the,0.029571744137481547
mRNAs,0.04132367393862343
produced,0.02728137015034191
by,0.04213824478533214
the,0.027858344146576675
PTEN,0.04079178933834323
tumour,0.0431609676835818
suppressor,0.028737777093549164
gene,0.06118804225236951
and,0.022144780835411913
its,0.027535218308162236
pseudogene,0.03183930418838396
PTENP1,0.06710907690241409
and,0.020320284772811774
the,0.018917700514926594
critical,0.02188270077209482
consequences,0.02204395162990192
of,0.020656567987559143
this,0.03363021141202603
interaction.,0.3507568204561187
We,0.5106101199281904
find,0.5867904940942065
that,0.6389472724026845
PTENP1,0.5048577225581459
is,0.5879044376210552
biologically,0.5401455607731326
active,0.5655775616349565
as,0.6215888658605438
it,0.6347944957102816
can,0.6619275842841952
regulate,0.6486063713878871
cellular,0.6503287378514938
levels,0.6040198550656207
of,0.6299060986809547
PTEN,0.5406816108957495
and,0.7029698937264067
exert,0.6984852202647179
a,0.6439573027019837
growth-suppressive,0.5764755060412471
role.,0.5951960254582196
We,0.3205779627954582
also,0.3760731229660266
show,0.47493305604117814
that,0.3725886261215656
the,0.29418757629596737
PTENP1,0.26907855557940735
locus,0.20885365732952788
is,0.21326870691177816
selectively,0.18461829541241367
lost,0.20606449996259693
in,0.23043637968167358
human,0.26607463930611225
cancer.,0.18449422836150337
We,0.07404853979414887
extended,0.03881347919407317
our,0.02400228854018242
analysis,0.02968619164901958
to,0.026078233962027065
other,0.023929461718500425
cancer-related,0.02162834017038579
genes,0.020895329364751362
that,0.018836198638916887
possess,0.0284482740460025
"pseudogenes,",0.015953566413811245
such,0.02303645905675102
as,0.03068171830736632
oncogenic,0.04678095036861948
KRAS.,0.04185773024715389
We,0.21651541203074184
also,0.17040725748804936
demonstrate,0.2274402314129522
that,0.17694312758334646
the,0.15157461828626187
transcripts,0.12449076542065915
of,0.16612664223716495
protein-coding,0.10940775443955322
genes,0.1268293394014024
such,0.10340163157006754
as,0.10375862565375092
PTEN,0.16481893941795375
are,0.14694926119628704
biologically,0.09027217849380946
active.,0.13921280685470566
These,0.18026034032841015
findings,0.1669017034687417
attribute,0.19422267065910415
a,0.19771810711042737
novel,0.1550093583586775
biological,0.12685418042784902
role,0.1341335140782873
to,0.13558575241939175
expressed,0.17696514235096963
"pseudogenes,",0.16373456532895972
as,0.34409854886439895
they,0.19778024212727224
can,0.2491613324867052
regulate,0.23611630023562497
coding,0.4316594786154685
gene,0.45911256707220127
"expression,",0.4593243480478724
and,0.4607598066846872
reveal,0.44405820775381255
a,0.397326810508476
non-coding,0.38478720016207896
function,0.3512618939505268
for,0.3519996437380683
mRNAs.,0.4663092474839756
To,0.039757551128106465
initiate,0.03962427918560734
adaptive,0.03954604122825245
"immunity,",0.046500729807368205
dendritic,0.03945733704909521
cells,0.045432776455436946
(DCs),0.026408221054495213
move,0.04284847522070954
from,0.043074890284327066
parenchymal,0.05821879140380005
tissues,0.0521887976052797
to,0.02627198905720765
lymphoid,0.025249542023148167
organs,0.03453323285246438
by,0.05188705934229666
migrating,0.030357860435318382
along,0.040248555552141636
stromal,0.026975781660047476
scaffolds,0.025869222031010598
that,0.02418826957723937
display,0.03221958335632126
the,0.03516196572528702
glycoprotein,0.03513290321357079
podoplanin,0.034820844843646705
(PDPN).,0.016365001903177315
PDPN,0.5866223879259254
is,0.6474432601003901
expressed,0.694968453353887
by,0.7814284315771491
lymphatic,0.7744098695135226
endothelial,0.8080001922811799
and,0.7317971170050417
fibroblastic,0.7787371656214611
reticular,0.7708235480383036
cells,0.7508087820787945
and,0.7749121182108154
promotes,0.7417001620767847
blood-lymph,0.6709666512078448
separation,0.7210819045576747
during,0.767164104127262
development,0.7510223601237618
by,0.8074390540107365
activating,0.7412570584210513
the,0.6432375043855045
C-type,0.5540031330738407
lectin,0.5895203291595749
"receptor,",0.6104071506739318
"CLEC-2,",0.5043834419100677
on,0.6796367987001496
platelets.,0.5453323883866319
"Here,",0.45520808607430474
we,0.5409895043099947
describe,0.3113734993940552
a,0.2619797972696035
role,0.27364509253269226
for,0.21776847241860775
CLEC-2,0.29265171388946387
in,0.04695505907099486
the,0.03147028849357485
morphodynamic,0.01579045881435486
behavior,0.03206476168324968
and,0.03241973183535641
motility,0.01755129385856104
of,0.02606833219649602
DCs.,0.06266174627850499
CLEC-2,0.5618877928174392
deficiency,0.561578729785357
in,0.6449809486801976
DCs,0.4475918323109736
impaired,0.6522501635353161
their,0.4872281031781044
entry,0.5753421114882105
into,0.5663211711483239
lymphatics,0.49333135468646155
and,0.5947847636183266
trafficking,0.48051102015369146
to,0.5196637721916606
and,0.46745421310151564
within,0.44056163894383926
lymph,0.42638456896059723
"nodes,",0.46769814734817555
thereby,0.5753657231075372
reducing,0.4728949323916563
T,0.2423817946971852
cell,0.42721634681225534
priming.,0.404763968550157
CLEC-2,0.038664647751278765
engagement,0.03815915816692002
of,0.02541780372405877
PDPN,0.023125713082550178
was,0.023068753720629893
necessary,0.024546993380225656
for,0.026658024253959214
DCs,0.03105257459515471
to,0.018297475595005584
spread,0.02351819761945596
and,0.03759226468976871
migrate,0.02350815800268966
along,0.01960315387038575
stromal,0.01254016049397428
surfaces,0.018592922965902595
and,0.04080003212960867
sufficient,0.035595977985879
to,0.019671054674805413
induce,0.022852300465815524
membrane,0.022544321391618587
protrusions.,0.01913478895654974
CLEC-2,0.6412263578865158
activation,0.7301305155462159
triggered,0.7798086570968117
cell,0.8551315378718125
spreading,0.8382770546991064
via,0.8601955509875975
downregulation,0.7919958081818408
of,0.8195428940539303
RhoA,0.7697548978270872
activity,0.7906006736431395
and,0.8324148495344967
myosin,0.7863610154007783
light-chain,0.816810312027416
phosphorylation,0.7745948995312799
and,0.7965405958795849
triggered,0.7733482559486297
F-actin-rich,0.5959865558348735
protrusions,0.6059385922769018
via,0.6794588767573362
Vav,0.6797979674812336
signaling,0.6880246140064995
and,0.6644006603648065
Rac1,0.6134128716025714
activation.,0.6335102402599526
"Thus,",0.7711184861725854
activation,0.7609164180080054
of,0.7780582692441959
CLEC-2,0.77342279574408
by,0.775622422065221
PDPN,0.7769995499744592
rearranges,0.7403702673651356
the,0.7507149675211161
actin,0.7969334262158737
cytoskeleton,0.7620131861658854
in,0.75945017404621
DCs,0.6783909755148704
to,0.778085276231388
promote,0.7691551529898417
efficient,0.7247822430616626
motility,0.7430527855721368
along,0.6789383040188092
stromal,0.6844918842316111
surfaces.,0.6558418585127123
Large,0.02751108695797113
noncoding,0.02827948070860578
RNAs,0.022984310263576165
are,0.014340561781851544
emerging,0.014597633458035855
as,0.014258035608868812
an,0.01341296329978705
important,0.013965894586432952
component,0.016654835668972096
in,0.013276801279708705
cellular,0.024851635766778353
regulation.,0.02363734635108879
Considerable,0.024539741395576735
evidence,0.042829602496647
indicates,0.05128061820267486
that,0.038740963689504956
these,0.04110017181895106
transcripts,0.03386282863180498
act,0.05681690367379747
directly,0.07484298587821703
as,0.08879939275501522
functional,0.04157313079898776
RNAs,0.032676905244364444
rather,0.09798677532445069
than,0.10720168906915181
through,0.12404833617402966
an,0.0614910747040223
encoded,0.06625963037689417
protein,0.02556078350747559
product.,0.050169120819317674
"However,",0.0069838413341512424
a,0.010838278342480695
recent,0.00914834721317954
study,0.010415489667109248
of,0.005811034062860164
ribosome,0.008550133285453678
occupancy,0.007861013933950944
reported,0.016297819742190262
that,0.010826641761723646
many,0.007946282106282539
large,0.006632365462602139
intergenic,0.006032397195381586
ncRNAs,0.01306900566762881
(lincRNAs),0.007516240147004123
are,0.006914446794485496
bound,0.008304822394182815
by,0.007365358455102926
"ribosomes,",0.006020542015178051
raising,0.0053216393378207605
the,0.004207307131053863
possibility,0.005316420884060086
that,0.005722701645178029
they,0.006007592271516626
are,0.005084159838603244
translated,0.007695940311061849
into,0.007535581547529788
proteins.,0.004877707332625648
"Here,",0.5319539183582884
we,0.5562813429245123
show,0.5360419884539495
that,0.5659964924716915
classical,0.4380307370562525
noncoding,0.3933209002593966
RNAs,0.3027815740846407
and,0.4206612880133676
5',0.37411859504589123
UTRs,0.3597137946913065
show,0.37143110768064824
the,0.332636671025503
same,0.34750289609784113
ribosome,0.3588457585722494
occupancy,0.31528199171475374
as,0.3300509100143183
"lincRNAs,",0.40561166471546806
demonstrating,0.6115946113893267
that,0.5621238481800884
ribosome,0.427940344962728
occupancy,0.4513021130394717
alone,0.09307711927426975
is,0.04392732063806587
not,0.04125226596074206
sufficient,0.050335310780285004
to,0.05394435724627391
classify,0.03294729014361544
transcripts,0.04790606955800838
as,0.0468146909346125
coding,0.048233072315181466
or,0.038903736221550064
noncoding.,0.02814283279060696
"Instead,",0.0648662842689178
we,0.14637208275035532
define,0.08033137870085114
a,0.08562591405237277
metric,0.11641075928554594
based,0.0732952845863693
on,0.07585020781420902
the,0.06974637679751117
known,0.09193685670838972
property,0.12507365939880064
of,0.12319145507652002
translation,0.1687394958816119
whereby,0.13857827615823104
translating,0.200328332001762
ribosomes,0.17881120286566682
are,0.16439117740615058
released,0.16600292402693945
upon,0.17266064145065085
encountering,0.15727145918472357
a,0.14366141241547078
bona,0.17398022218523335
fide,0.15834610652845066
stop,0.1642670241356855
codon.,0.22056005884205124
We,0.37652505116069407
show,0.39099851761906823
that,0.26498244594638287
this,0.16898163821908244
metric,0.1334521792431782
accurately,0.19001795174862568
discriminates,0.16036148880273285
between,0.11604385032735463
protein-coding,0.1689288964567959
transcripts,0.14839520013312535
and,0.10496347130571428
all,0.12297390570521619
classes,0.0746376653131459
of,0.0839852206342175
known,0.09801679750383552
noncoding,0.08621413484225056
"transcripts,",0.12649841968870862
including,0.08564773802928631
lincRNAs.,0.1380762480394686
Taken,0.13892232969721652
"together,",0.13985927891519687
these,0.17023978425990807
results,0.13155215681561055
argue,0.22306840381312115
that,0.18301874242318247
the,0.17813481130757544
large,0.1827387786624669
majority,0.15536198870187368
of,0.19787315531246416
lincRNAs,0.18655164931717721
do,0.14884303570736934
not,0.1635664691406331
function,0.1586740581133538
through,0.16810846602433982
encoded,0.10840366737595666
proteins.,0.11129888758922059
Despite,0.07260204842609197
being,0.05627443306590909
surrounded,0.05219744284791564
by,0.057773785296477566
diverse,0.0379837975328528
"nutrients,",0.05724405590430747
mammalian,0.050249840852358466
cells,0.07750671172965203
preferentially,0.05457116871801787
metabolize,0.06972092680274798
glucose,0.06766568207704418
and,0.0685446775357107
free,0.0701852910286086
amino,0.038513009136758994
acids.,0.046045813604356695
"Recently,",0.14011337437283883
Ras-induced,0.2131928508670985
macropinocytosis,0.20232212335810323
of,0.20967326476961534
extracellular,0.10979696186468428
proteins,0.1197304665688783
was,0.11230258928480297
shown,0.1310365489442262
to,0.10945102379314695
reduce,0.1393534823602647
a,0.14183599416565942
transformed,0.12798077374334896
cell's,0.16111053978560105
dependence,0.20250389600121407
on,0.14216424354678694
extracellular,0.09187669391145988
glutamine.,0.12099960423737817
"Here,",0.26533189643131955
we,0.386433587796103
demonstrate,0.21758063763127927
that,0.15189495393264815
protein,0.1022769088015342
macropinocytosis,0.10961240681406312
can,0.09061232950611561
also,0.08594324881432544
serve,0.09992473201460948
as,0.07796595769115996
an,0.08805761888376136
essential,0.09300383690979525
amino,0.06574728251239953
acid,0.07330739061585465
source.,0.0961883485515572
Lysosomal,0.55634515592957
degradation,0.5402707857728868
of,0.5118237442532939
extracellular,0.4180826187447803
proteins,0.4492309758951825
can,0.5691012354393408
sustain,0.5761720035335146
cell,0.5666260565026771
survival,0.5298123550429372
and,0.6376392264181501
induce,0.6370231945683686
activation,0.6667650339855167
of,0.6575971317069249
mTORC1,0.5329339136624536
but,0.5265864897260573
fails,0.45682587867252117
to,0.49213376078261944
elicit,0.5475329644556578
significant,0.5174561321755645
cell,0.5498370630125358
accumulation.,0.514155546837388
Unlike,0.5743603125711738
its,0.4850886673136412
growth-promoting,0.5681543499001921
activity,0.6438026833002429
under,0.6272619660900252
amino-acid-replete,0.5347839957428465
"conditions,",0.5657567106665597
we,0.7237478363114161
discovered,0.7185520543228551
that,0.7307009760439525
mTORC1,0.7035904007304074
activation,0.723072165229964
suppresses,0.6906635753500356
proliferation,0.5807675465643604
when,0.6194087892299732
cells,0.5658327181517879
rely,0.5389019421944928
on,0.5579789259225519
extracellular,0.5404525879709582
proteins,0.51646666420742
as,0.5509951236597338
an,0.5751643698254478
amino,0.5010101427550748
acid,0.5104596938582
source.,0.5955356068792115
Inhibiting,0.9400357844722544
mTORC1,0.8925875958895922
results,0.9328631548454435
in,0.9294922733046457
increased,0.9308520748455951
catabolism,0.925943882896883
of,0.8897554559418595
endocytosed,0.9122808837722921
proteins,0.8701642389776878
and,0.9241243436143842
enhances,0.9173962316816945
cell,0.8767077449982343
proliferation,0.8723893969171007
during,0.8828238062671081
nutrient-depleted,0.8627095282797657
conditions,0.8673632230504069
in,0.8249588819299485
vitro,0.8321494791389604
and,0.8543021168669076
within,0.865518820478103
vascularly,0.8225059537908409
compromised,0.8510319781989972
tumors,0.8177573396844917
in,0.813855052156648
vivo.,0.8387517712695814
"Thus,",0.8932369601124089
by,0.8779728555433439
preventing,0.7982873911947169
nutritional,0.745536785600584
consumption,0.7030763116211939
of,0.7240481313644084
extracellular,0.7243071397070889
"proteins,",0.6786523264099481
mTORC1,0.7718420598230181
couples,0.6859345601853003
growth,0.683949951002315
to,0.6439297346232726
availability,0.5971326611982365
of,0.631526368045128
free,0.5825497955479083
amino,0.5679342633030682
acids.,0.5694468456768266
These,0.09712456250137082
results,0.08423667228834927
may,0.027140441500620106
have,0.02863230838147269
important,0.04546625842166606
implications,0.05416655927808857
for,0.19605427863197472
the,0.11591806906259418
use,0.17077248260673036
of,0.19345887822812596
mTOR,0.29056692923173866
inhibitors,0.18695157880117105
as,0.13094850672916497
therapeutics.,0.18987302022747302
Mitochondria,0.22064148069803477
are,0.25357849825700857
the,0.28829891078183406
primary,0.2919574565308456
energy-generating,0.35258191707421355
system,0.3260374061123683
in,0.27094830879954357
most,0.18864211512705306
eukaryotic,0.25166862044732324
cells.,0.27524214894655985
"Additionally,",0.3052651310881974
they,0.2651770468948732
participate,0.3344341165952456
in,0.4197711594153637
intermediary,0.40648957461738333
"metabolism,",0.405150797237654
calcium,0.3841011208777495
"signaling,",0.43984530165837904
and,0.33530902442618615
apoptosis.,0.45288487343478095
Given,0.0568112503138738
these,0.05808473579374314
well-established,0.02541681448063703
"functions,",0.055095721261773804
it,0.03703355801202996
might,0.028384950187076
be,0.022510036881347107
expected,0.03305625999535651
that,0.05101758364376797
mitochondrial,0.030715722035687017
dysfunction,0.02605277405400041
would,0.05965496038567246
give,0.03689679214052734
rise,0.04091261903225178
to,0.031591895542556515
a,0.02963607498014186
simple,0.020919421899316216
and,0.04508152746859504
predictable,0.021462007320816674
set,0.01594339627913583
of,0.01715687749400008
defects,0.022393971237833925
in,0.018433689586380492
all,0.018330807130942345
tissues.,0.0169736061521416
"However,",0.009088948819305078
mitochondrial,0.013858821614455147
dysfunction,0.012320125127618793
has,0.007846992869027633
pleiotropic,0.006365876122517752
effects,0.009114655489119317
in,0.0078011595387595545
multicellular,0.010410553944162482
organisms.,0.007957329822581995
"Clearly,",0.0037916052384884785
much,0.004100018782615315
about,0.005428853386769037
the,0.004551784023622476
basic,0.004460721721080974
biology,0.007289417452741689
of,0.01022764099600417
mitochondria,0.02011596362086615
remains,0.0022561243926728703
to,0.002076551950757759
be,0.002209627411715746
understood.,0.0029414977941167623
Here,0.22220701595479536
we,0.2025465132755553
discuss,0.1065422119652088
recent,0.09371955829371811
work,0.13493469889737464
that,0.13876355476713167
suggests,0.12276865805672575
that,0.13682533098990926
the,0.07661671087033037
dynamics,0.0887318525896281
(fusion,0.3163812296884523
and,0.2438485782644491
fission),0.16879865492022716
of,0.15094222691181935
these,0.20019628052954133
organelles,0.18753056409196373
is,0.11936057866567858
important,0.1682839198619462
in,0.13720924911864574
development,0.18645748192303918
and,0.15199439342665672
disease.,0.0836893808768261
Leukemias,0.02410674126574962
and,0.006860108996251059
other,0.005207392676200373
cancers,0.0054366214044716185
possess,0.00959240847161404
self-renewing,0.006909353897287673
stem,0.005064963974602929
cells,0.006564135723855635
that,0.006308464370124801
help,0.00575504102021589
to,0.0058055284046753045
maintain,0.00810960942481212
the,0.007622164077993547
cancer.,0.006539837959571058
Cancer,0.002132315966362037
stem,0.001350115581478059
cell,0.0020632117849903363
eradication,0.0013057736294577336
is,0.0011011853940215547
thought,0.001176386940687144
to,0.0011160137282800442
be,0.0010290254769339219
crucial,0.0011504561590744687
for,0.0009548422379814887
successful,0.0010809308202522805
anticancer,0.0010356433887167944
therapy.,0.001053751447467183
Using,0.08743295808785764
an,0.04916013505448148
acute,0.017501011855043352
myeloid,0.020358781975429917
leukemia,0.03059700628839824
(AML),0.0012905332156012469
model,0.03096700013636691
induced,0.01973647119701357
by,0.03222978470076925
the,0.030374743635617332
leukemia-associated,0.04682157482960904
monocytic,0.028452481835675537
leukemia,0.04425443622373265
zinc,0.03382584429444529
finger,0.03609976003101879
(MOZ)-TIF2,0.016750521782185928
fusion,0.031899425554596586
"protein,",0.035271368533594416
we,0.18314871894521814
show,0.11482582741250033
here,0.1651268252202589
that,0.08586697571682117
AML,0.061157911730225015
can,0.0487332796946864
be,0.03224720558040174
cured,0.030359579929596703
by,0.05915135057806028
the,0.05232290965219997
ablation,0.027025358222843444
of,0.039715048006957056
leukemia,0.06060947826868251
stem,0.040341972728202107
cells.,0.06080374983904143
The,0.34108211484079815
MOZ,0.23660909227041255
fusion,0.29493997667435323
proteins,0.38870024567731487
MOZ-TIF2,0.3113571470684587
and,0.448694387301667
MOZ-CBP,0.35037682595183306
interacted,0.3026681141348946
with,0.2877282300781839
the,0.37425927483999244
transcription,0.39561607000372334
factor,0.37205301648752037
PU.1,0.28811834640803874
to,0.41243229381733265
stimulate,0.4628486802558237
the,0.39763306626587364
expression,0.4303651755822913
of,0.3642802068518806
macrophage,0.3286534699180675
colony–stimulating,0.337941139352597
factor,0.29641314200433166
receptor,0.2765352502890746
"(CSF1R,",0.2465697354193839
also,0.14453294997632263
known,0.18104342330859124
as,0.1813433099168115
"M-CSFR,",0.2794724573001629
c-FMS,0.23909285867261126
or,0.19999360984915626
CD115).,0.29565075834958404
Studies,0.12944880964103375
using,0.1164002881314339
PU.1-deficient,0.10115291582225594
mice,0.12484525557591021
showed,0.17146830603832883
that,0.1601613695351638
PU.1,0.12510909419443214
is,0.1516390473884412
essential,0.14466619371086936
for,0.1863399981742239
the,0.18857612006487937
ability,0.17810634794102395
of,0.2158801488343597
MOZ-TIF2,0.18201625584415246
to,0.17766853853385242
establish,0.15499078616867262
and,0.19388337022657584
maintain,0.15197909806605758
AML,0.14922343715132141
stem,0.12748569453848557
cells.,0.16581711408712446
Cells,0.4140827312748716
expressing,0.40479982242243784
high,0.36234521139140885
amounts,0.3791982751417738
of,0.4162249211141154
CSF1R,0.39659897561284624
(CSF1Rhigh,0.38074850641929464
"cells),",0.4062443170729506
but,0.4035124479785716
not,0.4217519101244315
those,0.4376376846536558
expressing,0.41926940955341
low,0.37852252180329027
amounts,0.4008119971980187
of,0.4178160398697039
CSF1R,0.44611737604699275
(CSF1Rlow,0.40712640800436495
"cells),",0.316161718032034
showed,0.3210803277764906
potent,0.2309083995518934
leukemia-initiating,0.25141515074525006
activity.,0.1950261015620097
Using,0.6448809139348042
transgenic,0.567652177316248
mice,0.5887019941932357
expressing,0.5239549213587895
a,0.5401773212474209
drug-inducible,0.49259489161900977
suicide,0.5439954097347683
gene,0.4882513233143999
controlled,0.5126339237669465
by,0.4884181776019976
the,0.5261720875181052
CSF1R,0.5758119822475791
"promoter,",0.5538914782908276
we,0.6319640919739035
cured,0.645691609234742
AML,0.5808728126543556
by,0.7319432308086842
ablation,0.6917547877798039
of,0.6910988898934419
CSF1Rhigh,0.5822059022081506
cells.,0.6549327738157293
"Moreover,",0.8316672706874817
induction,0.8585205476407418
of,0.8637435161770339
AML,0.8116156894065046
was,0.8305451004167198
suppressed,0.8514276767457787
in,0.8570541159402779
CSF1R-deficient,0.8473648661077231
mice,0.8649632299755243
and,0.8646190803291274
CSF1R,0.8592986785008301
inhibitors,0.8523833293198256
slowed,0.849281172746969
the,0.8254483218495011
progression,0.8441437186919961
of,0.8235612590318533
MOZ-TIF2–induced,0.7696982758977556
leukemia.,0.8285362072779014
"Thus,",0.27684225587650113
in,0.2034366660202539
this,0.19296228308580426
subtype,0.13611892385003496
of,0.17969651715876914
"AML,",0.21601882270891956
leukemia,0.22193610067556502
stem,0.1800012964263323
cells,0.19062898106067708
are,0.15663213524554545
contained,0.1429548661307251
within,0.14688657680579137
the,0.24115271571640537
CSF1Rhigh,0.4652799582087368
cell,0.4718368746931401
"population,",0.40078086837372806
and,0.3621349022461908
we,0.5431121535525933
suggest,0.31503499618328534
that,0.23475826730719251
targeting,0.36348389370248774
of,0.4570090769332243
PU.1-mediated,0.5077528345946755
upregulation,0.4294266980338526
of,0.46377787408073995
CSF1R,0.5623222144227152
expression,0.4957564082325349
might,0.12722828785289428
be,0.14152703150246948
a,0.12545634242869808
useful,0.13877877784348494
therapeutic,0.18170515175359944
approach.,0.16855946986330067
OBJECTIVE,0.0015395658883240635
Although,0.00203219700775993
the,0.0013868448918867096
Polypill,0.00127263818145213
concept,0.0012332950865247296
(proposed,0.0010212005769509103
in,0.0011199422242120702
2003),0.0010441469291558743
is,0.001250226100491231
promising,0.0011680662625243165
in,0.0014430459433536652
terms,0.0015345563469496522
of,0.001138938977611513
benefits,0.0007763995349101708
for,0.0009389503365125468
cardiovascular,0.0010229457417565554
risk,0.0005614489113606037
"management,",0.0007283729240661633
the,0.001098402725992043
potential,0.0008911392420574888
costs,0.0006799295576340489
and,0.0008556066807595492
adverse,0.0005283831807211579
effects,0.0005492807281642472
are,0.0009008180424087964
its,0.0008480670073982486
main,0.0008005167783503268
pitfalls.,0.0007411353474508414
The,0.0008073903184851414
objective,0.0007721051061796003
of,0.0010110704542743213
this,0.0007934856155928858
study,0.0006772471567078731
was,0.001027173800369613
to,0.0007546533865600474
identify,0.0006766968235383849
a,0.000750662257260695
tastier,0.0007654815766971867
and,0.001587834624514833
safer,0.0009201031954851432
alternative,0.0009371427242263055
to,0.0009057867247230921
the,0.0007914544267350055
Polypill:,0.0008588167010198646
the,0.000897855944760592
Polymeal.,0.0009786423029181544
METHODS,0.006235410560881713
Data,0.0018436774110120264
on,0.0016803716638585818
the,0.0015252002480144933
ingredients,0.0016547091822811852
of,0.002342496528272042
the,0.00320322096262383
Polymeal,0.002879545082277428
were,0.0024868360339400904
taken,0.0013199668595894215
from,0.0017084199094257047
the,0.002117549002378007
literature.,0.00216174535325338
The,0.0023290418423108678
evidence,0.0023967861661600694
based,0.0016929305900618761
recipe,0.0024692264897202055
included,0.00290157292649283
"wine,",0.0014750637948882969
"fish,",0.0011975944279537536
dark,0.0013748987476328413
"chocolate,",0.0015302080705199797
"fruits,",0.001118128956444887
"vegetables,",0.000913069046395243
"garlic,",0.0012179441452917906
and,0.0017688652125874725
almonds.,0.0012354310885750329
Data,0.016932231481255843
from,0.01338645871662017
the,0.015281931038556797
Framingham,0.014020171525326995
heart,0.0035485395000419725
study,0.003283380057777769
and,0.002723652127406107
the,0.0022070248613935404
Framingham,0.003135981213565616
offspring,0.0024742814568547364
study,0.0023842682575090594
were,0.002052329933143325
used,0.0014479157412506352
to,0.001234124123518597
build,0.001005304509517427
life,0.001335059692276459
tables,0.0008817833964427522
to,0.0009330359576290436
model,0.0009974181743254754
the,0.0009018097244820416
benefits,0.0011416504773703907
of,0.0017786793339632822
the,0.0025330014917215233
Polymeal,0.00180624290552711
in,0.001329430512907855
the,0.001398712184982113
general,0.0008867479325352462
population,0.001120615350639926
from,0.0011210739375141336
age,0.0010392395142119974
"50,",0.0009410626491945533
assuming,0.0010109632976041461
multiplicative,0.0009209269773242065
correlations.,0.000777212508334265
RESULTS,0.009624128244622927
Combining,0.005943092875607397
the,0.004034104081099045
ingredients,0.004057616323327664
of,0.005906485222361376
the,0.00814835037212298
Polymeal,0.005280482262095108
would,0.008403932739536811
reduce,0.005816207138518748
cardiovascular,0.00584422843997191
disease,0.003634354649043056
events,0.006245313777917918
by,0.026667326988539353
76%.,0.007244484690967471
For,0.8465120178364136
"men,",0.8292928205955152
taking,0.8040350590133466
the,0.7357835030390585
Polymeal,0.7080235866784653
daily,0.8364744549748896
represented,0.8709570234448497
an,0.8649570058870704
increase,0.8183999252096441
in,0.8652940665156234
total,0.8920326407435084
life,0.8597498888185239
expectancy,0.8553085733792153
of,0.8661123239906551
6.6,0.8527566615040897
"years,",0.8355642029836468
an,0.8570234289080629
increase,0.8249243134748432
in,0.8564530135687275
life,0.8507077719011995
expectancy,0.8343608601793505
free,0.8308947916152023
from,0.8636974567399158
cardiovascular,0.8396980033836876
disease,0.8349368966929944
of,0.8383289168459156
9.0,0.8009652922235697
"years,",0.8175172899012982
and,0.8405534898763228
a,0.8298693149582329
decrease,0.7794240735288469
in,0.8055392204914971
life,0.8236080757238686
expectancy,0.8021536825042045
with,0.27700496642007166
cardiovascular,0.16760575572467432
disease,0.1694027027678227
of,0.23217569817261666
2.4,0.21469832305122663
years.,0.11930941976243405
The,0.02158477607392643
corresponding,0.017103244298904207
differences,0.016953917663494366
for,0.026027607292451786
women,0.0272309107879188
were,0.025579668452101818
"4.8,",0.04219707693310191
"8.1,",0.03130416599799449
and,0.02973858147484261
3.3,0.05313028080350939
years.,0.01630527696100884
CONCLUSION,0.9043126959584422
The,0.8185071242391209
Polymeal,0.8074362367044181
promises,0.8745098502416995
to,0.9113593919954712
be,0.9185378587754687
an,0.9216358350890156
"effective,",0.8993307256876215
"non-pharmacological,",0.8915349980838555
"safe,",0.8307644790283049
"cheap,",0.8345125068536804
and,0.9156145751566085
tasty,0.899082607715934
alternative,0.9071299243404631
to,0.928547857369648
reduce,0.8937228335546228
cardiovascular,0.8822808445877721
morbidity,0.8840567377327182
and,0.9342427217322931
increase,0.9073362387402611
life,0.8648179242212186
expectancy,0.8962614819060588
in,0.8628829842085765
the,0.883033855390486
general,0.8524839709354659
population.,0.8312156116547578
Recent,0.16230680330848393
studies,0.1742722624908325
have,0.1327046365126629
investigated,0.11245860271708331
the,0.08960387771519825
dendritic,0.1706058375453514
actin,0.1752470070787532
cytoskeleton,0.10873224051721846
of,0.12310165724734999
the,0.11402168588267533
cell,0.15518089540234906
edge's,0.1565638510278526
lamellipodial,0.1641320864349135
(LP),0.0993301812785918
region,0.15736825631589627
by,0.16704080181518763
experimentally,0.20070303789080518
decreasing,0.17117168624937681
the,0.12527445713428373
activity,0.22347815351759862
of,0.185947375349587
the,0.19814453482537944
actin,0.2935989344731399
filament,0.31497481494347523
nucleator,0.29499180201865466
and,0.3067269517563874
branch,0.16346262977314374
"former,",0.3141092019924333
the,0.11097300301449915
Arp2/3,0.2943485908735234
complex.,0.20492259448752215
Here,0.21399971441104018
we,0.1823002107792273
extend,0.11893323033277166
these,0.10979327415422092
studies,0.12627773910164275
via,0.14009407942873964
pharmacological,0.10683121803277283
inhibition,0.11897322213360577
of,0.12320245840796053
the,0.12488193768833583
Arp2/3,0.1867095905536545
complex,0.12574486758886666
in,0.1507580931402858
sea,0.11280177087261155
urchin,0.11914393948475374
"coelomocytes,",0.1457039519723451
cells,0.16458404748011188
that,0.15470161012648054
possess,0.1943715350842389
an,0.17286323484197336
unusually,0.1526376933392614
broad,0.1513696666403951
LP,0.14831820454498315
region,0.21056139941045132
and,0.2693194853851141
display,0.15234954513856577
correspondingly,0.14758653147446574
exaggerated,0.1459452876067676
centripetal,0.10336529317353724
flow.,0.14046569827061525
Using,0.3331992558155572
light,0.20569725977634767
and,0.17682689991955508
electron,0.11353652397857092
"microscopy,",0.1723857806587443
we,0.4038024875406526
demonstrate,0.3671329366388983
that,0.39281685901017366
Arp2/3,0.7743045465876998
complex,0.7937783308178076
inhibition,0.8288895196899391
via,0.7387060238549369
the,0.7426611798896913
drug,0.7199307759150184
CK666,0.7979572646235656
dramatically,0.846366862658605
altered,0.8520628826379731
LP,0.774906810783563
actin,0.8464207046565028
"architecture,",0.7892373919019539
slowed,0.8688498026265444
centripetal,0.8129846398564304
"flow,",0.7756636629450553
drove,0.8586710966583017
a,0.8566404610943059
lamellipodial-to-filopodial,0.7815780866151192
shape,0.7635526087416425
change,0.7708153876240688
in,0.8267157048638386
suspended,0.7509594616607711
"cells,",0.7606768585383431
and,0.8439022399685707
induced,0.8312393007434639
a,0.8109840744547653
novel,0.7843358019127694
actin,0.770371074370278
structural,0.6717131005375832
organization,0.7393422814391493
during,0.8006239352466088
cell,0.6952656457613368
spreading.,0.6314349805056453
A,0.16342656703837496
general,0.11710593355814133
feature,0.13212143304715893
of,0.17707130522858808
the,0.14565625269131358
CK666,0.22127842495602038
phenotype,0.13091934229595328
in,0.16420810881326608
coelomocytes,0.15576858987857417
was,0.19854618715769015
transverse,0.1672483197437652
actin,0.2325783590316253
"arcs,",0.16809029521974042
and,0.19802341068050577
arc,0.195254167209369
generation,0.23828143709347557
was,0.1948807475310712
arrested,0.1906562130143676
by,0.23353955118605055
a,0.21032080020465613
formin,0.1764174704654228
inhibitor.,0.2092478197114417
We,0.48390171352029665
also,0.40945455610922193
demonstrate,0.49129627412932386
that,0.4359593050187141
CK666,0.3917211964381526
treatment,0.38921576087998294
produces,0.3554985387123615
actin,0.47494553971403003
arcs,0.3592916055732971
in,0.36910011033428614
other,0.3323385935959099
cells,0.28354184285790973
with,0.28934400385691306
broad,0.23886642859243698
LP,0.215231246381484
"regions,",0.2702493229622708
namely,0.29512650945909147
fish,0.28936975470426557
keratocytes,0.3231282368133001
and,0.3718935984225425
Drosophila,0.28943004040902354
S2,0.35449317334804914
cells.,0.3621617077727673
We,0.5113185229288503
hypothesize,0.3481329834142759
that,0.5010622323342365
the,0.5119690175558788
actin,0.615163089211909
arcs,0.4897813694623701
made,0.5024798784086998
visible,0.5622324065977774
by,0.6204014222395559
Arp2/3,0.6123786000680724
complex,0.5704132511469678
inhibition,0.5911979754138317
in,0.5559532029519517
coelomocytes,0.6150088058764102
may,0.4350534035369725
represent,0.47623155392588085
an,0.4584112651992704
exaggerated,0.48375482024392275
manifestation,0.5315635580212004
of,0.507538224248923
the,0.5476496706514662
elongate,0.5410458378445064
mother,0.5576396301360191
filaments,0.5640799315089504
that,0.4756502310157586
could,0.4213233919968344
possibly,0.43060650094236796
serve,0.5140454408529814
as,0.521024633748164
the,0.5578238576481845
scaffold,0.5428187151201274
for,0.5182053732139726
the,0.5457060091886663
production,0.5500653380053118
of,0.5054713818153959
the,0.5155333044416577
dendritic,0.5136873305401352
actin,0.5865481203529281
network.,0.5590702118175003
Although,0.0025880125115201468
susceptibility,0.0015512110724354411
of,0.0020753275351789763
neurons,0.0033462272627815676
in,0.001995930858672004
the,0.001831736368383079
brain,0.00240967222943577
to,0.0018357219477658424
microbial,0.0013456290589504447
infection,0.0018444664637396891
is,0.0010794472081716382
a,0.001125458902836776
major,0.001113374981579073
determinant,0.0011150660879244143
of,0.0012692438759793476
clinical,0.000997891755316261
"outcome,",0.0011325911005029433
little,0.0011884852612208574
is,0.0010417277985556323
known,0.0010801258618074547
about,0.0009432311577823649
the,0.0009452875675736008
molecular,0.0008458309320202684
factors,0.0009680444306056925
governing,0.001174755960474901
this,0.0013832053509103147
vulnerability.,0.001494988562551134
Here,0.1914143246593782
we,0.3267218506576494
show,0.23782074258211688
that,0.14583483912580503
two,0.044120928000361014
types,0.030284613506707
of,0.042965638041721516
neurons,0.0632358746275982
from,0.04270824660404102
distinct,0.023226674510881555
brain,0.036424181953316044
regions,0.026936974608053985
showed,0.10487224920666055
differential,0.051950291328921004
permissivity,0.03427055132624181
to,0.052664426894425694
replication,0.027405391878474045
of,0.026349727930006454
several,0.027236039493914347
positive-stranded,0.022118370403152173
RNA,0.021459138427778964
viruses.,0.033264122126904966
Granule,0.09863637704929579
cell,0.14332246759239617
neurons,0.13031407334255588
of,0.13052187356925846
the,0.11691610342654356
cerebellum,0.07576616206600628
and,0.11066000192563372
cortical,0.0712098384573357
neurons,0.10843498774741518
from,0.08277024973316137
the,0.09133024028366396
cerebral,0.11996658304661949
cortex,0.08142599147217428
have,0.10805051051644823
unique,0.06751111052114099
innate,0.07434916992814823
immune,0.06875132454047349
programs,0.12017152488264861
that,0.08804120749395346
confer,0.09757371709124255
differential,0.08456494310163933
susceptibility,0.06858838560805246
to,0.06963920624679291
viral,0.0711081969598554
infection,0.055118303255385234
ex,0.14676946245033545
vivo,0.07671824619855927
and,0.0979022956864045
in,0.11663631421040675
vivo.,0.11402289617065417
By,0.46462074153705774
transducing,0.39828622318801427
cortical,0.43678096848697134
neurons,0.425437615157296
with,0.3333666063775768
genes,0.33943868196147625
that,0.32660937040265936
were,0.28008418687808695
expressed,0.3174566021701391
more,0.38666175082760523
highly,0.5665478735832553
in,0.5904678844063581
granule,0.4667688098450107
cell,0.5413196035333377
"neurons,",0.5274219851207373
we,0.5585637040482989
identified,0.5494767381036814
three,0.38983162912721725
interferon-stimulated,0.44412519068280615
genes,0.40907533446033645
(ISGs;,0.353297808401651
"Ifi27,",0.427784923556426
Irg1,0.41800780958785205
and,0.4525029620889011
Rsad2,0.3960090956948006
(also,0.31540943153224044
known,0.25495979965582927
as,0.30124080072653664
Viperin)),0.3903187653200564
that,0.470273664631174
mediated,0.5639040172152053
the,0.5304309771521051
antiviral,0.4737741708542489
effects,0.48475776792285663
against,0.4684614920834634
different,0.3987307787098317
neurotropic,0.4667990932986993
viruses.,0.3986527885201295
"Moreover,",0.6249887147016995
we,0.595013799890826
found,0.6569212446526459
that,0.6179627849837159
the,0.4337656789848751
epigenetic,0.36827785361340504
state,0.3580194424636547
and,0.42873345834382975
microRNA,0.34239876154949855
(miRNA)-mediated,0.2493179844231235
regulation,0.38042355096332764
of,0.3574006928214047
ISGs,0.3583657881341015
correlates,0.4709717795960457
with,0.43308091334075016
enhanced,0.49057384400634535
antiviral,0.320927353446407
response,0.34748546190928814
in,0.39722279839111213
granule,0.4357131957221236
cell,0.46603130032075574
neurons.,0.43601672811881836
"Thus,",0.2734785255020894
neurons,0.198803094065502
from,0.11111071612652414
evolutionarily,0.1287818062838997
distinct,0.06515373921846708
brain,0.15870348537790951
regions,0.10608087054245273
have,0.11814071431574882
unique,0.09346543706215098
innate,0.1401257050572102
immune,0.1285633511175925
"signatures,",0.15913862227850878
which,0.1692099883205899
probably,0.12108815656048744
contribute,0.13480479274019508
to,0.16205190626597551
their,0.07438757445376702
relative,0.1720776451920008
permissiveness,0.5131579537383576
to,0.3454775320168621
infection.,0.4488281113623861
Leucine-rich,0.025758123914753874
repeat,0.018456245501091095
kinase,0.01518270023460906
2,0.024172554302311907
(LRRK2),0.019188818443121754
mutations,0.008786853057063003
are,0.005667490397937285
the,0.006170372024718835
most,0.0038561556990019986
common,0.004669555249489223
genetic,0.0053652665275262515
cause,0.006493570934030601
of,0.008375788650959125
Parkinson's,0.010498575551327135
disease.,0.006590296102747277
LRRK2,0.029460669272515942
is,0.013034401451647236
a,0.02348294604081161
multifunctional,0.014370032121652315
protein,0.025489708258959857
affecting,0.017693438667492383
many,0.011490646966866152
cellular,0.011139056926955495
processes,0.012200004506447712
and,0.018554536300421823
has,0.006025097968382406
been,0.004571321639762713
described,0.008332856116575178
to,0.006655849155760269
bind,0.018634528680709733
microtubules.,0.012340914723112358
Defective,0.0022893580863356387
microtubule-based,0.0028325848650816734
axonal,0.00230685195220254
transport,0.005385156325606178
is,0.0016188182925220397
hypothesized,0.0011657861574990642
to,0.0012985917217974109
contribute,0.0018362523805125616
to,0.001774438952230154
Parkinson's,0.0016722625017800317
"disease,",0.001670253249576568
but,0.0017329800725860527
whether,0.00195418906777139
LRRK2,0.0030598495883062213
mutations,0.0022190819414784437
affect,0.0017017083705230549
this,0.0014929954257395356
process,0.002025024430087683
to,0.0014448352408349672
mediate,0.0019029450017186947
pathogenesis,0.0017117069509088201
is,0.0014761390986357077
not,0.0014503894208362494
known.,0.0017802361229444924
Here,0.5531702250560219
we,0.580005055805528
find,0.5479301933224993
that,0.5888649996381369
LRRK2,0.46566281608150045
containing,0.501491553382299
pathogenic,0.5025263791106811
Roc-COR,0.557061692161746
domain,0.4915790940122894
mutations,0.4497882547725988
"(R1441C,",0.5124066576466672
Y1699C),0.4550540152067896
preferentially,0.47745889519983115
associates,0.45745975813536166
with,0.42520890244744514
deacetylated,0.5092938998377907
"microtubules,",0.4360969199650613
and,0.5323300057831375
inhibits,0.5106360960551741
axonal,0.4015650454820718
transport,0.44378745130176983
in,0.4150067036580789
primary,0.3447242057046944
neurons,0.4262740629734479
and,0.3992262068998429
in,0.40580670746340286
"Drosophila,",0.3114264895287453
causing,0.48382660080245915
locomotor,0.3887424091672672
deficits,0.46898645186486804
in,0.3807066277918764
vivo.,0.33765635298328034
In,0.811245629771014
"vitro,",0.8204633687514828
increasing,0.8536916186039376
microtubule,0.8620732600083291
acetylation,0.7962531736342411
using,0.816732376348609
deacetylase,0.8296743349903701
inhibitors,0.8298464660486943
or,0.8433781632583875
the,0.8401734502219474
tubulin,0.8013904479441023
acetylase,0.8312278286318397
αTAT1,0.8595530472316953
prevents,0.8387687316579442
association,0.8254536291941427
of,0.8328289779907934
mutant,0.8183556637925842
LRRK2,0.7734142724157134
with,0.771557049288347
"microtubules,",0.8190409142163959
and,0.787498494106689
the,0.7391153834356942
deacetylase,0.7536173328847212
inhibitor,0.6911750152204345
trichostatin,0.6024844910976886
A,0.6713520667094011
(TSA),0.6845098087500091
restores,0.7400917114203565
axonal,0.7296528180326113
transport.,0.7405083845529454
In,0.34864371408464956
vivo,0.33656104001499015
knockdown,0.1458916403935847
of,0.15368666917835078
the,0.15255696436671146
deacetylases,0.20866650510303403
HDAC6,0.6316742936178248
and,0.7176662957872133
"Sirt2,",0.6420528198171744
or,0.6900201396170261
administration,0.6785163440253378
of,0.7186414633315152
TSA,0.6855816078629101
rescues,0.7149687181190351
both,0.7525932878674272
axonal,0.776820239479227
transport,0.7055152349817955
and,0.7706834817543393
locomotor,0.7129809880261968
behavior.,0.7481234668467892
"Thus,",0.09783967567126733
this,0.05142165140539524
study,0.0660626995096702
reveals,0.04849031572269048
a,0.025886720516620946
pathogenic,0.017848184672544072
mechanism,0.03680009272403011
and,0.027467044401047063
a,0.018566842411991698
potential,0.012972205717219095
intervention,0.023374988472180808
for,0.024792596877387125
Parkinson's,0.037166280620419295
disease.,0.022507183231959597
To,0.0011073896200712806
identify,0.0007039591893251242
new,0.000624971324955817
genetic,0.0007891988382657655
factors,0.000780189604950984
for,0.000945652173585931
colorectal,0.0010297254361209276
cancer,0.0011905358092785584
"(CRC),",0.0008433409456231313
we,0.002156078145951496
conducted,0.0011617338335900929
a,0.0011774505616740124
genome-wide,0.00063323917067357
association,0.0011639821833544501
study,0.0010213903097096456
in,0.0011725895800687957
east,0.0012457919242655335
Asians.,0.001160850249777347
By,0.002917818314204335
analyzing,0.0019758756577760014
genome-wide,0.001009694174158719
data,0.0014664779538344358
in,0.0016812217905254646
"2,098",0.0012381125527649523
cases,0.0014803942236260464
and,0.0018862882345728287
"5,749",0.001086793259168819
"controls,",0.0010751345378517364
we,0.00273245162263331
selected,0.0017971732276422412
64,0.0012008508271530369
promising,0.001311667192295872
SNPs,0.0012892727125701274
for,0.0014252158539705424
replication,0.0012792182321461894
in,0.0014717031224580107
an,0.0016454389122434205
independent,0.001083712632845884
set,0.001092469925707369
of,0.0013660557372254232
"samples,",0.00126406340853143
including,0.0014223918294888071
up,0.0011929545981993746
to,0.001382053190421918
"5,358",0.0008719216937627863
cases,0.0010002982924668807
and,0.0012997709507579593
"5,922",0.0007686107741624901
controls.,0.0009426855878788231
We,0.06529546970504145
identified,0.05825443029346435
four,0.04662599900505844
SNPs,0.040679116110687016
with,0.03278742296096151
association,0.0339046544601108
P,0.04664793155716677
values,0.061993740400849796
of,0.059136723660996635
8.58,0.05206273458168067
×,0.08499908299687217
10(-7),0.060967877891449584
to,0.08369985776942819
3.77,0.08687297395718659
×,0.07650366686382569
10(-10),0.04885865390832165
in,0.0477754347534558
the,0.047079063689928265
combined,0.04579907513793985
analysis,0.05048341876889169
of,0.03289941684174319
all,0.03890480152150081
east,0.021357747175268362
Asian,0.030812085031631808
samples.,0.041803055815833594
Three,0.03934760377997018
of,0.03733821059661053
the,0.04210652852188218
four,0.039453645938082205
were,0.028803038527980423
replicated,0.0243031799576209
in,0.03720563648693743
a,0.043583740370273884
study,0.039577104746186614
conducted,0.03632286135663374
in,0.35995337174264924
"26,060",0.1555861154243287
individuals,0.2702847772282752
of,0.16361343724680205
European,0.2637584426331805
"descent,",0.21092958110727708
with,0.2412218817121704
combined,0.2864263812622017
P,0.2888317944472927
values,0.29242413170771214
of,0.30027670703082876
1.22,0.29436995049235837
×,0.32907551141726227
10(-10),0.23857446478853903
for,0.2903629558602255
rs647161,0.30358896767744964
"(5q31.1),",0.30573399231025017
6.64,0.41756021645184555
×,0.4351777931156417
10(-9),0.3194035249836727
for,0.3191170587897646
rs2423279,0.3181917849771037
(20p12.3),0.3251362198842355
and,0.33895053865486036
3.06,0.34440165823801056
×,0.3946151483442416
10(-8),0.23233906100617835
for,0.29124275307406083
rs10774214,0.2720903301897684
(12p13.32,0.24083866379639016
near,0.2930022149080203
the,0.22343999854857713
CCND2,0.26765401305995284
"gene),",0.297872888916623
derived,0.18782889315872303
from,0.18511714212822397
meta-analysis,0.11513305993176884
of,0.16950309842965225
data,0.17348165518305744
from,0.12211490020324058
both,0.12005552787873076
east,0.09091190597983555
Asian,0.15026898515559364
and,0.11024547368057953
European-ancestry,0.11512477748025746
populations.,0.13948504054623156
This,0.14312970115405654
study,0.12207232504785487
identified,0.10096372761640006
three,0.10259250005773121
new,0.08049612619604629
CRC,0.14208075774206952
susceptibility,0.06324009760333359
loci,0.0515390610280366
and,0.1792555155018225
provides,0.06680414309783639
additional,0.0848453548095826
insight,0.0698229022281433
into,0.06437465794763729
the,0.10066991647447066
genetics,0.24356000664315075
and,0.19134057921737724
biology,0.18670270290687843
of,0.22619793700223556
CRC.,0.2940754030508992
OBJECTIVE,0.0016883263803037843
To,0.0012458708356390216
investigate,0.0011179694633072427
the,0.0011266149655890106
long,0.0012463132470786414
term,0.0012305543008351073
effect,0.0010121055212308733
of,0.0014952063893085604
radioactive,0.0013072603329232107
iodine,0.0020749078732169163
on,0.001158420060690558
thyroid,0.001587565533945781
function,0.0012377499728233007
and,0.001568385231127968
size,0.00106985560745353
in,0.001365938652901416
patients,0.0011782014195845774
with,0.001363461419195675
non-toxic,0.001775344612330752
multinodular,0.0014978484571379442
goitre.,0.0019724737238998088
DESIGN,0.001435252588592958
Consecutive,0.0017965193786719895
patients,0.0019760792452109886
with,0.0018566449756386113
multinodular,0.002089327890077731
non-toxic,0.0023738309826332902
goitre,0.003275603152075547
selected,0.0016338565759486932
for,0.0025768130922814714
radioactive,0.002008637093451224
iodine,0.004229872938003802
treatment,0.0018398488460731595
and,0.0033648754322605557
followed,0.0022200962615272625
for,0.0028808617914927305
a,0.003249154043450828
minimum,0.002256691206649813
of,0.003983508062985582
12,0.0027129979145679318
months,0.002264686250279465
(median,0.0018324243791256834
48,0.0026285718875768247
months),0.0021168921567432304
after,0.002164934729514619
an,0.002872315607672669
intended,0.002422560566712861
dose,0.00144815050788532
of,0.0031547897561197687
3.7,0.004734710493432444
MBq/g,0.0021519769780828225
thyroid,0.002944685274237809
tissue,0.002948076621360808
corrected,0.0020375450784964767
to,0.00259946755127806
a,0.002301921411854808
100%,0.00270694354398209
uptake,0.002774846087294526
of,0.0024497135398666462
iodine-131,0.002879658721495251
in,0.0031087660772203957
24,0.002802898789778829
hours.,0.0016214124910029764
PATIENTS,0.011514651977360678
69,0.010549493541959002
patients,0.015026338993740042
with,0.01806807957679627
a,0.014733956819543037
growing,0.014691537386462741
multinodular,0.012084633760806254
non-toxic,0.024776236820489267
goitre,0.00628291399277169
causing,0.0050476263858961696
local,0.004285231365014861
compression,0.004203600915557464
symptoms,0.004768582638785644
or,0.004066167549199839
cosmetic,0.0035813948515089305
inconveniences.,0.004447174043328592
The,0.0019786745844699617
treatment,0.0014038991111377226
was,0.0015994429889280685
chosen,0.0011291371496551293
because,0.0022175779457539687
of,0.0025749588819447646
a,0.0024443144581203927
high,0.0017266332409368406
operative,0.0017771052944024225
"risk,",0.0014025918158098835
previous,0.001553321739928596
"thyroidectomy,",0.0013631452649119802
or,0.0016766553574597445
refusal,0.0016025912641073193
to,0.0022795831346276037
be,0.0024329627404018855
operated,0.0012770455429628482
on.,0.0020721397343689933
MAIN,0.0016590741690883882
OUTCOME,0.0014996923949267057
MEASUREMENTS,0.0018608210375930935
Standard,0.0011000973152072752
thyroid,0.0014210287696523388
function,0.0009415382033883285
variables,0.0011004909021627457
and,0.0023129926717075098
ultrasonically,0.0014256672124839586
determined,0.001351916945562827
thyroid,0.0013231286133925414
volume,0.0011667940792645219
before,0.0017457341326849996
treatment,0.0011770059382041293
as,0.0019362025808859248
well,0.0016525538042558529
as,0.0018711110015474698
"1,",0.0025459162214384245
"2,",0.0035728849000361156
"3,",0.004350780875913918
"6,",0.0021882504825235373
and,0.0019242682195326148
12,0.001385042888786303
months,0.001161735493534202
after,0.0011722673821109217
treatment,0.0011066021387242642
and,0.0017601961080071207
then,0.0019020119390661932
once,0.0014470738587779304
a,0.0020241712960659586
year.,0.0013214070883478556
RESULTS,0.013768474096157208
56,0.003952975190075254
patients,0.0038358820404144124
were,0.0032601500865153303
treated,0.004462901209654404
with,0.005164268363533939
a,0.004779092178523206
single,0.0032535272964033797
dose,0.004819806952869094
of,0.014621989485132807
"131I,",0.004809914697857747
12,0.004364536574065856
with,0.0037483842175317066
two,0.005033392857457201
"doses,",0.004140107252393574
and,0.004325392415274463
one,0.00485372865390737
with,0.005624853711752174
four,0.006748156096993386
doses.,0.004887701219725254
In,0.6601638667465858
45,0.572831375395307
patients,0.633211390459682
treated,0.5447459136127908
with,0.5588925641362211
one,0.6272541654773325
dose,0.5807681161734587
and,0.6175288801225615
remaining,0.6132476050680485
euthyroid,0.5790903277646384
the,0.6458772958163277
median,0.6448192987054456
thyroid,0.614074250039302
volume,0.6616764853053212
was,0.6225151137032328
reduced,0.603588919050781
from,0.6592563340086429
73,0.6359263268945962
(interquartile,0.5933756546949959
range,0.5910083265851702
50-106),0.6100397357075953
ml,0.6690382754161714
to,0.6825601160744782
29,0.6471541189233945
(23-48),0.5610975754226855
ml,0.6622535119452122
at,0.6384007975189115
24,0.6054953032593487
months,0.6627979053632864
in,0.6272327143219156
the,0.5946138617917883
39,0.5418423937470322
patients,0.6506117518765091
in,0.46348500303608114
whom,0.6040440939671352
this,0.5917508804625016
was,0.42673252131207134
measured,0.45625289919311146
during,0.4822066242864792
follow,0.5179082037319162
up.,0.4779404089376908
The,0.25647747174728264
median,0.2049199675813257
reduction,0.27793060423551535
was,0.24896190298878867
40,0.16771184078963267
(22-48),0.18442346433351905
ml,0.30021497729041163
(60%,0.19498806659010653
"reduction,",0.3897352806520092
p,0.2636231489031321
<,0.2997784302322436
"0.0001),",0.15822364570534933
half,0.23427418293392652
of,0.25514171677453384
which,0.21703937337256304
occurred,0.26824424544872205
within,0.19464930308496006
three,0.21587387315029732
months.,0.15248963480360953
Patients,0.1335016707159959
treated,0.14782742721288192
with,0.19052662802640982
two,0.12505196048656259
doses,0.16789484153697015
as,0.1451577673642616
well,0.1405448050258396
as,0.10035946498692634
those,0.1457333865911161
developing,0.1923040729561093
hypothyroidism,0.15822452690065342
and,0.15215342166790277
hyperthyroidism,0.15472596932155713
had,0.28542183876364174
a,0.24563050655408636
significant,0.21239424475518712
reduction,0.18071918078573865
in,0.21289158601965297
thyroid,0.2127542251361357
volume.,0.279568850102376
Eleven,0.15600259638109507
patients,0.26665332657675034
developed,0.6578922806297532
hypothyroidism,0.6199622967597671
(cumulative,0.6372103436879261
five,0.6389155581872791
year,0.6296675776721429
risk,0.6565022595282806
"22%,",0.6338585668369927
95%,0.6879166485082318
confidence,0.6633947461080609
interval,0.6362497951834235
4.8%,0.676495643312865
to,0.6148389729248137
38.4%).,0.6139200672728247
Side,0.015981889656245432
effects,0.026247259107825324
were,0.036717088943934675
few:,0.018450933759958082
three,0.07644421021791907
cases,0.0407352337519104
of,0.09631288732727668
hyperthyroidism,0.045560365219192205
and,0.11060540756154497
two,0.10793824664916422
cases,0.050406759743478136
of,0.0962258920441482
radiation,0.07155047222213944
thyroiditis.,0.06517940389214304
Only,0.01171776359118362
one,0.006726301523568795
patient,0.007538495665908999
was,0.011637503707251534
dissatisfied,0.009589439419351442
with,0.014537187946508807
the,0.014226915698138599
result;,0.022320514094953958
she,0.009819996091305053
was,0.009203624314415076
referred,0.006526529841480548
for,0.009170993871865311
operation,0.00804825061700119
six,0.008005642769221638
months,0.005543479510805983
after,0.007154834351898775
treatment.,0.0069619293116721425
CONCLUSIONS,0.7969813425945049
A,0.8046564312780314
substantial,0.799733802274745
reduction,0.8026386736840359
in,0.8553161192949774
thyroid,0.8123010333958506
volume,0.8548593982826344
accompanied,0.8395035805861203
by,0.8392129440435856
a,0.8483653385516307
low,0.8167145769683497
incidence,0.8215940935373579
of,0.8752702925683277
hypothyroidism,0.8273460678411354
and,0.8326667883497891
few,0.7447752095569519
side,0.7902560557671624
effects,0.7643404511204829
makes,0.7054232964566718
the,0.7247180944977836
use,0.6796542989518238
of,0.7118315579146629
radioactive,0.6918854642516291
iodine,0.6399612511639909
an,0.6522286942300329
attractive,0.5647768569089048
alternative,0.6792221150172043
to,0.6653488023903902
surgery,0.6285672989475416
in,0.6096400254858865
selected,0.5550878593406486
cases,0.6170570879951642
of,0.6085863707503033
non-toxic,0.4616316023532244
multinodular,0.4184214763446334
goitre.,0.44178767821483633
BACKGROUND,0.062471965479851094
Human,0.034886525762668166
papillomavirus,0.04814840677705788
(HPV),0.02679870870345751
testing,0.062083071800249925
is,0.057041933133448026
more,0.2126662317496766
sensitive,0.10296820432420004
for,0.0970064692756486
the,0.0570731165122983
detection,0.07520158562542176
of,0.11104452975268277
high-grade,0.10809835946513617
cervical,0.06531998540686094
lesions,0.07233449978297248
than,0.1514535487684769
is,0.010910984763854588
"cytology,",0.005549897190424969
but,0.008723041226683688
detection,0.0022773024602897977
of,0.0033816868960925756
HPV,0.009606042456821638
by,0.004625079548034007
DNA,0.0023061107400380925
screening,0.0029132930914621867
in,0.002495963141275161
two,0.0039111798921529495
screening,0.0017284884445327693
rounds,0.0017248481711689995
5,0.0030284461167341898
years,0.0016056608745670786
apart,0.003180436124091771
has,0.001212827814093996
not,0.0016876140524799644
been,0.0012597265913034514
assessed.,0.0013923872820550845
The,0.0009751053783145498
aim,0.0009776057979301966
of,0.0013761665055591285
this,0.0009645682860948612
study,0.0009789805867502512
was,0.0014548360581340058
to,0.0009132739485744868
assess,0.0007362108250648344
whether,0.0009234005471261838
HPV,0.0017380656978276047
DNA,0.002683790129395419
testing,0.002731640933050023
in,0.0019583650699759314
the,0.0011329096903904237
first,0.0014872319494818073
screen,0.0014307287839630772
decreases,0.0023874841664167246
detection,0.001814883101245768
of,0.0017468978885106245
cervical,0.002887869671082598
intraepithelial,0.003125575002188179
neoplasia,0.002363083471233218
(CIN),0.0007861838321140169
grade,0.0013699130794384922
3,0.0023182744020406997
or,0.00099760705702857
"worse,",0.00253099092487837
CIN,0.002021283133615509
grade,0.00198786549966461
2,0.004614343127077443
or,0.0010649299534513659
"worse,",0.002789378371175237
and,0.0035848388899628394
cervical,0.004874206703608336
cancer,0.003985386232508377
in,0.002599350723487915
the,0.001433118209760388
second,0.0023923465872788914
screening.,0.0016201528593164569
METHODS,0.06268155725746516
In,0.12866567628204548
this,0.14625795039419529
randomised,0.0010116177321740413
"trial,",0.0008838663777193346
women,0.0009444201945962573
aged,0.0009546807729439287
29-56,0.00107362358603881
years,0.0010158471643238742
participating,0.0008634878846701764
in,0.0010800579515460006
the,0.0010278805801412444
cervical,0.0009224139270344092
screening,0.0008561700150811956
programme,0.0011297396535618733
in,0.0011765267401202262
the,0.0016840048036840245
Netherlands,0.0013180297445756785
were,0.0011303513619046691
randomly,0.0011274392261346807
assigned,0.0008737555413539784
to,0.0011412525144400322
receive,0.0007915462549795289
HPV,0.001094335709236629
DNA,0.0007037618119545384
(GP5+/6+-PCR,0.0007620578642461266
method),0.0007477744106210131
and,0.0013295815108394185
cytology,0.000938169441151157
co-testing,0.0009090774244071522
or,0.0009311381335959035
cytology,0.0008490293862460109
testing,0.0006711051151835016
"alone,",0.0007205921399929492
from,0.0011300663233330668
"January,",0.0010579640725071329
"1999,",0.0008649375948664129
to,0.0010520923414454688
"September,",0.001133893810490729
2002.,0.0009321900299221964
Randomisation,0.0010601175910812642
(in,0.0011660060540865749
a,0.0017329734732606265
1:1,0.0015768965946652577
ratio),0.0010820628406278167
was,0.0015712794566053545
done,0.001111582923868772
with,0.0010780465031753719
computer-generated,0.0009955725703318008
random,0.0009806146646435872
numbers,0.0007819156081863901
after,0.0012548326009966058
the,0.001099297734562378
cervical,0.001063102858004693
specimen,0.0008013901121119633
had,0.0014236297659676726
been,0.0011981095859759767
taken.,0.0009016335939453403
At,0.028674637973635307
the,0.013543273365401887
second,0.022101217685777334
screening,0.007402343122333753
5,0.013991543356534922
years,0.010497371906001286
"later,",0.012130577886731218
HPV,0.008228957637731226
DNA,0.00646209214772706
and,0.0076808483815372095
cytology,0.005738432418340553
co-testing,0.005137976568833003
was,0.03561027114529399
done,0.02354498399697719
in,0.02814001914065526
both,0.034674853969577604
groups;,0.019013473354009748
researchers,0.017518258771582675
were,0.023641569789976412
masked,0.04135386661528107
to,0.0522591487568154
the,0.010951919721453958
patient's,0.009510152621227865
assignment.,0.0013245940490938495
The,0.0007695332869679184
primary,0.0005477584019328165
endpoint,0.0006431841336493213
was,0.0007690668538169712
the,0.0005969930200317042
number,0.0004890482363364388
of,0.0005374309309388531
CIN,0.0006705864512769873
grade,0.0006635395367634387
3,0.0007464524596023372
or,0.0009182885225133865
worse,0.0008336929088873632
detected.,0.0005677128598306945
Analysis,0.0007240808235538161
was,0.0015387081598462577
done,0.0008242291775928702
by,0.0015811082051218033
intention,0.0007622906472447312
to,0.001146091268836084
screen.,0.0007298661251983236
The,0.0015032217338983348
trial,0.0009169901486002085
is,0.0014588061868639115
now,0.0011476562600414204
finished,0.0010664454466011587
and,0.0024702779008585634
is,0.001319985402783681
"registered,",0.0009764543265801417
number,0.001014763560540808
ISRCTN20781131.,0.0009455587003480299
FINDINGS,0.0020566442705659527
"22,420",0.0010776691477966485
women,0.0008930709088330228
were,0.0012379713403240973
randomly,0.0009082661796754984
assigned,0.0007267523854541947
to,0.000962651555802995
the,0.0010529682125919343
intervention,0.0007797096591621521
group,0.0009526963019851787
and,0.0014274489256582942
22,0.0006966932698272325
518,0.0007649470681205691
to,0.000753422845039859
the,0.0009233609565143588
control,0.0007125400334384221
group;,0.000908634050529845
19,0.000804309702829072
999,0.0008194796588830037
in,0.0006618407675410967
the,0.0009248005045506873
intervention,0.0006108060909268175
group,0.0008797933366477605
and,0.0012629399911675125
"20,106",0.0007592072374634808
in,0.000570062724238597
the,0.0007471470513000463
control,0.0006527875886083619
group,0.0008368522804313512
were,0.0009413325712955838
eligible,0.0009073927584395077
for,0.0013842856309196929
analysis,0.0007275595171634487
at,0.0011456172764422326
the,0.0014571126967655233
first,0.0011110633852442725
screen.,0.0007662208775012588
At,0.009937389784613632
the,0.005950334247092883
second,0.005098573682439802
"screen,",0.0026998380793492064
19,0.004104202144056936
579,0.0031359528910966214
women,0.005715464719298788
in,0.006876500308703143
the,0.004176479840368571
intervention,0.003346781516309054
group,0.0038010304592888777
and,0.0074607741109913245
"19,731",0.004871000952994196
in,0.00700148754538032
the,0.003528964259409109
control,0.0022512067052161493
group,0.0037753390320468335
were,0.005043390650781969
"eligible,",0.002632052604242706
of,0.0065204773785236215
whom,0.010153485045708814
"16,750",0.01314473990637422
and,0.033750149780325256
"16,743,",0.015169959276569613
"respectively,",0.010021638150461702
attended,0.007363990244267009
the,0.006138610010592192
second,0.005795749706016332
screen.,0.007019312631982509
In,0.10042333513792069
the,0.06425436778155702
second,0.055435005586603414
"round,",0.037706692917546226
CIN,0.07230848267455778
grade,0.08514410726032018
3,0.1193226477237279
or,0.08219904566484608
worse,0.058886595564062144
was,0.07056237939518437
less,0.08704415961006687
common,0.06875971293922119
in,0.08981391513029846
the,0.06418832895913033
intervention,0.04249175282906694
group,0.034625357286094255
than,0.14733848711431088
in,0.09511084365879394
the,0.06169810977484142
control,0.021422846560464025
group,0.03379755159086977
(88,0.13495056972158617
of,0.08546598202574619
19,0.047137450561109115
579,0.06350663327210364
in,0.08542674453560706
the,0.07254461984450071
intervention,0.05063656378567103
group,0.043866051630396655
vs,0.11490139563484184
122,0.06685377402123976
of,0.07749663767623774
"19,731",0.04720330451478727
in,0.0769780960150392
the,0.050640403484997105
control,0.026959459257610247
group;,0.04530925607886444
relative,0.0651432189843489
risk,0.10305338244158468
"0·73,",0.04436909321299899
95%,0.17215517117452464
CI,0.13202461702190585
0·55-0·96;,0.0604493673005371
p=0·023).,0.14535885877234578
Cervical,0.2518764994584541
cancer,0.15433221832757923
was,0.13104338354496825
also,0.1419578128245723
less,0.15804605113991405
common,0.14869282106585732
in,0.12286282042968782
the,0.133700454642139
intervention,0.09232906330212434
group,0.08677935868549784
than,0.18963414109718105
in,0.12859409882153153
the,0.12845335454188983
control,0.06211487105835816
group,0.08065901616615515
(four,0.17601218360692092
of,0.12619085913963018
19,0.06594275945135238
579,0.08682958360269849
in,0.09705248771168913
the,0.12861005617106253
intervention,0.0829965798297933
group,0.0748609408111332
vs,0.14323548200305095
14,0.07577524487214403
of,0.09121444870386423
"19,731;",0.05142033729298168
"0·29,",0.0744804031960021
0·10-0·87;,0.07030229166502268
p=0·031).,0.1673046863217312
In,0.17750262622501864
the,0.11708613441104344
baseline,0.05382072282961538
"round,",0.1035231269945536
detection,0.09972391274082883
of,0.07216151594850939
CIN,0.07105250075486791
grade,0.07681268535190931
3,0.08980876987854186
or,0.06117211605334448
worse,0.0626347738092961
did,0.21714528371925057
not,0.222969798702514
differ,0.1135223191972275
significantly,0.1446564585174155
between,0.0846916201708982
groups,0.06449947345486631
(171,0.12679565915637145
of,0.1217970965356498
19,0.04690126711111924
999,0.058623109617603995
vs,0.10871595831433638
150,0.05969393858403296
of,0.09807408789014646
"20,106;",0.03615633676201905
"1·15,",0.07240879958927676
0·92-1·43;,0.07351764031245461
p=0·239),0.11973419186654628
but,0.24059484358846334
was,0.17875419806417628
significantly,0.1974213179738175
more,0.20146851244516817
common,0.13571927849065282
in,0.15074351815059137
women,0.13321600071835835
with,0.1223747869680221
normal,0.16193306809250746
cytology,0.07514620680609517
(34,0.12520033008617318
of,0.10180662278997915
"19,286",0.047659588219656865
vs,0.09285421425176019
12,0.04224379789298798
of,0.08714369924660728
"19,373;",0.033139697721511194
"2·85,",0.10687019418023667
1·47-5·49;,0.13337140893181798
p=0·001).,0.1375568245513344
"Furthermore,",0.4429374971102747
significantly,0.46639241942393483
more,0.460189961025378
cases,0.3236111476187152
of,0.42888792355543726
CIN,0.28046416494976883
grade,0.2674826286852277
2,0.3666579993581396
or,0.3089133002836956
worse,0.2918602442676669
were,0.3595711357993338
detected,0.293810930468854
in,0.3526141499507474
the,0.3039614221617335
intervention,0.24063604401422015
group,0.23652635399046462
than,0.5313780589038581
in,0.3190571635018024
the,0.28603689284409056
control,0.2125945830100626
group,0.3547762785343798
(267,0.18611739947756753
of,0.2081027837560133
19,0.09523482254758929
999,0.12599498695724087
vs,0.16317700112996641
215,0.1260541704104449
of,0.18396842147961665
"20,106;",0.09650491826172952
"1·25,",0.15385354049492939
1·05-1·50;,0.1649015291012124
p=0·015).,0.16176034543849913
In,0.294579032101806
the,0.19480091167926372
second,0.2583978946087094
"screen,",0.14022626598368407
fewer,0.3272292195570875
HPV16-positive,0.1794392382731463
CIN,0.14579012539700312
grade,0.16667504042241077
3,0.2781245341426484
or,0.26927111612601357
worse,0.22905938039937276
were,0.24750907934618777
detected,0.19274510070126252
in,0.23266303686872844
the,0.17774240636779556
intervention,0.11448657739299194
group,0.13004752497908073
than,0.434338865237919
in,0.2357520433552988
the,0.17127445387067627
control,0.07354530884802676
group,0.11354872645116754
(17,0.22700220501213056
of,0.1938180191830398
9481,0.16783201435249345
vs,0.156774039859271
35,0.13019554635799668
of,0.19157387162386397
9354;,0.15288476062478276
"0·48,",0.07014682328876626
0·27-0·85;,0.06873690847916637
p=0·012);,0.13013910053421254
detection,0.08080369956057942
of,0.07826918398292557
non-HPV16-positive,0.10342013937737497
CIN,0.0631607171979611
grade,0.07772804638560989
3,0.06491443815746965
or,0.04715891006801117
worse,0.09321519868206479
did,0.15161303998001885
not,0.16897958755641515
differ,0.09108258807257168
between,0.05406259565849878
groups,0.06062651662275182
(25,0.15466088855116364
of,0.12164019419333691
9481,0.15393115139858385
vs,0.09525651856024711
25,0.06064881580123582
of,0.12487040840108955
9354;,0.13861685963130305
"0·99,",0.059408034235947704
0·57-1·72;,0.12929826992191787
p=1·00).,0.10694268485752838
The,0.014393127782275047
cumulative,0.011646403114464588
detection,0.012823794591015321
of,0.008718100974270218
CIN,0.011109695221488159
grade,0.007488818549139885
3,0.014435005191721003
or,0.006995882123162629
worse,0.008917180522895033
and,0.018203203389015925
CIN,0.011340346961994437
grade,0.006922261942807134
2,0.011811150090123505
or,0.00518975226272767
worse,0.007058242105772867
did,0.04144948740244392
not,0.04325163892924484
differ,0.018086539794290302
significantly,0.0260126496746167
between,0.014987864483743476
study,0.007881910366947792
"arms,",0.006756986144757386
neither,0.044883841495804704
for,0.022967154479494396
the,0.013263399161670944
whole,0.013264759680749355
study,0.010100210166256153
group,0.005791773894692214
(CIN,0.02865952467284118
grade,0.010977663989534356
3,0.01525670051236903
or,0.012307534655964694
worse:,0.010082459492261962
259,0.010074600297628406
of,0.016121269317358494
19,0.006809508090306179
999,0.00922283074451934
vs,0.022765259873775555
272,0.007607296712487135
of,0.01590911447608232
"20,106;",0.006499247576482194
"0·96,",0.00952056096018716
"0·81-1·14,",0.011386596145893817
p=0·631;,0.05089282158517907
CIN,0.025004450602502917
grade,0.011482977438775141
2,0.01617545134347965
or,0.012060361146470144
worse:,0.012698584233723399
427,0.017585891464277702
of,0.023840798712369417
19,0.01465081626919049
999,0.020646072951719347
vs,0.030641741634885623
399,0.021235988944449738
of,0.02515971582200244
"20,106;",0.01708936616141033
"1·08,",0.03054258350328657
0·94-1·24;,0.022066670841294458
"p=0·292),",0.056653820549795
nor,0.03516848967863384
for,0.04609452034960033
subgroups,0.011188780036910347
of,0.008216587740381183
women,0.010740572278906388
invited,0.010318954496114507
for,0.015297371706069181
the,0.010402068637640491
first,0.013875031759866891
time,0.00911720965283538
(CIN,0.011738182151114445
grade,0.005028763396544409
3,0.006914091545494264
or,0.004265613825833275
worse,0.005257275103164351
in,0.01170754540756775
women,0.008119196378442314
aged,0.004732906497444006
29-33,0.0028267018384652383
years:,0.002933771484328152
102,0.007665702391334771
of,0.014897295338402086
3139,0.007846554820744055
vs,0.012112036645188229
105,0.0077229760641554695
of,0.015477537373693803
3128;,0.007732899778707618
"0·97,",0.007912140895345162
0·74-1·27;,0.008212401868065256
CIN,0.012630847130979245
grade,0.006473430928334821
2,0.010872236723553691
or,0.00657720688756938
worse,0.008289036360752528
in,0.014182271199727479
women,0.010335697732937459
aged,0.005415387996255575
29-33,0.0034857298748925502
years:,0.00451313454670527
153,0.009220798319386183
of,0.013040442025585167
3139,0.009055401108926647
vs,0.012282377357995283
151,0.007776197338283415
of,0.013001678892199392
3128;,0.008407146028552328
"1·01,",0.008261445743401739
0·81-1·26;,0.007424805073331593
CIN,0.012207172399711003
grade,0.006356576508102962
3,0.008173952277058211
or,0.005374702633113538
worse,0.008106280798654377
in,0.011638916080413907
women,0.00921291462051137
aged,0.0054535521226281945
34-56,0.003404875304549043
years:,0.004693931399081419
157,0.007984762752229441
of,0.009836992024729627
"16,860",0.006118978337504087
vs,0.00913064035808634
167,0.009564974356589083
of,0.008732284077367074
16,0.00972924293488909
978;,0.008199519562303413
"0·95,",0.0074830295403000395
0·76-1·18;,0.007763009510207189
CIN,0.009572270307845398
grade,0.0062390592427099415
2,0.010785976615045118
or,0.004688400951143249
worse,0.00973572738826037
in,0.012219978033457157
women,0.005132072930415419
aged,0.003912135795946193
34-56,0.002943328285476012
years:,0.0038622406976615087
274,0.003376041171794628
of,0.0068124095158121544
"16,860",0.0030977267947913936
vs,0.00577244172746122
248,0.0038806443822598127
of,0.006025235042598267
16,0.003788175645033125
978;,0.004454509963503916
"1·11,",0.005812826344789396
0·94-1·32).,0.004825234052527698
INTERPRETATION,0.7904354910985726
Implementation,0.8138625828973838
of,0.8515282083470204
HPV,0.8760471694822916
DNA,0.8531860006483283
testing,0.856928280303132
in,0.9083009312019734
cervical,0.8671423762470322
screening,0.8577988113944792
leads,0.8822493059129901
to,0.902465113975532
earlier,0.9206977420586492
detection,0.8946742983817219
of,0.9134646061509503
clinically,0.891565986092447
relevant,0.914591527180788
CIN,0.8901730954997396
grade,0.8812719677014831
2,0.9085127939075477
or,0.8779551145855266
"worse,",0.8557525168759613
which,0.9112563966627252
when,0.917658966954053
adequately,0.8778290758560082
"treated,",0.8901121801540809
improves,0.9142502254658464
protection,0.8777771735841196
against,0.8625229968237927
CIN,0.8428483993598923
grade,0.8669482611590256
3,0.8921731291242981
or,0.8554830710300353
worse,0.8552011247987562
and,0.88385754168259
cervical,0.9053688508607112
cancer.,0.8212061433609473
Early,0.41604162883105966
detection,0.31811530962347406
of,0.35437253708362654
high-grade,0.3640363693217713
cervical,0.5076211003587221
legions,0.5106337797401708
caused,0.2893264656234935
by,0.3921062855772732
HPV16,0.2955291647853394
was,0.3830561572270384
a,0.313469246752457
major,0.25138291179797095
component,0.29560806232918235
of,0.360640099592541
this,0.3518561626079413
benefit.,0.292814698932798
Our,0.15028742708168727
results,0.12665225891552298
lend,0.11568605003595318
support,0.09324870777992438
to,0.09426869665181956
the,0.06834429110441018
use,0.07850841226031349
of,0.06548701273022746
HPV,0.06369625807762606
DNA,0.0054815213520637614
testing,0.003417971701520904
for,0.003502508045989699
all,0.0047623724840122434
women,0.007425335726688
aged,0.0032752614493791734
29,0.003061084779880424
years,0.0028125927844870873
and,0.005586852413368662
older.,0.0037636987832921904
FUNDING,0.016613375736432526
Zorg,0.01833785097289105
Onderzoek,0.017950130990632515
Nederland,0.021082127363060945
(Netherlands,0.011431207609820079
Organisation,0.005770821870885906
for,0.007325158454105418
Health,0.0064736456071992346
Research,0.0053241273688231765
and,0.008955577051306314
Development).,0.005609479081841551
Combining,0.013853283411777845
DNA-demethylating,0.016017663426808677
agents,0.0069142618008135506
(DNA,0.005818816081502568
methyltransferase,0.009090140636425369
inhibitors,0.006951429285533186
[DNMTis]),0.007497732168407172
with,0.004800616700859498
histone,0.004740522526516122
deacetylase,0.00660101091811735
inhibitors,0.0030479465824124535
(HDACis),0.0031267994843741493
holds,0.004962319304006189
promise,0.0038460526046650454
for,0.00523031257029434
enhancing,0.004897028795851911
cancer,0.0037327735136396248
immune,0.004110032812283259
therapy.,0.003240709277110815
"Herein,",0.010384064977073063
pharmacologic,0.002053768018448754
and,0.006437960724501283
isoform,0.001629495767545461
specificity,0.0022337996075720333
of,0.004430845733805997
HDACis,0.004290599954256854
are,0.0037916106418616953
investigated,0.002031684531627009
to,0.0026063647103340476
guide,0.0023994938070363487
their,0.0049327936270024434
addition,0.0036289471926821727
to,0.003093469668246538
a,0.0027828953082271917
"DNMTi,",0.005749778918713183
thus,0.003417949774280146
devising,0.001820634075887257
a,0.0034993190757459072
"new,",0.0025181127901765595
"low-dose,",0.0021979107170738694
sequential,0.0027004280990827988
regimen,0.005676218230766627
that,0.006237210253058157
imparts,0.004107271018438844
a,0.005344002344355843
robust,0.004531860551728717
anti-tumor,0.003811414027177971
effect,0.009387365250259195
for,0.007969271081446011
non-small-cell,0.006280400328481377
lung,0.008638450916553053
cancer,0.004881980654184922
(NSCLC).,0.00302297226735389
Using,0.016005693794585264
in-vitro-treated,0.3839157968604674
NSCLC,0.2805911669078599
cell,0.4523939452057137
"lines,",0.38868848353622987
we,0.4419217053300605
elucidate,0.37333961372458063
an,0.37183349144283717
interferon,0.331491313480206
α/β-based,0.3043490752290701
transcriptional,0.3396196681917839
program,0.39694300264941
with,0.3645195749891777
accompanying,0.42709415425229763
upregulation,0.4249067552247513
of,0.409316091204484
antigen,0.28017496561383526
presentation,0.35337497395299994
"machinery,",0.37529824778844295
mediated,0.3851543894727746
in,0.46903103950178515
part,0.42553918667290397
through,0.45619678898294763
double-stranded,0.2100495142418452
RNA,0.23961647163502464
(dsRNA),0.23728172227226832
induction.,0.38477598985225436
This,0.43141294769405614
is,0.3490652188264483
accompanied,0.45831350024634054
by,0.47051557486223256
suppression,0.4546826900570088
of,0.48873077614610666
MYC,0.43172099177280604
signaling,0.5359734608976021
and,0.5674994681688352
an,0.4885859569302246
increase,0.44625393545282843
in,0.43649303163048414
the,0.3777689941303914
T,0.36664095385899065
cell,0.4882162858836091
chemoattractant,0.4069490350953947
CCL5.,0.37139649602114955
Use,0.012484998538995264
of,0.012861580234307408
this,0.015619575681364354
combination,0.007860484000280636
treatment,0.008378042439259928
schema,0.00464936583431596
in,0.007097039841039621
mouse,0.00636245067766488
models,0.0035409871767850313
of,0.008651636460531265
NSCLC,0.019977726338678448
reverses,0.015080381622958024
tumor,0.008784527636164966
immune,0.009044295686083777
evasion,0.02518246138663809
and,0.0614526567079115
modulates,0.008076720245593345
T,0.01751328190815007
cell,0.05196208202604442
exhaustion,0.036390093988247996
state,0.03475391944262877
towards,0.020931609059831442
memory,0.011387162455120965
and,0.02457483630266104
effector,0.013553383843254545
T,0.014620004084213184
cell,0.027000136087401455
phenotypes.,0.008712842253418661
Key,0.022735167947005475
correlative,0.03191377510486168
science,0.0619779787184848
metrics,0.012593294890241455
emerge,0.02057479072142478
for,0.008111744216826228
an,0.006982229406226439
upcoming,0.008823454760828365
clinical,0.007154290713836444
"trial,",0.006979601516188712
testing,0.008680434669107463
enhancement,0.009834630576387424
of,0.00991516064448505
immune,0.01587574702129483
checkpoint,0.010261635701990967
therapy,0.01325501753284203
for,0.015205277081613035
NSCLC.,0.02259929169533207
BACKGROUND,0.027644328496694317
Taxing,0.007834369735841765
sugar-sweetened,0.008094876736045052
beverages,0.008073700957448244
(SSBs),0.004320690194890827
has,0.007257382096923902
been,0.0056708059660656425
proposed,0.008254533542115031
in,0.008255310390367563
high-income,0.0048546074055829565
countries,0.005432278712885632
to,0.007409548217631279
reduce,0.009473373598372511
obesity,0.012029947824047827
and,0.018155567256434593
type,0.009605062618568506
2,0.012996215689148332
diabetes.,0.010290663540305492
We,0.002099512682258455
sought,0.0015794357498724
to,0.0011166060463269646
estimate,0.0011396050538603165
the,0.0010373380995000875
potential,0.0010967541025604394
health,0.0013510423410698713
effects,0.0010247932213634605
of,0.0016423156635329054
such,0.0015841046798559329
a,0.0016727326432075752
fiscal,0.0014154328533208123
strategy,0.0014975079618899303
in,0.0014686696352409615
the,0.0014999369723790873
middle-income,0.0015422531769691938
country,0.001382991635021295
of,0.0021699993859846324
"India,",0.0019209929095901528
where,0.002149870750361619
there,0.0017363341223836702
is,0.0017433993987720643
heterogeneity,0.001704351608450176
in,0.002153138432276131
SSB,0.003395863385201303
"consumption,",0.0018950792419696267
patterns,0.0014490520062572369
of,0.0019890639739680296
substitution,0.0021010062531913376
between,0.001810628525921721
SSBs,0.0038272396306527796
and,0.001625853094127527
other,0.0013265657514604078
beverages,0.001653386338814529
after,0.0023324319721061432
tax,0.002778017279554552
"increases,",0.003066819864552542
and,0.002137827263147566
vast,0.0011997398090833136
differences,0.0015773793924532824
in,0.0019242668458376749
chronic,0.0014337082525687592
disease,0.0011272384064505226
risk,0.0013895197004461894
within,0.0016630088431632364
the,0.0024161503497697177
population.,0.001303819751562873
METHODS,0.032299075730042245
AND,0.01205204062751646
FINDINGS,0.03978506673533816
Using,0.01811973171129983
consumption,0.013348326210738696
and,0.006091205005002487
price,0.007744221065491715
variations,0.007970969538285015
data,0.010638102605124176
from,0.008361390891352821
a,0.009961466874265903
nationally,0.005528415200564898
representative,0.0066042385901839504
survey,0.009703883970271283
of,0.008994188413237125
"100,855",0.005588520291583379
Indian,0.03191631279294045
"households,",0.024056273123869345
we,0.0355145283075247
first,0.04572668458532909
calculated,0.0140101261664151
how,0.02241402578168277
changes,0.019765616665402497
in,0.025460861772046896
SSB,0.049144535103756104
price,0.02804515754892705
alter,0.023257355470001004
per,0.024898340345424732
capita,0.022782024199802794
consumption,0.03337033510042163
of,0.029604531309414577
SSBs,0.048192952861207054
and,0.014871726166791688
substitution,0.029610377758099056
with,0.026722642345936812
other,0.02590104821624574
beverages.,0.03200662142823527
We,0.029124159484699756
then,0.028317485589006187
incorporated,0.016804552811760288
SSB,0.03198087022404996
sales,0.03216799621097727
"trends,",0.022800922716113448
body,0.03733059713436486
mass,0.03878574619865373
index,0.01913140406803221
"(BMI),",0.00948023764895325
and,0.012963461131860551
diabetes,0.028203877577366084
incidence,0.02578042308146366
data,0.016281479507348304
stratified,0.008822946007583467
by,0.01999491146936596
"age,",0.01751017668808895
"sex,",0.01945269544520227
"income,",0.02970419699443689
and,0.012373297397270467
urban/rural,0.02670250604002033
residence,0.03480457840319249
into,0.01543443086097408
a,0.016548023305031488
validated,0.011254516052412344
microsimulation,0.012202245822524722
of,0.013643018035815102
caloric,0.016491769233360147
"consumption,",0.06193487848016426
glycemic,0.021823926860840833
"load,",0.04154025988030846
overweight/obesity,0.022128173006423377
"prevalence,",0.029191157090442232
and,0.016632117815882645
type,0.022737620703330137
2,0.01931941639274716
diabetes,0.034450753354877676
incidence,0.024651583951063837
among,0.01624500052199102
Indian,0.023571849534143322
subpopulations,0.012157342054535796
facing,0.01909198756718213
a,0.018265635717252506
20%,0.01857891960363399
SSB,0.05220744612666344
excise,0.016892442636649265
tax.,0.029933609874045905
The,0.17144189643142838
20%,0.1774878681030143
SSB,0.17569628337019857
tax,0.22440297238377666
was,0.21583115761784502
anticipated,0.1486359562048221
to,0.26335510896147873
reduce,0.8839289024383478
overweight,0.8863158537977628
and,0.8727200319738818
obesity,0.8793160437814073
prevalence,0.8812961259092238
by,0.8919815851863481
3.0%,0.9089403101795077
(95%,0.8684797837431406
CI,0.8762624419927112
1.6%-5.9%),0.886593630521373
and,0.9024983560558418
type,0.9132717652738811
2,0.9062747410720365
diabetes,0.8744005656771131
incidence,0.8858998691353578
by,0.899154469622806
1.6%,0.8841226246509393
(95%,0.8534827741044795
CI,0.8971222311963157
1.2%-1.9%),0.8886604263944725
among,0.8881622508440038
various,0.8669952401729742
Indian,0.8122658065228753
subpopulations,0.8609718118271403
over,0.8207984570348761
the,0.8252738988057904
period,0.7596551035532524
"2014-2023,",0.8281002847045982
if,0.8246491236399194
SSB,0.8349016203925838
consumption,0.8147091371760744
continued,0.796729851693508
to,0.7826778896326128
increase,0.82976088931062
linearly,0.7970799555189003
in,0.7827754249769538
accordance,0.8032681093311439
with,0.713872419890539
secular,0.7130867160026703
trends.,0.7429744375830768
"However,",0.7866038154504775
acceleration,0.709959958278123
in,0.7101187835960365
SSB,0.7125346534683334
consumption,0.7444701554372892
trends,0.7691465064570797
consistent,0.7461388575501353
with,0.6865682077292711
industry,0.688121168122244
marketing,0.7007677515881533
models,0.7071750905576548
would,0.6982828092302232
be,0.6693029387460385
expected,0.6824925363425016
to,0.7237464956279771
increase,0.7369555991920576
the,0.7596716664346052
impact,0.7531509097472361
efficacy,0.7982986491980998
of,0.7755296985834156
"taxation,",0.7734935118231443
averting,0.8059158520264211
4.2%,0.7700077364198842
of,0.7705941890031762
prevalent,0.7665291511869996
overweight/obesity,0.5704061308829883
(95%,0.6126897238647081
CI,0.6849536658853101
2.5-10.0%),0.6956171222824923
and,0.6222469638593727
2.5%,0.6532696195785997
(95%,0.5521635219866557
CI,0.6562993098306252
1.0-2.8%),0.645610123147073
of,0.6195630743906878
incident,0.6066152267222356
type,0.606626641140521
2,0.5338921461596662
diabetes,0.6128318639112592
from,0.5457722996388241
2014-2023.,0.5580915076154946
Given,0.1340446944770009
current,0.11034329779894485
consumption,0.18122961313990346
and,0.1116989051580365
BMI,0.12097765869984631
"distributions,",0.14320927569098402
our,0.1776751831277727
results,0.13771433334332087
suggest,0.13376380865711684
the,0.09340105578024233
largest,0.08305988454336409
relative,0.07100985068532605
effect,0.10152112829162706
would,0.1049026413311972
be,0.06583280832416306
expected,0.08571001727173849
among,0.10358722344987023
young,0.10625977591503835
rural,0.10450415018846548
"men,",0.11938099865986551
refuting,0.12352061266236845
our,0.18880676496145252
a,0.1561674809478068
priori,0.1065973570770472
hypothesis,0.16304134449931243
that,0.1405058516297426
urban,0.11858578214013292
populations,0.11607305448893628
would,0.12859055223095373
be,0.1399923779257748
isolated,0.08812711432726787
beneficiaries,0.09234923562407042
of,0.1106027749137338
SSB,0.14024198273558527
taxation.,0.13398297083082256
Key,0.13563999930886214
limitations,0.10131830851046922
of,0.0978322314282665
this,0.12136360612817643
estimation,0.1068571779859731
approach,0.1175804573544337
include,0.1595237732353198
the,0.19004021760384696
assumption,0.23158976504117895
that,0.2577364713950712
consumer,0.2535974013029883
expenditure,0.2510338381714806
behavior,0.23686932689690374
from,0.20729069239951195
prior,0.22481740903859335
"years,",0.19680316630871816
captured,0.2101882766161514
in,0.2210035227894801
price,0.22485521686423862
"elasticities,",0.1595116104738563
will,0.013286699878670628
reflect,0.01092455795094443
future,0.0059934215715875365
behavior,0.00553882474203617
among,0.005548856446181265
"consumers,",0.004883480846374186
and,0.008224281272714505
potential,0.005188878388471742
underreporting,0.004511143699505974
of,0.00605422139768566
consumption,0.006844908766319057
in,0.006873885894694974
dietary,0.005577937206297362
recall,0.008454314530825425
data,0.00541627797602264
used,0.003786045633614511
to,0.0036124639211562028
inform,0.004555991527713771
our,0.009934339646909564
calculations.,0.004198574969507113
CONCLUSION,0.9036850842267785
Sustained,0.8808562294116897
SSB,0.865926078193606
taxation,0.8635891847567173
at,0.9049748622453209
a,0.8973742675313932
high,0.8696730846128029
tax,0.8564195659292706
rate,0.8661289668746855
could,0.8506743471261875
mitigate,0.8868772437021128
rising,0.8530642472150637
obesity,0.8891389764315174
and,0.8847528883143719
type,0.9000998232587937
2,0.8864480577609707
diabetes,0.8287627849570542
in,0.8503903172613001
India,0.7683836209252357
among,0.8605287022655697
both,0.8434243816323833
urban,0.7980760990175919
and,0.7745157093021898
rural,0.6985165201316231
subpopulations.,0.7684877736721006
Maintaining,0.011109142556269712
hematopoietic,0.005936937984482791
stem,0.008368831052862374
cell,0.011433268900500804
(HSC),0.0050228011161634785
quiescence,0.007004660900349689
is,0.007987176636352514
a,0.007803950326594871
critical,0.009048807639849415
property,0.012782062388216517
for,0.01012490949705456
the,0.012626979333076192
life-long,0.0055124360846741036
generation,0.008608940169927434
of,0.009416745307501374
blood,0.01569612441293133
cells.,0.009482517056322285
Approximately,0.02710375851095919
75%,0.02013963239809622
of,0.021772394949457704
cells,0.02156772615372311
in,0.034010279255138866
a,0.023086628859027163
highly,0.016664109890169983
enriched,0.018562728626469023
long-term,0.013784340196109995
repopulating,0.0158097379027156
HSC,0.013485861967385939
(LT-HSC),0.019116882336766887
pool,0.02343250305474407
(Lin(-)Sca1(+)c-Kit(hi)CD150(+)CD48(-)),0.021915302522164677
are,0.018217958638519646
"quiescent,",0.0077780831273659996
with,0.02893022190302301
only,0.02791061846850947
a,0.02270749567956949
small,0.03591749420379535
percentage,0.020822696858850572
of,0.032397986566824036
the,0.0292641960631917
LT-HSCs,0.039794503818149446
in,0.03212823782396457
cycle.,0.03289888204882489
Transcription,0.1652561535795619
factor,0.18098998095485583
GATA-3,0.25400121822454647
is,0.09347657352596603
known,0.0835790893335201
to,0.06778199743466265
be,0.11748052501612251
vital,0.16623093716674758
for,0.15153198968745352
the,0.19608445618104248
development,0.14846200305655569
of,0.11314348427226459
T,0.08818772982750353
cells,0.12992488511236447
at,0.11007262364087489
multiple,0.0632808084241165
stages,0.06426753582229076
in,0.08915930847970635
the,0.10798953125245359
thymus,0.06945128084594412
and,0.06816189071291001
for,0.08305044277620689
Th2,0.11654233142114205
differentiation,0.10829256034534457
in,0.07374829144931346
the,0.08726443729143105
peripheral,0.043473042991785574
organs.,0.08549053239305007
Although,0.006784290588051911
it,0.009992689281215404
is,0.00647347846375941
well,0.005266612216125492
documented,0.008799695373029959
that,0.009501381034536604
GATA-3,0.05084042793861672
is,0.009147039790546355
expressed,0.01825835626697179
in,0.019217487837170057
"HSCs,",0.013544257638969309
a,0.004384417635842946
role,0.010148631492757474
for,0.006934637314868459
GATA-3,0.04371661938178995
in,0.012360590689240294
any,0.007704856104817241
prethymic,0.01282262357325878
progenitor,0.015590521280368417
cell,0.024668411593000372
has,0.002647946895538523
not,0.0027533684724775453
been,0.002519024409132938
established.,0.0032328126109461733
In,0.6737203906342774
the,0.6628141140460446
present,0.6361133640939127
"study,",0.6403352475833144
we,0.6991873999324834
show,0.7400645663810258
that,0.7662881670441696
Gata3-null,0.6953168267189713
mutant,0.7305117481122202
mice,0.7499782101376241
generate,0.7239224720989026
fewer,0.7395831032199779
LT-HSCs,0.7429650982892294
and,0.817866085527034
that,0.7792299785607805
fewer,0.7348947880819741
Gata3-null,0.7070225838616038
LT-HSCs,0.7188769319632682
are,0.7309634450003045
in,0.6773036942793713
cycle.,0.7178436092799833
"Furthermore,",0.7559776673126375
Gata3,0.6541843220163676
mutant,0.7135828833430506
hematopoietic,0.6859488643587153
progenitor,0.6355513975705784
cells,0.6845720350692561
fail,0.6271212940467495
to,0.6278993921921782
be,0.6396383188293725
recruited,0.6332247492966151
into,0.7364767326438638
an,0.7332751074598722
increased,0.719444596166442
cycling,0.6751875686354681
state,0.7174585038962582
after,0.692545080083108
5-fluorouracil-induced,0.6349130750772654
myelosuppression.,0.7663626570507162
"Therefore,",0.6979578851647655
GATA-3,0.5988728774280598
is,0.5833170076899834
required,0.6242256076608821
for,0.6397904120325023
the,0.642183245452249
maintenance,0.6205807271426296
of,0.6256611428226245
a,0.5955272797067453
normal,0.5792403943394834
number,0.5442018977409008
of,0.5455083269678419
LT-HSCs,0.5644386103533152
and,0.6074373812857639
for,0.5733192486496185
their,0.5312866291301231
entry,0.5688918227436217
into,0.5878770634156956
the,0.6037862608281055
cell,0.6085991540830451
cycle.,0.5934489140600632
CONTEXT,0.04151059154348581
Antibody-based,0.007680117905083154
induction,0.016814535662642172
therapy,0.014935474232024404
plus,0.015570460067679846
calcineurin,0.01607575245773877
inhibitors,0.010385772797824728
(CNIs),0.009405331999644155
reduce,0.018116915369636163
acute,0.012523826991637975
rejection,0.010782237810966011
rates,0.009202287327213723
in,0.012313065706499026
kidney,0.008410221354376544
recipients;,0.017212319341687213
"however,",0.007340612863306565
opportunistic,0.003355854994820512
infections,0.0025507304377152995
and,0.005447998326055457
toxic,0.002690530381464347
CNI,0.009959567170640332
effects,0.0034279615241554697
remain,0.00362306918455766
challenging.,0.0023266022223158416
"Reportedly,",0.0018471776127673646
mesenchymal,0.001861722854968814
stem,0.0017589083847894193
cells,0.0016770365178579527
(MSCs),0.0022480129770638007
have,0.0028111527975471238
successfully,0.0019317027617714781
treated,0.0015431940625706035
graft-vs-host,0.0015539660048009623
disease.,0.0015583119465332458
OBJECTIVE,0.0018888251979505058
To,0.0017330143069893215
assess,0.0014016794681261148
autologous,0.0014286953388180455
MSCs,0.0014423191691083858
as,0.0016164637012827834
replacement,0.001033290943418119
of,0.0025868748246808664
antibody,0.0013839692677831237
induction,0.0013491258531519257
for,0.002223721175103797
patients,0.001656862634363403
with,0.00213176510989255
end-stage,0.0010666905743680376
renal,0.0019694154821596668
disease,0.0017093309877697226
who,0.0022992782243614184
undergo,0.0020447195869361078
"ABO-compatible,",0.0015910805213358418
cross-match-negative,0.001775091116189873
kidney,0.0027634664894689463
transplants,0.0012833134004235991
from,0.002072132339188688
a,0.002879790165203899
living-related,0.0018631757153224813
donor.,0.0027097538367085723
"DESIGN,",0.0016422808724209442
"SETTING,",0.0029803652891558993
AND,0.0016443821670415497
PATIENTS,0.0018144698040912764
One,0.00218356612666294
hundred,0.0020917899509594207
fifty-nine,0.002054027508387857
patients,0.001436908735606437
were,0.002338356943425942
enrolled,0.001902388097148363
in,0.003178701889038053
this,0.0029672346297476143
"single-site,",0.0033110713368656023
"prospective,",0.0024278834196269986
"open-label,",0.0030097274315823716
randomized,0.0018826616435527817
study,0.0015440634768744538
from,0.001999712871446891
February,0.0025262306921001367
2008-May,0.002609992975856199
"2009,",0.0021895445002668643
when,0.002666440806720857
recruitment,0.0016045868559233637
was,0.003150542812208602
completed.,0.0019058077016119827
INTERVENTION,0.004167279052472652
Patients,0.0015195777752379696
were,0.0028434795439652386
inoculated,0.0018269275075929348
with,0.0022804812870979418
marrow-derived,0.0028748391470118794
autologous,0.002352747669186667
MSC,0.002573871600060037
(1-2,0.002034361465541009
x,0.0024248583233607087
10(6)/kg),0.002443783165934357
at,0.0030871470081568777
kidney,0.0017938115797861657
reperfusion,0.0030953142460463543
and,0.002801770151650876
two,0.0020568429496426667
weeks,0.0021495587779755032
later.,0.0028002091942974407
Fifty-three,0.0025914279509460037
patients,0.0029913921600476334
received,0.0035774322487519814
standard-dose,0.002287249912860314
and,0.004972751111073858
52,0.002775136387637509
patients,0.003402702963703052
received,0.0021332013877399985
low-dose,0.001674993232654758
CNIs,0.0017804848438283075
(80%,0.0017364655426025284
of,0.0022481113756405873
standard);,0.0016692485341597311
51,0.0012247561098527402
patients,0.0013575726825874814
in,0.001351240831206037
the,0.0014880638601574387
control,0.0012886858806078958
group,0.0014068180969528134
received,0.0014668334039104215
anti-IL-2,0.001756974172345371
receptor,0.00155459943436128
antibody,0.001951977361452194
plus,0.0012733853803371233
standard-dose,0.001227364161815238
CNIs.,0.0013382540449032665
MAIN,0.0018446618041259224
OUTCOME,0.0019392541084665017
MEASURES,0.001830684794767582
The,0.0017541029261727771
primary,0.0015209646137222996
measure,0.0010995862813673524
was,0.0015553334545147083
1-year,0.0017982423908530381
incidence,0.0008143424227252542
of,0.0012555538122914754
acute,0.0009591010896057337
rejection,0.0008154903302164909
and,0.0017798857692382646
renal,0.0011045023793336735
function,0.0009907261415900489
(estimated,0.0009695547286215405
glomerular,0.0011277837634386585
filtration,0.0014500980183559677
rate,0.0007060143886811228
[eGFR]);,0.0018242399478740113
the,0.00176830328760049
secondary,0.0011739231462194021
measure,0.0010335232890438647
was,0.0012611612338990503
patient,0.0006620959602473268
and,0.0016416711701507047
graft,0.0009075650407387867
survival,0.0007385659550138139
and,0.0009673520267432609
incidence,0.0005571970840847027
of,0.0006679378616387222
adverse,0.0006119996523579176
events.,0.0006306002009347122
RESULTS,0.017912063664042355
Patient,0.011930450210183855
and,0.010994849702327567
graft,0.008479726859925854
survival,0.009309221182692224
at,0.011466664394751743
13,0.006028791488107972
to,0.011713302660525702
30,0.007627231538839645
months,0.0048184931428169485
was,0.014127819021386151
similar,0.012546491833913336
in,0.013603648088306636
all,0.014869312720732242
groups.,0.008375913405592388
After,0.08365227794526917
6,0.061998821811262074
"months,",0.042388980211789926
4,0.6895545203602947
of,0.7313691061824933
53,0.7076532390989121
patients,0.7632673013666167
(7.5%),0.6701879497532466
in,0.780256341945235
the,0.7592262105223053
autologous,0.791641191839614
MSC,0.7624481090324627
plus,0.7934470811451455
standard-dose,0.7757965803838265
CNI,0.78936699790352
group,0.8428064016533666
(95%,0.7829289217690967
"CI,",0.7988017366735419
0.4%-14.7%;,0.8073522220720872
P,0.827517263739553
=,0.8157076249170413
.04),0.8157684395864326
and,0.7640190285789882
4,0.783384567198325
of,0.7724920627000095
52,0.7722228688025476
patients,0.806954739910231
(7.7%),0.7378164992610554
in,0.7918563905335626
the,0.7644217469230923
low-dose,0.7558242021477698
group,0.7960235913173062
(95%,0.7240008614303027
"CI,",0.7784143584718188
0.5%-14.9%;,0.7461580050040817
P,0.7608787187739955
=,0.7691598095353687
.046),0.7630985588913421
compared,0.8168224500880491
with,0.7243883114733128
11,0.6980149102450701
of,0.6871537393322574
51,0.6848624527973355
controls,0.7405961192085583
(21.6%;,0.6821117764357756
95%,0.779672031382563
"CI,",0.7437823179975207
10.5%-32.6%),0.7299115774276744
had,0.7191747614848675
biopsy-confirmed,0.6574569715803125
acute,0.6745198034979142
rejection.,0.6840161724895105
None,0.30163083820687225
of,0.34876261089413824
the,0.3276942285251243
patients,0.3873608783816926
in,0.3989218871100688
either,0.6211619901843635
autologous,0.6921464328673461
MSC,0.6478570387846865
group,0.697691205467519
had,0.6919709598188255
glucorticoid-resistant,0.6929137564878525
"rejection,",0.6739129104230198
whereas,0.6251816974568075
4,0.6702531682059532
patients,0.6847200477656099
(7.8%),0.5980011187826513
in,0.6270277446677422
the,0.6850647140986967
control,0.6191977373733478
group,0.7322061832872274
did,0.656084022469012
(95%,0.6610367270456212
"CI,",0.7020345958077909
0.6%-15.1%;,0.67514729622626
overall,0.7160791554755435
P,0.6909286932509883
=,0.6511880488301712
.02).,0.6414879132783665
Renal,0.4293002591131922
function,0.4505235510070571
recovered,0.37437900688932385
faster,0.3667963515299283
among,0.429204761184461
both,0.4168893962430287
MSC,0.3601310538115975
groups,0.47824853164969044
showing,0.4583607714982971
increased,0.3672832311188599
eGFR,0.44728764025211076
levels,0.3868276933989462
during,0.39411951225530695
the,0.34998843352122627
first,0.3029754162396167
month,0.26518421307403856
after,0.23234968680282791
surgery,0.3213771165377116
than,0.3725896432719922
the,0.30161580297010193
control,0.2667345043735093
group.,0.40310389790466744
Patients,0.4560888733034607
receiving,0.45608894446220455
standard-dose,0.4765693026205004
CNI,0.4795564083781395
had,0.47297105999719025
a,0.4907748505568911
mean,0.5583460617279007
difference,0.5310094688627387
of,0.5088147067317017
6.2,0.5366393661052599
mL/min,0.4575383268518421
per,0.45084053649135847
1.73,0.44888822458635175
m(2),0.4640896131346823
(95%,0.4918625015569701
"CI,",0.5313117004243922
0.4-11.9;,0.5368497213278463
P=.04),0.65653568550411
and,0.6620467049951599
those,0.6368117951907057
in,0.6364334878488523
the,0.6517160865888905
low-dose,0.6236602884145453
CNI,0.6115837687267813
of,0.6492878242067162
10.0,0.6342399702105062
mL/min,0.5633276772161885
per,0.5806069136571761
1.73,0.5301571745652051
m(2),0.5813210467776229
(95%,0.5745221123206528
"CI,",0.6201599257752982
3.8-16.2;,0.7018643017986697
P=.002).,0.6146593819583012
"Also,",0.8903542208946544
during,0.8772152544903042
the,0.8484863861631008
1-year,0.8236022046874844
"follow-up,",0.7548041445324182
combined,0.8744822047124345
analysis,0.853072853808291
of,0.8351894046913678
MSC-treated,0.7596869825965703
groups,0.8306044341916409
revealed,0.8548962162749686
significantly,0.8739639186817268
decreased,0.864994381589546
risk,0.8677427250312424
of,0.887844599595636
opportunistic,0.8891377073644811
infections,0.791516343404386
than,0.8804250897816376
the,0.8170184544093143
control,0.7577209018675048
group,0.8238832271927982
(hazard,0.8211899349191032
"ratio,",0.7911393598545708
0.42;,0.7780903191965982
95%,0.8826840959028144
"CI,",0.7730624875918546
"0.20-0.85,",0.7128539165851652
P=.02),0.7847324475326246
CONCLUSION,0.8881798987367426
Among,0.8440013824590005
patients,0.7874472205766833
undergoing,0.924085181808634
renal,0.9326244466942232
"transplant,",0.8852707605165795
the,0.9190409324401276
use,0.9020672207744576
of,0.9077760154861834
autologous,0.9158829811776543
MSCs,0.8909442079808073
compared,0.9391964543899468
with,0.9084475512569637
anti-IL-2,0.9312169487402053
receptor,0.908600845997579
antibody,0.929278574935202
induction,0.9397100979605368
therapy,0.91292266404797
resulted,0.9342336108171945
in,0.9369988134598287
lower,0.9388030138232796
incidence,0.9418219939568919
of,0.9457462954673397
acute,0.9465785826898478
"rejection,",0.9205491006649608
decreased,0.9284379530139348
risk,0.9393162397350195
of,0.9445167674591639
opportunistic,0.9383496706357939
"infection,",0.915408604452855
and,0.9304120218723002
better,0.9206430470760895
estimated,0.9021368203553158
renal,0.9179221268669161
function,0.8944530887280635
at,0.9103764282202812
1,0.8890166998560826
year.,0.9165224424274068
TRIAL,0.009776136481983465
REGISTRATION,0.012706370289944952
clinicaltrials.gov,0.006047755769456098
Identifier:,0.010593996307207691
NCT00658073.,0.005319553615968864
Viral,0.03881480452314631
replication,0.03526593745685475
and,0.04125286945795528
microbial,0.02397423593800286
translocation,0.028172975206756226
from,0.03414213366440483
the,0.02800151103601778
gut,0.024340345539836262
to,0.024468138734521604
the,0.022755990152863347
blood,0.02099741000690797
during,0.03574261778715641
HIV,0.017829013484119464
infection,0.016881789111473224
lead,0.03608370627320977
to,0.04266174080939312
hyperimmune,0.0338020091446938
"activation,",0.03519017311067137
which,0.04089235100599792
contributes,0.026611641280241353
to,0.029306661822517694
the,0.029240774144872205
decline,0.020483033790261385
in,0.022954007774312363
CD4+,0.03117576982341611
T,0.021821254941534127
cell,0.02273962336125351
numbers,0.02012055088697414
during,0.01912569829192949
HIV,0.011665258350777126
infection.,0.01096101400878609
Programmed,0.00303643471315292
death-1,0.005322375149403664
(PD-1),0.004952568367488896
and,0.005895342694184444
interleukin-10,0.002763534165519492
(IL-10),0.004145254432559724
are,0.0037941555823450828
both,0.0030331474998383815
upregulated,0.002484291803492265
during,0.0042501874110473375
HIV,0.0033059036772622227
infection.,0.0031313464332730005
Blocking,0.2509572879222779
interactions,0.2706023620929267
between,0.16047540347832462
PD-1,0.27704742312791397
and,0.18871950744421642
programmed,0.19867007593637181
death,0.23407428238161013
ligand-1,0.15441626824909482
(PD-L1),0.14745029740190027
and,0.1749650623057702
between,0.1428838548883548
IL-10,0.2693667867704451
and,0.19447288964535556
IL-10,0.23402349503180225
receptor,0.18515541210795045
(IL-10R),0.10990957958719959
results,0.2738112961174783
in,0.35489308071189424
viral,0.19693248439678404
clearance,0.2047916146789277
and,0.37383886197969785
improves,0.24138740375245685
T,0.14198085823167056
cell,0.21248015123723432
function,0.16884446330931457
in,0.11818358122462742
animal,0.06604783655862177
models,0.11789082440588064
of,0.14246160115938694
chronic,0.23475134479489104
viral,0.21910321376633843
infections.,0.21455248024179535
Here,0.5213789560520435
we,0.5454813062355359
show,0.5992994290945178
that,0.6059212408444177
high,0.4476453685480098
amounts,0.40336491986306644
of,0.43035758641960875
microbial,0.4525209365642113
products,0.43371382140123266
and,0.49598755593165356
inflammatory,0.49071634571350525
cytokines,0.5099704970043825
in,0.4615542328105514
the,0.47191921959524286
plasma,0.48254676814938974
of,0.4191365517124251
HIV-infected,0.35766671988225796
subjects,0.4876690537296534
lead,0.46776350150433105
to,0.5109540710164595
upregulation,0.42737309255467254
of,0.45953874359452784
PD-1,0.46106281960707285
expression,0.4681535537032759
on,0.48357070514057227
monocytes,0.4616568938123071
that,0.4550976446345553
correlates,0.44232680137667274
with,0.3714280009615572
high,0.31890760678281355
plasma,0.3316546326230098
concentrations,0.3340266629134798
of,0.28908632512814464
IL-10.,0.395314479468646
Triggering,0.6104759342482545
of,0.6057387506565886
PD-1,0.5850906411741693
expressed,0.5809460268427182
on,0.6140504747347977
monocytes,0.5005969998383687
by,0.5690768128430328
PD-L1,0.560424604634327
expressed,0.5972290608223391
on,0.5947659426634284
various,0.4180767676548992
cell,0.5639438679100691
types,0.5075111801112174
induced,0.5834963048759793
IL-10,0.5242627158561274
production,0.5696308709167495
and,0.5872808278068767
led,0.5723687269929566
to,0.5622348611241704
reversible,0.5935926689771517
CD4+,0.5650760078836143
T,0.45749625018954904
cell,0.5833359892324876
dysfunction.,0.4430273151171453
We,0.5021999112864923
describe,0.38022587113260325
a,0.41696341928079345
new,0.4148616922425414
function,0.4877669381010628
for,0.3328110401960838
PD-1,0.431424829393642
whereby,0.5118368015325307
microbial,0.4918058982994053
products,0.5574644798047408
inhibit,0.6063137435254641
T,0.5658403877799292
cell,0.6753763091710117
expansion,0.6156359728435237
and,0.6163919492467222
function,0.7272193844144718
by,0.8022657624607011
upregulating,0.805052591395932
PD-1,0.7641639070785547
levels,0.7975757563870111
and,0.8173087514798403
IL-10,0.7695821543205537
production,0.7869213260692869
by,0.7954578132161517
monocytes,0.7943452360389268
after,0.7549332707530778
binding,0.6869364018902501
of,0.7442974604556726
PD-1,0.7616674744448322
by,0.7199460086183331
PD-L1.,0.7284537044395252
BACKGROUND,0.00493531502599801
The,0.001285231997014409
purpose,0.0007735599843532568
of,0.0010962093750155704
this,0.0010210690009348276
study,0.0014396408898937159
was,0.0010452892615945297
to,0.0007977179295263093
test,0.0007459276742471416
the,0.0007483817921655701
hypothesis,0.0009818559257462206
that,0.0018224421936478285
vasodilator,0.0020600856889507867
responses,0.0028921169318795775
of,0.002048572898782558
porcine,0.0014124344784994338
coronary,0.0016547844113643487
resistance,0.0013504949551914301
arteries,0.0011724991100139578
are,0.0016747552372185736
increased,0.002011448353792363
by,0.00243037522381282
exercise,0.0012586405899441423
training.,0.001146735033118957
METHODS,0.005367695925816672
AND,0.0016964567769922735
RESULTS,0.0031839482854305228
Yucatan,0.0024434623538024205
miniature,0.0014691802038740447
swine,0.0012612783583031784
were,0.0012487114041998708
randomly,0.0005732112328185413
divided,0.0007137116718854671
into,0.0007697423113532247
groups,0.0006858103928065777
of,0.0008853629249741727
exercise-trained,0.0006555954151890886
(ET),0.0008621539624901013
and,0.0009529035061988844
sedentary,0.000798342642157725
(SED),0.0006532033106050329
control,0.0008536422974898976
pigs.,0.000704517242973583
ET,0.0009324065481757963
pigs,0.0010018314197909755
were,0.0010511308252826013
placed,0.0009098241575205356
on,0.001342557769629754
a,0.001198833348728126
progressive,0.0007480094273628902
treadmill,0.001053484951861743
training,0.0009753418441146374
program,0.001061544578017854
lasting,0.001280104313099453
16,0.0011997003835323835
to,0.0013628762343903468
20,0.0009932592431231113
"weeks,",0.0010349985710583827
and,0.0019002543506414884
SED,0.0011826422682884557
pigs,0.0012568597998002396
remained,0.0010944962656567901
inactive,0.0012204917884298745
during,0.001050634506858035
the,0.0013580298082651377
same,0.0011894524510981895
time,0.0011840549236503918
period.,0.0016231443908730357
Coronary,0.1172814118856281
resistance,0.09026210525693185
arteries,0.052231140359414674
64,0.1550534970436126
to,0.24493977649729334
157,0.11580139569758215
microns,0.15836682471227964
in,0.09591902015434585
diameter,0.07562078137645614
were,0.0450631897462871
isolated,0.04124511421919616
for,0.10304029270299735
in,0.129656451449096
vitro,0.05746079518307641
evaluation,0.0246268459523318
of,0.015816568991327506
relaxation,0.037914053728342334
responses,0.023564398666875912
to,0.021856776865556815
the,0.02837481595793204
endothelium-independent,0.0361580857761759
dilators,0.021425390784494003
sodium,0.04222687198546311
nitroprusside,0.0569841240070749
(1,0.0703575612977682
x,0.14479883829638782
10(-10),0.11996721232170982
to,0.10121624725624956
1,0.18067270832162152
x,0.22103967650029807
10(-4),0.16998908465391338
mol/L),0.18307763752147393
and,0.1140305435226497
adenosine,0.1300571480871315
(1,0.10091310913962805
x,0.23724684903528787
10(-10),0.14735628727208583
to,0.07258288352469273
1,0.1003375695784207
x,0.14625860534659466
10(-5),0.1222187275050491
mol/L),0.2082796952141128
and,0.02878309710225351
to,0.04799749290014255
bradykinin,0.057324738918741985
(1,0.04193327248868713
x,0.12485337017636289
10(-13),0.10099785019149962
to,0.041549772463490724
3,0.19442979248810577
x,0.08798259129629654
10(-7),0.08488791986590166
"mol/L),",0.12259944529558657
an,0.031669911893293864
endothelium-dependent,0.07485697800277662
agent.,0.059839311680593386
Relaxation,0.06621055664384248
responses,0.05127779965033575
to,0.07265804498852178
adenosine,0.06722289733884765
and,0.06547444383405125
sodium,0.06018984789633729
nitroprusside,0.07819040010057965
were,0.03848466175056618
not,0.05473872564201428
altered,0.03651471341241175
by,0.058268224523303776
exercise,0.07166638885852396
training.,0.07157147280508483
Endothelium-dependent,0.4323946806739902
relaxation,0.4616349779619662
to,0.4359500433744064
bradykinin,0.3743078290636705
was,0.46317196536077115
enhanced,0.461386331595277
in,0.4678295245428746
coronary,0.41015522444235475
resistance,0.3609247400257415
arteries,0.3331724131772962
from,0.4364650920741877
ET,0.29591942192958715
pigs,0.4226623921607022
(IC50:,0.3619666089608433
"ET,",0.3424756259873672
0.07,0.26233445224422713
+/-,0.2863003194467329
0.02,0.2388163288255567
nmol/L;,0.27495598550756506
"SED,",0.3348597326747115
1.59,0.3493561306763601
+/-,0.3000618339951254
0.09,0.2204286661685912
nmol/L).,0.289574302161622
To,0.009355513543338384
determine,0.0057032674572671015
whether,0.00925455518963606
prostanoids,0.05528079869501002
and/or,0.01731757353399938
the,0.019635823654433095
nitric,0.034320439887951554
oxide,0.0423593369640251
synthase,0.028455876186065508
pathway,0.05624077469307922
were,0.014649417222527193
involved,0.0353487727696183
in,0.036636835920935466
the,0.021788866207341356
ET-induced,0.04358459507097553
changes,0.04192762157547115
in,0.04274225904441344
bradykinin-induced,0.06953457513154027
"vasodilation,",0.04528164558125287
responses,0.02141303232422538
to,0.037381353151466616
bradykinin,0.04380701129041487
were,0.01253361984950147
examined,0.01167381012390097
in,0.02677088439440638
coronary,0.0365598545385031
resistance,0.027830163889000285
arteries,0.021932119841389902
from,0.03864821662551385
both,0.048096760463371004
ET,0.03476320632793885
and,0.04588003827577811
SED,0.041899956981893104
pigs,0.05010636486821904
in,0.023716102994816666
the,0.013980832927613623
presence,0.019544805453950653
of,0.04108828714170705
indomethacin,0.26936985435692296
and,0.2779285228924904
in,0.28642987761613203
the,0.22844007215656276
presence,0.21338171748668727
of,0.2120307907661923
nitro-monomethyl,0.2006784172418772
L-arginine,0.2285191366430181
(L-NMMA).,0.19440018139767426
Both,0.5571923790543645
indomethacin,0.5169939179420091
and,0.5752198183338914
L-NMMA,0.48145170922288855
produced,0.6059957509771847
significant,0.6293771844460518
inhibition,0.6609613448353585
of,0.6667075811115444
the,0.6472805974414614
bradykinin-induced,0.5071166343260474
relaxation,0.5929136161274621
in,0.5736369045152766
vessels,0.5246772246298662
from,0.568410738153073
both,0.3794728265716081
groups.,0.3903793190133366
Despite,0.19930758888979286
decreased,0.22561825693179946
bradykinin-induced,0.20268375803703279
relaxation,0.3037711319472107
after,0.20600029417500687
"indomethacin,",0.1977092291790611
bradykinin-induced,0.15044638033718766
vasodilation,0.2300771479384882
was,0.19569675628210684
still,0.15584017474231307
enhanced,0.21189146680135246
in,0.16521495597630687
vessels,0.16686261377008793
from,0.18912230917902356
the,0.16782271592553916
ET,0.13052986240068554
group.,0.22343729405557225
L-NMMA,0.7288474813206095
caused,0.8200297749391826
greater,0.8391267073150769
inhibition,0.8587123577407458
of,0.8366352748120518
the,0.8476688581791574
bradykinin-induced,0.7850948960874534
relaxation,0.8112930948751855
in,0.8386844233425812
coronary,0.8594122068967285
resistance,0.8172530049484742
arteries,0.8412115581524291
from,0.8376040730017115
ET,0.7136643444511825
pigs,0.8217300045317542
relative,0.8115215401578891
to,0.7800098891456243
arteries,0.6508675966886854
from,0.725446956525569
SED,0.6043024714593066
pigs,0.6798902077487766
and,0.7629738717077758
eliminated,0.7046619318933708
the,0.7847164074055535
training-induced,0.6874682801868327
enhancement,0.7384347174532745
of,0.7604183274759758
the,0.7269729175938997
bradykinin,0.6548105533612192
responses.,0.6888635728466576
CONCLUSIONS,0.8160879269066433
These,0.7889481922956036
results,0.8351056774814931
suggest,0.8407947436601064
that,0.8941942561364049
exercise,0.8917409795392807
training,0.9042850988979213
enhances,0.9152310007771306
bradykinin-induced,0.9084124917724051
vasodilation,0.9098896879696449
through,0.9276788497591841
increased,0.9240585923810664
endothelium-derived,0.9218587847167524
relaxing,0.8654192258130892
factor/nitric,0.8865872538441515
oxide,0.8141192008500058
production,0.8795230346100469
by,0.8867418480327321
the,0.8832045775210576
L-arginine/nitric,0.8215891048360419
oxide,0.7575614271395321
synthase,0.8816440887315476
pathway.,0.8835917482257128
CONTEXT,0.019659198439431563
More,0.0036323945114209344
than,0.0029468686818869736
1.5,0.002222898735812353
million,0.002098005695329477
US,0.0018173073358648281
adults,0.0019557446604112137
use,0.0018042507235015188
stimulants,0.0017751865954943452
and,0.0016774201603031956
other,0.0013137476111252596
medications,0.0018600170340082546
labeled,0.0013041988655033397
for,0.0013494956310932597
treatment,0.0014055261573652235
of,0.001891629784563358
attention-deficit/hyperactivity,0.0025932156717627707
disorder,0.002167560462225586
(ADHD).,0.001456162509755067
These,0.002942203416520687
agents,0.002935410862706515
can,0.003395790766099526
increase,0.0039522636910656475
heart,0.0025633695486697475
rate,0.002646225366533515
and,0.005378602862868702
blood,0.0021369068802548435
"pressure,",0.0023967217492564144
raising,0.0021795237444860263
concerns,0.0018158231946053772
about,0.001992546615804808
their,0.0017352723798934743
cardiovascular,0.0017268765408353952
safety.,0.0011931446650064186
OBJECTIVE,0.0017929869773037309
To,0.0013699652668789696
examine,0.001297172003507249
whether,0.0012522002453164809
current,0.0014682780862428494
use,0.0016868526396400852
of,0.0023469733260612375
medications,0.0014113947622986878
prescribed,0.0016557981705879622
primarily,0.0022862696982736868
to,0.002119292341372194
treat,0.0010622271671851958
ADHD,0.0009767008898557575
is,0.0010934926530915025
associated,0.0010387822042410442
with,0.001321302949355561
increased,0.0010475230340082258
risk,0.000903534825997172
of,0.001953827792612455
serious,0.0011929105661092946
cardiovascular,0.0010844665385552161
events,0.0010908338343306638
in,0.001446599890489005
young,0.00145565160673155
and,0.0018497989722432954
middle-aged,0.0014203100250133336
adults.,0.0012662794673288142
"DESIGN,",0.004442356893322976
"SETTING,",0.016876242315537086
AND,0.004754994556929802
PARTICIPANTS,0.008797119185631305
"Retrospective,",0.0013322646553765747
population-based,0.0004892567729048863
cohort,0.0008207028366780926
study,0.00074127961874385
using,0.0008216999569949641
electronic,0.0007670588345911734
health,0.0006000863882957702
care,0.0007039853539437014
records,0.0006078771818601616
from,0.0008418616209638961
4,0.0007246993608036414
study,0.000619355915280407
sites,0.0007180516597410766
(OptumInsight,0.0010019502575652577
"Epidemiology,",0.0008341255765477636
Tennessee,0.0005088041617966474
"Medicaid,",0.0007276517385540322
Kaiser,0.0008004290587205652
Permanente,0.0013975780706801742
"California,",0.0007439814439801026
and,0.0009929652223367533
the,0.0010073288727668163
HMO,0.0010532661847144462
Research,0.000904738733542634
"Network),",0.0011084260352115282
starting,0.0008500410483051811
in,0.0010946279081962486
1986,0.0007666229388546484
at,0.0010414189491800287
1,0.0008318590486850841
site,0.0007899777763710302
and,0.0012724545558119153
ending,0.0007550724078874265
in,0.0010889854262124835
2005,0.0008789707219354114
at,0.0009511102882619584
all,0.0007462997147065782
"sites,",0.0007649195506644814
with,0.0008100773622642482
additional,0.0008410882677843655
covariate,0.0007697401108011154
assessment,0.0006599944225581481
using,0.0008239733737621549
2007,0.0006836759853743379
survey,0.0006281881697050868
data.,0.0006939752022554868
Participants,0.001973189607359475
were,0.0014939753018432809
adults,0.0013836648364549333
aged,0.0012954493505009889
25,0.0011896243964116327
through,0.0014642306255959446
64,0.0017068644698301834
years,0.0010569214243495424
with,0.0014260684644320384
dispensed,0.0010720019019030487
prescriptions,0.0008839855535982868
for,0.001452487931510909
"methylphenidate,",0.0012404382360861376
"amphetamine,",0.001383253762633975
or,0.0008545981722080403
atomoxetine,0.0014758980445306364
at,0.0009093193361107379
baseline.,0.0007019582998241961
Each,0.005839503936533471
medication,0.004444439889138158
user,0.006575521546903595
(n,0.008696850623190911
=,0.014445007909456105
"150,359)",0.008136314219302403
was,0.00751634686028245
matched,0.0010586685668668842
to,0.0010257570550840833
2,0.0010864449296221059
nonusers,0.0009947737737104035
on,0.0008630488399936264
study,0.000809160834828357
"site,",0.0010804358851630538
birth,0.0009689092470479936
"year,",0.0012977861797051388
"sex,",0.0007959807748188588
and,0.001015039853180701
calendar,0.0008413561949492351
year,0.0010771159319031961
"(443,198",0.0007369517239660002
total,0.0005662538863001776
users,0.0010068798350656447
and,0.0012161855317166913
nonusers).,0.0008264958038750151
MAIN,0.0017015564916108732
OUTCOME,0.0024134911196127718
MEASURES,0.0016750825394856316
Serious,0.001816633637336289
cardiovascular,0.0013833611307249665
"events,",0.0013030612332907998
including,0.0013560566048537747
myocardial,0.0022629242411357146
infarction,0.0015533890387058546
"(MI),",0.0022461746767761573
sudden,0.0012090387748218813
cardiac,0.001280138757088038
death,0.0014763977659970166
"(SCD),",0.0014202860167547569
or,0.0014668882304881823
"stroke,",0.0014972791069564478
with,0.002061856873268953
comparison,0.0014571505089775996
between,0.0014608017400465395
current,0.001571952861080457
or,0.0016165071811027963
new,0.001684514325265195
users,0.0014011973284331293
and,0.0015774567439144403
remote,0.0014514474545076132
users,0.001319035634536879
to,0.0022751696429717393
account,0.0013035990405887926
for,0.0014901242080995268
potential,0.0014213559609757293
healthy-user,0.0012647628136551762
bias.,0.0012677792207740819
RESULTS,0.04689105278516709
During,0.03939445272689073
"806,182",0.014182826215236363
person-years,0.019469583557657086
of,0.019517046676271237
follow-up,0.017738696041985604
"(median,",0.01360687650010073
1.3,0.014370741277336637
years,0.011205135440340127
per,0.010524052492826678
"person),",0.010121464381766098
1357,0.012989672617307036
cases,0.021888450124412845
of,0.03421838071379233
"MI,",0.033120360517706164
296,0.009971050795702898
cases,0.02617122714771954
of,0.044476590584421535
"SCD,",0.12906455563173527
and,0.04452886764563489
575,0.012221566718169813
cases,0.019907830143527715
of,0.021719659777483784
stroke,0.01549770992024944
occurred.,0.02037058032783577
There,0.04155126314689054
were,0.02004120341352708
"107,322",0.011932622926384863
person-years,0.042375225176485384
of,0.016767289352873464
current,0.021973184621945502
use,0.054802959479403786
"(median,",0.03215440795454485
0.33,0.018386287751617814
"years),",0.013763333951531918
with,0.15068513824342744
a,0.21893046490000195
crude,0.2967863912649051
incidence,0.26418097118952444
per,0.23336112486916058
1000,0.17789894003263226
person-years,0.2273287477537064
of,0.24047183732641006
1.34,0.2382814587303669
(95%,0.23852839647988505
"CI,",0.4199180682550483
1.14-1.57),0.33447440388288147
for,0.3201155260464318
"MI,",0.43315067929882506
0.30,0.2819058135813286
(95%,0.3404275521228304
"CI,",0.5336013573115795
0.20-0.42),0.3317271041889151
for,0.33061230045567247
"SCD,",0.4006379440843363
and,0.37746842179938733
0.56,0.2812592042265717
(95%,0.2990734211658511
"CI,",0.4918195864671144
0.43-0.72),0.3029000293875479
for,0.3275154675828789
stroke.,0.2762380599425808
The,0.20118472781830843
multivariable-adjusted,0.200834650897516
rate,0.19765795294997737
ratio,0.19591601605935494
(RR),0.11517796056647171
of,0.18482485203760848
serious,0.23863524532430305
cardiovascular,0.23250144568267817
events,0.23433361688427615
for,0.19667696351132272
current,0.23271927009346166
use,0.406322737360914
vs,0.3421100636836314
nonuse,0.35776744292336626
of,0.3697941508428932
ADHD,0.3926894126467647
medications,0.4053282605714926
was,0.3378680499224147
0.83,0.3208875149779664
(95%,0.34263813282779454
"CI,",0.46681720002011123
0.72-0.96).,0.3678639070821159
Among,0.301690248820383
new,0.23988257193784673
users,0.24682627441113517
of,0.2795204816057894
ADHD,0.3304528047941062
"medications,",0.3169966156417096
the,0.21849634491537942
adjusted,0.29652607484920446
RR,0.2932139218241746
was,0.30971055809581277
0.77,0.29427874277883276
(95%,0.3201309958894485
"CI,",0.4056271948831477
0.63-0.94).,0.3034145999686921
The,0.4043866085015947
adjusted,0.4623033085965755
RR,0.46378919050090944
for,0.40764059086573917
current,0.4138918115189061
use,0.39705870499161133
vs,0.4725430322781301
remote,0.42083210568539264
use,0.4216822359649407
was,0.4722752694931193
1.03,0.4259840899520545
(95%,0.4298796265841311
"CI,",0.5402972070625311
0.86-1.24);,0.4149021954881121
for,0.4997091982841557
new,0.4640471427089063
use,0.37599531288811017
vs,0.48111585418228225
remote,0.45639872928574066
"use,",0.3784793643152264
the,0.4223438315591499
adjusted,0.47514175244843626
RR,0.49363219151384635
was,0.4795682214104975
1.02,0.4457123925953373
(95%,0.42422325856030363
"CI,",0.5514857154643527
0.82-1.28);,0.4235265667908264
the,0.45370501089071186
upper,0.43996758943450265
limit,0.4072022191313198
of,0.43422179472645117
1.28,0.42985642269531776
corresponds,0.1954697333807518
to,0.14985397602048248
an,0.14274345954692313
additional,0.12292041823274903
0.19,0.09302231608066171
events,0.12834543864666142
per,0.09951629480548989
1000,0.08003063803521522
person-years,0.08600648645764725
at,0.12243661960567986
ages,0.0726771076684548
25-44,0.042510759869796966
years,0.0578736452890454
and,0.158318829883541
0.77,0.09310233998105209
events,0.10719465534014971
per,0.07722105619836805
1000,0.06522289697829106
person-years,0.07022613669573899
at,0.08939312362817045
ages,0.046895144655527105
45-64,0.045184769844505
years.,0.042173763873406864
CONCLUSIONS,0.9337071800041482
Among,0.8953505657835932
young,0.8809976481210794
and,0.8467252468567716
middle-aged,0.832907732036959
"adults,",0.8646480946256037
current,0.9240603323721415
or,0.8769078971922298
new,0.9265607491551823
use,0.9030742091634334
of,0.9216941027857061
ADHD,0.9059438969970363
"medications,",0.8754520998050895
compared,0.9462672514892478
with,0.9299968342185261
nonuse,0.9302593619946821
or,0.910035590667385
remote,0.9073312873672209
"use,",0.8906732430200324
was,0.9284029608247318
not,0.9328241343877791
associated,0.9391275247390751
with,0.9305832492899397
an,0.9219095117654268
increased,0.9146273618603598
risk,0.9180609883439586
of,0.9254669879665024
serious,0.896576511330353
cardiovascular,0.8790718234305144
events.,0.8894886711257693
Apparent,0.04766759667898262
protective,0.047183899836078076
associations,0.058815002599050724
likely,0.03714225828250414
represent,0.0480923234549293
healthy-user,0.05025959310385966
bias.,0.04333092714958698
Molecular,0.030698900068954683
motors,0.04699853958640558
play,0.025802168704981247
critical,0.02856552355124757
roles,0.028581373148384603
in,0.0340356591626935
the,0.037341938609680235
formation,0.039549419124271096
of,0.04102733715003993
mitotic,0.03221757245382671
"spindles,",0.02436490494907545
either,0.018868005446387396
through,0.03987454555770911
controlling,0.03784746285451247
the,0.031049418360863855
stability,0.046621102887495935
of,0.035016473597769174
individual,0.03170621564915208
"microtubules,",0.0359266386473224
or,0.02340665633085896
by,0.04175103934801895
crosslinking,0.037487158861322686
and,0.0503965868069006
sliding,0.026666878330621046
microtubule,0.02809777553740559
arrays.,0.03287708027024761
Kinesin-8,0.050003841404872955
motors,0.046129137826643817
are,0.018696338679733734
best,0.009886541950529584
known,0.016333804362699475
for,0.014496329741495945
their,0.02120134521676143
regulatory,0.013219608597926681
roles,0.01868184585861611
in,0.02015311887841576
controlling,0.010296359316289014
microtubule,0.01826435316469467
dynamics.,0.014214315437019842
They,0.03540398370780629
contain,0.024971674740543105
microtubule-destabilizing,0.02386354458191142
"activities,",0.019944054221060166
and,0.04327206118440013
restrict,0.033034258480756126
spindle,0.024746551691977467
length,0.030165130080314427
in,0.019542692510238595
a,0.016494364257827857
wide,0.012725966886569705
variety,0.012532404180471881
of,0.014025340285896266
cell,0.02736233228525262
types,0.011697837675303897
and,0.013427411434105264
organisms.,0.014634072491736561
"Here,",0.2950434776919331
we,0.34872557566401335
report,0.26862356315448066
an,0.25918596178338554
antiparallel,0.19216595385465138
microtubule-sliding,0.18722701230639047
activity,0.21538416270396368
of,0.20562971161775132
the,0.19817944422884995
budding,0.2178261440212225
yeast,0.19973258980528347
"kinesin-8,",0.20715066870366466
Kip3.,0.23189675697727893
The,0.16433315944154922
in,0.21537801834922807
vivo,0.2800550008706028
importance,0.13347598202140404
of,0.1187781831983103
this,0.15228614565582185
sliding,0.044114427815625704
activity,0.03871070743653443
was,0.039712856711858875
established,0.02789402462537939
through,0.031010271024375317
the,0.025780470986080176
identification,0.026335247389023493
of,0.019919912408263955
complementary,0.019260306097890024
Kip3,0.042654856981272776
mutants,0.03505591013792989
that,0.018244435787918005
separate,0.02393617571126718
the,0.029973644395593045
sliding,0.02978914868590591
activity,0.04056598930824331
and,0.0214489576370757
microtubule-destabilizing,0.03662514102928507
activity.,0.038541040844441876
In,0.29679501829806376
conjunction,0.26152826556732706
with,0.21708194779140824
"Cin8,",0.24496377002218933
a,0.20971025693903356
kinesin-5,0.16179802739631735
family,0.16261035815419034
"member,",0.12066734721507867
the,0.19893394697706623
sliding,0.13233716560629352
activity,0.18373988992126813
of,0.1930422145823546
Kip3,0.1761075795198156
promotes,0.16785713131785185
bipolar,0.16577223523367604
spindle,0.14849213163370048
assembly,0.17932418433000877
and,0.17137825229276982
the,0.15331418558027238
maintenance,0.12226769836136753
of,0.12006397839510823
genome,0.1188317413811732
stability.,0.11933675393524085
We,0.16471509295445522
propose,0.06500297695767733
a,0.056988832556975726
slide-disassemble,0.0446392352332737
model,0.03803703352787702
where,0.043481237809118244
the,0.04144884799920603
sliding,0.06645204796010531
and,0.06582681895910662
destabilizing,0.051704707969729695
activity,0.062036733223876366
of,0.05752210225665005
Kip3,0.06724619286206125
balance,0.07792377128480832
during,0.06062206313840989
pre-anaphase.,0.07886594557866428
This,0.05919634046374146
facilitates,0.057133097458342684
normal,0.07629440980186691
spindle,0.04915085251809555
assembly.,0.06945007899503577
"However,",0.24414569135808548
the,0.2812149856838059
destabilizing,0.2543271784881185
activity,0.29395878271161063
of,0.28365031671768953
Kip3,0.30606302348885717
dominates,0.26220359246917907
in,0.30587530504060906
late,0.30081548969486555
"anaphase,",0.3174632276071119
inhibiting,0.7768707361518233
spindle,0.6134506771665816
elongation,0.69780396801299
and,0.7336758510252961
ultimately,0.7364026792258893
promoting,0.7934724488764724
spindle,0.5932725156832697
disassembly.,0.6334197338515428
Synaptic,0.027193910259924167
long-term,0.02632426373380652
potentiation,0.02914440094709539
(LTP),0.011944183116334143
at,0.0337201391674131
spinal,0.014747442113219756
neurons,0.020013474115293133
directly,0.024402125669624405
communicating,0.02979282510246795
pain-specific,0.03536237253300104
inputs,0.03194620884274136
from,0.019753995432586897
the,0.010137043528971231
periphery,0.01786408165536005
to,0.015446202972101622
the,0.008299355608320827
brain,0.013135169721604667
has,0.005120635685102447
been,0.004432616122535933
proposed,0.005691681633328952
to,0.004450116895945217
serve,0.006481163825098991
as,0.004597154023850571
a,0.005362511394710196
trigger,0.00499666404226001
for,0.00587296020456796
pain,0.010306043216581136
hypersensitivity,0.007342082757889634
in,0.0055152285876037335
pathological,0.0040171890102079786
states.,0.0067711073105240355
Previous,0.006779593111539081
studies,0.008268148633858852
have,0.006828251072805748
functionally,0.0033641079521259686
implicated,0.005804243259242879
the,0.006774008526723132
NMDA,0.009998313835262044
receptor-NO,0.008723828790630763
pathway,0.01121386789662668
and,0.0072305711218149625
the,0.008692200354696263
downstream,0.006374997453025322
second,0.009337701714590184
"messenger,",0.011187842350052473
"cGMP,",0.013022671795900324
in,0.004856881607931669
these,0.0056467350825360595
processes.,0.009177896691498226
Because,0.23741376666250705
cGMP,0.18570276668781374
can,0.10139475958565151
broadly,0.09563789471533106
influence,0.11973765968725529
diverse,0.08980094044554364
"ion-channels,",0.12524852928825667
"kinases,",0.11153679596070001
and,0.09584393301588923
"phosphodiesterases,",0.12224165351048245
pre-,0.18333889168736797
as,0.12772932046020785
well,0.1189663498626884
as,0.0941015688694814
"post-synaptically,",0.1837724139702614
the,0.1581456876060431
precise,0.005624297658612321
identity,0.004244885296388208
of,0.006080198791003396
cGMP,0.008722342374243713
targets,0.005430675238241677
mediating,0.006028447178707783
spinal,0.012743791908753481
"LTP,",0.014522156938071943
their,0.005309559004158443
mechanisms,0.0035655062568105155
of,0.003972287730228259
"action,",0.0048754292101705985
and,0.003770450619586537
their,0.003961630383736374
locus,0.0034388815583190754
in,0.004500958994455521
the,0.0044825622453604375
spinal,0.00665413276741543
circuitry,0.00392699002404029
are,0.0031335873747525083
still,0.0033506821659971733
unclear.,0.0036215615904061052
"Here,",0.6753562708432084
we,0.7306409026275984
found,0.77237529321618
that,0.8056890512558857
Protein,0.7172990894942153
Kinase,0.6955540611484671
G1,0.6949175491499652
(PKG-I),0.7615344219671583
localized,0.7652990252035107
presynaptically,0.8007994370271091
in,0.7793451997310163
nociceptor,0.7590583747441798
terminals,0.7671402385162344
plays,0.7898874193905533
an,0.7908251722123997
essential,0.8039534437007018
role,0.7914544101025727
in,0.7646580739865974
the,0.7552895562604708
expression,0.7778960235186334
of,0.7021256681428562
spinal,0.6786148335261953
LTP.,0.6238089837187805
Using,0.3045530580112498
the,0.2219316851996003
Cre-lox,0.23180310861214604
P,0.2524196030051067
"system,",0.19078004046643332
we,0.29016489238181337
generated,0.2947840677612303
nociceptor-specific,0.3662562698130431
knockout,0.31607211696948734
mice,0.3702376043081926
lacking,0.4400364264410347
PKG-I,0.37227137556352696
specifically,0.4780675078087261
in,0.5335891777616848
presynaptic,0.6071172833008891
terminals,0.5577213399848174
of,0.5748394544835983
nociceptors,0.5717016666719801
in,0.5399142858668438
the,0.5378854944606364
spinal,0.4850362050483997
"cord,",0.5086583965860921
but,0.4464448218063284
not,0.4954800868459955
in,0.4898756242892641
post-synaptic,0.5958706186221415
neurons,0.3236317013730389
or,0.14072198370970862
elsewhere,0.19646424898513043
(SNS-PKG-I(-/-),0.17997147416857723
mice).,0.3175319789524637
Patch,0.6595791629792694
clamp,0.6855801559980598
recordings,0.7150814932360035
showed,0.7752725605199251
that,0.8801740952982392
activity-induced,0.8301747004197182
LTP,0.8632510021154729
at,0.8362678667534791
identified,0.8617285616550838
synapses,0.8424679554396202
between,0.8328390271711116
nociceptors,0.8757772263545514
and,0.8527153069242147
spinal,0.849820024400772
neurons,0.8309866786161489
projecting,0.8214458537133962
to,0.8345575528488869
the,0.8462368746079106
periaqueductal,0.8527046542248766
grey,0.8234020213811842
(PAG),0.8110159504467618
was,0.8495670500644845
completely,0.8120083762464945
abolished,0.8221804687884949
in,0.8275438396002863
SNS-PKG-I(-/-),0.7541393857180316
"mice,",0.8460842724372389
although,0.8005748458869921
basal,0.7482818160242111
synaptic,0.7762474057675897
transmission,0.7784277850802034
was,0.7173984798914397
not,0.6895572891675448
affected.,0.7458223180858812
Analyses,0.1069894642464574
of,0.09127672302921004
synaptic,0.10255753810926446
failure,0.11751524724887011
rates,0.11232084449627962
and,0.08238148608489065
paired-pulse,0.12562305431312146
ratios,0.10997150355880966
indicated,0.16088160459791723
a,0.14586203075048296
role,0.15966009628442915
for,0.15623809942534925
presynaptic,0.21779314105123299
PKG-I,0.24774211297547347
in,0.1719654479957236
regulating,0.12336440607702177
the,0.10811921014658278
probability,0.14941934324569472
of,0.13808346950338454
neurotransmitter,0.3368685333909342
release.,0.3224421611346959
Inositol,0.3163373646352721
"1,4,5-triphosphate",0.35091361536844723
receptor,0.34237510461631515
1,0.4106634422713749
and,0.3947927534772941
myosin,0.4259191942899776
light,0.4349306032884544
chain,0.38862386975460433
kinase,0.35817821610049333
were,0.3975555334817205
recruited,0.3852379325129718
as,0.4182625301255007
key,0.4065987842970355
phosphorylation,0.4621611030470988
targets,0.39274266426598986
of,0.5109077984944185
presynaptic,0.5587950050681866
PKG-I,0.4557103873613465
in,0.4851159296768119
nociceptive,0.4334158914818113
neurons.,0.4718303920214675
"Finally,",0.2673759749998844
behavioural,0.1695822118052266
analyses,0.20495316263652383
in,0.2794388096871832
vivo,0.2647477900067698
showed,0.23326779497711134
marked,0.14939087733383188
defects,0.13668960167307928
in,0.1581465208355231
SNS-PKG-I(-/-),0.21591829007903443
mice,0.24531807547898166
in,0.13593604494610637
several,0.12608811561297528
models,0.11499559223200155
of,0.0757967453856875
activity-induced,0.1497404962258892
nociceptive,0.20650255683399033
"hypersensitivity,",0.11888636315470945
and,0.14559893426042647
pharmacological,0.09610699916486924
studies,0.1022209642059345
identified,0.11150912062627263
a,0.10406019714303874
clear,0.070107605655065
contribution,0.15328545176493813
of,0.17707794098207189
PKG-I,0.25836080929051936
expressed,0.23432997547868983
in,0.2165119136027647
spinal,0.20405672855266377
terminals,0.23842206752249473
of,0.21552201097298085
nociceptors.,0.2306229563657405
Our,0.276204372441714
results,0.18789750676557876
thus,0.25513547535557835
indicate,0.26794717018546155
that,0.7982194301036307
presynaptic,0.9076421507176037
mechanisms,0.8733530746906957
involving,0.8749725129529162
an,0.8539068268168256
increase,0.866215670940509
in,0.8584738664775237
release,0.8585499168006354
probability,0.8405383991866551
from,0.8587034337602394
nociceptors,0.8643493783445301
are,0.8611615130929415
operational,0.8572067173244851
in,0.898609193975207
the,0.8964252732431449
expression,0.9031065618199585
of,0.9086380672905795
synaptic,0.9152596579163841
LTP,0.9024017072667514
on,0.9032137334435993
spinal-PAG,0.8889639485077352
projection,0.9009985166780851
neurons,0.907488902965053
and,0.8737963109599274
that,0.8662720593921922
PKG-I,0.8464832761762789
localized,0.8186250269923285
in,0.8057328675623525
presynaptic,0.8617078721151678
nociceptor,0.8729804941838504
terminals,0.8540035087009603
plays,0.845652214795877
an,0.8452313770035245
essential,0.831700262106589
role,0.8516504333756371
in,0.8726854007966678
this,0.8454006564900645
process,0.8530852026440698
to,0.8043094543574655
regulate,0.8364105252643169
pain,0.7666558136603986
sensitivity.,0.8162853895730409
Acute,0.014866976481293006
Myelogenous,0.007682671239058277
Leukemia,0.020975988389140846
(AML),0.004865177479984241
is,0.009345324774299736
an,0.020536217326926887
aggressive,0.023223469865154035
cancer,0.009748569889001593
that,0.02520592701431583
strikes,0.025856863138179382
both,0.03685215214400602
adults,0.014462692219917722
and,0.011563535637307531
children,0.00621001001740343
and,0.027729756539556314
is,0.007109759098627257
frequently,0.010940847437150276
resistant,0.005451387838025893
to,0.010672837655319876
therapy.,0.005031432666276745
"Thus,",0.002030118411564402
identifying,0.0011220400385852747
signals,0.0012923244202431045
needed,0.0011265175756873798
for,0.0017128607001538423
AML,0.002856470196089367
propagation,0.002056011169963042
is,0.0012313254934425617
a,0.0011420719689725573
critical,0.0011292509014752007
step,0.0010473464118507774
toward,0.0011036675330200045
developing,0.0012171876999710898
new,0.0010721280330388975
approaches,0.000968382283848713
for,0.0013979517908373823
treating,0.0009825776575074104
this,0.0013396756036117795
disease.,0.0011800501669937723
"Here,",0.13824223734827615
we,0.32521950999733834
show,0.16866295231637904
that,0.09698245467959007
Tetraspanin,0.0655067569186461
3,0.0888291494391935
is,0.04154795427879469
a,0.04885752933453825
target,0.02984286045744687
of,0.06109066962079352
the,0.0405892265176341
RNA,0.026547225746330276
binding,0.03545138919955505
protein,0.05726061769613425
Musashi,0.07940890238311443
"2,",0.0568700391353798
which,0.04366025467230883
plays,0.026395308345706525
a,0.033297435892582855
key,0.048755599926412214
role,0.055318146000863606
in,0.049295125490360386
AML.,0.026512999500741923
We,0.23636780121412326
generated,0.22168633907346713
Tspan3,0.22945314589630444
knockout,0.16804025025921113
mice,0.22722894625462067
that,0.1479964294122791
were,0.21545201087701538
born,0.2120396737687675
without,0.17114536362211683
overt,0.1820914067473078
defects.,0.1358782829660629
"However,",0.2958709292317965
Tspan3,0.4667701002879299
deletion,0.3690669897284012
impaired,0.5282321769979047
leukemia,0.49214291714459624
stem,0.5138596396474722
cell,0.606278256979304
self-renewal,0.5587841370827609
and,0.5777331794832337
disease,0.43286900713800097
propagation,0.3903395594376591
and,0.6658857475652071
markedly,0.5116198571495499
improved,0.5191138194304276
survival,0.3805786525087497
in,0.4196302073324925
mouse,0.4850910654303274
models,0.44230943456036115
of,0.39598126761313246
AML.,0.3433175139534002
"Additionally,",0.5509851967094046
Tspan3,0.49454664527370606
inhibition,0.4142984921771635
blocked,0.4660348091085199
growth,0.34416922730719995
of,0.2869279362199657
AML,0.24535458671634058
patient,0.31878073843236915
"samples,",0.30858018940750137
suggesting,0.2671468546924317
that,0.2387629645515367
Tspan3,0.3253511578512395
is,0.14791155904764347
also,0.19341831370905402
important,0.20071845204641453
in,0.11938103625699371
human,0.13012685445775696
disease.,0.13294880755225044
As,0.663404399005503
part,0.6664322736960562
of,0.6537798365975563
the,0.6606269817022188
"mechanism,",0.6376126805115354
we,0.6660790743618428
show,0.7060741781163155
that,0.719821355981152
Tspan3,0.6807291351330189
deficiency,0.6850776958866899
disabled,0.7220128250178837
responses,0.6794976352255837
to,0.6783173925199484
CXCL12/SDF-1,0.704003290685857
and,0.7244432328119575
led,0.7162389553724182
to,0.6737096466028671
defects,0.62474740768765
in,0.6532224761183351
AML,0.5846023466236777
localization,0.6780939948225341
within,0.550104642489199
the,0.5965321429589598
niche.,0.6129060095465809
These,0.4431309443107916
identify,0.4451700787127687
Tspan3,0.4718147403709301
as,0.52930576518573
an,0.551021479050305
important,0.5222574964820051
regulator,0.5207500727596085
of,0.5560394101557973
aggressive,0.5248519036142798
leukemias,0.5319399962753858
and,0.46636990253517996
highlight,0.36684413050599823
a,0.33565105374402654
role,0.3804968323237653
for,0.35219679118013625
Tspan3,0.4459769174587253
in,0.3879025349691207
oncogenesis.,0.42222770116159525
Two-component,0.008894345801602359
signal,0.006312982558042768
transduction,0.00327008421866513
pathways,0.0076142367565999545
comprising,0.009211062779092285
histidine,0.009781783528379991
protein,0.015062500043746358
kinases,0.01051862416224515
(HPKs),0.005730899927317847
and,0.003032552761628787
their,0.005233387382092888
response,0.0047184274766119095
regulators,0.004485763700867922
(RRs),0.0028562325243766287
are,0.002375787636943144
widely,0.002677788029839297
used,0.0025478434854033687
to,0.0020481747174874994
control,0.0024957429258565603
bacterial,0.004528920856862512
responses,0.0016396771475817998
to,0.0016731897742200636
environmental,0.0017250743860946227
challenges.,0.0020675022183258337
Some,0.003981439785568723
bacteria,0.004676295179157759
have,0.004789482712734682
over,0.0025715803807424154
150,0.0020192646840243873
different,0.0025819452885418024
two-component,0.0030602852675852333
"pathways,",0.004739924132856883
and,0.002948748768883654
the,0.0017890769830010544
specificity,0.0012335371007645502
of,0.0018243797460670303
the,0.0020250692403779966
phosphotransfer,0.002121847185301309
reactions,0.0042218197510984525
within,0.0017184169560022187
these,0.0020911022722815286
systems,0.001906918226703831
is,0.001577134596283993
tightly,0.0012333549982540902
controlled,0.0013848203168993062
to,0.0011503394518234292
prevent,0.0011677775645508467
unwanted,0.0020666612198771703
crosstalk.,0.0014806349535249903
One,0.0036286127254089254
of,0.002783363793984067
the,0.003334092454720259
best,0.0026487617851262252
understood,0.0031664200348228808
two-component,0.0031636157933136572
signalling,0.006210959134305109
pathways,0.004992140433561962
is,0.002807428557218445
the,0.003869898310330535
chemotaxis,0.00536333931300322
pathway.,0.004719973969209769
"Here,",0.285857036231585
we,0.3522822795462003
present,0.191261406579112
the,0.17306367894112332
1.40,0.18821967957416033
A,0.1509636322231126
crystal,0.1311346242430482
structure,0.15566241053250526
of,0.1518248323361606
the,0.15388579169785035
histidine-containing,0.2132787778657161
phosphotransfer,0.2280308473689046
domain,0.0928344850305923
of,0.06404742917761379
the,0.05970433099774287
chemotaxis,0.04693040847602638
"HPK,",0.07287178950316006
"CheA(3),",0.08172271547902973
in,0.06596414436581272
complex,0.0632588782000439
with,0.049895588214091645
its,0.057735478060540774
cognate,0.03866465218225168
"RR,",0.079032223495693
CheY(6).,0.08321598749130481
A,0.08396306621637063
methionine,0.11703691718396214
finger,0.13080601966353805
on,0.13361193964954007
CheY(6),0.09348838301291205
that,0.09464220060118392
nestles,0.10080897891327159
in,0.10407694169733327
a,0.10266245562373542
hydrophobic,0.0768018234006266
pocket,0.1766330140855486
in,0.1309283012939958
CheA(3),0.07215665532556075
was,0.026860925476816278
shown,0.036833974891656816
to,0.026756939316637807
be,0.04259646992357235
important,0.06084283064704334
for,0.03524465491821785
the,0.0463610845679195
interaction,0.07922704554261514
and,0.037976554118319066
was,0.019112747388335554
found,0.01857414256401491
to,0.012676227039000116
only,0.025616895895930115
occur,0.055863511562319466
in,0.025837931999809195
the,0.026369069812921624
cognate,0.0181022171412577
RRs,0.04273960089089631
of,0.031725596549329355
"CheA(3),",0.06121739878835764
"CheY(6),",0.0813716227199547
and,0.033742484385068224
CheB(2).,0.09272512894517598
Site-directed,0.1247953991335201
mutagenesis,0.09211250307714938
of,0.11706005425295607
this,0.11655944220850303
methionine,0.1323127069011815
in,0.11634412079786617
combination,0.13695509360262315
with,0.11162439730977201
two,0.12028847643358036
adjacent,0.10901352240023729
residues,0.1429643306752872
abolished,0.17309661643714502
"binding,",0.12156786781318864
as,0.05624553305773743
shown,0.058662831484015084
by,0.11401859698946905
surface,0.10933779661517354
plasmon,0.29053720229039337
resonance,0.23292410543950645
"studies,",0.300991059512484
and,0.3726514094064163
phosphotransfer,0.302354840384014
from,0.33679434639917105
CheA(3)-P,0.25496731768161857
to,0.3199144540943708
CheY(6).,0.24664602483873826
Introduction,0.7014272123684914
of,0.7044308450262612
this,0.6613630174439705
methionine,0.6551523183970854
and,0.685898560642033
an,0.680151031435389
adjacent,0.6380493932809649
alanine,0.6050484756026684
residue,0.6308780598658892
into,0.7235208937062287
a,0.7327517263189115
range,0.6446699586934596
of,0.658453164511023
noncognate,0.6742183659826374
"CheYs,",0.5404867897018946
dramatically,0.7539751900062499
changed,0.7108740271898548
their,0.5953677678500124
"specificity,",0.647051366741978
allowing,0.7769999527572792
protein,0.6153696818980172
interaction,0.6374397018507338
and,0.7865476812834288
rapid,0.7387724244231614
phosphotransfer,0.6102953205953761
from,0.618473887921867
CheA(3)-P.,0.4960621152321235
The,0.42835002589336185
structure,0.298158616595679
presented,0.21561797427185478
here,0.3349896807571946
has,0.42176997102326347
allowed,0.5120357080180133
us,0.40726592797613886
to,0.47166932024627495
identify,0.3747777533539841
specificity,0.3511814149201492
determinants,0.47339933594146133
for,0.4957904841710243
the,0.4309811115465933
CheA-CheY,0.34078529162137955
interaction,0.45256169356593173
and,0.554348299114236
subsequently,0.5360139812124894
to,0.523852692831969
successfully,0.5817032066202703
reengineer,0.6096090422052579
phosphotransfer,0.41934846135204584
signalling.,0.4313618259889132
In,0.21848583139676583
"summary,",0.20096347629461675
our,0.26361947807996167
results,0.17316813029566372
provide,0.2217244857970484
valuable,0.16485122783354939
insight,0.09692338048688862
into,0.0738922485357326
how,0.08552695736022332
cells,0.14009308853148378
mediate,0.12606671260960634
specificity,0.08395763846019977
in,0.11742561060668726
one,0.11147147976538471
of,0.11124128311537797
the,0.10896655630332802
most,0.0775668741831195
abundant,0.10813141874579683
signalling,0.14993379359804956
pathways,0.12537260659337834
in,0.08004261489460816
"biology,",0.08619560729929739
two-component,0.09680208696987667
signal,0.1517271793151484
transduction.,0.11780967383562589
IMPORTANCE,0.0014936758666563668
Combining,0.0014022672685736878
pharmacotherapies,0.0008596057265808537
for,0.0007196819590950096
tobacco-dependence,0.001268510884174783
treatment,0.0007890967547979565
may,0.0010033597251206017
increase,0.0010357832548854096
smoking,0.0012978362410638762
abstinence.,0.0013770996469851583
OBJECTIVE,0.00101895467992619
To,0.0009227765325249377
determine,0.0009490807838946314
efficacy,0.0009534372699797197
and,0.0015481293028380115
safety,0.0008379384675485216
of,0.001133564955731505
varenicline,0.0011221127234246325
and,0.001229058432941599
bupropion,0.0011667854656114353
sustained-release,0.0012140269672258077
(SR;,0.0008436443570008457
combination,0.0009923963510773627
therapy),0.0008953837675376644
compared,0.0011583513713631518
with,0.000932598680789051
varenicline,0.001060879860769121
(monotherapy),0.0009409113562643524
in,0.0010156296738141487
cigarette,0.0008747320430341353
smokers.,0.001225463849577464
"DESIGN,",0.0019513917408200087
"SETTING,",0.0028751289420881924
AND,0.0014805574081483562
PARTICIPANTS,0.0032369831594688133
"Randomized,",0.0017767014306384421
"blinded,",0.001698717432101917
placebo-controlled,0.001933398285819583
multicenter,0.0022688484450638716
clinical,0.0016130224997115607
trial,0.0017223347050530095
with,0.002472998368356548
a,0.0034903947284937913
12-week,0.0026105423058305362
treatment,0.0019134055318033073
period,0.002198862547872014
and,0.0025297404683317253
follow-up,0.003100881093289318
through,0.0024866698466802315
week,0.0028969433498745537
52,0.0025177768559481936
conducted,0.0020019309216753028
between,0.002838670407938815
October,0.0028694231577485524
2009,0.002065132559633892
and,0.0026062705045357118
April,0.00267588426113076
2013,0.000655174737483712
at,0.0008028494420590334
3,0.0005740358476057774
midwestern,0.0006098887227919784
clinical,0.0004859586200943483
research,0.0005548265793848208
sites.,0.0004898223317360343
Five,0.0005668378899300135
hundred,0.0005160978593989347
six,0.0005416001476515252
adult,0.0005086371113374859
(≥18,0.0006236043231490269
years),0.0005755067692172466
cigarette,0.0005357041961706736
smokers,0.0005032898788050305
were,0.0005565850752526322
randomly,0.000507244656190283
assigned,0.0005257633411058868
and,0.0009251140242032342
315,0.0005631600765839836
(62%),0.0005695689023588156
completed,0.0004552028554868886
the,0.0007463486110120868
study.,0.0004711214942879965
INTERVENTIONS,0.0011089998042976576
Twelve,0.0007138939787533225
weeks,0.0010096465588965554
of,0.000937305467799183
varenicline,0.0007899973490586948
and,0.0010358599796155916
bupropion,0.0007824323260545848
SR,0.0008356213764467888
or,0.0005139825778560183
varenicline,0.0008278613712341767
and,0.0007339243955360271
placebo.,0.000751919999956796
MAIN,0.005100709922465522
OUTCOMES,0.0063485972469112485
AND,0.0035503735744801326
MEASURES,0.0030221101251475266
Primary,0.00614741937122377
outcome,0.004334731884272522
was,0.009335917639422991
abstinence,0.00984961682705686
rates,0.006204835820050541
at,0.005919223932849857
week,0.007648673013048142
"12,",0.005674283536736557
defined,0.004372515155567352
as,0.0071381138372127095
prolonged,0.02202949791758863
(no,0.010080023064087063
smoking,0.028018108542713055
from,0.011121336315384487
2,0.014060466977515352
weeks,0.008588977759976826
after,0.017836124868994767
the,0.007735278374714892
target,0.005055360122094036
quit,0.013062301951943646
date),0.008857180557767817
abstinence,0.012933038592280196
and,0.01048668378336593
7-day,0.019677936295295063
point-prevalence,0.010472811249037267
(no,0.00960916862090845
smoking,0.034070420619627506
past,0.02618464415960763
7,0.037680186576919655
days),0.02078667229504134
abstinence.,0.0375438997504245
Secondary,0.004634634128998211
outcomes,0.007522770210070738
were,0.01107469534365977
prolonged,0.010182520077729879
and,0.011966891290162837
point-prevalence,0.005238040240586185
smoking,0.012002010285596262
abstinence,0.0065769046784698235
rates,0.005249632502841002
at,0.007185597053107414
weeks,0.005872623350323155
26,0.004974480851389517
and,0.008274763003222926
52.,0.003569833070893453
Outcomes,0.004728292910226934
were,0.003729772551246159
biochemically,0.003439540182597864
confirmed.,0.00286986659639923
RESULTS,0.8882453185513243
At,0.9169120385909277
12,0.9108888329739105
"weeks,",0.9092718588907639
53.0%,0.9203364253395743
of,0.9288676891057999
the,0.9233449915805428
combination,0.9148032277231486
therapy,0.9165312889736968
group,0.9347842762257851
achieved,0.9159722437802522
prolonged,0.9258021532095974
smoking,0.8842252107473945
abstinence,0.9214727073393894
and,0.9159887943467333
56.2%,0.9235532396239808
achieved,0.9101406041066872
7-day,0.9096789338207765
point-prevalence,0.9141368793689769
smoking,0.9013927969685571
abstinence,0.9196100442504621
compared,0.921952497546908
with,0.8984676006397537
43.2%,0.9160438926228405
and,0.8917483676760308
48.6%,0.9286851805635365
in,0.9158501240255394
varenicline,0.8118425418465824
monotherapy,0.8840896394496099
(odds,0.9003331651999078
ratio,0.8808981718726878
"[OR],",0.8868281454468606
1.49;,0.8849846430654967
95%,0.9139795075988242
"CI,",0.8790346374143659
1.05-2.12;,0.8667618291287648
P,0.8817033798789803
=,0.8537698902776335
.03,0.5570764166625493
and,0.5389682554865965
"OR,",0.6418244729729976
1.36;,0.5729005183507911
95%,0.6277621746619929
"CI,",0.6288048517952433
0.95-1.93;,0.6226678774098672
P,0.6696515481268749
=,0.6667434698723858
".09,",0.6085699271480987
respectively).,0.47546606864826346
At,0.888270657219594
26,0.8777433162767108
"weeks,",0.8806465071622718
36.6%,0.896013377304296
of,0.9145257249610163
the,0.9064699245597199
combination,0.88970592498311
therapy,0.887094400918445
group,0.9168215564351886
achieved,0.898519999245393
prolonged,0.9055420503457619
and,0.8737291789829021
38.2%,0.8916918981788289
achieved,0.8927433391645588
7-day,0.8805643243028133
point-prevalence,0.8839737387971425
smoking,0.8669043766484852
abstinence,0.9011352855402944
compared,0.8941980907640475
with,0.8594702993959449
27.6%,0.9004310539119966
and,0.8624328370369116
31.9%,0.8882011309984262
in,0.9012944562985843
varenicline,0.788172517742332
monotherapy,0.8502416237741154
"(OR,",0.8558509925453137
1.52;,0.8621473679722739
95%,0.8977364820708178
"CI,",0.8329736197033288
1.04-2.22;,0.8398753227172595
P,0.8465336544330485
=,0.8508299790812215
.03,0.8141527706486329
and,0.8097460773385429
"OR,",0.8446402795480694
1.32;,0.8161294862317776
95%,0.8653423028841031
"CI,",0.8070108623696183
0.91-1.91;,0.48811609633790193
P,0.6341191858290639
=,0.6217516104888209
".14,",0.6088617142903718
respectively).,0.5388656817554416
At,0.7325334759013609
52,0.6594237456492276
"weeks,",0.6807803542275631
30.9%,0.7347954027088388
of,0.8101456643928351
the,0.774175420435396
combination,0.7565154940230089
therapy,0.7636632195812271
group,0.8078992707774735
achieved,0.7952612334356782
prolonged,0.8182917906574559
and,0.763140089685674
36.6%,0.787730060051981
achieved,0.7793454047307041
7-day,0.7648845041091397
point-prevalence,0.7815474573116808
smoking,0.7381561787250458
abstinence,0.7768119879187722
compared,0.7707780155833512
with,0.7061304706415309
24.5%,0.7649844768941685
and,0.7146946085115744
29.2%,0.7680114585703474
in,0.7637083283857704
varenicline,0.6249035287166796
monotherapy,0.6776176265567091
"(OR,",0.7013878150750656
1.39;,0.7254440242119048
95%,0.7794666893506688
"CI,",0.6996939619550944
0.93-2.07;,0.6515682993630206
P,0.7084927900139214
=,0.680211239437035
.11,0.6479581476442403
and,0.6252739946775321
"OR,",0.7010675015062041
1.40;,0.608173562753048
95%,0.6853393339326664
"CI,",0.6404441665441966
0.96-2.05;,0.5384797472467503
P,0.6376183134096142
=,0.6124861084157999
".08,",0.6080135855639927
respectively).,0.6168193922013875
Participants,0.4347716103796656
receiving,0.7411252327704568
combination,0.6554950604532076
therapy,0.7235037537515682
reported,0.7366571016519528
more,0.773281285411588
anxiety,0.6894693792911069
(7.2%,0.7374734143469601
vs,0.7086412471406548
3.1%;,0.7709455139932586
P,0.7598570477825819
=,0.7679679147390895
.04),0.7279499942561107
and,0.7544821245236302
depressive,0.7404701284547004
symptoms,0.6806909252304815
(3.6%,0.7308488684880903
vs,0.7208093390709679
0.8%;,0.683172786443678
P,0.7467155157370683
=,0.7336840267779163
.03).,0.7284641151753057
CONCLUSIONS,0.8145607264372635
AND,0.7359255877527539
RELEVANCE,0.7669706014750086
Among,0.7890499323409915
cigarette,0.6894933862309568
"smokers,",0.6661689947527553
combined,0.8117477418975856
use,0.7794063655796083
of,0.8002920558567582
varenicline,0.6376807203609542
and,0.7830004200966534
"bupropion,",0.767213427023581
compared,0.8274355847852891
with,0.7296201777298129
varenicline,0.6559907539494121
"alone,",0.7368989089745769
increased,0.7520809231357126
prolonged,0.769437379532889
abstinence,0.7589213986713398
but,0.7520921865941916
not,0.7083744441558264
7-day,0.6676825671120217
point,0.6807055287083723
prevalence,0.6830392623614083
at,0.5978641237894734
12,0.6934287154098431
and,0.5414541094692131
26,0.6081412985844843
weeks.,0.6910910388390775
Neither,0.13112459388667871
outcome,0.27610623796976974
was,0.11474232851725764
significantly,0.10364603336101465
different,0.1012880343078445
at,0.12384619214568361
52,0.07462509386310134
weeks.,0.21351346816797678
Further,0.008480484625018572
research,0.009193945831881049
is,0.0055334482896162536
required,0.0056123630460659735
to,0.003746232004330206
determine,0.003903984184528186
the,0.003992524687260596
role,0.007223887603068304
of,0.006240694374647488
combination,0.031208461650490134
therapy,0.010500349071816366
in,0.010282519994262171
smoking,0.03339218718256523
cessation.,0.01843841392186014
TRIAL,0.014513042702937707
REGISTRATION,0.03284191595857896
clinicaltrials.gov,0.021567864513318002
Identifier:,0.0200133244810223
http://clinicaltrials.gov/show/NCT00935818.,0.008887020108837811
BACKGROUND,0.06655037665653284
Deep,0.07189612509439276
vein,0.061720314664064274
thrombosis,0.07477730869591483
(DVT),0.06072773251632101
and,0.11722974865555767
pulmonary,0.04608783251640521
embolism,0.06316863200766719
are,0.05237750115832862
common,0.0516214802607945
after,0.07191018194026483
stroke.,0.03673702041121747
In,0.08348202677046988
small,0.028445605361739554
trials,0.022989951310135592
of,0.020895924457038816
patients,0.017351436032306822
undergoing,0.009777756849340302
"surgery,",0.025296601707743577
graduated,0.06063240302358348
compression,0.026091983230690462
stockings,0.023366365968449192
(GCS),0.02060180687153572
reduce,0.048149554099448565
the,0.03788605596048981
risk,0.029111646479358433
of,0.043199231566005296
DVT.,0.03810265145269461
National,0.0010579741514123652
stroke,0.0009392154026997606
guidelines,0.001116382427987932
extrapolating,0.0013866672604741443
from,0.0012927565255934207
these,0.001283831451242335
trials,0.0010034409814634329
recommend,0.001282968149202411
their,0.0010392330788025958
use,0.00114072455767244
in,0.0009842423484978258
patients,0.0007427861642422047
with,0.0007352273288779573
stroke,0.0007378425948141048
despite,0.001272507580300714
insufficient,0.0011657003757456672
evidence.,0.0010286267986423447
We,0.001898276121491139
assessed,0.0008866575308244095
the,0.0008726007249118253
effectiveness,0.0008544898755920803
of,0.0012005526064691858
thigh-length,0.0010151341434544699
GCS,0.0010715850597195389
to,0.0006820776278031011
reduce,0.0008346089673716898
DVT,0.0010571034360003686
after,0.001296736571602261
stroke.,0.0007965101955652443
METHODS,0.005993356234516868
In,0.005968546794723694
this,0.006812741830752567
"outcome-blinded,",0.0025350980537684636
randomised,0.0012466732857473756
controlled,0.0011173514091780744
"trial,",0.002251481979911367
2518,0.0027157350505753646
patients,0.002199160210127135
who,0.003927895673583459
were,0.0031047823479041048
admitted,0.0013961207505963798
to,0.004095793959282791
hospital,0.0016574361508036302
within,0.0022301800533933106
1,0.0017384661734583683
week,0.0012756350742950673
of,0.002940177915214938
an,0.001609068394470688
acute,0.0012408045571695096
stroke,0.00159214854597305
and,0.0027399540673060142
who,0.0014511026367495575
were,0.0013030292759565803
immobile,0.0012651739659319172
were,0.0011670922619548298
enrolled,0.0009195344114511579
from,0.0011192049969757833
64,0.000762972336263493
centres,0.0008623897667002252
in,0.0010761308022231822
the,0.0012079066713531518
"UK,",0.0010847803899508468
"Italy,",0.001601071423931865
and,0.00097949418070027
Australia.,0.0011440629636271197
Patients,0.0008165241095350559
were,0.0010649827095266173
allocated,0.0008610903585189718
via,0.0011355470862187344
a,0.0009701218414924095
central,0.0007778237694070485
randomisation,0.0009946195399188295
system,0.0009459783886578844
to,0.0007622868335343322
routine,0.0008815735832705036
care,0.0009581904703218968
plus,0.0008245952544121862
thigh-length,0.0010315645092712562
GCS,0.001015540658859366
(n=1256),0.0011718015520582273
or,0.0010733346872720088
to,0.0008068819277352665
routine,0.0009429465416284764
care,0.0009834650486648644
plus,0.0009755748816721826
avoidance,0.0009752187260885112
of,0.0013852684647388197
GCS,0.0012311214365941583
(n=1262).,0.0016172230344461231
A,0.013390477252389567
technician,0.011881096279893531
who,0.011486263372918599
was,0.010767513806836751
blinded,0.010323211471177589
to,0.012806148471459116
treatment,0.008042441589506046
allocation,0.007820112782755092
undertook,0.01350947189151966
compression,0.010139886046678662
Doppler,0.019466591149217904
ultrasound,0.009110496261541264
of,0.028808744734288787
both,0.020505116534188357
legs,0.01383350380221527
at,0.014323219863725213
about,0.017694453928495557
7-10,0.018621102361671207
days,0.008532356013582628
"and,",0.021288484358309545
when,0.015589782155599521
"practical,",0.018570309633155486
again,0.021876516699534165
at,0.02104260606462119
25-30,0.010134574911310743
days,0.007667191529734212
after,0.016682470189336898
enrolment.,0.007070269657593146
The,0.04913502143914887
primary,0.04749563149981008
outcome,0.0512656455972093
was,0.0886870699625509
the,0.06579937845744352
occurrence,0.06601996863117067
of,0.17069358620769526
symptomatic,0.028940019273032126
or,0.006250734774352897
asymptomatic,0.0048776089662075205
DVT,0.019088531979318306
in,0.018074840250679538
the,0.011565293446910659
popliteal,0.013461491653542152
or,0.005071172122892629
femoral,0.005532642794211839
veins.,0.017179876898513243
Analyses,0.0012127483939462517
were,0.001513273354110512
by,0.001427406785556421
intention,0.00112135911394196
to,0.0017682574154521133
treat.,0.0010757400255670922
This,0.0016215228759007467
study,0.0012355743653708828
is,0.001600755511542939
"registered,",0.0011060525253470835
number,0.001246520709277518
ISRCTN28163533.,0.0012021678279899035
FINDINGS,0.0015639773607497409
All,0.0013226145661453784
patients,0.0011198864819553713
were,0.0016065505108880382
included,0.0011282240541117317
in,0.00175616020446625
the,0.001918677159595817
analyses.,0.0010968533629589139
The,0.8399456338563646
primary,0.8231219752790391
outcome,0.8184286516575111
occurred,0.8241148210093343
in,0.8226416418499861
126,0.7172625016317538
(10.0%),0.7878822098247609
patients,0.8216951894882396
allocated,0.7459039640857237
to,0.6809080720579674
thigh-length,0.7872207609486888
GCS,0.7408285382666039
and,0.8276917850544683
in,0.8206096313816591
133,0.7325004193753656
(10.5%),0.770551369761227
allocated,0.7910890272841304
to,0.8031573062172523
avoid,0.8059634512909819
"GCS,",0.8144123860665666
resulting,0.8759539047334237
in,0.884108536247103
a,0.8884001827515439
non-significant,0.873401688018916
absolute,0.8807717490990004
reduction,0.8611918833303991
in,0.8880519630124453
risk,0.8836788260135486
of,0.8841661995097071
0.5%,0.8631152865504468
(95%,0.8823571967905078
CI,0.8720706239450079
-1.9%,0.8598930311920511
to,0.8421754509081643
2.9%).,0.49487554344155615
Skin,0.5807986643205497
"breaks,",0.5820361823304041
"ulcers,",0.5529673849715041
"blisters,",0.509071151877247
and,0.6374027695970367
skin,0.5422228108884903
necrosis,0.6400303555201695
were,0.5298031681817652
significantly,0.5077853045327454
more,0.6333508798452566
common,0.6184875831800378
in,0.5525433553926183
patients,0.4302274655700638
allocated,0.5971114646768118
to,0.5377118027695357
GCS,0.44404387299234743
than,0.7134889315680958
in,0.5652029917265919
those,0.48332208944170735
allocated,0.528220097248102
to,0.6122791072511966
avoid,0.5149789242144395
their,0.39968399088079315
use,0.46992102786213613
(64,0.4826777453680279
[5%],0.36243123914107267
vs,0.4953460659072309
16,0.3491436588732454
[1%];,0.37027021608574723
odds,0.33289952593064015
ratio,0.4360597885542851
"4.18,",0.4692096251949496
95%,0.3761057531822616
CI,0.3924431495700539
2.40-7.27).,0.42401427267980546
INTERPRETATION,0.014521856678864426
These,0.011113362883161256
data,0.006465330440737729
do,0.0076275924680707236
not,0.00568208955853423
lend,0.005617248394178222
support,0.0052331403877191405
to,0.005149030978686366
the,0.004023588240021613
use,0.004500975018717123
of,0.004389080552005776
thigh-length,0.001801068307674761
GCS,0.0039599373322120055
in,0.002777998785868897
patients,0.0019003126846928041
admitted,0.001447626902892506
to,0.0025269763683208224
hospital,0.0015980493731785953
with,0.0018352475716359037
acute,0.001737082689157956
stroke.,0.0017470089013779245
National,0.0013401155431661523
guidelines,0.001608879196408631
for,0.0015004730397497423
stroke,0.0013125660318074042
might,0.00199739081185738
need,0.0018674233210226661
to,0.0016733502774852955
be,0.0018743281841425742
revised,0.0014324397386250571
on,0.0017625977620480827
the,0.0018148355910463463
basis,0.0021399624459831645
of,0.002584449754127038
these,0.00299030868504664
results.,0.001552199906292324
FUNDING,0.03324014817773632
Medical,0.05694386642211745
Research,0.01971377811924274
Council,0.005208353651951941
"(UK),",0.010967433589976615
Chief,0.005916246322064819
Scientist,0.009708962441854605
Office,0.00457368517255336
of,0.007206841415078786
Scottish,0.004611325005603921
"Government,",0.004403960238843583
Chest,0.011472995417606624
Heart,0.010882102140973321
and,0.00677619046407237
Stroke,0.006127267484044988
"Scotland,",0.009184349029640866
Tyco,0.01632237564996665
Healthcare,0.00981675798527758
(Covidien),0.014648135308858102
"USA,",0.015069963350389829
and,0.006513959880274448
UK,0.008927443555868617
Stroke,0.008898274768814156
Research,0.00785506026192269
Network.,0.004791988061948894
The,0.0013824036749197953
importance,0.0010605903459917525
of,0.0013966111212809099
neuropeptides,0.0019041227339364809
in,0.0012919988976999874
the,0.0018912525992837782
hypothalamus,0.001517651256324273
has,0.0010239914900517346
been,0.000909202162250638
experimentally,0.0009779604950710386
established.,0.0008749735771097728
Due,0.0025312906927535106
to,0.0023212297835682534
difficulties,0.001897297033434225
in,0.00156345362492304
assessing,0.0018119018685405599
function,0.0021350977778822728
in,0.002364285485271993
"vivo,",0.0031081853689334145
the,0.0014403018498552935
roles,0.0017278689998511969
of,0.002122418207016992
the,0.003229831554312839
fast-acting,0.0024716342342768196
neurotransmitters,0.002254281083058187
glutamate,0.0028917470588394312
and,0.0034130797185015138
GABA,0.004323819652648135
are,0.001523257908911506
largely,0.0012395397300462509
unknown.,0.00132902318882847
Synaptic,0.00978271654832241
vesicular,0.009552945481169535
transporters,0.02090175675135212
(VGLUTs,0.014901274088031687
for,0.028001121690238676
glutamate,0.025880970559406073
and,0.026089450897207114
VGAT,0.043269494944892246
for,0.029790926541909256
GABA),0.024508884615555084
are,0.011790097761907184
required,0.014858254573711573
for,0.01938904402896521
vesicular,0.0206097170836049
uptake,0.023217578229656668
"and,",0.039849429005685576
"consequently,",0.022960401032756157
synaptic,0.010636790300559876
release,0.020513040697663472
of,0.012068444293481174
neurotransmitters.,0.013474693445905125
Ventromedial,0.3972389955959614
hypothalamic,0.3291532971025229
(VMH),0.3124018840919708
neurons,0.4615057694677365
are,0.4114441233031725
predominantly,0.44943622775410447
glutamatergic,0.499873675408667
and,0.5196365656417484
express,0.4174291461040386
VGLUT2.,0.024671256968974938
To,0.004723266844651482
evaluate,0.0021135209672004576
the,0.0017279158823324072
role,0.0014387544863629657
of,0.0021668757650183655
glutamate,0.0037486201635894972
release,0.004480237082917581
from,0.005734437246549248
VMH,0.008523697721575678
"neurons,",0.00598184666579807
we,0.009340688425466325
generated,0.006980417874955572
mice,0.00603016034697395
lacking,0.007374194278627318
VGLUT2,0.012547228824946206
selectively,0.003286593126602309
in,0.0064952077142397015
SF1,0.007896912281178647
neurons,0.00849575043283905
(a,0.003706655874665586
major,0.0030704156604039515
subset,0.003779047856177869
of,0.0048804531306272814
VMH,0.010782223824650584
neurons).,0.01015582400363195
These,0.8367126850080534
mice,0.9176630562991299
have,0.933435359025676
hypoglycemia,0.9500534921373276
during,0.9505259755947234
fasting,0.9507835825583432
secondary,0.941750951830025
to,0.928050625296453
impaired,0.9521066846511708
fasting-induced,0.952357430921636
increases,0.9501779733800158
in,0.9512559925483434
the,0.95107044287302
glucose-raising,0.9133584144007089
pancreatic,0.9667019271273232
hormone,0.9408357775847268
glucagon,0.9339394848991123
and,0.9483967836569726
impaired,0.946097550656008
induction,0.9473392544599126
in,0.9525621804038348
liver,0.9364024574519257
of,0.9365580375132954
mRNAs,0.9200525316116365
encoding,0.8911663099572837
PGC-1alpha,0.8856321499892419
and,0.9204595650138133
the,0.8867538556718185
gluconeogenic,0.8825779721432888
enzymes,0.8406229608203475
PEPCK,0.849460577717201
and,0.8400018936115029
G6Pase.,0.7944906113036599
"Similarly,",0.8959868060360657
these,0.5501182483135534
mice,0.6293480388228584
have,0.6055374962100789
defective,0.6146384767398533
counterregulatory,0.632428981636409
responses,0.5633705939215323
to,0.5296008929756972
insulin-induced,0.5664134878082795
hypoglycemia,0.6114331454029468
and,0.5993974399586555
2-deoxyglucose,0.4934939465560189
(an,0.49411178827046653
antimetabolite).,0.5304919634562204
"Thus,",0.661163258368757
glutamate,0.69444736534865
release,0.7021577360013379
from,0.7646607769832031
VMH,0.6723057189487044
neurons,0.7253882471877842
is,0.6151134432103952
an,0.6418355546020892
important,0.660373273458341
component,0.6770422833120007
of,0.6977770632922823
the,0.7002511528235558
neurocircuitry,0.6901517956502238
that,0.5890058764197497
functions,0.6002307629349284
to,0.5460806118244134
prevent,0.5938329528185707
hypoglycemia.,0.6042181029311676
Numerous,0.40848694702205934
reports,0.3630788686388805
have,0.35459198190136315
demonstrated,0.47185802830068996
that,0.595720176011802
CD4(+)CD25(+),0.5978800065901673
regulatory,0.5672434473974252
T,0.5220476728756985
cells,0.5776454966023709
(Tregs),0.5193838431628464
from,0.5873692344493641
individuals,0.5433009007527237
with,0.45037879186503854
a,0.5216454812606651
range,0.40544204374045
of,0.4424751735268685
human,0.4789857786306573
autoimmune,0.4080435158319214
"diseases,",0.42769349941852464
including,0.5108099296127795
type,0.5210581991354679
1,0.5087280235596641
"diabetes,",0.46909583244147735
are,0.5803389219313163
deficient,0.5534126332763945
in,0.5991928429689101
their,0.579947896342157
ability,0.5767434207762285
to,0.5752236040376176
control,0.5545603086327375
autologous,0.5881299052794721
proinflammatory,0.6291900382097713
responses,0.5172256962902902
when,0.5431116049220106
compared,0.6027872112729985
with,0.5153258154249443
"nondiseased,",0.6128476431005626
control,0.4822328869269391
individuals.,0.5264078319149122
Treg,0.025194125665649107
dysfunction,0.017270296120954282
could,0.02521141955163091
be,0.01827094642532872
a,0.017341784002154338
"primary,",0.01788087804837402
causal,0.017129865656950353
event,0.02197351766504249
or,0.025323789810449082
may,0.012845471421878064
result,0.018043448253751027
from,0.019508436990493472
perturbations,0.011531214569209748
in,0.017843949355499697
the,0.019069711139881453
immune,0.012961001002205836
system,0.015967578565036247
during,0.021579351386134902
disease,0.009836683170180308
development.,0.01961762031932022
Polymorphisms,0.18725303162691131
in,0.17126690745565404
genes,0.2289113917368856
associated,0.24063511278562555
with,0.19185325131499587
Treg,0.1602237708021761
"function,",0.20447489120398102
such,0.1524832182333383
as,0.1762673351962691
"IL2RA,",0.2872587880714595
confer,0.19323706136809582
a,0.1569540915606647
higher,0.19611456206693098
risk,0.17984284282220783
of,0.25210959264475874
autoimmune,0.05486511926628608
disease.,0.014446331711222846
Although,0.005674640020076563
this,0.008688431398685829
suggests,0.010069893395818022
a,0.0067504592467333814
primary,0.0075240804589255745
role,0.012856613873215102
for,0.013967595399644267
defective,0.016835310064492896
Tregs,0.02240618829664782
in,0.01571579726348504
"autoimmunity,",0.005394735959003923
a,0.002437009136619146
link,0.003726818253752638
between,0.0025281581227035574
IL2RA,0.021879001348414216
gene,0.00634967421179503
polymorphisms,0.002191915807740781
and,0.0026760624235868564
Treg,0.0031907127284143705
function,0.0047827869686305575
has,0.0013072914600643565
not,0.0014890954508119108
been,0.0013234692165434963
examined.,0.0015064182828172074
We,0.00425069295841418
addressed,0.002320083823896028
this,0.0027564791408364545
by,0.0029439517650146803
examining,0.0020983850866779998
the,0.0016175783845339248
impact,0.002165258715879958
of,0.00427992026627764
an,0.003675685891196248
IL2RA,0.0077876957370114
haplotype,0.0060144713116466655
associated,0.00427992026627764
with,0.004417279343619957
type,0.002487908533408877
1,0.001978976402636445
diabetes,0.004059417476181053
on,0.0029622780724582088
Treg,0.003605742985821283
fitness,0.004701601036211803
and,0.0017922540306193216
suppressive,0.0025554625756006753
function.,0.003776924751840004
Studies,0.0016876670750079325
were,0.0019407724353872897
conducted,0.0010014981287320758
using,0.0011540631910016994
healthy,0.0010930104542961323
human,0.0009497626106217215
subjects,0.0009055308685554644
to,0.0009469845504250914
avoid,0.0010121337257059805
any,0.0009065046291443177
confounding,0.0009643870310096247
effects,0.0008216347756413634
of,0.0012618365001564947
disease.,0.000886333385460549
We,0.7287963195036481
demonstrated,0.7653571964635872
that,0.8003073832213291
the,0.7726382452074685
presence,0.77922367239451
of,0.7977949202810943
an,0.7856780226002229
autoimmune,0.8048766193692648
disease-associated,0.7739410803890515
IL2RA,0.7764916522602717
haplotype,0.8131946409239699
correlates,0.8471535471103558
with,0.8326978380034297
diminished,0.8411184003665849
IL-2,0.8058057506060001
responsiveness,0.8159080180115352
in,0.8705605535068182
Ag-experienced,0.8407162503250527
CD4(+),0.8611320496354795
T,0.8466822397917543
"cells,",0.8764702560614624
as,0.8102886128838441
measured,0.843784308987881
by,0.8473522150043101
phosphorylation,0.8448651556548085
of,0.8614271100095254
"STAT5a,",0.8427121084715392
and,0.8867203380546982
is,0.8785456976170851
associated,0.8921438020401877
with,0.8771692675046513
lower,0.8976039770961598
levels,0.9072662860955005
of,0.9214007184596628
FOXP3,0.8851275823477434
expression,0.884013200435895
by,0.8889671961021228
Tregs,0.8648907955683559
and,0.9124055918717953
a,0.8844850334247906
reduction,0.8880606141487601
in,0.8829189366120327
their,0.8970666618295516
ability,0.9045241675413778
to,0.8997233858789598
suppress,0.8985756060771098
proliferation,0.8849601727209914
of,0.8929171395094646
autologous,0.9035780049145524
effector,0.9049273771844198
T,0.8275655385471183
cells.,0.8696746586824381
These,0.06596686200389518
data,0.04392417164636855
offer,0.034121301042283336
a,0.028145747798334092
rationale,0.026625518882813348
that,0.026764800602474555
contributes,0.025202649623482978
to,0.02536908895773802
the,0.025048194641574324
molecular,0.023475951653650556
and,0.030558033496073403
cellular,0.020916958445898852
mechanisms,0.0199885190582467
through,0.025539372457353743
which,0.021707459381042734
polymorphisms,0.027522746441122358
in,0.024945646570719772
the,0.02780083849626134
IL-2RA,0.0980107323417808
gene,0.06821067607131058
affect,0.021675339451454514
immune,0.03459311925952649
"regulation,",0.03206081787494544
and,0.03443832805985897
consequently,0.031860190418962
upon,0.025071628702863447
susceptibility,0.01602573892998273
to,0.026464414050566685
autoimmune,0.023522545403468716
and,0.03270462721719826
inflammatory,0.03715326329110215
diseases.,0.024039433233447975
CONTEXT,0.01772939299979856
Many,0.006902350708383445
individuals,0.00395033258632098
take,0.005264147175033011
vitamins,0.0031562056717175588
in,0.004935694400297843
the,0.003947112417255572
hopes,0.0048355649401149
of,0.005364727092479898
preventing,0.002971027567165148
chronic,0.00195665002178074
diseases,0.0018343751440074486
such,0.003651555857611312
as,0.0038108129894279443
"cancer,",0.0030665210118592297
and,0.007940425887860394
vitamins,0.002951113362285826
E,0.008894673675309104
and,0.008403330755930605
C,0.006153862569700803
are,0.0028386609597664232
among,0.002312466754601551
the,0.0029423593895348734
most,0.0020440945267923
common,0.0022418523866543105
individual,0.002046282828492083
supplements.,0.0026475703927117656
A,0.0019075604301479051
large-scale,0.001432543415807617
randomized,0.0013277839436822458
trial,0.0013968365832650559
suggested,0.0024229426068966193
that,0.0017854916232168745
vitamin,0.0011935362581729277
E,0.0013745360908153752
may,0.0014898439867345665
reduce,0.001343826462983289
risk,0.0012484640382682268
of,0.001965823031025248
prostate,0.0012942490749637112
cancer;,0.0012561548886761164
"however,",0.0016410187264972126
few,0.0015101431669427307
trials,0.0011499105310226185
have,0.001681429886903219
been,0.0015258851731541206
powered,0.001281398274477617
to,0.0012583148520574085
address,0.0014094229837479245
this,0.0013910370380353586
relationship.,0.0012231930042038578
No,0.0016183991059751973
previous,0.001620036011961598
trial,0.0013510841599089927
in,0.001020482100994817
men,0.0008676142540243223
at,0.0010248403297608275
usual,0.0010311329213891231
risk,0.0007965874281951986
has,0.0013730370545529517
examined,0.0011429284832924777
vitamin,0.0008091700874991686
C,0.0008631462948147797
alone,0.0007149256024907202
in,0.0008942091244822128
the,0.0009994107240902076
prevention,0.0007059802432607204
of,0.0011894133632052795
cancer.,0.0007467139232258798
OBJECTIVE,0.001868797011762067
To,0.0013516279224648664
evaluate,0.0010263750976647681
whether,0.0013259689132879059
long-term,0.0015138440920128564
vitamin,0.0011563952971066405
E,0.0020692965052941112
or,0.0026877732043185136
C,0.0020248856690139806
supplementation,0.0013395958620677382
decreases,0.0010210344680767747
risk,0.0008561881670077859
of,0.0022397804016298715
prostate,0.0015006116412426963
and,0.002069742611345332
total,0.001076618126307782
cancer,0.0010310364099152243
events,0.001154177527005845
among,0.0016487705822181666
men.,0.0009732080630099147
"DESIGN,",0.0014825487884989113
"SETTING,",0.0019228382752341595
AND,0.0012557592224980273
PARTICIPANTS,0.0018998587211103615
The,0.0014032003770247348
Physicians',0.0010163515148282946
Health,0.0011722026181546928
Study,0.001111975319081586
II,0.0014501397916616865
is,0.0015432598211148594
a,0.0014106479698696285
"randomized,",0.001281603635107188
"double-blind,",0.0015657918748398067
placebo-controlled,0.0012450119789331289
factorial,0.0009223805305389167
trial,0.0010002949569565222
of,0.0014630998916974486
vitamins,0.0009662800546053671
E,0.0011245008411258082
and,0.001857373265216956
C,0.0012566206961211418
that,0.0022514380622416417
began,0.00197410772578478
in,0.0022109256272742025
1997,0.0014763390698410107
and,0.002111802965237278
continued,0.001205507551729572
until,0.0017482346686365558
its,0.0019522091503282927
scheduled,0.0015825447060805605
completion,0.0014592080672062423
on,0.002116041179231285
August,0.0018707298866829359
"31,",0.0025620726720763836
2007.,0.0016134956005470016
A,0.001866083943766699
total,0.0017105617129669173
of,0.002763651781228631
"14,641",0.002087739284118042
male,0.0011724580657142096
physicians,0.0011538320799313825
in,0.0016575888326574738
the,0.002252712557629914
United,0.0012061352475438846
States,0.001561889416694272
initially,0.0014645593815143633
aged,0.0019158471374074604
50,0.002250135381686076
years,0.002466986535616928
or,0.0035618928646898172
"older,",0.002511274184516075
including,0.0018935506323977582
1307,0.001563136193016868
men,0.001054094578138081
with,0.0019573843930427966
a,0.0025276669604914815
history,0.0012685918369366401
of,0.0025315760468791544
prior,0.0016805704550277556
cancer,0.0014113426789500287
at,0.0024226106952571318
"randomization,",0.0013150883734419788
were,0.0014733262053292567
enrolled.,0.0012594959401752885
INTERVENTION,0.0053382620066955225
Individual,0.002120746974695131
supplements,0.0023220006982539797
of,0.0038881342646930727
400,0.0015936713101168637
IU,0.0034166831050485673
of,0.0030602910867586898
vitamin,0.001334832428767884
E,0.0021066107042823326
every,0.0030045194137475455
other,0.0029754399097088984
day,0.0023926920044570195
and,0.003089783799467895
500,0.0019076829952568463
mg,0.0019238506613454861
of,0.003068383847754815
vitamin,0.0015782259586296706
C,0.002305025411106782
daily.,0.0013746925321292004
MAIN,0.006678063086093766
OUTCOME,0.0059948705320255
MEASURES,0.0038194964629258673
Prostate,0.004670289983992745
and,0.005789454208310176
total,0.002484643962991879
cancer.,0.0024546650235026703
RESULTS,0.011888335320990021
During,0.007038793971534103
a,0.004929295759283019
mean,0.004696582034167382
follow-up,0.004405242038143609
of,0.005761536948025242
8.0,0.003934078482251777
"years,",0.003393450032817807
there,0.006246912056648696
were,0.004840991319392162
1008,0.0023626692606585615
confirmed,0.0030729023504701314
incident,0.002686721463005019
cases,0.003163666169578212
of,0.005763241646060509
prostate,0.004505413787858957
cancer,0.002660464119165099
and,0.004626789931014525
1943,0.003452744840663859
total,0.00262998738766273
cancers.,0.001988996768413462
Compared,0.9206734809634738
with,0.87302042217381
"placebo,",0.783719574163699
vitamin,0.8736847647641195
E,0.8937504579645451
had,0.896033079712414
no,0.867071041025013
effect,0.8645337999897329
on,0.851904756226214
the,0.8756458496306033
incidence,0.8928929042468435
of,0.8867841990419607
prostate,0.9098201900838556
cancer,0.884295826302455
(active,0.8844914763633073
and,0.8411957854469049
placebo,0.878931976179207
vitamin,0.9005498060972495
E,0.8973422280630949
"groups,",0.8899112605939835
9.1,0.8880194212128452
and,0.8594384690945209
9.5,0.8819648924435904
events,0.8749438852074062
per,0.8627829112892821
1000,0.8402062071890172
person-years;,0.8899959094889913
hazard,0.8664173335788304
ratio,0.8617970678780346
"[HR],",0.8571105096775476
0.97;,0.8522695884374604
95%,0.8970983262536449
confidence,0.8645224561069828
interval,0.8604317271803187
"[CI],",0.8318131731885667
0.85-1.09;,0.8328005289730248
P,0.8670206417599765
=,0.8642795119582868
.58),0.8647553510333181
or,0.8521920191697796
total,0.895424329612651
cancer,0.8678326249165507
(active,0.8321623164853077
and,0.7901489264856623
placebo,0.6344330954068089
vitamin,0.7304734347899247
E,0.694592305672101
"groups,",0.7000245674934437
17.8,0.5936906153360759
and,0.6399101968003695
17.3,0.5582640879911996
cases,0.6327670303446198
per,0.6474555320604919
1000,0.6203506776757659
person-years;,0.6829381944492582
"HR,",0.686653240894161
1.04;,0.6678384213186943
95%,0.7442151405548927
"CI,",0.696627342406554
0.95-1.13;,0.6475214939130882
P,0.7386029962619769
=,0.7299602981047489
.41).,0.7056531392748583
There,0.885644097116058
was,0.8674524779844867
also,0.8641189106103194
no,0.8265229684019934
significant,0.8234192077399832
effect,0.8318518861751747
of,0.8334167010988482
vitamin,0.8575430517698239
C,0.8507282628177408
on,0.8129506446896638
total,0.8461920564945958
cancer,0.8215315302924007
(active,0.8161658334939856
and,0.7429918009087473
placebo,0.7487567025103825
vitamin,0.8363970844212666
C,0.8338173350727921
"groups,",0.8193033881793776
17.6,0.7863678645024852
and,0.7653205595838949
17.5,0.7522383970388353
events,0.7740970534716362
per,0.7419006539066205
1000,0.7080259524662985
person-years;,0.80279093293441
"HR,",0.8267432150660129
1.01;,0.7691015768215389
95%,0.8315770644844037
"CI,",0.7752665996917495
0.92-1.10;,0.7083225292691884
P,0.8083556385049225
=,0.8128542977028257
.86),0.7695355187284292
or,0.8206622189182418
prostate,0.8860181570495794
cancer,0.8473051956317895
(active,0.7889339896907936
and,0.7572046849157318
placebo,0.7481340917785405
vitamin,0.851126401835219
C,0.818986780907524
"groups,",0.8376031973755745
9.4,0.7557767053369108
and,0.756581933773344
9.2,0.7218153760593898
cases,0.776220446508928
per,0.757259093023605
1000,0.5109874349443833
person-years;,0.622651429258472
"HR,",0.5709420590499117
1.02;,0.571628560580956
95%,0.5964220982240345
"CI,",0.6154641835826736
0.90-1.15;,0.5850638549824658
P,0.5477410547621309
=,0.6427123680042344
.80).,0.5517015742147526
Neither,0.2715340396864305
vitamin,0.10586936580426648
E,0.19562651063880482
nor,0.2368006370235371
vitamin,0.07449886993927461
C,0.14384131197292352
had,0.2916225976228112
a,0.24298859627861458
significant,0.18969139080153458
effect,0.1987671385419318
on,0.22071603466088163
"colorectal,",0.19954065788609154
"lung,",0.2223285617342353
or,0.16907258201901526
other,0.13196598275145763
site-specific,0.12088602786721125
cancers.,0.126324990658719
Adjustment,0.003076419702103557
for,0.003931417651101139
adherence,0.00361197823106837
and,0.003840902393472793
exclusion,0.0030240316009502075
of,0.00425637918879638
the,0.004554909290241813
first,0.0036104143393096257
4,0.004198446382277696
or,0.00314907404445882
6,0.0039382839886595725
years,0.0032024110829189344
of,0.003480689151831517
follow-up,0.003273824196428853
did,0.003412028870082337
not,0.0029625146829938727
alter,0.0030370403167757527
the,0.003273183977043806
results.,0.002434401115216448
Stratification,0.00851855726990922
by,0.00701596824512597
various,0.00694373268603607
cancer,0.004989080010540267
risk,0.0027169512190468588
factors,0.004700534567695742
demonstrated,0.01316451108320959
no,0.011483302201424274
significant,0.007839232243571801
modification,0.007483939757060177
of,0.00742342765884481
the,0.006950780858962535
effect,0.010897241943379748
of,0.014381504413585744
vitamin,0.014537939386804826
E,0.02162332593980804
on,0.011664675625764207
prostate,0.013666952313665324
cancer,0.009718817502013885
risk,0.01140346583620707
or,0.011138347881888291
either,0.008285552422175102
agent,0.011333746334395697
on,0.011413345020354173
total,0.011517650997053763
cancer,0.009463865619163276
risk.,0.011618293074434096
CONCLUSIONS,0.6775179739203326
In,0.3300900217078925
this,0.30459309112353106
"large,",0.34253333678966325
long-term,0.8138936153768574
trial,0.8023962807936166
of,0.7619880969916505
male,0.7984105798326766
"physicians,",0.7755514099904472
neither,0.7918933461099275
vitamin,0.7159777999844603
E,0.7586604270142258
nor,0.7452012367506536
C,0.7469404610231417
supplementation,0.756802769581471
reduced,0.8026822541508041
the,0.7809106452390064
risk,0.7863131022636183
of,0.8095918455998597
prostate,0.8322826763317811
or,0.7563495660277344
total,0.8063785012310206
cancer.,0.751607453583208
These,0.016168312308706162
data,0.01670325061863872
provide,0.015130472503154677
no,0.01244084527112634
support,0.010600585822123634
for,0.00852637189105765
the,0.00836780027218973
use,0.010912950709349773
of,0.008502436783034544
these,0.015289549842333805
supplements,0.013460594046802415
for,0.008189089110883892
the,0.006486786668933604
prevention,0.005962617231166267
of,0.00651852855155835
cancer,0.007003798614576554
in,0.007340239355088225
middle-aged,0.0062516752643428045
and,0.009557672627874445
older,0.005250520290618807
men.,0.0079375697881423
TRIAL,0.00698220956941509
REGISTRATION,0.011364146057958673
clinicaltrials.gov,0.0051795702613047475
Identifier:,0.008617319698558449
NCT00270647.,0.004543862643396079
"Historically,",0.009629292708470124
the,0.01062846854957306
ribosome,0.009532698022034086
has,0.003910567827193764
been,0.004300926343549868
viewed,0.005140113383275756
as,0.007679343893323699
a,0.007839899843871541
complex,0.006293393140578609
ribozyme,0.007866104961573438
with,0.011118397387398681
constitutive,0.0047978780353299
rather,0.01097124107364726
than,0.01217214560859869
regulatory,0.0065810371028473934
capacity,0.009919824044643448
in,0.009573931816102603
mRNA,0.011210382828251842
translation.,0.011446139386112185
Here,0.2535959628110999
we,0.27373772687057135
identify,0.20177024984381411
mutations,0.13340803676935464
of,0.12172368298707123
the,0.09822894584521226
Ribosomal,0.14786462900302988
Protein,0.10744737671886123
L38,0.13102611098233213
(Rpl38),0.13590421450004145
gene,0.1864578435830494
in,0.16686794186911022
mice,0.1767926062979712
exhibiting,0.1427094014151432
surprising,0.1348077125381694
tissue-specific,0.10858133536671341
patterning,0.09984617509328554
"defects,",0.11868240716288353
including,0.24952255454304179
pronounced,0.2018608877806472
homeotic,0.20553354448595046
transformations,0.16604496408928118
of,0.18267173189974084
the,0.09885169459651412
axial,0.14634743344640228
skeleton.,0.12041311419084572
In,0.25186926077088456
Rpl38,0.20774420174791647
mutant,0.25366020377623816
"embryos,",0.24929547326755966
global,0.17276103299744447
protein,0.16594350148614562
synthesis,0.21595752616759964
is,0.18541134672107504
unchanged;,0.17973177833144852
however,0.16737336960690016
the,0.21540245550302226
translation,0.24168271686965234
of,0.20199079114555527
a,0.18593986882001098
select,0.17648752523465266
subset,0.17207132746598727
of,0.23637690842495915
Homeobox,0.25218020492656323
mRNAs,0.24220215530519074
is,0.17810004843768815
perturbed.,0.14164128756209707
Our,0.46162461505799257
data,0.399469118240423
reveal,0.4808911097165643
that,0.5567644415517885
RPL38,0.5343489113058092
facilitates,0.5520796575785197
80S,0.12443349727686163
complex,0.10535383886717865
formation,0.11503752142471513
on,0.12785756984946003
these,0.14036327477910937
mRNAs,0.1339219763719039
as,0.12274160364021532
a,0.11977997157373002
regulatory,0.09305622575579568
component,0.11861283576518826
of,0.14230895076347605
the,0.11799306268009867
ribosome,0.11905102143338417
to,0.12081889360951228
confer,0.10538135900403925
transcript-specific,0.07630986927094459
translational,0.10473684112856259
control.,0.1020720295365695
We,0.515491506442963
further,0.4391025298947598
show,0.52104807780297
that,0.48776735136077254
Rpl38,0.3504967607081724
expression,0.3621041617087184
is,0.34347136078770996
markedly,0.2847991538591684
enriched,0.28246444591694786
in,0.2989350405113445
regions,0.26762575180205206
of,0.2696176039361717
the,0.4208103326202113
embryo,0.39167860089904194
where,0.23838356202347646
loss-of-function,0.1637577205351195
phenotypes,0.26332524794804346
occur.,0.19557486926141476
"Unexpectedly,",0.13040650465408207
a,0.15867936551604955
ribosomal,0.12073287125763216
protein,0.1106336137568851
(RP),0.08111321522171273
expression,0.16773902362665735
screen,0.14067813989081213
reveals,0.13377653085490765
dynamic,0.1403365299324051
regulation,0.14922934719630063
of,0.11098816966592122
individual,0.1108171721898823
RPs,0.18414765667012725
within,0.1352197505817991
the,0.14634735153602063
vertebrate,0.15590151868776791
embryo.,0.16039818482164056
"Collectively,",0.3589670983881013
these,0.3015128654132814
findings,0.2325518753508324
suggest,0.3830596963448257
that,0.4088228863944697
RP,0.38405956573237715
activity,0.3650732469292822
may,0.3146837260653333
be,0.34083823185708284
highly,0.33303438005403196
regulated,0.3359819524659036
to,0.402644404343514
impart,0.3559839393745311
a,0.3703326864086627
new,0.3265045514401485
layer,0.30078864372277664
of,0.33378438283595624
specificity,0.28504226873298283
in,0.35350083156125134
the,0.32167504459199525
control,0.32494712516153645
of,0.31289413839696595
gene,0.32217970141235447
expression,0.36026427784549253
and,0.3126019607868933
mammalian,0.26037066434011735
development.,0.35502314923335776
Expression,0.024419454666873647
of,0.02226243846755895
the,0.024804064984963865
intermediate,0.020133820243065984
filament,0.022384948370463384
protein,0.025367202620232135
keratin,0.019704744892054437
17,0.03177315643227605
(K17),0.02010042576335964
is,0.010262405754496936
robustly,0.011548361331549042
upregulated,0.009262990544746524
in,0.016375271369562853
inflammatory,0.010365314399156087
skin,0.012435163851095294
diseases,0.013794290798591187
and,0.020019476755979045
in,0.01853718194703943
many,0.016222402509377235
tumors,0.013635036306359484
originating,0.016066930363767412
in,0.016639623977430674
stratified,0.011875542909697135
and,0.013765806681610569
pseudostratified,0.008070768679461372
epithelia.,0.019414663432573132
We,0.7626332533497908
report,0.8087906054272496
that,0.8568604883746558
autoimmune,0.8236977241673741
regulator,0.7568263880187386
"(Aire),",0.797292574389753
a,0.8532835924750726
transcriptional,0.8830928195556313
"regulator,",0.7867705834954742
is,0.8258144530707584
inducibly,0.8625698492573355
expressed,0.8187820701004498
in,0.8392553488251007
human,0.8533713232477355
and,0.8519778347854335
mouse,0.8752657179554286
tumor,0.8400166729618362
keratinocytes,0.8722734354564359
in,0.8704114807176242
a,0.8691610009058961
K17-dependent,0.756904554708904
manner,0.878700859820662
and,0.8583587704112937
is,0.8400613247170979
required,0.8434880662177827
for,0.8503608158361393
timely,0.848099532863995
onset,0.7992830492471614
of,0.818000808846066
Gli2-induced,0.7737401699582993
skin,0.8255491396387887
tumorigenesis,0.7724866730608354
in,0.8089346467942016
mice.,0.8235200113792402
The,0.6282579022721634
induction,0.5964143314270345
of,0.5009015118247387
Aire,0.5313600836976677
mRNA,0.5779157143406267
in,0.504404765221735
keratinocytes,0.4891774930599709
depends,0.4329434993019949
on,0.35292873578587364
a,0.3516489917659257
functional,0.276167553848871
interaction,0.29530246834951246
between,0.22315315239868094
K17,0.3596835109980325
and,0.24742933092565364
the,0.28765951103230214
heterogeneous,0.22444971574953101
nuclear,0.27380410218940826
ribonucleoprotein,0.25425115154003164
hnRNP,0.26564586163293896
K.,0.32474443527477287
"Further,",0.5748479727011163
K17,0.524302729129917
colocalizes,0.6520703930919953
with,0.5403686576812989
Aire,0.5713487097136194
protein,0.6097926700304506
in,0.6377532575301121
the,0.662603804393758
nucleus,0.6250281512013416
of,0.6328261492283188
tumor-prone,0.5872700362353938
"keratinocytes,",0.6488995445185773
and,0.669535200836037
each,0.5632698855986782
factor,0.584589443080862
is,0.586139665841258
bound,0.602024784484301
to,0.5877033991988274
a,0.5625140312120639
specific,0.5135533987115131
promoter,0.5888061870127271
region,0.600720364717941
featuring,0.5710947368790847
an,0.5572402380008372
NF-κB,0.5992117579051655
consensus,0.5505454376121417
sequence,0.5380238147058192
in,0.5664586622987471
a,0.5326013256910042
relevant,0.5474114398600192
subset,0.5019046478978784
of,0.5380345185143556
K17-,0.5429989688966499
and,0.495327742798098
Aire-dependent,0.558238909679625
proinflammatory,0.5688284057205227
genes.,0.5665033009568703
These,0.13879181509628757
findings,0.11568520245538706
provide,0.07778359441040215
radically,0.0651584516922586
new,0.05529630892479974
insight,0.07010586484670608
into,0.06835836515004896
keratin,0.06636225161227688
intermediate,0.09894371062425636
filament,0.07924711030245925
and,0.06005525077654272
Aire,0.09550311238165939
"function,",0.07630222319611629
along,0.09856780434729177
with,0.08916550449958313
a,0.06817822463823545
molecular,0.059364730838713145
basis,0.07570441631010472
for,0.06075714780652276
the,0.06439817658617189
K17-dependent,0.11652537008139567
amplification,0.047524449230373536
of,0.12452056782480049
inflammatory,0.34241375094220644
and,0.30368262591747175
immune,0.32375095201825155
responses,0.3080597384234268
in,0.3305049182733502
diseased,0.30063899446425324
epithelia.,0.3965856235820272
Limited,0.3355147860608372
neural,0.39285670654261495
input,0.45324349885689286
results,0.3533128228079847
in,0.45092540735700914
muscle,0.4205414906424203
weakness,0.4077903412764133
in,0.41231136762697695
neuromuscular,0.3281361524116867
disease,0.36813842523333545
because,0.4026234740851807
of,0.3529962980635506
a,0.4436434147698178
reduction,0.3850541672248582
in,0.34293776173413965
the,0.35949048902374886
density,0.40461870240167286
of,0.33446914974767206
muscle,0.39999473679066994
"innervation,",0.39093867456218373
the,0.3365032348874016
rate,0.3343847873602768
of,0.32068207071478955
neuromuscular,0.3577329656074564
junction,0.359070904712868
activation,0.3110204666818001
or,0.2197123672499837
the,0.29356994660732666
efficiency,0.29518222907033204
of,0.28568836481537396
synaptic,0.29583886821670136
transmission.,0.3359663544640133
We,0.5314503225479095
developed,0.5389921070236076
a,0.5069902252303254
small-molecule,0.4866991027064541
fast-skeletal-troponin,0.580378970479782
"activator,",0.6510277568830856
"CK-2017357,",0.5867052452873909
as,0.6673817371912042
a,0.7167156268583584
means,0.6886765018406262
to,0.6888799311217224
increase,0.7759932302286547
muscle,0.6837231180791179
strength,0.7431486279289502
by,0.8340011936910648
amplifying,0.7929946274131342
the,0.7648108560918142
response,0.699518918752823
of,0.7411523057861531
muscle,0.6546230741072637
when,0.685052786544826
neural,0.6895837197477842
input,0.7553752880088311
is,0.6047934240637897
otherwise,0.6172946609395912
diminished,0.698396815000194
secondary,0.7682025697354367
to,0.7773153066129735
neuromuscular,0.7563775198212763
disease.,0.6977777043455671
Binding,0.6221084285779032
selectively,0.6739248232845532
to,0.5800661822761071
the,0.6095405829355396
fast-skeletal-troponin,0.5912502156581151
"complex,",0.626915958012202
CK-2017357,0.6503023152260473
slows,0.6335629087922737
the,0.61494115409545
rate,0.6199097247866745
of,0.47477847030582865
calcium,0.3735495942268602
release,0.4723842997647423
from,0.5171204713362931
troponin,0.39617142867023486
C,0.5415025508831635
and,0.57514843753022
sensitizes,0.45769676421100697
muscle,0.4207552848213993
to,0.41945105544421374
calcium.,0.3563274539448953
As,0.24814922209584347
a,0.19098688459400465
"consequence,",0.21369904124664268
the,0.20240225574219492
force-calcium,0.24240202779051012
relationship,0.22647272312676003
of,0.17842960158210158
muscle,0.23650659814766467
fibers,0.22231249063136752
shifts,0.16906673727059843
"leftwards,",0.1903892181820273
as,0.2768489383429472
does,0.16194859955613933
the,0.15382282318585289
force-frequency,0.22580013909854765
relationship,0.16553534830806518
of,0.16480337550733767
a,0.18191934174337399
nerve-muscle,0.18689009672850568
"pair,",0.1921693774574681
so,0.30022137455619924
that,0.30730365910442076
CK-2017357,0.36589412468148397
increases,0.22911868206906533
the,0.21893587710685336
production,0.25509633567854717
of,0.21131727683640097
muscle,0.22745994258180047
force,0.32484294508311273
in,0.22233579116709812
situ,0.16123902286552466
at,0.21909284239831506
sub-maximal,0.2358689106864635
nerve,0.199155070545862
stimulation,0.2132199421960419
rates.,0.22692594210891331
"Notably,",0.6036314997297103
we,0.6328633241443641
show,0.6901262202316525
that,0.7327963466846803
sensitization,0.7578067058651813
of,0.7104566398359574
the,0.6386501123666656
fast-skeletal-troponin,0.6394807868724867
complex,0.6036895406942904
to,0.5794297462773103
calcium,0.5638255517517584
improves,0.7093568746121323
muscle,0.6296510307750091
force,0.7140472052733678
and,0.742845261322993
grip,0.6470244888613278
strength,0.7018632915397796
immediately,0.6394825767086594
after,0.6685259896586347
administration,0.5426886670851139
of,0.5610071367806205
single,0.5663668263937842
doses,0.5551491233910941
of,0.5710208926941945
CK-2017357,0.5768325904832006
in,0.6178194856208954
a,0.5837936919314507
model,0.5525683499225169
of,0.44316666141261224
the,0.4610014263312675
neuromuscular,0.5211323899870475
disease,0.4917480168942689
myasthenia,0.38605449978096246
gravis.,0.4179403522823022
Troponin,0.254041757929719
activation,0.26944875697385867
may,0.1193920338563492
provide,0.13898823188479925
a,0.16463866076128364
new,0.09990432519267722
therapeutic,0.10321898218937411
approach,0.13353710122395882
to,0.1342406010477709
improve,0.14635837254681344
physical,0.17610084262780415
activity,0.17921331754839015
in,0.15314370407023625
diseases,0.10140914127370243
where,0.1584474145817428
neuromuscular,0.19136196731293584
function,0.21762237027652684
is,0.1587781397165403
compromised.,0.17281799429666525
In,0.3873511290386392
systemic,0.1827041447951259
lupus,0.18157130405529023
erythematosus,0.2139215992886237
"(SLE),",0.1997527596001406
self-reactive,0.3101146587075698
antibodies,0.33155698699771313
can,0.31156259493598265
target,0.31618416714764797
the,0.30123649730596935
kidney,0.25439725940302643
(lupus,0.25206958577333416
"nephritis),",0.2765612111445984
leading,0.3207301804835274
to,0.31829233501644916
functional,0.30134558977134046
failure,0.2535065161244872
and,0.24403650078708816
possible,0.23317761906618023
mortality.,0.19308392635538105
We,0.8553902038506184
report,0.8628895990187988
that,0.9037654872748252
activation,0.8990214363274487
of,0.9190960229787095
basophils,0.9258471462308602
by,0.9210632984535941
autoreactive,0.9179687460200163
IgE,0.917836394983259
causes,0.918435640060794
their,0.9233516232054227
homing,0.9451603433185463
to,0.9161060954808972
lymph,0.9449164289368134
"nodes,",0.9056024277741198
promoting,0.9323576655281323
T,0.907122673175113
helper,0.9219651403373241
type,0.9437783625109281
2,0.9068664728715417
(T(H)2),0.8808177844932884
cell,0.9361711273852243
differentiation,0.9193319049516414
and,0.9365383437355497
enhancing,0.9358455399205792
the,0.9189416512921132
production,0.930781595038258
of,0.92436981012806
self-reactive,0.9203436443650281
antibodies,0.9004550238686182
that,0.8655119172754191
cause,0.8906170247225863
lupus-like,0.8313832429585797
nephritis,0.8896151866070153
in,0.8808717107063543
mice,0.8720859374216293
lacking,0.8331734364010673
the,0.7939902977029273
Src,0.7064700341241301
family,0.7248835955334163
protein,0.8372087386890431
tyrosine,0.7971668522300718
kinase,0.7673654964875739
Lyn,0.7800710147690533
(Lyn(-/-),0.2412472094173275
mice).,0.36830440754106036
Individuals,0.7574313845501119
with,0.6804521182938076
SLE,0.5957991190900886
also,0.7753674669058054
have,0.7940569179037349
elevated,0.8471918083968955
serum,0.831169948540827
"IgE,",0.7473471735241533
self-reactive,0.8575307237790614
IgEs,0.7228546120932506
and,0.8471198401153223
activated,0.8541099193056315
basophils,0.8272691795970326
that,0.8362400103252265
express,0.8269464632057445
CD62,0.8102479464412803
ligand,0.8053186273992927
(CD62L),0.719450467180861
and,0.8371107044955466
the,0.8231590618728674
major,0.7786706485620603
histocompatibility,0.6104273913640403
complex,0.7776145412348879
(MHC),0.6544855171966116
class,0.7857281517073494
II,0.786481186903693
molecule,0.7928849233803776
human,0.8126950801634211
leukocyte,0.7355247423458185
antigen-DR,0.7527140607076983
"(HLA-DR),",0.6636134450922625
parameters,0.824452351033601
that,0.7655240755484124
are,0.703565072746077
associated,0.796771501448638
with,0.765990704396013
increased,0.8233904503995892
disease,0.6937990609803761
activity,0.7498714815414795
and,0.7902985050574851
active,0.8153191308072261
lupus,0.715309566531618
nephritis.,0.7288056970713255
Basophils,0.2916974820709071
were,0.32945489475523343
also,0.3054248211141889
present,0.3209945015212875
in,0.4101739363605755
the,0.43944007959803494
lymph,0.3783283913493581
nodes,0.35231012208734663
and,0.40730849235347655
spleen,0.3841889933644215
of,0.403559651848252
subjects,0.2995798791878154
with,0.2969170344921514
SLE.,0.28224384058797064
"Thus,",0.3675021263247606
in,0.7698462361738352
Lyn(-/-),0.7033539409350137
"mice,",0.8092505357235839
basophils,0.7980484150488646
and,0.8496185228616713
IgE,0.7743810036871734
autoantibodies,0.8362634106339748
amplify,0.898616068935274
autoantibody,0.8963529975756132
production,0.8942537692799627
that,0.8808561230695088
leads,0.8804341756592017
to,0.8811818638646697
lupus,0.9105604955638958
"nephritis,",0.902703988568167
and,0.839327463627553
in,0.7858025719274689
individuals,0.7799537843792362
with,0.7177749957862479
SLE,0.7534603429869781
IgE,0.7994572282434492
autoantibodies,0.7646966700969084
and,0.7668816109564843
activated,0.7901127959419797
basophils,0.7886352851501311
are,0.7023170672502513
factors,0.7552078647452473
associated,0.7203424094880606
with,0.7063786219600442
disease,0.696436619619051
activity,0.7291325652636962
and,0.6324319571748519
nephritis.,0.7163581671261624
The,0.07066481879528125
number,0.0440844121346385
of,0.04297030973527274
women,0.03960601961914779
dying,0.02291792958662464
from,0.027752732881899594
cervical,0.04917510427724692
cancer,0.0331943658831166
in,0.049898594758414905
1997,0.041215713563839455
was,0.07340545652465595
7%,0.08494427717360956
lower,0.0631445095386685
than,0.08236338359184
in,0.08102068921682497
1996,0.043796795861952745
and,0.1256237155704576
has,0.054797087357504
fallen,0.04826862315069631
by,0.11397732240504006
over,0.08355756172982923
25%,0.04837258234317254
since,0.04837727987896536
1992.1,0.04962637009721395
Such,0.2026851547230378
rapid,0.1502428895506449
change,0.14394918299749787
must,0.1742361640301876
be,0.19636325708705635
at,0.20911815905581074
least,0.24425816080649893
partly,0.22410913177233013
due,0.19889349574272347
to,0.19561319721448894
cervical,0.16176643938054192
"screening,",0.17940834800199354
although,0.23483815144960865
strong,0.20074964643067086
cohort,0.2115005150844037
effects,0.15612932684564573
have,0.13715273194050684
caused,0.15166048018486752
large,0.16534093424768428
fluctuations,0.10910605946462537
in,0.0970612058353989
cervical,0.128714411665257
mortality,0.12188588362775145
in,0.08700010955950767
the,0.0810723352548349
past.2,0.1521106133474961
We,0.006966046318868321
modelled,0.002546226229830004
mortality,0.002376041939305742
"data,",0.002414871487018534
taking,0.0017864556338960922
into,0.0018447171177391655
account,0.0018721469924936967
the,0.0025078949334465914
effects,0.001568023500791736
of,0.0038091624318430037
age,0.00163253988363524
and,0.003232649741613754
year,0.001651818799282117
of,0.0025645091217991784
birth,0.002061841175043529
and,0.0025724317792226274
looking,0.0019280968419395797
for,0.0014500296646293655
trends,0.002192446184344015
in,0.001717978156560344
time,0.002077801804936554
within,0.0018188801248029988
four,0.0023128793363879642
age,0.002062147802594811
groups,0.00193051673208106
to,0.0016057392284404743
estimate,0.001907471915790538
the,0.002165365863509716
beneficial,0.0017834480076828801
effects,0.0017559073532605837
of,0.004514139405119989
cervical,0.003950161853588335
screening.,0.00342813501449106
We,0.04230293993717029
obtained,0.027536447282042124
mortality,0.04544259519072636
"data,",0.022655031679455075
in,0.02432258469681137
5,0.022497164162131236
year,0.018484537416056265
age,0.020877172394567996
"bands,",0.013666923388395733
from,0.015007764510127204
death,0.030540673963448457
registrations,0.01787827397967145
in,0.033891810293754
England,0.00860498936849789
and,0.004480636933851446
Wales,0.004546150542676859
and,0.007606484990029456
calculated,0.004819308372014763
rates,0.0021656368469885057
using,0.003229361071303723
mid-year,0.002832291939050053
population,0.0033786549239551247
estimates.,0.0026560097935385027
Mortality,0.006528428469177173
since,0.011743858826476836
1993,0.008126474682982995
was,0.010121000980470982
adjusted,0.010218313333188477
upwards,0.016989157707312186
by,0.025842049056598818
4%,0.012694698948388136
because,0.011316775863720329
of,0.010497696331937586
changes,0.006572398103784653
in,0.007843986415680192
classification,0.004673193476700784
of,0.004650833508894275
cause,0.0032466301176727404
of,0.0041243190025341695
death.3,0.003223087083908734
We,0.369793206279186
modelled,0.2675081648843734
the,0.1631375876391963
data,0.17422612200550108
assuming,0.29002277920921393
that,0.3491076545340565
the,0.2355901944967894
age,0.17074353340522072
specific,0.1973626670779792
mortality,0.19771755873109526
is,0.2553427531834743
the,0.23041440535084726
product,0.27890999772001523
of,0.2758669525522558
a,0.2857433411578312
smoothly,0.293356186508699
varying,0.2062485703648142
age,0.20080216964007824
"effect,",0.2837510172960913
birth,0.24231771530930063
cohort,0.22719042198357817
"effect,",0.2747101752308337
and,0.21488743508293276
age,0.15408545930599987
dependent,0.2756199531954812
…,0.29601813525415527
Gene,0.09796132770051616
expression,0.1184215003756099
is,0.05104614277912925
a,0.05207171313972544
fundamentally,0.04588571100369294
stochastic,0.04179017955157478
"process,",0.07420237122224843
with,0.07552355935660837
randomness,0.056456609807676465
in,0.0762815865045214
transcription,0.11642448092328342
and,0.07907302267642605
translation,0.10350199237677467
leading,0.08552854704886592
to,0.09401825689781224
cell-to-cell,0.09253698085249525
variations,0.046533775662647665
in,0.061673114912789484
mRNA,0.11606516580093246
and,0.056457441688428166
protein,0.06007143654301304
levels.,0.06054101707052433
This,0.0071537081690359345
variation,0.004926901319689134
appears,0.0075234537899151665
in,0.00770773123540856
organisms,0.007063263377061055
ranging,0.006632762884685954
from,0.008728943485577156
microbes,0.007874137833048361
to,0.010346441083402136
"metazoans,",0.010772144360506263
and,0.008917538730801495
its,0.006377495857038909
characteristics,0.004716637489899974
depend,0.006280190529592739
both,0.007517252205078508
on,0.005902827015042401
the,0.006858929813580183
biophysical,0.00500389391952393
parameters,0.005939803471715927
governing,0.009313166710933948
gene,0.005371493016204949
expression,0.008239586516148284
and,0.01172051110069123
on,0.0071033075216550235
gene,0.0078281379444999
network,0.012471040721462712
structure.,0.007902688062263956
Stochastic,0.04556756601818065
gene,0.0784463190993675
expression,0.06929416361153042
has,0.037664680243116234
important,0.046974838575444065
consequences,0.03404784628262013
for,0.03317436316814401
cellular,0.05643930803089747
"function,",0.04138705517119089
being,0.03773628181425181
beneficial,0.04637994061276539
in,0.0388443199076939
some,0.04917887234243551
contexts,0.04893893318401996
and,0.058701485138049764
harmful,0.04063861596842892
in,0.05544021791458871
others.,0.04622530178800898
These,0.03719624309707916
situations,0.0473340653216996
include,0.04454445614630528
the,0.05832885340034436
stress,0.06523511564453723
"response,",0.07441160296659584
"metabolism,",0.094283003282077
"development,",0.10924802782442643
the,0.06230254573952854
cell,0.10081307442637572
"cycle,",0.10156745931434041
circadian,0.08109716124284454
"rhythms,",0.07296548832282394
and,0.04540132771329556
aging.,0.08815700771085108
Despite,0.06261320643377893
accumulating,0.03085611240175666
evidence,0.06100186755971279
suggesting,0.06223385721866175
local,0.04568928270031571
self-maintenance,0.036055716774250395
of,0.04630527613921457
tissue,0.06331118614070949
macrophages,0.05208812073267257
in,0.0314331718027189
the,0.032313166657603906
steady,0.02556816893922874
"state,",0.03192632548904272
the,0.03586848271543675
dogma,0.026296219725686954
remains,0.03380943446966851
that,0.03963377045257987
tissue,0.0406636182673641
macrophages,0.03961875873893892
derive,0.04259329541538458
from,0.04393922767557311
monocytes.,0.03172081798736065
Using,0.026378972496071903
parabiosis,0.012653566150190957
and,0.018673785461294338
fate-mapping,0.016177025989881563
"approaches,",0.016907207781316987
we,0.07130375917372493
confirmed,0.05876906451076869
that,0.04271134156316868
monocytes,0.03968400335286838
do,0.03249085648222489
not,0.027877776349954347
show,0.03199133811672889
significant,0.01667323478472687
contribution,0.02352771831668482
to,0.03203903179567595
tissue,0.032274664531826494
macrophages,0.02890758471052679
in,0.022192874320130864
the,0.02032106555172176
steady,0.018543503006097726
state.,0.021987599653893623
"Similarly,",0.567327560516616
we,0.6429248235120418
found,0.6997151588488322
that,0.7327978697394343
after,0.6296270681600109
depletion,0.4894286373593979
of,0.5065285628287975
lung,0.562653104125463
"macrophages,",0.5381592115939158
the,0.5910457769630588
majority,0.5986632302595727
of,0.6169337817857484
repopulation,0.5774636388674799
occurred,0.5872905782083045
by,0.6200349124624496
stochastic,0.5364171066484231
cellular,0.5802865596161972
proliferation,0.5284631220336028
in,0.4148293396684347
situ,0.5743760188378486
in,0.5085696550860879
a,0.5723934063821642
macrophage,0.5119997586755469
colony-stimulating,0.5716613929628189
factor,0.566840425009092
(M-Csf)-,0.4986484940482552
and,0.5736699961577744
granulocyte,0.5592647606874528
macrophage,0.5450221637333534
(GM)-CSF-dependent,0.5314705185628562
manner,0.6112758932777232
but,0.5820101491180718
independently,0.5572415743963467
of,0.5347399792781918
interleukin-4.,0.48067206729665357
We,0.7177088598461427
also,0.7145595002777817
found,0.7917171497356622
that,0.8302573564830321
after,0.7784833872483916
bone,0.6697582244207143
marrow,0.7347533476603052
"transplantation,",0.6617662054238841
host,0.7374278640564343
macrophages,0.7215525196310201
retained,0.7543348948694509
the,0.7766329887287902
capacity,0.7421738747807334
to,0.7746511278659268
expand,0.7203957188326757
when,0.7203375885279347
the,0.7306577472623933
development,0.7333292012421074
of,0.7265950353595432
donor,0.7019061322711208
macrophages,0.7101277710116243
was,0.7175199034455602
compromised.,0.6648649004186499
Expansion,0.5263507499469652
of,0.4696889651515933
host,0.5284100667874493
macrophages,0.49450630300301857
was,0.5894573420874518
functional,0.5203705799453751
and,0.6429991322136633
prevented,0.5625877557725008
the,0.5217442163830618
development,0.5139471730450931
of,0.5372638062206957
alveolar,0.5364308651459314
proteinosis,0.5370493669827107
in,0.51875274134766
mice,0.5249580047899454
transplanted,0.4341461271857763
with,0.410809383443926
GM-Csf-receptor-deficient,0.49582917790632586
progenitors.,0.44057913917448055
"Collectively,",0.22702978646882593
these,0.22872306999918535
results,0.22837169822240397
indicate,0.2877535716266282
that,0.275307519956231
tissue-resident,0.3316904280874537
macrophages,0.3585839949326233
and,0.32207367686788874
circulating,0.22049118990812425
monocytes,0.20794456626107222
should,0.10177706378874694
be,0.057385864528478145
classified,0.0754545809571877
as,0.13129625910098247
mononuclear,0.15552974197478045
phagocyte,0.21777418374606616
lineages,0.18764532718681512
that,0.13327871294943064
are,0.11289188103036074
independently,0.11830319777566826
maintained,0.12995237177257934
in,0.14381012554996525
the,0.14898572748108577
steady,0.13910300458418143
state.,0.16710520906900683
West,0.00543113884517703
Nile,0.005055771463860475
virus,0.007255070388057252
(WNV),0.005680155567864425
is,0.0035585426508678636
the,0.004075151815922757
most,0.002368310313026993
common,0.003709427714064516
arthropod-borne,0.006305689566073425
flavivirus,0.007890526617166686
in,0.0045560715434408835
the,0.003756370078083155
United,0.003162579122103239
States;,0.0041807309636376295
"however,",0.0020342869243058378
the,0.0019389874042872136
vector,0.0019022011404700703
ligand(s),0.0018275419515967528
that,0.0015588020504782919
participate,0.00207218607809859
in,0.0019548904201297677
infection,0.002036331018637176
are,0.0015007102418382505
not,0.0012378245436103865
known.,0.0018077837639931895
We,0.5973397750865358
now,0.49556871185098506
show,0.7115850814305489
that,0.7439436885037938
an,0.6493897488300583
Aedes,0.5881506853291353
aegypti,0.620105047568487
C-type,0.5989352816552664
"lectin,",0.6767467336578614
"mosGCTL-1,",0.6461000064707423
is,0.7400931789772546
induced,0.7329221405841716
by,0.7881843198490642
"WNV,",0.5193467358791992
interacts,0.7312614385944666
with,0.6795169567422736
WNV,0.5701189162579751
in,0.8000237841861854
a,0.7971142741187461
calcium-dependent,0.6879024635645806
"manner,",0.7805443069224985
and,0.7817201518529783
facilitates,0.7444574273694824
infection,0.5873991413229778
in,0.6328457357622527
vivo,0.6794664157540835
and,0.5302463221340084
in,0.5721429941614055
vitro.,0.5760845172778718
A,0.2870117362554687
mosquito,0.2689761402778395
homolog,0.21248090425893695
of,0.301638654187082
human,0.26676699621674954
CD45,0.3553817016594691
in,0.30879884016644776
A.,0.33466157107003025
"aegypti,",0.32682088635995665
designated,0.20480304945113936
"mosPTP-1,",0.2823871065077642
recruits,0.3138563952106185
mosGCTL-1,0.32988162337725885
to,0.3480079315782264
enable,0.3982945082328731
viral,0.3148900084281816
attachment,0.31681157739966137
to,0.2966686253015273
cells,0.3126163955437806
and,0.39081696903113383
to,0.3820685603292409
enhance,0.38606276074057266
viral,0.3030784161362297
entry.,0.29367003599495933
In,0.3102353951064476
vivo,0.32146369222842325
experiments,0.2987817296980109
show,0.3159276095246427
that,0.3347574514381049
mosGCTL-1,0.3361160329054195
and,0.3002622612934557
mosPTP-1,0.34622098976440957
function,0.31310272719094784
as,0.34134105715296553
part,0.3054125497076761
of,0.2922421863622107
the,0.2946235121038484
same,0.25223053787489
pathway,0.36712834227133867
and,0.4509840120374701
are,0.29254903061803855
critical,0.411655698491865
for,0.40241869534802527
WNV,0.4214854777291143
infection,0.3666453830268426
of,0.36953256565782655
mosquitoes.,0.3379721923681035
A,0.16353569578575594
similar,0.15820146630012638
phenomenon,0.17290991681304319
was,0.15605554558653556
also,0.145659182522522
observed,0.18456222357418423
in,0.18926120424455045
Culex,0.22065427752004957
"quinquefasciatus,",0.20060493208464986
a,0.18807342559667323
natural,0.11707773004886857
vector,0.14424067747188773
of,0.2009229168485109
"WNV,",0.1736761988578686
further,0.18600176858400608
demonstrating,0.151775347130442
that,0.14148259444422875
these,0.13738263361990738
genes,0.16420895139293729
participate,0.12746829177933827
in,0.13223193964995414
WNV,0.1562847553543341
infection.,0.13983506636827028
During,0.25509881612546903
the,0.21629330261446678
mosquito,0.18111220600666417
blood-feeding,0.20698636713232998
"process,",0.19114921904522292
WNV,0.24043424825586418
infection,0.27109224669281556
was,0.2322430136564598
blocked,0.2508690248087898
in,0.27817914240546426
vivo,0.290193344511195
with,0.22653295135350196
mosGCTL-1,0.2137470343114549
antibodies.,0.19338276694995996
A,0.07747770306603523
molecular,0.03615703469614676
understanding,0.055296944115856554
of,0.057998333371004886
flaviviral-arthropod,0.2974768309695226
interactions,0.26193696354754165
may,0.14011838697013798
lead,0.16722125025246395
to,0.16567835418182608
strategies,0.17056687587685498
to,0.11943034743222299
control,0.16064535339133332
viral,0.19836243913463494
dissemination,0.19534252877351893
in,0.12169392815444195
nature.,0.10835629860811818
OBJECTIVE,0.0013655188579087842
To,0.000972870381564481
determine,0.0008935535210077779
the,0.000798898373790779
effects,0.0008614541186238401
of,0.0011187394472618754
"smoking,",0.0008826427014440789
plasma,0.0007052207243292075
"lipids,",0.0008777975182522586
"lipoproteins,",0.0010265978209731772
"apolipoproteins,",0.0008080462765328544
and,0.0009176701452231328
fibrinogen,0.0012939141334920251
on,0.0010142604803833166
the,0.0009933586101099892
patency,0.0008694251737111823
of,0.00145365615722141
saphenous,0.0009445518022376462
vein,0.0010761802679993557
femoropopliteal,0.0009288157444678378
bypass,0.0008284384234203075
grafts,0.000880499676388328
at,0.0009624770795718065
one,0.0013156922248860339
year.,0.0014176968587859729
DESIGN,0.0007390570403291236
Prospective,0.000576569978202136
study,0.0009082205307924539
of,0.0007058204713519524
patients,0.0005451778972010214
with,0.0006160564048065188
saphenous,0.0007088768499964799
vein,0.0008841708766038368
femoropopliteal,0.0008336382950787501
bypass,0.0006459768444638793
grafts,0.0007299923778077814
entered,0.0008376546663265259
into,0.0012240202137821013
a,0.0012538096277087516
multicentre,0.000820302920163273
trial.,0.0007042482280965425
SETTING,0.002910268172589866
Surgical,0.002787288131559695
"wards,",0.0014416624330724761
outpatient,0.001420251526726365
"clinics,",0.0017831980248268632
and,0.0015927671831957298
home,0.002142249081331626
visits,0.0014996181369543837
coordinated,0.0014171238551641658
by,0.002358827919699525
two,0.002343096694738589
tertiary,0.0009563754670025375
referral,0.0010609389860569576
centres,0.0016326409207830172
in,0.0019325353926393216
London,0.0016575130817656702
and,0.002302870524145232
Birmingham.,0.001864564035956338
PATIENTS,0.002433609759422301
157,0.0010798689056704359
Patients,0.0010221483757100183
(mean,0.0011395939267858518
age,0.0011593777210201677
66.6,0.0019783826979690128
(SD,0.0010585495639214486
8.2),0.0016253024814661618
"years),",0.001100162815930344
113,0.0008508901211560036
with,0.00116584196066503
patent,0.0007366726149322057
grafts,0.001265602429172303
and,0.0014078209282551454
44,0.0011582126258141525
with,0.0010925721814542245
occluded,0.001266885370270241
grafts,0.001162460839052242
one,0.0013506718182943749
year,0.00184038484882944
after,0.0009229077648662698
bypass.,0.0008753692617335245
MAIN,0.001682125595644087
OUTCOME,0.002027323558664038
MEASURE,0.0020745919483329454
Cumulative,0.0029681757083530416
percentage,0.001496801190842497
patency,0.0015389594567326156
at,0.0030814699733265165
one,0.002254184559957811
year.,0.003151132907045827
RESULTS,0.09043142889763922
Markers,0.03597843887058507
for,0.05464567929898052
smoking,0.09186571381824472
(blood,0.06086311234493406
carboxyhaemoglobin,0.09253020899373568
concentration,0.06906047254706557
(p,0.06522565162553398
less,0.056264481684356105
than,0.08589063833716858
0.05),0.04174308009173786
and,0.03679212008513939
plasma,0.07592838367008191
thiocyanate,0.07969042838710283
concentration,0.06739517395612848
(p,0.0701790598914793
less,0.06654218669597659
than,0.09575832284174235
0.01),0.053002902488530325
and,0.03223152489186775
plasma,0.05636573121716928
concentrations,0.04766932840582803
of,0.07435404333818833
fibrinogen,0.08892075749133428
(p,0.06105041494063235
less,0.05967002841491242
than,0.08188963211237331
0.001),0.046319618513285934
and,0.03041052322258164
apolipoproteins,0.6511325481470627
AI,0.5933424528529686
(p,0.4879670957332628
less,0.41531435426555235
than,0.41173511663810936
0.04),0.3340667798938447
and,0.5495415921290635
(a),0.45152381826128113
(p,0.435831268272679
less,0.44189669014038724
than,0.41770151277634543
0.05),0.3571514421595018
were,0.5319556421517012
significantly,0.5329500135612836
higher,0.5359679069786154
in,0.5246612625278578
patients,0.5495398718029194
with,0.4883227016623362
occluded,0.5392033001521184
grafts.,0.5361522748017474
Serum,0.2583086764201353
cholesterol,0.31082834998908393
concentrations,0.3085386948757209
were,0.3144834630151927
significantly,0.27992003750816763
higher,0.2795429110827003
in,0.29493605992985666
patients,0.33851913938191797
with,0.2299667091448427
grafts,0.24311694176114906
that,0.281473639801272
remained,0.26386238429975273
patent,0.20599095461311748
one,0.2045274462873045
year,0.19004431870222913
after,0.2143978345842801
bypass,0.31441967697305595
(p,0.1966630922804284
less,0.2154786909893891
than,0.21277032344847172
0.005).,0.15410435459761684
Analysis,0.017078174364895116
of,0.010795130648389382
the,0.021873667600918235
smoking,0.020358969802417762
markers,0.013640716220661656
indicated,0.024374623782983048
that,0.018188579081805965
a,0.014337473481527205
quarter,0.012165086847078307
of,0.014452864216345685
patients,0.012837187307895709
(40),0.018712865061751238
were,0.019646348119389884
untruthful,0.016283457663244356
in,0.04263340416341357
their,0.015082510045570385
claims,0.023123712233242482
to,0.01239649299754648
have,0.01445632517836693
stopped,0.01754885613649467
smoking.,0.02344534679118401
Based,0.2613715838375408
on,0.27298478440559487
smoking,0.2118024655464382
"markers,",0.19791597662548613
patency,0.20573397656937983
of,0.2278883975781007
grafts,0.26590007704320745
in,0.22935727666492017
smokers,0.17357283917649166
was,0.2087284882431501
significantly,0.21127964987922285
lower,0.20827933155015124
at,0.23491365683974405
one,0.22613481469131658
year,0.1832467122078656
by,0.31979354482756694
life,0.2325081305526141
table,0.31478729523285764
analysis,0.4811601672706016
than,0.49950911329998543
in,0.4759704892098634
non-smokers,0.4440614744039583
(63%,0.4836801298165359
v,0.561588139282079
"84%,",0.5917737537042298
p,0.49318323055988816
less,0.4876803412482886
than,0.45966725895016736
0.02).,0.41415698231170206
Patency,0.22081809511645287
was,0.25698916917576364
significantly,0.2933635198148209
higher,0.2523360029065823
by,0.3128440503574282
life,0.30563320531908283
table,0.27441897918395486
analysis,0.29428927709350294
in,0.3514283862664566
patients,0.4160319618857388
with,0.35552622790397737
a,0.3381047084826838
plasma,0.4045131006810315
fibrinogen,0.3712762717258656
concentration,0.34926429085958366
below,0.39517312006034117
the,0.35949460635148384
median,0.38038283808472834
than,0.438855911644654
in,0.38574218550785316
those,0.4020182394507168
with,0.3905238444970864
a,0.3624186523130014
concentration,0.3607449834105888
above,0.3928148491670844
(90%,0.40491473865368954
v,0.4919014652701679
"57%,",0.45594883949128656
p,0.4107610911190301
less,0.4355277629925487
than,0.4263779851167347
0.0002).,0.3779221986980505
"Surprisingly,",0.7771390057483544
increased,0.8872873585115671
plasma,0.8753831741802454
low,0.867906162575871
density,0.8743287184616069
lipoprotein,0.8436705584207519
cholesterol,0.8795419745389516
concentration,0.8589721903130995
was,0.8755379461715561
significantly,0.870772158515472
associated,0.9004795335308053
with,0.891847305277913
improved,0.8809144112952904
patency,0.8221709352710275
at,0.8328386786527092
one,0.8544879458110287
year,0.8695470728607748
(85%),0.8192741694442526
at,0.8234530912646504
values,0.8279010141410714
above,0.8071776523931073
the,0.8324309132481535
median,0.8737914797399573
compared,0.8687888940991313
with,0.841500902030856
patency,0.7957529091481437
(only,0.8019555175555941
68%),0.8054626938618709
at,0.7903976934330089
values,0.792600844047564
in,0.7653952421667222
the,0.8176363589735081
lower,0.7641329746748698
half,0.7247771483756984
of,0.7697622871696386
the,0.818950072285689
range,0.8094739511067031
(p,0.7942356334467792
less,0.7333061214605608
than,0.7708453379761397
0.02).,0.3334156478658072
CONCLUSIONS,0.7002920246133738
Plasma,0.3988362156519339
fibrinogen,0.42961432817095496
concentration,0.3282870440430788
was,0.34069059562086756
the,0.27250196315427166
most,0.24706975897896571
important,0.2941692843339689
variable,0.24457445330980218
predicting,0.2572797773472701
graft,0.4012188997600679
"occlusion,",0.2947374735631188
followed,0.2324912457972298
by,0.22745913086003267
smoking,0.3522379430045671
markers.,0.27816210578718864
A,0.07362469688410149
more,0.06264692512994487
forceful,0.08719864079097253
approach,0.0676369967776671
is,0.04901175822162401
needed,0.03707548113586354
to,0.06101550526847985
stop,0.07135478694384534
patients,0.10720245921013195
smoking;,0.1436604518303892
therapeutic,0.1918995089581297
measures,0.16728682571466588
to,0.12912396923838282
improve,0.2716437477037138
patency,0.2508376108797857
of,0.26339086409946927
vein,0.29453653759707754
grafts,0.2671939373710149
should,0.14630377315373042
focus,0.21977784451614915
on,0.3164236830587921
decreasing,0.33875252927347543
plasma,0.39783365847693225
fibrinogen,0.3889092311608996
concentration,0.4527823413185509
rather,0.42700529099041334
than,0.4133845255824425
serum,0.363830857293642
cholesterol,0.47441479871781567
concentration.,0.4483251229364119
CONTEXT,0.03001407091812426
Population,0.012048037157511196
surveys,0.014110654402270302
indicate,0.009625969134017115
that,0.009518321945953128
physical,0.007525773792489484
activity,0.00810961134261412
levels,0.00668647423705756
are,0.007627368689950995
low,0.006207179709309917
in,0.006716892502345629
the,0.004270887983033838
United,0.0050756369486006665
States.,0.005286419057820282
One,0.1216066367657181
consequence,0.1864425910416049
of,0.30209405650972565
"inactivity,",0.23396739528818283
low,0.3754151961817587
cardiorespiratory,0.222913352569611
"fitness,",0.2177280799198886
is,0.08414541105330212
an,0.09208578907730564
established,0.054662937410827596
risk,0.03765468735373858
factor,0.0645833298538705
for,0.07284533667793174
cardiovascular,0.026205090992587506
disease,0.022891773203406057
(CVD),0.03177291072344924
morbidity,0.041274280214883254
and,0.03249276769419898
"mortality,",0.03230498939485138
but,0.01697339133424797
the,0.004720660589920153
prevalence,0.004483780616299008
of,0.00417310681104675
cardiorespiratory,0.005955406166607632
fitness,0.005169619028087028
has,0.002152247825725046
not,0.002164879105561203
been,0.002063782281482284
quantified,0.0018770215014390875
in,0.0020127189639308333
representative,0.002303907709819331
US,0.003640861459944547
population,0.0020716640314208893
samples.,0.0023341824602020997
OBJECTIVES,0.002050223469501429
To,0.0031125795676447752
describe,0.0023780168144577796
the,0.0017752444770375022
prevalence,0.0025894838142866855
of,0.003304940692099547
low,0.00277493713277881
fitness,0.0035658442465037734
in,0.0032419902745182846
the,0.0025727480670666705
US,0.002379454475900393
population,0.002587782965022168
aged,0.0019959147115523315
12,0.0024877629824373946
through,0.0040652871009014815
49,0.0028902652898718404
years,0.0013741715664559151
and,0.0019928116628726267
to,0.0017198498647699413
relate,0.0015946139069240028
low,0.0022481423934740544
fitness,0.0027941620281809625
to,0.002911194004897795
CVD,0.0027251031380984368
risk,0.001378253262118683
factors,0.0016781909035800983
in,0.0024953838560304907
this,0.002211872558109828
population.,0.0023438519967444874
"DESIGN,",0.0016582245661611805
"SETTING,",0.0015404127265339002
AND,0.0008300280326631155
PARTICIPANTS,0.001546775173169669
Inception,0.0012066190198845896
cohort,0.0008850656057478148
study,0.001261236312395413
using,0.0010180309342461996
data,0.0006949495828021492
from,0.0008549846504562973
the,0.0010593715113971537
cross-sectional,0.0006771981053620301
nationally,0.0006594185058595693
representative,0.0008008313130968054
National,0.0007062034798920689
Health,0.0009100504430065945
and,0.0013634523295493184
Nutrition,0.0009329037308879843
Examination,0.0006283088214653722
Survey,0.0008682518764407535
1999-2002.,0.0009355195144055324
Participants,0.003390471998154292
were,0.005244608671374105
adolescents,0.004192180268626579
(aged,0.004922715002851892
12-19,0.002847740238883734
years;,0.002009013741053564
n,0.002484602008492626
=,0.007634130023746249
3110),0.002568881863065212
and,0.0038883835904213846
adults,0.004565875390008924
(aged,0.004889051206439094
20-49,0.0033762682001699635
years;,0.0025959186961231565
n,0.0034964004715110986
=,0.00872561447147838
2205),0.004404244586404395
free,0.008525009512408272
from,0.021416981975420205
previously,0.010303470659640915
diagnosed,0.007984928943271248
CVD,0.01254510953714484
who,0.005041399079957407
underwent,0.005039145302993168
submaximal,0.013798368407278825
graded,0.0096221491093529
exercise,0.009123619719022997
treadmill,0.006905741052025647
testing,0.009623317000361904
to,0.013876737976026345
achieve,0.0211026133580836
at,0.011545289108609934
least,0.011606580982521639
75%,0.04796610002061995
to,0.027776947804233502
90%,0.03709192935438472
of,0.03433453948994509
their,0.007106355104012036
age-predicted,0.01580092040889965
maximum,0.008674327099188773
heart,0.0113929747721693
rate.,0.01105883588344502
Maximal,0.037666741350441034
oxygen,0.04472838426012075
consumption,0.04198680549122227
(VO2max),0.028356643631495072
was,0.02582251371686781
estimated,0.018123893388075654
by,0.0320149694873688
measuring,0.03001702104060141
the,0.0013572540140359647
heart,0.000612472154567954
rate,0.0007434474130385334
response,0.0008833624791677719
to,0.0011681424817811164
reference,0.0008929617826756223
levels,0.0008535137896730618
of,0.0012712909968958922
submaximal,0.0009424202166927345
work.,0.0010644565338149227
MAIN,0.0015718054356942154
OUTCOME,0.001399374037201687
MEASURES,0.0009967349313065254
Low,0.0010511656239095856
fitness,0.0010114278857283508
defined,0.0009223453776381997
using,0.0011747128790529355
percentile,0.0009046734359532959
cut,0.0010729801893644972
points,0.0009989756816863801
of,0.001317780588190967
estimated,0.0008876103797374792
VO2max,0.0010720532206777292
from,0.0013191154101641765
existing,0.0008596153508154335
external,0.000696751036355926
referent,0.0008741537991130876
populations;,0.0007506263117869465
anthropometric,0.000724453884705182
and,0.0012570890707702175
other,0.0008234092368239111
CVD,0.000937525852856655
risk,0.0006171113969748647
factors,0.0006982657935350802
measured,0.0007622160109487875
according,0.0009110051886694388
to,0.0009421959890893615
standard,0.0008028819570097942
methods.,0.0006338124735534345
RESULTS,0.4077520429282456
Low,0.2939447111616277
fitness,0.36799503340320167
was,0.3298989700592006
identified,0.31175037851827336
in,0.3401562722274648
33.6%,0.34607409068319606
of,0.37505009827287605
adolescents,0.3434234392988198
(approximately,0.32394519332566446
7.5,0.3677081742648662
million,0.23118238334052557
US,0.2908172989437782
adolescents),0.32594042770727244
and,0.38271500931479985
13.9%,0.3758787504738396
of,0.35228834541824394
adults,0.31752164572264674
(approximately,0.2902053028778644
8.5,0.4306360040497241
million,0.23797590747463854
US,0.2949734685541102
adults);,0.30083441369742187
the,0.36599716360364404
prevalence,0.32762458918438775
was,0.3236616403255138
similar,0.35565662933573006
in,0.3907283531102024
adolescent,0.3978560077951259
females,0.40414518807586486
(34.4%),0.37209649525585686
and,0.41030708535417465
males,0.4030997254193464
(32.9%),0.41382331265197425
(P,0.4863045358038965
=,0.57159225608533
.40),0.5455391683556238
but,0.5839689535790519
was,0.5552304336005006
higher,0.5551399280483695
in,0.5395054135910544
adult,0.49586147953071247
females,0.43672878010889926
(16.2%),0.4317941553745956
than,0.5672670755270245
in,0.48436511579585106
males,0.41246942559983635
(11.8%),0.38016157816979895
(P,0.390553284274513
=,0.4874971221989241
.03).,0.431558046785306
Non-Hispanic,0.2578145374449786
blacks,0.2251526270295343
and,0.29765455266292934
Mexican,0.21446636574697003
Americans,0.2529972178053281
were,0.24077240570940686
less,0.2576832349930429
fit,0.2693767521080228
than,0.2629921894354757
non-Hispanic,0.23791066025292726
whites.,0.17330690697448495
In,0.23202248919742421
all,0.176117386859595
age-sex,0.16676125665812494
"groups,",0.16846123973596772
body,0.2916832277566823
mass,0.3030116565524612
index,0.22462895149511958
and,0.133726601065428
waist,0.21054689475796723
circumference,0.16721040185637462
were,0.14004821708792098
inversely,0.09801578574200007
associated,0.1400488703298158
with,0.13442190755439698
fitness;,0.27487809665914287
age-,0.19982396157031374
and,0.15332020523118836
race-adjusted,0.1754069155752155
odds,0.24754899055608795
ratios,0.20756513568948767
of,0.22893493830313288
overweight,0.2826215257993047
or,0.1747794899530055
obesity,0.2687185085476525
(body,0.1788877712869177
mass,0.3539262329846556
index,0.28182304174699585
>,0.25349868813390847
or,0.1640422946224241
=25),0.1855514457802433
ranged,0.1770207183673375
from,0.16086788570231625
2.1,0.30165510892789826
to,0.19621490265642044
3.7,0.2876477921504179
(P<.01,0.2592409568998194
for,0.28138420774788175
"all),",0.35643528635400495
comparing,0.38215915415235924
persons,0.3265935543637707
with,0.2894868885591464
low,0.26814803176939694
fitness,0.3153345316969248
with,0.2373496181766887
those,0.3010421333512685
with,0.27548603568926383
moderate,0.31682513645227073
or,0.2449596690177747
high,0.2330676021525119
fitness.,0.2866950475053608
Total,0.6467773784365369
cholesterol,0.6751925359202262
levels,0.6410556692037186
and,0.6122155482040869
systolic,0.62169138193079
blood,0.7283895367118528
pressure,0.6597005992375017
were,0.5265431522357141
higher,0.6045405099359099
and,0.6053914693018405
levels,0.5643570870806366
of,0.5967749424263904
high-density,0.6044265667520151
lipoprotein,0.6397998454549404
cholesterol,0.6053491819136463
were,0.5045237871390414
lower,0.5743336572925054
among,0.5704630337579634
participants,0.5878555183695012
with,0.5441196444854202
low,0.5711703553583736
vs,0.5843417524804707
high,0.5253893175504112
fitness.,0.5832795554635987
CONCLUSION,0.7384823191355645
Low,0.48209547120422724
fitness,0.4784548544533289
in,0.5301919153621444
adolescents,0.4438675052109304
and,0.5074290697621903
adults,0.4231311821723351
is,0.43444466844326257
common,0.4439840840537992
in,0.42197258855916686
the,0.4953725315818977
US,0.4084814943034416
population,0.4366185332395553
and,0.5908923138033223
is,0.46982198871615183
associated,0.5985328454100343
with,0.5656124132754096
an,0.5883471214805559
increased,0.5546596598702787
prevalence,0.47210701636387375
of,0.5464634367436334
CVD,0.5888706559173369
risk,0.49879175659757524
factors.,0.536834911260318
CONTEXT,0.03732289950070349
Although,0.016308017151136004
acute,0.023726637933633127
hypoglycemia,0.03614248046922929
may,0.012196381905446344
be,0.014258204830919594
associated,0.02316120437925128
with,0.026137897463633143
cognitive,0.012251830907691883
impairment,0.01397374367042636
in,0.028961621696907185
children,0.010609551667399924
with,0.005627425334832048
type,0.0070404021979858355
1,0.0072573786614500745
"diabetes,",0.00956168179898223
no,0.0019020807374033615
studies,0.0013459116736751781
to,0.0014375017057389583
date,0.0012171677006967562
have,0.0013669856123536398
evaluated,0.0010841532942692934
whether,0.0012733514210302743
hypoglycemia,0.0032649407488062015
is,0.0011913191154398262
a,0.0009701504946802745
risk,0.0009734062765067951
factor,0.000876793995875741
for,0.0014045306431133301
dementia,0.001315944120261297
in,0.0012943483106799475
older,0.0012325311732206494
patients,0.0012468632903028041
with,0.0013934833491004743
type,0.0014813757162019945
2,0.0021884410223182616
diabetes.,0.0016869225018400266
OBJECTIVE,0.0023479504642818223
To,0.0009995121342472207
determine,0.0009131147212463833
if,0.00104176203809493
hypoglycemic,0.0012862030883600182
episodes,0.001430623194325807
severe,0.0015014460207418826
enough,0.002881909150958053
to,0.0021622833632981863
require,0.0013253650850882995
hospitalization,0.0009879196757433028
are,0.0012159069601328943
associated,0.001019777245768033
with,0.001358410109078221
an,0.0010658182774380132
increased,0.0012226956071689913
risk,0.0007777372375327272
of,0.0017295242264738545
dementia,0.0014632221570564578
in,0.0012534731993877513
a,0.0013011879329780155
population,0.0011585442083497765
of,0.0014274305741709087
older,0.0009065456570806508
patients,0.0009314904088957524
with,0.001031241476883004
type,0.0011323462167173613
2,0.001899396729907158
diabetes,0.0011444518212007598
followed,0.0011501299015858222
up,0.00150848317718689
for,0.0013822763054989037
27,0.0010526038881006562
years.,0.0011941964029701282
"DESIGN,",0.002731399981039338
"SETTING,",0.008593643362576162
AND,0.0030301389583483706
PATIENTS,0.0034893284491772786
A,0.005997662893257181
longitudinal,0.0027427776682035308
cohort,0.0035279792746734408
study,0.005271953327211144
from,0.0035579635963963415
1980-2007,0.0017960307506712987
of,0.0010802917968647577
"16,667",0.0009150981208125773
patients,0.0007564088922682256
with,0.0009210044160325041
a,0.0010214156100713662
mean,0.0008372133886414073
age,0.0009319666801511715
of,0.001253221608752811
65,0.001222967577936149
years,0.0010981924261622281
and,0.001048887618889203
type,0.000896926504451986
2,0.0012590653443497295
diabetes,0.0006632632438871252
who,0.0010197952194828325
are,0.001140348642550349
members,0.0007470605479902061
of,0.0011150002319718065
an,0.0009024122647909901
integrated,0.0006552187601452437
health,0.0006591414150453544
care,0.0008874243364493309
delivery,0.0007016483007990954
system,0.000762161718085951
in,0.0008277909687808059
northern,0.0008401709078220387
California.,0.0008411860503169229
MAIN,0.0010813183299269381
OUTCOME,0.001346190821898061
MEASURE,0.0012194453774815105
Hypoglycemic,0.0011246119837827384
events,0.0009328337360750129
from,0.0014855069243321583
1980-2002,0.0011429053478912764
were,0.0010845347257122271
collected,0.0006350199444730746
and,0.0020202474593984786
reviewed,0.0007713803466483473
using,0.0011981697877580142
hospital,0.0006785597904660903
discharge,0.0006652742057583432
and,0.00122001582467137
emergency,0.0008058511314240139
department,0.0010215820242041648
diagnoses.,0.000808225511632041
Cohort,0.001797775115402555
members,0.0013388643749268278
with,0.002097324460365376
no,0.0016471423279074279
prior,0.0011530464832720257
diagnoses,0.0011696361569315885
of,0.002046118271845502
"dementia,",0.0014480357053550245
mild,0.0011253750130964621
cognitive,0.0009508511541253934
"impairment,",0.001208000157813676
or,0.0015107174013662722
general,0.0008947198441512805
memory,0.0008279785247094901
complaints,0.0010570331954295345
as,0.0014126184328763273
of,0.0018568933044933308
January,0.001007603623162889
"1,",0.0018944259048688193
"2003,",0.0012612882693281734
were,0.0018288193328543497
followed,0.0008696586144871903
up,0.0017633379069218122
for,0.001559023593818588
a,0.0011284626725661768
dementia,0.001602484454604544
diagnosis,0.0009255925500708433
through,0.0013171679389186886
January,0.0012142174958860589
"15,",0.0016372279638049677
2007.,0.0016356706571953863
Dementia,0.015476787173309692
risk,0.004602627580030955
was,0.003520679658814893
examined,0.0021045743209774054
using,0.0023032523602900218
Cox,0.004925039648134484
proportional,0.004614876456202941
hazard,0.008522930084291011
regression,0.005143647831275263
"models,",0.00397258110892727
adjusted,0.0028525816507758294
for,0.0037694369858976
"age,",0.0015601652070966797
"sex,",0.002613075058992375
"race/ethnicity,",0.0028370403874675215
"education,",0.004545259409296448
body,0.005884271269564821
mass,0.00534537627384607
"index,",0.004941685098205241
duration,0.003020823115796839
of,0.0048464283579065385
"diabetes,",0.0042186075602747425
7-year,0.00896961102798432
mean,0.0037644873368975523
glycated,0.0026860545931566703
"hemoglobin,",0.007381471750937958
diabetes,0.009727103452724886
"treatment,",0.004447764147958888
duration,0.004455793718417017
of,0.007988002207241445
insulin,0.005168059584696215
"use,",0.009327755779869709
"hyperlipidemia,",0.004269722144801292
"hypertension,",0.005753415107709901
cardiovascular,0.004979039328692351
"disease,",0.0034807834279658076
"stroke,",0.0025064561616065526
transient,0.003520899649435819
cerebral,0.007732233901883854
"ischemia,",0.014686402773499538
and,0.0036726076444419773
end-stage,0.0029352112980640757
renal,0.003499137838887356
disease.,0.002970611618688495
RESULTS,0.3785920187957737
At,0.41512005082385767
least,0.30876707388307223
1,0.3976684305204464
episode,0.39885753401264024
of,0.38877604059489007
hypoglycemia,0.31778291201868614
was,0.3182749789755539
diagnosed,0.3925192516656892
in,0.286837091113655
1465,0.24751470218019964
patients,0.3541529286024932
(8.8%),0.3513432168504244
and,0.4117428253469758
dementia,0.2522874662494085
was,0.27487690268000387
diagnosed,0.3543962796407391
in,0.24143512636130998
1822,0.2761337823107397
patients,0.30474211135959195
(11%),0.26854354303183225
during,0.282022259648654
follow-up;,0.24765701671740406
250,0.15918543048309086
patients,0.2774339617648669
had,0.20588266589802687
both,0.32463954077138013
dementia,0.4571768708939385
and,0.4783975192806324
at,0.39818451651303044
least,0.37231211453872787
1,0.3431246588784416
episode,0.38938693340636366
of,0.44088180538929644
hypoglycemia,0.37109452714916724
(16.95%).,0.37844224102084767
Compared,0.833831028335556
with,0.7220309490032144
patients,0.7938623254071113
with,0.7383376318249305
no,0.7830108714643995
"hypoglycemia,",0.7215568547182272
patients,0.839080347675989
with,0.7520905251583926
single,0.6882597501977907
or,0.629355206265616
multiple,0.64159567800247
episodes,0.7339410970431373
had,0.793826438135521
a,0.8072841575530659
graded,0.7619578654178393
increase,0.8043960312732036
in,0.8395021912234425
risk,0.8443886833863493
with,0.816646061380231
fully,0.7597015636155661
adjusted,0.760809404010789
hazard,0.7638079909236736
ratios,0.7816781038210315
(HRs):,0.6689239021002844
for,0.8567816333726631
1,0.824687181923598
episode,0.8213685668531938
"(HR,",0.7745659255953409
1.26;,0.8298997174773993
95%,0.8730855514200626
confidence,0.8401302007782524
interval,0.8567760162063652
"[CI],",0.8152340425680955
1.10-1.49);,0.838345016507331
2,0.7943519934813849
episodes,0.7975571446914145
"(HR,",0.7669592931867649
1.80;,0.8139643422328495
95%,0.8604789552050252
"CI,",0.7947491273581094
1.37-2.36);,0.810512003383167
and,0.7681245396771827
3,0.7692017578133111
or,0.7415321112535646
more,0.7315172757504469
episodes,0.7649055342784796
"(HR,",0.7484187089807747
1.94;,0.7784313729497501
95%,0.8303750428337379
"CI,",0.40949526121534885
1.42-2.64).,0.41008098678055427
The,0.15548042887699035
attributable,0.12275365072685114
risk,0.18895531992676512
of,0.20453216897889756
dementia,0.10847556163038838
between,0.2895552689534295
individuals,0.19763015888175642
with,0.27483519859374045
and,0.24187401813082418
without,0.2316292466494784
a,0.21966230555579272
history,0.2807956021621883
of,0.2543724186056987
hypoglycemia,0.1727516033572137
was,0.2069455427867784
2.39%,0.32678653960193293
per,0.22045231690568923
year,0.15087022957638088
(95%,0.19688164763358373
"CI,",0.3501875394289708
1.72%-3.01%).,0.3677561173675576
Results,0.0054374542553521504
were,0.005710323877184038
not,0.00583781832489624
attenuated,0.00398744802979005
when,0.005068347222723135
medical,0.0034769044967576327
utilization,0.0030714076134982877
"rates,",0.004352122681152331
length,0.002711072404586793
of,0.004066082585384847
health,0.003300994276887456
plan,0.002894950981126747
"membership,",0.0032149275912211773
or,0.004319288314176962
time,0.0027433163849391634
since,0.004364623602703843
initial,0.0056015650724600945
diabetes,0.005058501794048951
diagnosis,0.004477464626294176
were,0.004648584733921263
added,0.002844079228457649
to,0.004551993604713782
the,0.003511867894303532
model.,0.004477259523885406
When,0.11211050827221339
examining,0.04008040931509562
emergency,0.04584177133816783
department,0.030434972338583527
admissions,0.0411589153593651
for,0.0367838576724263
hypoglycemia,0.05019753134860796
for,0.034333579053924076
association,0.052062616916977424
with,0.054252377233338256
risk,0.05447521621112568
of,0.07290957158506509
dementia,0.03642392673363012
(535,0.06467816912269256
"episodes),",0.0878044239518007
results,0.0877579599569443
were,0.10322957587381972
similar,0.10970104681952794
(compared,0.12649720784965823
with,0.13385171077507288
patients,0.10041815527761519
with,0.12384420013881142
0,0.09943725489546887
episodes),0.1093102980149767
with,0.15459420981742272
fully,0.1989762854021936
adjusted,0.16223093133813588
HRs:,0.1274114834092839
for,0.21603683657811532
1,0.1628634842969227
episode,0.21886152629621533
"(HR,",0.21651104911313707
1.42;,0.35668124406995333
95%,0.3559341877970131
"CI,",0.38722393260702553
1.12-1.78),0.4042098962401007
and,0.19899574226010708
for,0.2479551366857485
2,0.3268296036574322
or,0.19302817136634204
more,0.21336844163403065
episodes,0.21056704691184336
"(HR,",0.17724565405378817
2.36;,0.44553478081197584
95%,0.47413494146864016
"CI,",0.36370645876514
1.57-3.55).,0.588643470411463
CONCLUSIONS,0.7926887877701925
Among,0.7840645044018337
older,0.6924611010461534
patients,0.6658911779045936
with,0.6570442978487835
type,0.7502721714322279
2,0.7128146044321776
"diabetes,",0.5983078901874201
a,0.7292521208762492
history,0.6636879755698153
of,0.7687374212816719
severe,0.7166664849646587
hypoglycemic,0.7093865201400278
episodes,0.7135770785193265
was,0.6515063783646216
associated,0.7430885058846555
with,0.7307807656509587
a,0.6819059781184712
greater,0.731788541837521
risk,0.7122634145040286
of,0.7424661910502803
dementia.,0.611648194333949
Whether,0.035248088317770335
minor,0.0950680692356489
hypoglycemic,0.19818037243135753
episodes,0.19085526849571963
increase,0.07943018161541408
risk,0.08456976969752197
of,0.1525917442867884
dementia,0.07949165175475971
is,0.012116162427494174
unknown.,0.018843322757205017
Background,0.09908158765810922
Checkpoint,0.08735593593527073
kinase,0.1370458818768253
2,0.1517440036321447
(CHEK2),0.14136323618215102
averts,0.23268305370458425
cancer,0.16414373945519195
development,0.2879363278930251
by,0.48663426174196134
promoting,0.38281900825957255
cell,0.34680062416095436
cycle,0.28820411434514837
arrest,0.4020017344240735
and,0.48033688291034027
activating,0.3833091244165102
DNA,0.23515798359441548
repair,0.292106900261712
in,0.30111792862009434
genetically,0.2060609212091703
damaged,0.15851961773048878
cells.,0.2218323227234536
Previous,0.0066098954856060954
investigation,0.005717513669984948
has,0.004562826016138172
established,0.004884841262604619
a,0.0037416904113773525
role,0.003997395145998857
for,0.0037402962205314626
the,0.006931731790074423
CHEK2,0.015559922216955404
gene,0.007433011564755755
in,0.00350371735074615
breast,0.006864054061615914
cancer,0.0044254421488212625
"aetiology,",0.00304242674645133
but,0.0028920481786749064
studies,0.0037353642859176217
have,0.0027772413107616575
largely,0.002020515702996742
been,0.0029415152752892883
limited,0.0020243417978373234
to,0.0029865366407722986
the,0.0041426480795126236
rare,0.004321547749707851
1100delC,0.05146087425020819
mutation.,0.008183763675991116
Whether,0.003545403103674602
common,0.0033176886718686784
polymorphisms,0.003224253862230733
in,0.005598774231916844
this,0.00735129274855253
gene,0.008728431882358167
influence,0.0043696306563065545
breast,0.008670174417734587
cancer,0.004378318942968694
risk,0.004278930752142417
remains,0.0026004635817053045
unknown.,0.00261971853869557
In,0.011572207333476092
this,0.012795484365685969
"study,",0.007919113317523575
we,0.014477138720892286
aimed,0.007435152568270793
to,0.004658216386264253
assess,0.004292935148373234
the,0.002902934183910436
importance,0.003293002062901244
of,0.00617160465849789
common,0.00928593808281339
CHEK2,0.028273329327591842
variants,0.016491937453030694
on,0.007045897917937595
population,0.010077922588583388
risk,0.00763322154701362
for,0.009214083363595688
breast,0.025621916117242675
cancer,0.012474156464102137
by,0.014899954720872277
capturing,0.009760680200703736
the,0.012119764348396764
majority,0.01161604005291763
of,0.013162745713331328
diversity,0.013650095909462806
in,0.01353536033182551
the,0.013317231952637969
gene,0.013699753791837873
using,0.013947510609537368
haplotype,0.01751020334883915
tagging,0.00687041672806602
single,0.004107598707955437
nucleotide,0.00485921566788901
polymorphisms,0.004597137658756058
(tagSNPs).,0.0028304132172059784
Methods,0.007781894725855321
and,0.003870416708895108
Findings,0.005127220613446511
We,0.02426280141956313
analyzed,0.013825374810177845
14,0.009162598228403002
common,0.010948779793003084
SNPs,0.015423560020620914
spanning,0.01591412638188482
52,0.013105177480570407
kilobases,0.008028526759680212
(kb),0.012825862238289371
of,0.032275472490107086
the,0.020936471207872523
CHEK2,0.02337073805230324
gene,0.04327341838903862
in,0.01306449669540544
92,0.004626490184274093
Swedish,0.014750884202709409
women.,0.012426842562868889
Coverage,0.009343859256379206
evaluation,0.010700146151986388
indicated,0.01906703763064455
that,0.017203579773973403
these,0.014546925477836427
typed,0.011382446297872932
SNPs,0.010170627390586823
would,0.02179340715116186
efficiently,0.016939388360060766
convey,0.01513622201585899
association,0.014833516147497545
signal,0.017165179454352253
also,0.020577416536247065
from,0.012963557228109941
untyped,0.006325477360095997
SNPs,0.007480173873004772
in,0.006313091740004278
the,0.004679101343431152
same,0.006563260463793244
region.,0.00635475162685805
Six,0.007531549282428122
of,0.009517746540602506
the,0.00893379951048416
14,0.00616687577652473
SNPs,0.009114145172093113
predicted,0.010808711687160385
well,0.008134521186458544
both,0.012013965148544333
the,0.010173508039205529
haplotypic,0.00812536590394429
and,0.012212710675854412
single,0.004685039990807994
SNP,0.007583795212819623
variations,0.008516807559051692
within,0.007100884846332865
CHEK2.,0.012892219170131317
We,0.16162439527829742
genotyped,0.15808916329653738
these,0.1527539925525891
six,0.1400736236163812
tagSNPs,0.1531942352803361
in,0.2142794047472814
"1,577",0.2049670323202057
postmenopausal,0.25849672958079484
breast,0.22169594987761157
cancer,0.231163812657196
cases,0.26096632997333835
and,0.17770324409856625
"1,513",0.12240195749145909
population,0.0638316863843653
"controls,",0.061231321373030126
but,0.09500476496085215
found,0.12795344325028343
no,0.08008713101107692
convincing,0.0539447040222277
association,0.08024630044887206
between,0.041094426364592124
any,0.07138073226582994
common,0.05711925390480609
CHEK2,0.09000587252770757
haplotype,0.0854752814317936
and,0.03339954868483509
breast,0.09801510596974515
cancer,0.059282799774646136
risk.,0.05324288116954646
The,0.7586762727704109
1100delC,0.5528218648461066
mutation,0.7196763059503143
was,0.6913584024270445
rare,0.6991066348477172
in,0.7338075403777641
our,0.6814841867794842
Swedish,0.6267641978476168
population—0.7%,0.7339709444275861
in,0.6943222480366457
cases,0.7712744695317021
and,0.7505421661356563
0.4%,0.6998205983518744
in,0.7400510017715042
controls—,0.7448674017801548
with,0.6833737478952209
a,0.6623218783689893
corresponding,0.6276741649433718
odds,0.6752996236051335
ratio,0.6366526919556025
for,0.6388721556530655
carriers,0.6734717309608209
versus,0.6431725437251323
noncarriers,0.6937684674652268
of,0.6302794735186172
2.26,0.6841477172276467
(95%,0.5545039859900368
confidence,0.6296369264070815
"interval,",0.6576763870171725
0.99–5.15).,0.5188393588942171
Estimates,0.1290184735260137
of,0.12323583412182955
the,0.1046683850659992
population,0.14638799119670487
frequency,0.12074747569848678
and,0.10341151787830437
the,0.06463323404032151
odds,0.09641634001042246
ratio,0.099371664793944
of,0.10772517503954965
1100delC,0.2183435734362961
indicate,0.13905869868877851
that,0.12955308580974517
our,0.22012366934411323
sample,0.18809934416565974
is,0.12315873336647656
representative,0.12511403304756574
of,0.15034268789922503
a,0.1431662703029522
Northern,0.09336419280097391
European,0.14357941530233198
population.,0.16878513259180822
Nuclear,0.005525584614977805
receptors,0.009931224796138328
undergo,0.012344838429006796
ligand-dependent,0.008606242363150518
conformational,0.00401205158326224
changes,0.010160354854446106
that,0.013799753831959007
are,0.011388751490313279
required,0.010911770842700544
for,0.013570755981902674
corepressor-coactivator,0.020451190331958847
"exchange,",0.014391137494496553
but,0.002833809420867138
whether,0.0015387165845882262
there,0.0016797758310070983
is,0.0015442961630224251
an,0.0013684141908708145
actual,0.0015945843000104711
requirement,0.0022956986144310487
for,0.002030280234837179
specific,0.0015162208715290902
epigenetic,0.0015428950617955833
landmarks,0.0018805714616767937
to,0.0018826907648474569
impose,0.0026602907878669007
ligand,0.0016046044256946596
dependency,0.0016103048563568222
for,0.0029446824742378934
gene,0.0026248223638758892
activation,0.0026714810488581717
remains,0.0012460245194827325
unknown.,0.0014863845796402948
Here,0.4694319890050327
we,0.5378544009777873
report,0.37589420431211146
an,0.308584104715346
unexpected,0.24665447534738708
and,0.2476730092967555
general,0.20566686739972223
strategy,0.27281542048697405
that,0.2860317667494718
is,0.274483077359206
based,0.298540464357014
on,0.2642618993205792
the,0.2951313700340925
requirement,0.2762768448256726
for,0.2599731473510824
specific,0.2323543486524756
cohorts,0.3092106040322315
of,0.2596301107270009
inhibitory,0.26853021951913264
histone,0.3047887606098455
methyltransferases,0.2795180808707372
(HMTs),0.2310242798871826
to,0.2794938881676622
impose,0.3760718782341375
gene-specific,0.3675346059488773
gatekeeper,0.431429873143012
functions,0.4318236035363008
that,0.3787717946127424
prevent,0.4032164446676855
unliganded,0.3878344718112531
nuclear,0.35057034684629823
receptors,0.34577123543449423
and,0.4538975287889297
other,0.3536875718756257
classes,0.2799464454787431
of,0.37603671173819464
regulated,0.3877306508147694
transcription,0.46467848032097486
factors,0.4718940595027948
from,0.48597385304210516
binding,0.4800833941926822
to,0.4972560643944505
their,0.2767716008524026
target,0.333454172406736
gene,0.4739400953860651
promoters,0.49673593955855344
and,0.5435166349020464
causing,0.43400458574158435
constitutive,0.4177395917424519
gene,0.4291887935066812
activation,0.45631397491930054
in,0.4263714596111061
the,0.42423855003221844
absence,0.41057046438840544
of,0.469173532089525
stimulating,0.4451940740423333
signals.,0.4516815486424105
This,0.40957001958738204
"strategy,",0.4022880004631225
based,0.4506428865053359
at,0.5167703655674503
least,0.49382515912652086
in,0.5749290738109188
part,0.5256694800547467
on,0.3380354562887202
an,0.3831909236063589
HMT-dependent,0.4600566737541709
inhibitory,0.3641904179740118
histone,0.4274755859387291
"code,",0.4491029794506148
imposes,0.48734428651947453
a,0.5120354809069746
requirement,0.4503747556180812
for,0.43834518195902705
specific,0.39597571125503345
histone,0.4641988509360679
"demethylases,",0.45648273567151393
including,0.42091099431281714
"LSD1,",0.488399504613292
to,0.42339556618680285
permit,0.5390282050785591
ligand-,0.49483556925524164
and,0.5275611581131119
signal-dependent,0.4878462751962747
activation,0.5275136550125297
of,0.5055619903327049
regulated,0.5169940932935166
gene,0.5023302527930333
expression.,0.5315232717760704
These,0.1188576387583755
events,0.11250493777372705
link,0.0989987611814718
an,0.1031936440130722
inhibitory,0.05731125750131219
methylation,0.04696335514729161
component,0.10594889125406914
of,0.09165838297667932
the,0.08975844228218582
histone,0.07652904692820808
code,0.09979144977150563
to,0.0753882446243163
a,0.09086562071465486
broadly,0.04290910149516032
used,0.06432980442018002
strategy,0.08141722266824652
that,0.10629689799643856
circumvents,0.0853352352870562
pathological,0.056353317648066406
constitutive,0.06124648747624099
gene,0.11455123791052949
induction,0.110097113413218
by,0.09689174830303031
physiologically,0.07242459856128643
regulated,0.08638533520091016
transcription,0.08788887011969704
factors.,0.07660919260894307
OBJECTIVES,0.001305657663612001
To,0.0008537346235808951
carry,0.0011858560823236027
out,0.0009377945380835379
a,0.0010163280342312011
further,0.0008853787426214915
survey,0.000906634197369742
of,0.0011110080844175209
archived,0.0008817579809808635
appendix,0.0007113721813173976
samples,0.0007974105055379268
to,0.0008455825297762707
understand,0.0008708672098988759
better,0.001072569864215682
the,0.0007301198698688362
differences,0.0009336651243741943
between,0.0009666598874037848
existing,0.0009868933345850918
estimates,0.0010146086471569736
of,0.0010683714043393437
the,0.0008720621109844981
prevalence,0.0009730699169848845
of,0.001477257738427414
subclinical,0.001147086553002523
infection,0.0011758584302954279
with,0.0013090179956334817
prions,0.0012933670740677473
after,0.0013530562586731077
the,0.0015802495626764117
bovine,0.002115914317159007
spongiform,0.0019010743567526827
encephalopathy,0.004501710059225812
epizootic,0.0011996415333059712
and,0.0015588094718568366
to,0.0008569137429435388
see,0.0007513686395363864
whether,0.000744584505238922
a,0.0008226802573348592
broader,0.0007388663760048974
birth,0.0010498985948057898
cohort,0.0009848675390202826
was,0.0011677895226856131
"affected,",0.0010118630433546237
and,0.0014608612105244424
to,0.0007778246959245613
understand,0.0007656758203909295
better,0.0008833530101392827
the,0.0006576420572736281
implications,0.0006991245890692326
for,0.000799516581862151
the,0.0007820378157293223
management,0.0005807414555214279
of,0.0007866666354540967
blood,0.0005793468861066814
and,0.0011304859659791776
blood,0.0006383564629030877
products,0.0004816493773861841
and,0.0010132311756186087
for,0.0007504294469421832
the,0.0008318009881685992
handling,0.0006452218787630235
of,0.0007724289120502795
surgical,0.0005817903462991705
instruments.,0.0005227418883500712
DESIGN,0.0009534967721463261
Irreversibly,0.001732791589228216
unlinked,0.0015274475583346289
and,0.0018671464821849192
anonymised,0.0018155077598521897
large,0.001665922342756477
scale,0.0014695926348762772
survey,0.0019062000315248583
of,0.001323762627642097
archived,0.0011559858686074464
appendix,0.0009409557330051247
samples.,0.000883100540119106
SETTING,0.0037928274967412383
Archived,0.003864239951821807
appendix,0.002732296351808779
samples,0.0008408478672312819
from,0.0006954007519749514
the,0.0007855465433775628
pathology,0.0005337603766329515
departments,0.000566463199833114
of,0.0007198417794681051
41,0.000528340373121242
UK,0.0006142570566448536
hospitals,0.0005676337286187943
participating,0.0005323875966934695
in,0.0008350152558335392
the,0.000782937820747578
earlier,0.0005112063730466278
"survey,",0.0006496941888862245
and,0.0010276343268009619
additional,0.0006545188067684351
hospitals,0.0005507504544281061
in,0.0006623757126353863
regions,0.00046629869168089477
with,0.0007673392101632662
lower,0.0006302922595102776
levels,0.0006241320269560775
of,0.0007345334853648587
participation,0.0005366815070377371
in,0.0007729091671393217
that,0.0007848547976369669
survey.,0.0006027884487838391
SAMPLE,0.0029435367970874707
"32,441",0.0007877256422896817
archived,0.0010115078674551217
appendix,0.0011580741726512284
samples,0.0011261589421523177
fixed,0.0011737154540745578
in,0.001887175425379162
formalin,0.0012913911467100079
and,0.0031762981898864986
embedded,0.001134516951773145
in,0.0013739124660224684
paraffin,0.001278776030392174
and,0.0020922145135963384
tested,0.0006253008042935618
for,0.0007843712367866607
the,0.0008073883950731065
presence,0.0007672580479043496
of,0.0011209583388722163
abnormal,0.0009306886657397754
prion,0.00115921400721356
protein,0.0011292675752806137
(PrP).,0.0008320923223522819
RESULTS,0.1490706602795997
Of,0.22407043382375222
the,0.1495705343936631
"32,441",0.05403374283271413
appendix,0.10699249960732657
samples,0.16266902288277255
16,0.1279125865030599
were,0.19419170310720632
positive,0.17576931650981037
for,0.21358561290167186
abnormal,0.12993350322151034
"PrP,",0.1619914305566622
indicating,0.24437214565398455
an,0.22462562946846912
overall,0.19926452226625344
prevalence,0.18176808411202425
of,0.264899914156951
493,0.14767668677170917
per,0.2444618357929157
million,0.1465201551675043
population,0.1838566145760361
(95%,0.2667861054409732
confidence,0.273135285953069
interval,0.31228124390259104
282,0.26390435505312826
to,0.29450440589866483
801,0.20379351663927692
per,0.3269945827795971
million).,0.16808334405118358
The,0.2206391079376885
prevalence,0.23912546726897166
in,0.25968948135612546
those,0.32993380317336196
born,0.24893565217521565
in,0.1934158774399048
1941-60,0.23762692890787435
(733,0.3147887962310036
per,0.346573910811785
"million,",0.2468245901507063
269,0.154120703039903
to,0.08526743806331714
1596,0.03492777408311317
per,0.07282584697175364
million),0.04164644031926391
did,0.05833507408420684
not,0.0449864424901056
differ,0.028194443037344665
significantly,0.03339964105027717
from,0.0318886739270987
those,0.04504114156063972
born,0.026735223791304934
between,0.02085109271470492
1961,0.03531610109463838
and,0.01987583164260821
1985,0.0194753694003214
(412,0.040141495000632035
per,0.047990248753007246
"million,",0.026779513945712072
198,0.02107589903165523
to,0.036536268037629965
758,0.01973281368131746
per,0.034601094419914394
million),0.019665485347622268
and,0.05167835925889678
was,0.03071099139720412
similar,0.018869839386941846
in,0.03273368916226639
both,0.024196149245641136
sexes,0.014806009735365564
and,0.024556309008530505
across,0.018045634444667367
the,0.01407535779904407
three,0.013747931333460441
broad,0.010701054764031808
geographical,0.007797510122069303
areas,0.00815593231960507
sampled.,0.012407098977047615
Genetic,0.03163456859717537
testing,0.07558877220870967
of,0.06580346014501585
the,0.055311960289133696
positive,0.051559110565786145
specimens,0.04042038743354008
for,0.05445528858233607
the,0.04747004824476256
genotype,0.02445216087362751
at,0.04055781499501782
PRNP,0.07815795349531245
codon,0.03463781973735665
129,0.0427560303199322
revealed,0.10751163261344591
a,0.053803933964453536
high,0.0612380165040421
proportion,0.03454592574290539
that,0.04568221949658307
were,0.04724633274298121
valine,0.04093389349433217
homozygous,0.050308011047355945
compared,0.07535625110582146
with,0.04296463807801671
the,0.04421921558523095
frequency,0.02959093502526647
in,0.055568204906733455
the,0.04098567576769672
normal,0.060439252934926115
"population,",0.040118691614073956
and,0.13078162512315264
in,0.10244866517645551
stark,0.09642005290506514
contrast,0.07480151892642109
with,0.05149594454975832
confirmed,0.05934389209642669
clinical,0.048790736062050796
cases,0.05848218113869694
of,0.0651069149010967
"vCJD,",0.0670143867929441
all,0.0743684355598641
of,0.0627912710610416
which,0.07791965999930159
were,0.0771369845227937
methionine,0.0860757678558941
homozygous,0.10294835344522221
at,0.06063469119218816
PRNP,0.12263984410903986
codon,0.06654463025711037
129.,0.06655502002463233
CONCLUSIONS,0.6778966858051365
This,0.151062425383308
study,0.12080300293289978
corroborates,0.11141021536336115
previous,0.5473149936337622
studies,0.5661913722818733
and,0.5515180737236156
suggests,0.4814862445212658
a,0.48639564014382725
high,0.42963342180088143
prevalence,0.4125864941448602
of,0.46071688475764955
infection,0.469383013641941
with,0.5024370535068242
abnormal,0.4601825796640934
"PrP,",0.521621280597679
indicating,0.4384938190218575
vCJD,0.4360753209616446
carrier,0.4626807308415305
status,0.37961329489562906
in,0.25996686912722994
the,0.22614406684313643
population,0.2843814707498518
compared,0.3662551560970674
with,0.2790558507252861
the,0.22532296476607105
177,0.20838554130739054
vCJD,0.3610396321506591
cases,0.29816928101033513
to,0.06970480750504869
date.,0.10209779029346398
These,0.018595311528686438
findings,0.015032992091573143
have,0.011476070264057427
important,0.016121193684608005
implications,0.012485977427742668
for,0.014860538852685328
the,0.011020335161463706
management,0.009507157146282464
of,0.011347729732394536
blood,0.007562333812480635
and,0.008555502947722083
blood,0.006922547129661502
products,0.008116364793950162
and,0.016172158353572996
for,0.011214440253306535
the,0.010266707476769433
handling,0.008840558677772333
of,0.008944387940870054
surgical,0.011123280729508392
instruments.,0.010729799922163174
BACKGROUND,0.05216081305012952
The,0.005392378783091425
prognosis,0.0027315376653070833
and,0.00471185966867519
treatment,0.0037798665468773964
of,0.0049503717212899855
the,0.005053372239782868
2,0.01015574011784892
main,0.004739584476673729
types,0.0034818653046663644
of,0.005954514213346026
cardiac,0.006480506786175815
"amyloidosis,",0.006495693904591274
immunoglobulin,0.0046105075939816805
light,0.008468586647815579
chain,0.012552128907919206
(AL),0.005952558590870788
and,0.008689817611018414
transthyretin,0.009883137471019656
(ATTR),0.004928706395270776
"amyloidosis,",0.009983421740768241
are,0.004546645811820991
substantially,0.004686377636996037
influenced,0.004432873902722311
by,0.004468376842399088
cardiac,0.004343603694816695
involvement.,0.005808168380473166
Cardiovascular,0.0015130691081059041
magnetic,0.0014166316887299112
resonance,0.0016525813388745733
with,0.0015219222400610847
late,0.0010576290035177983
gadolinium,0.001630288376309546
enhancement,0.0014664611960329005
(LGE),0.0013684093037458116
is,0.0016863002678776968
a,0.001155034857635343
reference,0.0010646231068908284
standard,0.0011730448284136103
for,0.001197143917443366
the,0.0012129892696066745
diagnosis,0.0011180006146048966
of,0.0012520308939447593
cardiac,0.0011139271683913198
"amyloidosis,",0.0013712301144101799
but,0.0013900206626558805
its,0.0013498378702531838
potential,0.001169342894385544
for,0.0010918815555644636
stratifying,0.0011985359138766956
risk,0.0008719320788782883
is,0.001269198844919324
unknown.,0.0011507762058227968
METHODS,0.0626650266961393
AND,0.016924627330549624
RESULTS,0.07240681393215265
Two,0.017183971446636255
hundred,0.008826845801624319
fifty,0.00968171714053162
prospectively,0.009504106495131946
recruited,0.008257715566165596
"subjects,",0.011970163165352023
122,0.011729965184635115
patients,0.010351021892854341
with,0.01737638096682403
ATTR,0.03393220130685886
"amyloid,",0.019855684173936693
9,0.01938319948795874
asymptomatic,0.014682623682596568
mutation,0.01846085886403506
"carriers,",0.015488720145461654
and,0.010326780583457491
119,0.007200725066953047
patients,0.007736762620369929
with,0.009234421645734361
AL,0.015028244624575783
"amyloidosis,",0.005271415723269922
underwent,0.003944858730524686
LGE,0.003113028650623618
cardiovascular,0.0019435036971548474
magnetic,0.0016716452683284851
resonance.,0.0031366960676688866
Subjects,0.0008888866713524199
were,0.001401976174787304
followed,0.0011781124809334925
up,0.0011821813290231872
for,0.0011524422672733539
a,0.0012984569148224853
mean,0.0013242938322584293
of,0.0016552043390123483
24±13,0.0011728607527664492
months.,0.0012377844575702933
LGE,0.004125840070669353
was,0.00252118917486925
performed,0.002107622362303248
with,0.00235834994334482
phase-sensitive,0.0010639364458015982
inversion,0.001370493776543706
recovery,0.0022513298784575123
(PSIR),0.0010930495013679415
and,0.002218748863848884
without,0.002053852556775508
(magnitude,0.0017830847164461566
only).,0.0017298515092253805
These,0.002112646210368459
were,0.0018949556813442339
compared,0.0019587369702109936
with,0.00239909034806511
extracellular,0.0012483281862194723
volume,0.0021509302593031156
measured,0.0011697130356180608
with,0.0016419283118801033
T1,0.0015566991411238547
mapping.,0.0015207539008333846
PSIR,0.15106873931416556
was,0.35969209080675846
superior,0.3952118240407202
to,0.374145427108598
magnitude-only,0.20291144514476117
inversion,0.21554847564746168
recovery,0.16666256471122398
LGE,0.31966064973322217
because,0.5824541336807301
PSIR,0.37917394508946667
always,0.5610318327511947
nulled,0.4533412089414558
the,0.4722797005663125
tissue,0.500585108728353
(blood,0.4033354959467497
or,0.3572835942806814
myocardium),0.5254541525696986
with,0.3496602003308143
the,0.4540489972776311
longest,0.44548710687049176
T1,0.361685255062978
(least,0.4752573815405871
gadolinium).,0.3586516233093751
LGE,0.3350843212762405
was,0.2757978860671059
classified,0.22730976173181205
into,0.22215593484322263
3,0.2663526605423835
patterns:,0.23767051238491255
"none,",0.19262703120870162
"subendocardial,",0.25003962801288476
and,0.19807781638653563
"transmural,",0.2864239447937314
which,0.29027891954681595
were,0.3004838406414377
associated,0.40789685671388515
with,0.41631862834192995
increasing,0.4613888677380123
amyloid,0.4452346409992692
burden,0.37813724673931887
as,0.3396397439031265
defined,0.2734079603584768
by,0.35580141060156906
extracellular,0.4453542010334436
volume,0.3669638092052727
"(P<0.0001),",0.36016041653703984
with,0.4219174900490862
transitions,0.43158408285050104
from,0.3988698468028411
none,0.40850225282971137
to,0.37599750541542687
subendocardial,0.4573842781671262
LGE,0.4733149002872971
at,0.4295481712217386
an,0.47682060221509986
extracellular,0.5234025439169919
volume,0.43107252547392394
of,0.4712198270780681
0.40,0.3637323801472782
to,0.4327320552730979
0.43,0.36496952232814567
(AL),0.34472570021678955
and,0.4681339738552684
0.39,0.35610432620319604
to,0.4170060645097548
0.40,0.3394871368447003
(ATTR),0.30657681554144367
and,0.39863772002892733
to,0.35744116574180207
transmural,0.355920926074302
at,0.3626881525089514
0.48,0.2659439012981013
to,0.3309609426015075
0.55,0.2421037157162408
(AL),0.25297434559798565
and,0.3609097333632806
0.47,0.24360969574982252
to,0.2981559006350683
0.59,0.22649118460266537
(ATTR).,0.2378739350580097
Sixty-seven,0.09118188359017389
patients,0.06103752829687314
(27%),0.07556192143549216
died.,0.04148822441396767
Transmural,0.23760568449736683
LGE,0.2557990198579066
predicted,0.35104997475298666
death,0.26652837335333784
(hazard,0.40401201973007106
"ratio,",0.5878789641941068
5.4;,0.596282579270703
95%,0.5418704418853968
confidence,0.6213566115722132
"interval,",0.6316017797560193
2.1-13.7;,0.648703561510912
P<0.0001),0.5952622854094751
and,0.24277722926284834
remained,0.14176729604121688
independent,0.12989474240116475
after,0.15407170857872218
adjustment,0.12753083183082597
for,0.19413906687017354
N-terminal,0.3009982327532136
pro-brain,0.3888581477912114
natriuretic,0.3053101786329903
"peptide,",0.23552783001799127
ejection,0.25096664366687904
"fraction,",0.3679120146136964
stroke,0.30079943710617485
volume,0.38960103873012125
"index,",0.3457439253677733
"E/E',",0.422233263420915
and,0.19906647542264821
left,0.3673096217067299
ventricular,0.46859175439880224
mass,0.42040841259196915
index,0.3447696415909962
(hazard,0.2574058583590542
"ratio,",0.4057127114103974
4.1;,0.3973628499406367
95%,0.3826321691882578
confidence,0.38866949602465495
"interval,",0.3853412581846642
1.3-13.1;,0.5075431394661707
P<0.05).,0.4748396515169862
CONCLUSIONS,0.7717735472310892
There,0.36314157315099693
is,0.3455668357526973
a,0.3301440405682996
continuum,0.13269667894782972
of,0.0767858753676387
cardiac,0.12222409895672891
involvement,0.11840499282270188
in,0.11598635342575794
systemic,0.09705461886012995
AL,0.15313158355863885
and,0.10310910190880064
ATTR,0.1445893005175556
amyloidosis.,0.09772928964114896
Transmural,0.14734095072382164
LGE,0.17037090982705846
is,0.1408141405175343
determined,0.12791683524561237
reliably,0.1660192389162609
by,0.1797922260693339
PSIR,0.12056040997490083
and,0.22769195353583813
represents,0.14300281497531092
advanced,0.1887842083003234
cardiac,0.17641092776612444
amyloidosis.,0.15441085546519967
The,0.07820011844005298
PSIR,0.060320220251732885
technique,0.08840966527582757
provides,0.08662286643914965
incremental,0.07537530365050019
information,0.06208666754764963
on,0.03919423984481114
outcome,0.06318226641306442
even,0.04715606040506082
after,0.08493618831487651
adjustment,0.06550404960901346
for,0.04341150260262429
known,0.050565825136019496
prognostic,0.05064551013900926
factors.,0.07280897748442683
BACKGROUND,0.032529337724832054
The,0.002467654905011578
Global,0.0014980249746210294
Burden,0.001848413707164123
of,0.0016551290908702674
"Diseases,",0.0011466935242780646
"Injuries,",0.0017523829277384078
and,0.0014022382232494388
Risk,0.0010965417676832246
Factors,0.0013761176862553833
Study,0.00248971975565422
2015,0.0024988389974447797
provides,0.0030784180395241603
an,0.002691545210285162
up-to-date,0.0010648533603350868
synthesis,0.0020839016982460747
of,0.0016634423365130021
the,0.0015337233114002002
evidence,0.0015987631547986977
for,0.0013067595989766489
risk,0.0008275628428337586
factor,0.0010650745316141171
exposure,0.000839689899136559
and,0.0015215060115570617
the,0.0009669505026143245
attributable,0.0008306608113212998
burden,0.0008304688894295024
of,0.0011608599254619438
disease.,0.0008695656035152996
By,0.003990174109508833
providing,0.0016434015941585477
national,0.0010011976176313477
and,0.0014682574628913012
subnational,0.0012986538737567463
assessments,0.0009670375659949094
spanning,0.0011496328859057889
the,0.0014537596372730147
past,0.0011119520150974357
25,0.0014036892204922682
"years,",0.0010348526489015594
this,0.0016107100641813911
study,0.001236084059214517
can,0.001391593213250036
inform,0.0012582803952927754
debates,0.0009739965191504996
on,0.0007415786692782509
the,0.0007622873783489362
importance,0.0008534483231867024
of,0.0010061949102994937
addressing,0.0008023326310808242
risks,0.0006497180282966573
in,0.0009089583330489294
context.,0.001009327257938286
METHODS,0.014855831068396622
We,0.019765609736386244
used,0.011615581562539399
the,0.01109289692588266
comparative,0.0049260107152506154
risk,0.002911801006472823
assessment,0.003118971943348783
framework,0.006992623318985928
developed,0.007103576571610653
for,0.009593033651240972
previous,0.0090353019471005
iterations,0.00692999561864976
of,0.005537033764705083
the,0.0048621945110358935
Global,0.0035006312435124885
Burden,0.0038170905206657735
of,0.004208625858192277
Disease,0.003044223615049688
Study,0.0046052880986123396
to,0.005338151870469774
estimate,0.0033662877317169153
attributable,0.0025240790162484534
"deaths,",0.005320575555914293
disability-adjusted,0.004917673460477014
life-years,0.004307129347762792
"(DALYs),",0.002824535359652649
and,0.0022409161052402192
trends,0.0009373092632536724
in,0.0013166888090028904
exposure,0.001078824219931344
by,0.002189939887663159
age,0.0007472962307214757
"group,",0.0007644606470386001
"sex,",0.0010874169595936323
"year,",0.0006319128134633265
and,0.0012086726102294363
geography,0.0008291815872591398
for,0.0017502321728802414
79,0.001120571050078927
"behavioural,",0.0006002770187396708
environmental,0.0005909162420985204
and,0.001729090003295019
"occupational,",0.0007585936068857192
and,0.001369123660478501
metabolic,0.0006104653346233349
risks,0.0008436184321659278
or,0.0009141338636773751
clusters,0.0007264283295833849
of,0.0011198264754465497
risks,0.0007634328934256503
from,0.0012858800242790032
1990,0.0012045792409643898
to,0.0010114435443039649
2015.,0.0009805450639991282
This,0.0013500840789565586
study,0.0013757409511527443
included,0.001379368103728884
388,0.0009588130596374481
risk-outcome,0.0008063460029023296
pairs,0.0008942638685511199
that,0.001392500994198072
met,0.0008433714827598263
World,0.0013128401486498771
Cancer,0.0010403061142254426
Research,0.0013170136450995763
Fund-defined,0.0011430904441994043
criteria,0.0009129446483765781
for,0.0011699255924537207
convincing,0.0009886362057959198
or,0.0009396761469910744
probable,0.0009691093558065725
evidence.,0.0007549670012468796
We,0.01220403341986998
extracted,0.002660141504243844
relative,0.001353182228018553
risk,0.0014381305277095277
and,0.0021984723521098455
exposure,0.001723046899269072
estimates,0.0016343136034895917
from,0.0016687694402738173
randomised,0.0012367547499610894
controlled,0.001121144690824657
"trials,",0.0014208819471212442
"cohorts,",0.0012109427719473715
pooled,0.0009576054632110803
"cohorts,",0.0014002725511495838
household,0.0017298683896348342
"surveys,",0.0012765715661196254
census,0.0010669840396314058
"data,",0.001027362439556842
satellite,0.0010223631212007641
"data,",0.001041859552507798
and,0.001171541504527793
other,0.0010659294651700077
sources.,0.0013237541174904769
We,0.009659422553763166
used,0.004670288875709266
statistical,0.0034236401237123276
models,0.0028455597110615175
to,0.0036278913116812718
pool,0.0036393499474186718
"data,",0.002676961688200907
adjust,0.0043378055650167315
for,0.004845649952295411
"bias,",0.0030329095906017354
and,0.005507369768608017
incorporate,0.006513830275220339
covariates.,0.009834817474900124
We,0.005649777388172888
developed,0.003489137780254805
a,0.002365767758961874
metric,0.0020863310698521677
that,0.002151714866818305
allows,0.0020607445568355145
comparisons,0.0014657170631804284
of,0.0012331740971891914
exposure,0.0018941054055351223
across,0.0014749633654383679
risk,0.0011896473432155693
factors-the,0.0010697970049276166
summary,0.0018819225612305844
exposure,0.002193974405403549
value.,0.0016067344635605613
Using,0.0023493711091572837
the,0.0020487688498809554
counterfactual,0.0019352698211466787
scenario,0.002084905945806868
of,0.0019415350467022737
theoretical,0.0016530408412417116
minimum,0.0015776595278566123
risk,0.0016315892744285586
"level,",0.0017954516653532918
we,0.005083784787810112
estimated,0.0024277581168257426
the,0.001707386179026288
portion,0.0019156328770976738
of,0.0025844091916134458
deaths,0.002517006950799757
and,0.002572119200141472
DALYs,0.0017742700368478326
that,0.0018678797723975207
could,0.0016831316388132176
be,0.0015930223651206838
attributed,0.0015977660033967497
to,0.002238008445119614
a,0.0019165128645518299
given,0.0016267891371353623
risk.,0.0021042684071516213
We,0.003956131540255786
decomposed,0.001868258529326379
trends,0.0018579364709027332
in,0.0023146228922851218
attributable,0.0015157094955855195
burden,0.0018253595016966833
into,0.002207881883528074
contributions,0.0023994761150544558
from,0.002672596108068418
population,0.0016089680477929995
"growth,",0.0017047414888834718
population,0.0015290584959136962
age,0.0009425396469401027
"structure,",0.0012998600859964343
risk,0.0012566299721376234
"exposure,",0.001321497390725285
and,0.001661621235673818
risk-deleted,0.0013527647377165504
cause-specific,0.0014087768450335662
DALY,0.0012856464274875166
rates.,0.0014054739556550835
We,0.0035195439555943155
characterised,0.0019054639689398396
risk,0.0013520981797163754
exposure,0.002071718251123626
in,0.0017602359063089213
relation,0.0013380861333886064
to,0.0016293282167367592
a,0.0011690939712953527
Socio-demographic,0.0012061654058324687
Index,0.0012725121253595775
(SDI).,0.0012785811690063295
FINDINGS,0.03768613489167236
Between,0.0453031511083004
1990,0.03964842903176175
and,0.022577633549961746
"2015,",0.016872941595913103
global,0.052615762259243914
exposure,0.09832128561974833
to,0.4080967917462525
unsafe,0.27292112330994467
"sanitation,",0.21298328413290593
household,0.33946100112871797
air,0.1777303852008925
"pollution,",0.24078005463829202
childhood,0.33982798631525785
"underweight,",0.33662637694359265
childhood,0.35297381635498243
"stunting,",0.33762796012882096
and,0.30349981750249294
smoking,0.23272796559127984
each,0.28280592548933403
decreased,0.25658746861227416
by,0.3550354499259025
more,0.3013407490364352
than,0.27034370173562444
25%.,0.24404843716993319
Global,0.0148044552560538
exposure,0.017726947593684983
for,0.019409927604974328
several,0.013393189491588445
occupational,0.011509223137510743
"risks,",0.009051330688993893
high,0.011068853066441734
body-mass,0.011174766358282495
index,0.013921339192542612
"(BMI),",0.006380634589934426
and,0.03250605174472565
drug,0.008491162613137699
use,0.015427036131046897
increased,0.021636486935079264
by,0.02802826843515435
more,0.017798990992096073
than,0.01531987904165242
25%,0.012128119622651895
over,0.02737481603108156
the,0.019901337120167034
same,0.01530765185442587
period.,0.011291927542850654
All,0.014382119496691236
risks,0.009305244341731923
jointly,0.02174699697303878
evaluated,0.011284637854806694
in,0.014698757475028542
2015,0.009829570562202057
accounted,0.01676725397747569
for,0.013437973922590392
57·8%,0.010081921714826742
(95%,0.01405580418446586
CI,0.020980770025614524
56·6-58·8),0.019063258776308614
of,0.01438901898999103
global,0.013929527087165676
deaths,0.009138266482899761
and,0.0181069598239334
41·2%,0.021130287898506087
(39·8-42·8),0.020945088964384042
of,0.01289623695904302
DALYs.,0.009216834951340666
In,0.2492371937544158
"2015,",0.18449104478433626
the,0.2535038823375031
ten,0.21134897251301696
largest,0.2390087703310761
contributors,0.25039289960812217
to,0.26505839900285894
global,0.20524469867840908
DALYs,0.5937011426524769
among,0.5468312770808396
Level,0.6095555312846224
3,0.4986332949761404
risks,0.7137924006611371
were,0.7216904915829003
high,0.7649911849908723
systolic,0.7092623226408454
blood,0.7266802034628381
pressure,0.732995213282605
(211·8,0.7488072746062844
million,0.8033322181396569
[192·7,0.6243544648948225
million,0.6601478834957409
to,0.6006891818639629
231·1,0.44524213839000437
million],0.6389918753968042
global,0.6897612503812048
"DALYs),",0.6327965002605769
smoking,0.7662386758073698
(148·6,0.8398025889560693
million,0.8350970098523433
[134·2,0.7504812794566256
million,0.7917659999204828
to,0.7367359935646781
163·1,0.5775524880350583
"million]),",0.7486056018495449
high,0.8231755727272334
fasting,0.8601476188276769
plasma,0.8162250826195462
glucose,0.7929679442208083
(143·1,0.8213858994337432
million,0.8549500723704923
[125·1,0.7576775954115437
million,0.8402250761909736
to,0.7758779384885856
163·5,0.6601285533376261
"million]),",0.8014301713562805
high,0.8184993498924099
BMI,0.7800702273824907
(120·1,0.8245338835680311
million,0.8407147417584532
[83·8,0.7401084561545578
million,0.7976848410468024
to,0.7536596019430237
158·4,0.5801501200901412
"million]),",0.768477640898715
childhood,0.7942746820190882
undernutrition,0.794988372121113
(113·3,0.8052900212256936
million,0.804967984500773
[103·9,0.715516595408941
million,0.7989814600517755
to,0.7397278208552723
123·4,0.5886189488507851
"million]),",0.7767864929952474
ambient,0.6470651813656462
particulate,0.566997046524331
matter,0.6205725169099094
(103·1,0.6270122979651351
million,0.6701855815829526
[90·8,0.607390348507802
million,0.6573019173262145
to,0.6056410996747696
115·1,0.5237973292265395
"million]),",0.6574250626047884
high,0.6890044646602832
total,0.6790400379885994
cholesterol,0.6856699784820067
(88·7,0.6852934411939821
million,0.7418354954917548
[74·6,0.6522086270356507
million,0.7259263532698901
to,0.6412196951552729
105·7,0.5453253306379149
"million]),",0.703820582426563
household,0.6639181280640004
air,0.5806524651275233
pollution,0.6616081050165822
(85·6,0.6793360684706938
million,0.7513729109576777
[66·7,0.6464719005911981
million,0.7309444028282941
to,0.6618572499595586
106·1,0.5874128490263852
"million]),",0.7297891403109231
alcohol,0.5598602513033143
use,0.6677944431040294
(85·0,0.6364098382451095
million,0.6563933073020979
[77·2,0.5792562512783608
million,0.681613722478251
to,0.619097188295587
93·0,0.6007439143887304
"million]),",0.6737839101725679
and,0.5995952337205737
diets,0.47803283038180605
high,0.5360816662640276
in,0.5403024663109489
sodium,0.3488725224984394
(83·0,0.37771687595176173
million,0.3045925861147351
[49·3,0.42096487810629063
million,0.4180748208795229
to,0.45024571258556745
127·5,0.323201786669984
million]).,0.3499719110242008
From,0.12470217169218845
1990,0.07666794413293575
to,0.047723572510569925
"2015,",0.05100063543409484
attributable,0.03749451907018877
DALYs,0.09854716245152546
declined,0.08811971904440125
for,0.47312724868464323
micronutrient,0.3127683731836453
"deficiencies,",0.25471217698591925
childhood,0.3674491230755406
"undernutrition,",0.255178946488201
unsafe,0.30976282541953
sanitation,0.15642473619604258
and,0.22242907260180667
"water,",0.15269461929001382
and,0.32111401977091664
household,0.3045199581257421
air,0.15815340900245353
pollution;,0.19472540930104892
reductions,0.41063428333055896
in,0.37699290751561504
risk-deleted,0.3173577460060617
DALY,0.33510450066356223
rates,0.3353004958325955
rather,0.42201227729509033
than,0.4240864843698891
reductions,0.2510737358390383
in,0.25119048313394854
exposure,0.23804272378084496
drove,0.24046633424457245
these,0.2472746618584336
declines.,0.1492067523425877
Rising,0.04957840542149813
exposure,0.04725068484129144
contributed,0.08860146448403614
to,0.11092239986840298
notable,0.07514674533005625
increases,0.05777493390867714
in,0.058770231676101736
attributable,0.030510211095250362
DALYs,0.04751541695294998
from,0.09554351223580403
high,0.07320079941339198
"BMI,",0.03508014945332607
high,0.0971034220936393
fasting,0.04712982120472186
plasma,0.051374212312907216
"glucose,",0.045676555132351124
occupational,0.05494655677750514
"carcinogens,",0.025529601720843564
and,0.09520373469367771
drug,0.02586468626527924
use.,0.04931272116557279
Environmental,0.09412308438796796
risks,0.09257569860223865
and,0.13811765161889833
childhood,0.10439794845890561
undernutrition,0.07926601386622026
declined,0.09117575903992971
steadily,0.10707567975458962
with,0.1757425490215481
SDI;,0.08337924466973774
low,0.25968553373498227
physical,0.29763049778822914
"activity,",0.29421483601540405
high,0.31907008095319056
"BMI,",0.1396433112483221
and,0.396300016341937
high,0.32541583742143604
fasting,0.19676294772050731
plasma,0.175148538037363
glucose,0.1702893732877742
increased,0.2277684976221336
with,0.2899985126911294
SDI.,0.12336140872676292
In,0.311154095386652
119,0.2553976276937629
"countries,",0.025252807747867943
metabolic,0.011211469071424519
"risks,",0.014268936880045024
such,0.03403030976257857
as,0.030174959381278055
high,0.024810144197268156
BMI,0.01373031133217406
and,0.05008780328319156
fasting,0.009218507199678793
plasma,0.009595672988164598
"glucose,",0.011497673911761796
contributed,0.009728411432902087
the,0.008370970176017336
most,0.00715162053922702
attributable,0.0034327548651851805
DALYs,0.010297027468778887
in,0.007357227844322155
2015.,0.005293547457602527
"Regionally,",0.0032416089266916934
smoking,0.004063194867453946
still,0.002676598891268264
ranked,0.003166552485139757
among,0.003008344850634484
the,0.003241157530292763
leading,0.002391617789409865
five,0.0026032094260840313
risk,0.001841009068009824
factors,0.0018251618580015217
for,0.003122433511044363
attributable,0.002606111230088898
DALYs,0.002368963281321694
in,0.0034335208203849494
109,0.002493975375663487
countries;,0.0019442979146276696
childhood,0.0031961072507001127
underweight,0.002684230487655079
and,0.005024699555081817
unsafe,0.002858560518929058
sex,0.0025871744266286844
remained,0.0033813727302211597
primary,0.0026515257062425745
drivers,0.0020309141263426837
of,0.0025246145122902307
early,0.0032819220960287154
death,0.002103069712833418
and,0.0041102338486095555
disability,0.002376129538629268
in,0.002520509938773004
much,0.0025059483460408206
of,0.0025536091146319885
sub-Saharan,0.0017399128724641365
Africa.,0.0020543588820842312
INTERPRETATION,0.010184928147307306
Declines,0.004552197793468165
in,0.004037808155136221
some,0.0033330143635920354
key,0.0037581272769655937
environmental,0.0024141938372438656
risks,0.002032024395260259
have,0.0031534156938551284
contributed,0.003066037077859935
to,0.004703658795942502
declines,0.002411048697592677
in,0.002468900584199636
critical,0.0020147227341842577
infectious,0.0014816017912353669
diseases.,0.001551032728235996
Some,0.003953164819519091
risks,0.0023174815690052497
appear,0.0029536357131432155
to,0.0024077564553838995
be,0.0026736677644969985
invariant,0.0022394458223844644
to,0.002812817472712477
SDI.,0.002190993559924962
Increasing,0.17400802868603651
"risks,",0.0717152911285026
including,0.5493728677347304
high,0.5475900058648409
"BMI,",0.3704513360278467
high,0.5629902463914643
fasting,0.5441746955996324
plasma,0.49406398038893246
"glucose,",0.4252286773775098
drug,0.2761155542478263
"use,",0.384322286784777
and,0.541908804768774
some,0.38074466981349037
occupational,0.3179964493247808
"exposures,",0.2713447809098862
contribute,0.35579891049831275
to,0.38411376912149653
rising,0.1808008665889168
burden,0.1837883021325268
from,0.23841063338914745
some,0.23032289314113394
"conditions,",0.17935301040016652
but,0.30527681136216706
also,0.23240318239043523
provide,0.20227833907921822
opportunities,0.09533112205478188
for,0.08987295836206176
intervention.,0.13371765266103133
Some,0.009168886124274632
highly,0.004898361589751241
preventable,0.005976762278805804
"risks,",0.006178381932018443
such,0.008006939861792753
as,0.009198579553577241
"smoking,",0.011765528126601548
remain,0.009925101079385686
major,0.0075819902542876
causes,0.00512101222584573
of,0.00723165454244491
attributable,0.004014516997964585
"DALYs,",0.0063608380964112355
even,0.003884215480427178
as,0.006864809860399344
exposure,0.006482409003267463
is,0.00519745853366654
declining.,0.005250951164313848
Public,0.002399634776831687
policy,0.002382933113606061
makers,0.001930954573146637
need,0.002064418261246745
to,0.0013753639915841899
pay,0.001288665935465756
attention,0.0015441851456750194
to,0.001470965438491987
the,0.0017919064335042703
risks,0.001509507700118577
that,0.0019551579117505374
are,0.0023382101101462305
increasingly,0.0021871840777313296
major,0.0019106560154093363
contributors,0.0019436970178868104
to,0.0025250990777584423
global,0.0022997043223766363
burden.,0.0026696649093933635
FUNDING,0.02516769028554758
Bill,0.02009116032459189
&,0.02178532963858336
Melinda,0.006080861603326517
Gates,0.01342344827110452
Foundation.,0.03168814835883039
OBJECTIVE,0.0010885809127521373
To,0.0008154341882644567
evaluate,0.0007148702474843077
the,0.000851865238455097
cost,0.0007892535514112866
effectiveness,0.0008632628849611917
of,0.0011484422908677545
standard,0.0009219565879667984
treatment,0.0006108213726677277
with,0.0007359730249629873
and,0.002709578591398071
without,0.0012520592169648992
the,0.001337039311851808
addition,0.0010253926112231187
of,0.0014608170421607375
ward,0.0013349087087145323
based,0.0011825980531370238
non-invasive,0.0010028596653940398
ventilation,0.001113357481569843
in,0.001032637751058913
patients,0.0009340584019487372
admitted,0.0008685344489343187
to,0.0012096423820926556
hospital,0.001045962654872502
with,0.0009664165470438786
an,0.001208310296954064
acute,0.0010253647702962397
exacerbation,0.0009924793207354437
of,0.0010649948843762702
chronic,0.0010965375893031005
obstructive,0.0010956891854745415
pulmonary,0.0011836847595284995
disease.,0.0010935869305959951
DESIGN,0.0007356390770383631
Incremental,0.0007340686632537002
cost,0.0010095708119661451
effectiveness,0.0010652099963134375
analysis,0.0007870919799662104
of,0.0011819071595332968
a,0.0010911412107536492
randomised,0.0009592429664228396
controlled,0.0007452331500375236
trial.,0.0007107206453707795
SETTING,0.003406014596739645
Medical,0.001069380000438497
wards,0.0008827629741616657
in,0.0010602680820853186
14,0.0006794660783852873
hospitals,0.000896416448092558
in,0.0008497968764252435
the,0.0010434242544399425
United,0.0007099272758382559
Kingdom.,0.00101557524798384
PARTICIPANTS,0.007941158385319091
The,0.00814505990622606
trial,0.004032884825683911
comprised,0.008339797860161762
236,0.005209052878839181
patients,0.005027072117053555
admitted,0.0034606629289293343
to,0.005915782212649266
hospital,0.003298372213482976
with,0.009318093247606721
an,0.0087891957047852
acute,0.006002123403504471
exacerbation,0.008307890068159943
of,0.013507797506013755
chronic,0.007930821352137294
obstructive,0.01911086571843068
pulmonary,0.005493743271937226
disease,0.011290918763253733
and,0.017384101009626295
mild,0.022778566350365233
to,0.012753563921618923
moderate,0.024924184251943652
acidosis,0.016179818986594728
(pH,0.005518621749199754
7.25-7.35),0.005967768859600006
secondary,0.002793270654263322
to,0.0033527210256099377
respiratory,0.0015930007508050046
failure.,0.0024311718908637957
The,0.001271662481250489
economic,0.0007651847434698643
analysis,0.0010487092682731059
compared,0.0008059375248251023
the,0.0010549045277245554
costs,0.0007271682262676618
of,0.0012112161696050158
treatment,0.0007849578287761074
that,0.0010464360824432443
these,0.0010582710181822421
patients,0.0009034282959711892
received,0.0008151933462103933
after,0.0010019426209796972
randomisation.,0.0008373186996382034
MAIN,0.0015306744093193346
OUTCOME,0.0017369627976113584
MEASURE,0.0019505788502199133
Incremental,0.0016617300025811488
cost,0.002114767868642493
per,0.0023705460234948795
in-hospital,0.0020102053291686348
death.,0.0016187789891788779
RESULTS,0.03685709876293972
24/118,0.00970285759533864
died,0.01779893263909571
in,0.024540323532104145
the,0.014952359221838678
group,0.017391581995383227
receiving,0.007440707603744419
standard,0.012980804915632133
treatment,0.015217146861640248
and,0.032816124649453465
12/118,0.009452797572276767
in,0.02791122653098491
the,0.01618715665657237
group,0.019877283125965334
receiving,0.009784635982718224
non-invasive,0.022971065678691227
ventilation,0.017463790048097422
(P=0.05).,0.021525017098073657
Allocation,0.43198970826742034
to,0.347436736196651
the,0.2609736929242387
group,0.24510912655266026
receiving,0.2406509712366243
non-invasive,0.39193204323846426
ventilation,0.32724616025575703
was,0.4883106414534627
associated,0.5754852085343649
with,0.5584945529391535
a,0.6187658813181185
reduction,0.5332803413968337
in,0.5769532323344141
costs,0.5409811491243317
of,0.6329105132718343
49362,0.4706714935366196
pounds,0.4504627121466962
sterling,0.3616320194084845
(78741,0.5681305346467503
dollars;,0.42268396090189436
73109,0.42831032020101156
"euros),",0.3850048871288225
mainly,0.587528502516482
through,0.6614948814014886
reduced,0.6004555230786459
use,0.4494081383062207
of,0.454251205374066
intensive,0.3011066708997908
care,0.27837992597862826
units.,0.3623962371733364
The,0.47399407851307446
incremental,0.49409536528416337
cost,0.4304025255158116
effectiveness,0.4576183017326599
ratio,0.48058443492181824
was,0.5448525383776526
-645,0.5927488620558712
pounds,0.4616126199431565
sterling,0.4001398506435135
per,0.5745066775707676
death,0.484774262268669
avoided,0.560224528427301
(95%,0.5730136037462393
confidence,0.5896454562083835
interval,0.5810576572881478
-2310,0.5787586805601337
pounds,0.5079315844037927
sterling,0.4673768025114575
to,0.5825868184506457
386,0.5745037990270611
pounds,0.4619507573246567
"sterling),",0.402919303724948
indicating,0.5253884327529004
a,0.47038163984088693
dominant,0.43083670560133625
(more,0.4919410857263531
effective,0.4612117641295241
and,0.5723748657585457
less,0.581267227601078
costly),0.43276002899400023
strategy.,0.40980676457436627
Modelling,0.03407457938572901
of,0.0375267766819096
these,0.05597453175504916
data,0.04147484853215616
indicates,0.08999040784226428
that,0.087810721091574
a,0.0769157960342881
typical,0.0770875757730405
UK,0.05650893275988051
hospital,0.05357248433168765
providing,0.05783664002862273
a,0.07017370821197645
non-invasive,0.05604006672929278
ventilation,0.04619458106816673
service,0.06159649886401411
will,0.09191909370863
avoid,0.05334838550876431
six,0.03397284220241704
deaths,0.026414609202313755
and,0.0529218959489458
three,0.08558304620596549
to,0.06952440651442174
nine,0.022491083000653295
admissions,0.028883874614417836
to,0.030116785692513293
intensive,0.015434322169592597
care,0.017507674856655234
units,0.023448256481843236
per,0.05289821641302683
"year,",0.027971595408158603
with,0.1557696323744003
an,0.1276308296224412
associated,0.13049849120727078
cost,0.06700586808551169
reduction,0.0888546395818521
of,0.1805372928991209
12000-53000,0.1518874061782881
pounds,0.040518922807413246
sterling,0.03657891408985711
per,0.08090829400475683
year.,0.04026094913639816
CONCLUSIONS,0.7015219764691213
Non-invasive,0.7490514401620751
ventilation,0.6786363182019843
is,0.8316374454773564
a,0.8676000961117949
highly,0.7767986929936401
cost,0.6684257506139244
effective,0.8379284491709769
treatment,0.7767848755942615
that,0.8802545059852916
both,0.8890625629884799
reduced,0.8236967460628245
total,0.7861677878542714
costs,0.690326586150035
and,0.8745344625408282
improved,0.8505646796471337
mortality,0.6149594382266944
in,0.7005806947710164
hospital.,0.6720674946618791
BACKGROUND,0.03907122409038209
Self-harm,0.008809029132597929
and,0.005278123420830129
suicide,0.003603301710469018
are,0.0033572579367662845
common,0.004325652201755722
in,0.007060481515791487
"prisoners,",0.0072082096451407405
yet,0.0036013266054881394
robust,0.0023248734427395164
information,0.002673474504152071
on,0.0016048271200924404
the,0.001036282190533209
full,0.0013597714609471586
extent,0.0012697713719461298
and,0.0014014478869365384
characteristics,0.001062779072124128
of,0.0017407147656855735
people,0.001365124218580067
at,0.001611172516462825
risk,0.001292178571094093
of,0.0018323493743028605
self-harm,0.0018393576470982515
is,0.0017845145412876138
scant.,0.0013339342421198155
"Furthermore,",0.0012770358123579538
understanding,0.001030612161179375
how,0.0011674127611842084
frequently,0.0019362500369514983
self-harm,0.0012306208195279845
is,0.0010008521412270856
followed,0.0023864463405470575
by,0.002958296548864093
"suicide,",0.0017280840939658888
and,0.0013551457694576275
in,0.0015079675862580911
which,0.001322506868288958
prisoners,0.0014155282240849968
this,0.0012380167388114673
progression,0.0018036518226259932
is,0.0008581438896701219
most,0.0010283668954934485
likely,0.0008705056993576185
to,0.001053567252169119
"happen,",0.0019826735140600644
is,0.0012094848277032228
important.,0.0010454971604023167
We,0.0023925696516611254
did,0.0017261911145491967
a,0.0014007447016706948
case-control,0.0009072980927449651
study,0.0015951256618337985
of,0.0016027347051919565
all,0.0011050714878260337
prisoners,0.001199175975407093
in,0.0010473823325912858
England,0.0012748938426964892
and,0.001911898109732129
Wales,0.001366685887996066
to,0.001241405380294853
ascertain,0.0014328988398552688
the,0.0011937122042856739
prevalence,0.0010393085736108594
of,0.001439997043851619
self-harm,0.0008586158249636981
in,0.0011377114869856395
this,0.001465250253055897
"population,",0.0009898944479657195
associated,0.0008817418078861886
risk,0.0008024823057122579
"factors,",0.001010260198001985
clustering,0.0010523354267162532
"effects,",0.0008122348611900654
and,0.0012901703570493866
risk,0.0008650299051823648
of,0.001448989911131702
subsequent,0.0012281868771613807
suicide,0.0009493842098745274
after,0.0016747472647565909
self-harm.,0.0012177481029044795
METHODS,0.03694894069006217
Records,0.05575810218182944
of,0.034243453094654264
self-harm,0.027484646823100835
incidents,0.04505817299600339
in,0.030151451658772505
all,0.046914468410501384
prisons,0.0007541109824296445
in,0.0007228387870918113
England,0.0007448589790347321
and,0.0008711305038394353
Wales,0.0007131295199510846
were,0.000695113851356742
gathered,0.0005568178831698148
routinely,0.0006159155036576417
between,0.000507558182404523
"January,",0.00043927515939141834
"2004,",0.0004145211412373889
and,0.0005284754806634806
"December,",0.00035512979801333557
2009.,0.0005145014197852322
We,0.001278745885832524
did,0.0011609387161779828
a,0.0008886842721641247
case-control,0.0005157360448550328
comparison,0.0007799439280009416
of,0.0007919923484753452
prisoners,0.0010497395734311266
who,0.0009799854020445375
self-harmed,0.0008868892564605686
and,0.0007004837680002674
those,0.0008694686672458173
who,0.0010545804733132537
did,0.0012431604526783639
not,0.0009736889453756637
between,0.0005700754929716694
"January,",0.0005108251005929316
"2006,",0.0006348021034714997
and,0.0005864946330294756
"December,",0.0003909104506944762
2009.,0.0005581586513967086
We,0.0013399301703368714
also,0.0010413780242003422
used,0.001291756193646849
a,0.0013587769284433794
Bayesian,0.0012164969007430956
approach,0.0011205630441400874
to,0.0009530247177009637
look,0.0007728855984133589
at,0.0007859518097232428
clustering,0.0007544405480286799
of,0.0007760823857824002
people,0.0007279314210541602
who,0.0007936703209433157
self-harmed.,0.0006704880382921379
Prisoners,0.0016552480711771753
who,0.0027817396493785766
self-harmed,0.0018526100861775828
and,0.0057289657157518865
subsequently,0.003085024231840012
died,0.0015768447946488738
by,0.0027372140652802044
suicide,0.0010150127765653492
in,0.0015734810606468645
prison,0.0010648711132164614
were,0.0012016017100464097
compared,0.0008916719986181928
with,0.0010404850197335204
other,0.0013049437520786578
inmates,0.0009077518429090371
who,0.0020976672960816784
self-harmed.,0.0014936637767081293
FINDINGS,0.17533466459752342
"139,195",0.1589983682304462
self-harm,0.17469915811995673
incidents,0.25673716100489224
were,0.18761803494694346
recorded,0.21629545469194186
in,0.2090420664210828
"26,510",0.12104369585518779
individual,0.2428996400849129
prisoners,0.19797407944474515
between,0.1544727634641389
2004,0.15176762777316347
and,0.14503071792108038
2009;,0.10566973466206885
5-6%,0.4111371144264825
of,0.4134500759741953
male,0.2889549834627344
prisoners,0.2662807040194672
and,0.28051337600048576
20-24%,0.2092333717011618
of,0.2811752528491056
female,0.2192584389417921
inmates,0.21489595762229563
self-harmed,0.23304332220890284
every,0.2639680314138172
year.,0.2200835869910027
Self-harm,0.16465606498771762
rates,0.16372228279365242
were,0.21575074212932316
more,0.2647828888324082
than,0.26489212033777654
ten,0.26943011373403475
times,0.23348128128059503
higher,0.23142136866106344
in,0.22599741475512192
female,0.18126004007597363
prisoners,0.20007031352874857
than,0.2723600193304094
in,0.2195116488465901
male,0.1810947034671021
inmates.,0.20973363016409322
Repetition,0.011667163402602166
of,0.017066569813438598
self-harm,0.015155728804554841
was,0.01922055955960124
"common,",0.015017064793492576
particularly,0.015566309117426513
in,0.023118574891121606
women,0.015120577577554596
and,0.01799473103328515
teenage,0.010198950354985567
"girls,",0.010600838384178638
in,0.011688210881185887
whom,0.013793781586469517
a,0.01010237723022935
subgroup,0.009254271009003999
of,0.010167747549250707
102,0.00682729395496617
prisoners,0.015051505422737213
accounted,0.011698005814261555
for,0.00988984253340338
"17,307",0.006283424586671657
episodes.,0.015181805475963917
In,0.15364084913959736
both,0.11168470617488142
"sexes,",0.08007660139231174
self-harm,0.10096631918766474
was,0.13013942441069312
associated,0.16488313557936754
with,0.12420282228390617
younger,0.10084690858238446
"age,",0.07562549799007191
white,0.09010932974591315
ethnic,0.062418958229594854
"origin,",0.07619969931799808
prison,0.082256851448732
"type,",0.08588120907867505
and,0.07699145868334573
a,0.08689452751928732
life,0.06519598126737551
sentence,0.05784555304869374
or,0.06570112997099739
being,0.09270896387941258
unsentenced;,0.07458601707526012
in,0.13092072578625705
female,0.089497878883676
"inmates,",0.08695407320615736
committing,0.0759555631366533
a,0.06362689009218767
violent,0.04677618229174344
offence,0.06614362137960783
against,0.057091839360116366
an,0.05418014983916397
individual,0.05880604189842019
was,0.10065965850505859
also,0.0715251151558517
a,0.06726991474061986
factor.,0.06422463603649231
Substantial,0.034182473986887445
evidence,0.07095468140645067
was,0.07068476874416851
noted,0.06025223357370366
of,0.04648810425772367
clustering,0.02643233161030748
in,0.034840229134573
time,0.027140328187870627
and,0.019132171377281803
location,0.018316600943720514
of,0.026625985401220343
prisoners,0.035078422437796866
who,0.023133607718243833
self-harmed,0.021176146775690886
(adjusted,0.03666410148253684
intra-class,0.051870096034204186
correlation,0.05704469037637814
"0·15,",0.02954250878294053
95%,0.04602429180239359
CI,0.06322260009559995
0·11-0·18).,0.03956666609995068
109,0.03835640961898233
subsequent,0.03437218289087716
suicides,0.03524850991442602
in,0.03248906528806412
prison,0.04331048330969537
were,0.04430874085655145
reported,0.04515871198207843
in,0.04751527128442223
individuals,0.038654927370163454
who,0.030607474127490545
self-harmed;,0.04183855798749461
the,0.06939040357886703
risk,0.04332667755075049
was,0.06921944949293928
higher,0.055434787115862895
in,0.0878136334777093
those,0.06386512566186187
who,0.03989757211797758
self-harmed,0.047892075981265145
than,0.07980373855409822
in,0.06452009886723231
the,0.0418437911664973
general,0.04781186460203612
prison,0.04067126880676842
"population,",0.04739744595506928
and,0.12191865236892095
more,0.06723867856470175
than,0.04852762067675986
half,0.04740908408313184
the,0.053262053490687855
deaths,0.024449931552273107
occurred,0.04920477126063244
within,0.0425053014272084
a,0.044567775049147246
month,0.03189289171028934
of,0.04162835460604132
self-harm.,0.03245274488465007
Risk,0.09684453105475509
factors,0.06706907055769883
for,0.09315528717317102
suicide,0.11477462076160702
after,0.12947819244333014
self-harm,0.12257317297513184
in,0.10535442314065768
male,0.11024925070778889
prisoners,0.13341558249941082
were,0.11505928300838919
older,0.10487359209345888
age,0.08246592809171538
and,0.11086319156569667
a,0.09915518487694205
previous,0.12166243436315727
self-harm,0.1022701502389996
incident,0.12259461744152307
of,0.09369799893726093
high,0.07588782766739881
or,0.08752971962803478
moderate,0.08802255479950866
lethality;,0.09911506974638117
in,0.15047613946673516
female,0.14694927613978911
"inmates,",0.1601959836914211
a,0.12830543510197323
history,0.13053178357030837
of,0.15018387808298622
more,0.007317560265739555
than,0.0022986575421769114
five,0.002455311376287095
self-harm,0.00182322260867501
incidents,0.0018561170555953933
within,0.0023179948396243734
a,0.0021228343264664616
year,0.0014630849140215747
was,0.002385780620424004
associated,0.0018581947006577166
with,0.0023074561802302693
subsequent,0.002171632366984322
suicide.,0.0013208377275166308
INTERPRETATION,0.012158928423691028
The,0.0033446548577847138
burden,0.003753232539268028
of,0.004235189561513086
self-harm,0.003941056141846808
in,0.005907605246476658
prisoners,0.003977333829294486
is,0.003498268364614662
"substantial,",0.005134302292003121
particularly,0.0033188848505993187
in,0.0065442262513543325
women.,0.005408274674501096
Self-harm,0.0057749449113565715
in,0.00599827695974548
prison,0.006469141900797766
is,0.004022275680971429
associated,0.0045734583161489
with,0.004854799761601458
subsequent,0.00587137353838417
suicide,0.0037395233740980206
in,0.004110766739841428
this,0.003983656581310145
setting.,0.004717475867310362
Prevention,0.001249096821724853
and,0.002147261802810427
treatment,0.0010762784373796702
of,0.0015284907634751117
self-harm,0.0015245348646621324
in,0.0015526614788868535
prisoners,0.0013124366510153204
is,0.001413627412366879
an,0.00132688828199433
essential,0.0012484554170211254
component,0.0011343435075030816
of,0.0014314889183077
suicide,0.0009490346680119724
prevention,0.0010536023823048135
in,0.0012895511827690131
prisons.,0.0012630130702016528
FUNDING,0.0030785351125663676
Wellcome,0.0016866149691878295
"Trust,",0.002198440972074679
National,0.0015029505025451766
Institute,0.0014064426795688653
for,0.002211607902814982
Health,0.001215822127187677
"Research,",0.001641439073696301
National,0.0011895082527046468
Offender,0.001889065235718761
Management,0.0011399953843011263
"Service,",0.0019266388424957449
and,0.0026269784841769853
Department,0.0017960504129279496
of,0.003177565890761541
Health.,0.001456105656876474
The,0.002327258664425367
clinical,0.0014700212797963189
course,0.0020162899546142124
and,0.0018955203378111375
eventual,0.0017762600341320316
"outcome,",0.0015890022186176834
or,0.0014826437332400122
"prognosis,",0.0015176140442069688
of,0.0026971239766570843
complex,0.0014639507356468448
diseases,0.001429654176908448
varies,0.0023056653589714816
enormously,0.0021680282221128873
between,0.0016405324923332622
affected,0.0014369326823489112
individuals.,0.001552547274031225
This,0.0016487270209079696
variability,0.0011014828301170666
critically,0.00119979666414907
determines,0.0013371303627040347
the,0.0009817567728999728
impact,0.0010806916891741723
a,0.001285737962988494
disease,0.0009622221855671578
has,0.000992597286679724
on,0.0013557789644706424
a,0.0012034487290067029
patient's,0.0012155621640610697
life,0.0012865443075209333
but,0.0011575709712497077
is,0.0011606083838402183
very,0.0011037697842350076
poorly,0.0009829046581706772
understood.,0.001045082150804046
"Here,",0.004599552682616173
we,0.0037764914831173355
exploit,0.0021036021592809317
existing,0.00167138825431086
genome-wide,0.001605209554147753
association,0.0016894599736067854
study,0.0019604734368444507
data,0.0016932025982611693
to,0.0016835118647757948
gain,0.0016873907334196982
insight,0.0017445628465491694
into,0.0016645010092093545
the,0.0015403122547517079
role,0.0011366339150335593
of,0.0017833822193293665
genetics,0.0018329874492063651
in,0.0017929191309098253
prognosis.,0.0017733387568330582
We,0.47807766572800026
identify,0.477989843735542
a,0.47403611400498924
noncoding,0.48933748104373037
polymorphism,0.44702633837945727
in,0.4862240483652677
FOXO3A,0.5002348981624882
(rs12212067:,0.4865124506946365
T,0.5254235746508796
>,0.4939659224489211
G),0.4911155329905457
at,0.619913944165494
which,0.5762391085430945
the,0.6033351173586724
minor,0.6028217226364841
(G),0.6416110321467872
"allele,",0.6099157135825455
despite,0.8175308942460161
not,0.7633997573517654
being,0.7356362632501573
associated,0.7133874907124202
with,0.7274726074227968
disease,0.658550659835435
"susceptibility,",0.7049236001080317
is,0.6368282928426245
associated,0.6510048779749089
with,0.6693702113774861
a,0.5551832861274697
milder,0.7176052356215237
course,0.6712222097417287
of,0.7359701702850298
Crohn's,0.6053892279745837
disease,0.6518430506886843
and,0.7657185995752278
rheumatoid,0.76561061818575
arthritis,0.7129165080278645
and,0.7641737625339231
with,0.7820851565859038
increased,0.7296562042044284
risk,0.6935830020701762
of,0.7402686049951843
severe,0.6584315424921395
malaria.,0.5406827405125348
Minor,0.8926771393014447
allele,0.901989905244876
carriage,0.8777450560252907
is,0.8782055938852478
shown,0.8971546559338206
to,0.8655680084051238
limit,0.9004569151714322
inflammatory,0.9037477357259938
responses,0.8973295328015084
in,0.8940700607859515
monocytes,0.9135277109196656
via,0.9172049219341208
a,0.9094180780691242
FOXO3-driven,0.903276460846564
"pathway,",0.9193568320725836
which,0.9208528456059795
through,0.9501541925997815
TGFβ1,0.9148172746153753
reduces,0.9196223549194246
production,0.9226728643495856
of,0.921356530466655
proinflammatory,0.9285202495246634
"cytokines,",0.9276928847244412
including,0.9039004360165696
"TNFα,",0.8898727612403836
and,0.9326772515179588
increases,0.9065572614768614
production,0.8921388408604453
of,0.8687307144385666
anti-inflammatory,0.8503036574091246
"cytokines,",0.8879793771183344
including,0.82448760524412
IL-10.,0.8485112573134436
"Thus,",0.2697133522475392
we,0.22013465389774003
uncover,0.09613001213414374
a,0.08021028693210865
shared,0.06401702948632772
genetic,0.06375238239486254
contribution,0.10476475563310257
to,0.073204770450227
prognosis,0.09937627917392203
in,0.07800740193260852
distinct,0.05519418243445272
diseases,0.06455729335719702
that,0.08104905664108888
operates,0.06878792292383777
via,0.11503267319382135
a,0.11812767431773318
FOXO3-driven,0.5614749192506541
pathway,0.6035533991887188
modulating,0.5766769999266442
inflammatory,0.5059079087890935
responses.,0.5570782770954914
Background,0.0019962889783017666
Extensive,0.0013072534850514916
debate,0.0008537527239181133
exists,0.0009712896812117566
in,0.0011968161206651665
the,0.0010143411690634932
healthcare,0.0006404558278895469
community,0.0006813176713034299
over,0.0006315484017331947
whether,0.0007239136813028483
outcomes,0.0005987021670562705
of,0.0009686826454608203
medical,0.0007611390474816948
care,0.000916891861709091
at,0.0011375183210436692
teaching,0.0009638090340018999
hospitals,0.000917863398080727
and,0.0007397470466115128
other,0.0005270451964190284
healthcare,0.0006809914698459506
units,0.0007533458457597269
are,0.0007423702418589524
better,0.0007070631027422599
or,0.0010081058058911945
worse,0.0006180687808011877
than,0.0008589341391143616
those,0.0006607397411621416
at,0.0011839686450617684
the,0.0008869925702469215
respective,0.0007814225009526933
nonteaching,0.0008468767124867279
ones.,0.0007910565016957301
"Thus,",0.0009013840629448534
our,0.0010476550211144591
goal,0.0009645372704540833
was,0.0011756814729482448
to,0.0008315969167798977
systematically,0.0005858658192369116
evaluate,0.0007284930175141699
the,0.0007129927618836084
evidence,0.0006198264137180081
pertaining,0.0006857550031868688
to,0.0009673411974590524
this,0.0009003698997747209
question.,0.0006707281849431674
Methods,0.0014285977217215835
and,0.0018464396917399328
Findings,0.0013515249447370458
We,0.0026643575493682627
reviewed,0.0011100998510473379
all,0.0019104491537753063
studies,0.001677089208612526
that,0.002280547469297212
compared,0.001403678192073373
teaching,0.0016199804834948481
versus,0.001686166216504018
nonteaching,0.0011741784090427267
healthcare,0.0018028381507443154
structures,0.0009705986573444754
for,0.001238438080707177
mortality,0.0010616942599411979
or,0.0010127544228478757
any,0.0008520858491687239
other,0.0009846533912340283
patient,0.001253098070253082
"outcome,",0.001083316525943526
regardless,0.0008122749155571195
of,0.0011814456624028016
health,0.0010733863254216232
condition.,0.0008183624009768866
Studies,0.0012264231294601552
were,0.0013073988543833592
retrieved,0.0010466005863196584
from,0.0017263603912249204
"PubMed,",0.001388319977656678
contact,0.0009486832209963074
with,0.0011181337495787265
"experts,",0.0008081804584714904
and,0.0015518747812904088
literature,0.0010045180095702173
cross-referencing.,0.0009419884184620101
Data,0.002229669741280898
were,0.003068162143976694
extracted,0.0012708597024356997
on,0.0021248736800018077
"setting,",0.001278888698160642
"patients,",0.0014216493805491398
data,0.0021758661551175137
"sources,",0.0018811989891915635
author,0.001862234639783487
"affiliations,",0.0028773409556499697
definition,0.002113121751728838
of,0.0036707804150771903
compared,0.004404242495546804
"groups,",0.0016187581819123123
types,0.0007281914330817822
of,0.0009911431944370185
diagnoses,0.0007285134978512642
"considered,",0.0007406799380712733
adjusting,0.0011252704946837062
"covariates,",0.0009116177759467398
and,0.001156390615532034
estimates,0.0011777534277660102
of,0.0008525966997757841
effect,0.0008953611596146817
for,0.001243723025535296
mortality,0.0009623049270363612
and,0.0013245281343233575
for,0.0012069434627067757
each,0.0011275238066145177
other,0.0009175516777148111
outcome.,0.0009222878176536317
"Overall,",0.001580633297975527
132,0.0012090724606192993
eligible,0.0013386941557384836
studies,0.0020624790114627347
were,0.0017154701930078113
"identified,",0.0011905825890045113
including,0.0015197814513220327
93,0.0014141050695826486
on,0.0020982877363161494
mortality,0.0012748176486837225
and,0.002114427274510098
61,0.001356980005904342
on,0.0020963825738865454
other,0.001351110538610819
eligible,0.0010965067742408508
outcomes,0.0014159771931607462
(22,0.0013513376740777257
addressed,0.002196745545898979
both).,0.001919494594692121
Synthesis,0.7104913560559029
of,0.6520898588793418
the,0.6314157682949466
available,0.6260566910337421
adjusted,0.7087589263665782
estimates,0.7194889337046565
on,0.6818848907809199
mortality,0.7687267239161301
yielded,0.7165335563757668
a,0.757978836808771
summary,0.7598715782410207
relative,0.8019806785227809
risk,0.8212683321508509
of,0.7379972916913852
0.96,0.7764402667880821
(95%,0.727048916203613
confidence,0.8087966614227858
interval,0.8132292628180533
"[CI],",0.7772396507175373
0.93–1.00),0.7718668620812708
for,0.7635652527113422
teaching,0.7731623141063937
versus,0.7792698018384915
nonteaching,0.7857861483186626
healthcare,0.8014192391207438
structures,0.8189333950769314
and,0.7716762673279248
1.04,0.796799991430939
(95%,0.7255869963497109
"CI,",0.827340073762866
0.99–1.10),0.7846144774626381
for,0.791829874235844
minor,0.8205412425497676
teaching,0.7876360700024402
versus,0.7586611418346232
nonteaching,0.08951892677249873
ones.,0.03250264776902263
There,0.016898452134637594
was,0.01561160999994567
considerable,0.01164684222345995
heterogeneity,0.0048247978750107275
between,0.006149352646458493
studies,0.00651827533919453
(I2,0.01492950177672114
=,0.03151814400167493
72%,0.016888707312534987
for,0.019590208945277136
the,0.011216275161783267
main,0.01068401838131897
analysis).,0.0134907951915338
Results,0.006009087359049428
were,0.01403044001376106
similar,0.0080074398188139
in,0.011678143368674666
studies,0.008951079439578503
using,0.007855666019633303
clinical,0.00596783816245759
and,0.009153693363726153
those,0.005962615818044154
using,0.006006446288140154
administrative,0.004638415888531907
databases.,0.003950493006739464
No,0.025053738133756963
differences,0.011426700995283078
were,0.020666399913811598
seen,0.01841784046560295
in,0.024713545020227747
the,0.015481021824250967
14,0.011110255772273928
studies,0.013703881183029678
fully,0.022058622909135857
adjusting,0.009768419151817889
for,0.008532670658083828
"volume/experience,",0.00569545276052734
"severity,",0.003408478967456024
and,0.00989649953556128
comorbidity,0.005213631043857579
(relative,0.00624978554043799
risk,0.005346343558507485
1.01).,0.006578760210721553
Smaller,0.008535777381406488
studies,0.012232554945344283
did,0.015004222869405774
not,0.008403960554994297
differ,0.008228971258284278
in,0.009367593742436646
their,0.008268479032263522
results,0.005264294495789938
from,0.005740538543620059
larger,0.005026913514089377
studies.,0.006406739156645347
Differences,0.2103968285036732
were,0.2673249201757504
seen,0.33872896445944917
for,0.28841318763618595
some,0.31848179373771707
diagnoses,0.15886019761265713
"(e.g.,",0.46865468605129185
significantly,0.5632001272225399
better,0.5746643204330683
survival,0.4536071646595474
for,0.5101594765479213
breast,0.5182481231749119
cancer,0.47038520647213367
and,0.49394390920145537
cerebrovascular,0.5487130895190849
accidents,0.4857342885307819
in,0.5598183513338995
teaching,0.5141243524754565
hospitals,0.44272986517313767
and,0.6042363155418977
significantly,0.621989915554396
better,0.6138519910842878
survival,0.51220441570152
from,0.6386930622768503
cholecystectomy,0.6140443052501245
in,0.3603048893582504
nonteaching,0.19734459569439217
"hospitals),",0.22092601645199825
but,0.16379531968562944
these,0.1509950418916633
were,0.1752504703303767
small,0.13045283248174655
in,0.1841150588067294
magnitude.,0.13473694333284086
Other,0.13574557603949788
outcomes,0.10993199047018988
were,0.1580725598209384
"diverse,",0.08446681811987826
but,0.16951610433893813
typically,0.18161997189900933
teaching,0.20776050664397078
healthcare,0.15350471080741274
structures,0.15003545995712722
did,0.24740888738306457
not,0.22126354302409204
do,0.1891380042155396
better,0.18000177150235286
than,0.23376684383498006
nonteaching,0.16019897472843697
ones.,0.13981022652425693
Conclusions,0.6670240864575402
The,0.6471457246253839
available,0.5377742032681898
data,0.6747211678339438
are,0.6283443628617467
limited,0.6627119832961236
by,0.7542879868755894
their,0.6813592444796781
nonrandomized,0.7150409857009336
"design,",0.6442569401676381
but,0.8011490573332457
overall,0.8384905090552766
they,0.7373555120735268
do,0.7888122016661754
not,0.7846423679102417
suggest,0.8087487256389262
that,0.8046703062810774
a,0.755179605294706
healthcare,0.7498921354690102
facility's,0.6573243058729304
teaching,0.7468569559262995
status,0.7477661344638958
on,0.7963856095968281
its,0.7660307886409518
own,0.7807132249774941
markedly,0.8357923002047393
improves,0.7761458513237852
or,0.7517365637918328
worsens,0.6980072838007001
patient,0.6006066547872533
outcomes.,0.6369847098646269
Differences,0.02422755204999223
for,0.022379908801108638
specific,0.01447278185426089
diseases,0.021630479383289405
cannot,0.02522934064949882
be,0.017479125553031116
"excluded,",0.018476108717989995
but,0.020816582419581724
are,0.018260815915317606
likely,0.012688426690335743
to,0.014331233173449946
be,0.013507114466350327
small.,0.013940203683322725
Autoimmune,0.007373250196225971
diseases,0.006617859275851413
are,0.006302860724385067
thought,0.004184645603873306
to,0.00421171548816104
result,0.006578104249478119
from,0.013250256650948858
imbalances,0.0058737091476992
in,0.009061734932453977
normal,0.0067914256866354866
immune,0.009184902296266144
physiology,0.009438710256120492
and,0.007735684638288157
regulation.,0.006569265242893402
"Here,",0.385465654621425
we,0.5198743005130477
show,0.5071215928461575
that,0.5081043316219072
autoimmune,0.2919388146465202
disease,0.3487277889947995
susceptibility,0.3495145565826169
and,0.3283996691216636
resistance,0.27859215473447213
alleles,0.28312201342921867
on,0.32884126999257146
mouse,0.32895310397510263
chromosome,0.30369127861080697
3,0.22841190778769185
(Idd3),0.28542935776533124
correlate,0.34614729541774497
with,0.2866009133926426
differential,0.2373267347856994
expression,0.260097814821627
of,0.16505594034433488
the,0.19606728122998815
key,0.27261205181456183
immunoregulatory,0.22532661143853158
cytokine,0.220518228993615
interleukin-2,0.21986839832755276
(IL-2).,0.17081247773886385
In,0.662503091709592
order,0.6269735119211763
to,0.46385264281784144
test,0.4413073985150565
directly,0.4960379869995771
that,0.4675956299853005
an,0.6036372504788957
approximately,0.5498033629714332
twofold,0.5376095764104881
reduction,0.5502959042713585
in,0.6089077931700687
IL-2,0.5796018313741637
underpins,0.49960408740569445
the,0.5780400645698646
Idd3-linked,0.5583546069064791
destabilization,0.5332536997009342
of,0.6034749207477075
immune,0.6067692826536882
"homeostasis,",0.6858938735385404
we,0.6332147267272563
show,0.5933197077775751
that,0.7393822417732203
engineered,0.7937775990463354
haplodeficiency,0.7152356100057221
of,0.7726790362842137
Il2,0.5885121697526535
gene,0.7133802758889086
expression,0.7571101755875551
not,0.8687043119601897
only,0.8600925006317894
reduces,0.7673638365866063
T,0.37854917633390417
cell,0.5164198298079924
IL-2,0.44256687466524103
production,0.3804491097606921
by,0.5946646493236938
twofold,0.4331124536041832
but,0.5348593233642611
also,0.5258509773265735
mimics,0.4312295052852736
the,0.40482343385589253
autoimmune,0.3365149325947644
dysregulatory,0.43496473437025923
effects,0.34176859631843526
of,0.3157497609304607
the,0.3364476901478429
naturally,0.30241497313323246
occurring,0.32510202679124617
susceptibility,0.3479048268258693
alleles,0.3302937337582411
of,0.3873700319547497
Il2.,0.3123812196292145
Reduced,0.6976254073994738
IL-2,0.6905723197387207
production,0.7134901804806967
achieved,0.7094533988088372
by,0.7213724391934393
either,0.6300833182930364
genetic,0.6591569539798848
mechanism,0.7123523116633138
correlates,0.7295289986740227
with,0.6659944719549843
reduced,0.7051338104506303
function,0.6950372110032679
of,0.6611554534881122
CD4+,0.7385934044087079
CD25+,0.7168900598133158
regulatory,0.5761461676240479
T,0.6365785810861386
"cells,",0.6898540596950901
which,0.6087307497190683
are,0.615746286006734
critical,0.6360158007952752
for,0.6346649233244024
maintaining,0.6171700106899356
immune,0.6161116280313704
homeostasis.,0.6928112435101733
Genome-wide,0.0037031902386120627
association,0.0014814081616714564
studies,0.0024047495129684514
are,0.003099719774240652
now,0.002363373517953638
identifying,0.00164380024828078
disease-associated,0.000992947721026006
chromosome,0.0013392893797010124
regions.,0.001282817245510211
"However,",0.003035455463668083
even,0.0037663717701408948
after,0.004812149795991413
convincing,0.0036234642569326837
"replication,",0.002437097818908251
the,0.002780005405965378
localization,0.0014748636450484548
of,0.0019321542046322002
the,0.0020801439027314265
causal,0.0017763606493723572
variant(s),0.001714155975158746
requires,0.0030612470357214397
comprehensive,0.002621171044356516
"resequencing,",0.001680106512184024
extensive,0.0033453765781297383
genotyping,0.0014864964020049097
and,0.0031888076928047442
statistical,0.001451917823824455
analyses,0.0017176903190958526
in,0.0017287896092569536
large,0.001913922388017539
sample,0.001272905788960851
sets,0.001238020571227416
leading,0.0024881984773221545
to,0.003126841101391922
targeted,0.0013240696600212416
functional,0.0010656604006127157
studies.,0.0015957378570337466
"Here,",0.3812030649773207
we,0.3935049050865117
have,0.306541115593088
localized,0.2973806077259961
the,0.2855617043674068
type,0.3112094031953967
1,0.3392099683435226
diabetes,0.2668195107827244
(T1D),0.3442763608555318
association,0.35280378867404055
in,0.41104795430105673
the,0.35570029589714963
interleukin,0.3476889673185711
2,0.2953851640889866
receptor,0.36439005416029524
alpha,0.35301687113265806
(IL2RA),0.3228521656165604
gene,0.3748085133827446
region,0.38832731872877235
to,0.36185140653572545
two,0.321969210933979
independent,0.29010681464389404
groups,0.31405904526623163
of,0.293239949086601
"SNPs,",0.33213588861298204
spanning,0.2403389274077847
overlapping,0.20682918253786592
regions,0.2691899656805053
of,0.2953853377685328
14,0.31201048725518354
and,0.3135626610636126
40,0.23660356930423143
"kb,",0.2893141733030989
encompassing,0.2595047526821802
IL2RA,0.40061674761568494
intron,0.40239308416008757
1,0.3965188285222649
and,0.2765366216333065
the,0.2671350979742649
5′,0.3469124834658968
regions,0.2975791396143829
of,0.288127811923708
IL2RA,0.5659235193818104
and,0.5430819435877521
RBM17,0.6153664882367361
(odds,0.6253836438347986
ratio,0.6434281018411934
=,0.6337682592774115
"2.04,",0.7496134380974415
95%,0.7580061386787987
confidence,0.6948109172957406
interval,0.6818840115869489
=,0.64443452758305
1.70–2.45;,0.6897626023923846
P,0.6817995899997422
=,0.6911099855227677
1.92,0.6768499136063778
×,0.6554833804464039
10−28;,0.6447726139951383
control,0.5970015312548356
frequency,0.6302196633019914
=,0.5925609905815304
0.635).,0.6244827733776054
"Furthermore,",0.8327931173188438
we,0.7624388138506624
have,0.718801568071422
associated,0.782030266314331
IL2RA,0.7806048460479141
T1D,0.8320572053472262
susceptibility,0.7939951431692621
genotypes,0.773560521552935
with,0.7690161460127044
lower,0.777335713641787
circulating,0.7761875207766632
levels,0.7862934720914726
of,0.8051747699058049
the,0.7695570562724139
"biomarker,",0.7812045135281515
soluble,0.7376592383911537
IL-2RA,0.7754828310979043
(P,0.7017065653231401
=,0.7260586595604772
6.28,0.7574033376638153
×,0.6768635338336724
"10−28),",0.7126831684630273
suggesting,0.7535970570551951
that,0.7575857781649983
an,0.7760560319865645
inherited,0.798787711904035
lower,0.7801832324347959
immune,0.7512680616266738
responsiveness,0.8235352224411395
predisposes,0.7453842372692712
to,0.7317666293313382
T1D.,0.724386675211983
OBJECTIVE,0.0006615859883890815
To,0.0005825288747881661
determine,0.000700824476035483
whether,0.000651493886230723
perceived,0.0004840583889326368
age,0.00047362672406187377
correlates,0.0006252993143942623
with,0.0005022435901167757
survival,0.0003940189484828565
and,0.0006144542356395559
important,0.0004238411039623765
age,0.000456384207198605
related,0.000456660325602447
phenotypes.,0.0004880739911048451
DESIGN,0.0005465071911813968
Follow-up,0.0007912807929741204
"study,",0.0006911402677292397
with,0.0007860997418402728
survival,0.0005725604974152832
of,0.0008003068393399771
twins,0.000642271573906256
determined,0.0007448224240071943
up,0.0007628400206321724
to,0.0008724629228239669
January,0.000874042610119829
"2008,",0.0008483381661800336
by,0.0011529671292807209
which,0.001044677258134773
time,0.0008131792759848433
675,0.0015063540917283405
(37%),0.0007917273028204099
had,0.0008235642133797134
died.,0.0006330504474291514
SETTING,0.0014136307779568506
Population,0.0013085193934136176
based,0.0023969674548576735
twin,0.0014252368915720983
cohort,0.0010034863922829614
in,0.0015451713468615255
Denmark.,0.0008094762563022237
PARTICIPANTS,0.0023203658454065182
20,0.0008347936917677444
"nurses,",0.0008732307760011307
10,0.00114969092846043
young,0.001690452692212674
"men,",0.0011685406273141893
and,0.0012127065199598651
11,0.0011340328869380552
older,0.0012719105005759089
women,0.0012440944629008867
(assessors);,0.0010466337394705644
1826,0.0009634355983356395
twins,0.000957145283445183
aged,0.0011429246727236312
>or=70.,0.0030936887831889974
MAIN,0.001762365376919343
OUTCOME,0.0022553490109077003
MEASURES,0.002830975828281892
Assessors:,0.0013508535290223482
perceived,0.001323506086335414
age,0.0012614195226610476
of,0.0016040560338512464
twins,0.0011337228913227962
from,0.002473976067482762
photographs.,0.0013705955869708906
Twins:,0.00557945163409643
physical,0.008530522833053852
and,0.035530342255395385
cognitive,0.020757528737874804
tests,0.022601743299034735
and,0.025848291876721396
molecular,0.014826110717265419
biomarker,0.01711036394263431
of,0.02266441174062152
ageing,0.011433120690874874
(leucocyte,0.019232217157786474
telomere,0.020637520214032565
length).,0.02054168989559793
RESULTS,0.08914493811328442
For,0.07764434424987271
all,0.057161532854747496
three,0.050858525554436616
groups,0.031956566194464374
of,0.02670853887418738
"assessors,",0.030227241391447456
perceived,0.04838910795232696
age,0.037749755219870444
was,0.06636360695710644
significantly,0.06547743448811712
associated,0.06354224045238077
with,0.058355662436568714
"survival,",0.04644117681581658
even,0.054418551607161275
after,0.0684432268646437
adjustment,0.0495670823964933
for,0.03010711747334121
chronological,0.030261523275069833
"age,",0.024365939290903957
"sex,",0.04235768317602978
and,0.04570811779428936
rearing,0.06554619618902649
environment.,0.042447206914401625
Perceived,0.03486749373248422
age,0.028660626457584173
was,0.06049080940024653
still,0.04290792654818146
significantly,0.04974727166047635
associated,0.054225831560329465
with,0.058675906521735516
survival,0.03732866080240748
after,0.04683107235407003
further,0.0441351531685279
adjustment,0.044135047557315794
for,0.03390328393164975
physical,0.04185150109004122
and,0.049920159875417945
cognitive,0.03654620624771374
functioning.,0.0395529150398473
The,0.4001771293271336
likelihood,0.4310217616093009
that,0.4362211219150237
the,0.41053022433679076
older,0.4047757016250789
looking,0.4061672340741848
twin,0.362636964348474
of,0.35586658341701266
the,0.3646102822307313
pair,0.35385205708983924
died,0.37633834409376377
first,0.435481047824918
increased,0.40701786950772584
with,0.4142527832104226
increasing,0.4310783626255269
discordance,0.33916283857473223
in,0.3321457660484079
perceived,0.3689665268263362
age,0.3354950528743465
within,0.3276313971834991
the,0.3846548042682323
twin,0.3343529639155457
pair-that,0.37123103129136265
"is,",0.5213057268776221
the,0.4666520758604531
bigger,0.5248688049305138
the,0.4000003032569414
difference,0.39141266864213187
in,0.34577796029841146
perceived,0.3942932103468149
age,0.371806705800199
within,0.3115211133561837
the,0.365131652790822
"pair,",0.3531798379288193
the,0.35147987015756466
more,0.5011751127213637
likely,0.49083168390905424
that,0.17145020253584087
the,0.14899702586662938
older,0.12920268489337677
looking,0.11824678198706226
twin,0.116667287864669
died,0.12558350868831458
first.,0.17363776896833952
Twin,0.007866445472093933
analyses,0.011859187348846213
suggested,0.014233457464776863
that,0.015359812745960613
common,0.009637467804066576
genetic,0.00646418805031416
factors,0.005655027587640889
influence,0.009855929425765731
both,0.008273102072614712
perceived,0.011098953245163043
age,0.0060619435394249745
and,0.007913707474518849
survival.,0.009395767393630043
Perceived,0.013570610764327454
"age,",0.011360983027276552
controlled,0.013251734307962093
for,0.013751471589143237
chronological,0.008437801914730085
age,0.009100766458109344
and,0.017404420890039535
"sex,",0.012207957269256033
also,0.02104806329853065
correlated,0.024040890426715606
significantly,0.02124660877586264
with,0.020588343735943513
physical,0.03063455452026414
and,0.04147474427146969
cognitive,0.033886662233790964
functioning,0.031242424183700834
as,0.04576645830540612
well,0.03444109502968539
as,0.0370214906028694
with,0.021731583034301217
leucocyte,0.027175634752370274
telomere,0.02465558842525003
length.,0.027825977775798306
CONCLUSION,0.6372648757745325
Perceived,0.35019705337159845
age-which,0.23695100018114432
is,0.1843343308499176
widely,0.14093697206862746
used,0.14352845524510158
by,0.1400653673278133
clinicians,0.1529007097062796
as,0.21403396429882485
a,0.18709474096993134
general,0.21287509150807185
indication,0.18580486340553437
of,0.13789159848492816
a,0.14108031048834874
patient's,0.15952154360585186
health-is,0.19162212758301994
a,0.4103873221535856
robust,0.3598354143252698
biomarker,0.3393595415397292
of,0.3618261851110258
ageing,0.24582522361406917
that,0.3953644249701156
predicts,0.36612077358734013
survival,0.28297232361483027
among,0.3013702647164508
those,0.2810829215482959
aged,0.17596733140426907
>or=70,0.2217139638674398
and,0.42973578844120897
correlates,0.38097635440442645
with,0.27108351931880864
important,0.26286632724650033
functional,0.2496471502334952
and,0.2774099934973147
molecular,0.28710845193305656
ageing,0.19011693862650308
phenotypes.,0.2551807987214741
Phosphatidylinositol-3-kinase,0.13404966218953396
(PI3K),0.0627480356853456
pathway,0.1295812584795666
deregulation,0.065638840743913
is,0.0842059998159097
a,0.094586189166166
common,0.10224295581383286
event,0.10715584307830954
in,0.08376500396199918
human,0.11556124555312447
"cancer,",0.08138471383282667
either,0.12864352599794718
through,0.15792698907133837
inactivation,0.16979784763030353
of,0.17316124326546994
the,0.22689096187285926
tumor,0.1838942176144943
suppressor,0.1979387998492341
phosphatase,0.18292377470095705
and,0.2749500680643968
tensin,0.24683998147574093
homologue,0.2174548962208224
deleted,0.19817689642450254
from,0.22095709257430954
chromosome,0.13714204589798293
10,0.1300334252187205
or,0.1889115331036886
activating,0.2349531247125179
mutations,0.17476052605890469
of,0.2283715196643946
p110-alpha.,0.14724799368091224
These,0.08968831249889417
hotspot,0.05768138258062854
mutations,0.05058500671960731
result,0.07929190964902115
in,0.16402625022271558
oncogenic,0.09968869100351557
activity,0.06912866819753241
of,0.11801037042045687
the,0.06944708985957097
enzyme,0.04944910057785455
and,0.14545500510361026
contribute,0.0512001441783813
to,0.0816483606937656
therapeutic,0.021628564677116796
resistance,0.027033064154425746
to,0.05709789760982144
the,0.042801657500709495
anti-HER2,0.027060070572169005
antibody,0.027406853540824352
trastuzumab.,0.05372176656497855
The,0.023963036121937176
PI3K,0.053266724349935714
pathway,0.031954246662005234
"is,",0.011551600421683147
"therefore,",0.012949232922255046
an,0.011699282094370583
attractive,0.010388674524964425
target,0.008993835654380467
for,0.009732385820990732
cancer,0.00722657430037767
therapy.,0.008754979521635495
We,0.13087338221239178
have,0.06711228612858251
studied,0.06265221752166161
"NVP-BEZ235,",0.14280884534255145
a,0.1306048599681668
dual,0.060940393284168934
inhibitor,0.09841549029530453
of,0.10331609384935367
the,0.0975065795206791
PI3K,0.08069480668778915
and,0.08516311713236914
the,0.09685988548670567
downstream,0.04310520350419682
mammalian,0.02989271452426628
target,0.058622175444017585
of,0.048694123889324765
rapamycin,0.06756325632011022
(mTOR).,0.043886265485417394
NVP-BEZ235,0.48101811450299753
inhibited,0.5863534749207746
the,0.5146800557418688
activation,0.5876595807394256
of,0.5576789400997696
the,0.45945356496861905
downstream,0.4662515502322696
effectors,0.5899385763702958
"Akt,",0.597667519129535
S6,0.5210833978035604
ribosomal,0.5645733679996635
"protein,",0.5338655528959091
and,0.5440412328378216
4EBP1,0.5272160310933345
in,0.585708258589389
breast,0.4735071463151366
cancer,0.4833212766040313
cells.,0.6390681280168818
The,0.1053489456890166
antiproliferative,0.09198071516803227
activity,0.11845122894969326
of,0.12248466617721417
NVP-BEZ235,0.20736621669056615
was,0.10039776121192702
superior,0.10471957811582851
to,0.09671068769643788
the,0.0928149251904458
allosteric,0.09774586254111665
selective,0.11696302341693131
mTOR,0.1318558079190425
complex,0.1347787393830758
inhibitor,0.1485703553501918
everolimus,0.18231881686671705
in,0.10667596681432741
a,0.10017582371715092
panel,0.11901121324367508
of,0.09199317137138835
21,0.06199351857460394
cancer,0.06108511766220419
cell,0.09199658688618145
lines,0.08199078707304695
of,0.06352721097457109
different,0.04115892006394316
origin,0.0434200428401279
and,0.04488607480084407
mutation,0.05898754394480808
status.,0.16516438898278915
The,0.10469209325353068
described,0.09873715696940248
Akt,0.11653421867505721
activation,0.14454359215969256
due,0.11972443594513792
to,0.09692010416663265
mTOR,0.07528119301314556
inhibition,0.06616051501430976
was,0.11161826810423708
prevented,0.08417529153629706
by,0.10350331421557792
higher,0.06870456457287345
doses,0.09252493896372721
of,0.10723370822049076
NVP-BEZ235.,0.11278060848145624
NVP-BEZ235,0.8990166095929765
reversed,0.9147383357896407
the,0.906499856681696
hyperactivation,0.9143424404700994
of,0.9006640381939679
the,0.9020631872580549
PI3K/mTOR,0.8891554320242473
pathway,0.9030538860145383
caused,0.9024989906887255
by,0.8884870585741578
the,0.8778504501356704
oncogenic,0.8967404476157167
mutations,0.8674160555052456
of,0.8727018631971604
"p110-alpha,",0.8224145546852009
"E545K,",0.8246977898555673
and,0.8865777601664807
"H1047R,",0.7832539200260089
and,0.9040393730451858
inhibited,0.929211812222279
the,0.8922051320298415
proliferation,0.8581445395795393
of,0.8539298238650513
HER2-amplified,0.7978617384636211
BT474,0.6823441826773045
cells,0.826042150677595
exogenously,0.7921999142484383
expressing,0.8074107590453522
these,0.7382093077148163
mutations,0.7324610412949423
that,0.7408589729228391
render,0.735796990678772
them,0.7517569589701522
resistant,0.6877411322458947
to,0.7218001518843121
trastuzumab.,0.6334954361746165
In,0.718420274714341
trastuzumab-resistant,0.6147104046204379
BT474,0.5041936152009563
H1047R,0.5730794401666595
breast,0.6824774695015895
cancer,0.6514689621094563
"xenografts,",0.6434546719191192
NVP-BEZ235,0.6140748521398375
inhibited,0.6620427641974478
PI3K,0.549516239791958
signaling,0.6418586148665432
and,0.639786658551177
had,0.5601403244220792
potent,0.5082685826585134
antitumor,0.5940133419633044
activity.,0.45782603719153797
In,0.05497754092512161
treated,0.03391292562116359
"animals,",0.028147795652452418
there,0.04333747033314644
was,0.060296858835073665
complete,0.08073686667568734
inhibition,0.05492099053146015
of,0.06190882823287647
PI3K,0.09305426390307635
signaling,0.11713781055365245
in,0.0614688781122027
the,0.06659571234997318
skin,0.04322140485061303
at,0.012230682571750341
pharmacologically,0.006691280352307076
active,0.0128721729846703
"doses,",0.02445763549443232
suggesting,0.016282986015815407
that,0.011949323434602418
skin,0.016632611103853015
may,0.007835832066379866
serve,0.008091004932471238
as,0.00848498047436613
surrogate,0.006784849682440244
tissue,0.01345235845195146
for,0.0072177808112643006
pharmacodynamic,0.005587441876903594
studies.,0.008526343673926493
In,0.43950985691234923
"summary,",0.5056721071903065
NVP-BEZ235,0.5561491300136789
inhibits,0.6490642412941423
the,0.6256706983667798
PI3K/mTOR,0.53608972471388
axis,0.651667011206302
and,0.724476309665372
results,0.6552047544512047
in,0.6856208646554974
antiproliferative,0.6655458561548335
and,0.6285554668567357
antitumoral,0.6464358489225815
activity,0.5735616222171975
in,0.660960750453455
cancer,0.5269091270957539
cells,0.6320298772140451
with,0.6053579107806021
both,0.5568398188812062
wild-type,0.5453405203388817
and,0.5643279065055826
mutated,0.5609108473178409
p110-alpha.,0.5665575139805618
The,0.043479844635729424
non-enveloped,0.03487561412500957
bacilliform,0.05772429853190124
viruses,0.04112344806735435
are,0.028509985043710037
the,0.03660286757284995
second,0.03898274231370615
group,0.0233003080068119
of,0.03369490482205643
plant,0.03816153842476967
viruses,0.037312518465376594
known,0.018454617271397442
to,0.02043643700992883
possess,0.026723327556118583
a,0.03477949414766942
genome,0.03084393012081145
consisting,0.03952201453253546
of,0.05181930198861949
circular,0.037143588438580045
double-stranded,0.03322665484689385
DNA.,0.03681547231439883
We,0.01678434293508838
have,0.009253720160399501
characterized,0.006822311658412856
the,0.007565464056323347
viral,0.009156180496896654
transcript,0.005377478022779357
and,0.009406364967449348
determined,0.0043831481118277
the,0.005289918081302757
complete,0.0030854326834851317
sequence,0.0037550560607707366
of,0.004317138686769518
the,0.005267780202136472
genome,0.0032140544183106336
of,0.004769234425503263
Commelina,0.010077244724652032
mellow,0.00849134527583504
mottle,0.007927839292429174
virus,0.010244765818300108
"(CoYMV),",0.00477615607099395
a,0.004042733630705908
member,0.0037989573102836425
of,0.005693086405125607
this,0.0057592880056746955
group.,0.006756203738116751
Analysis,0.0428543082592586
of,0.027470181199996526
the,0.02829894243114164
viral,0.05217965257668297
transcript,0.02154630849992726
indicates,0.052330363949016634
that,0.04431317823770856
the,0.03269350780467453
virus,0.060731982457273265
encodes,0.03379825230410834
a,0.04486945786972014
single,0.018718220116213047
terminally-redundant,0.020765875625835616
genome-length,0.029659512239643027
plus,0.05385160635721649
120,0.03772331499590972
nucleotide,0.027911187718102044
transcript.,0.03569208408565792
A,0.0820121445849959
fraction,0.09169868156840902
of,0.11470499006476526
the,0.08781609713806884
transcripts,0.09400801698057987
is,0.06909312875550076
"polyadenylated,",0.12576867483469842
although,0.1418021239906206
the,0.15100486854429462
majority,0.1427125006437387
of,0.1774472099302767
the,0.14276410192539318
transcript,0.1236206042858265
is,0.13910555281848735
not,0.32076993072627125
polyadenylated.,0.2899577296056152
Analysis,0.28765689120544796
of,0.24997273932293812
the,0.23777571959727406
genome,0.22069895013232033
sequence,0.21975803736540375
indicates,0.3213607505032012
that,0.3917619010931025
the,0.29720260688940126
genome,0.27967665251295154
is,0.34577408043205454
7489,0.36262775652748014
bp,0.33970719409161426
in,0.39532020715908267
size,0.29750725671855954
and,0.5337522169538658
that,0.45039222578132404
the,0.3690800784683017
transcribed,0.35127599274245563
strand,0.37158838138808803
contains,0.3966614020612064
three,0.43896163458301585
open,0.3775830663686837
reading,0.3160326619137123
frames,0.4051311721936775
capable,0.4172449434761017
of,0.49596524055964397
encoding,0.4047061403744718
proteins,0.3622389623961806
of,0.4541909785447948
"23,",0.5035731146931925
15,0.43221570779328694
and,0.41790620656164756
216,0.32812131683689905
kd.,0.35227024314743993
The,0.00940281780361373
function,0.009997759262246905
of,0.012183462962993972
the,0.05054582089224019
25,0.03463064542854145
and,0.02022689641210993
15,0.02596254485954973
kd,0.04533675878345497
proteins,0.03753298594133448
is,0.007207911069205648
unknown.,0.008543456198489955
Similarities,0.1292969681284332
between,0.077169798319637
the,0.11741108870144805
216,0.14819345052084876
kd,0.16575932735881618
polypeptide,0.06573854013078717
and,0.11234877309122232
the,0.11605158489521683
cauliflower,0.20753812729092075
mosaic,0.1684979308041991
virus,0.18988261979228901
coat,0.17987812641158085
protein,0.17674309666902835
and,0.12758071953151745
protease/reverse,0.16580068320841312
transcriptase,0.17220896640323521
polyprotein,0.14217064038623553
suggest,0.21843040990807658
that,0.187742646501526
the,0.14665302216102666
216,0.15454901752286157
kd,0.22365555383298788
polypeptide,0.18798584615034114
is,0.15465682077165133
a,0.17082567320545322
polyprotein,0.22016389509036682
that,0.20110729731181717
is,0.1515624924290391
proteolytically,0.246214953167214
processed,0.15909924119897703
to,0.15759803704303543
yield,0.19849690964833872
the,0.2015928114678064
virion,0.15343267596747645
coat,0.11234189587712796
"protein,",0.08874318880792202
a,0.08970085395219035
"protease,",0.11178374752972457
and,0.07202418207672859
replicase,0.08664268462067823
(reverse,0.06568208482072814
transcriptase,0.08697622716522077
and,0.08114610516082414
ribonuclease,0.0878232927208091
H).,0.06964864498075893
Each,0.040170662481083176
strand,0.03352550971305912
of,0.033162206596382186
the,0.03952493338188101
CoYMV,0.11078854922242955
genome,0.03427095375526723
is,0.028604815743082216
interrupted,0.023498108891719008
by,0.053960158979524143
site-specific,0.014242616232542494
discontinuities.,0.017897830337444298
The,0.016473709940286473
locations,0.009592603269634004
of,0.011880574274213502
the,0.014832390816896779
5'-ends,0.030400043325226972
of,0.01686449393310037
these,0.027582941599669897
"discontinuities,",0.013058792348251235
and,0.017218121919491215
the,0.010471338776669514
presence,0.011604332940133162
and,0.016389021251593486
location,0.008864848457320742
of,0.010110453534642884
a,0.010938612125855002
region,0.025037841644751722
on,0.023177171080612312
the,0.01738466507938096
CoYMV,0.06729114537319249
transcript,0.017530583817419773
capable,0.02960765818111323
of,0.031354018079215146
annealing,0.018479745266685145
with,0.03560391794773877
the,0.02808851865545276
3'-end,0.046162656748120534
of,0.03779281274946243
cytosolic,0.038065129723810494
initiator,0.08669867593183775
methionine,0.04294671602845051
tRNA,0.033954576535754795
are,0.016443823984580073
consistent,0.012671578906085267
with,0.019182465623904413
replication,0.012641957570280738
by,0.01950032106824169
reverse,0.007608558562602735
transcription.,0.01286238241410899
We,0.3987207951437108
have,0.391341202243147
demonstrated,0.38264052223918243
that,0.36365965244319376
a,0.31098997319450217
construct,0.2659555257084268
containing,0.2658207711017026
1.3,0.2695372442676683
CoYMV,0.28584557424665286
genomes,0.36729636398157894
is,0.4080149747026957
infective,0.362648336930033
when,0.4473032305096433
introduced,0.3950725820435797
into,0.45339459608468563
Commelina,0.42370202713107874
"diffusa,",0.396195890450995
the,0.49105688576433587
host,0.3380371201540224
for,0.3997707312157447
"CoYMV,",0.4174886179146547
using,0.49914604135934126
Agrobacterium-mediated,0.3724419871307312
infection.,0.4047852021521647
UNLABELLED,0.22020914640482073
Congruent,0.36639934231575394
audiovisual,0.2711239953293073
speech,0.366873550228673
enhances,0.44848674630894925
our,0.3415933008545068
ability,0.3087240898692711
to,0.3007817616457965
comprehend,0.31019249609713206
a,0.2948335257394774
"speaker,",0.2802918685679301
even,0.28757305815161255
in,0.27941240701925557
noise-free,0.24795988268454658
conditions.,0.24514822534920097
When,0.5341624198640019
incongruent,0.39524516885622424
auditory,0.5020517070173706
and,0.5018190512271489
visual,0.43177649987035077
information,0.4443083043893559
is,0.48848126896025224
presented,0.4067505362582421
"concurrently,",0.43344675640367947
it,0.6102743300654898
can,0.599049619079301
hinder,0.5187263480050676
a,0.4302660797681204
listener's,0.4210075271911754
perception,0.41854806170873354
and,0.6512597702049233
even,0.6144628147314074
cause,0.5419165821555759
him,0.4279271997532613
or,0.3857404916281335
her,0.39919798006949153
to,0.44150404255849746
perceive,0.4251012261954442
information,0.3456109676542028
that,0.33183108830374825
was,0.4441551167512388
not,0.4076353708172342
presented,0.33445466791834544
in,0.28721177018658745
either,0.31946995024147684
modality.,0.2808073986949031
Efforts,0.015419710042187597
to,0.0060211355793855425
investigate,0.008251700026943186
the,0.004276583853250001
neural,0.005460293508297339
basis,0.005933066975346509
of,0.0066187119844892586
these,0.011245682050168777
effects,0.009411991615900008
have,0.010740128969548995
often,0.009924494301554546
focused,0.01591146810508248
on,0.010383525980877512
the,0.010365458694556037
special,0.010633275719234288
case,0.010549690148008198
of,0.020882402397152135
discrete,0.015140416465645205
audiovisual,0.02395863958186869
syllables,0.027490612343931107
that,0.01914408979530059
are,0.01305764931575439
spatially,0.012414211632425164
and,0.01781345165182097
temporally,0.010290979215957148
"congruent,",0.018961588902115578
with,0.025686911196504097
less,0.020750335697080492
work,0.0144960742867982
done,0.014345435654251145
on,0.01356049717998388
the,0.014646323611305781
case,0.01753906543593584
of,0.07072916194867361
"natural,",0.04074525939503834
continuous,0.02729973692787813
speech.,0.05307890897798848
Recent,0.02112230789918069
electrophysiological,0.015327658605485102
studies,0.016154729395998112
have,0.014458696357661754
demonstrated,0.02106814565246047
that,0.02040156231795309
cortical,0.021136317378882465
response,0.020968302791309804
measures,0.017615241202813266
to,0.014638339632698488
continuous,0.017551014305254246
auditory,0.0173803627201626
speech,0.03342806282718524
can,0.011933320077275938
be,0.009825185755281834
easily,0.008426166496073096
obtained,0.009862525412206493
using,0.0107857883724916
multivariate,0.013999072619121396
analysis,0.010745906075606092
methods.,0.009107582478563738
"Here,",0.041423450012646953
we,0.032400535308199266
apply,0.010916927415785881
such,0.017093511616240967
methods,0.01024060972849758
to,0.008209407985117585
the,0.00894391031735991
case,0.008515865399787497
of,0.012115498955990801
audiovisual,0.013761897121145665
speech,0.02233878337884727
"and,",0.027528866799324116
"importantly,",0.015294367802577247
present,0.012310433223354787
a,0.009157874293287967
novel,0.00787239094561499
framework,0.008818328942036059
for,0.012827317334761437
indexing,0.007755081782643941
multisensory,0.009642860210109476
integration,0.014314659258746436
in,0.00801794227960485
the,0.006687117176978184
context,0.0064917561870714655
of,0.009996954595552667
continuous,0.009593436868200692
speech.,0.015292315858125821
"Specifically,",0.015369410773401817
we,0.03367772220465896
examine,0.014518775963340716
how,0.010103998657095579
the,0.009195902878937337
temporal,0.012779974638055453
and,0.012067693865823305
contextual,0.009244424028523714
congruency,0.014026570120920193
of,0.016866438919216194
ongoing,0.017456245839885046
audiovisual,0.02454505531755063
speech,0.04145480665589586
affects,0.01019000808978046
the,0.012007443885228763
cortical,0.02804913843814754
encoding,0.03814430228008186
of,0.019969099539617775
the,0.019153271892844284
speech,0.05268093947922851
envelope,0.03491351197562165
in,0.020719817275819678
humans,0.02480176403008813
using,0.015027858185754528
electroencephalography.,0.013601591129800033
We,0.44681052531428006
demonstrate,0.32888493299749266
that,0.3921567244207195
the,0.3022964241195453
cortical,0.2809127743888011
representation,0.3648937117343427
of,0.5948766969517018
the,0.5205035719020107
speech,0.4690130604479148
envelope,0.5055436734770663
is,0.5001803152184995
enhanced,0.5331527157212067
by,0.5809673899455221
the,0.5513862495823284
presentation,0.5193459184722485
of,0.49121354363447
congruent,0.48020763896733715
audiovisual,0.48941021101526716
speech,0.5272450728456052
in,0.4505890573526615
noise-free,0.44178233415078205
conditions.,0.46368707494112654
"Furthermore,",0.6110628127198396
we,0.7240559913362121
show,0.7192437515340018
that,0.7211985793451884
this,0.6451234036345301
is,0.5481430865989688
likely,0.5691395413496202
attributable,0.5412581155697452
to,0.6493804526749161
the,0.6957565652274017
contribution,0.6929810416759938
of,0.6783517141452237
neural,0.7082369489650994
generators,0.6906748133254221
that,0.7175364540844276
are,0.6827032705648961
not,0.7191171083822352
particularly,0.6542401377037955
active,0.721220570878478
during,0.701446928619199
unimodal,0.7141798735380892
stimulation,0.7169189593258365
and,0.75163798704011
that,0.7041752680393707
it,0.707213524681357
is,0.6409060909625244
most,0.6133015565096189
prominent,0.6422018925986863
at,0.5845433694743797
the,0.606568493955353
temporal,0.6797905850575726
scale,0.5891124356992676
corresponding,0.5440954915878529
to,0.5432165342784115
syllabic,0.5754656586482261
rate,0.6030390942947135
(2-6,0.5068755416376672
Hz).,0.5785642795030995
"Finally,",0.5296638134742373
our,0.5126376294596191
data,0.4227800089774457
suggest,0.506505759894248
that,0.46654870880605387
neural,0.4082295347047843
entrainment,0.41124283627062286
to,0.3850979998063049
the,0.4233166250502163
speech,0.37837117365522455
envelope,0.45098412733401205
is,0.40379636387147083
inhibited,0.38113726821844135
when,0.4143485191806651
the,0.3829153271321021
auditory,0.39745184712873405
and,0.3920679096619375
visual,0.4294670232421034
streams,0.4157320870085355
are,0.3173739002113543
incongruent,0.3015765375854161
both,0.41270002315035226
temporally,0.3180936404803893
and,0.3668653506791725
contextually.,0.3110844221196433
SIGNIFICANCE,0.049190928088135424
STATEMENT,0.04277510148319449
Seeing,0.09688131754591472
a,0.04273997155970862
speaker's,0.028050636694487624
face,0.05364768773635215
as,0.07849865024703558
he,0.03587153760418712
or,0.03774249407336246
she,0.04265520260787186
talks,0.039017202776476835
can,0.08855888697805696
greatly,0.09579676435148399
help,0.05738250502758211
in,0.050948664166290396
understanding,0.05021419837020583
what,0.04102202819331066
the,0.034791053317627385
speaker,0.033853883017327197
is,0.04469894771089849
saying.,0.04449571943629998
This,0.25611267769784657
is,0.26776933253775265
because,0.3666014210738231
the,0.25506793059526306
speaker's,0.16117298202666547
facial,0.2054992676374459
movements,0.23689498139087614
relay,0.23678998895327055
information,0.16300259982139204
about,0.18152320426315535
what,0.16259847630090388
the,0.13987925672996682
speaker,0.09675613807750673
is,0.15683338157495227
"saying,",0.11937748963962538
but,0.3231813824386008
"also,",0.29290756392793144
"importantly,",0.23246627919792606
when,0.19681809558834906
the,0.12887317129285308
speaker,0.08396467535060685
is,0.12022346320503469
saying,0.13369849400727155
it.,0.12219426439197384
Studying,0.0021440713713521517
how,0.0014271699405180624
the,0.0023502206653573175
brain,0.0038513029918330554
uses,0.0017075040325780426
this,0.002770984018339352
timing,0.0016344120269689698
relationship,0.002504337366853659
to,0.0018485272000896206
combine,0.0022679467712677756
information,0.002179355754876242
from,0.0021999157936086005
continuous,0.0022237650823269967
auditory,0.002913899836726841
and,0.002998053737249015
visual,0.0035108568022171553
speech,0.0037027011910728746
has,0.0016666338605337045
traditionally,0.0012050253722909177
been,0.0014897496455596275
methodologically,0.0012841384069734723
difficult.,0.0014627839996736516
Here,0.27654793240225345
we,0.23851706168931572
introduce,0.12218392670100543
a,0.1007885251715042
new,0.07575934227029235
approach,0.07677908126173295
for,0.1395270343332616
doing,0.07328964113368101
this,0.08968704724797368
using,0.08976128142223946
relatively,0.06553166758972576
inexpensive,0.06527158804589078
and,0.13716056881676258
noninvasive,0.07360951856449817
scalp,0.07252835970272582
recordings.,0.06965661707559229
"Specifically,",0.18086130320015403
we,0.631745109802691
show,0.7420550120453397
that,0.7671885003352391
the,0.6993938263090809
brain's,0.6678150045397598
representation,0.6618550268195296
of,0.6402996862203858
auditory,0.6378773514231675
speech,0.616190168329339
is,0.6406208013668057
enhanced,0.588325698837944
when,0.6672493586681963
the,0.5206405252298607
accompanying,0.5466188438167251
visual,0.6445447173123356
speech,0.6337896957234439
signal,0.6319942144050259
shares,0.49854823796128345
the,0.5176608630191947
same,0.5159047953742179
timing.,0.5170910983140815
"Furthermore,",0.6546092609581255
we,0.6981893965451179
show,0.6730405439567234
that,0.6609378930789601
this,0.5622654970614325
enhancement,0.620898987055054
is,0.5568798207134074
most,0.523404870839391
pronounced,0.5608538054601699
at,0.5258829644895928
a,0.5082138421694313
time,0.5254122812412632
scale,0.49319098517428483
that,0.44380471870235394
corresponds,0.437137288558588
to,0.4264482293157044
mean,0.5558001911270113
syllable,0.48826186007033956
length.,0.4510732503673177
Histone,0.07554963579761645
levels,0.06153455411471696
are,0.053801470071000244
tightly,0.059965908901889096
regulated,0.06079635035153647
to,0.061707744551369514
prevent,0.07126988562715353
harmful,0.04504186966870137
effects,0.0637518345138746
such,0.09121698835295532
as,0.08840291625269006
genomic,0.08239358947241322
instability,0.0953909175746163
and,0.10356484878247124
hypersensitivity,0.07302847314759736
to,0.09448680500393863
DNA-damaging,0.06893678468664988
agents,0.06855547082385176
due,0.08561366944346178
to,0.11215907436175503
the,0.11158038822478014
accumulation,0.08045836989345262
of,0.0927256203546682
these,0.10552931668186792
highly,0.09165958391148493
basic,0.07787727394953001
proteins,0.08061291125204605
when,0.10164735909262283
DNA,0.08059065393746669
replication,0.09605140308920807
slows,0.10400025749451598
down,0.08335608787423343
or,0.08539815114530619
stops.,0.08494249812067971
Although,0.08166142979171213
chromosomal,0.04582311315129635
histones,0.0748130367806198
are,0.05167388433691249
"stable,",0.044247972735241226
excess,0.05662022904404229
(non-chromatin,0.06752087469367174
bound),0.08198036142221042
histones,0.06991424767074757
are,0.04206313725077419
rapidly,0.053606208921684086
degraded,0.0355450840837615
in,0.08963107113814107
a,0.10069947065885936
Rad53,0.05690795398736749
(radiation,0.04761200755225442
sensitive,0.07224526341748429
53),0.047814616221513576
kinase-dependent,0.04939464813445914
manner,0.08247040212539894
in,0.06670565921195637
Saccharomyces,0.052194847953574354
cerevisiae.,0.05969256019409449
Here,0.5778077162583753
we,0.6861782382022131
demonstrate,0.6011421830619162
that,0.702168399915742
excess,0.5526338124569145
histones,0.5366118715245367
associate,0.5515023189722363
with,0.539358974364147
Rad53,0.563385141807916
in,0.6449719134520412
vivo,0.6809244670866815
and,0.6097305446484652
seem,0.5632676344363439
to,0.5431117713137738
undergo,0.5476618764265171
modifications,0.5286437770354852
such,0.5587665330862492
as,0.5707343629741408
tyrosine,0.609442266261437
phosphorylation,0.2771589112309549
and,0.23146129673535643
"polyubiquitylation,",0.2400031704415731
before,0.21433268676492273
their,0.1787174421471198
proteolysis,0.2180781618658132
by,0.21791541735849423
the,0.18473871943377948
proteasome.,0.1963974309496015
We,0.31773939842451926
have,0.2867630376409137
identified,0.2814340173219002
the,0.30916677113645735
Tyr,0.2782982431017103
99,0.3198734113426638
residue,0.28738127213061954
of,0.33005856412280465
histone,0.24030328940270276
H3,0.2577893272264304
as,0.36584799858726413
being,0.34572095428369204
critical,0.4239327309056161
for,0.3839378279088681
the,0.40015009434217036
efficient,0.3887497316494445
ubiquitylation,0.3609381997132776
and,0.39962504220360817
degradation,0.30934251171544924
of,0.30811916729287125
this,0.24817176961456563
histone.,0.23537889593926628
We,0.18078397010986103
have,0.16052348562855515
also,0.13731351614606094
identified,0.12596852458459218
the,0.13197811617065897
ubiquitin,0.2166982365058403
conjugating,0.15035218265840813
enzymes,0.1407160161277847
(E2),0.14987318858571375
Ubc4,0.19782710606571893
and,0.22605164080528975
"Ubc5,",0.1738085523746193
as,0.12141527644492348
well,0.13058392814803751
as,0.10956659842353539
the,0.11124164258352734
ubiquitin,0.1622772176163445
ligase,0.15285484240579475
(E3),0.11017841817031016
Tom1,0.23724190364252412
(temperature,0.12015163713257902
dependent,0.12530869938527028
organization,0.14627390810803706
in,0.14376231093623737
mitotic,0.16639771304345102
nucleus,0.14074141585347047
"1),",0.13812581153867506
as,0.1399490472417223
enzymes,0.14754584899415954
involved,0.1397273964139668
in,0.15652972588053807
the,0.14588981331874834
ubiquitylation,0.18926137801519521
of,0.16613945741448524
excess,0.14637061561092454
histones.,0.17530258929819748
Regulated,0.17272204786445733
histone,0.16411506195426423
proteolysis,0.2377482819503919
has,0.08349419503565998
major,0.10945500353807287
implications,0.0799632005678711
for,0.10085548085365235
the,0.1092682261091268
maintenance,0.11417069558974932
of,0.13493568686412058
epigenetic,0.10611526327272153
marks,0.12716046953072319
on,0.1589521942882649
"chromatin,",0.1539314774319093
genomic,0.12754562195257468
stability,0.1623493135093741
and,0.11413555010014398
the,0.12211998656557985
packaging,0.1284626635586982
of,0.15396390504428664
sperm,0.12451508377503354
DNA.,0.16663402322650842
Genome-wide,0.0036267444116263115
association,0.0017494034193508382
studies,0.0029514978223226123
(GWAS),0.0012516666275139753
have,0.0024629590219942183
now,0.0022849066895165287
identified,0.0022921349240202305
at,0.0021653097133708696
least,0.0018499667000838995
"2,000",0.0017753974285750578
common,0.0018167222676346256
variants,0.00185935762042794
that,0.002231692046056435
appear,0.0018310708392143447
associated,0.001861923564226042
with,0.0016806788601034842
common,0.0014638420007880959
diseases,0.0013054064913677263
or,0.0010913337873056637
related,0.0010432232274548794
traits,0.0017917239186562273
"(http://www.genome.gov/gwastudies),",0.0018030329523080126
hundreds,0.0011910578616635085
of,0.0013489039064905422
which,0.0015150370657041866
have,0.0017208731065466204
been,0.0013994490024313289
convincingly,0.0014728822216183537
replicated.,0.0011669274600633586
It,0.13647624870345493
is,0.06394458885976462
generally,0.07399422802891527
thought,0.13022260913086126
that,0.20717439926976636
the,0.1879167256658513
associated,0.16906933305590277
markers,0.1904551106736306
reflect,0.2162455971600555
the,0.20442973287835167
effect,0.19776552261871777
of,0.19469087648716055
a,0.1874260489690419
nearby,0.1603058637878167
common,0.18701799729500246
(minor,0.22734270923986924
allele,0.1958583275075652
frequency,0.17463646691901
>0.05),0.22262928903802595
causal,0.19057594201054004
"site,",0.17506910553705488
which,0.19015371549243051
is,0.12480219584616578
associated,0.16742732710928274
with,0.19065290197974827
the,0.16444845834308686
"marker,",0.17581539432194881
leading,0.16296723673087052
to,0.18034798348469702
extensive,0.10466808902294583
resequencing,0.04792860117408031
efforts,0.07124107482178546
to,0.036464658125167436
find,0.0364587403542711
causal,0.05300531989185315
sites.,0.05481203125125355
We,0.2477908481999641
propose,0.1411456306993087
as,0.12456700861615407
an,0.10384715539428482
alternative,0.08161553545071186
explanation,0.15065608492269825
that,0.1693893599512177
variants,0.13298178413409453
much,0.12951366895836158
less,0.15470567107383898
common,0.12341086333668175
than,0.2190050007797264
the,0.1370076661283396
associated,0.12106744664870304
one,0.17983279418655268
may,0.1548026296339846
create,0.23203583454524213
"""synthetic",0.1041852969681221
"associations""",0.12726415822565676
by,0.14201769089535868
"occurring,",0.09597212233235192
"stochastically,",0.07884909468800655
more,0.1832710585151093
often,0.1090566665151869
in,0.16499763555028196
association,0.09758045620967751
with,0.09558512280259089
one,0.1090011916461964
of,0.09205082220473619
the,0.08387897180432419
alleles,0.05228733674680698
at,0.13105281809891983
the,0.07136589401515914
common,0.08790310533445404
site,0.12103049354699989
versus,0.15668284845875138
the,0.052266641710876756
other,0.10378453002263294
allele.,0.017525076004552383
Although,0.0026142571859536067
synthetic,0.0015953067894558916
associations,0.001675223287130912
are,0.0018800846228283733
an,0.0015907828598193817
obvious,0.0014128447934818294
theoretical,0.0013792738523118497
"possibility,",0.001309399866200017
they,0.0016337628524533345
have,0.0017066934456202415
never,0.001602603089882141
been,0.0013777040511870394
systematically,0.001343956374086914
explored,0.0013690229370995155
as,0.0014406880070820707
a,0.0015301825717083449
possible,0.0012339801331619795
explanation,0.0015591694510658362
for,0.0015151073971521505
GWAS,0.002902689207196963
findings.,0.0017573957273925164
"Here,",0.11577893242995756
we,0.0625854211924859
use,0.012740962061830629
simple,0.020350649981099467
computer,0.010269026205427965
simulations,0.01597073128110573
to,0.009288425707631632
show,0.013213165948164449
the,0.01149866571923574
conditions,0.012062345561558389
under,0.007103431956001913
which,0.010110303208392544
such,0.015606940932044377
synthetic,0.029929290161321315
associations,0.03332723305826623
will,0.007153042703102187
arise,0.01006766194428094
and,0.007894409685260288
how,0.00602642029267813
they,0.009565236364120686
may,0.004996972241424084
be,0.002817207160874995
recognized.,0.006140978511802172
We,0.3075404792755803
show,0.33618535428474294
that,0.4052191824561382
they,0.12518574026288626
are,0.2201561432165924
not,0.37163347434378347
only,0.2563470411503993
"possible,",0.10920082812595779
but,0.1271455323450737
"inevitable,",0.10987173569113166
and,0.45798546521099487
that,0.4346522921720822
under,0.26510731958150535
simple,0.24431115961444952
but,0.3197275149545937
reasonable,0.26454366091380144
genetic,0.18663846986847063
"models,",0.24561460832627902
they,0.2116868933140722
are,0.2818915094854546
likely,0.2468774818322464
to,0.25863478789886274
account,0.2925646544337852
for,0.2674285657231457
or,0.2736228825090819
contribute,0.2839063877240624
to,0.2542287017875994
many,0.22299939143077765
of,0.22205640280331415
the,0.1914425372190563
recently,0.1820596552778497
identified,0.20981594562351089
signals,0.06683174217256371
reported,0.03349649465866454
in,0.048413195208312235
genome-wide,0.02119426384716936
association,0.03431201756704596
studies.,0.04239219823819618
We,0.4250206733837592
also,0.32570069114005934
illustrate,0.2717646367434335
the,0.22499920735074563
behavior,0.19217388372987088
of,0.23570086978352384
synthetic,0.20665539980944064
associations,0.1901246570032654
in,0.2078266237435956
real,0.19410656166393042
datasets,0.21444290441867023
by,0.4306547927638702
showing,0.5055909173385534
that,0.6402421208515735
rare,0.5838044199178322
causal,0.6815659622357981
mutations,0.5502999643102783
responsible,0.7533296697325556
for,0.7471649588993666
both,0.8222183723219693
hearing,0.5888171221249232
loss,0.6783147718241171
and,0.7808750123503795
sickle,0.5678036622986302
cell,0.7074462693356729
anemia,0.7203939899785218
create,0.6304991472691178
genome-wide,0.4658607059156373
significant,0.557245524295011
synthetic,0.5129301755876408
"associations,",0.4848949240258253
in,0.6239851608974349
the,0.61745062892228
latter,0.6431188162276353
case,0.6471228958947732
extending,0.4366550466128055
over,0.4499223769209381
a,0.5415125851704905
2.5-Mb,0.4460209779999076
interval,0.5081998841249261
encompassing,0.40714531271385407
scores,0.4239064343003994
of,0.35426374780233455
"""blocks""",0.4047994167253857
of,0.3066138103570935
associated,0.3013289093436389
variants.,0.271407068270397
In,0.06140767167929731
"conclusion,",0.06399413321731764
uncommon,0.042260942584691326
or,0.03003132444011421
rare,0.03871095585545887
genetic,0.029014456932856324
variants,0.05043807811528541
can,0.0628815903442542
easily,0.04880680503025238
create,0.0865123570504735
synthetic,0.03438651673718087
associations,0.05604575512204185
that,0.039378594475958116
are,0.023463077897244448
credited,0.02738002504543497
to,0.030325579539635102
common,0.023048948569236238
"variants,",0.01907132568041287
and,0.027799472408099303
this,0.014308114338133445
possibility,0.008348914393825757
requires,0.01119308041186358
careful,0.00917607350035683
consideration,0.009180680947899065
in,0.012010422579378174
the,0.009720809440118557
interpretation,0.010939594936462897
and,0.009952888141048648
follow,0.007983265299080725
up,0.007882915332524755
of,0.00871836677455295
GWAS,0.01856274817243759
signals.,0.01213171933988846
Intestinal,0.2610739136881592
microbiota,0.2779819709911609
metabolism,0.3006147577737804
of,0.29197523658711594
choline,0.24306643806964381
and,0.2759121414706469
phosphatidylcholine,0.22144953132145606
produces,0.19226196189523836
trimethylamine,0.1647724973133317
"(TMA),",0.10986088194764618
which,0.16875265995103056
is,0.10606729478969189
further,0.15245174712306192
metabolized,0.10207048352807922
to,0.14677408283897458
a,0.12400325269171387
proatherogenic,0.13457941354487873
"species,",0.1430154526210316
trimethylamine-N-oxide,0.12768932812155664
(TMAO).,0.07669083335088835
We,0.66571546191435
demonstrate,0.6651288634329989
here,0.6496161125030692
that,0.7665224042549581
metabolism,0.7133304882079198
by,0.7879559045455989
intestinal,0.826822276999084
microbiota,0.8054063978955646
of,0.7827035284155973
dietary,0.8039331321574403
"L-carnitine,",0.6772378112283465
a,0.7670214920330852
trimethylamine,0.7321865890809419
abundant,0.7785635913824367
in,0.7791309517250716
red,0.7189928148746078
"meat,",0.7075110483554873
also,0.8056584239084614
produces,0.8040834299480846
TMAO,0.6903318294709279
and,0.8546288490527509
accelerates,0.8096303596729928
atherosclerosis,0.8480924606732317
in,0.7650945757678952
mice.,0.6767560337598514
Omnivorous,0.4685615781353773
human,0.3884467368925557
subjects,0.43629222378384647
produced,0.4436938055147407
more,0.4548855357280575
TMAO,0.3918148701725408
than,0.4958826377373714
did,0.42240599499160913
vegans,0.3545064955471099
or,0.18738385521451523
vegetarians,0.1684769040553066
following,0.18760765579354657
ingestion,0.1445646647193989
of,0.2055036906893601
L-carnitine,0.15537986189249753
through,0.19921556720281017
a,0.15248590654135055
microbiota-dependent,0.16978916827171514
mechanism.,0.15150579814177706
The,0.04146868810376511
presence,0.04022318106996115
of,0.03031840468317765
specific,0.022889138906362284
bacterial,0.029997035120822618
taxa,0.022716338543399932
in,0.03460514837603761
human,0.0337258222246459
feces,0.038365816033142874
was,0.04823125547822956
associated,0.042250599014861376
with,0.033798528700407976
both,0.042816673327541875
plasma,0.0316483316113546
TMAO,0.045877481330620605
concentration,0.03497196196158145
and,0.04486432885777682
dietary,0.027229758221505508
status.,0.03262526520158702
Plasma,0.005412351858692377
L-carnitine,0.007703851791998187
levels,0.003636853171596289
in,0.008263284104765543
subjects,0.002847049084399414
undergoing,0.003116629566484531
cardiac,0.0028296300544545278
evaluation,0.0026561430560714428
(n,0.00473837001037431
=,0.0041450211815873715
"2,595)",0.0037958519525431995
predicted,0.005534892963500073
increased,0.004694657696532789
risks,0.0023803567808331817
for,0.004777840428931322
both,0.009652730877341224
prevalent,0.005877466432228992
cardiovascular,0.0031221374184908497
disease,0.0022362171406436373
(CVD),0.003032298321281339
and,0.005840871602537312
incident,0.002940169528042907
major,0.0033900611614431754
adverse,0.0021693779152403207
cardiac,0.0022772591235209988
events,0.002425245916408623
(myocardial,0.00511860284099874
"infarction,",0.004818146740545925
stroke,0.0026927006344071437
or,0.0044089023322284576
"death),",0.002994605782995272
but,0.011134118173711042
only,0.011720842501635057
among,0.011365332753741249
subjects,0.005727845419629236
with,0.01301658421078582
concurrently,0.016002872174687943
high,0.005301907443099717
TMAO,0.020315019435455123
levels.,0.005185876330745074
Chronic,0.10749127954215312
dietary,0.07998637428671813
L-carnitine,0.7446921804390825
supplementation,0.875697717805948
in,0.8478552515057516
mice,0.878251533527434
altered,0.8881701663522503
cecal,0.8900673330006069
microbial,0.8748326597676594
"composition,",0.8245246390203571
markedly,0.8995427906945347
enhanced,0.9109501130741602
synthesis,0.8502000664716277
of,0.8633679166001803
TMA,0.837610348210984
and,0.8761157474785783
"TMAO,",0.8284064097332007
and,0.8908545082483325
increased,0.8886020575832837
"atherosclerosis,",0.8691277839023468
but,0.8187925677124455
this,0.8103634315898756
did,0.7736381277598566
not,0.756321247551888
occur,0.765003845358268
if,0.6686208037638005
intestinal,0.811450227400128
microbiota,0.8306718335243514
was,0.7095983553416968
concurrently,0.7307091978722433
suppressed.,0.7277550541625109
In,0.5076109880766618
mice,0.4731412589824526
with,0.41308799723160833
an,0.4118185079322498
intact,0.4564302386684651
intestinal,0.5372998929842204
"microbiota,",0.5385977405249855
dietary,0.5189980666694552
supplementation,0.4737706378512215
with,0.48315292110788544
TMAO,0.441181964136642
or,0.4745497730009166
either,0.43739399222259073
carnitine,0.4246352610917842
or,0.42637247642934195
choline,0.4591119352325864
reduced,0.48111660004848705
in,0.5225229896038193
vivo,0.4918948322701642
reverse,0.49451862629217863
cholesterol,0.5060150589803664
transport.,0.5017563758818362
Intestinal,0.09583177996148759
microbiota,0.058142123784890316
may,0.04806146071218721
thus,0.06970702611981351
contribute,0.05019496809372854
to,0.05456223290023633
the,0.05865886211146198
well-established,0.037691020446947936
link,0.05952875113867232
between,0.039473840409212105
high,0.04293199951182536
levels,0.0353424929657601
of,0.03705709587270897
red,0.07546611215204428
meat,0.09207249946272349
consumption,0.07255704076586336
and,0.03527594440506882
CVD,0.08084517351101952
risk.,0.05025451192304103
Deinococcus,0.010690945708677348
spp.,0.007390729034652772
are,0.008295167149504424
renowned,0.00875420779034798
for,0.00860260185669986
their,0.007718908218876887
amazing,0.007130314985126625
ability,0.009203135150433483
to,0.008929489970894822
recover,0.0072103529276058885
rapidly,0.005259724469071229
from,0.004551066767223749
severe,0.004024698611972943
genomic,0.003567444836624564
fragmentation,0.0032204203208356648
as,0.0054159068123781125
a,0.003888842576085807
result,0.0034951928529044027
of,0.0043642537429241825
exposure,0.002459500138578034
to,0.0035569451955692805
extreme,0.0022092389888374656
levels,0.002465296173829477
of,0.0028770639336982546
ionizing,0.002364706727995141
radiation,0.0028279325983814165
or,0.004008196859014893
desiccation.,0.0026323136085038916
Despite,0.0031103964800803102
having,0.002629079479525375
been,0.0022790496169939286
originally,0.002188687290891881
characterized,0.001803840272539914
over,0.0014998491341418206
50,0.0017751004104102162
years,0.0021714040271226735
"ago,",0.0020724690931030825
the,0.0020954799963985677
mechanism,0.0020452703816041095
underlying,0.0017219805624548853
this,0.0021711901739582336
remarkable,0.0016884055463657888
repair,0.0022132679137203707
process,0.0020094578742537884
is,0.0017733294718201428
still,0.0016176107279566477
poorly,0.0016527729138286619
understood.,0.0019103859631403493
"Here,",0.22488997973773456
we,0.2435688468369817
report,0.15916497644553884
the,0.1203069076221135
2.8,0.10026937072164667
A,0.10047892857751461
structure,0.08117946073581307
of,0.07972287017948411
"DdrB,",0.11801508545483548
a,0.08895892207436878
single-stranded,0.043658204001014916
DNA,0.07308799493064606
(ssDNA),0.06622291774110697
binding,0.058284423082020476
protein,0.11875103456557927
unique,0.06688453172957248
to,0.07539744371918346
Deinococcus,0.08239229163783547
spp.,0.07889929337375375
that,0.06865008217162404
is,0.038464199136765985
crucial,0.06891966284686057
for,0.06006416758563096
recovery,0.052511039239395034
following,0.04036129608503769
DNA,0.06351172393764624
damage.,0.04473777769792977
DdrB,0.34894351512724214
forms,0.4756851314365924
a,0.5435678019192363
pentameric,0.5354976756940334
ring,0.5070726501825691
capable,0.5846570974397685
of,0.7029852638644887
binding,0.5435886224544397
single-stranded,0.4945544597715589
but,0.5824512779801415
not,0.6041830595011984
double-stranded,0.07196672130141384
DNA.,0.05735223916115745
"Unexpectedly,",0.04681987770582787
the,0.05102282441382594
crystal,0.031514370749518295
structure,0.03141998907853724
reveals,0.08172872736251671
that,0.07230178984356399
DdrB,0.11548456327548788
comprises,0.04428459762320183
a,0.0498318695313727
novel,0.03423831658262518
fold,0.033459110101926405
that,0.0248011153022113
is,0.01584977873921997
structurally,0.015272978430924079
and,0.017498968350422726
topologically,0.010304027425729225
distinct,0.013470458295331864
from,0.02014348847337244
all,0.013144313112986203
other,0.014295255070183605
single-stranded,0.022356817139391427
binding,0.030634685502327258
(SSB),0.014924884644076231
proteins,0.0380502522718039
characterized,0.009441497067721863
to,0.003852699969424599
date.,0.007168326649911379
The,0.04192100901625617
need,0.03892861092130957
for,0.029663986359372677
a,0.033566728416357515
unique,0.024164921067441787
ssDNA,0.05702384103222484
binding,0.07000967741407953
function,0.06659293360293096
in,0.03955798736120534
response,0.034078475730696924
to,0.030432393963424172
severe,0.029172886165378588
"damage,",0.0483293809373603
suggests,0.05626323471315635
a,0.027719068843967402
distinct,0.021853193845946983
role,0.04521053327894825
for,0.042708909443397974
DdrB,0.11018183087187935
which,0.03923069484834291
may,0.033507908600032874
encompass,0.027001795971179906
not,0.10802778763860593
only,0.07142929647670841
standard,0.051349312039426075
SSB,0.07019994905296474
protein,0.0775036518860922
function,0.06888699844935524
in,0.05303894694788161
protection,0.0527126102045518
of,0.062117739293496385
"ssDNA,",0.0659334202608383
but,0.08048956179024264
also,0.04687631314502831
more,0.04358167822223373
specialized,0.031581863991714414
roles,0.03817303042496285
in,0.04333121870641879
protein,0.05780335753036398
recruitment,0.08560419309378198
or,0.03746490601338043
DNA,0.06582091073054235
architecture,0.06473571229453202
maintenance.,0.0400128595810533
Possible,0.02098332654526526
mechanisms,0.021192814714884815
of,0.030041055913586377
DdrB,0.14882911175802538
action,0.052724927483602586
in,0.04009969980381193
damage,0.05311711267760895
recovery,0.052057304617457174
are,0.01333800266432396
discussed.,0.014906066073242113
Background,0.03795488406863351
The,0.02920793490580337
catalytically,0.023444339672677277
active,0.03420528013355492
66-kDa,0.05304346161676542
subunit,0.03460636305911764
of,0.03579691096346229
the,0.03141414873423572
human,0.04128999605959545
immunodeficiency,0.022920374900561098
virus,0.03208068597076601
type,0.02361257359094358
1,0.028970466913972207
(HIV-1),0.03750179460959113
reverse,0.02077276355402404
transcriptase,0.045294670418501576
(RT),0.04218701323606779
consists,0.03077493058434034
of,0.05883941017167152
DNA,0.032507821348360784
"polymerase,",0.028438852370047528
"connection,",0.019455728969345124
and,0.026334443481210088
ribonuclease,0.030041795797237984
H,0.025414204239209506
(RNase,0.027729740469661552
H),0.04002810601161352
domains.,0.028495091282477427
Almost,0.0033705554059579243
all,0.0043317858233345215
known,0.004011545726059658
RT,0.008585710795558688
inhibitor,0.003891593002515079
resistance,0.0035130770807622795
mutations,0.00314040115003066
identified,0.0029845771948084285
to,0.0029606511812073086
date,0.002457239180793858
map,0.004383730798716431
to,0.0025111314503924046
the,0.0029974580219266542
polymerase,0.004569180535026366
domain,0.003180706734669985
of,0.0037365312059571445
the,0.0038425182828274408
enzyme.,0.004024419556924465
"However,",0.003115182482741752
the,0.0032402225841880188
connection,0.002938426911699723
and,0.0036037956553325486
RNase,0.004612266247149215
H,0.0032887752079150214
domains,0.002915885799413215
are,0.0025019537756547873
not,0.0020097151242899204
routinely,0.001991066981842124
analysed,0.002113037292609512
in,0.0022190882762432203
clinical,0.0017468093327335497
samples,0.0019246606784657895
and,0.0065459501373614105
none,0.0025181247672667107
of,0.003280861598499315
the,0.0034567677401897375
genotyping,0.0023109930622390827
assays,0.002495277035285303
available,0.0020369202684834067
for,0.0020581010424191594
patient,0.0018820649800191122
management,0.0018262602454855495
sequence,0.00295080751369002
the,0.0028673549077881185
entire,0.0023948566886088127
RT,0.0036373508348863837
coding,0.002593066442513874
region.,0.0022618150714335656
The,0.08506174159390156
British,0.035675433894569515
Columbia,0.09249699179109917
Centre,0.002744415668196639
for,0.001627299580665738
Excellence,0.0020997085000323216
in,0.002156656820600741
HIV/AIDS,0.0024065982185512425
(the,0.002341353460061474
Centre),0.0019873882978893847
genotypes,0.00500558931480745
clinical,0.003483616206198053
isolates,0.0025278004125309935
up,0.0030557089969343158
to,0.003582875571083451
codon,0.005999247937739821
400,0.007846430464000218
in,0.008563824839558783
"RT,",0.0037981868229656096
and,0.0040543860734069724
our,0.004941329883617854
retrospective,0.0018909195863900526
statistical,0.0016727768377118705
analyses,0.0022344517176294096
of,0.002520198258696025
the,0.001989579923060846
Centre’s,0.0018260147021197043
database,0.0014806451757180695
have,0.004772121004879286
identified,0.0048399886993929124
an,0.006011752379334839
N348I,0.009435714785223304
mutation,0.006619647895127198
in,0.0054818839894299805
the,0.0029469093121991417
RT,0.002911386404508518
connection,0.0043235035263011375
domain,0.0031404787743684014
in,0.007054273064731832
treatment-experienced,0.0021048527361186994
individuals.,0.001716336003527438
The,0.0010019032457582522
objective,0.0010616216919165139
of,0.0016389306953671565
this,0.0011335744042513293
multidisciplinary,0.0011708294592025286
study,0.0008632419099117782
was,0.0013649223919197234
to,0.0010137508887009873
establish,0.000862831353907369
the,0.0007112298292501211
in,0.0019146348305326703
vivo,0.0029562368109611863
relevance,0.0008887704343901158
of,0.0007797895367491776
this,0.001029111505828727
mutation,0.001132494273388847
and,0.000998545822971437
its,0.0011904479250611339
role,0.0010002623171915196
in,0.0008900844358706453
drug,0.0007393078132119047
resistance.,0.0006813947815200963
Methods,0.0026474595926849727
and,0.002868567173338753
Findings,0.003423440017190972
The,0.007391873010380062
prevalence,0.009312022909102765
of,0.007241380017317138
N348I,0.01571987492536226
in,0.011204391860579954
clinical,0.005201450405305743
"isolates,",0.0036482984102006234
the,0.004866992384764552
time,0.008765094809851106
taken,0.004097224775884482
for,0.009242402171638237
it,0.007649376994274674
to,0.008193517004899384
emerge,0.00969450397137891
under,0.007666953901316927
selective,0.005365809833852696
drug,0.004586005396325621
"pressure,",0.005773537849618936
and,0.004650880967721985
its,0.0070109969568360655
association,0.009959590679631843
with,0.00965407796323846
changes,0.006526818929343849
in,0.012887506519375064
viral,0.010183558218259637
"load,",0.009506802421793085
specific,0.004444346001573458
drug,0.012655618619102195
"treatment,",0.002483613623152197
and,0.0009101408428661427
known,0.0007232811668936295
drug,0.0008676229344549616
resistance,0.000785548789081969
mutations,0.0006747651713361507
was,0.0009229462368418664
analysed,0.0005420564292071767
from,0.0006285877863148876
"genotypes,",0.0005832055242376552
viral,0.0007284291503272736
"loads,",0.0006901820773554178
and,0.0006588625568076446
treatment,0.000961900913517867
histories,0.0007314775688157999
from,0.0006665087013346568
the,0.0011381670331582845
Centre’s,0.0021799157704911762
database.,0.0006861979183681652
N348I,0.0092186781430349
increased,0.011878678170781367
in,0.013892171821877719
prevalence,0.009097694557551734
from,0.015697327123927053
below,0.012468527543824576
1%,0.009711553108752477
in,0.013760801799146896
368,0.006014558257839453
treatmentnao,0.015324512135588273
¨ve,0.019975110145193053
individuals,0.007123357548302878
to,0.019505801232612866
12.1%,0.009388414002359574
in,0.009770161656579165
"1,009",0.004774570866273169
treatment-experienced,0.005304405167400229
patients,0.00725031702386927
(p,0.009181036629695525
¼,0.010102404649277976
7.7,0.007351266651594416
3,0.010378364044951446
10,0.02672248112249493
12,0.007409673592821738
).,0.005911800211792289
N348I,0.2654556956108265
appeared,0.24082104787925013
early,0.28524875531511285
in,0.25494848326394853
therapy,0.23665928751447016
and,0.3817726984798818
was,0.3079123039029459
highly,0.2535801848831112
associated,0.2879432876207554
with,0.2712426184291219
thymidine,0.17778584467760875
analogue,0.19864628789412117
mutations,0.22517793293908037
(TAMs),0.15804544041992463
M41L,0.26232751436292107
and,0.304412883375182
T215Y/F,0.2779296951419804
(p,0.220572391151959
",",0.2327456819049836
"0.001),",0.12855720767095496
the,0.2333027206759901
lamivudine,0.27248715167205656
resistance,0.26516953241206415
mutations,0.28472197510429387
M184V/I,0.20474659851063445
(p,0.18158639761930992
",",0.20627610846901864
"0.001),",0.11368483686734579
and,0.1522833294293855
non-nucleoside,0.06243844633603618
RTI,0.0838776664517072
(NNRTI),0.07395148749727043
resistance,0.10614685512705525
mutations,0.1178986594604367
K103N,0.19747067762790874
and,0.16327909840837898
Y181C/I,0.17610514072421132
(p,0.1384505994222802
",",0.1757742213521137
0.001).,0.1031317036919854
The,0.011645549643160157
association,0.017030092340394803
with,0.01256080211801242
TAMs,0.012574009518278619
and,0.013661756375735917
NNRTI,0.02093455064951251
resistance,0.010969546685489601
mutations,0.010281345714115854
was,0.013813303826895128
consistent,0.01160421535365311
with,0.010079751857159886
the,0.010299882785498732
selection,0.014598792688642755
of,0.012345355868810585
N348I,0.023041015057601155
in,0.013788453809599237
patients,0.016421160027859923
treated,0.01329584254640808
with,0.012220720545489202
regimens,0.018497358513930078
that,0.017575012190072497
included,0.014914593187044635
both,0.023526406498855953
zidovudine,0.04120950989903221
and,0.024850783549107067
nevirapine,0.030912779444857506
(odds,0.04462922108469034
ratio,0.09462880519310828
"2.62,",0.11786555570974817
95%,0.15237945923106752
confidence,0.14913971081728317
interval,0.1616589577995675
1.43–4.81).,0.20202035566401944
The,0.5523664436415174
appearance,0.510813490721434
of,0.4820762743116417
N348I,0.4946731109320081
was,0.5723949929117728
associated,0.5595579040614606
with,0.5576806042796404
a,0.5768041354343996
significant,0.5393598647446798
increase,0.47932546642021023
in,0.5410592125976077
viral,0.49302819110963214
load,0.5277912531795819
(p,0.5082799263197525
",",0.4657750019891588
"0.001),",0.21289824800920867
which,0.17361029994862126
was,0.20713667507224257
as,0.16129328877581758
large,0.14513365014684576
as,0.1652613583330562
the,0.14372321639984584
viral,0.13690077029183656
load,0.15058076912282858
increases,0.13067179595277026
observed,0.12373153487118183
for,0.11947499837612609
any,0.07904863284943553
of,0.09878467602485481
the,0.11901603161592779
TAMs.,0.12466378521499467
"However,",0.013754702250420765
this,0.010326907291109595
analysis,0.007589101316040124
did,0.008068675114526464
not,0.006851686969376055
account,0.0065188960356621015
for,0.005736348818179435
the,0.005860128789090771
simultaneous,0.005591726286041795
selection,0.005260403109236061
of,0.005460833436009511
other,0.004740684510661354
RT,0.010029304946575503
or,0.006401561328392003
protease,0.010547385854232774
inhibitor,0.009255434018292293
resistance,0.006631313115216616
mutations,0.005451160340411255
on,0.005443229683535136
viral,0.004890483943378516
load.,0.0064296118965785475
To,0.01137981065311055
delineate,0.004359595354551232
the,0.0054542414081193
role,0.005211493492141286
of,0.006203536325877694
this,0.009152458696732483
mutation,0.008869122887266722
in,0.0055869424846924755
RT,0.005897036430847062
inhibitor,0.0061864241599126155
"resistance,",0.007033431965370599
N348I,0.017340536735273537
was,0.015744898501668773
introduced,0.013805530616329085
into,0.015240643634529157
HIV-1,0.013922448749066889
molecular,0.010144891081359492
clones,0.01171410583539631
containing,0.010022839844760765
different,0.010803856647291174
genetic,0.013519795963615265
backbones.,0.013717006116409922
N348I,0.2693975046880262
decreased,0.22770698942138232
zidovudine,0.289193827871588
susceptibility,0.2667403799993507
2-,0.5025860492509763
to,0.43371423130075065
4-fold,0.4601116944992326
in,0.273138812336353
the,0.21807662713762463
context,0.251463475046773
of,0.22418220861248597
wildtype,0.2479859923241187
HIV-1,0.1934703178101265
or,0.18115553487836045
when,0.24933343513462672
combined,0.22421858749910453
with,0.19564650316584417
TAMs.,0.1806988178786878
N348I,0.7314824596742858
also,0.8753400262087268
decreased,0.8659261543134373
susceptibility,0.8628093146057553
to,0.8007685148343818
nevirapine,0.8557742645963702
(7.4fold),0.7970026649880586
and,0.8922412528267002
efavirenz,0.8838685975694954
(2.5-fold),0.8018889496054978
and,0.8816517075450756
significantly,0.8753138255312716
potentiated,0.8618351287702383
resistance,0.79269443944353
to,0.7285737310352186
these,0.7189559809579459
drugs,0.6967078923150593
when,0.7768382815827871
combined,0.7509350874630604
with,0.763757034053633
K103N.,0.6863212904308973
Biochemical,0.019657613236319652
analyses,0.016501016082554807
of,0.017358213893237284
recombinant,0.017979073508452025
RT,0.017485219222027816
containing,0.017077852189498074
N348I,0.028154628314169285
provide,0.012546750292836258
supporting,0.011477974535047985
evidence,0.012741795804940649
for,0.014375409057459702
the,0.013422583160299314
role,0.011276422413971515
of,0.016363202040029733
this,0.025862142370047903
mutation,0.01948560686621399
in,0.015837808050080802
zidovudine,0.020050537634000613
and,0.015814357196669585
NNRTI,0.029495087536058617
resistance,0.014864734869480142
and,0.01831361098047166
give,0.008461122563874442
some,0.010103757811229921
insight,0.009117521972762742
into,0.009260527167763747
the,0.008897442163479992
molecular,0.008504463004863926
mechanism,0.008319564168374587
of,0.01106395552607346
resistance.,0.00977350799004357
Conclusions,0.05339868379174362
BACKGROUND,0.0041858588696497
Elderly,0.0008254079200875127
and,0.001308771475451047
frail,0.0008187738553923717
patients,0.0006643314330941653
with,0.0007172400305207378
"cancer,",0.0006159982791796371
although,0.0012808592448021437
often,0.0009579620377863069
treated,0.0005729766262895269
with,0.0008357290754804314
"chemotherapy,",0.0007031482329121019
are,0.0011020031427271164
under-represented,0.0006785138773172873
in,0.0008490310042676764
clinical,0.0004578311649966716
trials.,0.0005145187071810287
We,0.0010602756576999625
designed,0.0009570260558618237
FOCUS2,0.0009462249268103847
to,0.0008811314378168284
investigate,0.0006882786964434096
reduced-dose,0.0006843896509792708
chemotherapy,0.0006692514391951447
options,0.0005448971047752279
and,0.0007468002085113953
to,0.000675489336921151
seek,0.0006108212271255359
objective,0.0005309716552824214
predictors,0.0005017400923177677
of,0.0006110058024672012
outcome,0.0005288157318458245
in,0.000626056192784917
frail,0.0006710120618397611
patients,0.0005558939905511684
with,0.0005612139008206422
advanced,0.0005436954374493961
colorectal,0.0006619298687798524
cancer.,0.0006831409394224867
METHODS,0.003723841520733663
We,0.00308397511755064
undertook,0.001896377565414172
an,0.0019238891168707772
"open,",0.0012057690998467086
2,0.00132651079324305
×,0.0016871469637417065
2,0.001157379674174854
factorial,0.0011591935791179957
trial,0.001141012009789814
in,0.0011803002958227626
61,0.0009360212538978804
UK,0.0012623323657574186
centres,0.0009530033797277475
for,0.0009928063028214879
patients,0.0009691389024657362
with,0.0011329749840421031
previously,0.0010419555870615875
untreated,0.0008868531311640491
advanced,0.0008808393151541397
colorectal,0.0011439926727024074
cancer,0.0010508634900463238
who,0.0011419131435679271
were,0.0010811934362420059
considered,0.000950415949444163
unfit,0.0008582669604542232
for,0.0014143801574504995
full-dose,0.0008545232588011279
chemotherapy.,0.00090852453929475
After,0.003257674160164825
comprehensive,0.002085271066052615
health,0.001975803255282221
assessment,0.0019026547571667032
"(CHA),",0.0025153727288468116
patients,0.0019111621250240635
were,0.003003337675933122
randomly,0.005113766833328663
assigned,0.003099615158921171
by,0.0038711098533282975
minimisation,0.004495025378796563
to:,0.0029387342751973013
48-h,0.02143534308799283
intravenous,0.010386382976202424
fluorouracil,0.018775626112676563
with,0.017310626725624313
levofolinate,0.023203967347605513
(group,0.006014913182305935
A);,0.016162112740525772
oxaliplatin,0.023428796102643378
and,0.02016088861872776
fluorouracil,0.0314548280426071
(group,0.008108598805738216
B);,0.01820356983694298
capecitabine,0.031485156491380846
(group,0.008684637378787906
C);,0.019282050104625248
or,0.0030241710523325185
oxaliplatin,0.003905106194908169
and,0.005896735938971139
capecitabine,0.03502684345827485
(group,0.003921300667049351
D).,0.007217451091305945
Treatment,0.002355115485859667
allocation,0.002121530690244935
was,0.0046587580792376015
not,0.0037349481870677967
masked.,0.0022114505978418704
Starting,0.002739118363468869
doses,0.0026062475733750826
were,0.002314532049720228
80%,0.0022737764566743706
of,0.0019771539506425293
standard,0.001486735291204715
"doses,",0.0021447830653399413
with,0.0021984645070591553
discretionary,0.0015586050257793123
escalation,0.002536214233794002
to,0.0018801709738494419
full,0.0018674091003731959
dose,0.0018277502918821239
after,0.0023774857610042084
6,0.0026524287309419355
weeks.,0.0018620104120112945
The,0.015282393873801352
two,0.042487659471103785
primary,0.02257596837889342
outcome,0.05755517450792462
measures,0.03488893808392827
were:,0.05160680445788145
addition,0.13940333007022548
of,0.13328349139249746
oxaliplatin,0.133542604768444
([A,0.1719511897933464
vs,0.1813800441036535
B],0.1929468288558794
+,0.12745590225120584
[C,0.044486308581307726
vs,0.02196963929978277
"D]),",0.017263881648241292
assessed,0.008449013828041143
with,0.009991307215273752
progression-free,0.009994418309293701
survival,0.00899275408769063
(PFS);,0.006639656342219921
and,0.010922486909827455
substitution,0.009162892607488031
of,0.00906194581434453
fluorouracil,0.007706298094982241
with,0.009173123769285984
capecitabine,0.015183119113569411
([A,0.009689300299596915
vs,0.032716123756198985
C],0.026322109700030766
+,0.016197350550911243
[B,0.01449403591722576
vs,0.027119904784882076
"D]),",0.019922288757184797
assessed,0.00444782326828183
by,0.003492179772946103
change,0.0034728351410082047
from,0.0029146182585374366
baseline,0.0020883925684878415
to,0.0030831564544054183
12,0.0027361976783345527
weeks,0.0025811785232134005
in,0.0035863908913061036
global,0.0026897762257355423
quality,0.0015739032427349953
of,0.002578745900884662
life,0.0030136339779655787
(QoL).,0.0020644113847441826
Analysis,0.0010444593230505316
was,0.0016870835171046916
by,0.0015489240600860708
intention,0.000833736006670686
to,0.0012920930385240518
treat.,0.0007842357735324144
Baseline,0.0009790985822552966
clinical,0.0008359351557188711
and,0.0016891660507779304
CHA,0.0009443351655559614
data,0.0010035944304841293
were,0.0015281138472127442
modelled,0.0008786987809769777
against,0.000995537476200279
outcomes,0.0007650726404581991
with,0.0011982499663863854
a,0.001217236974945994
novel,0.0009437302855513227
composite,0.0010027034627205513
"measure,",0.0009117956378829108
overall,0.0008175181045428974
treatment,0.0007898133096602379
utility,0.0007840859503786908
(OTU).,0.0012114457789666067
This,0.0017309420743628796
study,0.0015020444862444823
is,0.0017827728372395216
"registered,",0.0009915025622136229
number,0.0010896132378360435
ISRCTN21221452.,0.001235181350020468
FINDINGS,0.014038389207347271
459,0.008763889311329183
patients,0.007092171013282958
were,0.003509008055105447
randomly,0.0019442169516057292
assigned,0.002075720613064876
(115,0.004636033363265215
to,0.00327032046536247
each,0.0023166432687797183
of,0.002190560982424618
groups,0.003323049198632796
"A-C,",0.00682077874947251
114,0.004954651965714822
to,0.00288236136587673
group,0.0028246864555932483
D).,0.00427286657799343
Factorial,0.02100778069617778
comparison,0.029959869967005892
of,0.023444781817066083
addition,0.043109319256683036
of,0.03690471879970752
oxaliplatin,0.06002846742539877
versus,0.03435887918052528
no,0.05060396610334967
addition,0.03771511123736101
suggested,0.04299913986288089
some,0.03720386010748594
improvement,0.028213834862960127
in,0.03412409844786668
"PFS,",0.03299157570882607
but,0.02365692069131861
the,0.01613451799436239
finding,0.022276260008177215
was,0.017749556342393034
not,0.01584511208624524
significant,0.011956348643959655
(median,0.07328374710819863
5·8,0.04388675068711021
months,0.04002430418780425
[IQR,0.1122773500198908
3·3-7·5],0.19735476423475684
vs,0.06536437411862855
4·5,0.16711561230811983
months,0.06813972417808685
[2·8-6·4];,0.1611987058568873
hazard,0.07005904122380538
ratio,0.1638933582644745
"0·84,",0.14768925362368254
95%,0.2846476428976
CI,0.2603801055421654
"0·69-1·01,",0.19362404868195002
p=0·07).,0.2502755938570892
Replacement,0.13145215600955104
of,0.1682270064524886
fluorouracil,0.1445379319700188
with,0.16123250162969602
capecitabine,0.1929995813165533
did,0.19832443975453254
not,0.20439144426998548
improve,0.197561095274994
global,0.2609346552980133
QoL:,0.14093013812729568
69,0.12216199436588206
of,0.17391281069706777
124,0.09323909233487829
(56%),0.13483830410729417
patients,0.2091812268978314
receiving,0.1849096412125347
fluorouracil,0.16011647716995395
reported,0.2625891421513444
improvement,0.20145095531519186
in,0.25265431207429784
global,0.18947984034293636
QoL,0.14450541155954308
compared,0.29282359493168303
with,0.19040884351820886
69,0.11696008082027665
of,0.15888335204237472
123,0.09356727519217073
(56%),0.1288907509062144
receiving,0.20057104985829755
capecitabine.,0.14816594480315615
The,0.4264003526161511
risk,0.490874547650697
of,0.5010145236785072
having,0.44963742721666844
any,0.5011287405538943
grade,0.4071238507103281
3,0.49027784752104114
or,0.424861447168562
worse,0.4228249405072909
toxic,0.36819229157509
effect,0.5203812021703728
was,0.4889798765718691
not,0.5547981032037029
significantly,0.4999556019903396
increased,0.4533215485125327
with,0.4903237329402499
oxaliplatin,0.4805142153171176
(83/219,0.47979671752391656
[38%],0.43601123536038916
vs,0.47415990106243094
70/221,0.4572260338965066
[32%];,0.426460558848319
"p=0·17),",0.48323365694210824
but,0.638343281046237
was,0.5593142366090543
higher,0.5762421613916677
with,0.5142752809233939
capecitabine,0.4249371212282345
than,0.6090460616185722
with,0.48751786842017664
fluorouracil,0.4058496832370858
(88/222,0.4732364162751872
[40%],0.4738386184353069
vs,0.4898197118836996
65/218,0.4335368850397572
[30%];,0.46237812562556674
p=0·03).,0.44447213589595874
In,0.5345962371694158
multivariable,0.26879453168960415
"analysis,",0.10711033356667259
fewer,0.21917557841759602
baseline,0.08253965151895919
symptoms,0.1051633329291704
(odds,0.15674688904379513
ratio,0.21461206052489606
"1·32,",0.2461029875256335
95%,0.3448275698962876
CI,0.2621367430257112
"1·14-1·52),",0.2939404495697721
less,0.21718915508158357
widespread,0.10181084690440712
disease,0.08107266385413607
"(1·51,",0.08315730972117423
"1·05-2·19),",0.11486303647669159
and,0.11938810469893993
use,0.05478856735142072
of,0.054628654110583826
oxaliplatin,0.0749274208842721
"(0·57,",0.037193762768799744
0·39-0·82),0.019079813141878076
were,0.041820865398996224
predictive,0.016034185185315134
of,0.017793992071731296
better,0.018556075483515375
OTU.,0.016374693423907707
INTERPRETATION,0.0074015040611407155
FOCUS2,0.006416148162522395
shows,0.0065159011767543205
that,0.009465327425870071
with,0.011621220183373903
an,0.006694364788632141
appropriate,0.004494333026595283
"design,",0.0035734943892294087
including,0.007384531183595804
reduced,0.010453729471148074
starting,0.00336401362806686
doses,0.00364318182747388
of,0.005205335447291494
"chemotherapy,",0.002965759414354498
frail,0.005364844135124251
and,0.006198277902018334
elderly,0.0029010149466647747
patients,0.0025748927503715905
can,0.0034209559254559734
participate,0.0022988899366302266
in,0.0030094162419963292
a,0.0033831512445012747
randomised,0.0020769867694108097
controlled,0.0018385195839913154
trial.,0.0023374399423144814
On,0.009109650437680297
"balance,",0.006855760337046838
a,0.005975102423325731
combination,0.007966828647673941
including,0.017182815857587783
oxaliplatin,0.6113141967408808
was,0.6013607608958222
preferable,0.581521583384213
to,0.55629141626909
single-agent,0.4983042122159325
"fluoropyrimidines,",0.40766288537609463
although,0.5078475959500898
the,0.4588391744762734
primary,0.4646606085148682
endpoint,0.4587276587145068
of,0.512805830977257
PFS,0.4936753718468657
was,0.49378116834363883
not,0.48444301119215744
met.,0.4599283041320907
Capecitabine,0.44747845119884716
did,0.47458587938762076
not,0.4548669309658597
improve,0.40642283262967055
QoL,0.3991699290247836
compared,0.5747439483489134
with,0.3800475547302377
fluorouracil.,0.348290280615667
Comprehensive,0.0015965543555370469
baseline,0.0009839842741059463
assessment,0.0014359433297163643
holds,0.0018606270886914087
promise,0.0014051524224317077
as,0.001548197482640377
an,0.0012517518718709233
objective,0.0009016494872413792
predictor,0.0008484834798824753
of,0.0015956729046109025
treatment,0.0009363019975187829
benefit.,0.0008138389640131041
FUNDING,0.005634071880542962
Cancer,0.0026805082218343775
Research,0.0042525834892660885
UK,0.004977661075767572
and,0.003736254306900077
the,0.003343477229041325
Medical,0.002035284744266534
Research,0.002797868718956411
Council.,0.0027279335294016992
OBJECTIVE,0.0010984634170034034
To,0.0009587429496416232
determine,0.0009526407072006505
whether,0.0012130565731446811
ultrasound,0.0015208798906032643
imaging,0.00620944650146275
can,0.0034965284004434068
reduce,0.003684081849813789
the,0.0013054151945492015
risk,0.0021435955096827386
of,0.0036406962699615662
failed,0.004225863997982115
lumbar,0.0014337577466503344
punctures,0.0029019606095841166
or,0.004383189729762413
epidural,0.001912598421964429
"catheterisations,",0.0016642023106605292
when,0.0020688061947955285
compared,0.0034371987968459775
with,0.005032089162148072
standard,0.002727354376797614
palpation,0.0015610545726221154
"methods,",0.0025687859542099863
and,0.001910690115627046
whether,0.001245370752506829
ultrasound,0.001533042902133579
imaging,0.0038765802840092715
can,0.0020987520631694408
reduce,0.0024084534974652483
traumatic,0.0012191779632039807
"procedures,",0.001247712429523661
insertion,0.0013193704732351787
"attempts,",0.00164263350854025
and,0.0018048296349396104
needle,0.0008469057635659764
redirections.,0.0011188662750604083
DESIGN,0.0008698581347940706
Systematic,0.001990635431171499
review,0.0013335369705131286
and,0.0016168550617002518
meta-analysis,0.00117823929770237
of,0.0009292709491180453
randomised,0.0007938098709692759
controlled,0.0006315166517195385
trials.,0.000726948412398828
DATA,0.0009434936108178404
SOURCES,0.0019704068634900673
Ovid,0.0028483604571784946
"Medline,",0.003410727919062624
"Embase,",0.0020486591734540757
and,0.0031524550294066878
Cochrane,0.0012764417775861694
Central,0.0013579108244114618
Register,0.0018904926055080841
of,0.0024182286487589625
Controlled,0.001174666722137697
Trials,0.001613633870451045
up,0.001911884460964965
to,0.0024347942834800494
May,0.0016687150245276456
"2012,",0.0018107836586628073
without,0.0018984509471649139
restriction,0.0021388462474068145
by,0.002931622840630307
language,0.0019020196334937022
or,0.0023320874678942134
publication,0.0015622910142149855
status.,0.001562482181095004
REVIEW,0.019856138895893546
METHODS,0.06109137390541485
Randomised,0.0005190239096123404
trials,0.0004982621193436548
that,0.0005788283374075972
compared,0.0004937009821516602
ultrasound,0.0004898100757074303
imaging,0.000680344722140883
with,0.0005153053455799481
standard,0.00048670393440262836
methods,0.0004772436540185532
(no,0.0005454317997837641
imaging),0.000650105618708672
in,0.0005302088703106587
the,0.0005611874231567178
performance,0.0004437392702976658
of,0.0006155636850148413
a,0.0004956363311915025
lumbar,0.0006519483941740854
puncture,0.0007087321263702937
or,0.0005369695839425947
epidural,0.0004819291746431381
catheterisation,0.0005190610151528843
were,0.0005554205088729048
identified.,0.0004775219173087646
RESULTS,0.0011075834784837132
14,0.0008280313872557947
studies,0.0008966285091856162
with,0.0010012453117908603
a,0.0011263094094997926
total,0.00084028099425917
of,0.001153419163027899
1334,0.0007800351651050066
patients,0.000636134369744365
were,0.0012283471572912521
included,0.0006585497667463073
(674,0.0009500766641539955
patients,0.0006301500563447959
assigned,0.0007246853757557459
to,0.0009262442804674125
the,0.0010525331941546438
ultrasound,0.0006276556926229391
"group,",0.0007034617433642591
660,0.0008523335207179206
to,0.0008580735714245823
the,0.0009252715952401485
control,0.0006368978294561106
group).,0.0007874291944721575
Five,0.0008222911312572605
studies,0.000941127432412694
evaluated,0.0007252491349676197
lumbar,0.0006393042851747187
punctures,0.0006813645857437825
and,0.0008581447073580022
nine,0.0006267121380254477
evaluated,0.0005323357120417582
epidural,0.00048565299031065725
catheterisations.,0.0004971538861241986
Six,0.0010308409588525454
of,0.0016602312275137167
624,0.000977570637981512
procedures,0.0010461926142731203
conducted,0.0008285943457508703
in,0.001333120454488459
the,0.0014022706071552015
ultrasound,0.0007538700988538269
group,0.0008941447991549318
failed;,0.0008129913898671684
44,0.0017124958668503717
of,0.0029253539100685664
610,0.0017905337630532007
procedures,0.0017188067756945603
in,0.0015828875501208936
the,0.0014648073045423642
control,0.0007390822194403762
group,0.0012045101125479948
failed.,0.0010739025876643476
Ultrasound,0.45482930799225213
imaging,0.5058552319759809
reduced,0.5421532888313388
the,0.494256797459479
risk,0.4576451226320203
of,0.42003919526521605
failed,0.1955537430209152
procedures,0.22726887779681032
(risk,0.36069815789886944
ratio,0.2744056930776377
0.21,0.3748891534868247
(95%,0.3731077159710765
confidence,0.47534046458928025
interval,0.46896301816273717
0.10,0.4479599164557261
to,0.39880353847055183
"0.43),",0.33794461666076964
P<0.001).,0.4244851366067711
Risk,0.17619278971644872
reduction,0.15188163231567234
was,0.1604927332328776
similar,0.18218053268639461
when,0.1898353773824385
subgroup,0.20569079344891716
analysis,0.18813637220178114
was,0.15952751331564102
performed,0.1714402369421926
for,0.17006974130264194
lumbar,0.21469531826028515
punctures,0.2537546073253027
(risk,0.2554359532049387
ratio,0.23850224690714256
0.19,0.1993064950175632
(0.07,0.23476336425124875
to,0.24897037039923922
"0.56),",0.18030279672866964
P=0.002),0.3177163410635521
or,0.18189750323953666
epidural,0.2722891799219238
catheterisations,0.22950725433343125
(0.23,0.24877163626665166
(0.09,0.23396492758405085
to,0.2973740164276233
"0.60),",0.23188718074535675
P=0.003).,0.32651891362159663
Ultrasound,0.6500700003997681
imaging,0.6860434697373015
also,0.7259231573175741
significantly,0.725691451271143
reduced,0.6934090875669379
the,0.7083402001503935
risk,0.70211361958824
of,0.7175097069928702
traumatic,0.6515800178679056
procedures,0.6989386585989477
(risk,0.6950573773793627
ratio,0.6277710965166163
0.27,0.579890543695827
(0.11,0.5563906714087172
to,0.5269749851826955
"0.67),",0.4232443976400758
"P=0.005),",0.6310088918457649
the,0.6528299451342079
number,0.5867194056065345
of,0.5586580232811001
insertion,0.5466561922142027
attempts,0.5802410343333121
(mean,0.6149644731861514
difference,0.6127182907601658
-0.44,0.6106925776608917
(-0.64,0.5457961045883299
to,0.5297003207314228
"-0.24),",0.6118900551717831
"P<0.001),",0.6371764656037735
and,0.6077440659006157
the,0.6101507088143717
number,0.5977625119080654
of,0.570283248340107
needle,0.5852038875126451
redirections,0.542069974677526
(mean,0.611746410334703
difference,0.6088163543289521
-1.00,0.617885500831182
(-1.24,0.5531043918328827
to,0.5546081110129099
"-0.75),",0.6199628703444559
P<0.001).,0.6359602049943072
CONCLUSIONS,0.7963699611497204
Ultrasound,0.6790137218853334
imaging,0.656074870326013
can,0.7367003388680069
reduce,0.7388568646171162
the,0.7432500487814553
risk,0.6981126371616032
of,0.7339304587773285
failed,0.7503451958423424
or,0.6816045303390299
traumatic,0.7185984966134993
lumbar,0.6426861668471298
punctures,0.6887877603614518
and,0.7360309552893084
epidural,0.7317367478772855
"catheterisations,",0.682680578117967
as,0.6186979460867554
well,0.6627755915720875
as,0.6587482666393182
the,0.5993461181769915
number,0.5957127355918593
of,0.5854176021102399
needle,0.523902663740154
insertions,0.5043975191622518
and,0.47468482717566984
redirections.,0.5508931527489828
Ultrasound,0.14500702466922782
may,0.0829568042809176
be,0.07915255869560248
a,0.09526639212075817
useful,0.10650488963674773
adjunct,0.12506718264985062
for,0.14908340061875358
these,0.31797177268936755
procedures.,0.28100167263510756
Successful,0.012098312579296125
pregnancy,0.017240396072338147
requires,0.009370063199985191
coordination,0.007285496974500802
of,0.00496498763923351
an,0.007618860933918782
array,0.005395804251754982
of,0.0056308097064623145
signals,0.005756184342903197
and,0.004191763257070818
factors,0.00325785454438548
from,0.005067176352541258
multiple,0.005591336538837282
tissues.,0.0038915754424249907
One,0.0081142825248361
such,0.008561879716329681
"element,",0.010101394961597893
liver,0.020646933478324813
receptor,0.011294153028714959
homolog-1,0.009325704855530888
"(Lrh-1),",0.006652793375872319
is,0.006359712544428164
an,0.0053652652552103166
orphan,0.0044413036367426445
nuclear,0.0066757164878617084
receptor,0.006453719872921636
that,0.008513772082464004
regulates,0.006195091800053776
metabolism,0.008142284841394343
and,0.007744583823289293
hormone,0.007417838030904256
synthesis.,0.007831710804568431
It,0.0103484455510825
is,0.01022141116601318
strongly,0.013684202518923324
expressed,0.02118206794927885
in,0.028339106281171516
granulosa,0.03086126400624528
cells,0.042554733238448494
of,0.048738331022953045
ovarian,0.015733496804933106
follicles,0.03469469090061939
and,0.06949594016426634
in,0.056604312421998586
the,0.055618500727766536
corpus,0.030512640693804972
luteum,0.03588722413520579
of,0.04359126427348195
rodents,0.015264525542324565
and,0.026756278102342962
humans.,0.01463528614683446
Germline,0.3999256507432429
ablation,0.3796996527502545
of,0.4648804521090909
Nr5a2,0.3924209145934852
(also,0.37939693365485516
called,0.26726176693403353
"Lrh-1),",0.34868112429371945
the,0.35268535548340874
gene,0.358684042812447
coding,0.4108534744499327
for,0.33560542657047454
"Lrh-1,",0.34194863934162395
in,0.40855669772022035
mice,0.3915658590133957
is,0.24810100670634447
embryonically,0.3897519330376063
lethal,0.2735154289979671
at,0.3066472941106416
gastrulation.,0.29936207615454885
Depletion,0.22659135770124492
of,0.2541180316885313
Lrh-1,0.26497884717111003
in,0.2555985413821344
the,0.2709905383997187
ovarian,0.24601560007944187
follicle,0.2600173843825905
shows,0.3038896165181047
that,0.2627457052765514
it,0.24058072459373275
regulates,0.22952276447083558
genes,0.2714965962795206
required,0.2673485904911271
for,0.28193999799337766
both,0.2899589874398802
steroid,0.2462741408003777
synthesis,0.31324860180157477
and,0.2440513072389526
ovulation.,0.24900219944235308
To,0.024804650348781772
study,0.015995459072468743
the,0.007398259061902442
effects,0.013478974294255892
of,0.03632314093149635
Lrh-1,0.0632069281963347
on,0.01797443946059357
mouse,0.02960199716857541
"gestation,",0.01629907926246052
we,0.02814593366447371
genetically,0.020575206313446233
disrupted,0.043989809292570424
its,0.04470369215720987
expression,0.04679785764257793
in,0.04030327421324687
the,0.04514633591610422
corpus,0.042242809164536134
"luteum,",0.04130713856502927
resulting,0.06865362644635901
in,0.04313541408636379
luteal,0.036187191180882816
insufficiency.,0.03732948330330236
Hormone,0.8268370157956756
replacement,0.8410539810702261
permitted,0.8683572217486815
embryo,0.8457653390874722
implantation,0.8312124005048057
but,0.8125208501292971
was,0.8425095837818573
followed,0.8615505381358907
by,0.8433323432833764
gestational,0.8583749659513914
failure,0.845282129971321
with,0.8711383778091913
impaired,0.859658134383317
endometrial,0.8853050994296794
"decidualization,",0.8773380150501916
compromised,0.8622583291499736
placental,0.8357621779292458
"formation,",0.8607495331961993
fetal,0.8737228987961485
growth,0.8605902698659763
retardation,0.8906147717470403
and,0.8430465472737003
fetal,0.8649338270347784
death.,0.8295743388434228
Lrh-1,0.6811877201288109
is,0.8312029674702545
also,0.8408852401857997
expressed,0.8176901309440551
in,0.8561117766936839
the,0.8701927819016734
mouse,0.8462589617083769
and,0.8403613307285228
human,0.8148621410477314
"endometrium,",0.8473269102184463
and,0.8613037960509335
in,0.8746428826854346
a,0.8613339550811965
primary,0.876139960059204
culture,0.8335781437793628
of,0.8717548701351079
human,0.850511753472803
endometrial,0.8599827766669051
stromal,0.8542593634404084
"cells,",0.8472054734439808
reduction,0.8583737486222608
of,0.8682488752241825
NR5A2,0.8235227747409759
transcript,0.8762407126646421
abundance,0.8686610889083197
by,0.8755771913121453
RNA,0.7768183690756884
interference,0.8326167039203363
abrogated,0.8765492820776875
decidualization.,0.8603986116272168
These,0.4549575567871464
findings,0.4680565352570031
show,0.5702089573852758
that,0.6059642272140943
Lrh-1,0.5020670875487622
is,0.5854504049159305
necessary,0.6023979128002543
for,0.673225569998496
maintenance,0.629574032620262
of,0.7043329007877523
the,0.6861742817614147
corpus,0.5598456871364155
"luteum,",0.5843300155262066
for,0.6585389255860293
promotion,0.6999498518473959
of,0.6715038418365736
decidualization,0.6676287845246315
and,0.6839445782313262
for,0.6625692795616327
formation,0.6371407534006658
of,0.656201275305985
the,0.6728864860947736
placenta.,0.5303950502239575
It,0.3703851757456324
therefore,0.3926799314288207
has,0.23179908599700444
"multiple,",0.16572735787260032
indispensible,0.16810304795989806
roles,0.22791196441504052
in,0.21227093162410757
establishing,0.20486913871207563
and,0.19415603910148088
sustaining,0.2436533502987547
pregnancy.,0.2611377704067481
Panic,0.06327030166236214
disorder,0.05173158399136424
is,0.06449644526634447
a,0.06114589351674067
severe,0.04905618880079383
anxiety,0.04429824225662087
disorder,0.05327251386638133
with,0.05238794537446975
"recurrent,",0.06308534714928486
debilitating,0.050325612983534385
panic,0.0353752003647098
attacks.,0.047663283856581605
In,0.5557874993691737
individuals,0.41580708110732933
with,0.3635450698162158
panic,0.4192753561407631
disorder,0.36733170508645296
there,0.6216030544092266
is,0.466678341564093
evidence,0.56841770013916
of,0.5591628603817951
decreased,0.5541950309201709
central,0.5515962120022385
gamma-aminobutyric,0.43895902858692754
acid,0.44664301360233577
(GABA),0.42987192288626597
activity,0.5651909036270115
as,0.5821482741656235
well,0.5966032097188779
as,0.5762984615709175
marked,0.5542049234990414
increases,0.5759739624803305
in,0.6057549710269283
autonomic,0.7192718609775662
and,0.6283761044861789
respiratory,0.5330400442279244
responses,0.5975160734035982
after,0.6007615128975895
intravenous,0.6674314583228529
infusions,0.6264543330268525
of,0.554015880926481
hypertonic,0.5015515858794386
sodium,0.32350751344821504
lactate.,0.48332740137879326
In,0.3869036264519994
a,0.33860025994992304
rat,0.28780167475325974
model,0.2995704396536045
of,0.2230515456829718
panic,0.27671569563953946
"disorder,",0.2511337415728272
chronic,0.5156174892037916
inhibition,0.5154578881283921
of,0.4711398286470006
GABA,0.4155028033204192
synthesis,0.4848589972774588
in,0.4449960110264709
the,0.4623941991106672
dorsomedial-perifornical,0.4466807123128706
hypothalamus,0.4156769163929587
of,0.4691602286376103
rats,0.3233735511231645
produces,0.35925531418098244
anxiety-like,0.38462385850715763
states,0.47272018392165327
and,0.2963929114539619
a,0.3294823035329659
similar,0.2848487576412206
vulnerability,0.2745620957200063
to,0.37288869081401477
sodium,0.30132327193583097
lactate-induced,0.3695447749793738
cardioexcitatory,0.29187734327768844
responses.,0.27698667898086504
The,0.10568642597677692
dorsomedial-perifornical,0.2115237908832726
hypothalamus,0.09220286890161773
is,0.09051220386256295
enriched,0.07066890544894283
in,0.10035752764519629
neurons,0.10781123530639165
containing,0.0815069752705349
orexin,0.11166564854635481
"(ORX,",0.10482334490136896
also,0.08316401748318719
known,0.10218756905090018
as,0.11516043092644981
"hypocretin),",0.09856447850715765
which,0.10238505033549239
have,0.06573971889810049
a,0.08287176006750414
crucial,0.10782255326405082
role,0.11410990966583201
in,0.09124144437719847
"arousal,",0.10420816288694153
vigilance,0.09653145236477718
and,0.08031093128382501
central,0.11574320404976242
autonomic,0.06738105913886377
"mobilization,",0.09019869844916058
all,0.05301854564816352
of,0.04567745930710479
which,0.06652994052689278
are,0.05734614267803783
key,0.07008490057124746
components,0.07315112565463251
of,0.07665866616286471
panic.,0.06859704501579024
Here,0.7542599651259962
we,0.7653762011187428
show,0.7632238578914455
that,0.8396476520401396
activation,0.7961325730613454
of,0.7969863092893767
ORX-synthesizing,0.7006952482201555
neurons,0.7685025878547391
is,0.7926335677765527
necessary,0.8118982572608766
for,0.8207976942916573
developing,0.7804687233617387
a,0.7944173880625456
panic-prone,0.6885474353647629
state,0.7680813398048499
in,0.7822363250129282
the,0.7917437454112305
rat,0.7764739108948102
panic,0.6755253456114383
"model,",0.7678601457922793
and,0.8141721149011594
either,0.7757073354765365
silencing,0.7703463793181526
of,0.7653158331643605
the,0.7638306144796837
hypothalamic,0.7415278386696372
gene,0.7159957081531505
encoding,0.7317903493054212
ORX,0.6806750614809999
(Hcrt),0.5590064640091439
with,0.6501478374996028
RNAi,0.6090658775769026
or,0.6074361269739282
systemic,0.6828057856962376
ORX-1,0.5768163829347043
receptor,0.6597977451822257
antagonists,0.6441450709580796
blocks,0.6568784310035628
the,0.6801981571709972
panic,0.585342182892753
responses.,0.6449532080175059
"Moreover,",0.8636817451231598
we,0.818274268571555
show,0.8678104454000134
that,0.8770564204585445
human,0.8544246729097231
subjects,0.8640245065478948
with,0.858328179448287
panic,0.7873122202874374
anxiety,0.8141365906258884
have,0.8794786903492264
elevated,0.8480362190750721
levels,0.8636594206366829
of,0.8816360278755536
ORX,0.8706861882176541
in,0.8772083978340883
the,0.8946250861535913
cerebrospinal,0.8788878249975132
fluid,0.8740924939989615
compared,0.874305008298638
to,0.831063789775641
subjects,0.8278886401799107
without,0.7945580942656559
panic,0.6977650402579791
anxiety.,0.7744348594568927
Taken,0.12469085179933788
"together,",0.11902337511474889
our,0.17723683172078297
results,0.11658957550570666
suggest,0.16999797398250344
that,0.11271472784522071
the,0.0921372596128858
ORX,0.13530308334470453
system,0.11821751413506476
may,0.08827110825052178
be,0.0847444796720885
involved,0.08279309553308098
in,0.08797821037263805
the,0.08071632510502191
pathophysiology,0.061975878829672766
of,0.06294107367664563
panic,0.06882335518215571
anxiety,0.08956472486599941
and,0.16435937068524245
that,0.13238008367210413
ORX,0.12663290325833537
antagonists,0.08917885630633782
constitute,0.08648990034009567
a,0.07416793869671313
potential,0.05080308690119036
new,0.051983585419517385
treatment,0.06067441770618768
strategy,0.047714813032325394
for,0.05995488933282715
panic,0.05161799622398093
disorder.,0.05625632303951815
Podosomes,0.05871086570496101
(also,0.03115286029224534
termed,0.03755980215611996
invadopodia,0.07707097979093673
in,0.05554042163309102
cancer,0.03582537408632618
cells),0.03973192759102048
are,0.02593272882691106
actin-rich,0.04542486192676954
adhesion,0.06574054624341594
structures,0.038070822077271235
with,0.022831807090052746
matrix,0.049177701760324904
degradation,0.02256528572835407
activity,0.027433224130444727
that,0.026604490561385644
develop,0.020299413985877292
in,0.021873848687705966
various,0.00889694600105874
cell,0.004846746884699927
types.,0.006831590711186215
Despite,0.004336547420048478
their,0.003122742248876934
significant,0.0025112359620326897
physiological,0.0022389472426818987
"importance,",0.0037886363449806826
the,0.002434786176278385
molecular,0.002048340901267892
mechanism,0.0030010683261094797
of,0.0037248641736493627
podosome,0.006646800910830664
formation,0.00457000583758574
is,0.002519325758988718
largely,0.002294786840388878
unknown.,0.0022631374188571765
In,0.003482830839892105
this,0.0034896459774237366
"study,",0.003940010859640903
we,0.005545849772956283
investigated,0.003745777331099719
the,0.002838924845515951
molecular,0.0026193609878264984
mechanisms,0.003113605080750175
of,0.004244026768393909
podosome,0.005229471591118223
formation.,0.004840253977361312
The,0.2992344294283211
expression,0.36461925440630927
of,0.2785296932026859
various,0.31440464457017914
phosphoinositide-binding,0.2987043233268501
domains,0.32432127297012275
revealed,0.45983582649820914
that,0.4957064607361019
the,0.3581109131584763
podosomes,0.4088263807825652
in,0.39959619459277823
Src-transformed,0.32908688158516625
NIH3T3,0.3796346564107427
(NIH-src),0.35350806026129944
cells,0.4594843421865491
are,0.34768220138317696
enriched,0.35584241751577045
with,0.37117246538728293
"PtdIns(3,4)P2,",0.3919230905373678
suggesting,0.45656999620464267
an,0.2701989561383401
important,0.23090476356547626
role,0.2146319433856109
of,0.19785323244113187
this,0.2058511424134627
phosphoinositide,0.2068753687593401
in,0.19792090634966517
podosome,0.21304392589414142
formation.,0.22586854690144817
Live-cell,0.2752053147364751
imaging,0.3626925991580951
analysis,0.3937620016494281
revealed,0.49195772670663335
that,0.5387163200998593
Src-expression,0.3863117080877448
stimulated,0.5383939525387837
podosome,0.4937081892238288
formation,0.5472940672240848
at,0.5103946291368615
focal,0.5177505978355051
adhesions,0.5236427685324107
of,0.5288149185469266
NIH3T3,0.4778650860142915
cells,0.525221761351776
after,0.5172261446549615
"PtdIns(3,4)P2",0.48483427662603606
accumulation.,0.4695385247108231
The,0.44297085946115555
adaptor,0.48838462614390094
protein,0.43009730071252333
"Tks5/FISH,",0.47718950471111776
which,0.511261625792411
is,0.40135299905810995
essential,0.4575554850450345
for,0.4847755793334415
podosome,0.45581535236688264
"formation,",0.42870679998540573
was,0.4003116658932639
found,0.44800731256763193
to,0.40033848271721134
form,0.4410576466680561
a,0.4576941187715837
complex,0.4179504088313761
with,0.38425118610073816
Grb2,0.4074442961377246
at,0.4307598410640058
adhesion,0.4069498730263101
sites,0.42752363105854946
in,0.49098676582084083
an,0.49590254062023065
Src-dependent,0.45093079632760225
manner.,0.48126369013380516
"Further,",0.6023313410475913
it,0.5870854500511147
was,0.5356127165714264
found,0.5890473127337954
that,0.5944699514443939
N-WASP,0.5539473420314369
bound,0.5237698058683524
all,0.5249361985087061
SH3,0.5879903058821118
domains,0.5197196704152536
of,0.5179072587219464
"Tks5/FISH,",0.4841533791899855
which,0.4884972021926469
facilitated,0.5584104354132141
circular,0.490373621593628
podosome,0.48042838537562943
formation.,0.4697618161484189
These,0.5096210238889671
results,0.4988610987690654
indicate,0.5585173785124018
that,0.6263900172453563
augmentation,0.6193337349203324
of,0.628089481525746
the,0.6199049348437193
N-WASP-Arp2/3,0.595030952874715
signal,0.622772014468413
was,0.6610320192356033
accomplished,0.6795903949561933
on,0.6167323930815783
the,0.6139794934302183
platform,0.5954104781406699
of,0.6253342898646417
Tks5/FISH-Grb2,0.5783515510233961
complex,0.5702098735399033
at,0.5480597369737289
focal,0.5338217740833978
"adhesions,",0.5854317726608195
which,0.5104519351445426
is,0.43951939083190594
stabilized,0.47885772763046014
by,0.5116247187027744
"PtdIns(3,4)P2.",0.4472508771996329
Human,0.013710137435665605
astrocytes,0.016339311869445698
are,0.008560274965286396
larger,0.007642435906912786
and,0.007443939373802617
more,0.00599597879552605
complex,0.005995640611485892
than,0.011886254578048157
those,0.009700211968254314
of,0.012717652576877535
infraprimate,0.009259890645682054
"mammals,",0.009379200927575422
suggesting,0.010167939513562096
that,0.00763703678620767
their,0.005686490613459126
role,0.0045266415891770245
in,0.004314225014105811
neural,0.004615479947737512
processing,0.007054936087807601
has,0.0031928085914655177
expanded,0.0033581834485567085
with,0.007482565619946782
evolution.,0.0036881700322907726
To,0.002339090135066359
assess,0.0016012135857565054
the,0.0013168819451450991
cell-autonomous,0.0017875112004258746
and,0.0019198879093380165
species-selective,0.0012253964420944209
properties,0.0012795134228249078
of,0.002084062841255296
human,0.0020692654882429884
"glia,",0.002279779982045682
we,0.003316053197028893
engrafted,0.002428086112009022
human,0.0019445445255925535
glial,0.0018096717364465451
progenitor,0.0019453201886533618
cells,0.002540434936760354
(GPCs),0.0022929872842908238
into,0.0026236754008404205
neonatal,0.002663149662013847
immunodeficient,0.0015005209058306275
mice.,0.0021503127033208435
Upon,0.31208825571864646
"maturation,",0.20654197831072374
the,0.24427976542276064
recipient,0.19638044222503004
brains,0.26486330247100487
exhibited,0.2850696610538558
large,0.22727784868301792
numbers,0.22871088359119174
and,0.2605901535696782
high,0.20129196726109422
proportions,0.21290941991774814
of,0.279025291459214
both,0.27090609510756786
human,0.21787733622645156
glial,0.2124699083408534
progenitors,0.2541127952925198
and,0.26989574595221244
astrocytes.,0.244765525231803
The,0.29954904108815994
engrafted,0.2742913150058406
human,0.31528494157512854
glia,0.30783330061202985
were,0.2978224882521092
gap-junction-coupled,0.2750511804636819
to,0.26212979122222485
host,0.339042675600444
"astroglia,",0.34375732126562664
yet,0.4257778718825522
retained,0.40790231983104486
the,0.45856648581471576
size,0.39412161161778925
and,0.37901376988240676
pleomorphism,0.30688557898900115
of,0.3639490725065873
hominid,0.27045569468795444
"astroglia,",0.40160151845367537
and,0.5113010304695268
propagated,0.3621758638462941
Ca2+,0.3580345669878976
signals,0.33870656193860355
3-fold,0.42357155309413375
faster,0.3081926545490431
than,0.3264771583574808
their,0.2687638982328928
hosts.,0.2463317058109309
Long-term,0.008059269313191402
potentiation,0.012055812555848477
(LTP),0.008677593647335674
was,0.017469692263535574
sharply,0.01755839926917133
enhanced,0.01899485836819619
in,0.03104031364796904
the,0.021452170532654257
human,0.011947175858254744
glial,0.006433318618015754
chimeric,0.01746480054841876
"mice,",0.01406595126211274
as,0.02387749677849707
was,0.017407721785593154
their,0.012929053606765556
"learning,",0.012705416214924655
as,0.008206376374559109
assessed,0.007317338588970736
by,0.00687796422557473
Barnes,0.007298100660542387
maze,0.006481392576141759
"navigation,",0.007490169011993206
object-location,0.004039293610463941
"memory,",0.005969170630063675
and,0.01146059612805085
both,0.009571160534219515
contextual,0.0031856058784208935
and,0.007549568443376057
tone,0.005492228538743837
fear,0.007440940033356236
conditioning.,0.006775007959928199
Mice,0.10766299434776165
allografted,0.11114968723275834
with,0.14770332204402334
murine,0.12032122154412975
GPCs,0.15351888485416712
showed,0.22545944437739124
no,0.18189411499476063
enhancement,0.18403214042651614
of,0.2642602884826205
either,0.1316004035511653
LTP,0.17854210836619083
or,0.1985442712704371
learning.,0.2167763421160917
These,0.31511077093347073
findings,0.32643788608286195
indicate,0.3620922217011576
that,0.34917205248662064
human,0.41896688386916653
glia,0.38716284952128827
differentially,0.343267419195901
enhance,0.3610442591046659
both,0.41270000170573945
activity-dependent,0.5488972260476565
plasticity,0.48130328284203305
and,0.3977968948411922
learning,0.525146175718829
in,0.5260565860366077
mice.,0.5591822011716975
BACKGROUND,0.03315762415051411
Birth,0.008566719046191497
"size,",0.008902966975804295
perhaps,0.015821093727330406
a,0.021852903356012674
proxy,0.017761234235769932
for,0.018353559523346167
prenatal,0.02208197213674402
"environment,",0.017473993828973453
might,0.009621419816712964
be,0.009035253916023616
a,0.007574609793550364
correlate,0.004641074970140934
of,0.00603733833392522
subsequent,0.006335701325199933
breast,0.003916163550021359
cancer,0.0013564657436092714
"risk,",0.002991460423543889
but,0.0029145746078153316
findings,0.0017774868289361062
from,0.001433832844377102
epidemiological,0.0011557915302503967
studies,0.0018503167322598247
have,0.0017519896761958522
been,0.002107962865644823
inconsistent.,0.0013967438002602983
We,0.0018020072620115808
re-analysed,0.0008914986957334536
individual,0.0009682438996791523
participant,0.0006924271818714511
data,0.0008933260139426073
from,0.0009888512189290015
published,0.0010724130316394592
and,0.0014461611946844268
unpublished,0.0009213287201410949
studies,0.001015738050366455
to,0.0009391545538935232
obtain,0.0009396542123252805
more,0.001067059006892107
precise,0.0008304378299493195
estimates,0.0008860405950249422
of,0.0008136993849540755
the,0.0007618810547568033
magnitude,0.000555562140367325
and,0.0011304385835190565
shape,0.0005452930093193156
of,0.0008089646259959637
the,0.0009230805715599114
birth,0.0009893101325965169
size-breast,0.0008162327771668047
cancer,0.0006675441001632045
association.,0.0008535146029528906
METHODS,0.00875942708329944
AND,0.0038008083790062627
FINDINGS,0.008962386962206475
Studies,0.003397303176611533
were,0.004792571390664891
identified,0.0010675569738319327
through,0.002176303603225679
computer-assisted,0.0010469600922506238
and,0.0014700037816417519
manual,0.0015823706751746669
"searches,",0.0011176457541392357
and,0.0015706340070440006
personal,0.001218576857928838
communication,0.001813487251131578
with,0.0016574898048420609
investigators.,0.0016179211036203797
Individual,0.01121564586578272
participant,0.007445644759811458
data,0.010558877432705378
from,0.011418088633789856
32,0.0063929428716166005
"studies,",0.02242701667418099
comprising,0.010990806052328309
"22,058",0.007901349786084214
breast,0.01574217014523777
cancer,0.008893545083474109
"cases,",0.009704784427871727
were,0.006169515320240988
obtained.,0.0032515593797105167
Random,0.0008575208334804334
effect,0.0014815908570167005
models,0.0013411548707871585
were,0.0016392779309760347
"used,",0.0009140365358269687
if,0.0008478165352764571
"appropriate,",0.0010363629014893078
to,0.0007860177203442584
combine,0.0009134351618697575
study-specific,0.0010407298876043242
estimates,0.0014317786318252918
of,0.001476753507521302
effect.,0.00104523050965694
Birth,0.873127742355726
weight,0.8753232382843389
was,0.8710463887812033
positively,0.8950976608935414
associated,0.891893761599584
with,0.8795761723145519
breast,0.9180824898871578
cancer,0.9016532415837569
risk,0.9082943679327893
in,0.8860185242368578
studies,0.9139419639187553
based,0.8991072876620392
on,0.882957717784081
birth,0.9197535499771812
records,0.9041763127023233
(pooled,0.9007064999625961
relative,0.9018894635066711
risk,0.9183075435835172
[RR],0.9061664713006633
per,0.8996804752029683
one,0.8891353395804139
standard,0.8847771235682305
deviation,0.9026332401581073
[SD],0.9030513864480911
[=,0.9018800066237909
0.5,0.8938686336637982
kg],0.9181167131830045
increment,0.9067936882338651
in,0.895764987644363
birth,0.919779730339693
weight:,0.9066653436688055
1.06;,0.903362382476391
95%,0.9241434412236169
confidence,0.911912260056312
interval,0.9037670009981669
[CI],0.8976370669325924
1.02-1.09),0.9072806474482654
and,0.8918440856798271
parental,0.9102960457242908
recall,0.9001446853534956
when,0.8768400243363697
the,0.8597736477830161
participants,0.8882723727078425
were,0.8144023859404962
children,0.8447537357600555
(1.02;,0.868593792760182
95%,0.9090878280082011
CI,0.8758966794673918
"0.99-1.05),",0.8192813090039807
but,0.8830173678923545
not,0.8681524203227872
in,0.8378176444325731
those,0.8701875100438573
based,0.8479742820959165
on,0.8320525243777199
adult,0.8778429337105501
"self-reports,",0.8880451720536622
or,0.8702168833501013
maternal,0.32114718085334154
recall,0.32137489039325645
during,0.3166949256421241
the,0.30945955095181327
woman's,0.3345504333923479
adulthood,0.3252086403244042
(0.98;,0.2984461242230046
95%,0.3347096348092849
CI,0.36948977516936427
0.95-1.01),0.2783442758326211
(p,0.301074724111225
for,0.2914070028497923
heterogeneity,0.1410880822833699
between,0.1583608664201841
data,0.17955798509503645
sources,0.18914491510157214
=,0.2538260884313133
0.003).,0.18909299677962213
Relative,0.7009397919525615
to,0.7044507133138467
women,0.7350747070372233
who,0.7329539973401672
weighed,0.6618904127907062
3.000-3.499,0.7011803433471716
"kg,",0.6892586519139497
the,0.7027808034663485
risk,0.7268937109632698
was,0.6646561825806638
0.96,0.6686218355148491
(CI,0.6525271404568913
0.80-1.16),0.6221813508694838
in,0.7354309241402289
those,0.7501223148462233
who,0.7456584711791853
weighed,0.6904862847800448
<,0.7085878648121974
2.500,0.7134997452155221
"kg,",0.7117246738885316
and,0.7803154923611567
1.12,0.6980030998894152
(95%,0.6535883032541246
CI,0.6718705492633535
1.00-1.25),0.6504738907927414
in,0.7322431427427839
those,0.7167441801604724
who,0.7126197227087389
weighed,0.6614797928647477
>,0.7200574533370168
or,0.6695166631993664
=,0.6422211205197468
4.000,0.6813836630718115
kg,0.6920802559163168
(p,0.6412761613454196
for,0.5423088031370653
linear,0.5940331020435188
trend,0.6299083940074548
=,0.5350636425913905
0.001),0.5583398039381395
in,0.26534752689719
birth,0.23199473811217994
record,0.23436162119351694
data.,0.2764901234831715
Birth,0.2870918484129637
length,0.271271143722786
and,0.20716332671366625
head,0.28256038153507096
circumference,0.2038992374281262
from,0.22798621589932705
birth,0.28849914847414937
records,0.28909478360126417
were,0.257506331709224
also,0.2739909869482041
positively,0.2805567151974286
associated,0.26108415906169735
with,0.2523240438624743
breast,0.380863119584602
cancer,0.3309723416534893
risk,0.33795207476239403
(pooled,0.28644395465847367
RR,0.3134032893725586
per,0.3089584336125172
one,0.27048505592235517
SD,0.272103947618295
increment:,0.29057584950736776
1.06,0.33221409239363736
[95%,0.35546890566961875
CI,0.4334161009725599
1.03-1.10],0.4337647813899273
and,0.3696838324589334
1.09,0.3818896743702647
[95%,0.30863431227267485
CI,0.437253557381455
"1.03-1.15],",0.3585578134318309
respectively).,0.28422410945950066
Simultaneous,0.04157581930911299
adjustment,0.033478167641493986
for,0.03170898992241229
these,0.0467211197987586
three,0.024365752256060035
birth,0.0555289918819151
size,0.02900781803827014
variables,0.025594743377588314
showed,0.05758792818821009
that,0.04253736784007886
length,0.0208219701303621
was,0.025330375697036108
the,0.017854941910034904
strongest,0.017537767261265488
independent,0.013423394594746242
predictor,0.014664591770481825
of,0.016616521348976
risk.,0.01711556921780039
The,0.10204588675772788
birth,0.18178664796312063
size,0.15274461250914587
effects,0.11575361163573204
did,0.13692384421325995
not,0.1068501698440724
appear,0.08259788755320524
to,0.07070809203784494
be,0.08910406490529084
confounded,0.06528788896217372
or,0.07622852924652351
mediated,0.10697059887196583
by,0.09605306951811696
established,0.12336428360341938
breast,0.1480713546328895
cancer,0.09079434805107145
risk,0.10884280699915719
factors,0.10444553453037421
and,0.15788299356905064
were,0.09027255050833903
not,0.09274257039879884
modified,0.13798258219710516
by,0.13956014168871067
age,0.03626783797651675
or,0.04826158108145244
menopausal,0.0445225789327576
status.,0.0732531667169258
The,0.06863108317579658
cumulative,0.05661482328749749
incidence,0.09698225632024535
of,0.08512741295100369
breast,0.1139975005341641
cancer,0.08342019330301503
per,0.09361036463235668
100,0.04987812313492606
women,0.06990219468760048
by,0.07276875796961593
age,0.025931500263946833
80,0.03149300936090673
y,0.09216679480873126
in,0.08706750455696109
the,0.05816003946271637
study,0.057505572823286534
populations,0.07580608210941346
was,0.08177049960267588
estimated,0.06575032136547783
to,0.0548672086812868
be,0.07749858080129424
"10.0,",0.07458293156793419
"10.0,",0.07404698273325096
"10.4,",0.07226956110828232
and,0.07622467628385413
11.5,0.0639623938743341
in,0.0943955391798406
those,0.07580819512808548
who,0.08458756473856614
"were,",0.08196517819996432
"respectively,",0.055174631693666286
in,0.09237037634822717
the,0.07048612025274216
"bottom,",0.06828507897825119
"second,",0.08617921911144241
"third,",0.0625212066480712
and,0.08751258803342299
top,0.06137335736976206
fourths,0.06576198005646604
of,0.058263998938192625
the,0.05296012449599205
birth,0.07003421554449923
length,0.060380933299982155
distribution.,0.07464543802820374
CONCLUSIONS,0.7007199733681032
This,0.49643678708978617
pooled,0.37143382476395354
analysis,0.3950341000203652
of,0.3688072105202767
individual,0.39937381538832456
participant,0.3683377817894909
data,0.41439592763660754
is,0.43687255538054387
consistent,0.5077347722016453
with,0.5317912634070501
birth,0.5249809970740952
"size,",0.4593676032404101
and,0.48963608092247785
in,0.5190205417439823
particular,0.4750556808229939
birth,0.5391572967128581
"length,",0.4581484965207261
being,0.5096880783186316
an,0.5199523838106893
independent,0.49031825951384256
correlate,0.4576260085436621
of,0.43031386215567086
breast,0.4633698504307
cancer,0.4431694843235433
risk,0.47040285220575284
in,0.45802458780019595
adulthood.,0.4782816422091066
G-quadruplex,0.019965828984126913
(G4)-forming,0.014114953582280614
genomic,0.008329895498618184
"sequences,",0.011543858038783803
including,0.013258569806855832
"telomeres,",0.010989440356760779
represent,0.013406434004762354
natural,0.01100543495405812
replication,0.00927693857400735
fork,0.007619650530182747
barriers.,0.009559742470574666
Stalled,0.006677079439137303
replication,0.007980541139939751
forks,0.006182141002061049
can,0.008978926079315743
be,0.00648671137899648
stabilized,0.004940413242572823
and,0.011655232346497508
restarted,0.007650987887247187
by,0.00946169790781959
homologous,0.004704821982761689
recombination,0.0044089577986525085
"(HR),",0.0046843007235540125
which,0.017257805129462598
also,0.010640137872163608
repairs,0.008971730616322735
DNA,0.0074905359117567035
double-strand,0.0035263041726404805
breaks,0.004860421747868952
(DSBs),0.005576236772995614
arising,0.009751600388225475
at,0.006826446887498365
collapsed,0.005860885829628768
forks.,0.004855454059200969
We,0.05419289429149815
have,0.021579932808585927
previously,0.025958825074091075
shown,0.04060266322399914
that,0.041980701798783326
HR,0.04356174230267108
facilitates,0.038049314162715876
telomere,0.01585982313500507
replication.,0.02533436688494611
"Here,",0.5967941528538698
we,0.6005354966784574
demonstrate,0.6224123915487452
that,0.6609308370278402
the,0.5117230887328116
replication,0.48120354355753314
efficiency,0.48232774205714557
of,0.4456500180830141
guanine-rich,0.5282748981018007
(G-rich),0.5055042228119919
telomeric,0.3868520247433473
repeats,0.4656934740832473
is,0.4694585355689772
decreased,0.4851096192791861
significantly,0.5470320975568868
in,0.46958330190717484
cells,0.4857554198135474
lacking,0.5021738182225903
HR.,0.4697331951316123
Treatment,0.37113582210303303
with,0.3450349551838939
the,0.4047063485929839
G4-stabilizing,0.5341224044554063
compound,0.4534938231106161
pyridostatin,0.46019192071553194
(PDS),0.5583196249202961
increases,0.5489343779094975
telomere,0.47715859951978135
fragility,0.5265358559145036
in,0.5572461341274696
BRCA2-deficient,0.5338328709888509
"cells,",0.5588164556958536
suggesting,0.5698492764254405
that,0.5785054499062126
G4,0.5535809632746574
formation,0.523652183585815
drives,0.48434619821771946
telomere,0.4289834582654556
instability.,0.4639657018294982
"Remarkably,",0.8139296268295654
PDS,0.7915494096086635
reduces,0.8760801942625674
proliferation,0.8861547217007869
of,0.8928714122181513
HR-defective,0.7930188817659516
cells,0.8508851492045508
by,0.9330808715467792
inducing,0.9244949243108981
DSB,0.8447239981652807
"accumulation,",0.8714489622344247
checkpoint,0.8856453406655875
"activation,",0.8615705792022714
and,0.9179917145000935
deregulated,0.8890868989887368
G2/M,0.7840389516160293
progression,0.8772774950372616
and,0.8655708519750343
by,0.913169405014142
enhancing,0.8920412684836733
the,0.8549932709218465
replication,0.7704810722881318
defect,0.851052999078367
intrinsic,0.7924936226411209
to,0.7343845898407521
HR,0.7201040623406384
deficiency.,0.7832353461825965
PDS,0.28658078729024367
toxicity,0.2257170263618504
extends,0.19876474642712963
to,0.2422099719157414
HR-defective,0.29255157801295834
cells,0.32560689916881264
that,0.27882208287958865
have,0.2902761750696542
acquired,0.3864755000966786
olaparib,0.46408073524479415
resistance,0.4246037387101012
through,0.42645855107316955
loss,0.3903299637397346
of,0.45096183553728003
53BP1,0.32493388720234395
or,0.2688880271683642
REV7.,0.3387171556508448
"Altogether,",0.2408441672481061
these,0.25746069249592385
results,0.26764684533970634
highlight,0.17926904241130606
the,0.12837544161514494
therapeutic,0.199366883510074
potential,0.19134062533032475
of,0.25505354763427507
G4-stabilizing,0.37805338214172035
drugs,0.2743575246539317
to,0.2670285323461105
selectively,0.29893081214992917
eliminate,0.3394881158671275
HR-compromised,0.3377844886273907
cells,0.39191898531674774
and,0.30466117692925077
"tumors,",0.3028986638499301
including,0.3037823577414416
those,0.3807708377281033
resistant,0.311031361715996
to,0.3594691341491865
PARP,0.35001232635307145
inhibition.,0.36221821818083055
OBJECTIVES,0.0010286799631649636
To,0.0009620924722524593
determine,0.0008541270190540744
the,0.0008612105690723831
incidence,0.0008515237798914642
and,0.0013815587139809256
clinical,0.0006464301243472108
importance,0.0010039351137147061
of,0.0008244923279927234
errors,0.001148079146172006
in,0.001246298408471932
the,0.0009774693564491804
preparation,0.0006238822411025603
and,0.0015986722022436634
administration,0.0007669132039916029
of,0.0012419222081973679
intravenous,0.0009953435322772287
drugs,0.0007313758020501181
and,0.001162116513375219
the,0.0009323319269812681
stages,0.000941570722931749
of,0.0012045012207986567
the,0.001084493141368357
process,0.0009774863523880953
in,0.00174922023025396
which,0.0013207377214723664
errors,0.0013433897848450253
occur.,0.0010087211523137313
DESIGN,0.0009654260908603868
Prospective,0.001028838983119205
ethnographic,0.0009048911128969546
study,0.0009855771625895638
using,0.0012476880670152758
disguised,0.0011093484881098325
observation.,0.0007125928312923277
PARTICIPANTS,0.001404123073610236
Nurses,0.0008175640673439015
who,0.0011093019906084447
prepared,0.0007693479627957319
and,0.0021309036036285334
administered,0.0009200972779721038
intravenous,0.0012234764477840132
drugs.,0.0008009683049570042
SETTING,0.0017716888970522602
10,0.0011369558069452962
wards,0.0009880140378357477
in,0.001963810321507199
a,0.0024229633528802283
teaching,0.001399043904736767
and,0.002427270248030332
non-teaching,0.00292308355242328
hospital,0.0010541259599573445
in,0.0013857946213709869
the,0.0015085251933941648
United,0.0011356609421455948
Kingdom.,0.0013724997227106232
MAIN,0.0015148441218051534
OUTCOME,0.0024084729740044735
MEASURES,0.0024802821182633617
"Number,",0.00153396320562609
"type,",0.0011173540701779985
and,0.0024380474428066785
clinical,0.0009736237781756538
importance,0.0014560546991678213
of,0.0017609038139167498
errors.,0.0015898183036680107
RESULTS,0.009903785163271398
249,0.002408202035084428
errors,0.0018798296196046315
were,0.0017544599053855438
identified.,0.0012447727550992833
At,0.008406430534132429
least,0.0050697396342437515
one,0.02153816730777141
error,0.25918370720270634
occurred,0.2315723965321767
in,0.22249160225938092
212,0.18657159439176438
out,0.2628922739102857
of,0.24000652446512627
430,0.21518407323256067
intravenous,0.24645879028815743
drug,0.23600587701161768
doses,0.29477394441843274
"(49%,",0.28169672569311627
95%,0.4364616422651672
confidence,0.4477205468370253
interval,0.4174702330368192
45%,0.5083628767281697
to,0.43347116584623924
54%).,0.37566873950200325
Three,0.3048402041475636
doses,0.2588341784073117
(1%),0.24079163185838737
had,0.238272133355323
potentially,0.22009223226279814
severe,0.26552861417955065
"errors,",0.22341442831821964
126,0.2201158263986821
(29%),0.2773076349202545
potentially,0.25596066995117084
moderate,0.3145571001594857
"errors,",0.2503992374205182
and,0.20789229504417375
83,0.18410439081583813
(19%),0.24384985314020813
potentially,0.20167938800980806
minor,0.25586684492836076
errors.,0.19190418140669888
Most,0.04287846501233351
errors,0.042160874728359096
occurred,0.05629403681001552
when,0.08442487321113701
giving,0.07499077150145918
bolus,0.07812867021677959
doses,0.06495036725786986
or,0.06491668861150991
making,0.05019451911062264
up,0.04554446923648824
drugs,0.06565638968804992
that,0.07423280410689333
required,0.0972798520422299
multiple,0.04576694768082069
step,0.04739775275338612
preparation.,0.07078775650987154
CONCLUSIONS,0.5235137927152032
The,0.03849357330830122
rate,0.01875554577018217
of,0.02074531485540873
intravenous,0.024761410071578182
drug,0.017402278389500127
errors,0.022250170927479242
was,0.039773095841085626
high.,0.023812079525634716
Although,0.0758208242561279
most,0.03366312285376452
errors,0.017474534156202898
would,0.05042022775349573
cause,0.023440772793096018
only,0.0237705771480894
short,0.031885071204478414
term,0.02081198073794889
adverse,0.012015006611152809
"effects,",0.015372427381315916
a,0.02525161642954972
few,0.024091116890310398
could,0.034005109917624336
have,0.032393778951618574
been,0.023458743571729536
serious.,0.01785219523839653
A,0.32939259232836626
combination,0.37249478491436444
of,0.3797683177178348
reducing,0.3634661250480035
the,0.3267378796844718
amount,0.3345220777483521
of,0.33953944462662894
preparation,0.2332421254156475
on,0.277350114249216
the,0.31110576775048915
"ward,",0.1499508872671324
"training,",0.5879879738710875
and,0.5404087710147243
technology,0.44208935256448684
to,0.5147141411939007
administer,0.4389214239015341
slow,0.5325100887591752
bolus,0.45665190202505845
doses,0.48983640765919756
would,0.4299971608601521
probably,0.3764946426094182
have,0.37842160667929514
the,0.3234363467388906
greatest,0.345944685840954
effect,0.3437290665075261
on,0.3842335227583968
error,0.36519026989085646
rates.,0.3947200568992297
CONTEXT,0.025384494246511048
Blood,0.009390247934461384
type,0.007008140962539284
and,0.007925087032435102
crossmatch,0.005965162804358246
incompatibility,0.007482154844073693
will,0.012596734364581622
exclude,0.011168840288969095
at,0.0068900684451415695
least,0.0058661502955113295
one,0.0101931707963799
third,0.0074706922551062245
of,0.007461155472127659
patients,0.006453495149607894
in,0.0033676262024468274
need,0.005260589001975884
from,0.007418945790321601
receiving,0.008639804719004818
a,0.006083532311632896
live,0.008594145102479939
donor,0.005268273706794897
kidney,0.009238300851492168
transplant.,0.00900944239542889
Kidney,0.015848588707245835
paired,0.013623629008050201
donation,0.018925569780614084
(KPD),0.019604785177221286
offers,0.034381110197715475
incompatible,0.032883137868104234
donor/recipient,0.012539912501970242
pairs,0.014902507817911123
the,0.02318178124442737
opportunity,0.022685738886219636
to,0.014223535609309137
match,0.014078279584967466
for,0.010524787404347785
compatible,0.014585323088733726
transplants.,0.013138979349147853
Despite,0.007132224228916782
its,0.006607388018817775
increasing,0.00893576502376518
"popularity,",0.00831772912403826
very,0.005617461475547916
few,0.0045324349493740985
transplants,0.0019522337708005977
have,0.0038302432071041664
resulted,0.0033353832940760824
from,0.005083002214196367
KPD.,0.011189719120461454
OBJECTIVE,0.0017892992571075896
To,0.001766246942270994
determine,0.0014323384559818868
the,0.0017038648900093308
potential,0.0013200074035210822
impact,0.001377775888935259
of,0.0023537725542270085
improved,0.001708763133799255
matching,0.0016262564015497544
schemes,0.001321039020469093
on,0.00247614697208924
the,0.001994030668399135
number,0.0015470528280259602
and,0.0027120059712442174
quality,0.0011293953263040329
of,0.001982218309154137
transplants,0.0014656982204345245
achievable,0.0014541192789932417
with,0.0016992762910624892
KPD.,0.0021795444848400464
"DESIGN,",0.003128705515499331
"SETTING,",0.006296073068283945
AND,0.0025595636617818107
POPULATION,0.0025519038525279227
We,0.0014577223212807046
developed,0.0013114585820198773
a,0.0010275060829982253
model,0.0007946353812020116
that,0.0008685667251375371
simulates,0.0005966309631950442
pools,0.0007437721446592181
of,0.0007102091184536202
incompatible,0.0007461697549991866
donor/recipient,0.0007226762356976691
pairs.,0.000904741750706774
We,0.0010599951435110333
designed,0.0008823380978410245
a,0.0007169610365771036
mathematically,0.0005171537697120796
verifiable,0.0006317989969073104
optimized,0.0006239449755327094
matching,0.0005388178638339113
algorithm,0.000579940239647635
and,0.0009076363842563484
compared,0.0005740057562994659
it,0.0006948601787262912
with,0.0005140705260235967
the,0.0006192946748890892
scheme,0.0006341561300568066
currently,0.0006017845978882069
used,0.0006356749760475272
in,0.0007314547397658298
some,0.0006420671568389126
centers,0.0004895567364008097
and,0.0007328709642583311
regions.,0.00045796942250315986
Simulated,0.0013433577993442393
patients,0.0008606383856348482
from,0.0007717626819406703
the,0.0011882410398528567
general,0.0006288514416905942
community,0.0007774762178532081
with,0.0009844592207599754
characteristics,0.0007042254093504031
drawn,0.0008727239961830456
from,0.0008902343492946041
distributions,0.0006831205944469186
describing,0.0008313174399909745
end-stage,0.0006727117557578801
renal,0.001265859516390157
disease,0.000839535090510737
patients,0.0010013965172787278
eligible,0.0009615323389294705
for,0.0024248456353472532
renal,0.0014303841136507787
transplantation,0.0010404409099809917
and,0.0007226197645273121
their,0.0009076787606341891
willing,0.0007727480671257121
and,0.0010983056796546105
eligible,0.0007653805529685369
live,0.0007257037082926271
donors.,0.0009875797174369813
MAIN,0.0029932507613691004
OUTCOME,0.005743384665633372
MEASURES,0.0065068785605449575
Number,0.004852152365174491
of,0.004050072478407081
kidneys,0.0020750298133163226
"matched,",0.002456519290549869
HLA,0.003514631523685448
mismatch,0.0030648967815800044
of,0.003845384021784995
matched,0.0027734735088823354
"kidneys,",0.0021230075652335866
and,0.0031815958292822485
number,0.0035707516551497327
of,0.0045326404163151665
grafts,0.0027987535711671463
surviving,0.002106232835510134
5,0.004099073610199988
years,0.003833551401157023
after,0.3119616198768845
transplantation.,0.2863337859128013
RESULTS,0.7268107265030541
A,0.8375479928163754
national,0.8036409943426045
optimized,0.7978937476640876
matching,0.7599663540594195
algorithm,0.7701810157608089
would,0.8576973203185723
result,0.8579368890913915
in,0.8819878428488749
more,0.8763667062049945
transplants,0.8174227668643408
(47.7%,0.8778774446243274
vs,0.7768946848668953
"42.0%,",0.7887176285888745
"P<.001),",0.8214487998717231
better,0.886960349562752
HLA,0.8559320745463004
concordance,0.8379658668874631
(3.0,0.8755662494602615
vs,0.7950416508826322
4.5,0.8637402261509538
mismatched,0.7913455316577243
antigens;,0.8469705592676544
"P<.001),",0.846309384705814
more,0.8884854286464611
grafts,0.8513965870391924
surviving,0.8301352598979806
at,0.8691402784034264
5,0.8547823134679833
years,0.84405069123576
(34.9%,0.8503874659189281
vs,0.7754247676234993
28.7%;,0.8221985195023614
"P<.001),",0.81454306116777
and,0.8864566370183344
a,0.8741479792497626
reduction,0.8320117405654797
in,0.8253705864492561
the,0.8517288546527256
number,0.7741730341202339
of,0.7786053912430013
pairs,0.7205878810014271
required,0.7145854977708761
to,0.6797408908300511
travel,0.7255422579916577
(2.9%,0.8077508209251367
vs,0.732051882798775
18.4%;,0.7807605897531126
P<.001),0.7726428941433333
when,0.8323499585736419
compared,0.8648133808559874
with,0.8001766102558139
an,0.7722002851720756
extension,0.7217639086274463
of,0.739390201205
the,0.7157138558322608
currently,0.6371902019884703
used,0.6900702982329316
first-accept,0.4331705886774952
scheme,0.396070151607869
to,0.38520716329769766
a,0.4172830495978738
national,0.38456760197066925
level.,0.4044273893526934
"Furthermore,",0.4940829036016142
highly,0.46372800723520025
sensitized,0.4167427250920835
patients,0.4427731397866702
would,0.4635427224189386
benefit,0.454349988725501
6-fold,0.5115008097877136
from,0.4684735228319306
a,0.4480925455859889
national,0.42928748133392314
optimized,0.42576096023066956
scheme,0.42738848758953507
(2.3%,0.4666653368722253
vs,0.4716362652332751
14.1%,0.519154588935165
successfully,0.5169548502660499
matched;,0.4097559553296606
P<.001).,0.510310162376229
Even,0.5076786323788682
if,0.5544934826248401
only,0.5383095934100012
7%,0.5023403853615994
of,0.6090906851594579
patients,0.5567647467656544
awaiting,0.5506529628858902
kidney,0.4703926175807539
transplantation,0.4971218445657
participated,0.6173121213748533
in,0.6063319234211128
an,0.5625210345899448
optimized,0.5588593209334471
national,0.4735580760031477
KPD,0.34440838058133044
"program,",0.566862723840605
the,0.44766215321702524
health,0.2840335937227918
care,0.32752977055585364
system,0.3303661744399985
could,0.5583210350509479
save,0.5069043531488358
as,0.5675755633119077
much,0.5812963810663812
as,0.5481107258728886
$750,0.4674170808892595
million.,0.45997612240807034
CONCLUSIONS,0.6730685108229275
The,0.23789527161359467
combination,0.13485237819681298
of,0.13142762516838577
a,0.1272475028134303
national,0.10895924730435026
KPD,0.13837899121691868
program,0.15150680190369326
and,0.09403299661970367
a,0.09112702279162443
mathematically,0.09276896886046385
optimized,0.09287889362543726
matching,0.09453881963342184
algorithm,0.09294309257883943
yields,0.13632170054918052
more,0.12362171497681275
matches,0.09726023576226676
with,0.1067083590540399
lower,0.11868173384278335
HLA,0.09449858090699852
disparity.,0.05312208933934338
Optimized,0.23984767573484445
matching,0.3332047052548514
affords,0.49969678003332835
patients,0.2703579579314117
the,0.4455083615773056
flexibility,0.342825284237381
of,0.37649535969852915
customizing,0.19318091507696136
their,0.16062618607972393
matching,0.1332893510356946
priorities,0.19462749586024708
and,0.47064129163288976
the,0.4239609039133896
security,0.2765037880364565
of,0.37504688155119775
knowing,0.2114997298136036
that,0.2384473938726377
the,0.14133221623667191
greatest,0.13721475302328037
number,0.14294074331360465
of,0.15834864057468487
high-quality,0.18271918689215
matches,0.17560822469141363
will,0.2326488842745891
be,0.149121823660204
found,0.11457398362866904
and,0.20809311847526996
distributed,0.13218214284459748
equitably.,0.19490813194500992
Finding,0.0075794898533441514
new,0.008729913137736505
treatment-shortening,0.0069323357770273855
antibiotics,0.005029383753732076
to,0.011567179638615758
improve,0.01192120999443592
cure,0.00635391464429771
rates,0.00707797984457382
and,0.018332840840021434
curb,0.011266530257646774
the,0.00887457994213075
alarming,0.0038475125636269415
emergence,0.005713556003753947
of,0.006352567573297521
drug,0.0023108831227756006
resistance,0.003384754554225207
is,0.0028742083966451465
the,0.0026308411815040545
major,0.002481286294417444
objective,0.0026077354169000665
of,0.00260787246507995
tuberculosis,0.003254016754510553
(TB),0.0022770191610567993
drug,0.0020447692107756644
development.,0.00222795134541958
Using,0.145111784083324
a,0.05629298554196313
matrix-assisted,0.03729326265965663
laser,0.029899898938085534
desorption/ionization,0.012350830996117054
(MALDI),0.007360498528982923
mass,0.030197315321841604
spectrometry,0.011055407580884816
imaging,0.0442059014112721
suite,0.037593347238424245
in,0.058803785428889255
a,0.06720793414092766
biosafety,0.05622781766185626
containment,0.02811147099804333
"facility,",0.030758699153309397
we,0.2521065526490448
show,0.3451579381400185
that,0.3855024994880846
the,0.31529254630021275
key,0.30664244994442585
sterilizing,0.29754349590826096
drugs,0.31090974005472805
rifampicin,0.4060398873406703
and,0.4338204971486547
pyrazinamide,0.3286925400030688
efficiently,0.41106949123846137
penetrate,0.32677106335069445
the,0.37951202969560444
sites,0.3865531778853365
of,0.38482544594697615
TB,0.30013664957619673
infection,0.34137642932529083
in,0.3608773063365323
lung,0.31109619980107006
lesions.,0.3492559053943585
Rifampicin,0.4450834277819813
even,0.467271516392416
accumulates,0.4569974013122214
in,0.4637105242031281
necrotic,0.488026197937581
"caseum,",0.47468274357447354
a,0.4400580272317573
critical,0.41037435232293595
lesion,0.40412684443032565
site,0.5164818631719708
where,0.4828498539011787
persisting,0.40420991687432695
tubercle,0.3900353008622681
bacilli,0.45687751862330994
reside.,0.39568872039238157
In,0.46299723971632883
"contrast,",0.5037571825695328
"moxifloxacin,",0.5050969742382169
which,0.5945610669761898
is,0.5858073288021907
active,0.6588915819142399
in,0.5485693885028443
vitro,0.5456164243012599
against,0.5673831889142225
a,0.5864162553248647
subpopulation,0.5677208150327439
of,0.6277715343807894
Mycobacterium,0.5455129232965347
tuberculosis,0.5867265399104957
that,0.5988760423523267
persists,0.556724611694003
in,0.5117073971160859
specific,0.46707819295028224
niches,0.5140034023863037
under,0.47386588542866087
drug,0.5321623409822266
pressure,0.4990260017317355
and,0.6344732738418976
has,0.49985342473211547
achieved,0.5953517358619272
treatment,0.5430799847660356
shortening,0.599612397912404
in,0.5056507491143459
"mice,",0.5343145518017555
does,0.45768640438425945
not,0.5069721589995695
diffuse,0.23277135599545723
well,0.44225817161816605
in,0.27214649671580243
"caseum,",0.37708604239046195
concordant,0.4520500079192701
with,0.3734474875622391
its,0.3559628341799124
failure,0.3197245915527563
to,0.28058838456725915
shorten,0.2080281663567077
therapy,0.1965796168258017
in,0.11974734742880015
recent,0.1354421187301637
clinical,0.14438014730649346
trials.,0.1450631590920521
We,0.43924368001557645
suggest,0.3616817804513939
that,0.3010397253393948
such,0.2615467304639271
differential,0.14813497582555354
spatial,0.12289880910809406
distribution,0.13816213163944807
and,0.13278647195175997
kinetics,0.1591336134725722
of,0.1158518282653777
accumulation,0.13365056957035876
in,0.13978009390890117
lesions,0.18135236239588884
may,0.19466120721038357
create,0.1942521399509554
temporal,0.1278987107759296
and,0.15182780279077077
spatial,0.12484178454060323
windows,0.1387112143178393
of,0.11469080930982338
monotherapy,0.14111888406762838
in,0.10962186604635513
specific,0.093496056360732
"niches,",0.09323619981216293
allowing,0.23952884248299675
the,0.19685392652071004
gradual,0.15343582316254284
development,0.15657964855188658
of,0.1502546621715345
multidrug-resistant,0.16594393871835975
TB.,0.09028857781386052
We,0.0743497360162543
propose,0.02576327281225534
an,0.012769271934905884
alternative,0.011136748755186884
working,0.008964574757927179
model,0.012129660800980333
to,0.008408509610079929
prioritize,0.015195530220813378
new,0.011682679157586813
antibiotic,0.01414127934541978
regimens,0.013235102910329302
based,0.010354532111180027
on,0.015003075977157618
quantitative,0.022800537583771607
and,0.019459863858987535
spatial,0.020596761093714416
distribution,0.01662562062568944
of,0.014054406634924726
TB,0.05213717842171927
drugs,0.027154225019198043
in,0.020713500268959878
the,0.02629597859336417
major,0.0352740580057876
lesion,0.024209964402488057
types,0.04249637528461225
found,0.04159567002963285
in,0.04202295596689633
human,0.030300567556160507
lungs.,0.03479701446112396
The,0.027884441942382984
finding,0.037952272447911085
that,0.024651214206967958
lesion,0.03448822587275418
penetration,0.04611447402801136
may,0.019855860493484413
contribute,0.02567359638287367
to,0.019143521233825688
treatment,0.02300804818884326
outcome,0.02373711666296308
has,0.015098326649434212
wide,0.016252039444623983
implications,0.013895007115645456
for,0.0197403623605062
TB.,0.044246369606788315
Genetic,0.12045599836515945
mutations,0.11736340776557494
in,0.14374617025417494
TAR,0.18855535375841365
DNA-binding,0.19915665338010383
protein,0.14356250755725863
43,0.12893222868678836
"(TARDBP,",0.15814552096057494
also,0.1261390185177972
known,0.17701144461639062
as,0.18207922759261191
TDP-43),0.3233517816798951
cause,0.3081777224937648
amyotrophic,0.38308970099039724
lateral,0.20623310455072077
sclerosis,0.22753932313042585
"(ALS),",0.1988244893289709
and,0.3967641905657332
an,0.30358804144776125
increase,0.2806377172098901
in,0.28757813205212734
the,0.22585607202562066
presence,0.2633615439623606
of,0.2880800950182847
TDP-43,0.33990910221848625
(encoded,0.2203372249013022
by,0.19383631597478443
TARDBP),0.22237264172578208
in,0.3208530594696159
the,0.19173898842549172
cytoplasm,0.08148417624492105
is,0.122016838094949
a,0.14658997265465695
prominent,0.12475023249584316
histopathological,0.05550329553424765
feature,0.11208186028861848
of,0.11617269995031342
degenerating,0.0381168929719325
neurons,0.08556832128986161
in,0.07163830222371312
various,0.026875054194356037
neurodegenerative,0.03421683249775156
diseases.,0.03550899992678438
"However,",0.0051838472300353225
the,0.00341101319434403
molecular,0.0033238776379814305
mechanisms,0.0041513028494141214
by,0.0037195549098956162
which,0.004200217044190164
TDP-43,0.037652112858608325
contributes,0.005178580176794671
to,0.004744421798878236
ALS,0.007535187496180014
pathophysiology,0.003864970546783704
remain,0.003172414420322887
elusive.,0.002465402300639429
Here,0.4701044193842949
we,0.5489051874044744
have,0.46377789446230644
found,0.5316805411621218
that,0.5653998838926999
TDP-43,0.39920124481234254
accumulates,0.43928992108960574
in,0.10921823524491552
the,0.0656128324591141
mitochondria,0.040283028072603914
of,0.06120206133570207
neurons,0.059345342799305395
in,0.06246498384901551
subjects,0.043534949588286596
with,0.030609005693349255
ALS,0.028138454308726562
or,0.02557428494815093
frontotemporal,0.027730920023976525
dementia,0.01845797537961763
(FTD).,0.01793326023538335
Disease-associated,0.011772441019607201
mutations,0.027634938067563185
increase,0.02809816618827252
TDP-43,0.06158048021321833
mitochondrial,0.021333028919335407
localization.,0.025500207664820397
In,0.4347016061913866
"mitochondria,",0.35560467789640965
wild-type,0.30928390417222534
(WT),0.2076109578656191
and,0.4303434894769548
mutant,0.4325049556879578
TDP-43,0.35259910057481275
preferentially,0.4690789708177578
bind,0.41024785287170185
mitochondria-transcribed,0.447831119480808
messenger,0.3704839861826751
RNAs,0.2755899773960923
(mRNAs),0.2714095080903685
encoding,0.4407317261361872
respiratory,0.34313233494174333
complex,0.3107669704137008
I,0.37162576673132625
subunits,0.34112703925801563
ND3,0.34008442795081606
and,0.4064924290438478
"ND6,",0.30591929557613884
impair,0.49219591595449513
their,0.2666176093648438
expression,0.4036120221069752
and,0.48205036431084247
specifically,0.35247524793345547
cause,0.3773976858041119
complex,0.19647329171961594
I,0.25108258450236703
disassembly.,0.21305298976641143
The,0.5165634137588768
suppression,0.542877754340961
of,0.5494307358767914
TDP-43,0.4244516821028024
mitochondrial,0.44429500641851877
localization,0.4941904961423518
abolishes,0.5367186061145529
WT,0.48498783828402264
and,0.8720390944031335
mutant,0.8927973753515408
TDP-43-induced,0.7882059226283791
mitochondrial,0.8965830771793302
dysfunction,0.8901623262873326
and,0.9063591050234708
neuronal,0.9136328682077323
"loss,",0.8758504435170174
and,0.8933619532532947
improves,0.8968706504055726
phenotypes,0.8793143486160617
of,0.8644544877319728
transgenic,0.8534342447955601
mutant,0.8468948654922764
TDP-43,0.7608147893861354
mice.,0.8558436463138206
"Thus,",0.10586267429661088
our,0.09621355576960167
studies,0.04745607329738043
link,0.04017818278445696
TDP-43,0.13694849945387927
toxicity,0.03570618044795326
directly,0.047666000296237396
to,0.03395860042638844
mitochondrial,0.025455792434698404
bioenergetics,0.020382916176824466
and,0.06519813908448222
propose,0.021159304016423738
the,0.01141459598277178
targeting,0.015040947849118814
of,0.018693139210362086
TDP-43,0.11693007985020117
mitochondrial,0.02727503127539071
localization,0.015487433195008258
as,0.014937954386407819
a,0.011108692062554083
promising,0.009075791151689015
therapeutic,0.013574200162115052
approach,0.009637483733327738
for,0.009898019322165797
neurodegeneration.,0.022290497817089153
OBJECTIVES,0.0006831686095609823
To,0.0006030674414578621
explore,0.0005759715617424285
the,0.0005005431302523176
association,0.0005072982067315078
between,0.00048571630009195874
a,0.0005036488470280656
stable,0.0004607721214689255
partnership,0.000504586344481412
and,0.0006517505270490473
clinical,0.00033806530595576205
outcome,0.00038176475163813133
in,0.00045345254943398704
HIV,0.0004679105225501624
infected,0.0004625027202407534
patients,0.000428231396624073
receiving,0.000386954454856819
highly,0.00045820467616058746
active,0.00046343235174310844
antiretroviral,0.000513269137226686
therapy,0.0004890681652812414
(HAART).,0.0005506589899545415
DESIGN,0.000515930136722115
Prospective,0.00046745123028866034
cohort,0.0005339646835902272
study,0.0007487233041473402
of,0.0005403275875604902
adults,0.00045188188488023544
with,0.0003714350929282569
HIV,0.0004175836770616272
(Swiss,0.00046663329013275147
HIV,0.0004739166575649731
cohort,0.0005191159362186739
study).,0.0006109337415814878
SETTING,0.0009503027654482703
Seven,0.0005160009572471938
outpatient,0.0005722518374668657
clinics,0.0004906807820185251
throughout,0.0006275544548557822
Switzerland.,0.0005797465319332688
PARTICIPANTS,0.0019952551656640025
The,0.0014866634434593721
3736,0.0012536528952224264
patients,0.0009584904134188218
in,0.0010766129981317552
the,0.0013159387936169152
cohort,0.0012229914583403387
who,0.0014481618852075946
started,0.001058921744700437
HAART,0.0006668128767813634
before,0.0012209022308151925
2002,0.0010107880185694883
(median,0.0011929276105967575
age,0.0014645464809004383
36,0.0021849514612262795
"years,",0.0012571704929652872
29%,0.0031420480917186
"female,",0.0015443752034073588
median,0.0016567770577742402
follow,0.0014710522880763172
up,0.0019708227825160213
3.6,0.005673107972139406
years).,0.0016188872683390429
MAIN,0.003040695982398834
OUTCOME,0.005718465216750988
MEASURES,0.008272435054563067
Time,0.023408885467679247
to,0.01601422170208078
AIDS,0.017928058481359924
or,0.024060656346883976
death,0.009026611375974746
(primary,0.01493541109335971
"endpoint),",0.015314355664049421
death,0.012073836504863798
"alone,",0.02480847140393914
increases,0.02689111478212247
in,0.0342686339328919
CD4,0.029872024606198387
cell,0.040989222930836226
count,0.032535806202921555
of,0.04372042202729099
at,0.020528195711907875
least,0.02137975466981045
50,0.022993812739134502
and,0.04781013338402604
100,0.02000276867933069
above,0.028376942441320867
"baseline,",0.012077898227164865
optimal,0.02473764313645469
viral,0.016543228223714148
suppression,0.02011233589417572
(a,0.025454204402301693
viral,0.020116572220690365
load,0.02518766209764645
below,0.05181028844262902
400,0.025155190159116426
"copies/ml),",0.020854882502557494
and,0.02011213854918697
viral,0.022456854040572644
rebound.,0.01642106760845968
RESULTS,0.052174741655100644
During,0.055545424408921275
follow,0.023907653231461618
up,0.02978930372739424
2985,0.01577351420382042
(80%),0.029019088577181894
participants,0.027866552057505774
reported,0.03921265865034919
a,0.02285270242403767
stable,0.018662549427406323
partnership,0.030038124341640014
on,0.026672587663499316
at,0.019533863970519743
least,0.018216455508917775
one,0.021081750955422994
occasion.,0.025874717051741408
When,0.11731039240557248
starting,0.06187420044365211
"HAART,",0.03356790404974737
52%,0.08372453711442218
(545/1042),0.06603468238781428
of,0.06468081581359135
participants,0.05019055799412047
reported,0.08511542329230748
a,0.07943086587951106
stable,0.044532230425850895
partnership;,0.050319032936565096
after,0.10157593361149311
five,0.11524920239666457
years,0.0791028466313025
of,0.09182140760294416
follow,0.046856908500374515
up,0.05475660993155173
46%,0.1380449894273056
(190/412),0.060898533606793405
of,0.06151156521989271
participants,0.046290653796821825
reported,0.07683965612840596
a,0.07884779593794009
stable,0.044547708422269676
partnership.,0.05489505821817349
In,0.1600801298342398
an,0.13026411377194744
analysis,0.1202773823110287
stratified,0.0820881304280757
by,0.11393002556257095
previous,0.10777559687118382
antiretroviral,0.05358092871499774
therapy,0.7345476225278048
and,0.7315868408077901
clinical,0.7285334645648418
stage,0.7129246630420819
when,0.7087170063145806
starting,0.6998048150783556
HAART,0.6475852804841187
(US,0.6479169530951093
Centers,0.5571813521363714
for,0.24047678527465616
Disease,0.36999816175021644
Control,0.3305397640241206
and,0.3373056034433553
Prevention,0.5531883719108011
group,0.5806699080317264
"A,",0.6507498045257533
"B,",0.6381620197526414
or,0.4988556039945221
"C),",0.5889608776769515
the,0.7336102179309844
adjusted,0.7437433437786206
hazard,0.7228871022315728
ratio,0.7526499619352572
for,0.7572296793779468
progression,0.7497660421641865
to,0.755050059657972
AIDS,0.7053003326718024
or,0.7361927732292917
death,0.6887280192769427
was,0.7323638855671607
0.79,0.7186543585941961
(95%,0.7470481479206308
confidence,0.7795989052816854
interval,0.7749099661403402
0.63,0.6957521744680001
to,0.7195819829146212
0.98),0.6867588864223247
for,0.7406218541809971
participants,0.7278600618309032
with,0.7274742913407812
a,0.7703472545375979
stable,0.7674663359465825
partnership,0.7475081297343587
compared,0.8004381300319572
with,0.7004763271471777
those,0.7095921280030147
without.,0.7280593684496969
Adjusted,0.5127737458032096
hazards,0.5005757012297868
ratios,0.539352129902497
for,0.4860671333970919
other,0.5305474606423388
endpoints,0.5269813916715296
were,0.5756895084937252
0.59,0.4729999887952642
(0.44,0.46754439597796105
to,0.47505855748665216
0.79),0.40507359164622747
for,0.5457415731069427
progression,0.6018634725304003
to,0.4782638429183454
"death,",0.5601969718851542
1.15,0.5552075605442313
(1.06,0.487184556637385
to,0.5239622024462645
1.24),0.47264913413034154
for,0.5881885791441296
an,0.6060084080437919
increase,0.6267338452582812
in,0.5769197738621652
CD4,0.6593964974028681
cells,0.6415511489995065
of,0.6382391186689613
100,0.5623221649126349
counts/microl,0.5414471327829277
or,0.5002302378253332
"more,",0.579580366088647
and,0.5713578688558476
1.06,0.43650702904894584
(0.98,0.3770014576254746
to,0.35655465160940053
1.14),0.38714459400882756
for,0.4174687839720786
optimal,0.4160141350893166
viral,0.4457121634297908
suppression.,0.36468742391924375
CONCLUSIONS,0.8810648958969123
A,0.8652583174590579
stable,0.8442136398844502
partnership,0.8267466728080693
is,0.8549056506076832
associated,0.8760492276846323
with,0.8745189814096719
a,0.8691157630054838
slower,0.8719800542879905
rate,0.846084862352508
of,0.8852234776671268
progression,0.8344094147120776
to,0.8732253780414019
AIDS,0.7757801165098775
or,0.8715569347558128
death,0.7931234967806374
in,0.8398744569963679
HIV,0.7509948189707114
infected,0.8120872946928681
patients,0.8128991126869229
receiving,0.809560879345238
HAART.,0.8311213642256211
INTRODUCTION,0.006514527704041406
Various,0.005408464481827696
perinatal,0.004744670605317063
"factors,",0.0053384291142506085
including,0.007088599179426123
birth,0.013911177224978144
"weight,",0.005899417143900334
birth,0.01712834838617888
"order,",0.011376895380606693
maternal,0.01006984586246157
"age,",0.0054820555681109025
gestational,0.005448471155359209
"age,",0.007471456003060398
twin,0.011406004737350432
"status,",0.013870080663254123
and,0.006163920410971498
parental,0.018634328120478993
"smoking,",0.014633247400416206
have,0.005144026055443944
been,0.004317706486688955
postulated,0.005372899457566469
to,0.007262550877080686
affect,0.007195867379988844
breast,0.009972345347745992
cancer,0.0052341545038750974
risk,0.008261318772736672
in,0.013136073733347867
daughters,0.011307946861451151
by,0.02240656169818214
altering,0.009601450320346691
the,0.005533727747676686
hormonal,0.00883917787651966
environment,0.02025354089499062
of,0.015065892486993322
the,0.009836156049630224
developing,0.013515289350520194
fetal,0.009143284951579332
mammary,0.007367356321701212
glands.,0.016037967864101953
Despite,0.0022319543208033765
ample,0.0016969518841850146
biologic,0.0013034072292943508
"plausibility,",0.0020102531604231904
epidemiologic,0.0015310628903970802
studies,0.0014874656450241238
to,0.0012155743214551774
date,0.00116678379846011
have,0.002043734656506394
yielded,0.0017136297537654567
conflicting,0.0016614666011440112
results.,0.0013922228634024026
We,0.002391737249290092
investigated,0.0016272635577838205
the,0.0011837580501755554
associations,0.0012328305755991017
between,0.0015817865682993019
perinatal,0.0015896858553122368
factors,0.0013009218215877154
and,0.0015226448420789154
subsequent,0.001206681085465525
breast,0.002080185475864596
cancer,0.0012707065902299495
risk,0.001097042504975519
through,0.001546606174218988
meta-analyses.,0.0009762824668965937
METHODS,0.010450042982741003
We,0.01663699088382731
reviewed,0.004918130827616015
breast,0.012117649304705998
cancer,0.00646869292722264
studies,0.0066581020900914325
published,0.0032525261849748305
from,0.0039860317315834
January,0.0020530332188370298
1966,0.003597455691006876
to,0.0025642956801449875
February,0.0026581282569925783
2007,0.002145881934590648
that,0.00523970643461446
included,0.003497095829784187
data,0.00550764269333723
on,0.002940109420674758
birth,0.008743466421414678
"weight,",0.004992511126046399
birth,0.006668640543633997
"order,",0.003327780149889918
maternal,0.0024986119924227082
"age,",0.003014160534469081
gestational,0.001440037155246424
"age,",0.002595248385323299
twin,0.001456249179993382
"status,",0.0050933445011283
and,0.0016310689461607767
maternal,0.001791377276833625
or,0.0010135888873241115
paternal,0.002602595412820332
smoking.,0.0015020909720256275
Meta-analyses,0.0009328728436411562
using,0.0008849857050387387
random,0.0006523715092749743
effect,0.0006904294373843628
models,0.0007534074086565278
were,0.0012823035727400343
employed,0.0007977945189396845
to,0.0007944271726430525
summarize,0.0008618042775176629
the,0.0010866625578177802
results.,0.0011887459513791588
RESULTS,0.8703585403464017
We,0.9201486083932189
found,0.9187971509062358
that,0.9390569870344986
heavier,0.9371620681007259
birth,0.9372245816295444
weights,0.9246659567402526
were,0.936605548305454
associated,0.9492470972517834
with,0.9460102032889094
increased,0.9433066277991373
breast,0.9336099568315732
cancer,0.9077369910679098
"risk,",0.9359215285506649
with,0.9290157814628649
studies,0.9366113804282822
involving,0.9277100351603144
five,0.9226161404447994
categories,0.9269318210228674
of,0.9362845719465548
birth,0.9373065071163054
weight,0.9281320525573152
identifying,0.9164347152058263
odds,0.9363270216613833
ratios,0.9106445445025435
(ORs),0.8895890553183398
of,0.9369807184795683
1.24,0.9258617701041788
(95%,0.898754414192786
confidence,0.9195315751004671
interval,0.9149017810251509
[CI],0.8821410504405801
1.04,0.9175060604592655
to,0.8884622176329366
1.48),0.8696207460412848
for,0.9122733757690343
"4,000",0.9079960987491166
g,0.8942384315145597
or,0.8941817983901297
more,0.913326202651942
and,0.8782899782537504
1.15,0.88992890024296
(95%,0.846701048378417
CI,0.8880440935262082
1.04,0.8812672029063866
to,0.8745647333329043
1.26),0.846130295794156
for,0.8988504603604325
"3,500",0.4738060018996051
g,0.5178585830944031
to,0.5326024709843388
"3,999",0.5767156207169539
"g,",0.49072354200794327
relative,0.512245140430405
to,0.48811913120020567
a,0.4781747431839778
birth,0.5140759882713373
weight,0.4743435847220264
of,0.5197100522568676
"2,500",0.5160741818189302
to,0.5194267761631112
"2,599",0.49468309206571354
g.,0.46825513839452965
These,0.3163825446269761
studies,0.3673067717204057
provided,0.27351670812217405
no,0.24749581912251536
support,0.2586243878602055
for,0.24084637410187243
a,0.22745937699480442
J-shaped,0.24540374500922618
relationship,0.2585064807589
of,0.18450771643883077
birthweight,0.2723526070806185
to,0.1221605050588507
risk.,0.2114188384737932
Support,0.26747699960093596
for,0.27465655880537326
an,0.22894439212884246
association,0.2743170916845979
with,0.28145479549592173
birthweight,0.5082947307461704
was,0.3084610551204722
also,0.29224309250245567
derived,0.24193865169271994
from,0.29177517682380644
studies,0.4650556378880922
based,0.3520932753504582
on,0.3424501176734699
three,0.3382958682640884
birth,0.577084866205094
weight,0.48724731047669
categories,0.39562193103392085
(OR,0.40915419032593053
1.15,0.38969165433551495
[95%,0.48973807274934217
CI,0.58086916441282
1.01,0.48757476857294807
to,0.5376591791530211
1.31],0.46551145257271276
for,0.38479196493354834
>,0.4505770135516159
or,0.3925530066641183
"=4,000",0.4519399585293066
g,0.5099943116710007
relative,0.4937034001908568
to,0.4599126020651262
"<3,000",0.5035309893739777
g),0.526447347706522
and,0.3538383831622828
two,0.3559748727493856
birth,0.5509745830947068
weight,0.48911486332005993
categories,0.3820372888929718
(OR,0.4266938622244433
1.09,0.4335124143478893
[95%,0.5009234350851275
CI,0.5869830259051647
1.02,0.5142053255389832
to,0.5275340274727369
1.18],0.45951468717474475
for,0.37728651528370877
>,0.4173216929752009
or,0.32312276802066037
"=3,000",0.37277992160808937
g,0.4406518906664059
relative,0.4334239097800611
to,0.2676858515941338
"<3,000",0.14111370429392597
g).,0.1174598800737958
Women,0.01623820453920939
born,0.01794760316642375
to,0.030327490074215556
older,0.013244215224170755
mothers,0.0190571361393637
and,0.01190790152347316
twins,0.013772309397475875
were,0.036646707858108724
also,0.04313215202295062
at,0.018173538757643163
some,0.022273165331280327
increased,0.015228316026438754
"risk,",0.0088358218124082
but,0.007314999266387184
the,0.004459916065840817
results,0.0035131905936776403
were,0.004166368888447949
heterogeneous,0.002674100743665092
across,0.003623486637044542
studies,0.0027805705860470546
and,0.003151260226217134
publication,0.00314543052792538
years.,0.002228585847394252
Birth,0.053718669942020875
"order,",0.04570086985319887
"prematurity,",0.02554877882066694
and,0.026259750798148938
maternal,0.02292688719183473
smoking,0.041178881516411345
were,0.042076372604942416
unrelated,0.0172745312388469
to,0.016746336391287246
breast,0.3102705610814289
cancer,0.060145286655976085
risk.,0.015795070712563013
CONCLUSION,0.7920348759801312
Our,0.6013038812419688
findings,0.585514361020042
provide,0.392258150740512
some,0.4728028321411962
support,0.42452725527572577
for,0.41047591442636233
the,0.45504079662774904
hypothesis,0.5011765916534329
that,0.6959639406587816
in,0.8280646204393207
utero,0.7572425046606711
exposures,0.7139840980807576
reflective,0.7748012259969492
of,0.7745999728206099
higher,0.7732899115458256
endogenous,0.7702098269652128
hormone,0.699243735103255
levels,0.7388644204151039
could,0.7194647774645023
affect,0.7418110433379286
risk,0.7691669053493484
for,0.7682728299221117
development,0.7482999807147588
of,0.7643573119595994
breast,0.6798774882495412
cancer,0.6067327745415334
in,0.7344273041892515
adulthood.,0.6314235433950529
Dnmt1,0.2549992369478697
epigenetically,0.08454653880842132
propagates,0.08649384683769216
symmetrical,0.12598180111789176
CG,0.19336653406348925
methylation,0.1100789295636205
in,0.11389221965276329
many,0.05449916792218583
eukaryotes.,0.08605557958657747
Their,0.04058176713094375
genomes,0.03902210190186801
are,0.022087906558012047
typically,0.021180412032267892
depleted,0.027965010035741866
of,0.034741092917162576
CG,0.08458797550447957
dinucleotides,0.09009523185058513
because,0.04874803162911594
of,0.040478367070234854
imperfect,0.03247532348413237
repair,0.059415382034125414
of,0.03288037807781414
deaminated,0.037022897351572256
methylcytosines.,0.034933862297500284
"Here,",0.23005843359233874
we,0.25841213802872537
extensively,0.13150902397950567
survey,0.13246181118141262
diverse,0.07901265956410279
species,0.09776184385965668
lacking,0.1055879509851715
Dnmt1,0.22574081975875845
and,0.14804993456369486
show,0.1830835434407401
"that,",0.14980173266172137
"surprisingly,",0.1306493182420922
symmetrical,0.1146169766372091
CG,0.17842774921999113
methylation,0.10103028857026325
is,0.08014072957950515
nonetheless,0.0976316114605616
frequently,0.09704719136189444
present,0.08740162269879054
and,0.11381063491266838
catalyzed,0.06855729015792487
by,0.08570974636299639
a,0.07725866173585001
different,0.05329330811554388
DNA,0.12446591851957466
methyltransferase,0.08204822156552583
"family,",0.06560630630797064
Dnmt5.,0.23261871358513875
Numerous,0.1544385747576931
Dnmt5-containing,0.2486937983038152
organisms,0.09596596338727402
that,0.09954413198662862
diverged,0.06473945829161999
more,0.07439338595764618
than,0.09920564739211508
a,0.1444167316913555
billion,0.04280259523197956
years,0.03747160848166897
ago,0.06340035510497481
exhibit,0.09293835415925833
clustered,0.04517835174108007
"methylation,",0.04586320146034668
specifically,0.05883974024717152
in,0.080126230752786
nucleosome,0.06885067223649033
linkers.,0.08704871635655498
Clustered,0.4663295889120944
methylation,0.37556551323709914
occurs,0.554141897625239
at,0.5240316522977722
unprecedented,0.5314222437796394
densities,0.4975971317501059
and,0.6876439441723562
directly,0.6467437503738864
disfavors,0.6158540702150737
"nucleosomes,",0.4964367293507191
contributing,0.582657004723233
to,0.5593582462519118
nucleosome,0.509734236804404
positioning,0.44628090162056283
between,0.3830055826515337
clusters.,0.3455987325843194
Dense,0.010364164998308206
methylation,0.009289494228848285
is,0.012717407107037807
enabled,0.015130412105600198
by,0.01666690154743562
a,0.015450050394794228
regime,0.012713819889464307
of,0.014061908092215244
genomic,0.009045411177233781
sequence,0.010116678505967178
evolution,0.011345378816738893
that,0.021534514800193874
enriches,0.010488131172902202
CG,0.022487710221333165
dinucleotides,0.017361975975772267
and,0.03738049952534129
drives,0.010891999528758987
the,0.015476763559835053
highest,0.010521445952631978
CG,0.01904444232849497
frequencies,0.011891635002299367
known.,0.007783645626815151
Species,0.08310164883109682
with,0.03233712107075578
linker,0.05269251190852603
methylation,0.03605204193386742
have,0.07362527415611597
"small,",0.05402904511005796
transcriptionally,0.05896804645795051
active,0.06641106761940635
nuclei,0.048613690860650996
that,0.04138259545503965
approach,0.03521380526868925
the,0.03626384236089331
physical,0.0236605609716017
limits,0.028881259899190277
of,0.02920968925958598
chromatin,0.04565911932539845
compaction.,0.032727612878546836
These,0.0320918556654076
features,0.032244720577466725
constitute,0.019968779925824708
a,0.02155546339577134
previously,0.026416402690611778
unappreciated,0.01659848536489554
genome,0.04932034463999295
"architecture,",0.3009969943589856
in,0.35755074989249735
which,0.3210475990810572
dense,0.2858175714163507
methylation,0.2512456970432604
influences,0.3070977565634536
nucleosome,0.310217653511848
"positions,",0.3079557016003973
likely,0.22408447604893453
facilitating,0.3031746549485934
nuclear,0.2893180460246684
processes,0.3147577324648395
under,0.22417606121292508
extreme,0.20363442714870725
spatial,0.21665003145507702
constraints.,0.21436683487422892
Modification,0.0030824940602212345
of,0.0021775315150075625
proteins,0.002257105134998225
by,0.002591667064414722
SUMO,0.0017937104047666744
is,0.0019853833144412134
essential,0.0019260255184627934
for,0.0022415596234842843
the,0.002034817969050227
maintenance,0.0018164494730560747
of,0.0020831838952556545
genome,0.0019347186674191126
integrity.,0.00207713502380871
During,0.06593881657710506
DNA,0.03443824878021517
"replication,",0.028426644935827857
the,0.060008540228280956
Mms21-branch,0.06556949930561463
of,0.06092197662276814
the,0.048491135258766034
SUMO,0.050095307687249346
pathway,0.06276098585031485
counteracts,0.0531607303963594
recombination,0.05991113885946972
intermediates,0.065457552670996
at,0.060338338272054766
damaged,0.046054967591105236
replication,0.0403614115163313
"forks,",0.035775122487900546
thus,0.09584046204977019
facilitating,0.06760482101502348
sister,0.04406590891241885
chromatid,0.04220903206009079
disjunction.,0.032669268165369594
The,0.03022614065971411
Mms21,0.0692902889078768
SUMO,0.05567953153460247
ligase,0.030181626794278753
docks,0.04901950428152799
to,0.0717176640363917
the,0.03609354673079075
arm,0.025127147577223743
region,0.043261782295892996
of,0.042854098002446335
the,0.03389095938721096
Smc5,0.03688637685663813
protein,0.046887717735714776
in,0.04282562464537851
the,0.025726973676927903
Smc5/6,0.026590777898153648
complex;,0.027779964441108605
"together,",0.012731605640928713
they,0.019067200394260502
cooperate,0.016946810359269867
during,0.019051672640435745
recombinational,0.005731764012441945
DNA,0.012139676743095622
repair.,0.011576047721566705
Yet,0.003134587007391583
how,0.002822294713896354
the,0.0032963780450888025
activity,0.004852868482874354
of,0.004726309659039968
the,0.004986726472342162
SUMO,0.010017466445329257
ligase,0.006444843867481277
is,0.002049696215431858
controlled,0.0023091269979051573
remains,0.0024015309667721777
unknown.,0.002816532100998096
Here,0.3259793842575002
we,0.36560318636728373
show,0.30831257349612906
that,0.33583354658949116
the,0.13482368894941063
SUMO,0.17481529022781475
ligase,0.12530835966694626
and,0.1155831481067808
the,0.11763168537532985
chromosome,0.16888719439280522
disjunction,0.09169620929089196
functions,0.10569220059751144
of,0.11142054207585458
Mms21,0.24931937886541822
depend,0.12169359050172422
on,0.08906782688485418
its,0.14089886573630148
docking,0.1503274227011826
to,0.09378543324051668
an,0.130487508069637
intact,0.12697799863766646
and,0.19144438249376142
active,0.17175643852347258
Smc5/6,0.22656553205087185
"complex,",0.15364672426984016
indicating,0.24040337879965173
that,0.20286254399520634
the,0.14843447124787304
Smc5/6-Mms21,0.22447804732867319
complex,0.14676696943120482
operates,0.12775290388488783
as,0.15662106516336843
a,0.15407894118077625
large,0.11986467811569294
SUMO,0.16130194075865475
ligase,0.1329713661118673
in,0.1987501758778954
vivo.,0.17730771564536388
In,0.374484928199167
spite,0.38938788292297316
of,0.29380290426332506
the,0.29296724263977075
physical,0.2683967967327578
distance,0.2631913886650042
separating,0.2047235206253629
the,0.21713577462651565
E3,0.2679510693318827
and,0.1866251512012919
the,0.19387854470568683
nucleotide-binding,0.23558458600249182
domains,0.20418734450443013
in,0.22099396426347717
"Smc5/6,",0.2605511703136145
Mms21-dependent,0.3883702220654295
sumoylation,0.33542430050507643
requires,0.32092020259345583
binding,0.3342435857422616
of,0.3433850560228571
ATP,0.3198673880834749
to,0.3041057811055329
"Smc5,",0.3071003597956447
a,0.43780107869109547
step,0.3138978566324595
that,0.30797311752429796
is,0.2893021692870719
part,0.3253708547478798
of,0.2955038072351214
the,0.3193869789298961
ligase,0.26741308790887225
mechanism,0.3501088884514927
that,0.2951093614246001
assists,0.24411057212432194
Ubc9,0.30960112659566924
function.,0.2609201608397588
The,0.2495621357723816
communication,0.277110067977834
is,0.2256030427259505
enabled,0.2618775834552678
by,0.3109711542629108
the,0.27293266725726995
presence,0.28714479014596944
of,0.3228236616478945
a,0.2815810064050495
conserved,0.24396452249914788
disruption,0.27597126906810354
in,0.2572972323980272
the,0.29325754018036415
coiled,0.22791260421515835
coil,0.2547791391798387
domain,0.3008843753197933
of,0.28736006357714244
"Smc5,",0.268180083019245
pointing,0.24668845655364124
to,0.1988881489302883
potential,0.16171804856543134
conformational,0.1583186630899359
changes,0.17168119932733744
for,0.1486677509395067
SUMO,0.2332403292595338
ligase,0.16470082432432884
activation.,0.18275271909769616
In,0.43868852609167514
"accordance,",0.4560214590546312
scanning,0.29818454834367863
force,0.3567914530009842
microscopy,0.3356710506572495
of,0.3891939013571472
the,0.3428836846516574
Smc5-Mms21,0.33209686621287665
heterodimer,0.28754137648333916
shows,0.47089189715500723
that,0.44277372159133616
the,0.25522125551328195
molecule,0.2803619945690854
is,0.34092282261929696
physically,0.35679919179011277
remodeled,0.3185603021613605
in,0.4304544607470573
an,0.4318921206590684
ATP-dependent,0.33679777464090616
manner.,0.4040788084576305
Our,0.5967733552893698
results,0.477813621048525
demonstrate,0.5998660508890475
that,0.6133929276361321
the,0.4789592159446879
ATP-binding,0.4781689613979502
activity,0.454529292747688
of,0.44462159153497977
the,0.380107768229676
Smc5/6,0.4430872148563919
complex,0.417044903468138
is,0.4522201083804277
coordinated,0.464265433761053
with,0.4265302074122059
its,0.37619848738495626
SUMO,0.4491776844329031
"ligase,",0.430139597824642
through,0.5058081145119109
the,0.45326543874527686
coiled,0.3919522962850756
coil,0.4054432363035768
domain,0.4352251576125914
of,0.4064597464184769
Smc5,0.4399028339679604
and,0.4895218084094541
the,0.49979481288452415
physical,0.44324173949787493
remodeling,0.38232331343430886
of,0.35299214607928325
the,0.3692068840064239
"molecule,",0.3425430074456234
to,0.43045225374714213
promote,0.49985987693438194
sumoylation,0.46880009282754664
and,0.36457066976775143
chromosome,0.4442075423797243
disjunction,0.3134852297818889
during,0.386656393263595
DNA,0.3787703430061686
repair.,0.39407765569739434
Small-vessel,0.014632625174360007
vasculitis,0.023289483302382178
(SVV),0.019231758455679523
is,0.01379732212942802
a,0.016179731698268734
chronic,0.012894399365247904
autoinflammatory,0.014747345115619228
condition,0.02581980294516573
linked,0.014962815146323982
to,0.014837671540727156
antineutrophil,0.012019147873157814
cytoplasm,0.013374337886461415
autoantibodies,0.007761086954440104
(ANCAs).,0.010854769530507133
Here,0.6163867997509719
we,0.6778001276263447
show,0.6805283878183033
that,0.7265453487895951
chromatin,0.5811881840647835
"fibers,",0.5805937948655379
so-called,0.5582459509463014
neutrophil,0.6008801459309618
extracellular,0.5727641277710388
traps,0.5530751796519873
"(NETs),",0.41231926156613485
are,0.5978009376132578
released,0.5443109633134852
by,0.6451446158068745
ANCA-stimulated,0.5710035887130323
neutrophils,0.6927890945521199
and,0.6177636991885449
contain,0.5573422511233159
the,0.5691228470190486
targeted,0.6290678035025203
autoantigens,0.5866949618935323
proteinase-3,0.5411201389669623
(PR3),0.5767634070544162
and,0.6128033172252126
myeloperoxidase,0.5552678562971824
(MPO).,0.47371981442140715
Deposition,0.5560616289549281
of,0.5132086736710066
NETs,0.49453076509179067
in,0.5518433712562462
inflamed,0.567339513068191
kidneys,0.5266479908481975
and,0.5182188297122241
circulating,0.5048685472276386
MPO-DNA,0.5277476958837968
complexes,0.5118525301897614
suggest,0.5977080582091672
that,0.7026605514819623
NET,0.7011018331427906
formation,0.7154193176951642
triggers,0.7713416946278953
vasculitis,0.7672694906401272
and,0.7933457044377863
promotes,0.753815372634181
the,0.7666609531646976
autoimmune,0.767249645387098
response,0.7606048989329736
against,0.7234058496732358
neutrophil,0.7520550997928808
components,0.7488471736311599
in,0.6823572633675967
individuals,0.6785872250465517
with,0.6111297083990108
SVV.,0.6563690997150617
Tumor,0.05938576288616516
cells,0.09594966534815048
have,0.06085258578386364
high-energetic,0.0549090003516763
and,0.07166750714207176
anabolic,0.05024650706314771
needs,0.07290141750673103
and,0.08116707095240808
are,0.04933088744311449
known,0.048094353624581705
to,0.04912042013704315
adapt,0.05691788433547873
their,0.038985859665073876
metabolism,0.06590773648619784
to,0.041979330622467594
be,0.05156695753764968
able,0.04151720383822038
to,0.042352756027356955
survive,0.035461401984981274
and,0.06015547966125019
keep,0.04706336432832375
proliferating,0.0381821835146378
under,0.025543956525372294
conditions,0.02920472730545836
of,0.022860125251091018
nutrient,0.021931158365837908
stress.,0.033647440403296945
We,0.2690466122549686
show,0.29887004495534536
that,0.2198258550927909
PKCζ,0.14757201487731175
deficiency,0.16201109348242704
promotes,0.17525407148001926
the,0.1739766845178509
plasticity,0.09220639618393667
necessary,0.1216871051778429
for,0.13806369281118108
cancer,0.07545519635692793
cells,0.11791757950564916
to,0.08390487198308721
reprogram,0.06934980770381265
their,0.07164397106759876
metabolism,0.10789288101826394
to,0.06482966127051099
utilize,0.09020598679551978
glutamine,0.102569580463891
through,0.08049834973456728
the,0.08033346597831707
serine,0.08414926042727656
biosynthetic,0.06998127559118789
pathway,0.09331385719513509
in,0.09915192125661185
the,0.09540365847218354
absence,0.1057985258427302
of,0.11355487011494732
glucose.,0.09597656464554359
PKCζ,0.3630642838562645
represses,0.4270688838713173
the,0.37172284913946196
expression,0.41894881568017056
of,0.34870130390812143
two,0.2682244791786646
key,0.24763001415324956
enzymes,0.31870560485204
of,0.22152051866034117
the,0.16726728956644302
"pathway,",0.20795651392607445
PHGDH,0.3284912375522576
and,0.37028141448991725
"PSAT1,",0.30206032871526844
and,0.44317615103194047
phosphorylates,0.3997825428039248
PHGDH,0.3958944289767491
at,0.357701303923231
key,0.22665665443545344
residues,0.3415455385909308
to,0.3233352651918414
inhibit,0.17316795961076206
its,0.21440095682122873
enzymatic,0.1243746938190803
activity.,0.19060189920656936
"Interestingly,",0.6425541078357959
the,0.7011139489162097
loss,0.6234377037724566
of,0.6983852391223884
PKCζ,0.5999659862582054
in,0.7121713304220698
mice,0.7367644087369514
results,0.7743008696020435
in,0.8060652108865722
enhanced,0.8268410779648112
intestinal,0.8754103960065496
tumorigenesis,0.8329098556291067
and,0.8365494488998934
increased,0.808687631093622
levels,0.8108952859907071
of,0.834932132198981
these,0.7088920946082443
two,0.7013396566928809
metabolic,0.773044260780394
"enzymes,",0.7737746758667554
whereas,0.7999508818593872
patients,0.7584273513813643
with,0.689580906413944
low,0.6797082370371168
levels,0.7662606360405281
of,0.8055639431889215
PKCζ,0.7017499055332768
have,0.7597907286175158
a,0.7658762265174544
poor,0.697186722530915
prognosis.,0.7772054282546684
"Furthermore,",0.30282194133224766
PKCζ,0.1997246776035807
and,0.06211953808032412
caspase-3,0.08792124761993139
activities,0.07318173149553651
are,0.05084635048976396
correlated,0.0688122020132329
with,0.07292148997582092
PHGDH,0.12432987845026128
levels,0.07140887587451736
in,0.06418548622544373
human,0.0581560628319621
intestinal,0.09478285520793323
tumors.,0.057022712858680664
Taken,0.20940321422699626
"together,",0.2642378301167559
this,0.2285024605768238
demonstrates,0.2966563378035702
that,0.36962244416318574
PKCζ,0.409056601318837
is,0.38496897380858025
a,0.4571091157366583
critical,0.41621383725793276
metabolic,0.460457053557377
tumor,0.4062802947937432
suppressor,0.427607323057236
in,0.47209340939908856
mouse,0.2648241874280088
and,0.4163316183097701
human,0.267025866655953
cancer.,0.30755200814481015
OBJECTIVE,0.0009988029547559909
To,0.0008487123134718407
evaluate,0.0007738709413248977
the,0.0008510133688738113
association,0.0008050540611857089
of,0.0010203843981173352
overall,0.0005953921621157255
and,0.0010208460170516378
specific,0.0005872394095152
headaches,0.0006808738484202235
with,0.0008500590704001951
volume,0.0006727689778237775
of,0.0008700991533099169
white,0.0008532074415876854
matter,0.000866932491366077
"hyperintensities,",0.0006584438629642057
brain,0.0006016191482314711
"infarcts,",0.0007478515535455251
and,0.00083338672053864
cognition.,0.0008205783061112277
DESIGN,0.0007568207738977262
Population,0.000886122068454079
"based,",0.0012498382516681406
cross,0.0008197373885377124
sectional,0.0010308488154675813
study.,0.0008929443407431554
SETTING,0.0011495220108601867
Epidemiology,0.001487359769319195
of,0.0010182161984661508
Vascular,0.0009197453639149583
Ageing,0.000897056200669001
"study,",0.0011782477152270563
"Nantes,",0.0013029495411667137
France.,0.0010511748870473967
PARTICIPANTS,0.0016013412753491051
780,0.0009718057254516532
participants,0.000984046618309996
(mean,0.0009317145323567149
age,0.0010160284016238837
"69,",0.0017849460907808762
58.5%,0.0019652454230247667
women),0.00102534450062277
with,0.0012494564734286198
detailed,0.0009312765432768235
headache,0.0007187143633945793
assessment.,0.0007520402104175545
MAIN,0.001964498759187735
OUTCOME,0.002939546847156932
MEASURES,0.002738838983745756
Brain,0.0012650823863996755
scans,0.0011403331631502029
were,0.0019920152052458418
evaluated,0.0011665801460393813
for,0.0012695119798117691
volume,0.0010471092161924726
of,0.0012138422494373405
white,0.0010334383685428167
matter,0.0013814797720264728
hyperintensities,0.001113483434733259
(by,0.0014958340641335758
fully,0.0016326521906980275
automated,0.0015303669012407045
imaging,0.0011525314659957227
processing),0.000612173643658652
and,0.0009786723730428365
for,0.0006606109771546485
classification,0.0005490438741137878
of,0.0005526124314571414
infarcts,0.0004333069078658286
(by,0.0005035125241546834
visual,0.0004187560503404917
reading,0.0003755374741560751
with,0.00041655274913206264
a,0.0005124311414285594
standardised,0.0003984776747529032
assessment,0.0004710132772770268
grid).,0.0004242082276407048
Cognitive,0.0006340002153329251
function,0.0005876909860563144
was,0.0007050581005332899
assessed,0.0004984020096877259
by,0.0005620230070716654
a,0.0005741885168812181
battery,0.0004765321246129302
of,0.0006017359905429857
tests,0.0005089619281213327
including,0.0005822595169257342
the,0.0005664185235955206
mini-mental,0.0004866416556307755
state,0.0004561453222014464
examination.,0.00047190467448688723
RESULTS,0.19629586788824427
163,0.15598461770412075
(20.9%),0.17785263009586844
participants,0.20085738198592196
reported,0.2627108550438516
a,0.28536432264062594
history,0.24970347806978252
of,0.24906837956582772
severe,0.21730430795958974
headache,0.1666602799240242
and,0.2743512117642374
116,0.14886715598071013
had,0.25874590244553325
"migraine,",0.24664212083595888
of,0.2712675735395691
whom,0.24428159750088468
17,0.11469030698925815
(14.7%),0.16141998542414907
reported,0.2750849234011904
aura,0.14573348305751496
symptoms.,0.2025975145459651
An,0.043650295840814576
association,0.03979350626446208
was,0.03890482826579278
found,0.0420589296746262
between,0.028572765659131187
any,0.03969292216101609
history,0.04446273656632292
of,0.050446003378446576
severe,0.055806995625410874
headache,0.0755108758344137
and,0.03343930784368926
increasing,0.0537146585203481
volume,0.044673360414015345
of,0.044640765502478086
white,0.044209925989087254
matter,0.06884532265221323
hyperintensities.,0.04642721556358887
The,0.15638158473243963
adjusted,0.1749052978972893
odds,0.21893884315936218
ratio,0.18420374745058557
of,0.25037541384125084
being,0.19241304443973248
in,0.22208654225146088
the,0.1799408553856742
highest,0.1788721263802821
third,0.19527157858987576
for,0.2122465592994715
total,0.17626075792953705
volume,0.1448080499908386
of,0.18627378336727246
white,0.0985738101780578
matter,0.22668454579886965
hyperintensities,0.5107221852440703
was,0.43709823382863583
2.0,0.5419626702668833
(95%,0.4977208422030346
confidence,0.6110800064925447
interval,0.5796692529852734
1.3,0.5823619584429368
to,0.5276208486626153
"3.1,",0.5665095749653868
P,0.5336670443255338
for,0.43817400751761004
trend,0.5182953744362964
0.002),0.44063915525253944
for,0.48313245948689004
participants,0.5226347491658901
with,0.4082225925176129
any,0.42840312941160563
history,0.4757836007647947
of,0.3770931276276035
severe,0.3258611797160308
headache,0.3912160431190194
when,0.42844103830864805
compared,0.5244555995265933
with,0.37495601110358795
participants,0.445970943743826
without,0.3779428714120139
severe,0.4076400439425677
headache,0.4082459408746824
being,0.35263996171029854
in,0.27394808610788474
the,0.3060159391055427
lowest,0.27696580212953065
third.,0.3250547585146248
The,0.011923718116103979
association,0.008628115456454933
pattern,0.010914191185024435
was,0.01352665012676371
similar,0.008201675887366486
for,0.01122447241756544
all,0.010973209993168132
headache,0.011310330100766507
types.,0.013157500536446182
Migraine,0.5540241042409231
with,0.5070534884361712
aura,0.5019944956441872
was,0.5115597576847436
the,0.48581501304088553
only,0.46340908164087524
headache,0.5001203455007679
type,0.5306875273061444
strongly,0.49782724928574235
associated,0.5220249657885545
with,0.5087796332740762
volume,0.49231786655811766
of,0.495816755861504
deep,0.45915214230310397
white,0.42148945180005604
matter,0.45979146314350233
hyperintensities,0.5203899048592505
(highest,0.5052170209365401
third,0.3791822374438847
odds,0.41406638482107977
ratio,0.3768253514992404
"12.4,",0.4420364685090062
1.6,0.4297333074399655
to,0.3963073019859194
"99.4,",0.35492481541316895
P,0.40210443099904064
for,0.37308126771908057
trend,0.4095988726014259
0.005),0.3228505758748354
and,0.5399351199741331
with,0.5180355077717596
brain,0.5802942577784437
infarcts,0.5304790295459196
"(3.4,",0.4907075646265424
1.2,0.4523602575420196
to,0.23498095532422758
9.3).,0.12159801627816505
The,0.06202001125564827
location,0.056394004185438946
of,0.04314550189656142
infarcts,0.04684278582921463
was,0.06533689451193694
predominantly,0.05054390440304041
outside,0.0637116590505559
the,0.06816224658268592
cerebellum,0.05711157581566111
and,0.07064749600082364
brain,0.05878679193909293
stem.,0.05904260219279061
Evidence,0.14453151288927704
was,0.09127357874218751
lacking,0.05636411439121188
for,0.10102211450483878
cognitive,0.09520006370167476
impairment,0.07649538821439829
for,0.0922736971922558
any,0.10193413953921879
headache,0.11449361126434861
type,0.1435349691440605
with,0.22358420297730025
or,0.07271380806578587
without,0.15354478817504094
brain,0.08853482981235289
lesions.,0.10666726521911088
CONCLUSIONS,0.3868876011615137
In,0.08945990391149178
this,0.06927639851350367
population,0.04133838261474293
based,0.04793138093363954
"study,",0.06631587517299924
any,0.07689435142863094
history,0.06748281608033294
of,0.057401045842986075
severe,0.062447114192464355
headache,0.060539328841673685
was,0.07748386359240873
associated,0.10048570593028856
with,0.08008158941111439
an,0.07506701612797592
increased,0.07701275440211505
volume,0.07137576216182634
of,0.062021703374533665
white,0.020288433180052315
matter,0.04964312734671778
hyperintensities.,0.05506000389638895
Migraine,0.16816549751926896
with,0.17931311453744864
aura,0.153655273765391
was,0.09626773705173611
the,0.07344294986881988
only,0.07001650009480563
headache,0.10322197260075441
type,0.11801049449821839
associated,0.07821608606937529
with,0.07675928516357633
brain,0.055041635662817216
infarcts.,0.06584746497761808
Evidence,0.13782291746717948
that,0.15387938136970045
headache,0.2766126960808658
of,0.228727964668669
any,0.17038744834420122
type,0.19635555377341676
by,0.2928763724745892
itself,0.23970509495439352
or,0.18685292697071432
in,0.2620457333839776
combination,0.30605321258975055
with,0.3081109080498124
brain,0.17790986298880215
lesions,0.2294660503771453
was,0.10396336110076246
associated,0.1886451165677851
with,0.17805321771364874
cognitive,0.1317337935221243
impairment,0.10357363654174451
was,0.08083081528757169
lacking.,0.05178991825388603
Regulatory,0.02662436652373759
T,0.03350610960324141
(Treg),0.02445119973884519
cells,0.03001655594381292
play,0.029241061773089837
a,0.03315936303837129
pivotal,0.03659241863747136
role,0.03985056474020556
in,0.05771850205907296
suppressing,0.03427140353427769
self-harmful,0.03648058164171226
T,0.02199919476067597
cell,0.0186332098180169
"responses,",0.044127414013859674
but,0.007386764962091845
how,0.003476379977660954
Treg,0.010797424813521092
cells,0.00882983540956054
mediate,0.007510710900401584
suppression,0.006528210439256042
to,0.005246421278487364
maintain,0.008804598223259536
immune,0.00892771357164328
homeostasis,0.0066066118661227335
and,0.007901901143588134
limit,0.0035825104404711965
responses,0.004864631524041101
during,0.010061357591319226
inflammation,0.007084467280170437
is,0.0018629886149407941
unclear.,0.0022111923051979254
Here,0.7465405396504583
we,0.7548481513192191
show,0.7756397239756935
that,0.8248041256068359
effector,0.8025594530796726
Treg,0.6388577266013616
cells,0.7723018466700778
express,0.7610749834065742
high,0.7484178897119851
amounts,0.7564048399447272
of,0.7790442566191641
the,0.7814795123053931
integrin,0.7905556737266122
"αvβ8,",0.7078802198672892
which,0.7196078137123202
enables,0.764064138805312
them,0.7406414219550966
to,0.7598099828061677
activate,0.7562148795629192
latent,0.7423620256938201
transforming,0.6374862884520757
growth,0.6920689223890507
factor-β,0.7170657156400728
(TGF-β).,0.6920964984355307
Treg-cell-specific,0.6625306384104834
deletion,0.5768280129030121
of,0.6704240119766216
integrin,0.6386874503728717
αvβ8,0.5803977614142468
did,0.6459878838058019
not,0.6332729466935081
result,0.6435203446318432
in,0.6510453709338428
a,0.6013606037192005
spontaneous,0.6163394638630062
inflammatory,0.17049435600739182
"phenotype,",0.16008620462414913
suggesting,0.20263483039608424
that,0.16354050636341272
this,0.15021297057308577
pathway,0.21349484675869076
is,0.11269627369900292
not,0.12074730484049902
important,0.09956323365521565
in,0.10979292461383933
Treg-cell-mediated,0.20917810620436236
maintenance,0.11556426722077401
of,0.10391928275505644
immune,0.1469264588776048
homeostasis.,0.17835153582708888
"However,",0.48522676007820686
Treg,0.6119034071845728
cells,0.7133302627195078
lacking,0.6692710182669503
expression,0.7199619258017399
of,0.7341891221776716
integrin,0.7070035265146776
αvβ8,0.6613217138704368
were,0.6958706998403725
unable,0.6531559328022085
to,0.6559321666417225
suppress,0.6340989053694706
pathogenic,0.731185165839418
T,0.626361278350289
cell,0.722146243594413
responses,0.675111694998052
during,0.6406467433919567
active,0.6773428533810846
inflammation.,0.5942963631164342
"Thus,",0.5220942096175445
our,0.4207852876204618
results,0.32803235658045016
identify,0.3469660163654644
a,0.3181339669210864
mechanism,0.39163852063166493
by,0.504436363457917
which,0.363841922487885
Treg,0.43264127303338445
cells,0.4865052484366168
suppress,0.42654178898451434
exuberant,0.508716355776821
immune,0.4693660849460073
"responses,",0.5239889215155369
highlighting,0.377425962769064
a,0.42932479944479435
key,0.46745097887684456
role,0.46373865646537205
for,0.40352695862341065
effector,0.5849140477910163
Treg-cell-mediated,0.540783691962692
activation,0.6825682199594526
of,0.6700676660878151
latent,0.7000227526138095
TGF-β,0.6677195901101397
in,0.692503016004317
suppression,0.6572348536475612
of,0.6688303315154029
self-harmful,0.6059842572056988
T,0.5554726304723703
cell,0.6810716235001215
responses,0.6774147688546451
during,0.6309611254496652
active,0.5698440705656677
inflammation.,0.6107844684907905
BACKGROUND,0.18366756270449638
The,0.13553046234342814
heritable,0.08490490500179312
haemoglobinopathy,0.09375183223756176
alpha(+)-thalassaemia,0.14617685928016597
is,0.13881103801282113
caused,0.15811225820653232
by,0.23781936506729753
the,0.2356990068260268
reduced,0.2331985726753832
synthesis,0.24756908101721856
of,0.2528438689505791
alpha-globin,0.17859083220357416
chains,0.2544662392203948
that,0.20203905013973886
form,0.1731569421817414
part,0.21065068256217906
of,0.19862405792692456
normal,0.1864786670699095
adult,0.17216408231946256
haemoglobin,0.1643607705681709
(Hb).,0.13983387626548663
Individuals,0.15674585697863425
homozygous,0.13875777791579805
for,0.1742886026502545
alpha(+)-thalassaemia,0.10228624557205099
have,0.1660892251288191
microcytosis,0.1914321208979491
and,0.24789131058596506
an,0.17040640644084926
increased,0.1351286103295938
erythrocyte,0.11897988231649598
count.,0.18728748191399397
Alpha(+)-thalassaemia,0.44477009008619073
homozygosity,0.5272210714332046
confers,0.5568986634851518
considerable,0.5239794620022812
protection,0.5190283164597772
against,0.4875661856890895
severe,0.4847142855685029
"malaria,",0.3976397483864822
including,0.5821464762973548
severe,0.5133458761535898
malarial,0.41949635795295037
anaemia,0.4645927324338206
(SMA),0.45016878614507233
(Hb,0.5404767908746355
concentration,0.45213763213861696
<,0.4453318509087903
50,0.4655700135887661
"g/l),",0.49442870877040884
but,0.5493209685179574
does,0.5661669379351356
not,0.0883844680948386
influence,0.02088882589226138
parasite,0.01162498076662448
count.,0.012866397081997806
We,0.00603567463049302
tested,0.003704339225704869
the,0.0026981284547612223
hypothesis,0.002917545035846405
that,0.006383821738952618
the,0.0071468667941462696
erythrocyte,0.008238538405424503
indices,0.00420528987549442
associated,0.006272900998481213
with,0.008544890174399335
alpha(+)-thalassaemia,0.0104242735559683
homozygosity,0.006639609167184217
provide,0.005806290819455834
a,0.004530330254131575
haematological,0.004968213684259832
benefit,0.0056587141990605645
during,0.0055668790812720215
acute,0.002121236952302889
malaria.,0.0037782885707689407
METHODS,0.006945324277945701
AND,0.002265314485278092
FINDINGS,0.00840557202052486
Data,0.001641564104752588
from,0.0018565504249671758
children,0.001136534306716778
living,0.0013212985448658628
on,0.0013557805784948438
the,0.0016344559887746845
north,0.0021609437295815937
coast,0.0016386299472511713
of,0.002139463062337936
Papua,0.00205492106860665
New,0.0029683140028443325
Guinea,0.0019216082922538327
who,0.0015089184786487837
had,0.0019142635438988398
participated,0.0014440374322411376
in,0.0021958228375700798
a,0.0016978402886145898
case-control,0.0008622040757633783
study,0.0012104010614767983
of,0.0013464751574088138
the,0.00148356278729923
protection,0.0016371414512484123
afforded,0.0018550740258980593
by,0.0030886413058849056
alpha(+)-thalassaemia,0.0028054909088718093
against,0.0018500252543218437
severe,0.0012198229349095616
malaria,0.0018489926818131533
were,0.0022439567105481456
reanalysed,0.0012726681822150764
to,0.0013763591784839658
assess,0.0010208917284305627
the,0.0014667894044427107
genotype-specific,0.0017097940338918316
reduction,0.0017371261002031746
in,0.0031702203905304197
erythrocyte,0.002986863221438308
count,0.002202332363121549
and,0.002450552082458463
Hb,0.0022820376183440376
levels,0.002311859017885939
associated,0.0023519548223557133
with,0.003218265855089491
acute,0.0012923693475544301
malarial,0.0020228429328905504
disease.,0.0018815714866445353
We,0.005453687903724264
observed,0.564362021448006
a,0.5761194115538238
reduction,0.49852676743434626
in,0.5304018051915691
median,0.5650997441901657
erythrocyte,0.5717244311002173
count,0.5808276228116329
of,0.6046429245985937
approximately,0.5459293240288177
1.5,0.5202732368962161
x,0.581522650411022
10(12)/l,0.4270705883920505
in,0.5491837871558688
all,0.503274488014489
children,0.48031371493675007
with,0.4573016308723839
acute,0.4740599754579752
falciparum,0.5117792467154316
malaria,0.47716969166917633
relative,0.401622212409982
to,0.3893889351867628
values,0.37705060124270506
in,0.3919278953694977
community,0.4185976582652138
children,0.43807330978595005
(p,0.36317679737409697
<,0.3562166665239334
0.001).,0.30100884857566884
We,0.16741546274387448
developed,0.048240821963737
a,0.03890628585638499
simple,0.03245955430980372
mathematical,0.025203844548995595
model,0.02978861121480193
of,0.027667088550414796
the,0.021844985137368277
linear,0.023701489740392517
relationship,0.02404903943083323
between,0.01968690456421987
Hb,0.05969535715237456
concentration,0.06329487886847364
and,0.0253867623202335
erythrocyte,0.036281748856157064
count.,0.047819012612068806
This,0.43151847484278905
model,0.5519879466637058
predicted,0.679400985954884
that,0.7818910809459277
children,0.7888807758048664
homozygous,0.8294581165884063
for,0.8277961401275507
alpha(+)-thalassaemia,0.7738249724865386
lose,0.8462345478661152
less,0.8487184400636416
Hb,0.768880665872382
than,0.8457407056228834
children,0.8069179680945819
of,0.8452335835980677
normal,0.8272151142430543
genotype,0.8369295839914245
for,0.8717778048375852
a,0.8340052370619994
reduction,0.8335917784044686
in,0.8523665139463883
erythrocyte,0.8749957240388161
count,0.8097085638553931
of,0.824872114904498
>1.1,0.8166329860142972
x,0.8234426277801439
10(12)/l,0.6750819849053971
as,0.7988669077668807
a,0.7725121957934233
result,0.7560168094964473
of,0.7647262001066152
the,0.815483727563459
reduced,0.779933713051668
mean,0.8218253060648432
cell,0.8236245536383768
Hb,0.3574481659734198
in,0.4449148266521673
homozygous,0.42331339116806793
alpha(+)-thalassaemia.,0.41260093993501273
In,0.7777709894930054
"addition,",0.8138298034984004
children,0.7595203732978728
homozygous,0.7724321902228224
for,0.8204374927626998
alpha(+)-thalassaemia,0.7523411897048874
require,0.8309142960182944
a,0.8260563252632446
10%,0.7692188996200406
greater,0.8452866822610733
reduction,0.8148002136797615
in,0.8335776393885744
erythrocyte,0.8551796374651429
count,0.8180373388964358
than,0.8442620083665573
children,0.7593593324810418
of,0.766961498412855
normal,0.7608111177948419
genotype,0.7717773214956466
(p,0.7582616325556117
=,0.6614178203138132
0.02),0.6773581919716867
for,0.7814289151436917
Hb,0.6912025910726396
concentration,0.7174569452427959
to,0.7297487139636454
fall,0.7256421074869286
to,0.6947996178339292
50,0.667237123834001
"g/l,",0.6894780570003813
the,0.6970304116889536
cutoff,0.7030174463256824
for,0.6389951448051472
SMA.,0.6419667618991975
We,0.7171408840983259
estimated,0.7457299010502424
that,0.7645133464929565
the,0.7406129573392237
haematological,0.6756876741494661
profile,0.6969288103635606
in,0.7518963413879819
children,0.7074585991528344
homozygous,0.7200959651251542
for,0.7269345790928876
alpha(+)-thalassaemia,0.6459266380500313
reduces,0.7547615445898936
the,0.7375914382717959
risk,0.7698064401767974
of,0.8088647974068032
SMA,0.7272413171124781
during,0.7821372336915635
acute,0.7742188815919099
malaria,0.700775694410701
compared,0.787650186896789
to,0.7470365634168845
children,0.7397687641236429
of,0.7481410045633877
normal,0.7431388149197333
genotype,0.7160308861758846
(relative,0.7243602621465008
risk,0.7206340159677667
0.52;,0.47505207675083894
95%,0.6277607261255237
confidence,0.5694131347548868
interval,0.5683139566195573
[CI],0.545205010818927
"0.24-1.12,",0.5110509035391432
p,0.519931596748203
=,0.5311592701591312
0.09).,0.49853603960190623
CONCLUSIONS,0.7572499717106363
The,0.8258598896751677
increased,0.8070763089599801
erythrocyte,0.8446181668695323
count,0.7978148905502229
and,0.8648128024735622
microcytosis,0.873031667744688
in,0.8274126557402304
children,0.7895200014391847
homozygous,0.8214666683373179
for,0.8184296968331586
alpha(+)-thalassaemia,0.731009092340696
may,0.7063480795446412
contribute,0.7225882979396012
substantially,0.7555132334835105
to,0.7488039672488489
their,0.7398531448032847
protection,0.706372279971846
against,0.7196133759685263
SMA.,0.699929997653117
A,0.44662344626646516
lower,0.48940397535106533
concentration,0.47276007972183187
of,0.4790827554754392
Hb,0.4949316814586511
per,0.5244761482697063
erythrocyte,0.5980035595855845
and,0.5122966329565853
a,0.4389034185982153
larger,0.4704118506778913
population,0.41322014275360486
of,0.4750457242258107
erythrocytes,0.5746125995245942
may,0.27419502618991787
be,0.3332551229593784
a,0.35310282786966757
biologically,0.31931060347522033
advantageous,0.3614357253194756
strategy,0.373748119645407
against,0.416137165906057
the,0.4437695477126427
significant,0.42849416631897586
reduction,0.42927032640076573
in,0.4175370256416561
erythrocyte,0.5110787234149654
count,0.5234269128959459
that,0.4214257607036396
occurs,0.4171731262508964
during,0.4773488034839901
acute,0.38065343535935864
infection,0.37166345983931504
with,0.36122754296740006
the,0.3481658263907892
malaria,0.3340396371889553
parasite,0.3324215831642985
Plasmodium,0.3767230365934012
falciparum.,0.4009999909122633
This,0.5729826337667467
haematological,0.5109806097826455
profile,0.536281791046401
may,0.43067119537409915
reduce,0.5173369476663116
the,0.46680129636500556
risk,0.5002266373330112
of,0.5443641385508934
anaemia,0.48448091942359217
by,0.5456903311232749
other,0.47339267424521153
Plasmodium,0.4289587643425133
"species,",0.42957629854912466
as,0.43265173768814025
well,0.4921677419548094
as,0.4260921634249863
other,0.4138150487329821
causes,0.4435433525502896
of,0.44450843292958114
anaemia.,0.45214724530729866
Other,0.13856745419479025
host,0.14167444434053858
polymorphisms,0.12928028737086456
that,0.16138436706344206
induce,0.21626557958486037
an,0.22732378521149377
increased,0.21284479157751426
erythrocyte,0.21146501601823234
count,0.23664133826396888
and,0.21643815280917172
microcytosis,0.2147867971849558
may,0.09071979208803528
confer,0.1028214672049762
a,0.10869833851988168
similar,0.0834687383854418
advantage.,0.11301436818503927
BACKGROUND,0.029978511094272273
Information,0.004353167281194673
is,0.0036024355437336312
scarce,0.0026024623543960527
about,0.003337689660008574
the,0.003417832831363681
combined,0.004354754807080736
effects,0.002894619281903836
on,0.004190081696550443
breast,0.008063312931912146
cancer,0.0055574091940865525
incidence,0.005033248383822776
of,0.005485444040949501
low-penetrance,0.00531151738222882
genetic,0.0036922039724302373
susceptibility,0.003869284410010791
polymorphisms,0.004624553825078941
and,0.004568962575807606
environmental,0.0018333813956005164
factors,0.0029976404293926813
"(reproductive,",0.0046732223099934
"behavioural,",0.0026584828676889287
and,0.005681428210916429
anthropometric,0.002365349140722179
risk,0.0021219153363339657
factors,0.0026285512609069733
for,0.004553907286561593
breast,0.004733564663276406
cancer).,0.0034628589797458414
To,0.0016207908476750885
test,0.0012346890803699743
for,0.001138127460353678
evidence,0.001248183432343022
of,0.0012904066183167945
gene-environment,0.0011664395826816586
"interactions,",0.001316056298126793
we,0.0031109376724400826
compared,0.0015743525206940985
genotypic,0.0012298907757250417
relative,0.0012096297078553265
risks,0.0009400119455154933
for,0.0014346940180616382
breast,0.002826375921093966
cancer,0.001421672396406902
across,0.0012776721064967384
the,0.0012342463815637771
other,0.0011844943087607734
risk,0.0008291772416463109
factors,0.0009111347484799285
in,0.0012220950977822147
a,0.001354244250866214
large,0.0011087130147017907
UK,0.0012461206556818214
prospective,0.0008525747650868262
study.,0.0011795481018955457
METHODS,0.10543199396228657
We,0.22371575675624703
tested,0.2512334135074737
gene-environment,0.2926090489721
interactions,0.3817876274044955
in,0.37392552473025165
7610,0.22850480379086266
women,0.36675678400583633
who,0.39288011139094986
developed,0.5058548219010415
breast,0.4185425175878697
cancer,0.39560810332627094
and,0.3460196210005548
10,0.2997505236509405
196,0.44149383812839654
controls,0.5002570468705938
without,0.5289833174357474
the,0.5186427971514664
"disease,",0.5067216206172698
studying,0.27288571864838945
the,0.2557821193284831
effects,0.3843960934372543
of,0.39674403656698215
12,0.3108290522380198
polymorphisms,0.39497950013994704
"(FGFR2-rs2981582,",0.39323072401272774
"TNRC9-rs3803662,",0.49242378693609623
"2q35-rs13387042,",0.5219868889901828
"MAP3K1-rs889312,",0.589151324030246
"8q24-rs13281615,",0.5677065994905085
"2p-rs4666451,",0.5557613007461254
"5p12-rs981782,",0.5036394456240122
"CASP8-rs1045485,",0.5596167007260506
"LSP1-rs3817198,",0.5220703803364755
"5q-rs30099,",0.5163325891847842
"TGFB1-rs1982073,",0.48553998593383735
and,0.4128644557273198
ATM-rs1800054),0.728263113100509
in,0.8052452318190583
relation,0.7867083704136026
to,0.7776194784600632
prospectively,0.8224197124516172
collected,0.7699702297539549
information,0.73804658109368
about,0.7444473523408642
ten,0.7274519449239585
established,0.7782926494402629
environmental,0.6868466157644715
risk,0.6941970008258103
factors,0.684170488528378
(age,0.6987233402577812
at,0.7043905910631982
"menarche,",0.7076522772786734
"parity,",0.7100067245955015
age,0.6624164863341491
at,0.6614059871047797
first,0.717041311857941
"birth,",0.7169643614629259
"breastfeeding,",0.7008197995622043
menopausal,0.6755346803362093
"status,",0.6831531116487407
age,0.6391814793507434
at,0.6632842521480182
"menopause,",0.6348201383992408
use,0.6924004172587641
of,0.7101800603891925
hormone,0.6732673519196962
replacement,0.7188793290463381
"therapy,",0.6628972428856499
body-mass,0.6809825583477388
"index,",0.6240272719888665
"height,",0.5592466097938807
and,0.5938803364432094
alcohol,0.6067650023620303
consumption).,0.6261207098984071
FINDINGS,0.10805646763806236
After,0.07690298277333925
allowance,0.0668922399507078
for,0.054105170026052
multiple,0.031831904187561856
testing,0.0283810775303961
none,0.039525625790427746
of,0.03649779041075049
the,0.048085807814937834
120,0.028446231327589184
comparisons,0.039932972209883275
yielded,0.04310965364732173
significant,0.028010129902080877
evidence,0.032268477038803055
of,0.02700966141064621
a,0.024718958850013326
gene-environment,0.03843834916145492
interaction.,0.04262349885629894
By,0.24723090336005915
contrast,0.18799157826003415
with,0.15192527090423902
previous,0.20899992854223623
"suggestions,",0.16926630333236728
there,0.19892482852577126
was,0.1894059426674879
little,0.18580123856864575
evidence,0.20460847058262735
that,0.13868707591872215
the,0.14438170095522615
genotypic,0.1194754874722265
relative,0.1354868499653725
risks,0.18007210234438475
were,0.13163822684449036
affected,0.11859685341799657
by,0.16548893366102183
use,0.19051313365535905
of,0.18561700738150927
hormone,0.20924213904104008
replacement,0.23394730699275954
"therapy,",0.20572010737446694
either,0.19143976933245155
overall,0.20141358669760015
or,0.10943185307780129
for,0.10558466931666045
oestrogen-receptor-positive,0.09147241894898782
disease.,0.13308233018119808
Only,0.08381589629031852
one,0.07254291547966397
of,0.0701826615975049
the,0.08366233479461706
12,0.06213879995442522
polymorphisms,0.046045232374200155
was,0.04654596861141972
correlated,0.04471753117009146
with,0.04321186195881163
any,0.05044940109655162
of,0.03839326515999693
the,0.04603323755246102
ten,0.04123284069354395
other,0.040408829715103824
risk,0.07198965434393939
factors:,0.04697117767609061
carriers,0.16516110979020898
of,0.16394825302183821
the,0.09257575868762812
high-risk,0.12267948454700947
C,0.13124070608520103
allele,0.12139770335885773
of,0.11736884752105423
MAP3K1-rs889312,0.1573927121682321
were,0.15178559918079443
significantly,0.12631953070003987
shorter,0.16154622957958958
than,0.23375333848741278
non-carriers,0.2649307020471919
(mean,0.143256856671495
height,0.18777752968385406
162.4,0.21629538396614467
cm,0.16443838900300764
[95%,0.2604032187705208
CI,0.344418736745619
162.1-162.7],0.2790013826772053
vs,0.23737911744415008
163.1,0.3149465318740925
cm,0.21349426626615914
[162.9-163.2];,0.23075966908460105
p=0.01,0.20163211912815476
after,0.12547766976591543
allowance,0.11368738935709365
for,0.08285014454981796
multiple,0.07550839595177156
testing).,0.10562036721891754
INTERPRETATION,0.17820557068318002
Risks,0.22824887354142032
of,0.3033901767504086
breast,0.17721293057939058
cancer,0.13875388880523132
associated,0.21819075694069656
with,0.2799278167680334
low-penetrance,0.8033620492079023
susceptibility,0.7316340537974576
polymorphisms,0.7447950647948258
do,0.7360128371201177
not,0.7817963757235095
vary,0.6643206154601559
significantly,0.7150586561804008
with,0.5850439383104341
these,0.587949594394696
ten,0.5555999698157369
established,0.4722402165853598
environmental,0.47784038667326495
risk,0.38941954694788616
factors.,0.5258167238153637
FUNDING,0.02796801410102299
Cancer,0.010957274629650997
Research,0.014767882775750371
UK,0.015446300868429835
and,0.021490809644301258
the,0.02373679621318797
UK,0.012061089816903472
Medical,0.012819047793533916
Research,0.012120580778573775
Council.,0.009573936337603124
Fast,0.0784333845518214
axonal,0.08220567406638554
transport,0.09510752469112776
(FAT),0.057752575515490845
requires,0.08724166161153217
consistent,0.08733168015917017
energy,0.10254790512722228
over,0.06106005767211738
long,0.056451790206311366
distances,0.05609403371580782
to,0.09545690174683771
fuel,0.08114693178709803
the,0.10830216704859809
molecular,0.07806983347957402
motors,0.0800557566514141
that,0.07425898286518141
transport,0.06642007048747733
vesicles.,0.0737845039618192
We,0.4289845866149006
demonstrate,0.3808217385540894
that,0.3586919441534249
glycolysis,0.29734137252882276
provides,0.3174487111516531
ATP,0.24547364753447876
for,0.3038998108367819
the,0.31449389392159954
FAT,0.276039635820753
of,0.2900593300615044
vesicles.,0.25942535745204387
Although,0.45789032823454384
inhibiting,0.4555769964795479
ATP,0.2633435227455907
production,0.35092288127918403
from,0.4189139540485809
mitochondria,0.42294008207216754
did,0.44074784951588686
not,0.33217643058785934
affect,0.28975273964361076
vesicles,0.21962333064907924
"motility,",0.22061343409823286
pharmacological,0.15426173612678026
or,0.2961469458262803
genetic,0.20867326677835019
inhibition,0.23485813212309029
of,0.22394568759122213
the,0.20773832554570398
glycolytic,0.15476950408204174
enzyme,0.18393186239728074
GAPDH,0.2756356023409767
reduced,0.24750680359371025
transport,0.17053221268164317
in,0.24362155757584453
cultured,0.16440020044432851
neurons,0.2324168194770175
and,0.2141458807461056
in,0.20735524432608857
Drosophila,0.08957996804497853
larvae.,0.15746030986113493
GAPDH,0.49772419861995426
localizes,0.45798070092028426
on,0.46965027793802405
vesicles,0.480230173778242
via,0.5053390414449531
a,0.4598912972015212
huntingtin-dependent,0.48998923099744124
mechanism,0.4819123620388941
and,0.458775190877464
is,0.43482554781149
transported,0.3924416109405196
on,0.45624935422171653
fast-moving,0.44269312981417064
vesicles,0.45394363893630996
within,0.40445658554924063
axons.,0.45790180364558475
Purified,0.38659137405578864
motile,0.34323120748154445
vesicles,0.39183848204724264
showed,0.40796168321254456
GAPDH,0.39176155312299416
enzymatic,0.33724331243998257
activity,0.35687446678325513
and,0.4059656788517066
produced,0.362189626016429
ATP.,0.38590530875445206
"Finally,",0.6186979953015818
we,0.6988528315466658
show,0.7152675004337316
that,0.7209906978277397
vesicular,0.7551215532812171
GAPDH,0.7001585383413158
is,0.7403911306224576
necessary,0.7134382534299065
and,0.7282178572341337
sufficient,0.7250392079969763
to,0.7405046335555955
provide,0.7421871733196744
on-board,0.7654536804666798
energy,0.7128155805642672
for,0.7451399928471786
fast,0.6794632742463746
vesicular,0.6734330429588463
transport.,0.6357560811254022
Although,0.8551381020515794
detaching,0.8046047939716895
GAPDH,0.7918248241658978
from,0.7684222100465725
vesicles,0.8102102979173763
reduced,0.8371559450776708
"transport,",0.7771012000307984
targeting,0.7968599728025868
GAPDH,0.7758633912502046
to,0.735998858543673
vesicles,0.8290702458956881
was,0.8239649243890534
sufficient,0.818052146272523
to,0.8150843846874998
promote,0.8211137958784313
FAT,0.7633577034614508
in,0.7929850483710085
GAPDH,0.7412919069634188
deficient,0.7865888674024631
neurons.,0.7603677701628822
This,0.4161928175389603
specifically,0.4181509033580948
localized,0.4127555752899581
glycolytic,0.4179102537295594
machinery,0.4254885078690013
may,0.28323216893094205
supply,0.3643093028774676
constant,0.30535479372216406
"energy,",0.42166390445316
independent,0.29490282459580197
of,0.2804340166117865
"mitochondria,",0.38563627877372664
for,0.35189028020054947
the,0.3673290281785566
processive,0.3734260658931901
movement,0.3077248938195563
of,0.2787165763564511
vesicles,0.34026074373445775
over,0.22248683863540072
long,0.19553313417662196
distances,0.2582854158379139
in,0.2947881537087361
axons.,0.3547716873069418
IMPORTANCE,0.20033414708860983
Bariatric,0.3043539779418133
surgery,0.3580064964241829
is,0.35817848672112224
associated,0.3880653147742948
with,0.43531302167418884
sustained,0.40941577567052045
weight,0.25688172777382273
loss,0.3743043697325124
and,0.45382010380540033
improved,0.40323986607551693
physical,0.2680228621429982
health,0.22248540028273053
status,0.3073446426343857
for,0.2984403617146167
severely,0.2905312988896168
obese,0.2369829280263016
individuals.,0.2656994332633568
Mental,0.0019959204105208586
health,0.0012805536817383646
conditions,0.001217012065386577
may,0.0020295663770945284
be,0.0026322222227803415
common,0.0034794637936128338
among,0.003636225141341676
patients,0.001505360733306661
seeking,0.001503049972221466
bariatric,0.002339653813806112
surgery;,0.005027447775513084
"however,",0.0015696491412045975
the,0.0011484168560653386
prevalence,0.001293088088816366
of,0.001314753054804951
these,0.0017067003512545088
conditions,0.0014031255451868035
and,0.0013174420744906659
whether,0.0014361775256010996
they,0.0011302792207108557
are,0.000995126397817466
associated,0.0013393152095392115
with,0.0014234518353685875
postoperative,0.001558253708224972
outcomes,0.0013913288449927045
remains,0.0010132014926637278
unknown.,0.0010827188977548885
OBJECTIVE,0.0016643627455359326
To,0.002120278800921744
determine,0.001024173203163483
the,0.0011680473475657236
prevalence,0.0011686653017116753
of,0.0018303349849370049
mental,0.0012094833876296661
health,0.001496962617502325
conditions,0.0013202095131415901
among,0.001361915751223571
bariatric,0.0012035679518673649
surgery,0.0017190334270862039
candidates,0.0010663717922586066
and,0.001799581986234922
"recipients,",0.0011382057941553819
to,0.0011004387477393704
evaluate,0.0010244379033700244
the,0.0011075993051567407
association,0.0012334342976596643
between,0.0011654544474845718
preoperative,0.001223591242158181
mental,0.0013347285043464722
health,0.0014172250757300605
conditions,0.0012241108649127604
and,0.0018266462280373923
health,0.0010844698961558806
outcomes,0.0008429775983193667
following,0.0011785215981300415
bariatric,0.0011490594623539826
"surgery,",0.0013064453765873909
and,0.0013523863372405683
to,0.0008350508627195517
evaluate,0.000903533104200008
the,0.0009361523611809791
association,0.0009920475288556368
between,0.0010896031173449365
surgery,0.0011650640110129312
and,0.0012503142241150663
the,0.0009408761701329523
clinical,0.0007085361126342707
course,0.0010589875707550343
of,0.0009497282248936014
mental,0.0010833900592870285
health,0.0011815258486759597
conditions.,0.0009690950444670641
DATA,0.0007215435239779655
SOURCES,0.001098732642946243
We,0.0010515201848576507
searched,0.0006822726665355147
"PubMed,",0.0006890822016791116
MEDLINE,0.0006747904123838369
on,0.0006306108689165469
"OVID,",0.0008667658508753155
and,0.0006984456553976216
PsycINFO,0.0005493095240140908
for,0.0006002548492998096
studies,0.0005209369312421772
published,0.000535520789603782
between,0.0007959409544493144
January,0.0007295856998976957
1988,0.0006693348394522159
and,0.0008594298472997452
November,0.0007488039343885333
2015.,0.0006655787696755981
Study,0.0008050926109579143
quality,0.0008788482438926241
was,0.0006848055790441475
assessed,0.0007452755845039228
using,0.0007302211140640488
an,0.0007353937525237341
adapted,0.0006074425242122804
tool,0.0006583870741695649
for,0.0006847225363667636
risk,0.0006072828995922486
of,0.0010064897280790792
bias;,0.0007489370289414873
quality,0.0009255760146532376
of,0.0010042168324136754
evidence,0.000687795764596872
was,0.0007443761004343831
rated,0.0008530155980234607
based,0.0011384028722039778
on,0.0008900464844225423
GRADE,0.0007382345248632705
(Grading,0.0008922630955556492
of,0.0013675666982603592
Recommendations,0.0010378560750402665
"Assessment,",0.0010533627678249208
Development,0.0009380854212511546
and,0.001905581864994508
Evaluation),0.0010000181483267926
criteria.,0.000977617906284434
FINDINGS,0.011664521703205201
We,0.012467071538886198
identified,0.004235660148161204
68,0.0027431331050555845
publications,0.004088916264001114
meeting,0.0024079586169568723
inclusion,0.002171468083851556
criteria:,0.0018653859821388256
59,0.00574896119332317
reporting,0.0050580554359443254
the,0.003581732640150216
prevalence,0.0033036333336404207
of,0.005503809920901333
preoperative,0.0045361283137040085
mental,0.0037554993677586935
health,0.003646677269353601
conditions,0.0029881301232987435
"(65,363",0.006122528841573267
patients),0.003000251636112112
and,0.00544209914444792
27,0.004151829213859969
reporting,0.006769975385184785
associations,0.0036503910980524457
between,0.003062482061763798
preoperative,0.006871540925073877
mental,0.004933872731841711
health,0.00461708051159162
conditions,0.004094248925175733
and,0.005350918649558737
postoperative,0.007850460988689772
outcomes,0.005381220743414099
"(50,182",0.15483220422772864
patients).,0.06942804847223409
Among,0.05879582905255904
patients,0.055283843133956664
seeking,0.04858876498195292
and,0.02357987083796043
undergoing,0.020448802356031113
bariatric,0.02999874868534704
"surgery,",0.05522967073988744
the,0.033464014238459606
most,0.033772253558947696
common,0.048890639751082
mental,0.05663439200687414
health,0.04617612751002428
"conditions,",0.056990927498709334
based,0.05177465874940554
on,0.05006082345611728
random-effects,0.032318933687779966
estimates,0.0677835416234559
of,0.03706189451252474
"prevalence,",0.05141436022671599
were,0.09665667410073017
depression,0.09564695808595797
(19%,0.11131911104099605
[95%,0.20296062505956952
"CI,",0.3162333629605095
14%-25%]),0.22828862684821546
and,0.08781507537987365
binge,0.16069121778556877
eating,0.13247814811218644
disorder,0.15855026225544175
(17%,0.12096683299203677
[95%,0.10758512974207401
"CI,",0.39066716897206244
13%-21%]).,0.21218559508670706
There,0.011319216973828145
was,0.009097183032219956
conflicting,0.0052652921400063914
evidence,0.00700983848866548
regarding,0.005710712394475434
the,0.004709989454184961
association,0.007173676979918307
between,0.005776507039582678
preoperative,0.009147530322462094
mental,0.012102559167682155
health,0.007335208388232573
conditions,0.008884307318457074
and,0.007527389132800808
postoperative,0.008129509700011271
weight,0.007814435696911058
loss.,0.010428524312849291
Neither,0.059321124407772124
depression,0.07080399737989707
nor,0.047981475465967156
binge,0.06504207603639357
eating,0.03754090181007991
disorder,0.06509764230712202
was,0.03784301791089398
consistently,0.04208692530697952
associated,0.03599261928832638
with,0.041188070096791485
differences,0.018471470002845637
in,0.03225769448084903
weight,0.05618911513515842
outcomes.,0.0423566918999419
Bariatric,0.44562958342595804
surgery,0.43853986448545473
"was,",0.3708112342226754
"however,",0.3004408289349922
consistently,0.36007888613409905
associated,0.48907150062955157
with,0.4765271730671431
postoperative,0.6550417917273923
decreases,0.6043663592861473
in,0.6061740921960855
the,0.5996127069130182
prevalence,0.5948206826580869
of,0.6131227119797207
depression,0.5989173038103632
(7,0.6084229877895526
studies;,0.6494536110284176
8%-74%,0.6815440608096205
decrease),0.5696529438318805
and,0.5866806802803226
the,0.5892682063941913
severity,0.5370319685640101
of,0.5797911587354203
depressive,0.5938152517975678
symptoms,0.5222155708673849
(6,0.5697173751232975
studies;,0.6233145821291151
40%-70%,0.6068806617998626
decrease).,0.5049321672116641
CONCLUSIONS,0.5845833596365475
AND,0.11549308134336705
RELEVANCE,0.18562549048083907
Mental,0.05244228702099879
health,0.04030914889291913
conditions,0.042808642116331785
are,0.04254749683270028
common,0.04729247041038104
among,0.05137888347486205
bariatric,0.0307232470852651
surgery,0.055817863519782455
patients-in,0.04778393902067683
"particular,",0.030629779355371364
depression,0.05487107862418587
and,0.07989548636555434
binge,0.07763232037649176
eating,0.04672711975766435
disorder.,0.084354316477477
There,0.012314100876898108
is,0.007670522724562432
inconsistent,0.006234776802047259
evidence,0.006920339694457539
regarding,0.006169434918892328
the,0.00508683543649784
association,0.008098171990826509
between,0.007331310311777894
preoperative,0.009895381746231172
mental,0.015771772799401704
health,0.007473975859987598
conditions,0.0099278378928464
and,0.008145778379085703
postoperative,0.008553535435783638
weight,0.00914974560391315
loss.,0.013506170974568304
Moderate-quality,0.18225927192026345
evidence,0.21673436755917516
supports,0.1819712318883501
an,0.1759610740740477
association,0.17972835126728273
between,0.17211403513426568
bariatric,0.16965856681443467
surgery,0.29493505595908204
and,0.14565859655236954
lower,0.19785084860904276
rates,0.21452525572381864
of,0.27582500061880616
depression,0.17002837037348043
postoperatively.,0.2809295888140399
Inflammation,0.017502092117169823
induced,0.016718366633206735
by,0.023969792770625258
recognition,0.016810348342125036
of,0.012945271953452618
pathogen-associated,0.00594417190137532
molecular,0.008549626009018804
patterns,0.010051868056089893
markedly,0.007083221301833308
affects,0.007405111467453858
subsequent,0.008769093601541694
adaptive,0.00537409598533489
responses.,0.005354408074610877
We,0.015561195007870284
asked,0.004408409444147629
whether,0.002467417228827647
the,0.0034461079607339194
adaptive,0.004504728396184235
immune,0.005449194689026553
system,0.010739443775550599
can,0.0031801534436972216
also,0.00299393175411094
affect,0.0039284152801407355
the,0.0026224198064620755
character,0.0024390281804711517
and,0.0030526389637035526
magnitude,0.0022977719241290794
of,0.003925624015412362
innate,0.004140229145173285
inflammatory,0.005809864760832576
responses.,0.005707222096558777
We,0.7975561534432728
found,0.8680601654083713
that,0.8991513294525072
the,0.8773813314271103
response,0.8750243611669813
of,0.8922517741162214
"memory,",0.8729959194753433
but,0.9163789091197064
not,0.9087723977947401
"naive,",0.889945235583339
CD4+,0.8975340963534264
T,0.8780991110678016
cells,0.8815614735404192
enhances,0.8869256180101119
production,0.8866912732719324
of,0.9097249383574656
multiple,0.8720261441556955
innate,0.9102442360776235
inflammatory,0.8363372423171551
cytokines,0.8809265161418911
and,0.8873897214341615
chemokines,0.851979646334075
(IICs),0.8119871844677468
in,0.8986062396789093
the,0.8996929983291382
lung,0.8503692117167968
and,0.870144870650962
"that,",0.8906588657631755
during,0.8599928028286528
influenza,0.8589410889902253
"infection,",0.8201525239321608
this,0.841070864702265
leads,0.8193596620334338
to,0.8286513708008765
early,0.8438086315657825
control,0.7827999609513899
of,0.7497848288657066
virus.,0.6902428838895479
Memory,0.6235984274653484
CD4+,0.5962404062123701
T,0.5388716839585859
cell–induced,0.6029734259923796
IICs,0.5094591956796392
and,0.4802057053170292
viral,0.48435983850113407
control,0.573559039065632
require,0.4876355186416309
cognate,0.4835985802810663
antigen,0.470187997137489
recognition,0.5199558135229122
and,0.5762300500266926
are,0.5573685098069054
optimal,0.5796808376286806
when,0.5919252491914576
memory,0.6365827626851364
cells,0.6730179111754929
are,0.5688124528910702
either,0.5195289885322311
T,0.5568253382235036
helper,0.5141783817495218
type,0.537750037174952
1,0.4346678103407221
(TH1),0.385797114963194
or,0.501912564955723
TH17,0.533383195744415
polarized,0.5541486791405098
but,0.6716723340733908
are,0.6610755101745076
independent,0.6559060695167072
of,0.6258490162199116
interferon-γ,0.6366066487686529
(IFN-γ),0.5149837031929564
and,0.7000464081389466
tumor,0.5781692870566744
necrosis,0.6382384649683276
factor-α,0.6338186157554777
(TNF-α),0.4440684086942259
production,0.6623839365291001
and,0.7629291836859685
do,0.6518297637751018
not,0.6478327504922768
require,0.5978667081675998
activation,0.5824385051755085
of,0.5075761986317182
conserved,0.4330359296050516
pathogen,0.49275099990496407
recognition,0.5059556500458926
pathways.,0.5579382709398139
This,0.20172857044522507
represents,0.15060303198343303
a,0.1742033897836271
previously,0.07693579844953158
undescribed,0.04076864154987347
mechanism,0.22160422487319506
by,0.30076950826089816
which,0.17711924511783542
memory,0.2312861409320995
CD4+,0.3538324005747477
T,0.3153502058170586
cells,0.3808371934303803
induce,0.37633957518593925
an,0.27813245031670314
early,0.29290280499922966
innate,0.24846063817587055
response,0.34141406822021453
that,0.26799319643664565
enhances,0.21641487381362684
immune,0.15743336282892514
protection,0.1915937378863746
against,0.2627408963793991
pathogens.,0.17137931879988716
Using,0.006185674431105402
the,0.0015014088479457302
Princeton,0.003708443637696628
School,0.0014222113445938407
District,0.001075940136752803
Family,0.0015268829674829959
Study,0.001292892280769038
"cohort,",0.001040214938753836
our,0.002103028684008765
specific,0.0009447023298445078
aim,0.0010446080911673634
was,0.0018797101825992037
to,0.001181427375066638
estimate,0.0012483935836121126
the,0.0008540977204786514
prevalence,0.0009387007728953572
of,0.001078441712584645
suspected,0.0011164278925405104
familial,0.0009493550387859553
ponderosity,0.001956063002032306
and,0.0016678517591556636
"leanness,",0.0016423379458675525
to,0.001553199722097572
provide,0.0013272260594927136
empirical,0.001229493417740689
risk,0.0011674800410474862
estimates,0.0013054723883262438
for,0.0014365875456850096
the,0.0010325642158834096
proportion,0.0012091902243200827
of,0.0015786197250621794
probands',0.002033787955460189
first-degree,0.0015027766253030417
relatives,0.001293400026625762
who,0.001394318994459331
were,0.001645681366189043
similarly,0.0016624658490320438
"affected,",0.0014218257321318994
and,0.002172442081679243
to,0.001234105315662145
estimate,0.0012083528825619766
the,0.0009684597876142548
contributions,0.0013936094271525046
of,0.0014517595194377731
"diseases,",0.001007420527897254
drugs,0.0011302889110515791
and,0.0013057521765553809
caloric,0.0008004542294577626
intake,0.0017655282687151644
to,0.0014588468214255755
relative,0.0011650584620404732
obesity,0.0013726977658465149
and,0.0015854725674232916
leanness.,0.0017468700324544326
We,0.0203952164696626
studied,0.008270733519890766
379,0.00419216334849929
"probands,",0.017442832056052786
125,0.006102468169598819
whites,0.006790555702875638
and,0.010485946556640528
52,0.006686566081858325
blacks,0.007497356048278756
from,0.006205066640854224
a,0.005806308711250619
random,0.002707298855749031
recall,0.007814187995437257
"group,",0.005003345531619348
147,0.008686597827916375
whites,0.007908155647633456
and,0.011536452470260325
55,0.008700277740710433
blacks,0.00852195703632933
from,0.008494684072659362
a,0.00889146901336493
hyperlipidemic,0.005936497586957807
recall,0.010890086110264785
group.,0.00952241371162204
Suspected,0.010999608058313078
familial,0.021053831493428588
obesity,0.08632088630341293
and,0.02641830667704977
leanness,0.04404179653688866
were,0.03222260923121508
arbitrarily,0.01734284445145216
identified,0.029154305787818996
in,0.03054137635005618
those,0.034092974064800295
kindreds,0.02169138221903539
with,0.021737448198140864
at,0.021896350555025017
least,0.02364537564270086
two,0.02200227018433988
first-degree,0.027893636731251233
relatives,0.020346339246586628
in,0.025910424782505707
the,0.026921558803932214
same,0.030641929300635355
Quetelet,0.05562965973465088
index,0.036130667615010076
decile,0.031442449725479014
as,0.025109787445976434
the,0.023755035413876326
"proband,",0.03919390764613452
top,0.020596780331751285
or,0.023518298912804013
bottom,0.015882188800977314
respectively.,0.02165503459391498
Suspected,0.21632813180103602
familial,0.23104707855006879
obesity,0.2120545424523484
was,0.22174606561237842
observed,0.2700638353574034
in,0.26619934058299444
2.4,0.2525869988865654
percent,0.20411745351236144
and,0.24295265814177866
6,0.17512800564077458
percent,0.20675090926908105
respectively,0.1848970197326199
of,0.2757658686153153
random,0.17463866630998504
and,0.1847540797028089
hyperlipidemic,0.16695997454766545
recall,0.1820351855282387
group,0.19119000115530826
whites.,0.17565456703407023
Suspected,0.41238927903376343
familial,0.39464347045488113
leanness,0.42204075875151853
was,0.3621691446297252
identified,0.43370542854555133
in,0.4077037044575667
2.4,0.4788165788139596
percent,0.30476305329851655
and,0.44091927156305155
1.4,0.37237181073792686
percent,0.31299023745563265
of,0.37533278322955627
random,0.29381151172445746
and,0.3339823487401449
hyperlipidemic,0.3301653290465962
recall,0.28781705654810186
whites,0.2714051942151269
and,0.42485680697026285
in,0.42930405778260067
3.8,0.48233565678565016
percent,0.30015382761562476
of,0.360356563431879
randomly,0.29521445338243707
recalled,0.27702157736034005
blacks.,0.2645223003477368
Approximately,0.19134460952102222
twice,0.17771724975591263
as,0.19531936992678173
many,0.1697075172438711
as,0.19077054423996048
expected,0.17195500037595132
white,0.16125270283732335
first-degree,0.15464247514361737
relatives,0.12075965144910529
of,0.15242500933831618
top,0.15747691641389738
Quetelet,0.16666221702459885
index,0.13916100980438198
decile,0.15020075177084172
probands,0.10909354573190327
themselves,0.17618429405727262
had,0.16001678041629516
top,0.1375271565119334
decile,0.18323757741409422
Quetelet,0.17853591918160258
indices;,0.10478172889484688
approximately,0.18963541428854966
three,0.14086107818968266
times,0.13571391602401373
as,0.1546589481626764
many,0.16097836373510452
as,0.16342646110078965
expected,0.1547204658182278
first-degree,0.1143546050048472
relatives,0.1041431929987804
of,0.15073510181272406
bottom,0.11196264451294952
decile,0.13881670984106279
Quetelet,0.1491641506347793
index,0.12242101324506918
probands,0.08854685044186313
themselves,0.1264242457779514
had,0.1350923080310541
bottom,0.10340053191501697
decile,0.15682801406229405
Quetelet,0.14285059354081148
indices.,0.0905443278544879
Nineteen,0.43616943326688157
percent,0.37891826375630966
and,0.4696860752082738
31,0.31448584986761474
percent,0.32525289192625617
of,0.35294855158444144
top,0.31242337515623697
decile,0.31030534655885555
Quetelet,0.24398326196714804
index,0.32130261498125595
white,0.28536106504046255
probands,0.32538271505016236
from,0.3688529064396712
random,0.28779279287560916
and,0.3316793460502685
hyperlipidemic,0.24334379715095014
recall,0.30666842962162166
groups,0.3465394138649057
came,0.35088890003468537
from,0.3818729443495244
families,0.3837550259964606
where,0.37870570839238765
at,0.33416099561740764
least,0.309502696607686
two,0.33904733051940683
other,0.39147701079738845
first-degree,0.35327749345147635
relatives,0.2956847191343902
were,0.3713523505890693
similarly,0.3771599976324475
obese;,0.44028235950602007
18,0.4533726634377477
percent,0.3745921147793733
and,0.4051825531204208
20,0.3574403648880384
percent,0.3541585455376151
of,0.4321346049162913
white,0.3375224602741931
random,0.3973693978183881
and,0.4143655618147665
hyperlipidemic,0.4595393370244902
recall,0.40546078992017404
group,0.4029152492640863
probands,0.33833660443713454
with,0.36825340300390463
bottom,0.3462155594027619
decile,0.3756180519404138
Quetelet,0.3370664357411594
indices,0.3083743303531212
had,0.3788202458573399
suspected,0.3797383227066086
familial,0.31999653499377523
leanness.,0.3152593390847951
Nearly,0.16922554887873764
all,0.17817611657378923
subjects,0.19609925498601236
with,0.1558504391884115
familial,0.14496170901049865
obesity,0.17751701109894477
or,0.16878552562194885
leanness,0.15724247688234755
had,0.2101657269873674
no,0.20915973276827027
overt,0.2169092665823232
metabolic,0.2236887770922948
or,0.14966137026936666
pharmacological,0.14442925963727093
explanations,0.1816065681838895
for,0.1478524778703443
their,0.1448440599857065
body,0.20183875357111208
habitus.,0.14565577798908677
Within-family,0.050590600498468086
clustering,0.06926770583709613
of,0.09005555340441473
hypertension,0.10902684446365465
was,0.07329374615930447
common,0.08620825597122053
in,0.09742057190309357
kindreds,0.05154844958824958
with,0.07211992708121244
suspected,0.08335155194069388
familial,0.06661091956055472
obesity,0.07890944752181221
and,0.14388692371302692
was,0.09643583023695326
absent,0.09123612176192604
in,0.09085909185604671
kindreds,0.060057148438896556
with,0.05960437180487617
suspected,0.060806152981658
familial,0.046995843290430266
leanness.,0.05736226165844713
Marked,0.01933350580839781
within-family,0.01796318541879758
clustering,0.03293857054862533
of,0.023730675327925922
both,0.0308725291338628
obesity,0.05527778554072831
and,0.021259947302928107
leanness,0.05540920043669454
is,0.006832072788076896
useful,0.00701938242740129
diagnostically;,0.008286972862930866
therapeutic,0.014381805192744786
intervention,0.013646270102667793
to,0.009743113199602077
reduce,0.020843201312732654
"obesity,",0.5218215864943173
to,0.3588795975019159
be,0.3191068599808895
most,0.33870122842946565
"effective,",0.4587329921359952
should,0.31258351121193123
be,0.4118930083651744
family-wide,0.3464807899647686
in,0.4272919993786879
the,0.35680206777984563
many,0.24183776049623124
kindreds,0.27582151819652734
which,0.26897688449472323
share,0.2047000856414679
familial,0.23733903401487064
obesity.,0.3356068818611288
CONTEXT,0.0032866829439224723
The,0.0005661907430471887
epidemic,0.0005945071380027431
of,0.0008753273498939752
heart,0.0006880353849727629
failure,0.0008276042439139433
has,0.0005586391249907906
yet,0.0006354308687612696
to,0.0007089432267162806
be,0.000710163095696575
fully,0.0005676748484196699
"investigated,",0.00047703784807900875
and,0.0009349768418297458
data,0.0004984457186227473
on,0.000541570207114989
"incidence,",0.0005250338068392358
"survival,",0.0005596933280373393
and,0.0006423917145675323
sex-specific,0.0005293784260740568
temporal,0.0005117905839062081
trends,0.0005710772341094405
in,0.0006535461067030216
community-based,0.0005914680214614152
populations,0.0005138236233734242
are,0.0007489430954762767
limited.,0.0006523166426657478
OBJECTIVE,0.0013027646496673495
To,0.0011867866554414938
test,0.0009512564220899496
the,0.0008724508687736513
hypothesis,0.0007918946202591738
that,0.0014827012677658261
the,0.0014611269444129002
incidence,0.0010683276402721586
of,0.00214382093154732
heart,0.0010437983322004588
failure,0.0014928802720189066
has,0.0016039876889323923
declined,0.002416711860890574
and,0.0035318017076776597
survival,0.0010684413796790753
after,0.002656566256189609
heart,0.001315162900292511
failure,0.0016188799467444124
diagnosis,0.0019748068147032423
has,0.0023255349298241463
improved,0.0030298018989502397
over,0.004941063782405569
time,0.0016341436132352042
but,0.0026193497762170225
that,0.0015428436424309263
secular,0.0013807971120935224
trends,0.0012241318526255648
have,0.0017182967146461279
diverged,0.0011388652040943918
by,0.001901682918208145
sex.,0.000806942094967529
"DESIGN,",0.00361005670354541
"SETTING,",0.0061890412230887
AND,0.003629536033155742
PARTICIPANTS,0.004804398728248559
Population-based,0.004453584915444838
cohort,0.0036906931408806883
study,0.0045449659990749545
using,0.005307039987218198
the,0.006185840785420733
resources,0.004818833853052891
of,0.006910440243878589
the,0.004655454727092467
Rochester,0.0061013215486709176
Epidemiology,0.0036843356426365555
Project,0.006126801440681294
conducted,0.004360963675864781
in,0.004285068599989849
Olmsted,0.009399749254730838
"County,",0.005124357359338369
Minnesota.,0.00224917692232283
Patients,0.0010861626730189727
were,0.001598458350900712
4537,0.0012124893759668895
Olmsted,0.0014206884622238408
County,0.0015809674491664852
residents,0.001414278466358691
(57%,0.001281780949100503
women;,0.0013049319448921837
mean,0.0012243814007490091
[SD],0.002289812852280659
"age,",0.001498194379613583
74,0.0022816620049088145
[14],0.001600864492379541
years),0.001593348511386158
with,0.0015470167374460522
a,0.0014661128167242207
diagnosis,0.0011067354992807489
of,0.0014131118984833221
heart,0.00130509601219949
failure,0.0012988168434973923
between,0.001349310890105871
1979,0.0015213951813573758
and,0.0018670931631974697
2000.,0.0015756808685626939
Framingham,0.0018296795434695344
criteria,0.0011832096078460475
and,0.002037388494493216
clinical,0.0009821482977870823
criteria,0.001108911594083067
were,0.0014582061772375388
used,0.0014482167044659855
to,0.0017784655722495014
validate,0.0013547289643955015
the,0.0016218617966909815
diagnosis,0.0010354690141215362
MAIN,0.0017156919133082494
OUTCOME,0.0017067129439535121
MEASURES,0.0014741854441426647
Incidence,0.001449246933217671
of,0.001490236666151252
heart,0.0010305105441510945
failure,0.0009630217059011583
and,0.0019710033383355066
survival,0.000924286280294809
after,0.0010623359565912816
heart,0.0011056029726851573
failure,0.0010175856134589782
diagnosis.,0.0011698860311170234
RESULTS,0.6479525561376284
The,0.6638663373155625
incidence,0.689440189944585
of,0.7286300341555214
heart,0.6604415279225799
failure,0.698545546330244
was,0.623814878995257
higher,0.7025135401133612
among,0.6980111849856483
men,0.7379455988113169
(378/100,0.7174233060561904
000,0.6741074535688811
persons;,0.7798563361211406
95%,0.80213851857609
confidence,0.8011974233489848
interval,0.7672505873847282
"[CI],",0.7307267962743419
361-395,0.7322919593240925
for,0.7013554810990765
men;,0.7545357692537418
289/100,0.7347220983659476
000,0.6908220831825564
persons;,0.7825217997509981
95%,0.8030286944734025
"CI,",0.7578872995670385
277-300,0.22967548083778305
for,0.17443261555116907
women),0.1262541321440078
and,0.2938944650202349
did,0.22049862497139772
not,0.1765850302264406
change,0.1674434090493159
over,0.12293086092215676
time,0.11109663553769207
among,0.11254049026683192
men,0.13430548804170964
or,0.09232185557947942
women.,0.09837215250592234
After,0.09152461700548994
a,0.07929367634327274
mean,0.07543711051747103
follow-up,0.07054747556179318
of,0.10783575313378613
4.2,0.08560750107632147
years,0.06569179332814219
"(range,",0.0699930928692979
0-23.8,0.05812921256123686
"years),",0.04724288782558427
3347,0.02231922902867415
deaths,0.03892228267785052
"occurred,",0.053842830238500596
including,0.04205241256862223
1930,0.037715016056130986
among,0.057883909329704886
women,0.05510275314734844
and,0.05789817391723205
1417,0.031208728364798013
among,0.05046528473312823
men.,0.04554366602576988
Survival,0.27037999864743684
after,0.43559427870246076
heart,0.35293572893885533
failure,0.439812521183583
diagnosis,0.4927365227512795
was,0.34755223436390115
worse,0.3699130488122214
among,0.3486540757305447
men,0.3432324301850073
than,0.4693804384492367
women,0.33298224151233713
(relative,0.42245315271539585
"risk,",0.48999940720776114
1.33;,0.44991180309598794
95%,0.4900037947758881
"CI,",0.5206878156915263
1.24-1.43),0.4901564138377759
but,0.3232113175671318
overall,0.35460471238440894
improved,0.28101314627585805
over,0.3208179467981144
time,0.20899090262518574
(5-year,0.27967456315878064
age-adjusted,0.19302665335284822
"survival,",0.24276901122779182
43%,0.2584222754976993
in,0.2753375064419215
1979-1984,0.2655512007819613
vs,0.3295684186196155
52%,0.26322413847141846
in,0.22879200698174598
"1996-2000,",0.20179955022267143
P<.001).,0.30587788666590426
"However,",0.248599748442217
men,0.22633181715709816
and,0.24965640642126674
younger,0.15980708541767716
persons,0.26460015229266726
experienced,0.2994358408540085
larger,0.2413376849899911
survival,0.16083166592565384
"gains,",0.20850021081941755
contrasting,0.28918095692054974
with,0.2535134418861332
less,0.19814546290478857
or,0.1510444020624091
no,0.19988040684981823
improvement,0.16874826626302947
for,0.20813960620322267
women,0.1805579282297715
and,0.18974531811884077
elderly,0.09950048021788423
persons.,0.1538031571223922
CONCLUSION,0.7893344110878379
In,0.5950752508092708
this,0.556150888245652
community-based,0.501406483367725
"cohort,",0.5686347747760472
the,0.5330045208876458
incidence,0.5823454718269434
of,0.6223544229524967
heart,0.4610451142772285
failure,0.5427855455272761
has,0.4581456268753213
not,0.5153310915262164
declined,0.4917643839305358
during,0.508753430654584
2,0.5141951804497954
"decades,",0.49726220441967545
but,0.6085776972911164
survival,0.5075333524432759
after,0.5025316156871303
onset,0.49816968364501873
of,0.5304672307211478
heart,0.4549224479508917
failure,0.5028178258497371
has,0.4119478918508582
increased,0.46565845267560635
"overall,",0.5701675998295724
with,0.45805723936605364
less,0.5056266951805122
improvement,0.44959023510699225
among,0.4190646892854583
women,0.4085886902258313
and,0.4290020886731766
elderly,0.271454865317147
persons.,0.380947956633287
Human,0.009945444678284666
tumors,0.008856238751748681
show,0.009117862305855642
a,0.007349313120462416
high,0.006057425925329561
level,0.0050076452136510186
of,0.00547932004447358
genetic,0.0035979898647282675
"heterogeneity,",0.003723799063685766
but,0.005452304387122704
the,0.002395283934811685
processes,0.00294167540764972
that,0.0020570602462245294
influence,0.002684932018663167
the,0.0021084298305978173
timing,0.002193328864575794
and,0.0025916824719649976
route,0.001878920836345007
of,0.0028959993171827174
metastatic,0.002762341206750904
dissemination,0.0031628482181215397
of,0.0032386005440082732
the,0.0041656260643489346
subclones,0.0052698807266499306
are,0.0017182108331055262
unknown.,0.0020237600315715933
Here,0.07665007261804782
we,0.05633709132297175
have,0.03992917904594195
used,0.02844958211950741
whole-exome,0.015995248927436718
sequencing,0.017223407829883405
of,0.028121031703493716
103,0.01713444235269161
matched,0.01418813411123786
"benign,",0.019369622529318335
malignant,0.015234658340522445
and,0.02087766706964097
metastatic,0.013993457782741789
skin,0.025387558699823426
tumors,0.024988729806774197
from,0.023240858559233215
genetically,0.012874278629982727
heterogeneous,0.022324018479073213
mice,0.026605901414450243
to,0.02617731335689365
demonstrate,0.03400118642663281
that,0.04104668382388071
most,0.024913588710104413
metastases,0.015223563230836552
disseminate,0.014953995723211195
synchronously,0.013394352045699545
from,0.027742197351951475
the,0.015085035496290691
primary,0.018265518146255065
"tumor,",0.021296582920810016
supporting,0.019507255872433956
parallel,0.01918039332823241
rather,0.04374189819511446
than,0.04000536435387437
linear,0.015610666550594397
evolution,0.01877690434660339
as,0.013697924084059282
the,0.014189221271126555
predominant,0.01333137137835624
model,0.01203538966521634
of,0.012773157199990573
metastasis.,0.01126369412378101
Shared,0.0582268248760605
mutations,0.08725143958990843
between,0.045438427539664594
primary,0.07460270553248476
carcinomas,0.06886407845703733
and,0.036561500557223306
their,0.044327619065983426
matched,0.04254278166018616
metastases,0.06204699320495689
have,0.07442313130468925
the,0.3464882332614779
distinct,0.2705573414414332
A-to-T,0.34148210741942725
signature,0.2965944943699978
of,0.2641084112640915
the,0.24921083990329523
initiating,0.2984573405501565
carcinogen,0.23118701822878837
"dimethylbenzanthracene,",0.2572990662199008
but,0.2643352628534931
non-shared,0.2880596136139171
mutations,0.25419475558765164
are,0.2386992425909724
primarily,0.287314555310426
"G-to-T,",0.3537585146224342
a,0.29541898929954075
signature,0.3059707889922773
associated,0.30691706014352615
with,0.29546464108189213
oxidative,0.298725331419002
stress.,0.31524238074669225
The,0.08628270777710648
existence,0.07634734519887694
of,0.07886346016837296
carcinomas,0.0656809655382737
that,0.0724561259236777
either,0.06327217396547763
did,0.13113835947789262
or,0.05604682727462721
did,0.12008625949138269
not,0.10181463511338072
metastasize,0.07881350735549228
in,0.09192622839162268
the,0.04966109954949332
same,0.06566166253536207
host,0.03633253918971165
animal,0.04820732526419171
suggests,0.08287924425422365
that,0.06608195021529606
there,0.04911325464202687
are,0.05280285298734965
tumor-intrinsic,0.05211771735937953
factors,0.06123566593486087
that,0.045460697154389294
influence,0.051670326860112796
metastatic,0.050786855517745484
seeding.,0.07383911836645482
We,0.3045675761428549
also,0.2103873028225911
demonstrate,0.2156468166865805
the,0.13452606609892392
importance,0.14293577066457602
of,0.15124100368908616
germline,0.1805866443818361
polymorphisms,0.16522140925739753
in,0.13358816465524892
determining,0.1473015744933427
allele-specific,0.1290528914275415
"mutations,",0.15554622948431876
and,0.2483367279525149
we,0.2447510145027816
identify,0.21148797088706486
somatic,0.2048531234159361
genetic,0.1627670708779013
alterations,0.21746216870982193
that,0.17381631568387815
are,0.13648939195627297
specifically,0.13840985840209696
related,0.15221779882793168
to,0.15816087278093777
initiation,0.16903196518232122
of,0.22928575527719564
carcinogenesis,0.26605139871966316
by,0.24869105865093685
Hras,0.2651418217554663
or,0.22145808655530258
Kras,0.2812570293464288
mutations.,0.19280172572070498
Mouse,0.4774958829096735
tumors,0.37965495852941056
that,0.5475253624701701
mimic,0.5498961706807846
the,0.529067413237502
genetic,0.5146380454481231
heterogeneity,0.4964352258068198
of,0.47485907991453935
human,0.5436484426356695
cancers,0.4082798248074412
can,0.613923411541209
aid,0.5782792106948195
our,0.5153142876365477
understanding,0.4955969189444765
of,0.5148652314539076
the,0.5264019118719739
clonal,0.5227535376795799
evolution,0.5875073149580556
of,0.5780539643461303
metastasis,0.4857922996445448
and,0.6511623620382152
provide,0.4937358088277024
a,0.5322309486232013
realistic,0.4381853335227284
model,0.3935554487093282
for,0.34646853028330554
the,0.3117993684919439
testing,0.2675962015943883
of,0.21006386022366158
novel,0.20340569637193606
therapies.,0.18325996007050596
The,0.054949670547475384
only,0.03021539396793857
proven,0.017368538150497423
requirement,0.04555501068396105
for,0.03931916253120101
ascorbic,0.08109781418435308
acid,0.07273612031808517
(vitamin,0.023991254587945085
C),0.0769754152666432
is,0.024070156002525833
in,0.06806313909634037
preventing,0.07220632132176655
"scurvy,",0.0813621509059895
presumably,0.045350464487804484
because,0.07485218161141603
it,0.12898779339244548
is,0.11847605853428991
a,0.17263251999970933
cofactor,0.14724167702849705
for,0.11871014708327632
hydroxylases,0.12579265636033182
required,0.146513335181786
for,0.1501260416322016
post-translational,0.18247694816240548
modifications,0.17614227902013407
that,0.14578907877316782
stabilize,0.11428627017753656
collagen.,0.11320514954382428
We,0.040505410716480235
have,0.01799167470161628
created,0.015419415042905213
mice,0.016235314046933073
deficient,0.010733349858541935
in,0.00921848542368059
the,0.012160815724730973
mouse,0.012976225203580658
ortholog,0.013544518849625202
(solute,0.013309928257496488
carrier,0.020038558009096836
family,0.016169825585862024
23,0.014117468670196138
member,0.013886933908895125
1,0.0154163205999797
or,0.015517409350763818
Slc23a1),0.015250852234836344
of,0.009977515799560669
a,0.00772947038952745
rat,0.012479889264536656
ascorbic-acid,0.01658950765341352
"transporter,",0.0170428427445827
Svct2,0.016375342414100873
(ref.,0.014546156491777344
4).,0.018070122747728828
Cultured,0.31631816120767753
embryonic,0.39833184879590705
fibroblasts,0.4311917701556157
from,0.44251790079608583
homozygous,0.43563189201023145
Slc23a1−/−,0.3933987207615093
mice,0.4187480325643049
had,0.3923278137923228
less,0.3516986897386807
than,0.37563500340865025
5%,0.3935689597577694
of,0.33432633857951566
normal,0.423508322845836
ascorbic-acid,0.4064509518139291
uptake.,0.43572849862902663
Ascorbic-acid,0.4661140251735489
levels,0.411307866635682
were,0.48013878157612844
undetectable,0.45956454472660924
or,0.42797678254864924
markedly,0.500320684120791
reduced,0.44588507860999793
in,0.4779628503685483
the,0.49785504688371407
blood,0.44312581660284023
and,0.37046930997402217
tissues,0.41013962026051365
of,0.482480934411583
Slc23a1−/−,0.37544587403522717
mice.,0.3991014981878393
Prenatal,0.09635727802871516
supplementation,0.15038786665454187
of,0.12270435845367127
pregnant,0.08635249632531056
females,0.09887778895790059
did,0.19746850507848673
not,0.16354526813205073
elevate,0.09127197697305298
blood,0.09375821326783658
ascorbic,0.09492394785555687
acid,0.09421853448312359
in,0.08760910049349539
Slc23a1−/−,0.08962911599796546
"fetuses,",0.045083493012781195
suggesting,0.08321060364275137
Slc23a1,0.0717385312855157
is,0.03981796006794977
important,0.051797640351667194
in,0.04357585502024605
placental,0.02893411701889032
ascorbic-acid,0.05588001206902642
transport.,0.05939754361539486
Slc23a1−/−,0.26294946864668306
mice,0.38756766030551726
died,0.2751249154952439
within,0.2529646868519453
a,0.2851861537889612
few,0.29008864144376
minutes,0.29240270986576
of,0.4088731492296299
birth,0.3859083086091473
with,0.4542844155624406
respiratory,0.3399804997053466
failure,0.34650121703409015
and,0.49458156411267634
intraparenchymal,0.3535127070976862
brain,0.4637307133130861
hemorrhage.,0.40103302375732497
Lungs,0.35749824402368585
showed,0.4998039268057717
no,0.5299021331699176
postnatal,0.5610663224737524
expansion,0.476628171739709
but,0.4822184292079677
had,0.4730893615671623
normal,0.49707798074818116
surfactant,0.431095272109394
protein,0.4822291319260736
B,0.5089210517276381
levels.,0.4908718777402756
Brain,0.49412051867612283
hemorrhage,0.32764358873827004
was,0.36190905049905997
unlikely,0.2546940677822497
to,0.22047840755168574
be,0.29450674650844766
simply,0.2810233887960834
a,0.3137240530393771
form,0.3723364633758342
of,0.3848949177888699
scurvy,0.4023129707790388
since,0.5422905642767636
Slc23a1−/−,0.6142179973708997
mice,0.6468212649918276
showed,0.6752828094506979
no,0.6660503621160556
hemorrhage,0.5814861054417595
in,0.6787455790341163
any,0.6398632289347158
other,0.6656400765447668
tissues,0.6322069759568493
and,0.6893735359765163
their,0.6001108705238797
skin,0.6404199132524706
had,0.6132305100872458
normal,0.6081821595066662
skin,0.6391330145392752
4-hydroxyproline,0.6507623587472402
levels,0.6274176578923646
despite,0.6398015899566165
low,0.5768451987658285
ascorbic-acid,0.619707765913295
content.,0.5945228838410186
We,0.2787575045623138
conclude,0.16504689663875607
that,0.1344630661086058
Slc23a1,0.13788717709794604
is,0.12602398157952785
required,0.14242349310495783
for,0.1597739556010268
transport,0.1629395783029446
of,0.17147317510613322
ascorbic,0.14909854653442442
acid,0.15749227478860364
into,0.13755876206988488
many,0.10045016975201955
tissues,0.12283061689932849
and,0.13305692980431505
across,0.1006309616279669
the,0.12324596492711835
placenta.,0.11462425339419353
Deficiency,0.20708095709824814
of,0.1590150107292742
the,0.1641140153466222
transporter,0.18500010416057208
is,0.14993199315833752
lethal,0.19015671239978943
in,0.2189048881744527
newborn,0.2372007469240696
"mice,",0.23267212996095407
thereby,0.24571272565550994
revealing,0.2082163854213264
a,0.3322612346561269
previously,0.24187809495543672
unrecognized,0.19353604491483198
requirement,0.3161741796339055
for,0.31967634774566894
ascorbic,0.3313488040056711
acid,0.32520579540498373
in,0.30672627999975355
the,0.3299950275374626
perinatal,0.34329136426973567
period.,0.35776498118737055
DNA,0.025176974995178375
damage,0.016372521986786032
tolerance,0.01835754833665918
during,0.02682855922943024
eukaryotic,0.021425375788201716
replication,0.015759974726952314
is,0.017222641072286278
orchestrated,0.01617451800979245
by,0.02154500922521342
PCNA,0.016479132447895103
ubiquitination.,0.013756500620299076
While,0.22965386848536865
monoubiquitination,0.16420109017780077
activates,0.17554097206223965
mutagenic,0.12465635758402412
translesion,0.12256842293356972
"synthesis,",0.18601285988551303
polyubiquitination,0.11159760119759321
activates,0.13855400777272336
an,0.13192430480130235
error-free,0.08169669546916204
"pathway,",0.1520093519900769
elusive,0.06213297843229447
in,0.10034942884026386
"mammals,",0.08408785489063564
enabling,0.14681902407914021
damage,0.11207426777675007
bypass,0.10448523118153058
by,0.12808700353850339
template,0.0814957222657245
switching.,0.11398223421668757
Fork,0.09368996150815624
reversal,0.09479808586336355
is,0.06295145208858023
driven,0.07119264453519368
in,0.06813837683781136
vitro,0.07669128073209355
by,0.09104792940543778
multiple,0.044453479209648906
"enzymes,",0.029769192765251733
including,0.028516635540053466
the,0.055115515726505596
DNA,0.04932026079805435
translocase,0.04561727017748649
"ZRANB3,",0.08506792068637288
shown,0.03809654389235571
to,0.029935638409155817
bind,0.035451878360313674
polyubiquitinated,0.03732976175807314
PCNA.,0.044987179998846064
"However,",0.00755476497694016
whether,0.005105947837959126
this,0.008902943834749023
interaction,0.022686225203425104
promotes,0.01295216480917567
fork,0.026088427126932084
remodeling,0.01965820594977759
and,0.012991078797661077
template,0.013069164039940295
switching,0.016771322629143607
in,0.013202815072817205
vivo,0.016114146244135676
was,0.00285823297731956
unknown.,0.0037057781596710293
Here,0.12813094411961
we,0.612180955612715
show,0.6917241888059243
that,0.6868926675161036
damage-induced,0.5193383702395751
fork,0.49369701605692434
reversal,0.5443937763144554
in,0.5846808549327261
mammalian,0.5658097919027899
cells,0.6077671130214695
requires,0.6218363502583295
PCNA,0.6222727356636589
"ubiquitination,",0.6422451567033517
"UBC13,",0.6176885453300172
and,0.6435240637932651
K63-linked,0.5528949527307673
polyubiquitin,0.6223322099229945
"chains,",0.6220229183179258
previously,0.607215424210528
involved,0.6061741642316194
in,0.6369571543692384
error-free,0.4959969500445316
damage,0.4909166656669323
tolerance.,0.5608678472466945
Fork,0.45939462948877263
reversal,0.5057522755373884
in,0.5927630516595341
vivo,0.6238997792347243
also,0.55038829615395
requires,0.49142800856303237
ZRANB3,0.504465835036891
translocase,0.5934134432458975
activity,0.564554882247868
and,0.5058607459292191
its,0.4885082680176962
interaction,0.4492627551873475
with,0.42764638864403526
polyubiquitinated,0.4401303124053112
"PCNA,",0.5078244205591054
pinpointing,0.28904410845699435
ZRANB3,0.32208761524583013
as,0.28026203512169573
a,0.3565986469003278
key,0.36876623084805604
effector,0.34115040014485104
of,0.2774267926577992
error-free,0.3016810884921589
DNA,0.3918127875794161
damage,0.36014113200017717
tolerance.,0.29067605398456997
Mutations,0.3400323335781927
affecting,0.42684154858748385
fork,0.35389174128143763
reversal,0.351806794262501
also,0.3832158665300305
induced,0.40680433560744095
unrestrained,0.3230630772417045
fork,0.29705052375431634
progression,0.3834807402858208
and,0.3711136198320965
chromosomal,0.36333696702766033
"breakage,",0.30082659077477736
suggesting,0.2962182472211603
fork,0.22966547855433014
remodeling,0.1618572400408616
as,0.18883979580630378
a,0.19045870397432157
global,0.1720477819687533
fork,0.21014402996425796
slowing,0.21919566405798757
and,0.18129450515320417
protection,0.148733500486324
mechanism.,0.15234524240115427
Targeting,0.04533588682961375
these,0.08274028915715365
fork,0.07647554975007508
protection,0.07187475431886164
systems,0.07320993066821788
represents,0.028891656589888425
a,0.02976213862167023
promising,0.023211763732415847
strategy,0.030331697166881076
to,0.02819938206800028
potentiate,0.030027209800405467
cancer,0.03479831571467714
chemotherapy.,0.04021519717250068
Mice,0.05583006557464082
lacking,0.04000419234471739
the,0.054837358180518256
transcription,0.04871291362339866
factor,0.04474061545643216
T-bet,0.06049111426980793
in,0.05020219781378511
the,0.04479318319987953
innate,0.024501381476266588
immune,0.03545983628840436
system,0.060378248306639265
develop,0.05128298450791934
microbiota-dependent,0.029786358072860567
colitis.,0.03752892957267273
"Here,",0.6331410628446622
we,0.6560408513797574
show,0.6621201224098369
that,0.6952729765648916
interleukin-17A,0.5850397841501161
(IL-17A)-producing,0.48155853863919873
IL-7Rα(+),0.5367090855904939
innate,0.5793380610413771
lymphoid,0.5204328252750903
cells,0.6581903647755066
(ILCs),0.49309947106404073
were,0.6347195012255642
potent,0.6385887063075499
promoters,0.6475692221084487
of,0.6531285886598921
disease,0.5696945660420518
in,0.6654138232423382
Tbx21(-/-)Rag2(-/-),0.5740094461887593
ulcerative,0.5383201786957516
colitis,0.4926992107093165
(TRUC),0.5485162402655058
mice.,0.6254617907245766
TNF-α,0.5443072123000464
produced,0.510178965255474
by,0.5466870273614393
CD103(-)CD11b(+),0.5893501482425159
dendritic,0.5909506184024215
cells,0.5626147706963374
synergized,0.5501634293831404
with,0.14167888747877974
IL-23,0.16514852770885252
to,0.12088509672227403
drive,0.11526105443446596
IL-17A,0.16616584166671025
production,0.09315852488567913
by,0.09544526601810575
"ILCs,",0.0690403186893465
demonstrating,0.058854555822904935
a,0.05340134118936617
previously,0.031229077238757418
unrecognized,0.01993682520697384
layer,0.03251671951633157
of,0.030504774269112387
cellular,0.03668852572538682
crosstalk,0.025913701493491495
between,0.02589160580101675
dendritic,0.0408697840988161
cells,0.04454834266782872
and,0.02765715202970557
ILCs.,0.035645860217742825
We,0.17354105255125882
have,0.13950871575455095
identified,0.1516365016902588
Helicobacter,0.16275564275852922
typhlonius,0.21920947689177214
as,0.2109633921406053
a,0.2505982475771222
key,0.1894995037367902
disease,0.15673787638674178
trigger,0.2945798124190132
driving,0.24874187358766373
excess,0.15802646939783033
TNF-α,0.22389914317807832
production,0.2683336702442549
and,0.3532065535954313
promoting,0.2327241872259857
colitis,0.1589194471879313
in,0.19982550550699094
TRUC,0.11266859146635039
mice.,0.13450021088479985
"Crucially,",0.3568459646662887
T-bet,0.38103219998870264
also,0.3827639991869052
suppressed,0.3620763237541197
the,0.3620611832966921
expression,0.4860547756271584
of,0.3906269732204614
"IL-7R,",0.4288033141822176
a,0.3902737316773898
key,0.4166638373736841
molecule,0.4365174602885774
involved,0.43932781570821977
in,0.4314756940574209
controlling,0.39311920310759046
intestinal,0.4737777586568036
ILC,0.42000095352368194
homeostasis.,0.49560346377270414
The,0.11329352289182351
importance,0.13449472950805963
of,0.127724207112979
IL-7R,0.2210028968329296
signaling,0.15329087479951606
in,0.10429457042414543
TRUC,0.12538831321959873
disease,0.14602251867649677
was,0.1383720623529855
highlighted,0.5397315886357671
by,0.6129195922111156
the,0.6236069791851161
dramatic,0.6035165963970163
reduction,0.6076660864854095
in,0.6756155808803485
intestinal,0.792557542931507
ILCs,0.6625377148159252
and,0.6374655575955578
attenuated,0.7271382770671292
colitis,0.734346237362936
following,0.628336272211103
IL-7R,0.6325222715695573
blockade.,0.589589122076244
Taken,0.09240280290095007
"together,",0.138344371124993
these,0.16172044035526148
data,0.15164687639706995
demonstrate,0.1560592587026136
the,0.10571334089960914
mechanism,0.11738250653121016
by,0.17652564531635778
which,0.10136016513584885
T-bet,0.18535095770912066
regulates,0.13882113485712594
the,0.1148580916292432
complex,0.12413806577689565
interplay,0.14192749696896043
between,0.1027977986541032
mucosal,0.165399155307606
dendritic,0.188054694938081
"cells,",0.19094387961555165
"ILCs,",0.16043171640925236
and,0.10133956873881518
the,0.10988587261481103
intestinal,0.17669873113945633
microbiota.,0.14462443947112302
S-nitrosylation,0.04572352200275647
of,0.033560386869101705
proteins,0.029827729880173234
by,0.06706451323906021
nitric,0.0339848275937079
oxide,0.038191286165284756
is,0.012768930808741374
a,0.01574797099947948
major,0.0183653995679556
mode,0.015582712816230049
of,0.018280911296725384
signalling,0.024798177492772265
in,0.02353454146808395
cells.,0.02558653312845009
S-nitrosylation,0.04522735805298897
can,0.024619075742589352
mediate,0.035848461051528446
the,0.03278511698700466
regulation,0.038457119036310446
of,0.02790121454499274
a,0.018105118128056985
range,0.014380122260965541
of,0.018892282341318026
"proteins,",0.01865751774832182
including,0.01769848445733527
prominent,0.025193906088597933
nuclear,0.020863511225783025
"proteins,",0.021223242096135037
such,0.01453915885090493
as,0.018610931618166855
HDAC2,0.03958735114092919
(ref.,0.03418170262172939
2),0.030094685856832486
and,0.030173082575305977
PARP1,0.04215496826159564
(ref.,0.03225560685614649
3).,0.03210249943489793
The,0.025404078737782578
high,0.01761131797684813
reactivity,0.0144796153302686
of,0.022390476999246428
the,0.02627234586098953
nitric,0.027355045783277222
oxide,0.029945907748449196
group,0.03268824536213158
with,0.02278326363057445
protein,0.02268291633308743
"thiols,",0.01411955274516933
but,0.013380927303360062
the,0.014121670316583998
selective,0.010737251698557184
nature,0.013907612782155304
of,0.018042685788414094
nitrosylation,0.020494179936090068
within,0.013076795831166011
the,0.01806381629832697
"cell,",0.01951227952926056
implies,0.016010559093494987
the,0.009587179835602953
existence,0.009754195411556386
of,0.00855298550239807
targeting,0.008444455024411827
mechanisms.,0.008616346150927018
Specificity,0.12726936176874648
of,0.12677308453887914
nitric,0.12454997340200424
oxide,0.13802855745573608
signalling,0.18407338786586977
is,0.10303076280069744
often,0.12740714297533098
achieved,0.09671349426618413
by,0.1791374991234712
the,0.17611032103452023
binding,0.19893180031338217
of,0.20934591791963109
nitric,0.16463062727846825
oxide,0.047014239754835825
synthase,0.022806429475337637
(NOS),0.01841641166224827
to,0.035777367792813534
target,0.03459120835105632
"proteins,",0.028296926512142988
either,0.01783290707133037
directly,0.04249985335649527
or,0.022659548313971566
through,0.05019330858018965
scaffolding,0.025399510264802843
proteins,0.03279420948184528
such,0.026508046304555142
as,0.026879197868436015
PSD-95,0.03547878813704413
(ref.,0.02944341342927855
5),0.03894321112082788
and,0.04102395566251512
CAPON.,0.03801342963352241
As,0.010500792498252459
the,0.007585945212726192
three,0.007230052574653376
principal,0.007422317478737844
isoforms,0.006714616629007059
of,0.006735032990440143
NOS--neuronal,0.009962612042151877
NOS,0.019277077796448595
"(nNOS),",0.032732730471183843
endothelial,0.01443907942321271
NOS,0.015438904164778808
(eNOS),0.02144932544472061
and,0.014676414669792488
inducible,0.006152352093720064
NOS,0.007246094978407317
(iNOS)--are,0.009200720144961988
primarily,0.003965787058217429
"non-nuclear,",0.005366998427677065
the,0.0059229161054505895
mechanisms,0.003632843239013018
by,0.0049574890820069115
which,0.004584286085336411
nuclear,0.005055486039506482
proteins,0.0059536026388603775
are,0.003643648328181293
selectively,0.0028744605435603652
nitrosylated,0.0027057344164236035
have,0.0027790769085384104
been,0.0017804793351537693
elusive.,0.0022530802002926004
Glyceraldehyde-3-phosphate,0.22577744047620119
dehydrogenase,0.23701595289058786
(GAPDH),0.09146138819877178
is,0.05950797855451995
physiologically,0.051557676545874946
nitrosylated,0.03957222036343059
at,0.08115501179653282
its,0.054080009457696435
Cys,0.048472360731759534
150,0.05746453347303754
residue.,0.04265433611243881
Nitrosylated,0.09278852502379396
GAPDH,0.10553858910787764
(SNO-GAPDH),0.11684451468562146
binds,0.13510139676360333
to,0.11661622783771529
"Siah1,",0.13469054544315684
which,0.1718533766322935
possesses,0.1669489490419824
a,0.18224512977373417
nuclear,0.10031808306055262
localization,0.13585735180618697
"signal,",0.1999624701790604
and,0.14165943420705593
is,0.10213319819599355
transported,0.09939810003783171
to,0.08808971738262515
the,0.07864955936068307
nucleus.,0.0626397502651012
"Here,",0.6969072596210385
we,0.7194520732752328
show,0.6948369595130934
that,0.7315328522096193
SNO-GAPDH,0.5368017525534392
physiologically,0.6296311372627498
transnitrosylates,0.6606209581686908
nuclear,0.5483659439742925
"proteins,",0.579825355094824
including,0.6341703446845964
the,0.6786125488459486
deacetylating,0.6515125324644088
enzyme,0.6346823193912459
sirtuin-1,0.5316029818808636
"(SIRT1),",0.6182709439777491
histone,0.5946021288018313
deacetylase-2,0.6437212195041191
(HDAC2),0.5880916290278094
and,0.6607065890212799
DNA-activated,0.6879588813403884
protein,0.6362951426246769
kinase,0.5982675893916993
(DNA-PK).,0.33768137099061646
Our,0.5175285757343872
findings,0.4824835440298547
reveal,0.4809295800446425
a,0.49898002624434523
novel,0.4742804375043151
mechanism,0.4879972752584464
for,0.5376200222743571
targeted,0.5944181704776584
nitrosylation,0.5410499048080568
of,0.5807889729698125
nuclear,0.5223843328807184
proteins,0.49600333850853495
and,0.5567530911508957
suggest,0.48694992683326727
that,0.5135259104082952
protein-protein,0.5467785197809542
transfer,0.5678055153732999
of,0.596649600325874
nitric,0.5384901033024461
oxide,0.4931749396069135
groups,0.5585511943342646
may,0.4288898520915609
be,0.43653250981478614
a,0.4422210230300992
general,0.41140087330633385
mechanism,0.5122613310571874
in,0.47312836675815834
cellular,0.49810766587167155
signal,0.510649813573715
transduction.,0.48377282291479073
White,0.009566521659180871
adipose,0.008145712885658511
tissue,0.011294549721840009
displays,0.006826438805296257
high,0.006551504674489271
plasticity.,0.0048706623503921714
We,0.011541094339410392
developed,0.007629014694186082
a,0.005347993288140517
system,0.00455085398839801
for,0.004238131582405651
the,0.004279741446037859
"inducible,",0.003035604098807537
permanent,0.0030475945092018207
labeling,0.003919914287613882
of,0.005193379789786138
mature,0.004377565513440572
adipocytes,0.005357662169970722
that,0.003702221001971472
we,0.006730174942686445
called,0.003906667343451384
the,0.0042495739729005435
AdipoChaser,0.00780577077867564
mouse.,0.005622545848616892
We,0.006664859125231614
monitored,0.0030115150679075253
adipogenesis,0.0023639908285951177
during,0.0028202234599465797
"development,",0.004291202989673617
high-fat,0.0015167659995019343
diet,0.003419122672360817
(HFD),0.001303461231565136
feeding,0.004217810400392679
and,0.0017836250116019755
cold,0.002197206522428672
exposure.,0.0016696768951694628
During,0.38258406217428353
cold-induced,0.16486701695250328
'browning',0.2942425489947301
of,0.11582227571323647
subcutaneous,0.12384650905840444
"fat,",0.2343933393992718
most,0.23142849302034021
'beige',0.36034757827068525
adipocytes,0.22918334354973235
stem,0.21583728107921796
from,0.262118579816131
de,0.2477097282143296
novo–differentiated,0.1766580935398679
adipocytes.,0.26560020269742507
During,0.6740014066820508
HFD,0.5098522478260705
"feeding,",0.5778167553083001
epididymal,0.6835931671571006
fat,0.6246997634950787
initiates,0.5943110036603757
adipogenesis,0.6802285739751248
after,0.5526160462546817
4,0.59638258684743
"weeks,",0.5835740929354076
whereas,0.6641497549631208
subcutaneous,0.6073053403101052
fat,0.5992256835718964
undergoes,0.20223141734199712
hypertrophy,0.15837099562503346
for,0.1788836914263536
a,0.19937224950388022
period,0.15128271553772485
of,0.19647724860295615
up,0.20813183070200938
to,0.1467734110463915
12,0.12990120297753785
weeks.,0.1508761780045373
Gonadal,0.5990288158435314
fat,0.5805982343310837
develops,0.5367815846607104
"postnatally,",0.5931544182390007
whereas,0.5783277535706358
subcutaneous,0.5492692683626166
fat,0.5544019079864423
develops,0.5135610266848443
between,0.44128501320547275
embryonic,0.5519783232243384
days,0.47391191218462514
14,0.39615968588105327
and,0.34522490753566404
18.,0.3392652783280126
Our,0.16144195660618918
results,0.11862975478318859
highlight,0.12320109340813913
the,0.10353307336697892
extensive,0.10615557021467449
differences,0.06955082772370375
in,0.06318474665291904
adipogenic,0.1256339490713881
potential,0.11066400843525413
in,0.08167942750285906
various,0.06976382014764872
fat,0.14552310454680167
depots.,0.12458821280711577
Pancreatic,0.06985037326491496
ductal,0.03266227310501774
adenocarcinoma,0.033627871468388706
(PDA),0.026295429185980705
is,0.03972376887316841
among,0.02315643911414794
the,0.03469850787055634
most,0.024371162662583556
lethal,0.028219381965886015
human,0.0254121729197596
cancers,0.020361295193512065
in,0.05702145650827761
part,0.04711054691772945
because,0.06950313283608558
it,0.07975479907814281
is,0.04590842947847414
insensitive,0.03117716687814948
to,0.05779529450771486
many,0.03492770175404037
chemotherapeutic,0.029555310759549275
drugs.,0.029381820220127662
Studying,0.1210851751598756
a,0.06952085919778382
mouse,0.076336795770639
model,0.053026494569343524
of,0.03781363053384957
PDA,0.05683389887617396
that,0.03614331103818278
is,0.01822066884355855
refractory,0.01380463148819785
to,0.036463971231034
the,0.025196459152949643
clinically,0.019014540657164028
used,0.014007583829817772
drug,0.023285925864937173
"gemcitabine,",0.026637190410062104
we,0.13844090909983497
found,0.3183210214419223
that,0.25672785153851096
the,0.1747383577242065
tumors,0.12501500736932603
in,0.12392399894155921
this,0.09880072367490832
model,0.12431387029442237
were,0.2329677609560321
poorly,0.16789360079732668
perfused,0.15539752553831138
and,0.27412479068079293
poorly,0.15777225239246717
"vascularized,",0.08108140326493611
properties,0.1041598826145304
that,0.08061254017722706
are,0.04156856641270314
shared,0.045833825476055946
with,0.03835384621644463
human,0.04971736790879795
PDA.,0.06736368909266587
We,0.14329853101232842
tested,0.0841845461487018
whether,0.055141757278863085
the,0.041869010002217905
delivery,0.08891220122546108
and,0.0392388283390071
efficacy,0.05893417344439232
of,0.07647847975249901
gemcitabine,0.09964511119780933
in,0.10152390109992775
the,0.12022468625824194
mice,0.11985017218255692
could,0.05921384334395096
be,0.04175547980346036
improved,0.06448781457648291
by,0.08267058826718508
coadministration,0.07049893808716223
of,0.07383454502613755
"IPI-926,",0.46527519244275584
a,0.6097726545650597
drug,0.5570212050126098
that,0.6774047362317235
depletes,0.6928909711306179
tumor-associated,0.5555638344684721
stromal,0.6828683376134002
tissue,0.7274670356758542
by,0.7918126800482785
inhibition,0.7830048761506557
of,0.69412632112397
the,0.6656265187498308
Hedgehog,0.4847254333233051
cellular,0.6911365785076904
signaling,0.6528672830036136
pathway.,0.6444071023894271
The,0.7872980969739943
combination,0.7791579267693405
therapy,0.7660043904113427
produced,0.8432975398985953
a,0.8458703373499755
transient,0.8606918266230922
increase,0.8112070741741344
in,0.8397134552699518
intratumoral,0.8916567499505951
vascular,0.8676748041715924
density,0.8278721970931443
and,0.8520939022353011
intratumoral,0.8858611894991172
concentration,0.8342696506062405
of,0.8523215201613951
"gemcitabine,",0.8169252195532084
leading,0.783824633787191
to,0.7894197057938196
transient,0.7843538688698855
stabilization,0.7654170058744018
of,0.7263057713135666
disease.,0.6934491471355204
"Thus,",0.43574822886612563
inefficient,0.3104648170107767
drug,0.2323554649545444
delivery,0.28400583113475586
may,0.18331999067032997
be,0.1964411683840639
an,0.2559410609091057
important,0.2574693641095742
contributor,0.29232202549556596
to,0.28838609902968737
chemoresistance,0.2787396972539938
in,0.31754293883083584
pancreatic,0.4056307620927363
cancer.,0.23040612440023678
Allergic,0.08946322978292978
asthma,0.09654702241773044
is,0.06895306862338108
a,0.07929310194612121
T,0.08237991357441435
helper,0.060809005552353634
type,0.04744185983454248
2,0.04707540576449243
(T(H)2)-dominated,0.05314143654431652
disease,0.08444181571886611
of,0.07625730200348843
the,0.08126253946280877
lung.,0.08753959344940772
In,0.6506673485411644
people,0.596258645566535
with,0.5577169434514418
"asthma,",0.5820796917380495
a,0.6174662669787991
fraction,0.6137869270817112
of,0.7046608030798093
CD4(+),0.6997338690160622
T,0.6339469726360296
cells,0.6486893143639332
express,0.6780077736692338
the,0.6740475572084216
CX3CL1,0.5931950481506575
"receptor,",0.6479578587224
"CX3CR1,",0.6188508122750546
and,0.6998245049675923
CX3CL1,0.6269796586570963
expression,0.685357360970111
is,0.5786902650395054
increased,0.6299656858163728
in,0.6702192522663794
airway,0.5653548988518441
smooth,0.6631398150442415
"muscle,",0.6270952052989123
lung,0.6170389928528129
endothelium,0.6724338929382718
and,0.6055229349434582
epithelium,0.6117928862978108
upon,0.6537048396276736
allergen,0.5913692160350758
challenge.,0.6282562631130373
Here,0.5131088696745474
we,0.4714650287139857
found,0.5585625117753588
that,0.558534675500793
untreated,0.3649548032367452
CX3CR1-deficient,0.46240034441260186
mice,0.45285179096030703
or,0.387501827819224
wild-type,0.27826412563044367
(WT),0.23335293540718816
mice,0.4973997857136766
treated,0.42709306817456805
with,0.35615671007902006
CX3CR1-blocking,0.47050369946328563
reagents,0.4442339386876255
show,0.40093015158254175
reduced,0.4665310326567377
lung,0.2845335637546088
disease,0.400972356331603
upon,0.3782736145377594
allergen,0.24449558543542724
sensitization,0.32799153005201664
and,0.28581503463466934
challenge.,0.24081082636472748
Transfer,0.7201523483250958
of,0.7559435023866193
WT,0.6492408406470054
CD4(+),0.7574100566325375
T,0.7244558094450502
cells,0.763320145602893
into,0.7967394659672979
CX3CR1-deficient,0.7080039267922916
mice,0.800472270371276
restored,0.7957867553834092
the,0.7513534077690428
cardinal,0.700164000322077
features,0.7688525377909841
of,0.7090804371389627
"asthma,",0.6861034270474629
and,0.7880382921812261
CX3CR1-blocking,0.7478125223598352
reagents,0.7853099174395496
prevented,0.7552143273591495
airway,0.6466521322371486
inflammation,0.7087127242894495
in,0.6988373642633514
CX3CR1-deficient,0.6475417500182777
recipients,0.7062697709698761
injected,0.648971051677063
with,0.6345009442422169
WT,0.5718781707185868
T(H)2,0.6246280970234671
cells.,0.6597366935245685
We,0.7999191835420458
found,0.853878241756955
that,0.8791851836922149
CX3CR1,0.7972888463423597
signaling,0.8539916623361781
promoted,0.88503358836287
T(H)2,0.7829751104807176
survival,0.8697248042682608
in,0.895310169395981
the,0.8801734415150247
inflamed,0.8759198728758876
"lungs,",0.8466713452664839
and,0.8886543931430427
injection,0.8609225398371756
of,0.8935582637445295
B,0.8455116269301904
cell,0.8520637917411402
leukemia/lymphoma-2,0.6125203046397387
protein,0.62643412296606
(BCl-2)-transduced,0.5627985111775954
CX3CR1-deficient,0.6515668649837761
T(H)2,0.6354241453327213
cells,0.7360364386431888
into,0.7646243812613517
CX3CR1-deficient,0.6465045264133515
mice,0.7849105624982867
restored,0.7941083295197265
asthma.,0.6535777786680974
CX3CR1-induced,0.5374975924549288
survival,0.523244925554125
was,0.5229743804434839
also,0.547349696170091
observed,0.5693058018952523
for,0.5810678031618014
T(H)1,0.528696186507558
cells,0.5960496241068428
upon,0.5700679286619299
airway,0.6209706546418219
inflammation,0.5903362986364507
but,0.6077687683603092
not,0.6364510858429991
under,0.4946122690259885
homeostatic,0.6448394508777422
conditions,0.5838686485905065
or,0.524847654383025
upon,0.5440767849309197
peripheral,0.518766628280108
inflammation.,0.5377231947037489
"Therefore,",0.16618672022244863
CX3CR1,0.30752765277854344
and,0.162719957398685
CX3CL1,0.26751510833530967
may,0.06977002491943078
represent,0.08207240365169867
attractive,0.06296183912990368
therapeutic,0.050173756377505305
targets,0.05672372588961925
in,0.0932720243919124
asthma.,0.06005930188260482
In,0.0702075281434541
"mammals,",0.03606659840445081
caloric,0.049462152296064356
restriction,0.06511475185398573
consistently,0.041662553491566584
results,0.05565659530802855
in,0.07923308970410925
extended,0.04724542051420134
lifespan.,0.030783664718264887
Epigenetic,0.01499170510053027
information,0.018168060203786363
encoded,0.02007010037411271
by,0.023318575482177407
DNA,0.014189881610767537
methylation,0.006138735105262511
is,0.011850828060442244
tightly,0.012176701702483325
"regulated,",0.012214005023206867
but,0.016816289715587275
shows,0.02310669165518371
a,0.019943168802612904
striking,0.015299072320106908
drift,0.013966301712319657
associated,0.020813462691440562
with,0.017721740273193985
age,0.011473092761738227
that,0.03334231803429203
includes,0.019643035243611457
both,0.029302263704571008
gains,0.014878552963578673
and,0.016673254329384907
losses,0.012900432071964575
of,0.012519791112709849
DNA,0.016388510086178282
methylation,0.009871994117403434
at,0.011156660789512177
various,0.008511405638216394
sites.,0.009641234662239984
"Here,",0.23047159557748959
we,0.2960308794569082
report,0.21828759821626995
that,0.1518518675346227
epigenetic,0.04412731847682968
drift,0.03695842252766613
is,0.04383407368649849
conserved,0.04450567460833583
across,0.03548590320549694
species,0.04380419008711594
and,0.06179819771244549
the,0.036753003463602885
rate,0.02128860606286525
of,0.027634082798677267
drift,0.028412843197249613
correlates,0.0545281996364811
with,0.04046755723212437
lifespan,0.03274315674961333
when,0.08845570554134224
comparing,0.06135029776041963
"mice,",0.07642137168707012
rhesus,0.06567893917005506
"monkeys,",0.06988121700500184
and,0.019898619131709094
humans.,0.04074220300072552
Twenty-two,0.1998545846526467
to,0.2464416217608838
30-year-old,0.23627555931077165
rhesus,0.27641297905015916
monkeys,0.3082134139494489
exposed,0.3681341132951405
to,0.48152854996948885
30%,0.3356438433034171
caloric,0.2573441228308754
restriction,0.3803255471811808
since,0.3515992766244501
7-14,0.33551310506330195
years,0.5829209227587064
of,0.5422835285309732
age,0.5459560092379182
showed,0.6329315034788694
attenuation,0.6170323483787842
of,0.5933930471652124
age-related,0.5512859253368847
methylation,0.480851997843183
drift,0.5575053611475544
compared,0.6230363164476842
to,0.6017881003428331
ad,0.5624536153001424
libitum-fed,0.517409774275157
controls,0.5901396021571914
such,0.6641645555781845
that,0.6493502767096245
their,0.5830252565975705
blood,0.5852280057611365
methylation,0.5081173904494165
age,0.5639889194552897
appeared,0.5807986479945082
7,0.577119820862287
years,0.5388280316517106
younger,0.5372958165780789
than,0.6058546048231286
their,0.525201593397464
chronologic,0.5277699058494678
age.,0.48498097702133974
Even,0.2877053755733399
more,0.2694285005278333
pronounced,0.23255018395598637
effects,0.2747610723175825
were,0.25758776609970185
seen,0.27236962295887757
in,0.31388689409761233
2.7-3.2-year-old,0.23431208450275473
mice,0.28236000904450337
exposed,0.2762652966009953
to,0.30800697915075975
40%,0.1272291482700384
caloric,0.2061856196209563
restriction,0.3082407893302404
starting,0.27433152016337403
at,0.22779269003835093
0.3,0.12678537774401755
years,0.13813429118855194
of,0.16358778653724496
age.,0.14194804814799655
The,0.023004224613976814
effects,0.013552296920641322
of,0.01901181915021942
caloric,0.014229226382439501
restriction,0.030550801844438386
on,0.019147530616989022
DNA,0.01883981655871657
methylation,0.01198620121486678
were,0.023885655679140444
detectable,0.009864902806895108
across,0.01931210678914717
different,0.014377219828662767
tissues,0.011306782080600054
and,0.025258283821369094
correlated,0.019255440591796718
with,0.016740756815046973
gene,0.013166944269581043
expression.,0.011815945708425308
We,0.3744345506400541
propose,0.2546881899692534
that,0.232536360581779
epigenetic,0.12804061357875418
drift,0.1121091792534549
is,0.14286269446490238
a,0.15554081960773816
determinant,0.1331250469973901
of,0.14950133080387637
lifespan,0.11853949432623381
in,0.223934054727088
mammals.,0.1321533948577771
Caloric,0.1972583064701534
restriction,0.24606504666487175
has,0.06715373525615319
been,0.06630392599369904
shown,0.09231873388836025
to,0.07595936177864
increase,0.11218017049136234
lifespan,0.0747463779286234
in,0.1195261120051294
mammals.,0.09176953926709411
"Here,",0.7128052090595154
the,0.62265063800354
authors,0.6743039362842305
provide,0.6787661721063404
evidence,0.7558939921350039
that,0.8311701660075522
age-related,0.7429356049243744
methylation,0.7296499609293736
drift,0.7723793067224896
correlates,0.8611814945145093
with,0.8087429081916838
lifespan,0.8319996021901309
and,0.8443550896765053
that,0.8427715663990847
caloric,0.8315246908192214
restriction,0.8065641388847612
in,0.8406343798850902
mice,0.8046703437547543
and,0.8366642093509788
rhesus,0.8127395707042259
monkeys,0.7994932046800539
results,0.8725304420311919
in,0.852214811542551
attenuation,0.8707978113557246
of,0.805165335499044
age-related,0.730660374777772
methylation,0.6545893830416616
drift.,0.7447737763150407
The,0.0037945989813332032
transition,0.002764980725519935
from,0.00302344798741447
androgen-dependent,0.004252404796770942
to,0.002959511972842317
castration-resistant,0.003065269061858773
prostate,0.0018546418832394041
cancer,0.004090905123007016
(CRPC),0.0014040378299566033
is,0.0014501584346817819
a,0.001497555733524737
lethal,0.0014059933819393889
event,0.0018987184118482404
of,0.0012246027131380657
uncertain,0.001374500092192705
molecular,0.0011798357728570877
etiology.,0.0013850125509599419
Comparing,0.020550287732273322
gene,0.012787247119695564
expression,0.022669741029927467
in,0.025915609332855003
isogenic,0.01412172342584665
androgen-dependent,0.024485442248276795
and,0.02450427645948172
CRPC,0.022488037781184633
"xenografts,",0.011185288173947448
we,0.04257047283777511
found,0.04887205650740442
a,0.03276698841911263
reproducible,0.01847548395956382
increase,0.026279980151732423
in,0.027849131611390323
N-cadherin,0.020468568687229852
"expression,",0.03395986360841238
which,0.029939315035846847
was,0.03123870812843372
also,0.029609774909060294
elevated,0.02371685376179876
in,0.025253374083409736
primary,0.015543179132292103
and,0.02535850660290418
metastatic,0.009798186560784076
tumors,0.0160749567658123
of,0.01774986602001549
individuals,0.019192626187865453
with,0.019210766331874362
CRPC.,0.02361257908768931
Ectopic,0.1118032962913705
expression,0.09966136874098712
of,0.09179557449472639
N-cadherin,0.08617078435559605
in,0.09583062825602423
"nonmetastatic,",0.057732099346011465
androgen-dependent,0.06512655973535669
prostate,0.050322992261133036
cancer,0.07670797904762952
models,0.09935198247003729
caused,0.10750980819032575
castration,0.055051395781350126
"resistance,",0.12986684177940552
invasion,0.11011979727928702
and,0.12682162322428744
metastasis.,0.06837060431300213
Monoclonal,0.2569275331465384
antibodies,0.21415902628774716
against,0.8317709501689867
the,0.8418522888304635
ectodomain,0.8662096130796689
of,0.8761318551513899
N-cadherin,0.7876644327004901
reduced,0.8874824149244536
"proliferation,",0.8257510233641415
adhesion,0.8990407520376765
and,0.8759691173742432
invasion,0.8375296798560237
of,0.8521654168871107
prostate,0.8879427069794674
cancer,0.8064548006862925
cells,0.8566283169481708
in,0.818909848745223
vitro.,0.8022555409664576
In,0.846234237631699
"vivo,",0.803695560720854
these,0.8550091582058712
antibodies,0.8060619683266904
slowed,0.859579827001255
the,0.8530201094556386
growth,0.8176995226683329
of,0.8464733305824297
multiple,0.8139176837923678
established,0.8101631008793367
CRPC,0.7857651584761874
"xenografts,",0.8323106716241134
blocked,0.8805492159873203
local,0.8384631999203477
invasion,0.7895881099766519
and,0.8392937811511708
metastasis,0.8317326560956346
"and,",0.8328741000883172
at,0.7483497439174965
higher,0.7151446916727444
"doses,",0.7494743588142779
led,0.7633893251088447
to,0.7483330914274523
complete,0.7213658620212293
regression.,0.700367035505114
N-cadherin–specific,0.8254749946923263
antibodies,0.8732501331797218
markedly,0.8896760156904994
delayed,0.8937664353441083
the,0.8422044526805618
time,0.8387504250173298
to,0.7950299858010778
emergence,0.8062701912172221
of,0.8776700356081629
castration,0.7927686205734057
"resistance,",0.800011854517738
markedly,0.9022423619763524
affected,0.8846227455715495
tumor,0.7931743864801577
histology,0.8339046409755195
and,0.8245565535082713
"angiogenesis,",0.8412178636942222
and,0.894288710188528
reduced,0.8980853436929565
both,0.9133196438650794
AKT,0.9004895110795955
serine-threonine,0.8877534912415146
kinase,0.8749846927136367
activity,0.8799986389376804
and,0.872796225328801
serum,0.9088559839064705
interleukin-8,0.42367348186341247
(IL-8),0.39742782319645076
secretion.,0.4683501629045853
These,0.3646858910294469
data,0.4192666340035813
indicate,0.45330064329595243
that,0.5721639666872643
N-cadherin,0.4503676214269332
is,0.4890056370365885
a,0.5286587183809754
major,0.5269803055452521
cause,0.4888253960021027
of,0.554270904027247
both,0.6087551816104395
prostate,0.591149005066993
cancer,0.4440957960199243
metastasis,0.5784989011613387
and,0.622824169761056
castration,0.5551229257648258
resistance.,0.5592216232463072
Therapeutic,0.046840603644083455
targeting,0.08847660425654545
of,0.08888033905187269
this,0.069888020358567
factor,0.09367340270910056
with,0.07840571668833848
monoclonal,0.08303362250797972
antibodies,0.07398574180924765
may,0.04505841920445782
have,0.050201868135278986
considerable,0.05482232748048082
clinical,0.029938096369100352
benefit.,0.04682084596364017
CONTEXT,0.0017092382308418173
Dexamethasone,0.000678634486799372
is,0.0010064942828516006
widely,0.0007937601369154065
used,0.0009080492056705669
to,0.000982768882350818
prevent,0.0008174402073868328
postoperative,0.0011956988652064285
nausea,0.000815374359570127
and,0.0021505378067961053
vomiting,0.0010099012544930674
(PONV),0.0007935120804578681
in,0.0013541684796452547
pediatric,0.0010209734304561175
tonsillectomy.,0.0014902160895967187
OBJECTIVE,0.001050206704670739
To,0.0008182887120096808
assess,0.0008259901504117101
whether,0.0009358520455981548
dexamethasone,0.0009212402822020855
dose-dependently,0.0006879888311215916
reduces,0.0006380413917424372
the,0.000873069997021313
risk,0.0005645298283379274
of,0.0011586647822401659
PONV,0.0005851473226877605
at,0.0007508101704175901
24,0.000964456634450868
hours,0.0008348660814638742
after,0.0008187937508425842
tonsillectomy.,0.0012123845716870887
"DESIGN,",0.0012665831366002363
"SETTING,",0.0021365342631034017
AND,0.001569687253569029
PATIENTS,0.0018938151546770729
Randomized,0.0013549047682542468
placebo-controlled,0.0016623273584590876
trial,0.0014092501814353402
conducted,0.0017147366375069157
among,0.001556481262226918
215,0.0011277442826692215
children,0.0015909191864369719
undergoing,0.0012912580086480452
elective,0.0015058187942226576
tonsillectomy,0.0020923991978010273
at,0.002806927336380325
a,0.0032332428711633744
major,0.0013801256325734262
public,0.0015099569561290243
teaching,0.0016458521629128067
hospital,0.0014162856889914294
in,0.0018916495911155374
Switzerland,0.001022887269877701
from,0.002225620555958557
February,0.0019855278779134324
2005,0.001274434015676772
to,0.0017375201566431392
December,0.0017403469093669748
2007.,0.001402581797798144
INTERVENTIONS,0.0023977172687829253
Children,0.0007180270255176782
were,0.0009457391232454433
randomly,0.0006866424281887665
assigned,0.0006191198410558862
to,0.0008775602223389674
receive,0.0006802917186600656
dexamethasone,0.000963493428939923
"(0.05,",0.0008976455180355418
"0.15,",0.001697947785109147
or,0.0008509249854776265
0.5,0.0012146819442322868
mg/kg),0.0008176803491774031
or,0.0008441823261623595
placebo,0.0009289356649571956
intravenously,0.0009492175623002548
after,0.001016981093637969
induction,0.0009606848552590293
of,0.001626000549078937
anesthesia.,0.0012466946598161438
Acetaminophen-codeine,0.0015442858696881592
and,0.002057705908809006
ibuprofen,0.001041009027858251
were,0.0015904860110975553
given,0.0008257438326599977
as,0.0012777372137078406
postoperative,0.0012507745922485333
analgesia.,0.001072314448294705
Follow-up,0.0011224759508563604
continued,0.0013819551364707135
until,0.0013108585438411473
the,0.0017461185021054775
10th,0.0013730370545529517
postoperative,0.0015341932763721572
day.,0.0011289580742410734
MAIN,0.004212337485389686
OUTCOME,0.006565895922761143
MEASURES,0.005928309018603924
The,0.008726750814966726
primary,0.006193828088058892
end,0.003903977694493341
point,0.006433088504882477
was,0.010096806730865606
prevention,0.004186751404958025
of,0.005311145801914836
PONV,0.006234215484046761
at,0.004533219215970185
24,0.004283685345788933
hours;,0.0043987876789258135
secondary,0.011018318910015222
end,0.005750131939238377
points,0.010608435531442991
were,0.014652212005304017
decrease,0.01279527957535804
in,0.006608123569668383
the,0.004223430770470431
need,0.006696784507165766
for,0.009413481057675603
ibuprofen,0.009326356873262238
at,0.008297430814891914
24,0.005076588184622224
hours,0.00485527550097464
and,0.0052163966897557385
evaluation,0.0032707059570215346
of,0.0033026827799046477
adverse,0.04770684577978261
effects.,0.037377925891635765
RESULTS,0.2670520605659659
At,0.567927560888585
24,0.387688271004935
"hours,",0.4913177724493534
24,0.4830221395295649
of,0.6438555225868007
54,0.5831144344002221
participants,0.614216871015274
who,0.536245756758676
received,0.5340021303319556
placebo,0.494092258825566
(44%;,0.6684368339977764
95%,0.74590853932018
confidence,0.7503433758490025
interval,0.7634097640398723
"[CI],",0.6236217101724842
31%-59%),0.7012676636140343
had,0.6700137558642604
experienced,0.6907533073203772
PONV,0.6757658482271031
compared,0.7644490361915015
with,0.6563993542407371
20,0.6628647724537621
of,0.7120532660854022
53,0.7417063683195497
(38%;,0.7041287913740514
95%,0.84392671244779
"CI,",0.7825162511485877
"25%-52%),",0.7753938296398358
13,0.6599306944628551
of,0.711485166143568
54,0.7177884343484998
(24%;,0.6877508091849382
95%,0.8204455184064486
"CI,",0.7724101975233989
"13%-38%),",0.7713138242896223
and,0.6322729924940318
6,0.6795666109305297
of,0.6738514465745091
52,0.6313031968266356
(12%;,0.653559387694017
95%,0.778020945509528
"CI,",0.7538397840999256
4%-23%),0.7471280528521516
who,0.6854177940632553
received,0.68978082871721
dexamethasone,0.6461326776390203
at,0.7216681217388591
"0.05,",0.6936827306809744
"0.15,",0.6537064081861914
and,0.6553797529622899
0.5,0.6372998025628993
"mg/kg,",0.11155988105046004
respectively,0.048583992856094875
(P<.001,0.03938281552832798
for,0.03976312197483165
linear,0.021955041233919597
trend).,0.04101653702279964
Children,0.11485857641001791
who,0.12059340859709465
received,0.12353501646594703
dexamethasone,0.09162898433714028
received,0.13052606748483148
significantly,0.11920849184840183
less,0.163591627820692
ibuprofen.,0.09330509798881169
There,0.13942455491459507
were,0.10890904501414371
26,0.05126321047539801
postoperative,0.045662293250985565
bleeding,0.1339522666834983
episodes,0.14657160049245427
in,0.06399974588229808
22,0.0331190320579502
children.,0.07267450465412793
Two,0.7039794364159411
of,0.7003800689045775
53,0.6851308055235094
(4%;,0.6707529672957282
95%,0.7392104267089014
"CI,",0.7099938997404741
0.5%-13%),0.71873331916832
children,0.6876861267456601
who,0.6612638793982781
received,0.7031528494439442
placebo,0.6691543260597438
had,0.7177657225896547
bleeding,0.7464706080833285
compared,0.7809492972113681
with,0.6947266080513327
6,0.7120002578916798
of,0.726491659414407
53,0.70221238078557
(11%;,0.678443764363618
95%,0.7866896168901912
"CI,",0.740980259313799
"4%-23%),",0.7745784042772226
2,0.6927565354926332
of,0.7242978856259812
51,0.618692455102973
(4%;,0.6559495496297205
95%,0.7573900472040065
"CI,",0.741453049577268
"0.5%-13%),",0.6829950186410465
and,0.578148764381486
12,0.5634518247724557
of,0.7126114465592441
50,0.582639202444142
(24%;,0.6323546972892494
95%,0.7253168000471198
"CI,",0.7287501650026996
13%-38%),0.5227016516960392
who,0.5341248368634337
received,0.5536246443372699
dexamethasone,0.4505221128313217
at,0.529803316199942
"0.05,",0.5005687137475777
"0.15,",0.4555170905340101
and,0.4677171889226999
0.5,0.4251671408833622
"mg/kg,",0.45284945968320317
respectively,0.43309245727859746
(P,0.46701745836154307
=,0.4798688696512219
.003).,0.4747452027593469
"Dexamethasone,",0.37015163553134756
0.5,0.3666204969323579
"mg/kg,",0.41850522761452685
was,0.4833559751995533
associated,0.5381569829564633
with,0.527739996669545
the,0.4441601493810552
highest,0.44467751168393266
bleeding,0.4959333173828212
risk,0.5370642506657684
(adjusted,0.33858551672413667
relative,0.3652619568264828
"risk,",0.5204518595570821
6.80;,0.3911901107997338
95%,0.2167868670347722
"CI,",0.4946015190890062
1.77-16.5).,0.3948532909307312
Eight,0.006855854491096825
children,0.003873626068512505
had,0.006828789510148948
to,0.007018272429556191
undergo,0.004508131783276256
emergency,0.003979615445204718
reoperation,0.004508079354710013
because,0.00680833432142325
of,0.007742544903720434
"bleeding,",0.0040712048124555734
all,0.003804055106718427
of,0.005361102572593169
whom,0.005962425049614933
had,0.005995001239692352
received,0.006974606276683354
dexamethasone.,0.006390869920472233
The,0.005187367300767818
trial,0.0032218985214936707
was,0.004566700098319362
stopped,0.0029932443577816983
early,0.004775834228670357
for,0.004226052616337288
safety,0.001805540214322828
reasons.,0.0045490506265518735
CONCLUSION,0.684229743861755
In,0.34966957635024815
this,0.26990875984972923
study,0.27768436659154117
of,0.9359350464912239
children,0.8837973209183527
undergoing,0.8652655026549865
"tonsillectomy,",0.865791690535247
dexamethasone,0.9274614635661422
decreased,0.9544717115620723
the,0.9550300562554275
risk,0.9498242779324509
of,0.9599227277022353
PONV,0.9314367947941858
dose,0.940101032611802
dependently,0.962531577376578
but,0.9552820410691001
was,0.9606036796016802
associated,0.9620933551594517
with,0.9568493795237892
an,0.9550611587744234
increased,0.9543782299370736
risk,0.9573389067246115
of,0.9625971413014693
postoperative,0.969609052581478
bleeding.,0.9247894351993131
TRIAL,0.007225690026337907
REGISTRATION,0.010813688748598636
clinicaltrials.gov,0.006365165855562876
Identifier:,0.009286337286774311
NCT00403806.,0.0050696506431962725
It,0.005282253333889886
is,0.002346623330121487
unclear,0.0025565791872525644
how,0.0031635962445308286
the,0.005816866159126714
immune,0.007929525238558029
response,0.016066679720018805
in,0.006834737762045872
early,0.009682345797795476
life,0.006134125731524767
becomes,0.004585271890239288
appropriately,0.006594608693150472
stimulated,0.008063909826779158
to,0.006021963241948752
provide,0.007121951359544182
protection,0.008438901095259237
while,0.01977600362612213
also,0.008987972515688626
avoiding,0.010223485750252972
excessive,0.009792149845147324
activation,0.01250157490206511
as,0.009177859833902348
a,0.005380073670015473
result,0.011868108853176145
of,0.01094521746580335
diverse,0.005140746186474924
new,0.010748831273571801
antigens.,0.007308464873996412
T,0.019271987329337093
cells,0.015217468420761137
are,0.011213081448990888
integral,0.010686574017792425
to,0.013991291737238782
adaptive,0.009389728986602924
immunity;,0.011582247367667876
mouse,0.007159779784268385
studies,0.008746709164637234
indicate,0.009202759055199126
that,0.0081982458107412
tissue,0.0063541193637248455
localization,0.005670697074072629
of,0.005199268494943388
T,0.00727542682919992
cell,0.0065358612730806774
subsets,0.007011772141250073
is,0.005404775968395247
important,0.007964345514398926
for,0.005762826352911375
both,0.009297227630938367
protective,0.005804865157257817
immunity,0.005964457398565919
and,0.00849425836893887
immunoregulation.,0.004400799149270012
In,0.0043441605230550105
"humans,",0.0044159951055499505
"however,",0.002708593047106421
the,0.004474248889654982
early,0.010840648048024148
development,0.009093472103196007
and,0.005630666870716745
function,0.005226208179415042
of,0.00581806582230373
T,0.005946072643471277
cells,0.007619607262531273
in,0.004729618156494624
tissues,0.002671199657118082
remain,0.0032139039478260197
unexplored.,0.0022422225280269653
We,0.27930616972509537
present,0.13763379137270082
here,0.203809910410726
an,0.1157962143471092
analysis,0.15221583742093228
of,0.1349231081378973
lymphoid,0.11928514674539313
and,0.1174693277878568
mucosal,0.10515387646992025
tissue,0.16236701725791167
T,0.14985315592450996
cells,0.19753648607607774
derived,0.12000947466754903
from,0.16232319035336207
pediatric,0.12324987446294818
organ,0.1515034994709452
donors,0.16349461482909258
in,0.14877724620180188
the,0.13308464763698452
first,0.14212809137986135
two,0.13424280393029683
years,0.18642578452383812
of,0.06660004370507758
"life,",0.05467307786791658
as,0.04791584126812025
compared,0.05603172431526003
to,0.05616606363244995
adult,0.04078720448032187
organ,0.02478578707208422
"donors,",0.03768635537707294
revealing,0.05729138541095435
early,0.04254133952897674
compartmentalization,0.013988313758821192
of,0.030651122744050848
T,0.025588667189804692
cell,0.031162306474366637
differentiation,0.027724389697799407
and,0.027405620655406224
regulation.,0.023038245934561323
Whereas,0.7177617017321081
adult,0.616280332527491
tissues,0.6000721374634466
contain,0.5934714047540497
a,0.6022397576552205
predominance,0.6304391260884118
of,0.6470124278842518
memory,0.6387483436971284
T,0.6814734028657474
"cells,",0.6932437373087729
in,0.6710256005742775
pediatric,0.6247448260617372
blood,0.6597182987159326
and,0.6743560333689336
tissues,0.6812318880330341
the,0.6458803291002936
main,0.5924756683383964
subset,0.5878342184891223
consists,0.5876375479943419
of,0.6799020448803152
naive,0.7018550036008407
recent,0.6483034235437877
thymic,0.577251394969684
"emigrants,",0.6594689428844599
with,0.5951509131409776
effector,0.6895348958903059
memory,0.6652019897025692
T,0.6646402933183799
cells,0.6818847485584537
(T(EM)),0.5441329798398705
found,0.6632622803436561
only,0.6497766836965525
in,0.6512840424346454
the,0.7223746526007916
lungs,0.620021231602919
and,0.6432198045296438
small,0.6579399097733309
intestine.,0.7670123104679222
"Additionally,",0.5966848654982302
regulatory,0.4910195591748549
T,0.4760109432889513
(T(reg)),0.509275795584115
cells,0.5836870884382193
comprise,0.5086386998861777
a,0.5016256071159761
high,0.48598039078603283
proportion,0.5142723322000556
(30-40%),0.5043615710064558
of,0.5955972406020672
CD4(+),0.5552607110842699
T,0.48461879475411
cells,0.5811784689290457
in,0.5008367450547186
pediatric,0.4462939371921139
tissues,0.5170085195453858
but,0.4802593986219599
are,0.06908148280119324
present,0.0510184320598695
at,0.04850780934636601
much,0.04433174006915618
lower,0.0421820617182125
frequencies,0.051667458849566604
(1-10%),0.06779304098519612
in,0.05893816689236231
adult,0.04826600553361689
tissues.,0.060823638007444496
Pediatric,0.32145940833142633
tissue,0.4233889162168771
T(reg),0.4296960891933232
cells,0.4881508331374667
suppress,0.5473374146343468
endogenous,0.633173451630984
T,0.47047875328755956
cell,0.5569158309960676
"activation,",0.6587642716401427
and,0.48452661030067673
early,0.3661371276031912
T,0.35431194294877233
cell,0.3642497436189752
functionality,0.37528394959107086
is,0.25782602257016757
confined,0.27287751690882495
to,0.3224025819833428
the,0.34142935351917697
mucosal,0.38055986283803395
sites,0.3667452182937161
that,0.25488697632995655
have,0.2019882547238112
the,0.20167066960806687
lowest,0.16925450276086035
T(reg):T(EM),0.26994281749389415
cell,0.27981221676313517
"ratios,",0.23456410519724966
which,0.17397113400647168
suggests,0.12734871513725762
control,0.10203052941413743
in,0.07282537206574217
situ,0.061627789518396425
of,0.09088381610423658
immune,0.12773294639412155
responses,0.11861578943222259
in,0.10965378605654798
early,0.16872497413277254
life.,0.12129773617326897
BACKGROUND,0.043277801203713835
Emerging,0.0069021644018427
evidence,0.010392201055811592
suggests,0.010361582974705663
an,0.009973956708995285
association,0.008226870065882665
between,0.00635416301797984
female,0.01189456569844362
prenatal,0.015180816311197626
experience,0.016934779513328113
and,0.006984567235671324
her,0.011713872605471472
subsequent,0.0093349761190846
risk,0.008294608192997122
of,0.01804032466981254
developing,0.012131707910545093
breast,0.011532031222626303
cancer.,0.006792926306876565
Potential,0.0032378302238170813
underlying,0.0025060776743015102
mechanisms,0.0030777515394644836
include,0.00414671722393785
variation,0.002896190026993918
in,0.0025113894527062012
amounts,0.002576805738967638
of,0.003045351176359226
maternal,0.0036265841673625014
endogenous,0.0041209057345170785
sex,0.0027391476706811104
hormones,0.0035067028592780073
and,0.004375847138025434
growth,0.004773643101647661
"hormones,",0.0034457591760059395
germ-cell,0.002982933839062539
"mutations,",0.002823786714245578
formation,0.0028276932607847398
of,0.002473698954758745
cancer,0.001613130010465921
"stem-cells,",0.0021463705579719953
and,0.0021897648457199713
other,0.0015074923644600707
genetic,0.001336955270406925
or,0.0019708588923592826
epigenetic,0.0014197714582892982
events.,0.001971852406447563
We,0.003061112428251791
reviewed,0.00119331685925319
and,0.0014395606902631239
summarised,0.0014011963276233583
quantitatively,0.0008462400580626633
the,0.0009967330320822382
available,0.0010839733423579825
data,0.0010295741262054809
on,0.001291594108699272
intrauterine,0.001579821920309066
exposures,0.0008780160544347241
and,0.0011433738628786002
risk,0.0006805746137343416
of,0.0015066772265568181
breast,0.0018378087327766345
cancer.,0.0008806901432855261
METHODS,0.00865530776523003
We,0.009847833557364044
systematically,0.003126456165045542
searched,0.0021044511490268037
for,0.0022512956034890694
studies,0.0042214148368918914
that,0.002651221193744043
assessed,0.0035738560571323377
association,0.0030043251627729782
between,0.004389880761924809
perinatal,0.004519861053971938
factors,0.003727907246699676
and,0.0039405320625303265
risk,0.0020899239904100114
of,0.004887681506172967
breast,0.009571818246180645
cancer.,0.004257854744946918
We,0.016206875997397254
reviewed,0.006374544400512694
separately,0.004975452175341587
each,0.0030999518560000934
of,0.0028281773352372905
the,0.0032235443985919304
perinatal,0.0021184358650038998
"factors,",0.00307440658152316
including,0.0025583684817475543
"birthweight,",0.007763679853232412
birth,0.013320753670476053
"length,",0.011645958533275018
parental,0.006870859226651721
age,0.005091012070114887
at,0.01314696223635905
"delivery,",0.012678921817132505
gestational,0.003547634194953618
"age,",0.004824840231737006
intrauterine,0.005384974993619934
exposure,0.004242652677426576
to,0.004597074380936213
"diethylstilbestrol,",0.002825990244621625
twin,0.002120163791251905
"membership,",0.0033590134339298258
maternal,0.0023140068842606677
pre-eclampsia,0.0032682026238852325
or,0.0026757328323441187
"eclampsia,",0.003379863372073903
and,0.0017199116760596893
other,0.0013073761296331305
factors.,0.0013089824639483001
FINDINGS,0.005122892912519998
We,0.006321585260839199
identified,0.0024861748990232884
57,0.001572134729686396
studies,0.0025547978240624703
published,0.0025633183437618603
between,0.0014497511046881082
Oct,0.0015224248361967558
"1,",0.0021035531125369426
"1980,",0.0014188638282715803
and,0.0013261627773327844
June,0.0014428652460445868
"21,",0.0012627688884689003
2007.,0.0014860657904683656
Increased,0.856795134300505
risk,0.8536894670570437
of,0.899420225824263
breast,0.8506724618305173
cancer,0.8233354822716532
was,0.8602550634883896
noted,0.8844394976691192
with,0.8743890769385415
increased,0.8644247678495285
birthweight,0.8958607663365799
(relative,0.8582510941799443
risk,0.8654082569479249
[RR],0.8275585468057636
1.15,0.8672057855734092
[95%,0.8196955383282573
CI,0.8346317877316518
"1.09-1.21]),",0.8257784229110625
birth,0.8822330074431413
length,0.85365669925728
(1.28,0.8186329741423718
"[1.11-1.48]),",0.40576091086492583
higher,0.4843760109269674
maternal,0.4113017672012678
age,0.4233722404843852
(1.13,0.4305895430297354
"[1.02-1.25]),",0.426333761241125
and,0.40581930127632276
paternal,0.4087920218568379
age,0.3967271532709987
(1.12,0.382102651670127
[1.05-1.19]).,0.39601180133147645
Decreased,0.2604033737432626
risk,0.2305803536642896
of,0.33546025875329205
breast,0.22408378169541673
cancer,0.1830395445513161
was,0.28624914838798354
noted,0.284906278067514
for,0.2782988775913061
maternal,0.23533618217130317
pre-eclampsia,0.22572787068009376
and,0.24748212645763062
eclampsia,0.20967466732250312
(0.48,0.2598865910695044
[0.30-0.78]),0.19776956531831855
and,0.30136574690377455
twin,0.19463109289695898
membership,0.21186196587220257
(0.93,0.2405082001092224
[0.87-1.00]).,0.1899887027524447
No,0.2359203297414845
association,0.20155462222835066
was,0.19669326997964004
noted,0.17813460187678615
between,0.1350892158902539
risk,0.250058512117241
of,0.2931815347788672
breast,0.3115187611513284
cancer,0.2595943825996298
and,0.14229645975233796
gestational,0.26571898798622196
age,0.23215787399026974
at,0.24633362572275028
birth,0.3341070782961158
(0.95,0.32187062698166286
[0.71-1.26]),0.11841509747347535
or,0.035503766285933554
maternal,0.03882293534440717
diethylstilbestrol,0.03771594191971037
treatment,0.040232252804051065
(1.40,0.05436608534048227
[0.86-2.28]).,0.06314468231527463
INTERPRETATION,0.060915620672523776
The,0.03202760639475227
intrauterine,0.05084861152899335
environment,0.05326819121174587
contributes,0.02600484035726938
to,0.030211010409008063
the,0.02244995157064194
predisposition,0.020876358520642332
of,0.03265638662338664
women,0.035089633358494215
to,0.0424266433173494
breast,0.03838165670577813
cancer,0.023092060460787236
in,0.03145794061102381
adulthood.,0.03279091624290948
The,0.007948611128853655
in-utero,0.009912095033231006
mechanisms,0.00754281539688046
responsible,0.006282666897992642
for,0.007799092926915277
such,0.007081135655598975
predisposition,0.007287918351332223
need,0.005879378021041205
to,0.003976324287824696
be,0.003775211700976407
elucidated.,0.004504465387314982
Mutations,0.0031803885050519028
in,0.0030313816475879907
cancer,0.0015547123095533265
reprogram,0.002048247817199552
amino,0.0022575857304880102
acid,0.0024352807648631413
metabolism,0.001998289737691906
to,0.0018540893814328217
drive,0.0021089330243541093
tumor,0.001405276209044313
"growth,",0.0017156825212604635
but,0.0012050882169045902
the,0.0009735780941603009
molecular,0.000962329682098224
mechanisms,0.0012112669337609738
are,0.0012376365041474652
not,0.0011735421724354458
well,0.0011024262908154482
understood.,0.001322223494724689
Using,0.02633628975371486
an,0.009884082395205666
unbiased,0.0030095206836600876
proteomic,0.004570684844223027
"screen,",0.008111397011444988
we,0.04146746559978515
identified,0.04785231823679548
mTORC2,0.05222521584881081
as,0.07417930131955144
a,0.10532016931992212
critical,0.06419839761901387
regulator,0.0734614475621416
of,0.07384855527125532
amino,0.04996581206279019
acid,0.047602505482772714
metabolism,0.10706580408543928
in,0.09148242542400423
cancer,0.05201674684022448
via,0.1387381837121024
phosphorylation,0.06441672424921514
of,0.17716875054699188
the,0.1377788549107751
cystine-glutamate,0.20272004530523705
antiporter,0.11309445654139415
xCT.,0.05852008607106289
mTORC2,0.36092560273154156
phosphorylates,0.35205663849485674
serine,0.26598862039843313
26,0.29262507564898926
at,0.28026703678535364
the,0.26930023202691283
cytosolic,0.3750334821555434
N,0.2872806572853762
terminus,0.3530431353443534
of,0.33432563884337146
"xCT,",0.299457034725823
inhibiting,0.24502201590591874
its,0.16118913962166523
activity.,0.24570712486722382
Genetic,0.07856258918546183
inhibition,0.10005238680042025
of,0.1658327629706777
"mTORC2,",0.16973633514469055
or,0.14925560042016717
pharmacologic,0.08211092160793038
inhibition,0.11219903172737447
of,0.1443273094350646
the,0.17094679185192604
mammalian,0.5092082861292757
target,0.604707935899295
of,0.6016190167060671
rapamycin,0.4846535072648182
(mTOR),0.5466846062614134
"kinase,",0.602761958603708
promotes,0.6548929777964952
glutamate,0.6984884840226666
"secretion,",0.7585482860154449
cystine,0.7048828829742776
"uptake,",0.7771956231788386
and,0.6976808211392522
incorporation,0.6596293619409507
into,0.7044931402468019
"glutathione,",0.675761479723028
linking,0.6823046933953578
growth,0.7087702024631218
factor,0.692468723337788
receptor,0.6888786280979663
signaling,0.7271417184342568
with,0.5577702309947736
amino,0.544532864636082
acid,0.5380109219404162
uptake,0.6284523322301178
and,0.517337046732916
utilization.,0.5943559948885301
These,0.28940198501104925
results,0.2509602346766949
identify,0.22288420158864974
an,0.21759491487331464
unanticipated,0.15021980311185174
mechanism,0.24623022487223833
regulating,0.20859769676288148
amino,0.18374053356451242
acid,0.19701876036953686
metabolism,0.23780014525669269
in,0.20144362979476113
"cancer,",0.15331874285603375
enabling,0.23969857193882768
tumor,0.19264873279999775
cells,0.25210783382727037
to,0.19406837379230285
adapt,0.1962787964762696
to,0.1723021030274671
changing,0.11072268344250803
environmental,0.11977907292454255
conditions.,0.15336936779900007
CONTEXT,0.0025630391730430226
A,0.000904014043438138
number,0.0008751232407909269
of,0.0010257138133581004
countries,0.0005566119990553008
have,0.00096714974649816
implemented,0.0007566433759606225
a,0.0006617642919673141
policy,0.0005415658194167224
of,0.0008875025544482641
universal,0.0005074377306112451
leukoreduction,0.0007816688294973382
of,0.0008777837177917512
their,0.0007705927449038905
blood,0.0005253332854082575
"supply,",0.0005225971624204599
but,0.0007275031846549274
the,0.000624980706460234
potential,0.0007426274458459286
role,0.0006880466960668473
of,0.0008613913267313126
leukoreduction,0.0008272754581020508
in,0.0008631989332148521
decreasing,0.0005117577782726348
postoperative,0.0007214782029358296
mortality,0.0005299239134067034
and,0.000867429092173379
infection,0.0005098562133096014
is,0.0006327547281768461
unclear.,0.0005660834965999879
OBJECTIVE,0.001109959741331127
To,0.0009250203758014485
evaluate,0.0007690690524458382
clinical,0.000513102333362614
outcomes,0.0005429171004241286
following,0.0008959634502331344
adoption,0.0006695249606873359
of,0.0012303342579763777
a,0.0009729301683765117
national,0.0006985766292793647
universal,0.0006088206836914867
prestorage,0.0008296465017006943
leukoreduction,0.0008863555544975713
program,0.0008076844620593219
for,0.0008490763101251759
blood,0.0006262383558114341
transfusions.,0.0007789250645563642
"DESIGN,",0.0016227920690603259
"SETTING,",0.002930363804228017
AND,0.001757870097508408
POPULATION,0.0029194196554823476
Retrospective,0.00343794368513982
before-and-after,0.004452703390505176
cohort,0.002265807604486012
study,0.0020980181742191848
conducted,0.0017883835116980662
from,0.0030279098749515544
August,0.001615380161284341
1998,0.001578688869748685
to,0.0013701893692662974
August,0.0016888918760571468
2000,0.0012386392194859888
in,0.0015549162458088383
23,0.001201646921005242
academic,0.0014332352435034107
and,0.0017322542971660345
community,0.00143953498619744
hospitals,0.0011201302747550898
throughout,0.0015542427285347212
"Canada,",0.002095147985378836
enrolling,0.0010630144969618336
14,0.0016771490864761261
786,0.0011085791521081724
patients,0.0010787309568252208
who,0.0016673163140621132
received,0.001458743674360503
red,0.0014448407444911098
blood,0.002645384206333516
cell,0.0024529813333618597
transfusions,0.0025689661680657495
following,0.0017119412243192275
cardiac,0.0013957009969542981
surgery,0.0020809854251882796
or,0.0017721654313695855
repair,0.002350552187161382
of,0.0027493276793794756
hip,0.001464273154024605
"fracture,",0.0016577300857381154
or,0.0014246794998893086
who,0.0016843916411741536
required,0.0018778087106802992
intensive,0.0013674097644817867
care,0.0013678688952745053
following,0.0016415601973881605
a,0.002091714305212585
surgical,0.0016136765060575404
intervention,0.0019590250316051266
or,0.0013284081663771311
multiple,0.0015033512837933371
trauma.,0.0013586417048573325
INTERVENTION,0.0014829391949338036
Universal,0.001085354856649728
prestorage,0.0015802533243356738
leukoreduction,0.0010769969095540146
program,0.0009705921842099032
introduced,0.0009231201501608807
by,0.0012526004586348696
2,0.001118353723246793
Canadian,0.0011694821361987607
blood,0.0008293248076867838
agencies.,0.0008177152174698501
A,0.0008876573195401589
total,0.0008066639791977239
of,0.0012949349427793715
6982,0.0008705438551806893
patients,0.000669281895828989
were,0.0009369851421329318
enrolled,0.0006600384543280484
during,0.0009715749758623365
the,0.001020588807101161
control,0.0006578555049839692
period,0.0009180800907444971
and,0.001189310267961605
7804,0.0009149597160401491
patients,0.0006312539853243836
were,0.000863479039882598
enrolled,0.0005983042882785969
following,0.0007038106061406722
prestorage,0.000993863642477352
leukoreduction.,0.0009077133550611302
MAIN,0.002349117419560079
OUTCOME,0.0034273222104323838
MEASURES,0.003809552384195664
All-cause,0.0044271126595468845
in-hospital,0.0048809823248909985
mortality,0.004395368401784883
and,0.0069459195737691095
serious,0.005003238709765959
nosocomial,0.006159814746894294
infections,0.004424189152544167
"(pneumonia,",0.013471050788830033
"bacteremia,",0.005974401512786437
septic,0.005757221441804247
"shock,",0.007774262346462327
all,0.006174818259803728
surgical,0.006989826057018021
site,0.005443289056197127
infections),0.07657097505481769
occurring,0.06863655450910056
after,0.0770937587619903
first,0.07745868750802581
transfusion,0.02185243705111746
and,0.065580799452294
at,0.053651555229741965
least,0.03286033082616739
2,0.05606489910161849
days,0.04356139463151094
after,0.0494002290913508
index,0.03855733542975559
procedure,0.05069197957795417
or,0.039682894883357404
intensive,0.02160072557871768
care,0.015727651371413277
unit,0.022210738599147725
admission.,0.038768261698048936
Secondary,0.006312231795914784
outcomes,0.01167794799454488
included,0.01087542931829919
rates,0.009304780596480423
of,0.011785433297182853
posttransfusion,0.007574726290592302
fever,0.0059721195179832254
and,0.010697100334540077
antibiotic,0.0037179039902379787
use.,0.0060531612466782955
RESULTS,0.5025960495242262
Unadjusted,0.45735674360078327
in-hospital,0.48796896846920373
mortality,0.4864298349248732
rates,0.5173240624847005
were,0.4591718477189506
significantly,0.46383323595662324
lower,0.43267856712819386
following,0.48839914822510927
the,0.46980455202211785
introduction,0.4231793054329615
of,0.5435623035423353
leukoreduction,0.5511694824232292
compared,0.6380747278171232
with,0.511434617695059
the,0.5398065013287072
control,0.5647288960656658
period,0.5613229669632758
(6.19%,0.531195855920875
vs,0.5468157205326901
"7.03%,",0.6153644849190081
respectively;,0.5660871763674485
P,0.6487284759778709
=.04).,0.641899343814906
Compared,0.755946262531479
with,0.66229962244821
the,0.6639690704087097
control,0.6762429700920614
"period,",0.6937971869234112
the,0.6731284309952169
adjusted,0.7039649655661595
odds,0.7002720082183923
of,0.6945849656867251
death,0.650328095722325
following,0.6649392106207085
leukoreduction,0.678016335823056
were,0.6224500303010874
reduced,0.6464220077998339
(odds,0.7046014934274277
ratio,0.7036613248521668
"[OR],",0.6746438770975075
0.87;,0.6805722900089665
95%,0.7616460555162163
confidence,0.7610627844613466
interval,0.7382524036688751
"[CI],",0.5121315670471598
"0.75-0.99),",0.3697095642551835
but,0.589029106962378
serious,0.5992904446956865
nosocomial,0.6123948741594827
infections,0.5729737996798243
did,0.532486838211904
not,0.5559376647887792
decrease,0.490837020456175
(adjusted,0.5121719011418278
"OR,",0.620049600655653
0.97;,0.486204675761012
95%,0.615710147389603
"CI,",0.5833504768269088
0.87-1.09).,0.49039556614506474
The,0.2770926359055963
frequency,0.2984030613930296
of,0.2906090562244171
posttransfusion,0.47427817759257285
fevers,0.34773195035601534
decreased,0.2791210410874847
significantly,0.3013292167832964
following,0.31895626802425525
leukoreduction,0.3763460559332971
(adjusted,0.29935002383299625
"OR,",0.4326416205130915
0.86;,0.2996874656301086
95%,0.3750556690601851
"CI,",0.45595801263716956
"0.79-0.94),",0.32905814071392187
as,0.38059031851346337
did,0.3027641471458808
antibiotic,0.2645786380362927
use,0.3170943047816634
(adjusted,0.27500697028794036
"OR,",0.42925074209286435
0.90;,0.26889083352212095
95%,0.42005742213981156
"CI,",0.3986366773961032
0.82-0.99).,0.1911988681113104
CONCLUSION,0.705376494089685
A,0.2833930961302204
national,0.2501797417492238
universal,0.2750513854808187
leukoreduction,0.8110697072873142
program,0.8936305459520815
is,0.8567303772442981
potentially,0.7966475083646503
associated,0.8484882711551706
with,0.8533816600834988
decreased,0.869286469392808
mortality,0.8074025192676904
as,0.8358821170843623
well,0.8719984440334295
as,0.8520038486705309
decreased,0.8814349811027371
fever,0.7730732893391704
episodes,0.8495118747538483
and,0.8641898470457532
antibiotic,0.8529417896800262
use,0.8479200567943128
after,0.8436609438231721
red,0.8253572011815017
blood,0.8224631636022754
cell,0.8500716836336921
transfusion,0.854930705308701
in,0.8290681257536334
high-risk,0.7362314931101254
patients.,0.7981351653216492
The,0.004549926302034797
signals,0.005018170634064406
and,0.0034227332301438665
molecular,0.003146173700235357
mechanisms,0.004131179489978642
that,0.003537412831627564
regulate,0.007060959570766778
the,0.0036451494967317337
replication,0.003344703338539902
of,0.007561330044276136
terminally,0.003371406062818335
differentiated,0.0051545603287526075
beta,0.013221600787307622
cells,0.012100750625082408
are,0.001962745190079892
unknown.,0.0024269631429363996
"Here,",0.06910864929654426
we,0.10928379761450148
report,0.07115331238929748
the,0.03821152173930163
identification,0.038909655899464504
and,0.02488715376999916
characterization,0.03659878180670539
of,0.030986731107651943
transmembrane,0.03040440776677461
protein,0.029186019171197935
27,0.028158386149017816
"(Tmem27,",0.03878356411085277
collectrin),0.10362639355785414
in,0.04373249490161152
pancreatic,0.07822189204768122
beta,0.04125284588368683
cells.,0.040615648966806736
Expression,0.010824943931595516
of,0.013685486529392844
Tmem27,0.025210883428649918
is,0.00903047662203545
reduced,0.012308636032169437
in,0.014806569665504372
Tcf1(-/-),0.02719699781487993
mice,0.013151412649987879
and,0.02050917043855804
is,0.008130530594792582
increased,0.010159805771843835
in,0.012409602850594025
islets,0.0065797964814115996
of,0.00888182621204251
mouse,0.00890093710088426
models,0.009769941375914797
with,0.006665692590991883
hypertrophy,0.008448718220608397
of,0.009053086543713623
the,0.011275707382775965
endocrine,0.014623081912398719
pancreas.,0.022487293571937874
Tmem27,0.26444124577353345
forms,0.2242788100509389
dimers,0.1657432142520011
and,0.3018592723414626
its,0.2062038828480931
extracellular,0.33476292684114695
domain,0.36852359154953757
is,0.2276739208300938
"glycosylated,",0.2725282729439326
cleaved,0.23815457617329253
and,0.3115078695469181
shed,0.22073397110397824
from,0.3338205799959135
the,0.28146450836924164
plasma,0.3049016447027267
membrane,0.4013945194203232
of,0.3627582648818063
beta,0.2759483614037814
cells.,0.35580903306191675
This,0.17363394174312077
cleavage,0.09533902327973988
process,0.16704311980017905
is,0.105558751236969
beta,0.07606333984837636
cell,0.12051535204588955
specific,0.09337515192903705
and,0.20619351695390756
does,0.10216961207843665
not,0.0895577359505827
occur,0.13851029668208856
in,0.08716023912326382
other,0.0760848399573411
cell,0.12489777403298882
types.,0.057121379032233174
Overexpression,0.7474780354272826
of,0.6758690705276171
full-length,0.7227057256482499
"Tmem27,",0.5898071117215569
but,0.8026067390209827
not,0.8071823186708503
the,0.693400318801156
truncated,0.703339153912784
or,0.6474472804812544
soluble,0.6423224483719849
"protein,",0.6077150396280246
leads,0.8011813972706944
to,0.8039684273762184
increased,0.7933975893651832
thymidine,0.6584891617672955
"incorporation,",0.728135844378005
whereas,0.8314191442933695
silencing,0.7289694005922892
of,0.7194266999377402
Tmem27,0.6919272544115858
using,0.7358080909996428
RNAi,0.6704774996571813
results,0.7800597661974948
in,0.7714032721361153
a,0.7691164270341178
reduction,0.7257949502669226
of,0.7090215809007262
cell,0.7041583007600385
replication.,0.6280647152390276
"Furthermore,",0.6986684930993555
transgenic,0.6358703940319694
mice,0.6094202855709907
with,0.6091799037069081
increased,0.6054082499697283
expression,0.582421049977931
of,0.5824345024395343
Tmem27,0.522925918943936
in,0.640688183059127
pancreatic,0.7724878306099832
beta,0.5782782031731438
cells,0.5898766191080278
exhibit,0.6005077228905407
increased,0.595237653742516
beta,0.56813286633739
cell,0.5644235064885524
mass.,0.5927028965337814
Our,0.3660317224130524
results,0.34763849803125424
identify,0.34025175937112995
a,0.35318546148679897
pancreatic,0.5135178696662804
beta,0.4550648285023574
cell,0.4518055035706019
transmembrane,0.3774517194824429
protein,0.39314664589443843
that,0.38011083430149817
regulates,0.4422504588280341
cell,0.48368277753727723
growth,0.4789402246082343
of,0.4259971144811036
pancreatic,0.5580859785640339
islets.,0.4313838589949856
The,0.02293063678407617
PI3K,0.03161286928494039
signaling,0.023184437623459644
pathway,0.022650003965544882
regulates,0.014822701821372849
cell,0.020677443373796872
growth,0.019277028214937438
and,0.015461004938351168
movement,0.009950320645008674
and,0.012879906460881824
is,0.006925512780834379
heavily,0.006531343961239382
mutated,0.005227465196092144
in,0.00883572158847587
cancer.,0.009615957542863323
Class,0.03738177353704696
I,0.04445199050656133
PI3Ks,0.04749251983335447
synthesize,0.048482687517548785
the,0.07343706882557685
lipid,0.08708508332492952
messenger,0.14455651252750712
"PI(3,4,5)P3.",0.10052218023135709
"PI(3,4,5)P3",0.15384640965944105
can,0.07430284618502676
be,0.05625586735283207
dephosphorylated,0.08117341455508346
by,0.15150841866147113
3-,0.15334779906421606
or,0.07105464096089145
"5-phosphatases,",0.10924700117545032
the,0.06040837803792549
latter,0.0767093468025563
producing,0.1075618292251535
"PI(3,4)P2.",0.1549562384550923
The,0.11408425015307708
PTEN,0.11211006921985091
tumor,0.15790130070183106
suppressor,0.13451032764263143
is,0.09389352191339481
thought,0.08966522906747741
to,0.07944519743782323
function,0.15097484770796046
primarily,0.13153340430210594
as,0.14294028328275413
a,0.1816120252545855
"PI(3,4,5)P3",0.19395598296875055
"3-phosphatase,",0.15055473568495714
limiting,0.16770673243974804
activation,0.12438689144986922
of,0.11101662011521288
this,0.11552841980470606
pathway.,0.15786756461083037
Here,0.36338792188651625
we,0.5248110270705506
show,0.4114826998030255
that,0.25886902084937224
PTEN,0.21783566477924787
also,0.1969054883565187
functions,0.19199014497822467
as,0.22521286641594276
a,0.22289594528174791
"PI(3,4)P2",0.21382100497001982
"3-phosphatase,",0.24117282433049078
both,0.24417837742577175
in,0.311547576330865
vitro,0.3331608031113883
and,0.24372939183865572
in,0.27330971622044176
vivo.,0.2435373855228797
PTEN,0.5483675367414164
is,0.6016664477091027
a,0.6090590333948946
major,0.6011302889670295
"PI(3,4)P2",0.561236184470437
phosphatase,0.6124376777839209
in,0.6277127699162843
Mcf10a,0.5968519401173333
"cytosol,",0.5902114692031047
and,0.7188945905848412
loss,0.619901416761892
of,0.6371870809637329
PTEN,0.643069394695058
and,0.6758412833484012
"INPP4B,",0.6461429107356257
a,0.5826236284438536
known,0.51395508591569
"PI(3,4)P2",0.5262107270142249
"4-phosphatase,",0.5778539628567065
leads,0.6626854764435783
to,0.7049575202928258
synergistic,0.6931324429401303
accumulation,0.6196237997251095
of,0.5890840797397975
"PI(3,4)P2,",0.5971105156104802
which,0.6150887868868475
correlated,0.4617528977914207
with,0.42393545975462266
increased,0.4767722546218193
invadopodia,0.45697721452457435
in,0.48440378566997216
epidermal,0.3754952646845139
growth,0.39605798659102637
factor,0.35238965320094845
(EGF)-stimulated,0.28574783004752186
cells.,0.453216933606842
PTEN,0.657634762552553
deletion,0.6527817300315968
increased,0.7274565655620697
"PI(3,4)P2",0.7198445618952907
levels,0.7264270600241365
in,0.7071267351454916
a,0.6299897470764362
mouse,0.7185417780498601
model,0.7386915217253704
of,0.6414893663193401
prostate,0.7178155698840816
"cancer,",0.6343473203170488
and,0.6902734238847995
it,0.7134899306984372
inversely,0.5658249481653865
correlated,0.6546282623934219
with,0.606112912796276
"PI(3,4)P2",0.6798692765388816
levels,0.6375569967988727
across,0.6049705507819966
several,0.5040865734137071
EGF-stimulated,0.6163205243096284
prostate,0.5981744659452402
and,0.4650150021101676
breast,0.40278102578318015
cancer,0.4440080898355917
lines.,0.513925645497604
These,0.13324915730097756
results,0.1278035102087987
point,0.117194057404655
to,0.09145183941801158
a,0.09573023473073354
role,0.11681647649539181
for,0.11213532310545105
"PI(3,4)P2",0.2327118785661456
in,0.12460727451934149
the,0.12904034386360697
phenotype,0.12264544313360524
caused,0.12529422285789174
by,0.1533083518102134
loss-of-function,0.10922690492141797
mutations,0.14294539480594484
or,0.13040911372953423
deletions,0.09872279968423597
in,0.14289714809383797
PTEN.,0.17984449565815439
BACKGROUND,0.030947034651339286
Interferon-gamma,0.007753542690719759
(IFN-gamma),0.007065919197005166
is,0.004819954478604238
an,0.004266353133938649
essential,0.004349576804142739
cytokine,0.005566269339726122
in,0.0042728249887019855
the,0.0031589515618813853
regulation,0.0038087589499261974
of,0.0031489617814373936
inflammatory,0.0025525642108351486
responses,0.002859360502932927
in,0.0032992368571551876
autoimmune,0.002725471195460132
diseases.,0.0024514428010998534
Little,0.0034182275296883065
is,0.003268098553948821
known,0.003486836479543592
about,0.0025575284160882935
its,0.003073368371765196
role,0.004076890053027192
in,0.0030516146103118534
inflammatory,0.0026109383915109007
heart,0.0025125872401861606
disease.,0.002836606052827559
METHODS,0.13599788270335625
AND,0.06321303415869375
RESULTS,0.15571340842954942
We,0.7482222526397674
showed,0.8338113883805779
that,0.8636636948807103
IFN-gamma,0.6569810209718868
receptor-deficient,0.7172248894136857
mice,0.7818168838931597
(IFN-gammaR(-/-)),0.7001281554261
on,0.7603617642657204
a,0.7166825878078982
BALB/c,0.6770563521834639
background,0.6833305352511234
immunized,0.8119994502637519
with,0.6914928531430943
a,0.733899229128872
peptide,0.787297827476553
derived,0.7312670141335916
from,0.7562982989427882
cardiac,0.7675180816664535
alpha-myosin,0.7339573565381367
heavy,0.8214885124707326
chain,0.7658534609504777
develop,0.8395958349778718
severe,0.8732865787857143
myocarditis,0.8656203843585571
with,0.8710966469946453
high,0.8797254115783156
mortality.,0.4223846379634163
Although,0.4637165502012818
myocarditis,0.4546555007492912
subsided,0.4041295213227796
in,0.44409712208392144
wild-type,0.3758419595926138
mice,0.4322546319011065
after,0.3926890673831336
3,0.4632584309880777
"weeks,",0.3990382062536016
IFN-gammaR(-/-),0.4390744727153257
mice,0.531274279307423
showed,0.5125135682776364
persistent,0.3906831490756213
disease.,0.4411760393227396
The,0.7684815593653571
persistent,0.770948071678873
inflammation,0.7649148591659496
was,0.7582264613491075
accompanied,0.7942943551982649
by,0.7736647385765507
vigorous,0.7970788661217038
in,0.8098596118170869
vitro,0.7652777624727308
CD4,0.8663859903905637
T-cell,0.8598771245453037
responses,0.8138856702865008
and,0.7975132760892825
impaired,0.7480123365096546
inducible,0.8647096218954918
nitric,0.827641914229975
oxide,0.7974998965831032
synthase,0.8532599962263512
"expression,",0.806173607950614
together,0.7422309093531779
with,0.7171900426732128
evidence,0.7068466755712357
of,0.697473651804003
impaired,0.7038543649279394
nitric,0.701501236500223
oxide,0.6918225697892713
production,0.7342158694976253
in,0.6887276614887099
IFN-gammaR(-/-),0.606499027722297
hearts.,0.7386799415078429
Treatment,0.06695196194952674
of,0.07611196184158026
wild-type,0.0568040262810008
mice,0.08707692846221454
with,0.046683087554032984
the,0.05843627697348436
nitric,0.04938515012703689
oxide,0.06107978494423463
synthetase,0.05895207321106314
inhibitor,0.07020957089221952
N:-nitro-l-arginine-methyl-ester,0.6123254360528539
enhanced,0.8196060189758045
in,0.7492620405949794
vitro,0.6580306585907002
CD4,0.8415799398031312
T-cell,0.8089895193819749
proliferation,0.7769793378730435
and,0.797092035002705
prevented,0.8006838597275443
healing,0.8083002205943621
of,0.8171067355160077
myocarditis.,0.7568810730405685
CONCLUSIONS,0.8145006934397586
Our,0.7210268590025652
data,0.7168748290882293
provide,0.6120925086609598
evidence,0.7319598835494313
that,0.8161632847164115
IFN-gamma,0.7262755446201544
protects,0.8318757624473221
mice,0.8366797094637587
from,0.8360684538668377
lethal,0.8492994903885965
autoimmune,0.8617139165989356
myocarditis,0.8394547944782655
by,0.9101525757667379
inducing,0.9074450037365618
the,0.8867806922615102
expression,0.8956240738886988
of,0.9060304562711444
inducible,0.8960389709133199
nitric,0.8337882772562626
oxide,0.7771960463516246
synthase,0.8812353294072698
followed,0.8764197363994033
by,0.8738587739124809
the,0.8755437852322976
downregulation,0.8402766246571974
of,0.8471654168205754
T-cell,0.7778226922500232
responses.,0.8289988084194959
CONTEXT,0.055204779417048315
The,0.00959343913351192
growth,0.013738102543126041
inhibitory,0.0038065712996594105
effect,0.008384264271304065
of,0.018909812342222204
"tamoxifen,",0.03225923888619877
which,0.010348238006146308
is,0.0079339358847924
used,0.008666355527426211
for,0.005506810902522295
the,0.006052611877006062
treatment,0.007952076779267202
of,0.011000214992324477
hormone,0.009778541738229831
receptor-positive,0.00823667239432012
breast,0.013262569187831646
"cancer,",0.006748082588067357
is,0.010998453937563652
mediated,0.009609602007615771
by,0.01750263739768689
its,0.01729129758147383
"metabolites,",0.007394266482072334
4-hydroxytamoxifen,0.024851629988935538
and,0.027481412838563087
endoxifen.,0.0381044646791468
The,0.010852273924638264
formation,0.010448805400218556
of,0.017169970610049805
active,0.008339458720803012
metabolites,0.008207732892710817
is,0.012123908436073126
catalyzed,0.010718439080039666
by,0.013375256562434691
the,0.011539088618834868
polymorphic,0.00864723293247496
cytochrome,0.01025669952269739
P450,0.010077249481434654
2D6,0.009066044525326047
(CYP2D6),0.00918859592557308
enzyme.,0.007801517560654737
OBJECTIVE,0.0017923777317173893
To,0.0013802919108688628
determine,0.0011281329731978992
whether,0.000979432824491379
CYP2D6,0.0016012353113276942
variation,0.001221770369149988
is,0.0013360515217575048
associated,0.0011086720885267662
with,0.0017301796773885477
clinical,0.0009088974942076109
outcomes,0.0009202160738468396
in,0.0011940712829335404
women,0.0010459546831879355
receiving,0.0010173580586724535
adjuvant,0.0011497218674330835
tamoxifen.,0.0021261328290088956
"DESIGN,",0.0014347647241623282
"SETTING,",0.003468680700182298
AND,0.0016038609339864404
PATIENTS,0.0019525064748686692
Retrospective,0.002115539312955773
analysis,0.002292872199919894
of,0.0017833966501156263
German,0.0015194649149711465
and,0.0014646441099877784
US,0.001275759616692498
cohorts,0.0009152971551991024
of,0.001362389258548355
patients,0.001026250677231691
treated,0.0008493629661024852
with,0.0009101995967453128
adjuvant,0.0008085162996446543
tamoxifen,0.0013291655956627346
for,0.0010147188483243489
early,0.0015585196932317016
stage,0.0012765369140271647
breast,0.001503306548453511
cancer.,0.0013068423671321074
The,0.001898379117617663
1325,0.0012082967734597548
patients,0.0012165710617554214
had,0.0014894496377163289
diagnoses,0.0008256891490600897
between,0.0010702383862843754
1986,0.0015486600788369447
and,0.0016402103682095852
2005,0.0011822314407846514
of,0.002066961677778762
stage,0.0017479446828376252
I,0.0019065806458749234
through,0.0021108269692930236
III,0.0030433040706776887
breast,0.0017515656637760615
cancer,0.0016784841184225182
and,0.002367663719021068
were,0.0013290608460426573
mainly,0.0011232011531423396
postmenopausal,0.0012314169781674547
(95.4%).,0.0013429765907335097
Last,0.0016545276224861803
follow-up,0.0013886327053110755
was,0.001741191685947828
in,0.001794310280825612
December,0.0016453327764252182
2008;,0.0014838001460273265
inclusion,0.0009354081027488027
criteria,0.0010971258527506208
were,0.0020700356360722405
hormone,0.000742172181186802
receptor,0.00102851949796722
"positivity,",0.0012993754867766463
no,0.0014318287411599535
metastatic,0.0011724692340890235
disease,0.001121260575692092
at,0.0011361080924538946
"diagnosis,",0.0011639971518161935
adjuvant,0.001070037040819816
tamoxifen,0.0011434985784400135
"therapy,",0.0014421110959934626
and,0.0021552514436383157
no,0.0017841348978561995
chemotherapy.,0.0009488106761378691
DNA,0.027108624991606173
from,0.016604031949221373
tumor,0.012454277075135791
tissue,0.025298036128556755
or,0.02284433193830054
blood,0.013375890548077685
was,0.018406342007501936
genotyped,0.013791858423815324
for,0.037514236300140044
CYP2D6,0.05343029743318252
variants,0.07153831325556008
associated,0.021439011655591332
with,0.028634238070399408
reduced,0.031364363494904006
"(*10,",0.035066839832397716
*41),0.051223707220560695
or,0.025072712673312677
absent,0.023714375214783652
"(*3,",0.03441126033075596
"*4,",0.061466106643608756
*5),0.050649642816326265
enzyme,0.01929130158145552
activity.,0.0252511733669993
Women,0.00697263822929489
were,0.004090291270791327
classified,0.0038602048852053946
as,0.0063737108674728135
having,0.0051329555498811925
an,0.008365837982164082
extensive,0.00670450613625025
"(n=609),",0.007675364224476547
heterozygous,0.008313737863203668
extensive/intermediate,0.009967426934944922
"(n=637),",0.006834961103636905
or,0.006610982034923076
poor,0.007880967977623783
(n=79),0.005407359075470005
CYP2D6,0.00573120424440987
metabolism.,0.005794263437676388
MAIN,0.004872113999603096
OUTCOME,0.005930540639270758
MEASURES,0.004748785111202656
Time,0.007103968393703925
to,0.006874750202530326
"recurrence,",0.0037493369961321904
event-free,0.0035141689593906323
"survival,",0.004227450459292156
disease-free,0.0029659349633093823
"survival,",0.0038991807920122448
and,0.004130606695058676
overall,0.002648183024051444
survival.,0.003767600242998246
RESULTS,0.06370604148852675
Median,0.06940033463664914
follow-up,0.04469548640056434
was,0.08895736661016587
6.3,0.05370913267408405
years.,0.041109940385984756
At,0.14678963928146954
9,0.09789413132518426
years,0.08735219145316975
of,0.13344299824513636
"follow-up,",0.0801967438980906
the,0.1643390693662802
recurrence,0.12958845205113192
rates,0.7640921389628502
were,0.7512549074350625
14.9%,0.8138252700189996
for,0.7449009290331954
extensive,0.7380895157348308
"metabolizers,",0.7309863366779962
20.9%,0.8298299106371502
for,0.7525631384174565
heterozygous,0.741995635736835
extensive/intermediate,0.6922573102160982
"metabolizers,",0.7332744254874476
and,0.7944788353758365
29.0%,0.8123640310156605
for,0.778709409122925
poor,0.7643624918970148
"metabolizers,",0.7145695785021087
and,0.7827986891027118
all-cause,0.7647553951329942
mortality,0.7319839668835587
rates,0.7521246525520818
were,0.7177423093605241
"16.7%,",0.7651205095852471
"18.0%,",0.7657361351368205
and,0.6235058812150904
"22.8%,",0.692916083800886
respectively.,0.6704081040877501
Compared,0.8608823050570125
with,0.7886740905220712
extensive,0.7825543488167294
"metabolizers,",0.7636041932051277
there,0.8599892646741332
was,0.8382235302663468
a,0.8457005138248821
significantly,0.8264930971288135
increased,0.8309264801267132
risk,0.833186782746754
of,0.8640130917093704
recurrence,0.8504742828603847
for,0.8244443022516497
heterozygous,0.7600751643367735
extensive/intermediate,0.7078992992127795
metabolizers,0.7268637377859472
(time,0.8053501269498752
to,0.6413162142658473
recurrence,0.7478768591306386
adjusted,0.7373995411430001
hazard,0.704780827819552
ratio,0.755541015524917
"[HR],",0.703213689593408
1.40;,0.8060041171218032
95%,0.8285544289399278
confidence,0.7752359006872065
interval,0.767346859369199
"[CI],",0.5745935159686464
1.04-1.90),0.6469478998374819
and,0.7074128619564843
for,0.6773307776360316
poor,0.6204647389260791
metabolizers,0.574179636917011
(time,0.6237243800370106
to,0.4999073520313376
recurrence,0.5668666706296587
"HR,",0.6283486500074614
1.90;,0.6271471973818425
95%,0.7058593775145409
"CI,",0.6179271511615916
1.10-3.28).,0.6627219355923657
Compared,0.9096929391396112
with,0.8591472746145074
extensive,0.8566724753699738
"metabolizers,",0.8434023326576354
those,0.8349054079144401
with,0.8720223593062286
decreased,0.8614276365211223
CYP2D6,0.830880670950645
activity,0.8605339673004406
(heterozygous,0.8894725459854559
extensive/intermediate,0.8493886416209743
and,0.8675430176473395
poor,0.8536392965702442
metabolism),0.8407634251004605
had,0.8847171289670145
worse,0.877450626923868
event-free,0.8632978427243138
survival,0.8649246631862492
"(HR,",0.8721487973762565
1.33;,0.8789965856879016
95%,0.9113230652130345
"CI,",0.8423252850458246
1.06-1.68),0.8750326585599533
and,0.899965140182131
disease-free,0.8506535623606826
survival,0.866512973593408
"(HR,",0.860194640648504
1.29;,0.8577315016653472
95%,0.8874892833073296
"CI,",0.826026013664863
"1.03-1.61),",0.5354815268405163
but,0.6221706461261348
there,0.5567528833837211
was,0.5484899514957355
no,0.5440055752940719
significant,0.5154070863581466
difference,0.5082195967705235
in,0.5348954459707456
overall,0.5429620305550461
survival,0.5077158792465389
"(HR,",0.500837362519855
1.15;,0.5747344025273681
95%,0.6297809376171201
"CI,",0.5842113096105392
0.88-1.51).,0.4801852130305764
CONCLUSION,0.8287125846305369
Among,0.8080656604958184
women,0.7867870720942661
with,0.73479282412114
breast,0.782199425979267
cancer,0.7514441114531589
treated,0.7566740255785771
with,0.718528837456516
"tamoxifen,",0.6614026399985985
there,0.7863403920301559
was,0.792396283387814
an,0.7468055491513834
association,0.7846736395642028
between,0.747695071836242
CYP2D6,0.8133703067811889
variation,0.722948750617063
and,0.6645580444827247
clinical,0.7748924215429308
"outcomes,",0.7898683167184319
such,0.8184724653019353
that,0.8389109519364228
the,0.8349777682320001
presence,0.8233600423150953
of,0.8036583849755332
2,0.8060315160717478
functional,0.7937847410537369
CYP2D6,0.8324382712155932
alleles,0.8133164475235942
was,0.8231443286225429
associated,0.8695682949588598
with,0.8511009329423787
better,0.8527269171165309
clinical,0.84853554290783
outcomes,0.8639285898006672
and,0.8038781176530584
the,0.8276614949495587
presence,0.8327527843548888
of,0.8316116391813028
nonfunctional,0.827598903584017
or,0.7494900378068106
reduced-function,0.8116866443446613
alleles,0.8091256770121321
with,0.8309232394733602
worse,0.8320409631029306
outcomes.,0.851374195806823
Nucleosomes,0.023689154234271242
containing,0.010119560748661337
the,0.01634381884694555
histone,0.010081336378739815
variant,0.019954393165580144
H3.3,0.020172807919097632
tend,0.010068498384200403
to,0.007051624929819799
be,0.008614967484465753
clustered,0.0066645024082669455
in,0.012688559602385107
vivo,0.015897653598296337
in,0.00931572537145843
the,0.009091040507243952
neighborhood,0.010257815343879885
of,0.00874708849257172
transcriptionally,0.00813352672243148
active,0.011188785312442983
genes,0.008922643688994633
and,0.009080644758813552
over,0.006599593052044175
regulatory,0.0027281644463780694
elements.,0.003049632169214759
It,0.0020845860219577566
has,0.0017008802884902583
not,0.0018564218614381411
been,0.0019370117965241897
"clear,",0.0022681884775733294
"however,",0.002502357231536257
whether,0.0019335243482399443
H3.3-containing,0.003138651378170077
nucleosomes,0.0033152881496326886
possess,0.0018307950226480088
unique,0.0016249516259224095
properties,0.0021372693927152638
that,0.0016758202999990106
would,0.0019789434405395774
affect,0.0022770668265359984
transcription.,0.0022771269514579797
We,0.2612184365744429
report,0.2016531089055033
here,0.2948293031128571
that,0.12092499581052277
H3.3,0.0839195018766711
nucleosomes,0.07305367948433932
isolated,0.04789963224795977
from,0.060638167733501024
"vertebrates,",0.07568307744032922
regardless,0.03912507514776647
of,0.044889672842213825
whether,0.028250883555296775
they,0.05851571857461112
are,0.04913342300297548
partnered,0.05993190888232027
with,0.057558776297717704
H2A,0.058717862520251775
or,0.01986485946686339
"H2A.Z,",0.05817828038239883
are,0.07580253269381235
unusually,0.12308288997214384
sensitive,0.10906273603444357
to,0.1956969720622956
salt-dependent,0.12020717366505455
"disruption,",0.1322584447062062
losing,0.13955640550985401
H2A/H2B,0.1508520113288614
or,0.11126765073774164
H2A.Z/H2B,0.1513096025362433
dimers.,0.22420340924876556
Immunoprecipitation,0.22215929260987086
studies,0.36549904884634143
of,0.23078132258286363
nucleosome,0.22742506657316972
core,0.18991440094538262
particles,0.2232268340178882
(NCPs),0.1987995576288781
show,0.42101447399944447
that,0.43434561312927983
NCPs,0.3052500128372027
that,0.3667872321170956
contain,0.37547541027551584
both,0.5008919751122508
H3.3,0.42154063510914336
and,0.482509030995287
H2A.Z,0.4370183219153127
are,0.4034438976472937
even,0.435155701809039
less,0.46068582080091053
stable,0.4016928632243609
than,0.49505219228691466
NCPs,0.41304515089479216
containing,0.4243823961469308
H3.3,0.49859017321075105
and,0.5132126154177614
H2A.,0.4674585564724843
"Intriguingly,",0.2416517708866275
NCPs,0.23325808337948561
containing,0.2514592341531243
H3,0.2882970273903038
and,0.2134881261267747
H2A.Z,0.24938200027051383
are,0.17446030310277683
at,0.09923871389732816
least,0.09718602627151533
as,0.11816853714473072
stable,0.12580321628909147
as,0.0936941674156746
H3/H2A,0.11586367920773753
NCPs.,0.1879349090640483
These,0.06695127683499942
results,0.055071013959658216
establish,0.044507388085304016
an,0.033614443076494326
hierarchy,0.027986969296810778
of,0.020984284094208445
stabilities,0.0251097757733459
for,0.031318715739842004
native,0.03404840693652012
nucleosomes,0.0368565063198299
carrying,0.02335218327937115
different,0.02042727514698001
complements,0.028127564767208117
of,0.0212618548929603
"variants,",0.02317541686231016
and,0.09550686591145413
suggest,0.05189563387621917
how,0.03713650332725714
H2A.Z,0.04242503544693037
could,0.05673755590912553
play,0.040938386487388935
different,0.029781263273890298
roles,0.04912720794980927
depending,0.02974529648152378
on,0.027227191168667144
its,0.050171932782314355
partners,0.03308713013329917
within,0.07155886306071925
the,0.2696124218250558
NCP.,0.1863337807283907
They,0.1923950490506692
also,0.23225894522594306
are,0.1868850244962495
consistent,0.1890554633501556
with,0.1524457323263957
the,0.17197267929920515
idea,0.1866842131229505
that,0.24370998444772948
H3.3,0.2306541676507456
plays,0.23271709891512402
an,0.23254078038250361
active,0.2753829924860998
role,0.26642725054632443
in,0.29201945537603413
maintaining,0.2218206190732633
accessible,0.1914103854864473
chromatin,0.21276588571642474
structures,0.22029217481774865
in,0.21370669817596885
enhancer,0.1858538311022761
regions,0.2253094084591238
and,0.1753815017983443
transcribed,0.1840756975044414
regions.,0.2082536108834354
Consistent,0.24119519221237912
with,0.2079715056729188
this,0.20888891787451666
"idea,",0.17964762791213207
promoters,0.3050094856367414
and,0.34038675058514695
enhancers,0.3463149784693229
at,0.29969712306715834
transcriptionally,0.3196768273775862
active,0.3397453990304434
genes,0.3291171108868828
and,0.30900933585965834
coding,0.25098285710520996
regions,0.2990884214283677
at,0.30331923761099944
highly,0.24649720376988146
expressed,0.2546246259107922
genes,0.30121328704007094
have,0.29863238406114984
nucleosomes,0.26881011284162076
that,0.27579557054302367
simultaneously,0.29201540731716685
carry,0.2912090607716348
both,0.32469640327554655
H3.3,0.26691135128596294
and,0.3229175505504296
"H2A.Z,",0.27883034084116526
and,0.3083053695585996
should,0.16119516782765483
therefore,0.23973714694066628
be,0.17762255422722303
extremely,0.18549125566652275
sensitive,0.16561218014456403
to,0.21918356559089588
disruption.,0.23567626023839724
With,0.038773530690056214
respect,0.01554824544691441
to,0.012219451394956208
cervical,0.021141837863500393
cancer,0.014636238574516854
"management,",0.014362517191195141
Finland,0.015751337937151534
and,0.01595439175423575
the,0.009165003320190837
Netherlands,0.0164419211346763
are,0.009915230860315701
comparable,0.009327807554417448
in,0.04109161264084219
relevant,0.01389732183073463
"characteristics,",0.011232355193072386
"e.g.,",0.02380580118469844
fertility,0.03355309165380013
"rate,",0.018761514112101776
age-of-mother,0.011216555447708462
at,0.028443398115189148
first,0.04440673435638285
birth,0.03138906171849136
and,0.03111879431112727
a,0.01886254659083913
national,0.019260429946488446
screening,0.019206681088809446
programme,0.019347960400903027
for,0.020912686528903622
several,0.01575179812799343
years.,0.008233348505120126
The,0.0014464404432849261
aim,0.0015349381384020702
of,0.002502232260388254
this,0.0021519749302150912
study,0.0017038133870946712
is,0.002016832146789064
to,0.0012857425552419328
compare,0.0010612935541522595
trends,0.0010808046842489757
in,0.0012566676753600963
incidence,0.001188989993258733
of,0.001330596838730277
and,0.0017639427566340997
mortality,0.0015087676174082628
from,0.002516255232794277
cervical,0.0034169851144591925
cancer,0.0028167283071294557
in,0.0017335192397166716
Finland,0.0019700219702828464
and,0.0017484085999423943
the,0.0010116642355248416
Netherlands,0.001627604063919562
in,0.0014708926008530044
relation,0.0011182575793167043
to,0.001134183864929732
the,0.0010353619868193184
introduction,0.0006777635406231599
and,0.001504527405116992
intensity,0.0007977129885261253
of,0.0012374835589201774
the,0.0013790321777222
screening,0.001158153326120711
programmes.,0.0009222829845358138
"Therefore,",0.0013392125309022132
incidence,0.0011012522708068414
and,0.002354260244609754
mortality,0.0013230410348748383
rates,0.0011086551904172634
were,0.0022774357260091876
calculated,0.0010533304052257589
using,0.0015080142550724907
the,0.001502835297682495
Cancer,0.002251285428208038
Registries,0.0010889141068499623
of,0.0017311723833516785
Finland,0.0019286447361031088
and,0.0022315518956419578
the,0.0014461109287681262
Netherlands.,0.0012547408727480824
Data,0.005056744185738924
on,0.003358869767986652
screening,0.00359947314522406
intensity,0.0029549208744933937
were,0.006538832721156959
obtained,0.0025789268116764626
from,0.005137748677875847
the,0.00496636593513369
Finnish,0.006630176138222687
Cancer,0.005377911606890462
Registry,0.0030872746851959587
and,0.00568794265349413
the,0.003840872290158259
Dutch,0.004573804575159956
evaluation,0.002946216571756946
centre,0.003516971157729192
at,0.006749567302938426
ErasmusMC-Rotterdam.,0.001683457770498411
Women,0.0013797537148228596
aged,0.0007325703612364803
30-60,0.0008531090757316836
have,0.0012164328825631776
been,0.001146083626645609
screened,0.001026764100356252
every,0.0009895964724153513
5,0.001066687779848407
"years,",0.0008703317382779869
in,0.0009413469214790837
Finland,0.0016896972399369323
since,0.0007444404779937239
1992,0.0011263091412691867
and,0.0010691660843887845
in,0.0007729734323922726
the,0.0010223726177901156
Netherlands,0.0009371779940994819
since,0.0006018504176268775
1996.,0.0007855270808747553
Screening,0.0007614744033487191
protocols,0.0008318840179338313
for,0.0007073030272973973
smear,0.0005766825080940856
taking,0.0006578506460063057
and,0.0008728553938243975
referral,0.0007011020392011741
to,0.000695650146806103
the,0.0006878626270091325
gynaecologist,0.0005926952732011394
are,0.0007945248345965539
comparable.,0.0006409114971454163
Incidence,0.004066889813019346
and,0.004497708312505745
mortality,0.002716314325982077
rates,0.002735133543432086
have,0.0028850384189394993
declined,0.0023217411210948876
more,0.0031936471690767985
in,0.004797160887251587
Finland.,0.003466821960868109
In,0.011031987713680861
"2003,",0.0053563740141981215
age-adjusted,0.00423163067703537
incidence,0.010285628595287638
and,0.012130687884481572
mortality,0.005965147253436927
in,0.009265579321261994
Finland,0.011675755072762672
were,0.01602307171057557
4.0,0.016026767213640356
and,0.017607205905279057
0.9,0.011490167642315953
and,0.015384514088498447
in,0.011556215634021722
the,0.006902734777098182
Netherlands,0.009821301367844888
4.9,0.016041173764794196
and,0.01620291161764861
1.4,0.020720354259973234
per,0.02594755735133604
"100,000",0.009796648415320023
"woman-years,",0.008462214754037757
respectively.,0.008114531985360282
Excess,0.14519126778601754
smear,0.13148660781586724
use,0.16614044005418385
in,0.1373019017443208
the,0.13400263429065523
Netherlands,0.14617426301598258
was,0.17744643564264398
estimated,0.15476660353262772
to,0.18730862169994592
be,0.18496211957347736
24,0.18641985415405843
per,0.18625634716963807
"1,000",0.12035151336242321
women,0.17805799805330644
during,0.20089676892117272
a,0.2821331093463362
5-year,0.26438452689091113
interval,0.20253507131960538
compared,0.2575142179713643
to,0.2140452247203379
121,0.17372716966342852
in,0.19278487138174732
Finland.,0.18234729752291173
The,0.05245138073604461
decline,0.048517411379720383
in,0.04161833506481287
mortality,0.06451183213807915
in,0.055601165238659274
Finland,0.07835689865011973
seems,0.056174513342477125
to,0.0443829042402017
be,0.04522055845869412
almost,0.06524788173631874
completely,0.06534820834256394
related,0.061282192731276074
to,0.06963824081290161
the,0.05824212337784483
screening,0.09196764823874415
programme,0.06308148608714755
whereas,0.12261594330080389
in,0.11665324043097998
the,0.07662972500696572
Netherlands,0.09008724799695489
it,0.09676303516053489
was,0.0898711544766102
initially,0.10691770261366461
considered,0.06891496612256608
to,0.0443514966652777
be,0.06113990576647933
a,0.07760903724144923
natural,0.06113333697968485
decline.,0.058314940965391034
Differences,0.1341458229127911
in,0.0891901810975004
risk,0.09155298909604977
factors,0.08569544535159918
might,0.12069021831220046
also,0.1380148925830572
play,0.0999059224409236
a,0.10172745077377292
role:,0.11189712811740314
the,0.30546451383019063
Netherlands,0.2827300584829935
has,0.2844518424782218
higher,0.3929120366105889
population,0.21010046279623365
density,0.24793055738760694
and,0.3366768180242148
higher,0.39841166928721183
percentages,0.22083407348132186
of,0.24551984631729756
immigrants,0.26576845163678886
and,0.25515768325681015
(female),0.2702237509223298
smokers.,0.1966886694085861
The,0.22953679959228362
greater,0.35972133833269176
excess,0.2958051082334207
smear,0.2685426239535942
use,0.2823446160688451
in,0.2706307744664271
Finland,0.23911603247629537
might,0.16238419559667763
also,0.1738333668235497
have,0.22033631359548808
affected,0.15804710602441085
incidence.,0.1860707748729602
OBJECTIVE,0.001303536962651102
To,0.000917154201943682
assess,0.0010108195569249105
whether,0.001065512697793756
population,0.0008953991241879787
screening,0.0008766964633537248
for,0.0008945348690441047
impaired,0.0009766220293645983
vision,0.0009821438530811604
among,0.0011473644035839997
older,0.0009386008318629318
people,0.0009523920453117133
in,0.0009209256611417639
the,0.00100401019909578
community,0.000937531659039204
leads,0.0008866488713307405
to,0.000995884915114129
improvements,0.000802840644122066
in,0.0009597521592099678
vision.,0.0008036048936139856
DESIGN,0.0010653535975366738
Systematic,0.0017224130033334632
review,0.0013177055994470564
of,0.0014388106627504114
randomised,0.0014599482051836313
controlled,0.0009638216603523963
trials,0.0011134993456189805
of,0.0014660220701538246
population,0.0010077130642508801
screening,0.0012031727848044091
in,0.0012881628061927302
the,0.0015689304104454004
community,0.0010921000114995278
that,0.0016055473637753685
included,0.0013190258984713355
any,0.0014007260260322483
assessment,0.0012430088975741056
of,0.0016790539163554794
vision,0.0011187485059140877
or,0.0015449308058362859
visual,0.0011971131292353794
function,0.001223920825875639
with,0.0016739402490746978
at,0.002458718186723185
least,0.0022326850296151904
6,0.00212297877530658
months',0.0015331823176720541
follow,0.0014949711235436047
up.,0.0017543797353188103
SUBJECTS,0.001541617430498106
Adults,0.0016264731915224752
aged,0.0016182785328606075
65,0.002169056926010748
or,0.0024780339280168757
over.,0.002553542315457142
MAIN,0.002074173915295366
OUTCOME,0.0027140715299369695
MEASURE,0.0022548216886318713
Proportions,0.003043557261402044
with,0.0020817262459686256
visual,0.001795753364776047
impairment,0.002066319508145273
in,0.003235997119461797
intervention,0.001904571369347773
and,0.0024332920157558165
control,0.0018056596740594517
groups,0.0019872951410123867
with,0.0018313519271943046
any,0.0019012376764656245
method,0.0019622870806942946
of,0.00444767652463355
assessing,0.001841747890803124
visual,0.0015781459398484337
impairment.,0.002059556393882809
RESULTS,0.019496341828335786
There,0.016267383401204486
were,0.012959030790510749
no,0.012634719072766755
trials,0.003419327402049451
that,0.01263103148259469
primarily,0.008127954569872404
assessed,0.00572565434287494
visual,0.014311198087913321
screening.,0.005109998266711042
Outcome,0.0009051912049015311
data,0.0013193415719896693
on,0.0011394400586148842
vision,0.001987109785976733
were,0.0014883554398292997
available,0.0009181391379680578
for,0.0014091602654947093
3494,0.0010026564156084038
people,0.001024928938462276
in,0.0012216656363631972
five,0.0008588727583179374
trials,0.0008548940221317097
of,0.0008196518601751378
multiphasic,0.0009504442475474076
assessment.,0.0007808513843756468
All,0.010763001991503159
the,0.00963130058872457
trials,0.010117929686325697
used,0.013569731512621376
self,0.013451205169301015
reported,0.010407142794119646
measures,0.012637559836419121
for,0.010207885933119588
vision,0.015689974139115374
"impairment,",0.012336518729606026
both,0.038254497315735214
as,0.019266371092485173
screening,0.011525204889082093
tools,0.015885425563977117
and,0.046927694569469096
as,0.018683751661288935
outcome,0.010440794207312998
measures.,0.016553287440788485
The,0.7641181708167395
inclusion,0.701164163919198
of,0.7472130243151591
a,0.6746782849469636
visual,0.6761318187216411
screening,0.6658280997131684
component,0.6744591774623611
in,0.6574348159133834
the,0.6128641927867406
assessment,0.6629579039631576
did,0.7635175044829425
not,0.7259905875850099
result,0.7425907692056998
in,0.76083743091573
improvements,0.716617743411641
in,0.7181618057352307
self,0.751930875829885
reported,0.7370826671979536
visual,0.6761949810582231
problems,0.716213351544564
(pooled,0.6538600702383792
odds,0.6494737721054201
ratio,0.6189839634337378
1.04:95%,0.6964406645813991
confidence,0.7042086422043428
interval,0.7069847894779382
0.89,0.6413235726691326
to,0.7102445663402571
1.22).,0.6437411705908116
A,0.05855105480418576
small,0.04548422962310875
reduction,0.05943337207778674
(11%),0.050683266352713065
in,0.05562032910757811
the,0.045987432258764165
number,0.04650422368115608
of,0.04864219795298708
older,0.029591034296252833
people,0.04330269454556025
with,0.04095840007992196
self,0.03565047058281947
reported,0.037405747320076274
visual,0.050001978358988404
problems,0.04964027598647104
cannot,0.03228507267942406
be,0.021083500199583452
excluded.,0.0252117769731216
CONCLUSIONS,0.6985303650420253
Screening,0.35134005858443246
of,0.40557799234291975
asymptomatic,0.3740443555654929
older,0.26892227883957465
people,0.29811425872701136
in,0.25292927541366506
the,0.19780537075096333
community,0.19043108008496276
is,0.15638390445691758
not,0.1671261239215851
justified,0.15484537077387042
on,0.15863870828009682
present,0.12909505027756368
evidence.,0.13039078354801464
Visual,0.29833480400128387
impairment,0.22584318600172293
in,0.37639812385639004
this,0.33638978817207704
age,0.2360514103088502
group,0.3381707192718458
can,0.28295965561260455
usually,0.2773688047516353
be,0.2800950156779474
reduced,0.33026194662083463
with,0.335967883664067
treatment.,0.3604546200169648
It,0.012402624217301993
is,0.008869883698399434
unclear,0.005918328950273222
why,0.017507328319168097
no,0.020595635699172023
benefit,0.02483949363139047
was,0.039673642138309595
seen.,0.03638364452719753
Further,0.0037553584315144035
work,0.003803217647298201
is,0.0024197584721685358
needed,0.002502209647226672
to,0.0019315726811815878
clarify,0.0026677301084024087
what,0.00218839937286196
interventions,0.0026168682060576784
are,0.0018367182737985888
appropriate,0.001508968769075944
for,0.0027314993468205246
older,0.002055042814428732
people,0.003543622099711536
with,0.005056816157763069
unreported,0.0018681300456743698
impairment,0.0037009847566302503
of,0.003545410684320367
vision.,0.003850314342871891
We,0.04130698750000555
generated,0.02052784097133793
a,0.01439612809980703
series,0.014374003837692986
of,0.02073906771192606
knockin,0.01365772821405204
mouse,0.018171037477586142
"lines,",0.01242778183493586
in,0.026559295369633952
which,0.015245833000559261
the,0.03417325018952621
cytokine,0.044805875152745624
receptor,0.03145585947917565
gp130-dependent,0.044603290839292875
STAT3,0.02755300372101772
and/or,0.05702691156529
SHP2,0.06329254654895779
signals,0.05877951042441893
were,0.01938772494712634
"disrupted,",0.019899939717117114
by,0.05570657135165534
replacing,0.03387430450636969
the,0.02644277297105797
mouse,0.02951960171682402
gp130,0.032247503197956634
gene,0.04003024984315815
with,0.028302145242823554
human,0.031032071791177153
gp130,0.026653839517122843
mutant,0.035859509140284546
cDNAs.,0.04564981174037158
The,0.5673328633222938
SHP2,0.4886137005693656
signal-deficient,0.6344600875833051
mice,0.6253184047120447
(gp130F759/F759,0.672171336313252
were,0.6223244628220871
born,0.7123857873733932
normal,0.6473633923703414
but,0.6843007432088268
displayed,0.7657392037664386
splenomegaly,0.7852620188852991
and,0.8276516155361197
lymphadenopathy,0.8092461284929868
and,0.8168745002201905
an,0.7919782116684483
enhanced,0.7609001741664918
acute,0.7944214473340659
phase,0.7534114788570261
reaction.,0.7325174822621809
In,0.5355426442178879
"contrast,",0.562579635363461
the,0.5499085869479121
STAT3,0.42218659985299456
signal-deficient,0.570068240919259
mice,0.5412936573024337
(gp130FXQ/FXXQ),0.1480093945631232
died,0.0885332185154313
"perinatally,",0.04505327474008018
like,0.06735464243493391
the,0.1002715162681056
gp130-deficient,0.06892656313247732
mice,0.08013805810055391
(gp130D/D).,0.06263689453226852
The,0.044464230677415194
gp130F759/F759,0.03320313556126633
mice,0.05418255066329244
showed,0.03761306694121039
prolonged,0.034211093263480506
gp130-induced,0.028164134751770386
STAT3,0.03792826233476065
"activation,",0.04660343536158191
indicating,0.045639446713306976
a,0.028519941535603895
negative,0.018714152239335837
regulatory,0.02897866734200939
role,0.034173151825788915
for,0.02983858449600635
SHP2.,0.05653530844179911
Th1-type,0.4870118517647686
cytokine,0.4563215146587549
production,0.43848979376309005
and,0.45226109174566803
IgG2a,0.539279113058517
and,0.5136635623551928
IgG2b,0.5430410502504144
production,0.42706123542554303
were,0.3508530655788939
increased,0.3718656428237503
in,0.41284275724981984
the,0.4400470110938568
gp130F759/F759,0.41928645299261685
"mice,",0.4652395337407898
while,0.4689939832607114
they,0.3354746558748055
were,0.32759560512053926
decreased,0.3620732605342302
in,0.39410859474385396
the,0.42612784152394956
gp130FXXQ/FXXQ,0.45157087198757095
immune,0.4447909721067215
system.,0.4764351891403846
These,0.3839578872884611
results,0.4003143702640943
indicate,0.38716667942948146
that,0.3938341185510435
the,0.4152888970677245
balance,0.38932875851391185
of,0.41942918052959444
positive,0.4680781697523996
and,0.35154087546545015
negative,0.3344208594014454
signals,0.4441306233115441
generated,0.38662037282276224
through,0.4933713274327458
gp130,0.4464925288324906
regulates,0.3475014601269374
the,0.36410681897260383
immune,0.37443607068803286
responses.,0.3877287556169148
Breast,0.017948483557634072
cancer,0.006943592945781
may,0.009990896877180256
originate,0.029722065098654413
in,0.03689120506283564
utero.,0.013857954904587246
We,0.0024241680763022275
reviewed,0.001123725825828712
the,0.0009322091259223999
available,0.0009145435379696595
evidence,0.001166902450003572
on,0.0008997828677200498
the,0.0009614778321075545
association,0.001178240981202502
between,0.0013522391921613859
birthweight,0.00313806435914519
and,0.0011436998402787326
the,0.0008820569215291857
risk,0.0009017008202039779
of,0.0016134372234725281
breast,0.001851185714102553
cancer.,0.0013825511352945536
To,0.0012283781627932917
"date,",0.0010495748266649793
26,0.0012791883817679889
research,0.0015655403027140847
papers,0.0012448444877861766
addressing,0.0010607800627293745
this,0.0011657045397628516
issue,0.000995092267447099
have,0.0018001915340634506
been,0.0015570297230308062
published.,0.0012138858969606649
The,0.010727306169658224
majority,0.011666635565248419
of,0.011909883600959582
studies,0.015983586385611384
identified,0.011578205764857285
a,0.008471023392501702
positive,0.008068724727882119
link,0.012073997184624199
between,0.009787075657570811
birthweight,0.02165431229003719
and,0.016640708541012968
"premenopausal,",0.01831167365432091
but,0.0360052327584237
not,0.05092640199561959
"postmenopausal,",0.022252432493410388
breast,0.016519738120300605
cancer.,0.013775402366075015
The,0.40637726478197356
relative,0.43084089127436676
risk,0.4291782150925826
estimate,0.40891843093412145
for,0.4736682478478541
breast,0.4729034109814313
cancer,0.44573080690471817
comparing,0.48736687386694616
women,0.5730051362326176
with,0.5607712465205386
high,0.5352018320282685
birthweight,0.6221866576598012
to,0.48697021073744234
women,0.5800373453346847
with,0.5838296519157271
low,0.5338545195922247
birthweight,0.6357908493289453
combining,0.534350055133916
all,0.48760162439543997
studies,0.5809884081273754
including,0.47479037438609967
both,0.5781683312518703
pre-,0.5750962397110786
and,0.5289157333009094
postmenopausal,0.5929335234296947
breast,0.5375707930739316
cancer,0.5526826121794863
was,0.42928914426529086
1.23,0.5474708318565461
(95%,0.5131289481957296
confidence,0.5883230119050712
interval,0.604908279734614
1.13-1.34).,0.5983349697278468
The,0.279495790648363
mechanisms,0.36114521545012584
underlying,0.26407562851801597
this,0.2254964231107953
association,0.24014274012930634
likely,0.1343428941076391
include,0.23189869455223924
elevated,0.2755096155710091
levels,0.28560111149751904
of,0.27381272128771267
growth,0.2646597601704126
factors,0.2778132804987108
that,0.24991911963987534
may,0.16948569692627302
increase,0.2547739956652499
the,0.22295802641877535
number,0.1872482330140984
of,0.16318174624010223
susceptible,0.1898184967984622
stem,0.18638692787898334
cells,0.18926804541282888
in,0.24953530692091644
the,0.2113485800832714
mammary,0.17065333479969402
gland,0.236821013083129
or,0.22746318948931019
initiate,0.2109251814012202
tumors,0.14990475323513272
through,0.1717739062314365
DNA,0.1020135688118779
mutations.,0.1345914653499718
Loss,0.20499080082773258
of,0.20430807109344826
imprinting,0.18069859727193657
(LOI),0.15850066410507163
of,0.19092058450508162
growth,0.2053725326737106
hormone,0.19503730259927732
genes,0.18604176825449517
relevant,0.19376846749820148
for,0.19881915815286896
intrauterine,0.18309469600233896
"growth,",0.24268751498918192
such,0.1311688151994031
as,0.14131191311612679
insulin-like,0.1578457189213187
growth,0.2282582549243017
factor,0.19067221696802397
2,0.19314617247162896
"(IGF2),",0.1266132205689986
leads,0.21966269890586718
to,0.2646639303757123
abnormally,0.18792839599560535
high,0.168531045077285
levels,0.16482937618534502
of,0.15037035884660527
these,0.1698122159792461
hormones,0.19716185596482863
evidenced,0.161373525497659
by,0.16365865398845145
high,0.1823520431538402
birthweight.,0.19436663500930965
LOI,0.061649763877762304
of,0.09488168376898351
IGF2,0.07637861466537076
has,0.03573329253193913
also,0.036931531596495065
been,0.028400643311692425
found,0.036049175228708256
in,0.060133956627455035
mammary,0.05130879437950361
tumor,0.04949661577547608
tissue.,0.06583366608375604
The,0.112875747168758
role,0.12140379392700472
of,0.10915909458959853
environmental,0.09177590337281313
factors,0.11074875561594942
that,0.11118153713449969
stimulate,0.1063845144684861
such,0.10287633301315605
epigenetic,0.07276753537256385
regulation,0.10966960943929645
of,0.124365450529135
gene,0.10987108280781299
expression,0.07412474587739602
remains,0.019932360482725228
to,0.009626266890860241
be,0.010813678547384903
elucidated.,0.01564381797952705
To,0.007047076483765028
assess,0.0020198730353922496
the,0.001225367554306775
relative,0.0013447108102331877
importance,0.0014763288773328054
of,0.00190707705552263
genetic,0.0014907664326986446
and,0.0025646640305529685
environmental,0.002191916329188814
effects,0.002369312092922906
on,0.002497542612050344
the,0.003335026658834221
body-mass,0.005852637249901201
index,0.00446208563065454
(weight,0.0035395657525312384
in,0.009697383884499644
kilograms,0.001942203674562262
divided,0.006552923142032772
by,0.00751807760386212
the,0.0030784356001975384
square,0.003441689348292884
of,0.006596431690835196
the,0.004761443688924196
height,0.011267728125427081
in,0.01479753334197975
"meters),",0.00435419455961909
we,0.008124612711579238
studied,0.004351325192196154
samples,0.0041221886835337155
of,0.0064631606827880985
identical,0.0042855263923131685
and,0.004518923568873684
fraternal,0.004497269585486347
"twins,",0.007104925336984459
reared,0.006279631099935855
apart,0.00444351270411644
or,0.00443139897039199
reared,0.006545494317881185
together.,0.0050414576795740785
The,0.009211497961314766
samples,0.010896706154615816
consisted,0.013633567797926651
of,0.01682248552373371
93,0.018530735083628735
pairs,0.034551941827609865
of,0.02507071377409468
identical,0.027286887781615397
twins,0.03315736428033232
reared,0.018130526010157095
"apart,",0.018540923567756343
154,0.01906450716611837
pairs,0.03678156850575622
of,0.023825070788200103
identical,0.03076822869297295
twins,0.038356396427810684
reared,0.02664792382873925
"together,",0.03157974940888784
218,0.015285738178789489
pairs,0.03384936428238611
of,0.018980467132722674
fraternal,0.02954833310101288
twins,0.03988568747059767
reared,0.021552524465844373
"apart,",0.018095188008383004
and,0.010739399448407736
208,0.011726615886624629
pairs,0.020979085435989826
of,0.013084829185119199
fraternal,0.02276546408247394
twins,0.024677003194154636
reared,0.017475187073500396
together.,0.014769374494514534
The,0.03803627020381044
intrapair,0.048098135851167886
correlation,0.04220412625961708
coefficients,0.059344857009778866
of,0.04140707990221092
the,0.03570891416220287
values,0.053915369344490094
for,0.05053072539760819
body-mass,0.042361348672376904
index,0.0656939956695521
of,0.055840529169847775
identical,0.04042803576047023
twins,0.040717047341117744
reared,0.043854908304935374
apart,0.03578509169081544
were,0.05495487085193956
0.70,0.17575411909065247
for,0.10324912153920683
men,0.120157056199752
and,0.19926950576695313
0.66,0.05160163531363694
for,0.08074270623528816
women.,0.10626441201245969
These,0.06056694945924297
are,0.04187592082568732
the,0.04072128470864206
most,0.036297482919671435
direct,0.03412272722001473
estimates,0.03081731497103456
of,0.02541587547231844
the,0.01955947431024881
relative,0.029843495517702323
importance,0.03671832855823922
of,0.02194648295010088
genetic,0.039330043010825974
influences,0.037353429139247316
(heritability),0.022320782042983482
on,0.02598882722463743
the,0.026999497215181367
body-mass,0.07270202543355217
"index,",0.062005442786253966
and,0.12752391480117883
they,0.04719599202722631
were,0.0731737514988899
only,0.09073080625456562
slightly,0.11778794441097004
lower,0.06163213968117643
than,0.09570961842244785
those,0.07676073823909448
for,0.07275596185541185
twins,0.10297000461305805
reared,0.09837009073624738
together,0.09548786791940275
in,0.09187199440652821
this,0.08650189103922983
and,0.07238325409958286
earlier,0.06528906021349899
studies.,0.08239042603322931
Similar,0.006453056426496279
estimates,0.006999661109813234
were,0.006144365532413311
derived,0.004790239636326963
from,0.008200039200728088
maximum-likelihood,0.004017973212734969
model-fitting,0.006103220168432549
analyses--0.74,0.0071538013053033984
for,0.009310681318936621
men,0.00456304151805862
and,0.012937551503138413
0.69,0.00588490169145814
for,0.007767478936164656
women.,0.005088588965836444
Nonadditive,0.03066316396034857
genetic,0.028131354945365554
variance,0.03931083749176993
made,0.03182987627519238
a,0.024675783841149438
significant,0.024569347535965052
contribution,0.025692583367561847
to,0.03108187783027973
the,0.02607639924072039
estimates,0.02189890890079149
of,0.018624631816199035
"heritability,",0.018431774303881404
particularly,0.023800552002817877
among,0.030277934553604564
men.,0.03360203793858194
Of,0.1992154911335972
the,0.1339974605515822
potential,0.13636656414170523
environmental,0.18010234248544577
"influences,",0.15127688403402806
only,0.22379155338227058
those,0.1946464719652747
unique,0.15195149893735954
to,0.12436511949527301
the,0.10631591920891822
individual,0.13864351467397382
and,0.2603831761328833
not,0.2898744865625847
those,0.1887681706858199
shared,0.1254845964228642
by,0.14872926686308768
family,0.1827470306594698
members,0.11253437070597
were,0.13708863323977555
"important,",0.1289100393036094
contributing,0.1109401354210603
about,0.11644144177779313
30,0.09699497293074742
percent,0.08965765902419554
of,0.10770771933164983
the,0.11819072494813845
variance.,0.11246715800673783
Sharing,0.37173504346098746
the,0.2908056391552689
same,0.2878305511471827
childhood,0.3418793149356752
environment,0.29980507455285765
did,0.4314346304273965
not,0.34936863606275365
contribute,0.3061400926317428
to,0.2735298430485668
the,0.2747454539910162
similarity,0.23741095013694913
of,0.22987937361332886
the,0.25099198377335463
body-mass,0.30089752786015334
index,0.27977613002660984
of,0.24961753532088926
twins,0.26846016088440355
later,0.2989379135682176
in,0.3748801789702267
life.,0.3293325207836846
We,0.40080291899323917
conclude,0.4031978923411494
that,0.45413866686898646
genetic,0.39048562593568986
influences,0.30886139207967855
on,0.3341900497100532
body-mass,0.41757558598915434
index,0.39000443409997737
are,0.3869256160056805
"substantial,",0.3511691920287757
whereas,0.4007725410076958
the,0.31915852277810713
childhood,0.3872546350363915
environment,0.3696831080643551
has,0.2725576214889005
little,0.28842556119242435
or,0.26422025133091975
no,0.31804653608354067
influence.,0.24929522228363654
These,0.10452516431801766
findings,0.09233590686068772
corroborate,0.06399056305838881
and,0.11328763106036766
extend,0.06472402088452608
the,0.06821754088310197
results,0.04588138464019482
of,0.06508911811901102
earlier,0.058182317229429785
studies,0.06166554414776804
of,0.0490059355494013
twins,0.05367894993542176
and,0.05177711098757806
adoptees.,0.06974947840207157
PLoS,0.1200733551653056
Biology,0.1160772375171114
publishes,0.15904373192624516
today,0.20916984861036858
a,0.22444221435054662
research,0.14205582458583157
article,0.13910012091525406
by,0.16012467728274038
Gunther,0.08652982964740048
Eysenbach,0.0903831783573298
that,0.19546277833377562
is,0.2525810688279658
not,0.29533125186261266
about,0.10625358906875326
biology.,0.09884445256017738
It,0.24631810073019517
is,0.2465178734396762
about,0.10631365394744147
citations.,0.09828595053040748
It,0.30319510485070506
provides,0.3464869342219627
robust,0.36587829384018444
evidence,0.3665629488339439
that,0.35149675907320194
open-access,0.14487436936279097
articles,0.17118964802237802
(OA,0.1756632238491469
articles),0.17109638824075324
are,0.33017940091514264
more,0.4013096962972465
immediately,0.2718027344805234
recognized,0.1875172418461055
and,0.33977706090654547
cited,0.14135272435557172
than,0.41366793199195984
non-OA,0.17092566592119898
articles.,0.15324768828377475
As,0.3991857574664585
"such,",0.305341231182936
it,0.3793475880036539
adds,0.36682284855108355
objective,0.2289520101023937
support,0.29093514773742624
to,0.25264300704059783
the,0.20927573159716337
belief,0.2178207414419294
we,0.18419055422535194
have,0.23714343123405057
always,0.20116342490240516
held,0.2526604965027135
that,0.29777357254892445
open-access,0.1294438257416408
publication,0.11102827976092261
speeds,0.2501505598843544
up,0.1948864570529689
scientific,0.08975725892524135
dialog,0.08682705991737824
between,0.07655136299677831
researchers,0.07211045059466241
"and,",0.34639449234873243
"consequently,",0.347636078403163
should,0.14363000185429545
be,0.10717036272044102
extended,0.08516559696465496
to,0.08108720336839727
the,0.048158077878408534
whole,0.0694892337918218
scientific,0.0373695627582696
literature,0.049043583379777815
as,0.09443270578677519
quickly,0.08761723370401706
as,0.06509289765213748
possible.,0.09271027243359746
It,0.028806880341691335
is,0.032214253429174916
therefore,0.03214388847556921
fitting,0.019855647054227384
that,0.03438893925946761
we,0.040948249326356795
publish,0.014428219583256057
such,0.025584996592708496
a,0.012633924961560052
paper.,0.01626945145248356
We,0.15010058237160998
have,0.11007100633947534
long,0.10195736441644586
argued,0.16743052595021193
that,0.15501591643866455
papers,0.10851300055489224
freely,0.0999226949181877
available,0.06169403819295711
in,0.050808571275394385
a,0.05728065356840112
journal,0.052827965525349525
will,0.1273357129394854
be,0.12244016761789413
more,0.04244879136040819
often,0.018837654979004453
read,0.01675415833150681
and,0.026334914207602863
cited,0.010301630382728234
than,0.03298414516274315
those,0.014698695322135205
behind,0.008035034602121124
a,0.006617842034706807
subscription,0.007955449846172776
barrier.,0.01831631157150312
"However,",0.002709465847633198
solid,0.0028301023483923594
evidence,0.002862624601249535
to,0.0024383814642001092
support,0.0025400144843357357
or,0.001770375084361769
refute,0.0016459614664319476
such,0.0027378311085515337
a,0.002281888885415959
claim,0.003522605668918934
has,0.0016036005832098944
been,0.0014684123198699611
surprisingly,0.001874886705600255
hard,0.0012959309445080046
to,0.0016637001106852946
find.,0.0023957118268666646
Since,0.00646328622421668
most,0.004653424582908475
open-access,0.0027908344401724877
journals,0.004105909825279181
are,0.003820400101487738
"new,",0.001878345023646187
comparisons,0.0024737595521359115
of,0.002155705783049662
the,0.0019232144253353374
effects,0.001546018687369473
of,0.002806416196397663
open,0.0028792657952491103
access,0.003830203180364642
with,0.0024034372261585784
established,0.002644506840286969
subscription-based,0.0028695057003832623
journals,0.003518850837576549
are,0.0024204624345023668
easily,0.0013768750715813475
confounded,0.0018418517703984111
by,0.002161023930010708
age,0.0014405377844378187
and,0.002260991483317372
reputation.,0.0015743019283724746
In,0.022022482499692478
the,0.012676286717885525
current,0.01044171059070876
"study,",0.012161901268669258
Eysenbach,0.019492686916451014
compared,0.013604505511511655
citations,0.009235885430839733
compiled,0.00467567378714577
by,0.00818458423881557
Thomson,0.012554638032388469
Scientific,0.010330190042774159
(formerly,0.005284566386169507
Thomson,0.014706742821464749
ISI),0.00683376355958279
to,0.00694689320540369
individual,0.007210629416147984
articles,0.01060682284511868
published,0.006500560876638467
between,0.007051359502893421
June,0.0040680275410427055
2004,0.006201364246268173
and,0.004934775287268587
December,0.006899974857154023
2004,0.005900693867887941
in,0.011939022482565438
the,0.008808887575733844
same,0.012470607632408792
"journal—namely,",0.00881959396734818
Proceedings,0.008607967560759175
of,0.015891798497858732
the,0.013432835416103307
National,0.011181340027701783
Academy,0.009265409704921089
of,0.01609267101677016
Sciences,0.009264686407827592
"(PNAS),",0.007459075876421112
which,0.02187883297540291
announced,0.029503868859829842
its,0.01583979635254324
open-access,0.010104587680332115
option,0.05659095207428178
for,0.0381137811634671
authors,0.026110577154047177
on,0.045400439077347005
June,0.020899856385158854
8,0.028669581642448726
of,0.04926173858071538
that,0.0412357862094172
"year,",0.028438075052365272
with,0.043909125543797924
an,0.04370373360181343
associated,0.04083003591377594
publication,0.028479331007638376
charge,0.04061745595360584
of,0.061369288650185046
"US$1,000.",0.06063055625204517
Non-OA,0.09007960188044417
articles,0.06506281213255247
in,0.07182603782874296
PNAS,0.08671709364342088
are,0.05755572413900335
subject,0.06503569693629459
to,0.08997385234854376
a,0.12059328849604428
six-month,0.08978972111727887
“toll-access”,0.13955558957389633
delay,0.09707556170452186
before,0.07857417954861859
the,0.06715584866308813
article,0.06155626671641198
becomes,0.03036383345134592
publicly,0.03462962918398954
available.,0.03136158580489959
The,0.09748748883491866
results,0.07939102192102046
of,0.14141233860424038
this,0.17268553063831824
natural,0.09594587041122041
experiment,0.12353826913740955
are,0.07868469874375016
clear:,0.0946176887533598
in,0.3482083262353684
the,0.2640814898351332
4,0.26439553965646057
to,0.29997696576652566
16,0.12510904852549987
months,0.1696286260108642
following,0.18581368226647219
"publication,",0.10186515832723547
OA,0.15457146432786142
articles,0.16161217583768733
gained,0.3055579909035517
a,0.27448134437251087
significant,0.30222421881660017
citation,0.13316400499933098
advantage,0.23958271498102982
over,0.2817529677911674
non-OA,0.2047107888258729
articles,0.12460733953628235
during,0.18626927964851758
the,0.14233130882835113
same,0.1679645345560377
period.,0.14076760522536497
They,0.08674188903959491
are,0.08383613839320016
twice,0.16842511436185367
as,0.1914198229995253
likely,0.08012154770412115
to,0.08534102296260508
be,0.05537007433334254
cited,0.0873328298547098
4,0.22459841611720663
to,0.14627241201107655
10,0.11461170834677759
months,0.08955741519158006
after,0.13374905025575295
publication,0.09887529289501559
and,0.17631078461945104
almost,0.153572136172458
three,0.12103385424730856
times,0.10558029014614008
as,0.14753853972676734
likely,0.06456625670039033
between,0.12087910460421401
10,0.08072064180080918
and,0.08726316023004126
16,0.062363476502259464
months.,0.05041680906730308
Given,0.3483257400870708
that,0.37154152313296573
PNAS,0.1580938598065321
delays,0.2766778925878537
open,0.23398245828976352
access,0.14742955098267455
for,0.2855502190893333
only,0.23746434933533325
six,0.2613804558802911
"months,",0.09448457645127813
the,0.05992482361981321
disparity,0.0443966687914295
between,0.04355002724373684
OA,0.04787063104978812
and,0.038372677647647055
non-OA,0.05311244820631684
articles,0.04862963831858521
in,0.04581076696173105
journals,0.05635968260954137
where,0.05004843821597801
the,0.05643227445890887
delay,0.06915011968852092
is,0.047696015376475394
longer,0.0792230105384461
or,0.05533328598802613
where,0.060623963978437084
articles,0.06003404384532083
remain,0.06675879449304786
“toll-access”,0.1412668672635329
is,0.04798414377818294
likely,0.04836685369162126
to,0.061717788024307864
be,0.06032240955177552
even,0.0868659008280842
greater.,0.08151226761715522
Eysenbach,0.02147917343695715
also,0.017602626819254667
looked,0.019741896428188785
at,0.012252996613852417
the,0.009284674780116905
impact,0.00955216273579004
of,0.014258689051485066
self-archiving,0.020997076737688164
non-OA,0.01788707991034053
articles.,0.014853235261387007
One,0.1578044034515887
route,0.1120656555651482
to,0.09790271681756486
open,0.05816018965245697
"access,",0.06855880503506528
it,0.10943041248848838
is,0.07780157109550886
"argued,",0.14295583008823665
is,0.15440325603826152
for,0.12029521280709132
authors,0.04339495643472125
to,0.08264712248445687
archive,0.06345254541291617
their,0.04363410554851112
published,0.04805132817485764
articles,0.04531487189989031
on,0.05874420970910046
their,0.0341807974697419
own,0.0623734941154846
Web,0.03329547514217035
sites,0.03505857974547872
or,0.0858468411730824
in,0.05935318249341255
institutional,0.03732296803161089
"repositories,",0.05163910227138195
although,0.18602675857509351
this,0.13197254437618214
does,0.14453059905548607
not,0.15954898019332647
include,0.13720933379269543
an,0.10882496683571653
explicit,0.1017181973541632
business,0.05623242315993048
model,0.08648263883373764
to,0.125286985131542
cover,0.08788717866166709
the,0.08149960399084488
cost,0.0857165660260488
of,0.07729935765161618
peer-review,0.03160262333953879
and,0.06091333622818041
publishing.,0.033928309376623576
The,0.3634136245402687
analysis,0.284158997258974
revealed,0.5446187583983083
that,0.5366483043151904
self-archived,0.17362429914150043
articles,0.15279649407588655
are,0.3105992590659595
also,0.4040016612295973
cited,0.18779230711133954
less,0.4003832836882232
often,0.26320391841482516
than,0.537039706029698
OA,0.1288751519922243
articles,0.06859658041323759
from,0.06193460836927002
the,0.05466638102468307
same,0.06939585395006916
journal.,0.057503007865413874
"Yes,",0.2613312392105748
you're,0.18052899519268514
right;,0.20109485802480975
we,0.15143387864759034
do,0.20612801830217403
have,0.14295851021068828
a,0.15618257818425219
strong,0.13460250438123855
and,0.17430779208650124
vested,0.08509064580539662
interest,0.11634893124194305
in,0.13087932139881686
publishing,0.07490807172754779
results,0.08070361065210767
that,0.12953372222382
so,0.16620440421797114
obviously,0.1397575195148812
endorse,0.124328762299348
our,0.08736688985388005
existence.,0.07625255763287968
"Moreover,",0.33776025681248045
the,0.16034688291627577
author,0.09712977375935775
of,0.11271555643626964
the,0.11746258641507813
article,0.06609168421403032
is,0.18659364895404335
also,0.2462364974632055
an,0.1759349922262915
editor,0.10716108386494905
of,0.10057815118218925
an,0.13241950064615576
open-access,0.10057298040436978
journal.,0.07461910108695463
But,0.16890996049403867
sometimes,0.10413178802649264
a,0.0918300416315347
potential,0.0704751006681493
conflict,0.06584929085622519
of,0.048399505750380344
interest,0.05658032447252436
can,0.091382513839812
actually,0.12107030716221016
help,0.12333148377734225
to,0.10488434133026968
ensure,0.1292559539292127
rigor.,0.08266445909967199
In,0.09303012106293762
this,0.08980875038945696
"case,",0.11370096343588174
we,0.08308883327395077
have,0.07824751440098034
an,0.07601396768956463
acute,0.06491668137520695
interest,0.05174938193128323
in,0.0795188888142366
ensuring,0.05506317954414432
that,0.052176433603974684
the,0.059540685266433954
article,0.037982704184421075
meets,0.050853789839915786
the,0.057843357155853224
"same,",0.0642298447943857
if,0.10054090960291817
not,0.08937753072961405
"higher,",0.05377229983753774
standards,0.047105217168797404
as,0.07019516776747671
any,0.05836502720078736
other,0.0590787071200849
research,0.04228174318595355
article,0.03578433897200742
we,0.043334233217347425
publish.,0.03407518362456447
Not,0.4925966463115297
only,0.5294549425884992
must,0.15697143553918852
the,0.10271420840586018
conclusions,0.08049642619400477
provide,0.1490334764794733
a,0.15074446816041953
significant,0.09633872562977945
advance,0.1123847373390324
for,0.05544379502453146
the,0.061082926409382225
"field,",0.04159627358028877
but,0.2826060818863892
the,0.1360602451179769
study,0.07143178320925124
must,0.12049567417114154
be,0.2021513727035269
technically,0.19181703211103673
"sound,",0.1421833293731933
with,0.17524864823978134
appropriate,0.19431181189615757
evidence,0.012492236169253771
to,0.008599552328645755
support,0.00642869658859306
those,0.012841848550881734
conclusions.,0.007170473435077951
As,0.008258332590110357
with,0.006810694962045427
all,0.005934806649683035
our,0.011043353000971966
research,0.007399150289050597
"articles,",0.005260053798273963
we,0.016333208703576678
consulted,0.006033549529766731
throughout,0.005798541947798258
the,0.0054669511436379594
evaluation,0.004927114059937752
process,0.0026938001866722234
with,0.003459931220442927
an,0.0040180142396911605
academic,0.006784917162443775
editor,0.004943945936800959
with,0.0035579990977641163
appropriate,0.005244061403919839
expertise—in,0.004042686592636249
this,0.007509575326918322
"case,",0.010528661425711044
Carol,0.014785511882620658
"Tenopir,",0.05409738584486948
professor,0.007424856028477148
of,0.007265922518153591
information,0.0065513774308242545
sciences,0.005260163579232896
at,0.009003845727069469
the,0.00834799065111661
University,0.0054592422906079175
of,0.0077830453790981476
Tennessee,0.01349861268050558
"(Knoxville,",0.006273018408941858
"Tennessee,",0.010850938048893422
United,0.009166519000736078
States).,0.009598351573960459
The,0.014637388789696042
article,0.014813859354517275
was,0.01919086470532423
reviewed,0.014630971761065812
by,0.010114014288701156
two,0.013933552386313075
experts,0.006985427170393361
in,0.016533384356881394
bibliometric,0.00653386454504926
analyses,0.006583968136354377
and,0.008555858886799998
information,0.004586367839324051
"science,",0.005512722329962515
and,0.013786447096742978
an,0.013693891846737513
experienced,0.012266051920622228
research,0.008074193592157391
biologist,0.007950985962622923
with,0.01269846167987672
expertise,0.007578582449697938
in,0.012691869406243424
statistics.,0.005887954329017358
They,0.014051202369465004
all,0.01638895591378683
enthusiastically,0.012753500881725756
supported,0.01520967963993737
"publication,",0.007709875969889234
although,0.025370701295107476
one,0.02483028113671882
understandably,0.02037240264141337
questioned,0.011116688390886672
the,0.005274423255194448
suitability,0.006886754228350957
of,0.007289931599422567
PLoS,0.00510864332556963
Biology,0.010131258045526658
as,0.009677749531498903
the,0.01202566691756724
publication,0.008742067594315624
venue.,0.010505378960909898
We,0.07572033752780437
have,0.05235858231471165
no,0.08135952249981893
intention,0.07515441761032332
of,0.08963311386297733
making,0.08775102209591978
PLoS,0.026796659920681434
Biology,0.05888915231432328
a,0.07354443162377118
regular,0.04896850388649625
home,0.1485266221633675
for,0.027180157592790823
bibliometric,0.014614303544274999
studies,0.01820927841115699
(even,0.02669463777090217
when,0.03995516228032562
about,0.019479581242253494
open,0.011317007946880737
access).,0.01152152236617862
What,0.010846192143384926
makes,0.005350433939393797
this,0.006344210040526731
study,0.0052037171519213575
worth,0.005007903002571014
publishing,0.004457270386103037
in,0.004673114740534429
PLoS,0.004063303891871438
Biology,0.008200859442757074
is,0.00876379196724549
not,0.02945773808670791
only,0.02322853800125519
the,0.009853149435148525
relative,0.008200562750077368
strength,0.007004385620745338
of,0.005445487588765418
evidence,0.0061467289581444646
supporting,0.005428396409878702
the,0.004375111787197413
claim,0.007709443692598182
but,0.02042434372330064
also,0.012342295145850444
the,0.0077986224795997105
extent,0.005162960336241391
to,0.003478173580884609
which,0.00655190193880131
many,0.006158920096352228
(especially,0.005542796094931026
other,0.005639640474266628
publishers),0.004509063829084746
have,0.00710432828354369
anticipated,0.006445781309092793
such,0.007084076525994453
an,0.005407375744662614
analysis.,0.007526706979103268
As,0.005327785144066209
far,0.004570746675694014
as,0.0051018037896601144
we,0.0064439676194884285
are,0.0036048042999071083
"aware,",0.002682951095386836
no,0.004109020948031555
other,0.003101503933447366
study,0.003378481520893338
has,0.0024608558363689364
compared,0.002629936731660187
OA,0.0033724604692965347
and,0.0040163086335791845
non-OA,0.003947012122027169
articles,0.002112862352292364
from,0.001998893684998958
the,0.0023993591229659484
same,0.003010856567932158
journal,0.002579770206966986
and,0.004216591917018405
controlled,0.0019373390809026383
for,0.002052783134151729
so,0.0036293179010606063
many,0.00237480346021864
potentially,0.0020602646017692646
confounding,0.0018330297627636278
factors.,0.0020624446614093935
Eysenbach's,0.0447268867816599
multivariate,0.04590501998059801
analysis,0.04223173691706634
took,0.038817530923860956
into,0.026537723556951772
account,0.017177439547602685
the,0.016480046352791648
number,0.02252398760442453
of,0.01732261345809936
days,0.03369969868237734
since,0.02749733781003401
"publication,",0.02174843243282018
number,0.019308939459076305
of,0.017267666126514543
"authors,",0.023286853133642267
article,0.016150338107629645
"type,",0.010627302815239348
country,0.01367045271691612
of,0.012176905318043045
the,0.01447849604164437
corresponding,0.014440014179790071
"author,",0.022343894625603888
funding,0.036209774506167317
"type,",0.005898230162852055
subject,0.0014179685932835236
"area,",0.002677761924248375
submission,0.0032893363915619143
track,0.005121748381824383
(,0.005897953374558298
PNAS,0.012744699330704767
has,0.007736553967045101
three,0.005924242815116095
different,0.003058538559550962
ways,0.006732140382478043
that,0.00863764547325492
authors,0.00421461125324473
can,0.004025035032718318
submit,0.004232031543344127
a,0.004081125497121258
"paper),",0.004721277849326264
and,0.0027529377485242066
the,0.0019744196542962338
previous,0.005609629362757035
citation,0.004484251027590996
record,0.003984463595728081
of,0.0022220834719244124
the,0.0030926095343496167
first,0.004036981752625296
and,0.005573656695916583
last,0.002451510434289549
authors.,0.004427896650115293
He,0.010545248731026259
even,0.004417510021674597
administered,0.0037940159043313468
a,0.0026526198432183594
supplementary,0.0012795280470416926
questionnaire,0.001172818299352497
to,0.0017784753073741136
assess,0.001404273516194827
whether,0.0020480168309945494
authors,0.003832499933438155
choosing,0.003071635391748063
the,0.004389947452640772
OA,0.005613293199356022
option,0.014113586727684677
in,0.010066827949098996
PNAS,0.008198348556634361
chose,0.00608787307631091
to,0.005845547326332402
do,0.007055948277606258
so,0.005349695538225227
for,0.004959761821478273
only,0.005952665809034802
their,0.004221916976355976
most,0.003578407187755024
important,0.0056200976903309436
research,0.008278485157595444
(they,0.007390484169718094
didn't).,0.011877481890360779
As,0.1159056574772648
Ian,0.057558220172731725
Rowlands,0.13732289299520073
from,0.07789486801900898
the,0.030768374448519136
Centre,0.015355855864595949
for,0.011558914811755852
Publishing,0.024979135298879747
at,0.03973598480893464
University,0.017955801480044064
College,0.01867798020025208
London—and,0.03034329764660195
one,0.030589405133134635
of,0.022873027613577523
the,0.03209466256347883
reviewers,0.03347526707299645
who,0.046467621764224545
agreed,0.044244040632073614
to,0.02142057750192449
be,0.018205943401732518
identified,0.02281994021566853
in,0.03361992303231102
this,0.04019080852650593
article—said,0.03450019202202906
at,0.0655081872374383
the,0.04034001134456539
start,0.040902240639051825
of,0.03920598076195996
his,0.055447746953529
review:,0.04054550547127943
“Many,0.2025105764689695
(most),0.0897804367755013
of,0.1111110693386265
the,0.11402174007443501
papers,0.0585254982501676
and,0.0648615553066211
presentations,0.08978821588452289
I,0.21732154768974343
have,0.020967646950738286
read/seen,0.014667964845913881
on,0.0077225119995033694
this,0.014562789190376013
topic,0.005332350761798755
have,0.012458239302413406
completely,0.009646692932585847
failed,0.010373831229569672
to,0.010656803389578574
address,0.00736598774248969
the,0.008366730055431905
kinds,0.005386398996194259
of,0.008182465263338714
confounding,0.004510667268145952
issues,0.004472372778252966
that,0.012141166470484103
are,0.007406816788685891
so,0.012007678646590423
convincingly,0.006150474718443505
tackled,0.0033704120488912024
here.,0.012067017383426502
For,0.008675145159716912
that,0.00575683933112368
reason,0.006088728613110957
"alone,",0.00380538530108795
this,0.00919646552488011
paper,0.011227388777404356
deserves,0.0062216875447528245
to,0.0055801382211821534
be,0.005719839951168036
published,0.0036244318921160503
and,0.008645863671621163
alerted,0.0037444047472947432
to,0.003577773914768982
the,0.005362844581564048
widest,0.0028262569873865203
possible,0.0024854424149640298
audience.,0.0036551261602346947
”,0.021056740743907267
In,0.01154322145950245
addition,0.014120877020407215
to,0.015111899017884428
providing,0.005352072232355204
evidence,0.004504732672877519
for,0.003546193262304896
the,0.004880941793770842
immediate,0.003055279050625888
advantage,0.003970089491913216
of,0.005248880552600356
open,0.004347033441809951
"access,",0.00487926641457491
Eysenbach's,0.014477807160179958
analysis,0.006337170952506016
also,0.006057909692772558
highlights,0.004515420976202308
several,0.006395836125716008
potential,0.0026048392422308004
challenges,0.002669393229432217
to,0.0028895604096744426
its,0.0036078276362817353
long-term,0.0033133491371248854
future.,0.002618226366544103
Although,0.03330681910833669
a,0.012234888607093918
limited,0.00872386796449944
"dataset,",0.008261785643629128
the,0.014331633954887214
citation,0.01848947572956386
history,0.0152993740324252
of,0.016952153475733516
the,0.023156789666960515
first,0.032837588283587876
and,0.02060514573473656
last,0.020069019577128266
authors,0.016229142502819614
differed,0.019960679273078884
between,0.010735096777655051
those,0.013899189235010581
who,0.014977959392724668
chose,0.015850507677219808
the,0.013579294596081051
open-access,0.007789342900708129
option,0.012176612800969662
and,0.011706901287981712
those,0.014541977325778744
who,0.013887231020181724
did,0.021843166483394304
not.,0.01539684869726192
In,0.12147508840742335
the,0.06380475729583068
group,0.06350837029489148
that,0.06252267396171006
chose,0.049433536932844004
open,0.0735257116803928
"access,",0.5884327396846608
last,0.5354099599533262
authors,0.35979521339523973
tended,0.47816571309645306
to,0.4763672378841245
have,0.5059407454064305
a,0.534215472568151
“stronger”,0.4722141308781345
previous,0.503215279813014
citation,0.3552222460808713
"record,",0.4598964164547993
whereas,0.4596043833770442
this,0.40840997331019924
situation,0.32363185304573927
was,0.3374297892928737
reversed,0.3063160534600072
among,0.31175512961315033
the,0.26907758259139003
group,0.2570320731504462
that,0.2667585320064518
declined,0.33880086968430206
the,0.36849794995318375
open-access,0.333856678038227
"option—here,",0.3458771684737653
it,0.4372146017356676
was,0.42720921456289274
the,0.3285690908336559
first,0.3426805979503239
authors,0.2653691537392851
who,0.33518326513785596
tended,0.3326025773605283
to,0.3602909492769446
be,0.3605517022478472
stronger.,0.35806435449607704
This,0.2027159414317438
may,0.14326867898409737
reflect,0.2053248591054594
varying,0.08347436086140268
attitudes,0.14023576628574802
of,0.09034617291544922
authors,0.11528611130776537
at,0.06364492524356645
different,0.06981082897557249
stages,0.07980136621264919
of,0.07771454955014823
their,0.057024360255504766
"career,",0.11588532012202496
a,0.16335104756500274
stronger,0.20505481209902293
influence,0.14795750953377487
from,0.12197025809382891
the,0.08515307773159486
leader,0.10340535610674934
of,0.06788424790121857
a,0.07598902897752371
particular,0.058370445584915366
"group,",0.08476411606854406
or,0.12164192640608706
an,0.13226666731865
age-,0.08652608424105107
or,0.09483540460143271
career-related,0.13973835159372655
difference,0.11413262123261739
in,0.11841891179988175
the,0.10141582220503313
ability,0.12613611456273502
to,0.09260364709494058
pay,0.1170470622633556
the,0.11171366170846285
publication,0.11857127308029825
charge,0.11942228647134291
"(e.g.,",0.12567407809042486
[,0.15744699401618623
1]).,0.17209797525081397
"Indeed,",0.33294089898194734
access,0.2947905420981678
to,0.2112290777597023
appropriate,0.20596772405681762
funds,0.226090737656076
may,0.20485503607596825
also,0.2607637205261803
be,0.2567240584350567
a,0.27822688665101564
reason,0.24994191419155778
why,0.2751230492361494
a,0.27403624573238056
lower,0.30208501488882056
proportion,0.2219703047293063
of,0.21514655952836018
authors,0.16886903179297974
from,0.17563523498017147
European,0.18621710677782827
countries,0.1673168599749503
tended,0.2710788259254631
to,0.21062602535110997
choose,0.23947578159896238
the,0.06480558415254084
open-access,0.028447325152643685
option.,0.05316764323516403
In,0.028087402431370614
many,0.028632891916701275
of,0.018254730428032932
these,0.027627568223663027
"countries,",0.026649967735573623
funds,0.045930458658588434
for,0.03447666848405949
page,0.022301136522850543
"charges—and,",0.04625453261264203
by,0.032794171670170624
"extension,",0.026763111416404247
open-access,0.024903382560814535
publication,0.013959572504058375
fees—are,0.037203783246753865
often,0.02446339011099394
not,0.027706715180981632
included,0.03175704622528472
within,0.019575560969587038
research,0.019435371860389843
grants.,0.014855503078874283
PNAS,0.03567017663038381
was,0.08643210613023763
one,0.049170907331696226
of,0.06235985184877217
the,0.06478809516465275
first,0.0667421376974843
journals,0.020224387629668827
to,0.057401374791707954
offer,0.054636812031019596
an,0.05706168545129544
open-access,0.03328514754998928
option,0.04761652680220844
to,0.0499866008326535
its,0.034021764162726585
authors.,0.025843051410515527
"However,",0.013280207788534412
such,0.010945965975654838
hybrid,0.010446160615442632
journals,0.008842650131759978
are,0.01037744214440869
increasing:,0.009817868140170168
"Blackwell,",0.012708096178959257
"Springer,",0.01247333413880739
and,0.010574858232651195
Oxford,0.009045150456367397
University,0.008355470350906205
Press,0.009644244644098745
now,0.008608549485372135
provide,0.010799230438988151
this,0.013422125368439921
option,0.00947970929801744
as,0.008434704625263181
well.,0.006821148619261015
This,0.03162072741593036
means,0.046247728041445724
that,0.034245562315211704
similar,0.01014879914877927
experiments,0.01672498963099524
can,0.015320224317860055
be,0.00953599195457174
replicated.,0.009672111715845299
"Moreover,",0.15544217696423757
although,0.23133647124455198
the,0.15550460635565955
evidence,0.19263728384301101
from,0.1316024266458995
the,0.09741448200215572
current,0.10984786685560184
analysis,0.11599410299969411
argues,0.25588451519997013
most,0.23758204454171689
strongly,0.2580850226106332
for,0.248815983957327
a,0.23424155110908987
time,0.19393380144532202
advantage,0.2196498258934542
in,0.20690130112142885
citation,0.17498971432576904
for,0.14552017698649197
OA,0.11932507173476165
"articles,",0.1406284150574348
a,0.10487076645345593
study,0.1330854040839536
over,0.12120583919701164
longer,0.10558274426310117
periods,0.09103631832323461
will,0.0759204046912112
reveal,0.08318558018036346
whether,0.06529627002317726
this,0.11146959653818718
translates,0.09270714897730263
into,0.11190787932338178
a,0.12473275281941514
sustained,0.16218173599229713
increase,0.3487405073125587
in,0.3070143264679819
the,0.28080913208843045
number,0.22530032616109047
of,0.24089592569031934
citations.,0.19389358982581262
In,0.19104474578797637
the,0.20495173005832912
"meantime,",0.14352234456697718
open-access,0.14028246357186017
advocates,0.12685512450847566
should,0.1431431303831998
be,0.15585889267557854
emboldened,0.11624061249218974
by,0.1829201845346159
tangible,0.10536015928497151
evidence,0.16585702190318125
for,0.14386165333735476
what,0.15959946774692704
has,0.14343596100005943
seemed,0.14293426648489557
obvious,0.10455593078011893
all,0.11836283387290746
along.,0.09725202497913994
BACKGROUND,0.2903895095582931
Human,0.7706360544404729
papillomavirus,0.6083920684802995
(HPV),0.712057060673532
testing,0.7621283233304397
is,0.7774552402446144
known,0.7714960630952258
to,0.7661222743840249
be,0.8069246821342669
more,0.8461388705713764
"sensitive,",0.8049019862245194
but,0.8196521002189601
less,0.8289995393036022
specific,0.8177618788006658
than,0.8285882348605119
cytology,0.7240689897582584
for,0.791067000283541
detecting,0.7255418722452831
cervical,0.6756809801487266
intraepithelial,0.6839900455259232
neoplasia,0.6530189453790579
(CIN).,0.6167719118469045
We,0.0017965394738271542
assessed,0.0009672704644754538
the,0.0007597587344244267
efficacy,0.0006713509211531193
of,0.0009155219656325321
cervical-cancer,0.001011700861428713
screening,0.0008017269536637801
policies,0.0006795871808432376
that,0.0009202829306617069
are,0.0010287348455514103
based,0.000825297617938338
on,0.0011627482241549204
HPV,0.0007824765042058736
testing.,0.000564578122514064
METHODS,0.014519453119671205
Between,0.0031132809644539667
"March,",0.0016989891553604297
"2004,",0.0027791786646944256
and,0.002486454588549756
"December,",0.0012480615786278812
"2004,",0.002541242810976946
in,0.002973003585524051
two,0.005765850203269092
separate,0.004951962137229335
recruitment,0.0025276447191681438
"phases,",0.0023767897455416924
women,0.002897006020816451
aged,0.0019813567716332153
25-60,0.0018837811207439222
years,0.0017557180521012735
were,0.0024757383107793657
randomly,0.0015838441377940406
assigned,0.0020356237558927705
to,0.0026471196669186838
conventional,0.0026614296666934005
cytology,0.0018751330074405395
or,0.0029095791786155943
to,0.0027971058411242625
HPV,0.0030997846080362016
testing,0.002427916334335902
in,0.001912225709320849
combination,0.0023733900537844478
with,0.002002217700062268
liquid-based,0.0024373128723363786
cytology,0.006119071135085147
(first,0.0013413151827075883
phase),0.0016211068488996999
or,0.0013854036959806454
alone,0.001014827611198675
(second,0.0009886708214039985
phase).,0.0012524546135056394
Randomisation,0.0007893259440432979
was,0.0014598011902117627
done,0.0009138068657321272
by,0.001203519802753624
computer,0.0006703842090717152
in,0.0009934329052496678
two,0.0010297781668370807
screening,0.0009274443974308268
centres,0.0006628376492085677
and,0.0013568003796144684
by,0.0010710012935307353
sequential,0.0009524206290544914
opening,0.0008280292174580525
of,0.0009654762219799095
numbered,0.0008267307259154852
sealed,0.0009134954337893382
envelopes,0.0007883793469839859
in,0.000923995930421876
the,0.0012655493907029844
remaining,0.0010291497431992828
seven,0.001004428532114707
centres.,0.0007468260070776879
During,0.007260440308813947
phase,0.0026020025814731543
"one,",0.0036760133297061015
women,0.003286622805098338
who,0.0024344086421437213
were,0.00293193576730494
HPV-positive,0.0047305497531322845
and,0.006585066048545122
aged,0.002082892482164783
35-60,0.002024973839013726
years,0.001781394856081755
were,0.004866744123289712
referred,0.0034164679801609683
to,0.004439036657864244
"colposcopy,",0.0032753260510376804
whereas,0.00807914450717852
women,0.0034587139663501245
aged,0.001996613431144609
25-34,0.0017685078329204849
years,0.0015624353170142363
were,0.00550390649088423
referred,0.0036204708676463517
to,0.004875104181019245
colposcopy,0.004117354501102375
only,0.004189954363122148
if,0.0031990413147838523
cytology,0.0025123159705804747
was,0.0060130618173571794
also,0.0033737741296256413
abnormal,0.003132314085697845
or,0.006804946352574149
HPV,0.004797659464613155
testing,0.003699300748668842
was,0.005512234806884301
persistently,0.0036304104169994186
positive.,0.0029763199074124658
During,0.0035423132305086543
phase,0.0019098200680925253
"two,",0.0029799069528210057
women,0.0016906522715655463
in,0.0016753161950194158
the,0.00167070055792637
HPV,0.002172251898262364
group,0.002366305206561886
were,0.0017558918908124098
referred,0.001129454769069191
for,0.0018813726927862616
colposcopy,0.0013343913617866589
if,0.0011618209838585645
the,0.0014133938599685013
HPV,0.002144245829361064
test,0.0017218248283108598
was,0.0021382789547428763
positive.,0.0016083768186870094
Two,0.043981247351310274
rounds,0.02575291320957189
of,0.05488755039396541
screening,0.0044641735973170674
occurred,0.0036159446005933735
in,0.00260893870954987
each,0.0023663355999073063
"phase,",0.0021819101765615154
and,0.005968456266181828
all,0.003602500584622866
women,0.0030578174780681896
had,0.003643382614546496
cytology,0.0015408337524459562
testing,0.0020287557424574607
only,0.0024308371202219456
at,0.002491404898719521
the,0.002443174123664066
second,0.0024266283732769654
round.,0.0017708179712014808
The,0.001822586191783018
primary,0.0014225869007928587
endpoint,0.0013086848459938937
was,0.0030209006656164677
the,0.0023420625201655203
detection,0.0014344863603573512
of,0.0016758873126937947
grade,0.001710314601617508
2,0.0019316664486423445
and,0.004371362166098888
3,0.001881154222818394
"CIN,",0.001998853257641292
and,0.002099155561567423
of,0.0014698382593891688
invasive,0.0010473693610708063
cervical,0.002051997909587736
cancers,0.0013888843269210176
during,0.0018666813252322257
the,0.002146376174978042
first,0.0018790719716542548
and,0.0025809409886948316
second,0.0018103605222805688
screening,0.0013467460852389975
rounds.,0.0011844342291719569
Analysis,0.001092876143009571
was,0.0017829743856040002
done,0.0011759343173071324
by,0.001617191468652332
intention,0.0009769147059014304
to,0.0014205393073888064
screen.,0.0009382172643449924
This,0.0016509363595840546
trial,0.0011273358585992136
is,0.001435127531924267
"registered,",0.0009074539289648498
number,0.00105925394318761
ISRCTN81678807.,0.0008477347438634531
FINDINGS,0.005495449960778736
In,0.004834668970763255
total,0.0023994527161815007
for,0.0032198915173734296
both,0.0037170686505477923
"phases,",0.0018863721765944841
"47,001",0.0013859546521373678
women,0.0021767116220749757
were,0.002270718223257651
randomly,0.0010919169216588767
assigned,0.0011951807579104105
to,0.0014038877468290278
the,0.002200926084604018
cytology,0.0016098606631476536
group,0.0013099618078062118
and,0.0024533594067450925
"47,369",0.0012236428157214828
to,0.002098591284633949
HPV,0.002532451573858886
testing.,0.0014463850024731292
"33,851",0.004347602060258653
women,0.007282297291670813
from,0.010679311947259419
the,0.006310755954553189
cytology,0.003357440625418398
group,0.012784397216448215
and,0.011139910466319392
"32,998",0.010923169486198874
from,0.012421799197913207
the,0.007991634212754289
HPV-testing,0.005074650981002567
group,0.0060480166132780705
had,0.00804999432704384
a,0.004720117333675715
second,0.005775867625192428
round,0.00305647171899419
of,0.00416188427732882
screening.,0.003952323759930085
We,0.008614627433454983
also,0.0044425403688437845
retrieved,0.003247502850679253
the,0.003377198934854756
histological,0.0015170686119086744
diagnoses,0.0011545615698995834
from,0.0021924832164007565
screening,0.0026227185249454656
done,0.0022856617625096544
elsewhere.,0.0035051952146910917
The,0.1112480012126933
detection,0.1460758489074503
of,0.11070614020173616
invasive,0.14161230333827954
cervical,0.16850519629117572
cancers,0.14953985399905012
was,0.17318659065280495
similar,0.15418070869215275
for,0.151188469855238
the,0.14384612732332464
two,0.15373462514319414
groups,0.12443608837178985
in,0.15277656521715893
the,0.13660773622251798
first,0.17131122526726986
round,0.1026217034572142
of,0.14613527157708422
screening,0.1477288881371464
(nine,0.1862037841997406
in,0.20572438298638748
the,0.19060446472977105
cytology,0.22947300604572127
group,0.21348923704710565
vs,0.18358980786329118
seven,0.14731091797922216
in,0.19257991707555663
the,0.18316213074791363
HPV,0.2280040352247704
"group,",0.22889891422008626
p=0.62);,0.18782539706331705
no,0.1789882936625809
cases,0.1532455458485028
were,0.12323228561104455
detected,0.11968637368965086
in,0.15388918320680042
the,0.1546568831124402
HPV,0.24835721729907848
group,0.1632015336513317
during,0.13605841996157772
round,0.09086015535173747
"two,",0.15409754057540231
compared,0.21084563619770125
with,0.15964627381515795
nine,0.13358448074826926
in,0.16076481905772705
the,0.1653465113058445
cytology,0.1788269486379131
group,0.12876946172687362
(p=0.004).,0.18944417925680446
"Overall,",0.10022831207164046
in,0.14660745929626043
the,0.12294020536594558
two,0.13301862384332291
rounds,0.061124969574686217
of,0.07725904416479612
"screening,",0.07428608825697212
18,0.09875284231989857
invasive,0.12130746920924057
cancers,0.09192234256462063
were,0.08430228988379032
detected,0.12174185754300451
in,0.10138068379454554
the,0.16971490823168164
cytology,0.2843219947453531
group,0.19623058320333206
versus,0.18552038064683987
seven,0.1321340912182532
in,0.16361511750155922
the,0.17208046445161046
HPV,0.15273778604741986
group,0.17564112072286409
(p=0.028).,0.1786540671757237
Among,0.3701580972835354
women,0.368400328314226
aged,0.23872230355554444
35-60,0.20683028747596272
"years,",0.20115960319991497
at,0.4052194841360552
round,0.38560250048503775
one,0.40146615559765364
the,0.37259911815206476
relative,0.4187162185141954
detection,0.42983648667877966
(HPV,0.4260453764792016
vs,0.36402550071493156
cytology),0.36716191598684567
was,0.40644709060545303
2.00,0.534480339330349
(95%,0.4370928919903755
CI,0.5145616208073467
1.44-2.77),0.5213990129153959
for,0.3728603463578239
"CIN2,",0.4396702922236417
2.08,0.5448322630453434
(1.47-2.95),0.4031807162675379
for,0.3687012513900706
"CIN3,",0.42587484148861093
and,0.47560172523331845
2.03,0.5189968803661383
(1.60-2.57),0.3572933087837033
for,0.3424206040597528
CIN2,0.37460716084197376
and,0.4230931734475134
3,0.3858382618799703
together.,0.4191944533617216
At,0.31521989047799903
round,0.2825900886706352
two,0.28085695946964706
the,0.25027549320038533
relative,0.289806487838414
detection,0.35736450300564926
was,0.31497699161031045
0.54,0.24055622324696027
(0.23-1.28),0.23340253376423206
for,0.2395293527750931
"CIN2,",0.30506972593182796
0.48,0.15067130130117673
(0.21-1.11),0.1209236969157593
for,0.1195175562112368
"CIN3,",0.10607322904776573
and,0.14557443743490675
0.51,0.0694972429658503
(0.28-0.93),0.10457597178090636
for,0.0983048054221696
CIN2,0.06276559999282437
and,0.09542819811838628
3,0.05666354991450764
together.,0.07849239865757436
Among,0.006315108204432684
women,0.007571667488746876
aged,0.0035512762013921004
25-34,0.00462228259552738
"years,",0.0036951625310063002
there,0.005306978317058979
was,0.00516467872091078
significant,0.006425455216232279
heterogeneity,0.006240092608407567
between,0.006634607358405425
phases,0.003748873933410105
in,0.004833594254979532
the,0.004747336238089605
relative,0.00495393383084679
detection,0.006486287313118345
of,0.006360084692995768
CIN3.,0.010100236387602156
At,0.0909952019365249
round,0.04236923680400351
one,0.04710932680413238
the,0.07701615238830874
relative,0.08529432229436289
detection,0.1096673455078623
was,0.1263623079728675
0.93,0.042397023295676475
(0.52-1.64),0.08245783750710299
in,0.09843892177869921
phase,0.05129466095245185
one,0.08161138958345586
and,0.11866251444166823
3.91,0.11300666677307948
(2.02-7.57),0.08268747725715757
in,0.10587798181053858
phase,0.04660706900103716
two.,0.07816607043350314
At,0.12357245245108928
round,0.0538482354392608
two,0.07175349660708528
the,0.11096370632469021
relative,0.10691248937801597
detection,0.11191995255244501
was,0.1545941786573472
1.34,0.1776025124830235
(0.46-3.84),0.1425264349596661
in,0.14661685581719086
phase,0.08871137166649978
one,0.17058585826567613
and,0.21325609120587
0.20,0.011335286586377013
(0.04-0.93),0.00396629187764791
in,0.00347714158874526
phase,0.0015096201812963967
two.,0.002651097003008392
Pooling,0.0017720718012552792
both,0.002364290546489163
"phases,",0.0014379261390047374
the,0.0026539397126708925
detection,0.001550561303983984
ratio,0.0024554270019998396
of,0.0025365912286106243
CIN2,0.0017357891237581881
for,0.0018054972451238436
women,0.001848917440073684
aged,0.0017268785958789285
25-34,0.002191313617887527
years,0.001651866767176724
was,0.0021325183885324756
4.09,0.0037790613200565045
(2.24-7.48),0.0029613965824275995
at,0.0021344593672793645
round,0.0019930615695219027
one,0.002817043068981452
and,0.0031092862945281846
0.64,0.0023922117344379735
(0.23-1.27),0.002640284453393607
at,0.0022131431328707156
round,0.00199547499012214
two.,0.0032503062824681813
INTERPRETATION,0.6068293218932148
HPV-based,0.710853065841907
screening,0.7123621921856609
is,0.7811077745407686
more,0.8546583488233198
effective,0.8423176852532993
than,0.8823821905323048
cytology,0.849536584563353
in,0.8916572278724775
preventing,0.7955075010519206
invasive,0.7976119079291115
cervical,0.8136454878050529
"cancer,",0.6839962359692515
by,0.907450255010929
detecting,0.8238506887462056
persistent,0.8466940698473041
high-grade,0.8570348367703484
lesions,0.7835992463439824
earlier,0.8673760865773916
and,0.9028274604581359
providing,0.8801452944832663
a,0.8677029216693287
longer,0.8876037361609267
low-risk,0.8059001887557435
period.,0.82083130518802
"However,",0.7351487962570451
in,0.6172183700721379
younger,0.5463196887601367
"women,",0.6268681284457773
HPV,0.6018831503466748
screening,0.6316057531773865
leads,0.032709616869285765
to,0.025882347069517635
over-diagnosis,0.01766460016437898
of,0.014316983987063919
regressive,0.01243118838147449
CIN2.,0.015344081294468865
FUNDING,0.010453258416661882
European,0.003557352521040535
"Union,",0.007089079124615486
Italian,0.010181205730622638
Ministry,0.005911279006674723
of,0.014276024426653898
"Health,",0.005210035166175376
Regional,0.004944767035335931
Health,0.005001997368878247
Administrations,0.007144781146453338
of,0.012066505782962552
"Piemonte,",0.015332587373978353
"Tuscany,",0.006516850429901585
Veneto,0.012587446948251708
and,0.008737853858201436
"Emilia-Romagna,",0.008651914566608434
and,0.008562642735351768
Public,0.005707511633431887
Health,0.0038797523491948967
Agency,0.005310504729217046
of,0.012896318905660765
Lazio.,0.007791729505870087
Delayed,0.08847470069318245
T,0.057016264723753506
cell,0.06878949597451758
recovery,0.09188033431140527
and,0.15008501808158617
restricted,0.08292708145623712
T,0.03667938849406991
cell,0.0532551531087866
receptor,0.06303972602129107
(TCR),0.02449107508016686
diversity,0.059384104836044276
after,0.10013610960358699
allogeneic,0.047144888305680116
hematopoietic,0.03292262204244166
stem,0.032006433067117125
cell,0.04165693747410375
transplantation,0.05514634734366162
(allo-HSCT),0.04051233303865938
are,0.07069722835674738
associated,0.052555522444786354
with,0.0651719083125227
increased,0.055513795243178884
risks,0.02961753064791495
of,0.04074580919658064
infection,0.016175993915456655
and,0.050094831185487666
cancer,0.016988590322131084
relapse.,0.015944077082238543
Technical,0.003797370492831649
challenges,0.0027439752497696547
have,0.005536792210676818
limited,0.005311802068030048
faithful,0.004183661138656485
measurement,0.004045903716234267
of,0.00392279932522087
TCR,0.0039334432315083255
diversity,0.003576549337176578
after,0.0074203803281393315
allo-HSCT.,0.005529432466681013
Here,0.11943177037228662
we,0.07562549799007191
combined,0.043595528700249776
5',0.04579523058674171
rapid,0.046817308190869364
amplification,0.02495780155579455
of,0.04880679949599707
complementary,0.05030481028630693
DNA,0.07385654999280572
ends,0.12170511574610861
PCR,0.045480865653119734
with,0.04943737979131875
deep,0.04289909095238599
sequencing,0.03076711955071758
to,0.04916956973119312
quantify,0.02357911881335565
TCR,0.0417737042317807
diversity,0.05083294154880531
in,0.03670267189820476
28,0.026504438114173794
recipients,0.07344277140319713
of,0.036174370886888116
allo-HSCT,0.03278356715813168
using,0.020956349089322743
a,0.016240583195982
single,0.012286956838272649
oligonucleotide,0.03320889905465316
pair.,0.033449658488308234
Analysis,0.1599256861200717
of,0.12735728674252197
duplicate,0.1512697288324072
blood,0.10076165349837624
samples,0.12277965459127449
confirmed,0.27027091139327053
that,0.30727878498035793
we,0.17831364828488458
accurately,0.18339413093972437
determined,0.1438387795634931
the,0.09105880675529102
frequency,0.10144412000613234
of,0.14357480526731822
individual,0.4903651780971855
TCRs.,0.48268760554524975
After,0.6737758243163254
6,0.6251357374900935
"months,",0.5937179511341084
cord,0.6992317703367879
blood-graft,0.6682145130757937
recipients,0.6617377676269175
approximated,0.6363500510097265
the,0.6217664935762772
TCR,0.6405360535190807
diversity,0.5863360653391587
of,0.6432083418177675
healthy,0.7267863044785029
"individuals,",0.6464613644434373
whereas,0.6948632279659077
recipients,0.7038576821771592
of,0.7206639061034898
T,0.7245964840463832
cell-depleted,0.7963741560652322
peripheral-blood,0.7274742913407812
stem,0.7292309487386766
cell,0.7597939921136075
grafts,0.7497141893471827
had,0.7084241497810436
28-fold,0.698985269677826
and,0.6799026351093042
14-fold,0.7112490166642367
lower,0.7386697531733835
CD4(+),0.7547208760969658
and,0.7430706745833191
CD8(+),0.7487423385998901
T,0.7328745288701937
cell,0.7005637902924394
"diversities,",0.6567175043690789
respectively.,0.6278174053671308
After,0.22260843693758744
12,0.20172295544923835
"months,",0.22638391825624657
these,0.305620341040975
deficiencies,0.21216100575723534
had,0.23977431375420238
improved,0.22509495664580748
for,0.23598601687289927
the,0.2360413390437973
CD4(+),0.2455728422010379
but,0.2394787017737432
not,0.2639105960356858
the,0.21725911728509426
CD8(+),0.23454566676802316
T,0.22566319046461103
cell,0.2581393005071315
compartment.,0.21632401412683314
"Overall,",0.12169866811928497
this,0.11816861788887456
method,0.10318477446978036
provides,0.08313405450300687
unprecedented,0.09885203441040796
views,0.0965290351787286
of,0.08553263094657701
T,0.12567179892924818
cell,0.15580337155125767
repertoire,0.12367329405637709
recovery,0.0766252714644163
after,0.14179442090110103
allo-HSCT,0.5713080198683852
and,0.547943541421861
may,0.4046701226780255
identify,0.4898182931365679
patients,0.48582371762497867
at,0.35398826940362343
high,0.41897563873034305
risk,0.40924108452029817
of,0.5413604098201588
infection,0.45921983092015844
or,0.4039894060311587
relapse.,0.5424152330611075
More,0.003955752946338228
than,0.0014830571136212833
"ever,",0.002041364012059838
clinicians,0.0007492596939796881
need,0.0013629826719721864
regularly,0.0011046462732358408
updated,0.0008282693104485962
reviews,0.0007949587803756502
given,0.0009270713471438395
the,0.001019927117368694
continuously,0.0014054435055515899
increasing,0.00122907511525686
amount,0.0011381987466032935
of,0.0009562007606460665
new,0.0006498720767280021
information,0.0008245351469665834
regarding,0.0007902985284087532
innovative,0.0006793757512916881
cervical,0.0013739170456570388
cancer,0.0012343189780014093
prevention,0.0007081344622530689
methods.,0.0005899173914198307
A,0.002636534566909263
summary,0.0018832441548787193
is,0.0029187076859077993
given,0.0020629962941452027
from,0.004927064965222953
recent,0.002031944621317966
meta-analyses,0.0013573386833810723
and,0.0025876765066499274
systematic,0.0014511748413116095
reviews,0.0015029322552245598
on,0.0023113262106740098
3,0.003560709231650224
possible,0.0018899217983056984
clinical,0.0014706457500674901
applications,0.001529114188700932
of,0.002263819076004376
human,0.002524672150905058
papillomavirus,0.0017005949060323194
(HPV),0.0016553118985691145
testing:,0.0014451813239390822
triage,0.0012910434177216938
of,0.0022783861469687747
women,0.0025732479665905765
with,0.002133483581872885
equivocal,0.001984682377831525
or,0.0018044542661835884
low-grade,0.002200720324607835
cytologic,0.003058625071639792
abnormalities;,0.0019332984538842322
prediction,0.0014236660326427798
of,0.0018668008244289163
the,0.0018632794710107421
therapeutic,0.0025789243585641196
outcome,0.001727197157144194
after,0.0022461415487532582
treatment,0.003461896494457036
of,0.004280514693831951
cervical,0.007484044244224197
intraepithelial,0.011383249853602994
neoplasia,0.008913651883777097
(CIN),0.0016714399722272152
"lesions,",0.005379708801105378
and,0.003773913526955651
last,0.005593956583707369
not,0.011543469013989189
but,0.0098486216905968
not,0.01853503925388865
"least,",0.009579870368135254
primary,0.002073394338048613
screening,0.002889040447139702
for,0.003874126562742193
cervical,0.012826779956509146
cancer,0.005145187742623077
and,0.003403543105929352
pre-cancer.,0.30466134107782533
Consistent,0.08780225179583416
evidence,0.17846221261037787
is,0.07303324260813562
available,0.07094941653255128
indicating,0.1459464837501054
that,0.3084912781540444
HPV-triage,0.3141996067783133
with,0.2862986539491086
the,0.18809988577696843
Hybrid,0.2602765456785381
Capture(®),0.15343020237893057
2,0.19781234136740647
assay,0.1594505203475715
(Qiagen,0.2424162961776208
"Gaithersburg,",0.1030713832353132
"Inc.,",0.12504047643496838
"MD,",0.22216961333433435
USA,0.22867103649004034
[previously,0.21141052103928462
Digene,0.16722445424750063
Corp.],0.1602214610755306
(HC2),0.28069110770599104
is,0.43993415989674756
more,0.6244784892549329
accurate,0.46598607515170715
(higher,0.6076593970017939
"sensitivity,",0.410260123412165
similar,0.5745569169521668
specificity),0.3113861905032373
than,0.6618001184534167
repeat,0.36757216147184496
cytology,0.33231099553811966
to,0.47774242637139774
triage,0.251955707239628
women,0.30507715613588104
with,0.3984095442421637
equivocal,0.29277689193293127
Pap,0.24538154900737102
smear,0.13838435684496236
results.,0.3376096586886392
Several,0.06522384183190603
other,0.05565111950252835
tests,0.04129966148091229
show,0.06318761156643783
at,0.04695816926944316
least,0.038769096871862335
similar,0.04897524402576002
accuracy,0.05792672600133026
but,0.09864604336617154
mRNA,0.057167688006037484
testing,0.09615519015031528
with,0.060263257033327
the,0.03947930984965509
APTIMA(®),0.03302491516594028
(Gen-Probe,0.041000395837670664
"Inc.,",0.02504958331391392
San,0.03438420916068125
"Diego,",0.07205763305353322
"CA,",0.057300715343340865
USA),0.05796170241323128
test,0.0787976618267996
is,0.15179141609091124
similarly,0.197934163130062
sensitive,0.17138285693262767
but,0.29019715666935
more,0.3219084707010937
specific,0.17204049722197554
compared,0.23001984687185562
to,0.22273906017939715
HC2.,0.20297716176474304
In,0.4513427766403367
triage,0.19961076512217643
of,0.2411878124548394
low-grade,0.22498565447216792
squamous,0.16975056494630225
intraepithelial,0.1738474315837532
lesions,0.2184975764355971
"(LSIL),",0.16367704375357855
HC2,0.3709737691747337
is,0.37286930833128706
more,0.4954388326583128
sensitive,0.35900272545814665
but,0.49097596727391923
its,0.349049210828594
specificity,0.2502921466596907
is,0.34671133082068345
substantially,0.42789736395261235
lower,0.4254027900957459
compared,0.46574789781041603
to,0.3544447488684596
repeat,0.372699348866875
cytology.,0.27409236027971084
The,0.004212395489793385
APTIMA(®),0.005185277356424389
test,0.004832056574792065
is,0.004602926880252795
more,0.006393011022329012
specific,0.0026436121630365635
than,0.007815010616173545
HC2,0.009112595015518485
without,0.025575366314025624
showing,0.006916236411771182
a,0.00922608616314965
loss,0.008563952370741612
in,0.008214054597861575
sensitivity.,0.002698374178914525
Identification,0.007693748456828594
of,0.0059490609460395045
DNA,0.006056465681769764
of,0.0062275248979992625
HPV,0.008693689898351831
types,0.006810166004699117
16,0.006850004769783198
and/or,0.00849013897121477
"18,",0.006452839368875947
or,0.007795715555356691
RNA,0.004277871391524586
from,0.00831281404897047
the,0.005508430202272617
five,0.0063157650398156
most,0.005717226339234259
carcinogenic,0.0063132757083753125
HPV,0.011516953418607792
types,0.005497475220445004
allow,0.009016895779776248
selecting,0.004591457022423225
women,0.007236698933571246
at,0.003776098623855143
highest,0.003374036281506713
risk,0.0026548328255153533
for,0.005945204624030911
CIN3+,0.007335548656335604
but,0.007159810290779764
the,0.004341066901451939
sensitivity,0.006634850917282771
and,0.008788445907094794
negative,0.005364592242147179
predictive,0.0043833312336832575
value,0.006591662025623013
of,0.007114062258943049
these,0.0052095829204401355
markers,0.007527754279440304
are,0.009347333609975831
lower,0.4506813860144336
than,0.5028028108430608
full-range,0.3793685569034281
high-risk,0.2759540599251562
HPV,0.2859204714985444
(hrHPV),0.34567531761111814
testing.,0.45465138375585296
After,0.8685268212687063
conservative,0.8567770840672079
treatment,0.8580107113357941
of,0.8695787460508839
cervical,0.8761877716869798
"pre-cancer,",0.8782217480849434
HPV,0.8689055883267329
testing,0.8671352551712647
picks,0.8815399763278814
up,0.9116328289974124
more,0.9163407632524361
"quickly,",0.9021140008489795
with,0.9202545271169933
higher,0.9035919213709777
sensitivity,0.8754445347308221
and,0.930441993636365
not,0.9300510708768434
lower,0.9055286816988369
"specificity,",0.8697879829804483
residual,0.9134516107589684
or,0.8994072086824912
recurrent,0.9160731800163128
high-grade,0.8951991537116019
CIN,0.876985480075066
than,0.9349407192385578
follow-up,0.8881551933736075
cytology.,0.8720845278226299
Primary,0.8647436672554325
screening,0.8386137533493323
for,0.8377514887459223
hrHPV,0.7523049053672194
generally,0.8513873865330216
detects,0.8741020709624973
more,0.8793444220994368
"CIN2,",0.8462259076461224
CIN3,0.8190778646392007
or,0.8460708436025556
cancer,0.8275314963498158
compared,0.8995312905578717
to,0.8614417734413056
cytology,0.8574747669689736
at,0.8704618420455437
cut-off,0.8601244435768262
atypical,0.830031148333543
squamous,0.8246036451149134
cells,0.8331051421080222
of,0.8118902830868151
undetermined,0.703030407099895
significance,0.7306988120699288
(ASC-US),0.7047292964368735
or,0.729334492829251
"LSIL,",0.7331343178396517
but,0.8180971215908341
is,0.83413073211068
less,0.8681700761412408
specific.,0.015052286577214712
Combined,0.017584659904978883
HPV,0.014286073015594848
and,0.012844691444553918
cytology,0.009014633564540755
screening,0.013808179647082933
provides,0.017853317686493616
a,0.017346367550659603
further,0.023970384030931078
small,0.01713865477712648
gain,0.017288812295401045
in,0.017672201757252756
sensitivity,0.007832112829394253
at,0.02210421170845475
the,0.019076522556337565
expense,0.02160130504489765
of,0.023629407728952993
a,0.015284815911162257
considerable,0.01725126788906672
loss,0.009121158587590116
in,0.01069957578452836
specificity,0.0031305338355296685
if,0.008648175190524054
positive,0.0029453349459708776
by,0.005201486181915549
either,0.005530891834409357
test,0.004642176483292043
is,0.0029804722680296792
referred,0.0034978719358741877
to,0.002780234769331356
"colposcopy,",0.002794140105748787
in,0.005310688604672306
comparison,0.008740830116891005
with,0.004104642642504354
HPV,0.005052286307017275
testing,0.0036303750581574198
only.,0.0029869903135378217
Randomised,0.003627439746673756
trials,0.006968504154790469
and,0.010538392429485238
follow-up,0.004047193201530085
of,0.0042803500748949935
cohort,0.0034916587645073714
studies,0.00693010227079486
consistently,0.010103950964393748
demonstrate,0.009225870407424421
a,0.008041578106433108
significantly,0.008722880423861384
lower,0.007472092518883888
cumulative,0.0036675328882554083
incidence,0.005930189258224068
of,0.00673028810339701
CIN3+,0.013370588320579555
and,0.016952538879729317
even,0.010228471280216301
of,0.005122269585592021
"cancer,",0.00608126508946476
in,0.0072311307834413375
women,0.004977792152895636
aged,0.0020318827382306125
30,0.00246544627717234
years,0.0020734180171009405
or,0.0029997988074863965
"older,",0.0025474448306778957
who,0.004260833685238278
were,0.005482107562704972
at,0.015047105547188657
enrollment,0.04290212569791119
hrHPV,0.004108408290682036
DNA,0.008671445019148422
negative,0.005894630127778923
compared,0.016444354199161768
to,0.007562539592347593
those,0.007545955478159925
who,0.0071980956166278285
were,0.008061983901745695
cytologically,0.006696013781704626
negative.,0.005510266852107984
The,0.19730492611440614
difference,0.1966233425367459
in,0.13754538375979256
cumulative,0.16131678627352322
risk,0.17532687371845063
of,0.18682408900964725
CIN3+,0.15498308146806275
or,0.15585653224868387
cancer,0.1561585896876364
for,0.1901581534982787
double,0.014636747477873
negative,0.00945560413501561
(cytology,0.014563538512815557
&,0.020404483391700035
HPV),0.01030108103682059
versus,0.01710840735402703
only,0.018686822765199902
HPV-negative,0.011203633802842798
women,0.015830741344268234
is,0.009891241058321615
small.,0.008733755660197856
"HC2,",0.007545941194012663
GP5+/6+,0.01155022574016634
PCR,0.005085031847638258
(polymerase,0.003120457864344783
chain,0.0035772036396480925
"reaction),",0.003215961495213259
cobas(®),0.005204207154965541
4800,0.0020919905249367305
PCR,0.002372138283897652
(Roche,0.002956447639904308
Molecular,0.002888342044594589
Systems,0.004371851968022138
"Inc.,",0.0027945334069574847
"Alameda,",0.0023799899306321606
"CA,",0.0025584043777208128
USA),0.0023159644728832462
and,0.0017099596704172224
Real,0.0010918383896763523
Time,0.001677572683507743
PCR,0.001758720016386179
(Abbott,0.0027379905990416865
"Molecular,",0.001918409627849673
Des,0.0016754318386327637
"Plaines,",0.002908779706805493
"IL,",0.0014786172750733463
USA),0.0016360027948103739
can,0.0012691196666565127
be,0.0011709964846774897
considered,0.001127222567915577
as,0.0012528095627323066
clinically,0.0007588797494361264
validated,0.0010404498309038383
for,0.0015321610820039702
use,0.0016326179925749795
in,0.0013117465228631615
primary,0.0010192197320393359
screening.,0.001097603852863327
The,0.0031504245069589863
loss,0.003527587033639984
in,0.004555844475430655
specificity,0.001823828430179442
associated,0.005289870408881295
with,0.004693096072531589
primary,0.0034144059017546793
HPV-based,0.008835575430594197
screening,0.0034592514452410064
can,0.002502226309536495
be,0.002115244389807222
compensated,0.0025659786910137575
by,0.0024947863119230795
appropriate,0.002252219603120526
algorithms,0.002157075019730302
involving,0.006510956478643944
reflex,0.0029296665844695644
cytology,0.0023405739083236015
and/or,0.0032023699854442727
HPV,0.005478471723261018
genotyping,0.0023193455420881773
for,0.05653492693226983
HPV16,0.04732728181401722
or,0.03821698097487129
18.,0.021340173069503175
There,0.022466750847776527
exists,0.018748666934365204
a,0.025039698299337814
substantial,0.0279959633549985
evidence,0.028535142010820372
base,0.015266597113397801
to,0.01605935056263314
support,0.04608029670769849
that,0.04880437001541538
HPV,0.04232467835602573
testing,0.04853433075341742
is,0.034635220877771926
advantageous,0.05559543794465254
both,0.05337477885078506
in,0.07501480949797532
triage,0.025052570523706907
of,0.033554166316445484
women,0.036764843164699405
with,0.04292253234293746
equivocal,0.05566645804893245
abnormal,0.05360288877911138
"cytology,",0.04047364002991138
in,0.08632698368755798
surveillance,0.059356190850930225
after,0.03722735248201161
treatment,0.045732620191432594
of,0.0457977102349933
CIN,0.049898628667788374
lesions,0.10073450201795658
and,0.06051752820501117
in,0.0778027685360027
primary,0.03684623735081677
screening,0.03861699868829819
of,0.019090956184113727
women,0.021752787565802397
aged,0.007638431843949387
30,0.011563328532945671
years,0.009930882538051045
or,0.005392908195130407
older.,0.009657595851854574
"However,",0.0036804964819608225
the,0.0014426327088075514
possible,0.0011775007535457327
advantages,0.001363002143159672
offered,0.0014337324873886302
by,0.0013657971893805874
HPV-based,0.0023738140440364695
screening,0.0012176802494214128
require,0.002076916105197509
a,0.0015769258736869115
well,0.001502031613512907
organised,0.0013094269910343779
program,0.0011952917620224309
with,0.0013845493220323165
good,0.00146978752162234
compliance,0.0011950185396523267
with,0.0013439237351423536
screening,0.0008094363398290188
and,0.0012403177282514619
triage,0.0009986545190879463
policies.,0.0010951129062473095
This,0.01471914031057046
article,0.010557751627302492
forms,0.010984523169948806
part,0.008356173642034843
of,0.011354876368775928
a,0.008297880089956253
special,0.005412967935696344
supplement,0.007874763677314508
entitled,0.007468617090709323
"""Comprehensive",0.006656509664748444
Control,0.0029361115394012285
of,0.005608566842909244
HPV,0.009954737238270518
Infections,0.00453564494977769
and,0.005259055894085161
Related,0.005386322358719302
"Diseases""",0.002903579502923007
Vaccine,0.015930445895800224
Volume,0.009437809732836715
"30,",0.004869409839940461
Supplement,0.00860762981820514
"5,",0.006554214616256267
2012.,0.011628748033004411
The,0.02091558401600506
Sir2,0.019669236371264498
deacetylase,0.01681455339935613
modulates,0.005127881029014142
organismal,0.0036582349961889284
life-span,0.005873923546668069
in,0.007168828923477099
various,0.003950319452772906
species.,0.005465329715294906
"However,",0.0026278706713582763
the,0.002793040218477081
molecular,0.003674864366770266
mechanisms,0.003345978395338836
by,0.0022650779338559465
which,0.0035126155548591454
Sir2,0.013311089944616059
increases,0.007481365225736657
longevity,0.004765183695796459
are,0.0023678698439773267
largely,0.002356641351323028
unknown.,0.0026446527333715587
We,0.30366236542050334
show,0.2785076429637214
that,0.22418494543600995
in,0.1781427000077502
mammalian,0.10682882367177068
"cells,",0.1523071301962829
the,0.14940068613067345
Sir2,0.10763420008106021
homolog,0.13294073453291483
SIRT1,0.14048800850558965
appears,0.1331580330602061
to,0.1388655697162938
control,0.1444618910377598
the,0.130765852044893
cellular,0.1394798036928912
response,0.10156661083132013
to,0.08816434832011354
stress,0.12245755031347437
by,0.24900386021119716
regulating,0.16427321855343413
the,0.14720101333354382
FOXO,0.17403744091849022
family,0.11704609515246499
of,0.15287787499551947
Forkhead,0.17506032975476954
transcription,0.19078016009174525
"factors,",0.18617536214624641
a,0.16039059143100703
family,0.09001408423353095
of,0.12431360426380608
proteins,0.14456248290184986
that,0.16259537609635683
function,0.14597337311694925
as,0.21525228846886874
sensors,0.12699538385096373
of,0.16780815726311468
the,0.14743894613668324
insulin,0.14412743383583335
signaling,0.17920902146506798
pathway,0.16615225686747073
and,0.19447232941052156
as,0.17384257772748316
regulators,0.12935101536287566
of,0.11800486148173674
organismal,0.08490425665757334
longevity.,0.09491470514720449
SIRT1,0.26484060821685457
and,0.35446338590485865
the,0.35143056673855205
FOXO,0.43518654876482843
transcription,0.4327305628656467
factor,0.4275653935679666
FOXO3,0.4305291304836781
formed,0.3689704872018041
a,0.3834117516520238
complex,0.3786203670703961
in,0.424958099659649
cells,0.4582947184741558
in,0.40084222139153075
response,0.38942937903527525
to,0.34277946699634143
oxidative,0.399200130653061
"stress,",0.4896538164043459
and,0.609405442656558
SIRT1,0.5333960874549822
deacetylated,0.5469526988332346
FOXO3,0.4986823231684241
in,0.4237617205073349
vitro,0.35395605796568824
and,0.3812172849894235
within,0.41033648917094334
cells.,0.4008234526350683
SIRT1,0.6782710442158358
had,0.7104190027794821
a,0.7110596813448774
dual,0.5508918789956624
effect,0.6573572086175553
on,0.6577438257771345
FOXO3,0.7657294631768498
function:,0.8200194915900482
SIRT1,0.881768784817159
increased,0.9130160809371834
FOXO3's,0.8815941050066852
ability,0.9204999913353792
to,0.9247167945449207
induce,0.9319753766944444
cell,0.9255829861447588
cycle,0.9366650280503698
arrest,0.9106224450145148
and,0.942245523753131
resistance,0.9094634758921495
to,0.8885958091490838
oxidative,0.9166092749713528
stress,0.8827726199516517
but,0.9064442702809016
inhibited,0.9369802890960047
FOXO3's,0.875085990461112
ability,0.9149604385505712
to,0.9063493815918895
induce,0.919515175924944
cell,0.8676666601686254
death.,0.8507035099231347
"Thus,",0.6433891955283558
one,0.40918845235257384
way,0.42148350023520337
in,0.5043906409449737
which,0.4166992961613948
members,0.33848587301584104
of,0.3668892642282223
the,0.33271283321546313
Sir2,0.37653114138319466
family,0.27834097137674085
of,0.333231085673939
proteins,0.3711451705904951
may,0.344016691103657
increase,0.4659011669972724
organismal,0.3346067327272838
longevity,0.462393835171354
is,0.364371278665335
by,0.5882679669686554
tipping,0.5236325818429298
FOXO-dependent,0.562979036598781
responses,0.6410589471359905
away,0.6266796893466515
from,0.6509749833544356
apoptosis,0.6951081642732401
and,0.615175495928132
toward,0.599018377181425
stress,0.535305427006533
resistance.,0.5457238583932384
We,0.04149396090731841
examined,0.008418066793157075
the,0.005724575401376544
contributions,0.008555432166132668
of,0.010307305412137712
genetic,0.008245369086342845
factors,0.007947751999748875
and,0.007496039775285522
the,0.005453425396638487
family,0.013045420134583168
environment,0.007132585539925298
to,0.005378105455739844
human,0.009681095381106586
fatness,0.014092692101444117
in,0.009465548728024683
a,0.009752150651050819
sample,0.009935072486589109
of,0.014601066827496411
540,0.010511395656628548
adult,0.01121648405346647
Danish,0.021195987600022455
adoptees,0.023091331693240284
who,0.013138048864862932
were,0.012324750431052595
selected,0.011546780219555899
from,0.01095970882988119
a,0.009897213257452962
population,0.009465642615335461
of,0.014179501442350986
3580,0.007425810183744792
and,0.009279296683649779
divided,0.006233679324539967
into,0.008047769068796133
four,0.009728902975296785
weight,0.013654226207426325
classes:,0.007996332548227498
"thin,",0.014787026195598369
median,0.015939328889513566
"weight,",0.01937442572241277
"overweight,",0.014280259154694892
and,0.026078352042453498
obese.,0.010299258193967232
There,0.12987893905687609
was,0.11783389124549974
a,0.13745016915192337
strong,0.12079823608148321
relation,0.14134378294413258
between,0.08868183364575
the,0.07416845440066971
weight,0.16004304400327785
class,0.1528092410213694
of,0.1155763119293821
the,0.14073799920865726
adoptees,0.13738615842711913
and,0.06857387175720653
the,0.07094691780822575
body-mass,0.18368755505799858
index,0.13329465313337716
of,0.10459857290184707
their,0.12359141297592721
biologic,0.10984136855832348
parents,0.18932661466715253
-,0.19825828680631985
for,0.21170252475214502
the,0.13517050192893637
"mothers,",0.18882306071975896
P,0.17589630716044788
less,0.14950482086162967
than,0.15480401778964362
0.0001;,0.12263879231223414
for,0.2432249865400775
the,0.177747188878786
"fathers,",0.23092086382686494
P,0.21442046402111142
less,0.1843019000601595
than,0.18053830698565437
0.02.,0.13641011308477535
There,0.14871209190026452
was,0.11607526829747648
no,0.1256441439979874
relation,0.12276519172406367
between,0.07600119602116039
the,0.07237136079078232
weight,0.11262559298004855
class,0.11701619205538627
of,0.09827897255453562
the,0.1343090362845529
adoptees,0.15293389372282362
and,0.07119362198690064
the,0.0682861711342536
body-mass,0.14357034193268461
index,0.11504792842800848
of,0.09642213529768327
their,0.13018442291353008
adoptive,0.13207966564310844
parents.,0.16728178582831343
Cumulative,0.18066310879136002
distributions,0.11889306283959174
of,0.1057951763774092
the,0.08327503052163206
body-mass,0.18677281037275073
index,0.12125301860388711
of,0.09569634580860904
parents,0.17080847620259856
showed,0.16568876865725723
similar,0.1010258496009712
results;,0.13819192180947146
there,0.39685322757076136
was,0.38489130526439136
a,0.37304345694219626
strong,0.3518526963900101
relation,0.2722052328828759
between,0.18680446268328063
the,0.1984133978929264
body-mass,0.3227326923054917
index,0.30525745182380115
of,0.20498315621741153
biologic,0.2771890341813989
parents,0.2838544535465771
and,0.18255131289328988
adoptee,0.3200837703252611
weight,0.2815377818873727
class,0.27845930626651155
and,0.3735234854946156
no,0.32157449242923863
relation,0.23967884612343662
between,0.15787120976006935
the,0.1805609619547808
index,0.27470468266242676
of,0.18968732302036503
adoptive,0.2986479708900947
parents,0.28518542474718855
and,0.16093748768671842
adoptee,0.2843618325900744
weight,0.2601257355540316
class.,0.2411477146466386
"Furthermore,",0.215352626389356
the,0.07402948115269865
relation,0.07778939237375426
between,0.05511333670395413
biologic,0.08893290267709598
parents,0.1313897239839132
and,0.06300352995749933
adoptees,0.1140616312964165
was,0.12328421468500779
not,0.20724263583289507
confined,0.08844428715176723
to,0.08324213821952518
the,0.07756276308561096
obesity,0.10199299665181888
weight,0.08492250463189421
"class,",0.09077154946107852
but,0.17266362153220569
was,0.1328956706646278
present,0.09883529450298195
across,0.08682280666536002
the,0.07187018982919045
whole,0.0861790266573697
range,0.04915359364639266
of,0.07037534091393544
body,0.12626647436368246
fatness,0.12427126620241448
-,0.16871658925880215
from,0.138702576780719
very,0.1278078090136966
thin,0.11202086597062555
to,0.14140583276394003
very,0.11564231826713652
fat.,0.14187314377797447
We,0.405248920269652
conclude,0.3247680670649453
that,0.34231042866209804
genetic,0.19926183083438928
influences,0.21024924568969233
have,0.164344234551118
an,0.18570449723811855
important,0.19549458373802642
role,0.18201408164650626
in,0.1851178074844818
determining,0.1802836551495131
human,0.24221663449465425
fatness,0.24578663208514376
in,0.25648000078250455
"adults,",0.2758803777670063
whereas,0.30722987738408175
the,0.1910596507598021
family,0.2545891291638154
environment,0.23392467237520778
alone,0.213187501888644
has,0.13244046272195228
no,0.17572528137640947
apparent,0.142679097562188
effect.,0.15412384235178236
IMPORTANCE,0.004390993795287502
Exacerbations,0.002318673677693513
of,0.0019464805568933387
respiratory,0.001338613197642126
symptoms,0.00125375618719574
in,0.002410588832169996
chronic,0.0011719248994748381
obstructive,0.0023317169467678774
pulmonary,0.0013959283063203845
disease,0.001432235475576365
(COPD),0.0016928701497197583
have,0.001844357608843945
profound,0.0013551796485602179
and,0.0032642021933374293
long-lasting,0.001699633053870024
adverse,0.0008098626028190293
effects,0.0011062722325839997
on,0.0016158993391384364
patients.,0.0009567482197163831
OBJECTIVE,0.0016255535810816488
To,0.001182608754741967
test,0.0009728115252651918
the,0.00094367768604076
hypothesis,0.0008728867908064544
that,0.0015706721432841607
elevated,0.0014931265838349222
levels,0.001421181697702591
of,0.0016796406982763205
inflammatory,0.0012146614075869576
biomarkers,0.0013581471856906444
in,0.0017537042807278444
individuals,0.00110066179726993
with,0.001110201375538744
stable,0.0015483696039100812
COPD,0.001985821761534894
are,0.0015758650434193216
associated,0.0013946742454451968
with,0.001854780034366416
an,0.001237151505863285
increased,0.0012976480574392534
risk,0.0008589930688023678
of,0.002022218772851849
having,0.000972584475242743
exacerbations.,0.0010510306917694394
"DESIGN,",0.002100975261696943
"SETTING,",0.00499575377978555
AND,0.002614881404952454
PARTICIPANTS,0.0036885467680724425
Prospective,0.0016327209777250464
cohort,0.002220459649503353
study,0.003990819433263983
examining,0.0027785972509862295
"61,650",0.001611612083999674
participants,0.0015372016046216262
with,0.00208758083750722
spirometry,0.0013312591505917199
measurements,0.001711956707863453
from,0.0020561354262993653
the,0.002374985914619503
Copenhagen,0.002008590734341287
City,0.0012465661240592184
Heart,0.0013491505875273002
Study,0.0017682489986731308
(2001-2003),0.0029286026158967878
and,0.0018407803821437279
the,0.0016310060520288965
Copenhagen,0.0009233257662830995
General,0.0008729720465816713
Population,0.0015721111529412774
Study,0.0013316972811661528
(2003-2008).,0.0016334859911550886
Of,0.0027941022401335607
"these,",0.002479810849900118
6574,0.0018192844665471304
had,0.002517670875281812
"COPD,",0.0030909274490074985
defined,0.0012589475258545908
as,0.002217134856896166
a,0.0019402529593351668
ratio,0.002442244580171327
between,0.0018793599671897325
forced,0.002394595820983414
expiratory,0.0023443041793044864
volume,0.0021782325268655143
in,0.0026720858552940537
1,0.0029091379205463557
second,0.0022780523166526963
(FEV1),0.0016285899569993133
and,0.0025346477406436767
forced,0.002320270362670556
vital,0.002099192519497906
capacity,0.00269272432417446
below,0.002436780780052524
0.7.,0.0024029730936200168
MAIN,0.004891191765154441
OUTCOMES,0.003957951737272596
AND,0.003114176436117626
MEASURES,0.0025539801854145613
Baseline,0.003736057295019044
levels,0.0027780555882939645
of,0.00403854266348369
C-reactive,0.009128319677792507
protein,0.006348180648574028
(CRP),0.002949874029176138
and,0.0038167877310698686
fibrinogen,0.006831712036081471
and,0.003698427404397841
leukocyte,0.006358150359202381
count,0.0026227110409782085
were,0.004431655628202864
measured,0.0022338612496203662
in,0.004213726809423036
participants,0.003422494142938025
at,0.002964425157996666
a,0.003853734076103986
time,0.003546816752209851
when,0.005837287000832722
they,0.0035901774462577495
were,0.004909179033929412
not,0.004224115664127027
experiencing,0.0031334540647644086
symptoms,0.002360028896909117
of,0.0031854809613200167
exacerbations.,0.0033791808069159527
Exacerbations,0.003082669903250404
were,0.002181246902038326
recorded,0.001688730688494639
and,0.0028841750471461486
defined,0.001077939444057359
as,0.0024619798106135784
short-course,0.0022423868177962416
treatment,0.0026196145075508778
with,0.0037514615812507114
oral,0.08585455953290821
corticosteroids,0.04581853181903703
alone,0.056112909082919965
or,0.0269588963717896
in,0.02588759829851275
combination,0.02628059025609807
with,0.03468402868741489
an,0.025606043351165748
antibiotic,0.018109185363473765
or,0.02918414122898463
as,0.03284362749213456
a,0.019418605902575558
hospital,0.01910202742981058
admission,0.030224005700305947
due,0.028795499746991877
to,0.030729729997574274
COPD.,0.048288500626762494
Levels,0.003702605324189078
of,0.005358582106808974
CRP,0.005237226593937067
and,0.006055697882864023
fibrinogen,0.007746582957808677
and,0.005418150875978863
leukocyte,0.005953788893577243
count,0.005298871756317508
were,0.0041147617098206985
defined,0.0031242604050563333
as,0.004048777272487776
high,0.003548406302916515
or,0.0038911817474435156
low,0.0032933017845257423
according,0.004506080032443626
to,0.0042476424206044534
cut,0.002455780336444303
points,0.003873249820229663
of,0.005377006220751501
3,0.009143701840473207
"mg/L,",0.0035557919222605435
14,0.007000257715493606
"μmol/L,",0.007970051459870212
and,0.004476798343305397
9,0.004962852621402933
"×10(9)/L,",0.006072623340147882
respectively.,0.0030175204753199168
RESULTS,0.023912816939454146
During,0.01128297407953322
"follow-up,",0.015714246512939917
3083,0.004695059881726922
exacerbations,0.007026879473612995
were,0.0077738816581260275
recorded,0.006442992284032972
"(mean,",0.008714790476509793
0.5/participant).,0.007448809912311374
In,0.5709650475490874
the,0.4534342505369036
first,0.5257057354911591
year,0.3910587436378476
of,0.4994243497709705
"follow-up,",0.2600667647531741
multivariable-adjusted,0.49431406631602465
odds,0.5351021207305166
ratios,0.5248081614787526
for,0.5914082635143443
having,0.5642736620581745
frequent,0.5677869434020122
exacerbations,0.7731375172032128
were,0.7570805578530649
1.2,0.7813229447565926
(95%,0.781890460891135
"CI,",0.8031565335108439
0.7-2.2;,0.7918456133686912
17,0.7298088657633306
events/1000,0.7973857396975358
person-years),0.7975793072841939
for,0.8439630738588233
individuals,0.8692680058312298
with,0.8569671234343198
1,0.8728014464328896
high,0.8427724825732194
"biomarker,",0.8479408542580184
1.7,0.8687723755033181
(95%,0.8323985683876879
"CI,",0.8635501820945439
0.9-3.2;,0.8764297681619222
32,0.8361291671814556
events/1000,0.8625658358793225
person-years),0.8538478520346211
for,0.8734709649099522
individuals,0.8727052004854794
with,0.8635453921394994
2,0.8597338535663962
high,0.8497450029787565
"biomarkers,",0.8520418893352794
and,0.8453725784146925
3.7,0.875317637542011
(95%,0.8131263242394172
"CI,",0.842109461882121
1.9-7.4;,0.8233252777516249
81,0.7960768732534298
events/1000,0.827369770082967
person-years),0.8182599273127991
for,0.8548583555232143
individuals,0.8635603795917817
with,0.847674030176046
3,0.8249187610180748
high,0.8276558581274611
biomarkers,0.8046888457177915
compared,0.8804677091782045
with,0.8103860642144619
individuals,0.8436417446326764
who,0.8190424425239822
had,0.840264160812116
no,0.8100977123170923
elevated,0.8098639714911402
biomarkers,0.7875436352664864
(9,0.8285114548561918
events/1000,0.801192401062835
person-years;,0.7986866046376923
trend:,0.25800866037765124
P,0.3186089254937764
=,0.31459902940611084
2,0.2864175673962486
×,0.365532345358732
10(-5)).,0.2971883396002881
Corresponding,0.09258050554405721
hazard,0.17225575494470563
ratios,0.14568809033831573
using,0.1541817813668827
maximum,0.1387699159477917
follow-up,0.12370471816941389
time,0.19838927277381732
were,0.18189030106066972
1.4,0.27285436719142414
(95%,0.2017351166221865
"CI,",0.4636042664424709
"1.1-1.8),",0.41321337819317117
1.6,0.3836155759317995
(95%,0.24639329739786728
"CI,",0.5244218937225572
"1.3-2.2),",0.4501122958088041
and,0.19574977794826068
2.5,0.3063750257264865
(95%,0.17941074360449782
"CI,",0.4946169548975146
"1.8-3.4),",0.419881508265054
respectively,0.1295940794089917
(trend:,0.13842603701971917
P,0.15685518419875744
=,0.2664771768421926
1,0.10643589154380022
×,0.2809951065051762
10(-8)).,0.08516281064079098
The,0.09166907774944151
addition,0.07850452284455546
of,0.057167739408669455
inflammatory,0.07128484750506728
biomarkers,0.058090188465531614
to,0.06581036364237575
a,0.048494177007586126
basic,0.060062323555170265
model,0.07566098958479028
including,0.05435155626251877
"age,",0.05808490536720863
"sex,",0.08656841351811304
FEV1,0.0684848786839597
percent,0.06760658689389096
"predicted,",0.1025806034706743
"smoking,",0.1758242171627861
use,0.11419045738897332
of,0.07659406958639142
any,0.07047660005027988
inhaled,0.10531562572551895
"medication,",0.12060823238761477
body,0.13054436647248954
mass,0.11728065906730045
"index,",0.11604426608720204
history,0.07291571187054935
of,0.03840536565346826
previous,0.0897086122431663
"exacerbations,",0.0522918323254673
and,0.049027979600937265
time,0.05589268611169206
since,0.0535464095718999
most,0.03307352905231735
recent,0.04256690179276953
prior,0.051674205631112094
exacerbation,0.03443168899951846
improved,0.07904826835614791
the,0.06440451182812443
C,0.09301811209405184
statistics,0.08472107581797074
from,0.09677256886051384
0.71,0.05502791596520347
to,0.09802277868193766
0.73,0.04890844227486799
(comparison:,0.06509082287355016
P,0.11954688898051215
=,0.11771412253203445
9,0.10531773743638848
×,0.15560094754219478
10(-5)).,0.09545380871150584
Relative,0.010323671854614828
risks,0.007680757522502933
were,0.012483381921705672
consistent,0.008390002717502017
in,0.011197733515889142
those,0.01542363243172371
with,0.016143376590734188
milder,0.007705973578272803
"COPD,",0.018730385131383462
in,0.01320312570008597
those,0.014006783680672453
with,0.009030278200280234
no,0.00824120374931156
history,0.007597692942366451
of,0.0053998912930009555
frequent,0.006092466675582436
"exacerbations,",0.004347337865344933
and,0.00648234604774288
in,0.007486008518105462
the,0.007610054691066716
2,0.009414634979755702
studies,0.005855490046307773
separately.,0.004621319578458977
The,0.20916629915110976
highest,0.25078198065081303
5-year,0.2853193442077095
absolute,0.19883578816963798
risks,0.31749106041631875
of,0.32466436438881596
having,0.28391042298073227
frequent,0.29912883244468086
exacerbations,0.17690049310743383
in,0.3414299566284805
those,0.400551537854594
with,0.3571789595152413
3,0.37152236925107446
high,0.3050394943883212
biomarkers,0.32335241417950983
(vs,0.34566127327790086
no,0.3909046563857103
high,0.29854283595199865
biomarkers),0.3243844615740921
were,0.2717037073776498
62%,0.2972916992374685
(vs,0.07914940469726643
24%),0.047148690607381534
for,0.06429217261179103
those,0.042089222632983925
with,0.02141370678726296
Global,0.016986701163253785
Initiative,0.013406301558769512
for,0.00625389597096038
Chronic,0.008369618567069793
Obstructive,0.005420388152429115
Lung,0.007966067423540193
Disease,0.01114442348124126
(GOLD),0.008196631123229414
grades,0.04786278033433009
C-D,0.05794857498868781
(n,0.02945853561391089
=,0.10316041979134305
"558),",0.033307272023406886
98%,0.0545630815284192
(vs,0.04025814402526121
64%),0.07749716606547569
in,0.05645741628731861
those,0.037591570321739584
with,0.023059817191271058
a,0.030747648325456792
history,0.04151359398859064
of,0.023577101636673516
frequent,0.03059200699714546
exacerbations,0.022780957333552128
(n,0.034390950236310364
=,0.0902790756719185
"127),",0.030656662764292634
and,0.0661385776320293
52%,0.06771160955014018
(vs,0.03995326921763587
15%),0.07218968796644155
for,0.05204914008839491
those,0.03939380763305941
with,0.03542327338781457
GOLD,0.041160689021773854
grades,0.05599922967971735
3-4,0.8249937203889938
(n,0.060087552334409336
=,0.11688299290412896
465).,0.11529677498511137
CONCLUSIONS,0.8911544121089812
AND,0.8843265045801075
RELEVANCE,0.8849837694192866
Simultaneously,0.9100505561400092
elevated,0.9239508005968599
levels,0.9196485567270029
of,0.9376278095837753
CRP,0.9211567928223005
and,0.9432481769687266
fibrinogen,0.9185016363948092
and,0.949268928267857
leukocyte,0.9177763944335333
count,0.9407273377737121
in,0.9411755338282738
individuals,0.9369840619467502
with,0.9414081578731417
COPD,0.9227450349878727
were,0.9444361116781071
associated,0.9418795065408414
with,0.9361649155676616
increased,0.9302309344552018
risk,0.9311100959104758
of,0.9346847306557109
having,0.9221992157847703
"exacerbations,",0.5388351734675917
even,0.5788843478703458
in,0.6060092423556237
those,0.6447587298900813
with,0.5872595908642299
milder,0.6725560424754248
COPD,0.6287297006347518
and,0.5667821965162055
in,0.6093788119794992
those,0.6142968074491294
without,0.5764126677462109
previous,0.5282104358381948
exacerbations.,0.5160343474215561
Further,0.0036079767694948907
investigation,0.0036013043617508546
is,0.0036213103854894216
needed,0.0032860402182090446
to,0.0021581894150190643
determine,0.0026575841066666006
the,0.0029494806652342934
clinical,0.0032339114243655695
value,0.0033810344920723093
of,0.0043923635869963906
these,0.00665768266216054
biomarkers,0.006358971325111842
for,0.0051850178632519865
risk,0.0026554755472178457
stratification.,0.005284330774645318
Excitation-transcription,0.007028651393422328
"coupling,",0.00413874996222063
linking,0.0030808269791419017
stimulation,0.006915655104125358
at,0.0044305733479004265
the,0.0044485306613925215
cell,0.005667541454088004
surface,0.0027569851438200895
to,0.00310306637348012
changes,0.003202124172637372
in,0.0032384066000433745
nuclear,0.0036121412646554943
gene,0.0038352798917403925
"expression,",0.0031362957591770653
is,0.0021482592088401227
conserved,0.002137554158010327
throughout,0.003284061285159679
eukaryotes.,0.004642277835572073
How,0.0019155494588077508
closely,0.001582255418470467
related,0.0019524358561983737
coexpressed,0.0025141855752313595
transcription,0.0037788261578483406
factors,0.0049183140196930025
are,0.0020504395803400822
differentially,0.0015096607915731743
activated,0.002798630473514043
remains,0.0017549393318866471
unclear.,0.0019308750836183352
"Here,",0.5681945942579483
we,0.6517716759858487
show,0.6181895395873009
that,0.5895142135833646
two,0.3369682631183526
Ca2+-dependent,0.0852451767449278
transcription,0.4003626902294595
factor,0.4475402763231808
"isoforms,",0.35655203205355684
NFAT1,0.38486289356780085
and,0.422937694057698
"NFAT4,",0.3649084554619223
require,0.4059086723993394
distinct,0.283748137241339
sub-cellular,0.3610233795775568
InsP3,0.4492281167193666
and,0.44819133981045367
Ca2+,0.40551502562949066
signals,0.4348293297401017
for,0.48297605142914846
physiologically,0.46721095870507945
sustained,0.4145651641391464
activation.,0.43843615820362225
NFAT1,0.6314891851288762
is,0.6211263946662832
stimulated,0.658659371671024
by,0.669915484385432
sub-plasmalemmal,0.5848841459726203
Ca2+,0.6542188744435455
"microdomains,",0.6865414062166427
whereas,0.6496029049992433
NFAT4,0.6432354252882395
additionally,0.6007093992547131
requires,0.6003037921356844
Ca2+,0.6223122256375934
mobilization,0.6457327138514352
from,0.16022946503503693
the,0.17880069170034965
inner,0.1455562079068382
nuclear,0.12130184658350222
envelope,0.1583174637686905
by,0.20280936806583905
nuclear,0.14564026186661122
InsP3,0.1882361322370052
receptors.,0.14507614759722534
NFAT1,0.4961779707202636
is,0.4872706803361971
rephosphorylated,0.501800054358097
(deactivated),0.4316670710541484
more,0.5980160509935665
slowly,0.545627909341346
than,0.6087998489669079
NFAT4,0.5433989186254122
in,0.6194712592917864
both,0.6277236274890843
cytoplasm,0.6168823237459997
and,0.6051651836999802
"nucleus,",0.4660792908167518
enabling,0.650860560289113
a,0.6082606350703293
more,0.6488169485556915
prolonged,0.5213354533974462
activation,0.4680271501003451
phase.,0.5519735934821626
Oscillations,0.20630695788992104
in,0.14560513315183427
cytoplasmic,0.18220831267057355
"Ca2+,",0.24798142939557344
long,0.07149092297960995
considered,0.08535598696295751
the,0.08711946359361082
physiological,0.1148435429748789
form,0.13150649834013037
of,0.09596575137278512
Ca2+,0.2094883116781079
"signaling,",0.18037375684110016
play,0.0996694983971238
no,0.08538506561509783
role,0.08705695409977249
in,0.09657901174586252
activating,0.13923759345553538
either,0.10234527187073424
NFAT,0.1606767724941785
protein.,0.16695310219043735
"Instead,",0.11522446240484072
effective,0.13716329170800784
sustained,0.1258388739454793
physiological,0.17401952580585403
activation,0.1851748551676762
of,0.16623294462308008
NFAT4,0.18525353382626097
is,0.08564293034741416
tightly,0.08045740855380197
linked,0.08997092418605444
to,0.1158525792211911
oscillations,0.1090991999292233
in,0.10670341614963967
nuclear,0.1070153498219841
Ca2+.,0.1987899738860685
Our,0.21999509184658622
results,0.15445886771783132
show,0.1650986671661526
how,0.09194878502499884
gene,0.11698149306329918
expression,0.13963801213022126
can,0.095335764017717
be,0.3222404115499317
controlled,0.3500700410880136
by,0.3253666942094834
coincident,0.26713636990111267
yet,0.2734797334621057
geographically,0.266452920690882
distinct,0.2613752661144132
Ca2+,0.40550410565024964
"signals,",0.393665551246168
generated,0.31203677463238433
by,0.36347683308271184
a,0.3405416985846486
freely,0.3606623335493203
diffusible,0.33191694216261486
InsP3,0.4278203503681653
message.,0.4407798560666226
The,0.11366874231803385
RIG-I-like,0.09482712632905743
receptors,0.09027891902385485
(RLRs),0.06509027879843937
"RIG-I,",0.11914220048683641
"MDA5,",0.1341920761079103
and,0.11477993796285892
LGP2,0.09179466016815559
play,0.06805487483039079
a,0.0898715347524504
major,0.08895109669587088
role,0.09482580125158102
in,0.0900382643524951
pathogen,0.03688552139576451
sensing,0.10965206358771727
of,0.07968141503305642
RNA,0.03304911633222239
virus,0.04521021423715448
infection,0.06388420041068227
to,0.10497761120292096
initiate,0.07037753246107524
and,0.10054517871641182
modulate,0.051135387106670246
antiviral,0.0373541021327293
immunity.,0.04493883610919262
The,0.23425323704546877
RLRs,0.21327486745415242
detect,0.27886745557856757
viral,0.23867663804756317
RNA,0.23970023391127124
ligands,0.2765755934148901
or,0.24965755648230345
processed,0.3088662461416024
self,0.2876033191716031
RNA,0.2238142705648814
in,0.35888449003482936
the,0.2836832422656575
cytoplasm,0.2920449890976995
to,0.31313974684101853
trigger,0.279298161082844
innate,0.24646045072999687
immunity,0.2644092422655287
and,0.3003463802533117
inflammation,0.24375463454946952
and,0.2979787889995333
to,0.28165298990705956
impart,0.3146667780346389
gene,0.2875934090280006
expression,0.3514672417135624
that,0.2654577701873159
serves,0.22969458989816022
to,0.24638017698438902
control,0.22719668539585952
infection.,0.17987803848164188
"Importantly,",0.1378661204597107
RLRs,0.15676538049218874
cooperate,0.1393306297645996
in,0.1177944913663364
signaling,0.14028164408298258
crosstalk,0.11126051314164576
networks,0.11447304247934449
with,0.10015592462212601
Toll-like,0.11851106039867977
receptors,0.10396295021873493
and,0.0891385352851936
other,0.059996202325641464
factors,0.07621929586592038
to,0.16444887603279504
impart,0.0713254311984226
innate,0.05477169771788936
immunity,0.07804548668584868
and,0.07328722032038801
to,0.07196350484419382
modulate,0.035410249605991685
the,0.06899333461509426
adaptive,0.03969276312316011
immune,0.05630992840504461
response.,0.047984606663010944
RLR,0.0396766852773143
regulation,0.04279590944156057
occurs,0.022227577982004063
at,0.02419837007566926
a,0.018887373263354358
variety,0.01374802831479185
of,0.016380598630360392
levels,0.016180597011701485
ranging,0.016266973255706457
from,0.01872488209727218
autoregulation,0.010432572489121088
to,0.015546488380978373
ligand,0.016369926617417516
and,0.02561057659996499
cofactor,0.022957216218693895
interactions,0.020464427055396955
and,0.019577746040668868
posttranslational,0.02355440286373336
modifications.,0.016875114976249956
Abberant,0.08262734036918117
RLR,0.08700115114677384
signaling,0.07946748404189723
or,0.05603273316188785
dysregulation,0.04529157237954484
of,0.05163522599184342
RLR,0.07410112973685658
expression,0.08836608583442668
is,0.02412697538665474
now,0.019028058241215833
implicated,0.02205516953128021
in,0.021990863218312205
the,0.02513261462834807
development,0.01888429412941882
of,0.012893181020689717
autoimmune,0.013198060269462113
diseases.,0.012533383788154448
Understanding,0.007478943773224357
the,0.005743658326585136
processes,0.0051746769517936
of,0.009092438810996464
RLR,0.023927083996612628
signaling,0.013922003606773883
and,0.007701836267548965
response,0.008454380485691842
will,0.006491357932930389
provide,0.005873388955932332
insights,0.006169341362270159
to,0.0061351810761293485
guide,0.006349245509893091
RLR-targeted,0.018435855298655213
therapeutics,0.0068756569465034025
for,0.005068305143670484
antiviral,0.00646577152448312
and,0.008240237268515587
immune-modifying,0.006620380097764844
applications.,0.004688564500477224
CONTEXT,0.13975621530987203
Increasing,0.07786065068365411
evidence,0.10998880247170299
supports,0.07204799674690555
the,0.05194170825889276
hypothesis,0.0811870901790918
of,0.07947900451395704
a,0.10004990731259927
causal,0.08235185178636147
association,0.08630025587372406
between,0.06074158494809122
certain,0.06278438941229807
bacterial,0.05515747306639396
infections,0.06726863571500656
and,0.08294324736757364
increased,0.10565528162527427
risk,0.09399756994455409
of,0.1230620474759607
developing,0.11171509309580498
acute,0.07595375591445012
myocardial,0.1054686023062012
infarction.,0.09722677899561853
If,0.16284939354813516
such,0.12179170299459686
a,0.10316931505670833
causal,0.09409934337775491
association,0.11055583621829744
"exists,",0.08139447326295414
subjects,0.1257945834415601
who,0.1369032352982803
used,0.20487133791443335
antibiotics,0.13411424969166127
active,0.21036455931061615
against,0.17213475931860397
the,0.19192041780004193
"bacteria,",0.11125602803640555
regardless,0.11448402740541552
of,0.05560308071989642
"indication,",0.13475242619362085
might,0.1466528878940789
be,0.13155336212009475
at,0.10475545938480683
lower,0.15160588705167927
risk,0.11622224442385697
of,0.20204445549105854
developing,0.1525961914680835
acute,0.1164806205974717
myocardial,0.12367714417530826
infarction,0.11303633974104313
than,0.20427472115016113
nonusers.,0.09066618897356002
OBJECTIVE,0.0018876753270335507
To,0.0013358005534172164
determine,0.0010083353760650408
whether,0.0008836005007248343
previous,0.000897450746161535
use,0.000838903750803304
of,0.00169639338461205
antibiotics,0.0008392295571958112
decreases,0.0007713356919415615
the,0.0010032027278104782
risk,0.0007199090106492948
of,0.001920104929197501
developing,0.0010282402746589212
a,0.0011059832502103943
first-time,0.0008664640384547234
acute,0.000673612966663739
myocardial,0.002045363330638117
infarction.,0.0012930674598434736
DESIGN,0.001120857967262128
Population-based,0.001586647869502606
case-control,0.0009541640408348671
analysis.,0.001303134769158716
SETTING,0.0035329682113421396
The,0.002385237058056295
United,0.001394323310050492
Kingdom-based,0.0015908381464305663
General,0.0007669700277011846
Practice,0.0012932830026482528
Research,0.0012386902466806245
Database,0.0013876521132680285
comprising,0.0011846361989325323
350,0.0009118399458828852
general,0.0007661741483475687
practices.,0.0010743177717626724
PATIENTS,0.002246425290031919
A,0.0017185744276228552
total,0.00126818923855015
of,0.0020926690352364432
3315,0.0016315892744285586
case,0.0022409161052402192
patients,0.001647713661849574
aged,0.0015677301460409211
75,0.002216737734470876
years,0.002404334307055926
or,0.003506138874594152
younger,0.0017688235356272913
with,0.0016725124843523734
a,0.002262685785760734
diagnosis,0.0013994340090645835
of,0.002192018013920765
first-time,0.0022613007644685925
acute,0.0021448203145976582
myocardial,0.004140337278856333
infarction,0.0025532544916760714
between,0.0016334988221743958
1992,0.0022116136901673814
and,0.0022476573876011037
1997,0.0015408447564056274
and,0.001689373520416267
13139,0.0011765009642276372
controls,0.0018382251489383302
without,0.0015788042428864651
myocardial,0.0031452914829267612
infarction,0.0015290290123168657
matched,0.0014190320643833725
to,0.0016172626850343196
cases,0.0010705455747266508
for,0.0017033653367662617
"age,",0.00156584443055766
"sex,",0.0011869545413146073
general,0.0008678618870390397
practice,0.0011444700819486136
"attended,",0.00110793831396946
and,0.0015412860798532325
calendar,0.001104061607082353
time.,0.0010044072405240739
MAIN,0.0014844636799805789
OUTCOME,0.0026822322227076276
MEASURES,0.0021278989135655436
Use,0.0030564949668369975
of,0.0030745929263939877
antibiotics,0.0015488252462014546
among,0.0021881349172708313
those,0.0025263370321770688
who,0.0028200705906778413
did,0.0035305005440348196
or,0.006599672769672076
did,0.004122770104866871
not,0.005236389476568949
have,0.0025976588532127583
a,0.0027700875043333195
first-time,0.00226201576887602
acute,0.001374903330550438
myocardial,0.003211995033765153
infarction.,0.001717566449325023
RESULTS,0.08440084935496497
Cases,0.03264902902158366
were,0.047202039227293296
significantly,0.056769904240744566
less,0.5876987666985481
likely,0.5377103415024861
to,0.48678489119530566
have,0.5138635010840034
used,0.5723367808892273
tetracycline,0.555602458810389
antibiotics,0.5936086511911011
(adjusted,0.654760510826516
odds,0.6455575082764579
ratio,0.653266824875809
"[OR],",0.6305314457357647
0.70;,0.6240111724529598
95%,0.7070719554962993
confidence,0.6795578109290512
interval,0.6941188926129035
"[CI],",0.6339517834772038
0.55-0.90),0.616520106550417
or,0.5772658667209256
quinolones,0.5703281511321677
(adjusted,0.6034029582559053
"OR,",0.6826663553535595
0.45;,0.5856625682524021
95%,0.6574520720220753
"CI,",0.6219844920621876
0.21-0.95).,0.451672882438176
No,0.1123006819073803
effect,0.11887326443483266
was,0.1180079509266934
found,0.1069501936263796
for,0.11195318054280921
previous,0.1303763345284829
use,0.13891439410669193
of,0.11614016997359443
macrolides,0.10320813569478597
(primarily,0.07792704332476882
"erythromycin),",0.14769664409571134
"sulfonamides,",0.0968333802507476
"penicillins,",0.10937841719106516
or,0.0697070570417352
cephalosporins.,0.16094395098550157
CONCLUSIONS,0.6109074896168544
The,0.1651158310424368
findings,0.1231721546081517
from,0.12739579880384858
this,0.19751210120188628
large,0.11524542212348426
case-control,0.06742571300014322
analysis,0.08649591904967253
provide,0.1500106593484918
"further,",0.15267817119974364
albeit,0.5021562479875077
"indirect,",0.44089162987527586
evidence,0.5128748211312252
for,0.45676361227950857
an,0.4307332033192679
association,0.4111930373165755
between,0.3918150104325773
bacterial,0.4042815322394095
infections,0.35173295154665196
with,0.3397598793475796
organisms,0.3866316954183732
susceptible,0.37765107028101347
to,0.43195900053501907
tetracycline,0.3693085753733839
or,0.37537088976259686
quinolone,0.3999833124729016
antibiotics,0.42268674442661447
and,0.30585669618550243
the,0.31003840673149263
risk,0.37581012583064394
of,0.4162992102551864
acute,0.3981190866448844
myocardial,0.45889474099946637
infarction.,0.36623616780550866
These,0.03398300389205323
results,0.017205309196952723
of,0.018243816582606164
preliminary,0.013063396204323037
nature,0.012265494436584569
should,0.021002488101708773
stimulate,0.015875443438102602
more,0.010884548060251204
research,0.011167947697238398
to,0.010758240843624712
further,0.007995994025265447
explore,0.008110276847068568
the,0.007248558256421685
role,0.007289905718695709
of,0.009924060911302195
infections,0.0099277394670854
in,0.007287035249589845
the,0.007388917224803692
etiology,0.007739129579180752
of,0.012412183209524214
acute,0.011015941968761192
myocardial,0.02585256965617706
infarction.,0.020050017653258877
T,0.23822743562014165
cell,0.25063586021620887
receptor,0.2037774961817131
(TCR-CD3),0.19440996892209825
triggering,0.23896879604572094
involves,0.2647724168876728
both,0.28301536715324266
receptor,0.2864604992150537
clustering,0.22193412451072744
and,0.25868892964104795
conformational,0.16602099674272977
changes,0.21464713021143147
at,0.19219441280911678
the,0.2109085355457548
cytoplasmic,0.1909089607808734
tails,0.1775883311037072
of,0.17279824444027134
the,0.18011799217010677
CD3,0.21789179511462747
subunits.,0.17923170394094667
The,0.005031498312029039
mechanism,0.00697190365498261
by,0.006360743162698458
which,0.005448143012656581
TCRalphabeta,0.02297120747856595
ligand,0.01214245046869706
binding,0.01207027791857983
confers,0.006061518344693775
conformational,0.005148077228481182
changes,0.007450013937129462
to,0.009059308534928177
CD3,0.014507880926166134
is,0.0038130592172037313
unknown.,0.004137724180356902
By,0.47386533744953585
using,0.3951819331406864
well-defined,0.26200331913367847
"ligands,",0.2896940606908618
we,0.48702898772068
showed,0.5225525649911246
that,0.5016503683891824
induction,0.3795179791637221
of,0.3532091680218672
the,0.33531630436992976
conformational,0.28779179718699005
change,0.32321789051659766
requires,0.4254205318304824
both,0.47039601751893245
multivalent,0.3786972746020454
engagement,0.36637041598481657
and,0.4139062952086852
the,0.4446068444693757
mobility,0.39392648369238153
restriction,0.3595615364148928
of,0.36837381137566694
the,0.37676499203866165
TCR-CD3,0.26811869647560055
imposed,0.34250319558596776
by,0.3528975140829764
the,0.34295642071741195
plasma,0.31454788576943066
membrane.,0.3471653807748369
The,0.25575303443343383
conformational,0.170585925731623
change,0.19991207081466827
is,0.1863301569710964
elicited,0.20056089080477252
by,0.30354280935406464
cooperative,0.2976604279294444
rearrangements,0.17771366115927023
of,0.17070384641821315
two,0.17314453436984184
TCR-CD3,0.31503746890109546
complexes,0.3341970755319991
and,0.4509681601966188
does,0.39121079423349947
not,0.408143432215371
require,0.35958695444035804
accompanying,0.36558480682103794
changes,0.378130360089607
in,0.37495297979577574
the,0.36366563784621186
structure,0.30926250646605136
of,0.311934101432771
the,0.3131725252082777
TCRalphabeta,0.3330140378247652
ectodomains.,0.4108048346609287
This,0.5596253416988808
conformational,0.5143035276651411
change,0.5338278931455536
at,0.5634337529451752
CD3,0.5911436010212124
reverts,0.6139344455639263
upon,0.5497158797813466
ligand,0.5042482504890888
dissociation,0.5180022421623496
and,0.6708174642186259
is,0.6199209345838862
required,0.6044432547598545
for,0.5721575029674816
T,0.5345397601356722
cell,0.5899461170472495
activation.,0.545973946366822
"Thus,",0.10633731670123382
our,0.11424743844405627
permissive,0.035197795109092954
geometry,0.04313906512146516
model,0.050553836567233335
provides,0.051340549999155584
a,0.045977140675470804
molecular,0.034885698947452484
mechanism,0.03717388319856313
that,0.04778883179523004
rationalizes,0.02597370129734586
how,0.03124086916095292
the,0.0219502472717973
information,0.03497880604501087
of,0.031084031952021595
ligand,0.02662171597304954
binding,0.03269978535557308
to,0.03544944484982256
TCRalphabeta,0.06529645919061527
is,0.015618245040934673
transmitted,0.019863543483128458
to,0.02135730366355441
the,0.02511104520289001
CD3,0.05694459941998087
subunits,0.04343775223271983
and,0.030333453795356177
to,0.017478255491632847
the,0.014585192874978883
intracellular,0.03604153727649423
signaling,0.03280798329511398
machinery.,0.024681473701112032
CONTEXT,0.011850654959329644
Bioterrorist,0.0022783460413969055
attacks,0.005110687993887814
involving,0.003127930771921599
letters,0.006068058990589198
and,0.003162249172383232
mail-handling,0.004431529401200658
systems,0.004178754176473006
in,0.0038356889053171384
"Washington,",0.0025937127532683754
"DC,",0.002346966068838442
resulted,0.004995881775475625
in,0.005588374547776009
Bacillus,0.0063583853405207455
anthracis,0.003970096091415323
(anthrax),0.005454275034018018
spore,0.004293250068452077
contamination,0.005591990109854863
in,0.005005797123145708
the,0.003812661662903542
Hart,0.009135756113825918
Senate,0.0046981470423697715
Office,0.0024788662229484285
Building,0.004544208828932202
and,0.0030481219097094866
other,0.0031370800240314452
facilities,0.0033305125673434906
in,0.0022052882046632695
the,0.002249510276548548
US,0.002913876977601029
Capitol's,0.0032709919962289748
vicinity.,0.0028884354298734957
OBJECTIVE,0.0018448725315123877
To,0.001645935217255416
provide,0.0016430002990090666
information,0.0014288851500074157
about,0.0013314036987443765
the,0.0011780799372355139
nature,0.0011106668148074587
and,0.002186673698549918
extent,0.0009063129021210397
of,0.0015604931806764044
indoor,0.001394038841544657
secondary,0.0011724156268589964
aerosolization,0.0015700796404465812
of,0.0017236527211289526
B,0.0015337141837448469
anthracis,0.001954866231384179
spores.,0.0016569509761164307
DESIGN,0.001531162030787971
Stationary,0.001817237705915105
and,0.0022415777534286045
personal,0.0011814912413018537
air,0.0013708047788874953
"samples,",0.0013933413590389316
surface,0.001363832523205351
"dust,",0.0012851925198322774
and,0.001909683732856881
swab,0.0018071015476360133
samples,0.0011818680378547297
were,0.0018977399992971113
collected,0.001148302816610683
under,0.0014374435270592357
semiquiescent,0.0022851366097934008
(minimal,0.0016205786713578817
activities),0.0018677370916020885
and,0.002819626780238234
then,0.002392487138183473
simulated,0.001650509655666158
active,0.0013320952741374995
office,0.0013684959713486388
conditions,0.0013915362273801389
to,0.0016765727508520783
estimate,0.001069204535193738
secondary,0.0017705065482667944
aerosolization,0.0037401833928007115
of,0.0022442951654989187
B,0.003458737797748569
anthracis,0.003064780225592907
spores.,0.0015153234613215047
Nominal,0.000724762037849353
size,0.0008226547802126021
"characteristics,",0.0007889134888676666
airborne,0.0007201850329474772
"concentrations,",0.0008770241905422993
and,0.0008895409727326975
surface,0.0006206597774796278
contamination,0.0007902932567839257
of,0.001011289378105672
B,0.001211821439752726
anthracis,0.0011561747328935577
particles,0.0009383024135359143
(colony-forming,0.0007436064837100135
units),0.0009415962908089734
were,0.0008135730089992457
evaluated.,0.0006328942011849234
RESULTS,0.03176607928710525
Viable,0.03116506708211379
B,0.01219467583026274
anthracis,0.014221702133653417
spores,0.0160032344710823
reaerosolized,0.01974904003170857
under,0.013520743574154828
semiquiescent,0.01663757207962747
"conditions,",0.017260231440652075
with,0.03205388220183606
a,0.027050069902478158
marked,0.030939896163457565
increase,0.02583668980633381
in,0.03561446354356038
reaerosolization,0.0264187543325363
during,0.016195234532913137
simulated,0.014664941446063192
active,0.013306493880908758
office,0.016811737433659598
conditions.,0.016076525560459964
Increases,0.007913634472956104
were,0.007675131792269035
observed,0.007845758600190461
for,0.00881257503472188
B,0.013997524327953226
anthracis,0.005206717134325474
collected,0.006843651153575755
on,0.010349302633207895
open,0.004358080556510459
sheep,0.006411688755461948
blood,0.00530573877217536
agar,0.00397349440005292
plates,0.004176007869297628
(P<.001),0.008244117511652636
and,0.009089249443255332
personal,0.00560628822005816
air,0.005276243609338015
monitors,0.004247023298597166
(P,0.006801337800462375
=.01),0.025091491254361043
during,0.008023041139049473
active,0.007058330666056025
office,0.015224875063817723
conditions.,0.008483394024079934
More,0.060063716668177926
than,0.08409109589411749
80%,0.6904550111236538
of,0.7446085441626675
the,0.7410208514847814
B,0.7241294753680083
anthracis,0.624779514975541
particles,0.6846171126770474
collected,0.6151528448272302
on,0.6457476988770589
stationary,0.6430278098452881
monitors,0.6517768099161622
were,0.721254359065244
within,0.7084403889085343
an,0.7771311290740714
alveolar,0.7003176632472383
respirable,0.7780825694632164
size,0.7514342310427535
range,0.7746002954270398
of,0.7611902209407291
0.95,0.6991716415557223
to,0.6997473126242288
3.5,0.7244693018612094
micro,0.7076397765294138
m.,0.6705257355297269
CONCLUSIONS,0.7929807724313526
Bacillus,0.7477781746137946
anthracis,0.7421981505499069
spores,0.7771552849557058
used,0.75159073923455
in,0.7266403179389632
a,0.7129207654871049
recent,0.7131701818483354
terrorist,0.6558379838764997
incident,0.6923342611137226
reaerosolized,0.7858267491837551
under,0.6976449395921392
common,0.7166586421168263
office,0.6653978987241496
activities.,0.7207759556753915
These,0.019307239740683248
findings,0.017261818833873614
have,0.009430421524104067
important,0.013953709211599188
implications,0.010117975056429727
for,0.014012362613047674
appropriate,0.014058037905010442
respiratory,0.012224098386349252
"protection,",0.011097937962341545
"remediation,",0.009369903860686089
and,0.011324810812186743
reoccupancy,0.011012389192475859
of,0.017568883672280437
contaminated,0.014316506226706074
office,0.02421508193151685
environments.,0.019076535940643003
OBJECTIVE,0.0008835752434098334
To,0.0008622774024771275
obtain,0.0008368401199157558
summary,0.0006563510947565667
estimates,0.0006724954137622659
of,0.0009042220847267964
the,0.000846596541735429
accuracy,0.0008187307502406344
of,0.0009356630321537998
a,0.001169616102452105
single,0.0008608514231674007
baseline,0.0006734579476134231
measurement,0.0005690683212073531
of,0.0008281008237832543
the,0.0007835832617963918
Elecsys,0.0007880347797072448
Troponin,0.0007945630698688903
T,0.0008833075602141653
high-sensitive,0.0009793171213294163
assay,0.0007210413914981583
(Roche,0.0007979085614561681
Diagnostics),0.0011025444442567876
for,0.0008749341852117034
the,0.001058992110633608
diagnosis,0.0006103417083225493
of,0.0008407681495432552
acute,0.0008256480403910523
myocardial,0.001179250110473643
infarction,0.0009692083868279453
in,0.0009489865199940453
patients,0.0007507683153730769
presenting,0.0006502235056203339
to,0.0013462594159576393
the,0.001296361476094119
emergency,0.0006904386493087425
department.,0.0007676019495363664
DESIGN,0.0008266734169024246
Systematic,0.0016789264342745157
review,0.0014275831705548897
and,0.0014916997473459934
meta-analysis,0.0012167631481812143
of,0.0011926909980479728
diagnostic,0.0006668124001578288
test,0.0006746090836524641
accuracy,0.000700580905500416
studies.,0.0008342533537378059
DATA,0.0009470826762361488
SOURCES,0.001783066044593807
"Medline,",0.002026430402692221
"Embase,",0.0019037928956020646
and,0.0018983755036240677
other,0.0019015715980168688
relevant,0.0013823947883008219
electronic,0.001350586277978318
databases,0.0016334362233049935
were,0.0012139919872113326
searched,0.0013936253536114848
for,0.0012025841432131664
papers,0.0012296368851971756
published,0.0011781789738664883
between,0.001755092207897057
January,0.0015418578234782457
2006,0.001449665856006602
and,0.0015714474066435367
December,0.0015380530025318668
2013.,0.0012738211706330152
STUDY,0.004555617418685376
SELECTION,0.00808194409915496
Studies,0.0030876012395016092
were,0.0021910185790620985
included,0.0009868026050140657
if,0.0017095515090597188
they,0.002764505466029259
evaluated,0.0021105829151104585
the,0.0014455715407212133
diagnostic,0.001113865093406853
accuracy,0.001277019696206482
of,0.0023639852057323555
a,0.0022923143133149818
single,0.0019935619510090953
baseline,0.000968632348013277
measurement,0.0015691462939862056
of,0.0018260346920286902
Elecsys,0.0019100754955798272
Troponin,0.0020717409252374087
T,0.0022681733701762933
high-sensitive,0.001678972390650649
assay,0.0011243634678967354
for,0.0010315836733031912
the,0.0010022722402734786
diagnosis,0.0009125556876367329
of,0.0010022235424080826
acute,0.0009310478678429235
myocardial,0.0017984529611647854
infarction,0.001097870515173627
in,0.0010773419566177766
patients,0.001020037166765498
presenting,0.0008243513160720909
to,0.0008929160515032867
the,0.0011234395130957397
emergency,0.0009584554837130723
department,0.000866631033854374
with,0.0010291573418201624
suspected,0.0009382478814066225
acute,0.0008958765913024548
coronary,0.0016885598705601338
syndrome.,0.0009508527395218721
STUDY,0.004723972998429661
APPRAISAL,0.0023039784066268753
AND,0.0019028594179980954
DATA,0.0018377597488306791
SYNTHESIS,0.005566529329622616
The,0.004056677033026934
first,0.003089078135118862
author,0.0017860675018798525
screened,0.0015398074281021102
all,0.0012709707657021767
titles,0.0010137605468279814
and,0.001698710963029317
abstracts,0.0009833008560952378
identified,0.0006690046480445421
through,0.0009651248989852328
the,0.0014185892205496342
searches,0.0008485960696239066
and,0.0014901082447096293
selected,0.0008908321332812975
all,0.0009547285273674726
potentially,0.0008918200548194475
relevant,0.0008957959288725166
papers.,0.0008855765925127753
The,0.005099558226070519
screening,0.0020433442201448207
of,0.002321736150750942
the,0.002623688502600126
full,0.0017939264224700264
"texts,",0.001855843656339682
the,0.002760827099394338
data,0.0013034876127971614
"extraction,",0.0014544457679715535
and,0.0024841476451757136
the,0.0023952298127538356
methodological,0.0013174897560583828
quality,0.001502147829664711
"assessment,",0.001191224365328197
using,0.0012411949261554244
the,0.001695164766526274
adapted,0.0024400302034422662
QUADAS-2,0.002295520599015626
"tool,",0.0016338931334559492
were,0.004200017608176948
conducted,0.0026349206853816995
independently,0.0025861847030194244
by,0.0028306998926491264
two,0.003650632172028197
reviewers,0.0014911962742940226
with,0.004180575128842587
disagreements,0.0025077690900340375
being,0.0017519513149085615
resolved,0.0022799687111955875
through,0.0018685942289310153
discussion,0.0028019253624785795
or,0.0017100475823031834
arbitration.,0.0009575272307442144
If,0.0007438924712865867
"appropriate,",0.0008479391361835492
meta-analysis,0.0005834810197406232
was,0.0008759445531044988
conducted,0.0006239211892248095
using,0.0005892241140715127
the,0.0006781798071699177
hierarchical,0.0008322594395840626
bivariate,0.0007882514545886511
model.,0.0006545434469063677
RESULTS,0.00927828959300256
Twenty,0.001622634862365713
three,0.0016763939833138834
studies,0.0019771807669428203
reported,0.0018796658988928868
the,0.0014133995805322727
performance,0.0011262541553422642
of,0.0016119374257102285
the,0.001384201919481141
evaluated,0.0010675257010848399
assay,0.0009041240883063459
at,0.002021082592659701
presentation.,0.0011458344645360666
The,0.002330579680741064
results,0.002447897582358373
for,0.003283945006141317
14,0.0019681398410032543
ng/L,0.0016916162972911897
and,0.0024618170368091155
3-5,0.003945757240282285
ng/L,0.0014245645204208554
cut-off,0.0009967430030500789
values,0.001561635496652015
were,0.001660420526058466
pooled,0.001383824292142899
separately.,0.0012702673270486142
At,0.569509287982036
14,0.45504335276287433
ng/L,0.3513014574752498
(20,0.2839585579002188
"papers),",0.22325617714873194
the,0.48243226329921907
summary,0.42408597667130254
sensitivity,0.5322934740738422
was,0.43976081969085995
89.5%,0.6186306495626892
(95%,0.5693375747777614
confidence,0.6058919203060186
interval,0.6352248718304947
86.3%,0.7402801223751406
to,0.6098044087782177
92.1%),0.7078943568944318
and,0.6233608792473296
the,0.5269463884917639
summary,0.4895909624546793
specificity,0.5464559687810535
was,0.5321374797460701
77.1%,0.7062919782877312
(68.7%,0.6012077613548757
to,0.6247217509367798
83.7%).,0.675225403972835
At,0.4691436696633637
3-5,0.602569485248449
ng/L,0.5920319500317013
(six,0.49823965859568453
"papers),",0.5658165720652765
the,0.6041898467103238
summary,0.5602751157065926
sensitivity,0.6056413532529721
was,0.5974338500331794
97.4%,0.7129815308120051
(94.9%,0.5919294064592396
to,0.5807045109132228
98.7%),0.7132162860827786
and,0.6574247379117116
the,0.5548788841886529
summary,0.5347416517364874
specificity,0.5549226383482583
was,0.5811459566797063
42.4%,0.6750224558902926
(31.2%,0.5724203808301233
to,0.5927462316699817
54.5%).,0.7047755446980242
This,0.6602767386961338
means,0.7171763571362286
that,0.7272886962542288
if,0.7045114767950237
21,0.6600593756198332
of,0.7383792230614162
100,0.6751069101014416
consecutive,0.6871972328318318
patients,0.7250782228754806
have,0.6245782385621769
the,0.6402839058439145
target,0.7360489510705065
condition,0.7325437993299492
"(21%,",0.6778787087951508
the,0.6341225151533146
median,0.7342406262496692
prevalence,0.6886396387366587
across,0.5454987176233328
the,0.5259877921443339
"studies),",0.6115846257900691
2,0.7768409216774153
(95%,0.7006555830388603
confidence,0.7643196597679476
interval,0.7173433247036222
2,0.7451782219048086
to,0.6247075192035357
3),0.6943638157414331
of,0.7385258291999083
21,0.6798191865825427
patients,0.7541909262084387
with,0.6855329748394344
acute,0.7298275237433383
myocardial,0.770985240058096
infarction,0.6989159817924061
will,0.6527179742899744
be,0.609916920743738
missed,0.6116090037968408
(false,0.5910068880870807
negatives),0.5379266964132349
if,0.6774770775191641
14,0.582857166780291
ng/L,0.6610639682796005
is,0.585061507244068
used,0.5781931056686086
as,0.57917474405606
a,0.6276026547324332
cut-off,0.5828767271686157
value,0.6171421931364852
and,0.6576080729052404
18,0.6317263272704029
(13,0.17228568075447584
to,0.15883969783273721
25),0.09865634655363659
of,0.16925568446471234
79,0.13541335156909215
patients,0.14130301725471073
without,0.16124358543901868
acute,0.14933167226000904
myocardial,0.16512267562974015
infarction,0.1295770231711662
will,0.15855057238288586
test,0.12061718431626471
positive,0.11826096454866904
(false,0.10000433632762006
positives).,0.09979278839723549
If,0.29184323207626667
the,0.2573454670334696
3-5,0.29702130728003867
ng/L,0.2503283472721645
cut-off,0.26134039514614693
value,0.2447542537495059
is,0.22101935170301482
"used,",0.22413015128928665
<1,0.26140166441816803
(0,0.23330837672130436
to,0.22199478923998275
1),0.21485556949733015
patient,0.23049025418337174
with,0.19595999173041956
acute,0.2438587444251628
myocardial,0.26378804579392634
infarction,0.21065586599911026
will,0.25935216061929206
be,0.21451728621005162
missed,0.1820918683603788
and,0.3073503336219032
46,0.19203977564202881
(36,0.17552263317058206
to,0.22489900873508611
54),0.1478253923764943
patients,0.17232158695876904
without,0.21513050668373668
acute,0.20742401971726157
myocardial,0.23124529623664167
infarction,0.18306118641559793
will,0.2355281627127207
test,0.1573535360784735
positive.,0.16580787207258987
CONCLUSIONS,0.6610421994173694
The,0.18483658061220018
results,0.15917025727614414
indicate,0.23256087499211747
that,0.19313987472212735
a,0.08953284618682068
single,0.054468124723934946
baseline,0.05074824525473842
measurement,0.07679830730413406
of,0.07164344777235966
the,0.04990558055038021
Elecsys,0.07853896453273539
Troponin,0.07120393328064085
T,0.09686190857558395
high-sensitive,0.09399963084205859
assay,0.05473658532490104
could,0.11254835444820711
be,0.0604809053089661
used,0.05705166098837254
to,0.05110316192044575
rule,0.056668271802818984
out,0.04850716560692763
acute,0.073595391576803
myocardial,0.15641778349149515
infarction,0.07317050960155604
if,0.12413332847573258
lower,0.2643569672840104
cut-off,0.2172583165245879
values,0.20833714033617456
such,0.20801105550615448
as,0.22655099330822165
3,0.29583121956574854
ng/L,0.22387960973023582
or,0.2054816831764306
5,0.2643454281509045
ng/L,0.2211252800843402
are,0.164789486308184
used.,0.20667104540937103
"However,",0.07009825705064036
this,0.09328056403586192
method,0.09841148152353092
should,0.0509098856476745
be,0.05083954493325756
part,0.046466417489743936
of,0.04602795574804206
a,0.04364198105646179
comprehensive,0.052876343838014546
triage,0.04160566533746541
strategy,0.04704633914313814
and,0.160509703082896
may,0.048949465249059576
not,0.07493028812265977
be,0.06187494776430504
appropriate,0.07665856912723605
for,0.054328161785377756
patients,0.06010140949519939
who,0.06845696629081394
present,0.08112127439842892
less,0.09499157470128364
than,0.11125449571081411
three,0.1472146840983531
hours,0.07864608681054297
after,0.08979020338112813
symptom,0.05226964153885244
onset.,0.10402774294221494
Care,0.006043969061168848
must,0.00689105061858089
also,0.006212432390339935
be,0.004949263194343256
exercised,0.0040530019147799875
because,0.02043051235615612
of,0.020004147449042668
the,0.01621388155945688
higher,0.055215197971886565
imprecision,0.01001698411414463
of,0.009335705954522756
the,0.0065143579689588334
evaluated,0.007628141112961602
assay,0.004210387800141289
and,0.05563582877674247
the,0.02984227027732179
greater,0.05655864871001352
effect,0.013063565268234809
of,0.018594969976219778
lot-to-lot,0.005314077580396389
reagent,0.006325991390975412
variation,0.014250444434348176
at,0.023002483177288324
low,0.02608721864370068
troponin,0.007807262903397849
concentrations.,0.012555291254374348
SYSTEMATIC,0.017171020736555617
REVIEW,0.015269694234006832
REGISTRATION,0.024672065894328896
PROSPERO,0.018191289255404353
registration,0.012438507964397948
number,0.018830592430119097
CRD42013003926.,0.010484573670393451
OBJECTIVE,0.0011949730086556565
To,0.0008621245941784201
describe,0.000780739405886984
the,0.000709610716886411
efficacy,0.0006024524497621845
of,0.00076546826414409
the,0.0007600755556192989
Finnish,0.0007188118008326162
mass,0.000653868829236067
screening,0.0007169986167021037
program,0.0005567085640868582
for,0.0006651534334592992
cervical,0.0009544099822837174
squamous,0.00099091092605534
carcinoma,0.0009242972885272727
and,0.0009480608800710101
"adenocarcinoma,",0.0008115134466706684
as,0.0007960340613796297
reflected,0.0006737585501351028
by,0.001054129725838373
changes,0.0006371551002709299
of,0.0009841551441376643
incidence,0.0006264737094625422
and,0.0012507826338169267
mortality,0.0005246351008751292
rate.,0.0005090259702158713
METHODS,0.0015425957516476104
Cervical,0.0012543017455925792
cancer,0.000863946909367528
incidence,0.0008995113501064002
and,0.0016345190157236922
mortality,0.0007510377309363265
data,0.001028506514853962
were,0.0013427144126329292
obtained,0.001057296306846842
from,0.0012523901965177298
the,0.0012169856934022933
Finnish,0.00111580351492338
Cancer,0.000986296458773806
Registry.,0.0007996882112170007
Data,0.0008885953665774244
were,0.0009583808342916282
available,0.0009727176869488889
from,0.0012281570463044279
the,0.001229611411183128
year,0.0008514890938947222
"1953,",0.0009690816566309269
when,0.00115413382513004
the,0.0009223633933326088
registry,0.0006231003739856137
was,0.0009485953230735407
established.,0.0006261516688474586
The,0.0012895711415947494
nationwide,0.0011766144384135848
mass,0.0014646441099877784
screening,0.001395665109380778
program,0.0010460363958319876
in,0.001744425002077103
Finland,0.002383739213168229
was,0.0014291753580771673
started,0.0010324210955257175
in,0.0015764961271558504
the,0.0016181163703870372
mid-1960s.,0.0015479236759696618
A,0.0015947384137978346
centralized,0.0012017765542493486
organization,0.0011224837031261325
administers,0.0014193415627431806
this,0.001940764122677826
program.,0.001373128264929597
Women,0.002636679394363475
age,0.0017913001123043505
30-60,0.0023350554185832028
years,0.001975257030914165
are,0.0022072621896755333
notified,0.0014822057673936826
for,0.0026214696209679346
screening,0.002443679711055685
every,0.002746567880825949
5,0.00469777692235553
years.,0.03869984060617404
RESULTS,0.12104221196033965
The,0.11079820302477499
mean,0.15499144970868192
incidence,0.16228228196345476
of,0.16539575718780622
cervical,0.17990596671731227
carcinoma,0.15897007603654092
in,0.13263227185214335
the,0.13603139184518914
early,0.11975821081853633
1960s,0.11645773627451543
was,0.16716934987841647
15.4,0.17039321985394823
per,0.17908814165310136
10(5),0.10354499574459544
woman-years.,0.1723758315213793
In,0.049438281727706215
"1991,",0.023378621791396794
it,0.0788072977419036
was,0.06111660324039404
only,0.0470455535067235
2.7,0.042235835639942994
per,0.07848088399087688
10(5),0.024040384175142576
woman-years.,0.05509273001857472
The,0.026338949341087495
mortality,0.013130888476007447
rate,0.013471101484654635
has,0.015859852905481524
decreased,0.013173979927973712
in,0.02314818104954166
the,0.02219677050071225
same,0.015056850589649508
proportion,0.01578993081895915
since,0.017731911408450783
the,0.026482961893007643
mass,0.02419977754867505
screening,0.016848043509292185
program.,0.02249567779892855
In,0.15660709855763488
the,0.10755673139838479
early,0.11498690591892616
"1960s,",0.10317591111638001
the,0.1435053032204369
mortality,0.1275140736735423
was,0.20247719983680154
6.6,0.21284549061757493
and,0.18921665897351153
in,0.14420120995397429
1991,0.11529215435825545
1.4,0.18826777928218028
per,0.19165751071465936
10(5),0.07592147520132507
woman-years.,0.09961244280899159
"However,",0.06354380104111693
the,0.06302244916828675
decrease,0.050987257210467
of,0.044117640089731215
the,0.05019098989488062
incidence,0.06795543639887629
is,0.04168771071106936
seen,0.0653292729004145
almost,0.060401517450729775
exclusively,0.06537394426259041
in,0.07776764777660893
squamous,0.05822208572066614
cell,0.06629361691355076
carcinomas.,0.04736420450762036
The,0.23916615909224345
mortality,0.23034917275178693
caused,0.19676300424262896
by,0.296722644657394
adenocarcinoma,0.14967896938134792
has,0.06524141116021896
decreased,0.06633478095561715
in,0.06663839260656834
screened,0.08598921265118652
birth,0.060537179634134144
"cohorts,",0.04539377483575469
but,0.06407438933746824
the,0.04538822717794618
incidence,0.039754875203075773
rate,0.031710325902918085
has,0.04060513838250084
remained,0.046855779815453295
the,0.043593262242047126
same.,0.03652350494634373
CONCLUSIONS,0.5238452689587941
The,0.03102985305382972
Finnish,0.03691319378985835
mass,0.02056521516361446
screening,0.019538857803831064
program,0.016626277443906348
has,0.025916163053157394
been,0.02439784069383896
effective,0.02641861328960045
and,0.049833472565245195
its,0.014113364460266335
continuation,0.018330753502370088
is,0.017746387128107034
of,0.024158462066901934
utmost,0.022085638163523207
importance.,0.019330947456343176
In,0.12642705666278067
the,0.10054342685111803
future,0.07921644536198601
more,0.17938287543050724
attention,0.18606938020077
should,0.10471249256929703
be,0.1011212876749406
given,0.12094869483218999
to,0.1576096855733685
glandular,0.31064164652879794
cell,0.3944956584397225
atypias,0.3117625664670211
in,0.2691246754166262
cervical,0.3035765613726487
smears.,0.2678853030871662
"Thus,",0.2297580944086242
it,0.16765745239713672
might,0.12318313714436087
be,0.12905017147228356
possible,0.16220208578144768
to,0.150589757808082
decrease,0.17227365384085494
the,0.16725354976390253
incidence,0.25113653276915754
of,0.277090295761085
cervical,0.3140216937821413
adenocarcinoma.,0.3655753026962869
Blood,0.019357645676576555
monocytes,0.016422072696900897
are,0.00840963284117738
well-characterized,0.004651118269091006
precursors,0.008200190444912889
for,0.012124009807454449
macrophages,0.010321998494650082
and,0.013589316540972122
dendritic,0.013527881376550286
cells.,0.015799231637053934
Subsets,0.0025392057919029418
of,0.0037585941566036455
human,0.005409856177063338
monocytes,0.007430902826078947
with,0.001864202884564256
differential,0.0019197641047653416
representation,0.0027033839839687777
in,0.0018782533926876357
various,0.0017911824534423831
disease,0.001990074223385263
states,0.0018417838316048141
are,0.0015849714502794677
well,0.0012643277099473019
known.,0.0016258190381888923
In,0.004501108556439058
"contrast,",0.004619008275280098
mouse,0.010137636851363043
monocyte,0.007950261968023982
subsets,0.00324926368941691
have,0.0020866165091616936
been,0.001985615754961364
characterized,0.0025321233663975788
minimally.,0.0022251001689800433
In,0.05823473516904395
this,0.04921496710424026
study,0.037632515956703985
we,0.10158985936398035
identify,0.04821236860109129
three,0.036771518067248134
subpopulations,0.025749913481504648
of,0.04235247559768838
mouse,0.045499665519732106
monocytes,0.0521375024381829
that,0.02844656078867032
can,0.011563238607193169
be,0.012795918050001213
distinguished,0.015254845155265397
by,0.027499792525217902
differential,0.019880379196617115
expression,0.04048915188652447
of,0.048755445121729094
"Ly-6C,",0.037016229563318966
"CD43,",0.0445781568446347
"CD11c,",0.04816374479848749
"MBR,",0.0593647508088566
and,0.02736617455695933
CD62L.,0.05310696884578974
The,0.138706543013374
subsets,0.08184434655171058
share,0.1880635686136861
the,0.24218233831371055
characteristics,0.24572234772352852
of,0.3031727031821677
extensive,0.26843396430419986
"phagocytosis,",0.31212598736258446
similar,0.24393499978289243
expression,0.315334628211157
of,0.2885307522236723
M-CSF,0.40146473409387506
receptor,0.38901461048951447
"(CD115),",0.20326710761098896
and,0.14865359159454397
development,0.16836841324321383
into,0.19850717977888435
macrophages,0.16460052091317767
upon,0.19756591439426008
M-CSF,0.14869568062483066
stimulation.,0.1683098583847632
By,0.01767198653462126
eliminating,0.01300083754593257
blood,0.019136429037675706
monocytes,0.00848194220852131
with,0.015412362052191547
dichloromethylene-bisphosphonate-loaded,0.01706970973901205
liposomes,0.010240000776158354
and,0.006772345268391491
monitoring,0.004508463488273012
their,0.005202829832502843
"repopulation,",0.004130454682291436
we,0.018716113819805525
showed,0.010661356668285243
a,0.004308118195705651
developmental,0.003350237922368935
relationship,0.003912590140831503
between,0.003207173575127493
the,0.004172590639070716
subsets.,0.004036532191393653
Monocytes,0.05013877248407707
were,0.02917302796716703
maximally,0.01565074563924324
depleted,0.02420966870519951
18,0.04922811645245336
h,0.04629225898686326
after,0.06670280199311361
liposome,0.03067507151830303
application,0.05416789070563964
and,0.04449247077912725
subsequently,0.02293950839553601
reappeared,0.0314111999408838
in,0.027844939499901317
the,0.023244728649422307
circulation.,0.030725945179207823
These,0.027927564939781383
cells,0.040844048644260264
were,0.029796891379858862
exclusively,0.023774378362163215
of,0.06285410827799379
the,0.0643012092611656
Ly-6C(high),0.05613796130759774
"subset,",0.038119161424268785
resembling,0.04253809126313025
bone,0.040435232187173945
marrow,0.04633835315256638
monocytes.,0.044175906904111883
Serial,0.02384609817709424
flow,0.04578971434880643
cytometric,0.03327106527157227
analyses,0.055087325068628575
of,0.6116351758167327
newly,0.58226575432269
released,0.5571825313951925
Ly-6C(high),0.5653867956156382
monocytes,0.5183831621991905
showed,0.611274664626604
that,0.619442076176606
Ly-6C,0.5535445668973353
expression,0.5139037683118367
on,0.5368618572168868
these,0.5286811595430493
cells,0.530692614045284
was,0.5140350913161865
down-regulated,0.5143582611958184
while,0.5516121301459884
in,0.431482871979373
circulation.,0.5361760067570345
Under,0.768079816187503
inflammatory,0.6980200426424105
conditions,0.7314986739724527
elicited,0.7702043413215596
either,0.7148459958886405
by,0.7638807379570589
acute,0.7784988202452412
infection,0.7062306955799131
with,0.7319187416688484
Listeria,0.6251555995121725
monocytogenes,0.7586300485413834
or,0.6894937818184982
chronic,0.7975167604279615
infection,0.712331426333392
with,0.7398340547183035
Leishmania,0.6571014450607747
"major,",0.808116240852568
there,0.7700175267166361
was,0.7378712751716087
a,0.7354669267360874
significant,0.7399838886112301
increase,0.7066021938578204
in,0.7350760941193797
immature,0.7628560619710079
Ly-6C(high),0.6847751882414482
"monocytes,",0.6862505884836182
resembling,0.6190610077706106
the,0.6576615753333729
inflammatory,0.6623838498875165
left,0.7152035292470197
shift,0.6498624951826427
of,0.5900599646383949
granulocytes.,0.655582646103582
In,0.5606808799982214
"addition,",0.634962299291926
acute,0.5835504358227378
peritoneal,0.5370194799365305
inflammation,0.5770603870754483
recruited,0.5684200812637971
preferentially,0.4879466266676932
Ly-6C(med-high),0.49783183875690656
monocytes.,0.22977174405487058
Taken,0.06511381572735009
"together,",0.06425120696563803
these,0.11368206221751408
data,0.11328326026052701
identify,0.09960916045673769
distinct,0.06364860531213655
subpopulations,0.07328118884838683
of,0.11909015330848419
mouse,0.12984425288244952
blood,0.18178785812208906
monocytes,0.18765205077714642
that,0.09297909255275802
differ,0.06515199662741823
in,0.08180749159940565
maturation,0.16416237749201182
stage,0.1411465555640664
and,0.08455599656464427
capacity,0.14524335448904885
to,0.09349798615262352
become,0.15239894524123435
recruited,0.20739832311564693
to,0.17838638517782152
inflammatory,0.1738083897503411
sites.,0.19570371293841557
Many,0.002542841791339691
fundamental,0.0018125475022238685
aspects,0.0021565798602515077
of,0.0027675688018012575
DNA,0.0037032570918360463
"replication,",0.0026847436916600624
such,0.0018251753231575654
as,0.001995962203452944
the,0.0018606492279567542
exact,0.001588095821966904
locations,0.0036771512953205914
where,0.003964462211674197
DNA,0.00593717719163584
synthesis,0.009402216005628784
is,0.0043519232952717425
initiated,0.005778768145920114
and,0.0069675654567724135
"terminated,",0.00487539566523896
how,0.0028239552261315184
frequently,0.0038116738423012845
origins,0.0037320474254095458
are,0.0015324324695657103
"used,",0.002996526206481698
and,0.0019599379713531994
how,0.002123120708369762
fork,0.002985653631370083
progression,0.004306775585301106
is,0.001354643490016731
influenced,0.0024000297645494816
by,0.0028653814675661748
"transcription,",0.002364428328219834
are,0.0014491979402617209
poorly,0.0014109280967480446
understood.,0.0016680002376311244
Via,0.006278496026521975
the,0.005428903592196432
deep,0.005753646963280124
sequencing,0.003840225581772414
of,0.004569551414797722
Okazaki,0.007868542818258602
"fragments,",0.004360936760734018
we,0.006540408024287088
comprehensively,0.0026511323053683856
document,0.004123406433912847
replication,0.004847318445285446
fork,0.003421502190173754
directionality,0.0028376764971251383
throughout,0.004623286407870894
the,0.004569810614647785
S.,0.007774168551966698
cerevisiae,0.00660116882490328
"genome,",0.004153957034154876
which,0.002850741693697552
permits,0.004605336187769135
the,0.0034952028177941985
systematic,0.0023360715033901736
analysis,0.0032832403962539535
of,0.0031704788320699607
"initiation,",0.002269618739272677
origin,0.0034887415537036446
"efficiency,",0.0028481789819928697
fork,0.0038311794058178607
"progression,",0.003181220806792242
and,0.0028349037498686413
termination.,0.0027163524320277534
We,0.378280830320181
show,0.41079574998960944
that,0.46658371645205876
leading-strand,0.24945665651831647
initiation,0.25524906562970423
preferentially,0.35903012404166446
occurs,0.3012287311631952
within,0.27490017694331165
a,0.32652853774323026
nucleosome-free,0.3302820194046208
region,0.31310645757154393
at,0.2897557817209624
replication,0.2349999960998027
origins.,0.22598667595137834
Using,0.3884863875835857
a,0.32398106592116754
strain,0.30330497344701673
in,0.30492749754020526
which,0.36103244082905916
late,0.8166982663841931
origins,0.6846205617270666
can,0.7644450167296352
be,0.7467745146697813
induced,0.7291217174005008
to,0.7420963157651346
fire,0.666030097416813
"early,",0.788739946379206
we,0.8153710987998793
show,0.7881076373744651
that,0.8089390410976791
replication,0.6617935280892431
termination,0.6879714718909828
is,0.7808709225621313
a,0.7928231139952762
largely,0.7234651491886724
passive,0.7196232315198066
phenomenon,0.6734415043176952
that,0.7684695121861801
does,0.7949244434744223
not,0.7653770252897194
rely,0.7690984436905949
on,0.7365987799733726
cis-acting,0.7618390648503568
sequences,0.649032891964941
or,0.70883059563838
replication,0.6031868549072433
fork,0.7297595871653141
pausing.,0.6508963375649363
The,0.34111761474013946
replication,0.2916974451261506
profile,0.25762602156309666
is,0.3076127536711725
predominantly,0.38235410464885666
determined,0.24888588602529746
by,0.2872583243377287
the,0.22891052902640532
kinetics,0.2821583162993696
of,0.2649303422132029
origin,0.3054975764391576
"firing,",0.2795891059504441
allowing,0.363837575634125
us,0.33661990818923015
to,0.3242363001066502
reconstruct,0.3014910175259286
chromosome-wide,0.2753369058598722
timing,0.2928762891518524
profiles,0.29237409334961123
from,0.3008571183808054
an,0.30226610273546156
asynchronous,0.37696490670436106
culture.,0.28008486592405757
CONTEXT,0.03275296687263076
During,0.0184930910580547
"pregnancy,",0.011376174051783887
serum,0.00987333886700448
levels,0.007778281851563278
of,0.011819439955332384
"estrogen,",0.007531371070803885
"progesterone,",0.011208136670038919
and,0.007912925082302744
other,0.004148457295663497
hormones,0.006896742455266991
are,0.011261758628742125
markedly,0.014778541414450687
higher,0.012377853517756414
than,0.018834392137509502
during,0.019297768698241468
other,0.016643307094719704
periods,0.010411674044552583
of,0.009013014998701337
life.,0.010025309916275553
Pregnancy,0.0959920495347659
hormones,0.045034014897834616
primarily,0.06592986699235812
are,0.03518255674911579
produced,0.06216877009370948
in,0.10113308827671286
the,0.08285124060307174
"placenta,",0.023017782750450733
and,0.06651371424614538
signs,0.028931065857437637
of,0.032753416288074
placental,0.015421731751170141
impairment,0.02282506592363432
may,0.027201136114381432
serve,0.02651151344735884
as,0.03094987690667302
indirect,0.018247841785833573
markers,0.021816764293056987
of,0.024895113502417476
hormone,0.014157818455576806
exposures,0.012149838207789473
during,0.027123374230578656
pregnancy.,0.014115992080877023
During,0.00624337419113374
"pregnancy,",0.004908557126752203
these,0.006215711299729815
markers,0.0038657334126987047
have,0.0038080072844013917
been,0.003549715728834432
inconsistently,0.003988406398071178
associated,0.0033289949848631386
with,0.003766829828431068
subsequent,0.004028714550234295
risk,0.0027138818098704615
of,0.004655611608425654
breast,0.004610797556161566
cancer,0.002394139655569058
in,0.0035443436567458085
the,0.004287598256919345
mother.,0.004192160362601533
OBJECTIVE,0.004059023255369952
To,0.005514434882154072
examine,0.0032207823447480267
associations,0.004455181403870673
between,0.00400537766871415
indirect,0.0035313972974679126
markers,0.005359242931865049
of,0.006628824267096996
hormonal,0.005660913355767472
"exposures,",0.004097538046192412
such,0.004490186470845625
as,0.0050409972722700955
placental,0.0031363158852036987
weight,0.004501815837970223
and,0.005482441639670073
other,0.003811326219086967
pregnancy,0.004093668593526483
"characteristics,",0.00626212340919333
and,0.0009847647985699963
maternal,0.000773241967905063
risk,0.0006896831862962284
of,0.001077038976296893
developing,0.0008283671825958423
breast,0.00093880184264707
cancer.,0.0007649864325587273
DESIGN,0.0007341220057662265
AND,0.0007797044581144372
SETTING,0.0010367154376091194
Population-based,0.000875970427143047
cohort,0.0007133679323823469
study,0.0009569522014752079
using,0.0010280122984652005
data,0.0008003607966113664
from,0.0008884637179618807
the,0.0010868434733677017
Swedish,0.0009713840760148198
Birth,0.0009314118674805639
"Register,",0.0005812732129740855
the,0.0009878857923012287
Swedish,0.0010023739404970598
Cancer,0.0007036436132505395
"Register,",0.0005624798645857698
the,0.0008898944828181815
Swedish,0.0009034635893775304
Cause,0.0006102881931678314
of,0.0007952504825374425
Death,0.0007633245020487127
"Register,",0.0005877089106948978
and,0.0009056210355913569
the,0.000946660018099847
Swedish,0.0008402914031771041
Register,0.0005183890738123025
of,0.00101333784836631
Population,0.0007611887339513629
and,0.0011363497295732612
Population,0.0008624082558166853
Changes.,0.0006104638800507997
PARTICIPANTS,0.00229912126073833
Women,0.0012624634269898906
included,0.001148669041013586
in,0.0019113754314089328
the,0.001869832168874818
Sweden,0.001296013336276264
Birth,0.0014149055654667222
Register,0.0009477626173693107
who,0.0017127367704203918
delivered,0.001807497253435412
singletons,0.0012501233966636623
between,0.0016180351026614129
1982,0.0014459188326427363
and,0.0018890710797144585
"1989,",0.0013454118511852923
with,0.001190171273838192
complete,0.0009395633455876981
information,0.0010703801154032444
on,0.0011967605466233068
date,0.0007655278988903264
of,0.0013032467874535606
birth,0.0009456307752830238
and,0.0013247359819686694
gestational,0.0008945751426277215
age.,0.000803077648291978
Women,0.0009561447338091383
were,0.0009153159054642254
followed,0.0008634327604933657
up,0.0012538762076198297
until,0.0010163149627934105
the,0.001305760882038535
occurrence,0.0009075356401921845
of,0.0013290143284623405
breast,0.0009339956621939858
"cancer,",0.00102797483782096
"death,",0.0009396743563869369
or,0.0011764962013527062
end,0.0012215472409285869
of,0.0015682079019262451
follow-up,0.001185623694112328
(December,0.0011796025966785914
"31,",0.001265209515034121
2001).,0.0012364688228614772
Cox,0.003794785548773953
proportional,0.0053228497573778845
hazards,0.005735097931538082
models,0.0038262116974058704
were,0.003963152864244155
used,0.002338906537489928
to,0.0034559539187180555
estimate,0.00421323964387581
associations,0.0009999614620259376
between,0.0008105931716117627
hormone,0.0006104692619864815
exposures,0.0007009548936635067
and,0.0013591477299902766
risks,0.0005138859502067591
of,0.0009213447408240124
breast,0.000830481748789706
cancer.,0.0006793584318761061
MAIN,0.001183316401735168
OUTCOME,0.0013892583716732239
MEASURE,0.0013897235047913186
Incidence,0.0010557580954993193
of,0.0011718660148143832
invasive,0.0010799635530788119
breast,0.0013604366139684332
cancer.,0.0008944477223583259
RESULTS,0.005906573416603029
Of,0.004024570550071798
"314,019",0.0020110281850076388
women,0.0018821827747547695
in,0.002624932218995262
the,0.0033382774069793757
"cohort,",0.0023398875604268843
2216,0.001770104602748983
(0.7%),0.002235712364170796
developed,0.0023989893512492123
breast,0.0023352892623458264
cancer,0.0018496603110817694
during,0.0031599254648217766
the,0.003052828347014131
follow-up,0.0018945020934035201
through,0.0018410866173563158
"2001,",0.0015868812966687547
of,0.0023528685499905055
whom,0.002286144617808539
2100,0.002029435031379512
(95%),0.002477811754780916
were,0.002029378053156178
diagnosed,0.0013587193435508217
before,0.0029631386927997513
age,0.001548889400768072
50,0.0016994081470634089
years.,0.001334723737365012
Compared,0.8429568610472564
with,0.7654507911625286
women,0.7490479780834505
who,0.7392741134409497
had,0.7724432436337898
placentas,0.7131225733427226
weighing,0.7526458007327658
less,0.7965221741196551
than,0.7230367820444081
500,0.6317702236219342
g,0.7360655391486196
in,0.6883788066614678
2,0.706111230957782
consecutive,0.720818946989975
"pregnancies,",0.7112871037763618
the,0.7820193084004673
risk,0.7680501599998868
of,0.8291084893354568
breast,0.726623043740404
cancer,0.7236048312506379
was,0.7549112538863394
increased,0.7650135747143362
among,0.7778338578457523
women,0.7631942569561202
whose,0.7784617293915123
placentas,0.7623151025644377
weighed,0.7516219639650216
between,0.7608923827095981
500,0.668236405968964
and,0.7165065490428489
699,0.7142780808468204
g,0.8017806874722773
in,0.7136602945630846
their,0.7785840810069175
first,0.7877252860224535
pregnancy,0.7451968228955809
and,0.7819111151470906
at,0.7230351766355587
least,0.6030007822906743
700,0.5650088788293758
g,0.5553760233982747
in,0.58577734814
their,0.5879905116476007
second,0.6001159988694532
pregnancy,0.5791500180165211
(or,0.4936230035302347
vice,0.5113233084036622
versa),0.5363494879621351
(adjusted,0.5494168950423687
hazard,0.6219862053004275
"ratio,",0.6354772338339828
1.82;,0.6768084807190732
95%,0.6958131687641521
confidence,0.659491289446095
interval,0.66687845840016
"[CI],",0.5675420672123213
"1.07-3.08),",0.6829407434596102
and,0.6355350252535421
the,0.5519894331066654
corresponding,0.5583884395766499
risk,0.5923648815040721
was,0.5262307176732965
doubled,0.5515456687074661
among,0.519335254975272
women,0.49123230493262593
whose,0.5012045833260147
placentas,0.5111950027881437
weighed,0.5534451928384139
at,0.5677245291207637
least,0.5249088268937532
700,0.4901123096083228
g,0.5246254667665462
in,0.5040476034022231
both,0.5354397947636109
pregnancies,0.5055048178549898
(adjusted,0.4453439942175112
hazard,0.5495372339057191
"ratio,",0.5350208175628715
2.05;,0.6345670531012599
95%,0.6456241013630064
"CI,",0.5699156244444161
1.15-3.64).,0.6036224332392993
A,0.7613864291968978
high,0.7084400995883268
birth,0.7264566485308371
weight,0.7026314477166409
(>,0.6907831956847776
or,0.6114251160688678
=4000,0.6041852831551536
g),0.6117801341004064
in,0.7363504601231962
2,0.6883945396127924
successive,0.7016036302932248
births,0.647619470586295
was,0.6902119439648585
associated,0.7504393265528816
with,0.7319972036551978
an,0.7263661177610149
increased,0.7163845017935035
risk,0.7138183426299186
of,0.794759078552587
breast,0.7100700707753126
cancer,0.6477743119960483
before,0.6797198506482113
but,0.6136686905843671
not,0.5856698507458041
after,0.6300968252240019
adjusting,0.6623456540500698
for,0.6302175128863379
placental,0.5653257185304749
weight,0.6277399066423819
and,0.424215948641927
other,0.36530742624983903
covariates,0.3960445171838907
(adjusted,0.42985714213449683
hazard,0.40617639185249704
"ratio,",0.4471856310630834
1.10;,0.44322099924296193
95%,0.6321393483891077
"CI,",0.5305638060144346
0.76-1.59).,0.47725378999359874
CONCLUSIONS,0.7743265138698411
Placental,0.6276839817511014
weight,0.6225507420713237
is,0.5933805452835406
positively,0.6174919356718702
associated,0.6292679660638234
with,0.6030436293870918
maternal,0.5765291431594017
risk,0.6285719468539993
of,0.6500867724555821
breast,0.46011214366303355
cancer.,0.43470900523666356
These,0.17614413869145545
results,0.1739895077615035
further,0.11920735909022126
support,0.1126031908294118
the,0.11467923826671428
hypothesis,0.13617982201658094
that,0.16794037924660685
pregnancy,0.16450098745971034
hormones,0.1955165395325128
are,0.1626126550685462
important,0.16770977746723045
modifiers,0.10747485201325856
of,0.16684803055571817
subsequent,0.1560781668809844
maternal,0.16802555988354398
breast,0.18425372353629282
cancer,0.14285809630506657
risk.,0.18713795904107935
Resistance,0.01664863615763377
to,0.017098936244191704
"apoptosis,",0.03128431167804939
often,0.015079014772070855
achieved,0.027985176010324245
by,0.030113864368610525
the,0.035267283996724984
overexpression,0.019711338609873282
of,0.02335332247926671
antiapoptotic,0.017399467642365177
"proteins,",0.017764416453871213
is,0.004279571776893208
common,0.007321263946250773
and,0.006896793077556931
perhaps,0.003808244255654333
required,0.005218447128155487
in,0.00529570969412574
the,0.005805002754263119
genesis,0.00285345526503774
of,0.003976844608941526
cancer.,0.0028639349572979044
"However,",0.0016864471747137745
it,0.0014059886955363073
remains,0.0013161283727437727
uncertain,0.0016601553560667377
whether,0.0016335046544891628
apoptotic,0.002239091052382818
defects,0.0022446689130942664
are,0.0013242616701995894
essential,0.0015881287109383343
for,0.0020476806317159036
tumor,0.002075183853137552
maintenance.,0.0021195273152211334
To,0.0584547303734887
test,0.036699978790836744
"this,",0.019835830202835292
we,0.11545938976326536
generated,0.1284653195700283
mice,0.12375831131964737
expressing,0.10188512403786885
a,0.05806203018987302
conditional,0.05771503351396623
BCL-2,0.07566372418881502
gene,0.09947821753807817
and,0.09866595100488193
constitutive,0.0526249794769049
c-myc,0.11568269023390701
that,0.09044926158532211
develop,0.10140225434834671
lymphoblastic,0.0520067898502447
leukemia.,0.162558096215528
Eliminating,0.7699659963934029
BCL-2,0.6289483168957084
yielded,0.8546529586740031
rapid,0.8497175203780695
loss,0.8062943127015305
of,0.8713733902196439
leukemic,0.7948128924162469
cells,0.8124038584179163
and,0.8564418748474052
significantly,0.8249843916534654
prolonged,0.7961169875437993
"survival,",0.6944673923334611
formally,0.612483770625393
validating,0.5123268565270601
BCL-2,0.5755236650857964
as,0.370302237707949
a,0.5341101561810309
rational,0.5202326701934691
target,0.5684649208461768
for,0.5381168070374669
cancer,0.5931589491681589
therapy.,0.3103501390498079
Loss,0.32987176766402115
of,0.35306729362124106
this,0.2889291198156669
single,0.24553036316989085
molecule,0.2896831879495484
resulted,0.4057365431283956
in,0.4336696689836233
cell,0.35374094610346046
"death,",0.32791539536244846
despite,0.34271327753714714
or,0.24578622326332206
perhaps,0.1717879322937252
attributable,0.17141267942990507
to,0.3226751691366005
the,0.3136178315961191
presence,0.29888083639175755
of,0.2988466080744072
other,0.31666717538600575
oncogenic,0.34648810504448885
events.,0.37750921611170735
This,0.16812101146220185
suggests,0.15884193566085375
a,0.14627503949326343
generalizable,0.09024004850275576
model,0.15222771386535558
in,0.16937587541531565
which,0.13968692795614363
aberrations,0.23411602498990525
inherent,0.18735353396049315
to,0.2097815384128419
cancer,0.1813228966730328
generate,0.25695130557256995
tonic,0.22377112070952254
death,0.3113794519107357
signals,0.3798132786114014
that,0.23310423314821171
would,0.25838079061633373
otherwise,0.23798220372050433
kill,0.24848485752632138
the,0.2509633943400724
cell,0.25800724545032994
if,0.24168674780178664
not,0.3034449896073655
opposed,0.2666920775713716
by,0.27840082048265824
a,0.1822083393153611
requisite,0.1251180064337827
apoptotic,0.2630966246235734
defect(s).,0.2896767245167876
CONTEXT,0.005567197176273603
Sexual,0.0012992699881376505
dysfunction,0.0013016499620385495
is,0.001394525161830252
a,0.0014197254884075012
common,0.0010756103959134156
adverse,0.0008031593438922079
effect,0.0012038712208569848
of,0.0016793884529002483
antidepressants,0.0010374460721337857
that,0.0018226976680173997
frequently,0.0016519650663873976
results,0.001514957000023858
in,0.002241093627484643
treatment,0.0011677558733627245
noncompliance.,0.001584606277791336
OBJECTIVE,0.0015023820771914791
To,0.0013770484995891997
assess,0.001467279758708401
the,0.0015177000308673329
efficacy,0.0015562452611139884
of,0.002261752659765001
sildenafil,0.001731239545400276
citrate,0.0034609893699753857
in,0.0019983810314254218
men,0.0014478368047683794
with,0.001769123715829839
sexual,0.0016862617370520716
dysfunction,0.0017727171901526333
associated,0.0018689050826366422
with,0.002953545140831763
the,0.0026121617930111754
use,0.0027869183755524626
of,0.0037368187766169798
selective,0.0026517236895993155
and,0.0033461445699554337
nonselective,0.0032200437977740835
serotonin,0.002034087999678138
reuptake,0.002985132749534134
inhibitor,0.002680982466870669
(SRI),0.0022757374414331447
antidepressants.,0.002328206569486329
"DESIGN,",0.002700616881183999
"SETTING,",0.00605036614471045
AND,0.0022022516808301693
PATIENTS,0.00328602225805059
"Prospective,",0.0022747242718209513
"parallel-group,",0.003019977377197997
"randomized,",0.002487919775503946
"double-blind,",0.0020341983496287713
placebo-controlled,0.0022688446671087596
trial,0.0028805008863589158
conducted,0.002591638714760919
between,0.0032850993937834035
November,0.0034643155541094726
"1,",0.003763897247272922
"2000,",0.0016688429242021545
and,0.001265936682869725
January,0.0007549768937363286
"1,",0.0013033085412623348
"2001,",0.0009312543608552184
at,0.0012139775329538317
3,0.0012559072462887053
US,0.000996604368056025
university,0.0010401465623887274
medical,0.0009959121936030375
centers,0.0008780907247067955
among,0.000938119385837373
90,0.0009618688380289555
male,0.0009812567180003285
outpatients,0.0009461996841234881
(mean,0.001105674857245329
[SD],0.0019473130578632394
"age,",0.0008187658583377032
45,0.0009582224232657453
[8],0.0013766593824938516
years),0.0007649933579933303
with,0.0011691864063538063
major,0.0012560050412603048
depression,0.0009148287411812557
in,0.0013439682138997166
remission,0.0011221560158945641
and,0.00158840356835406
sexual,0.000966182012902763
dysfunction,0.0009844578138671627
associated,0.0013467422373621392
with,0.0013564657436092714
SRI,0.0012681155584397474
antidepressant,0.00103474864261367
treatment.,0.001095418356521417
INTERVENTION,0.0014431957400002084
Patients,0.001144460542715668
were,0.0017073097817519656
randomly,0.0011366033278564492
assigned,0.001108942229171594
to,0.001711122425556203
take,0.0010704777562594641
sildenafil,0.0016476897379295345
(n,0.0016144794945827962
=,0.0023286125367803557
45),0.0016741139737231749
or,0.0017450121621339777
placebo,0.001913035848790341
(n,0.0015771834023085268
=,0.0026931949612787665
45),0.001902212456938834
at,0.002061374207389714
a,0.0018873070129095163
flexible,0.0011165930162070447
dose,0.00115512975850372
starting,0.001605127023217189
at,0.002193778687879477
50,0.002182657250019633
mg,0.0013908807261939118
and,0.0026203365810929173
adjustable,0.0012234878101992312
to,0.0017354735241159227
100,0.0014829702624221167
mg,0.0012357668001535802
before,0.001884876143802645
sexual,0.0011268127224733837
activity,0.0019085075633450388
for,0.0018974266162323993
6,0.0023322444578812987
weeks.,0.0017438077417043704
MAIN,0.003454557481554376
OUTCOME,0.004403840023864794
MEASURES,0.0053550861664724714
The,0.004033331109113439
primary,0.003547070392191922
outcome,0.0023357697985021924
measure,0.002093847865160093
was,0.003280129586666569
score,0.0015801051217235918
on,0.0029695892960593276
the,0.0029700425201207034
Clinical,0.001418162721195633
Global,0.002752971130501227
Impression-Sexual,0.0009206817611100015
Function,0.0009632919547772955
(CGI-SF);,0.0007991146065988951
secondary,0.001121051510980631
measures,0.000805945588681377
were,0.0009751801677866206
scores,0.0006929227735200628
on,0.0010939745433063313
the,0.0009460205254580164
International,0.0006417040791297595
Index,0.0009763871139851091
of,0.0011047799245627152
Erectile,0.0006908638474354658
"Function,",0.0008996210616524703
Arizona,0.0007349331139189649
Sexual,0.0008392559470502238
Experience,0.0008211483297195251
"Scale,",0.0008485980911201154
Massachusetts,0.0007643910794872139
General,0.0008027498014930274
Hospital-Sexual,0.0008618777755701816
Functioning,0.00085798159403888
"Questionnaire,",0.0007146189044833669
and,0.0010026506841312249
Hamilton,0.0007972532292906806
Rating,0.0008178235329254662
Scale,0.0008605307591771863
for,0.0010581404671973988
Depression,0.0007911808906920957
(HAM-D).,0.0007511866128332862
RESULTS,0.004682541401090002
Among,0.0030044579948063687
the,0.0028244131457213903
90,0.002216454570997006
randomized,0.0016471654597562146
"patients,",0.0012777210887160305
93%,0.002882007124853377
(83/89),0.0027025189205828587
of,0.003420403246060277
patients,0.0011641845510512504
treated,0.0011596124269558914
per,0.0025574274564100583
protocol,0.0013716395794179696
took,0.0019873197302215447
at,0.0039682712740153284
least,0.0026791745376500936
1,0.003270466573806806
dose,0.0020595769750434787
of,0.0031292454211166816
study,0.00154473884120611
drug,0.0016743279666622318
and,0.004124957528473626
85%,0.0045608014426773485
(76/89),0.002367525186077032
completed,0.001336465770202223
week,0.0016203410668043689
6,0.0015248847628108206
end-point,0.0012101108458016877
assessments,0.001479529257992514
with,0.0028427380567025663
last,0.0018468752009611175
observation,0.0013362675385472195
carried,0.0016942374338919863
forward,0.0014117385605400894
analyses.,0.0012251014684970735
At,0.02294061992060976
a,0.012352349220065601
CGI-SF,0.005481495357470042
score,0.0071218316607617
of,0.033902054015724235
2,0.05146877109985087
or,0.014556956723228045
"lower,",0.02489599035306017
54.5%,0.5289658571578377
(24/44),0.3984597320425584
of,0.5424531875651953
sildenafil,0.40374898806136983
compared,0.5773819822895115
with,0.44476865932016246
4.4%,0.49168987547760473
(2/45),0.391005961861998
of,0.4892139648914676
placebo,0.3556048998455027
patients,0.5316653157744028
were,0.46215827669908993
much,0.4742109278203551
or,0.3878339256608615
very,0.35455021113075363
much,0.438610079434089
improved,0.4709907182940604
(P<.001).,0.41247964150602556
Erectile,0.2687220926922686
"function,",0.33751789889729966
"arousal,",0.3194365212719162
"ejaculation,",0.32984291948041994
"orgasm,",0.2998005013177405
and,0.21761533240295808
overall,0.23359109252517013
satisfaction,0.22880581085619112
domain,0.27812874651129865
measures,0.23650931578661455
improved,0.22302760291473964
significantly,0.254565223296371
in,0.2615658869571387
sildenafil,0.17755084047541575
compared,0.3013503050598467
with,0.20510174433659217
placebo,0.12245691619846576
patients.,0.2858083672824605
Mean,0.013451151383464472
depression,0.013302891386420417
scores,0.013451898076399777
remained,0.010779649376826565
consistent,0.010137105730512427
with,0.01711316689827475
remission,0.007850858397113768
(HAM-D,0.014146836262954304
score,0.018001401545678652
<,0.03499699883011976
or,0.014187667257957302
=10),0.014917190796116794
in,0.014542084950942483
both,0.009626057778230676
groups,0.011381610605739481
for,0.013990242549302628
the,0.012378161009911733
study,0.01062331019383531
duration.,0.009831721913715605
CONCLUSION,0.7761991073000998
In,0.8486735193317495
our,0.7857564490584691
"study,",0.7518903258837458
sildenafil,0.7439205820703121
effectively,0.8742491957051973
improved,0.8465310913159547
erectile,0.8189479865953144
function,0.8597791450671062
and,0.8728891322891769
other,0.8654479148503985
aspects,0.8533252550900965
of,0.8268306066319302
sexual,0.7710040620698285
function,0.7203774454739656
in,0.7596117991407482
men,0.7224590377017193
with,0.7735282009632667
sexual,0.7426318118310341
dysfunction,0.7364985608702932
associated,0.7663245442232711
with,0.7408850914317475
the,0.7695707972814193
use,0.7006651839640227
of,0.7605109200099207
SRI,0.7123546321997224
antidepressants.,0.6855716952798051
These,0.4666056346436402
improvements,0.5621970407245294
may,0.24358862000824022
allow,0.39382064210747614
patients,0.3961055754221902
to,0.3561918578276592
maintain,0.44247419789881615
adherence,0.44118243621213316
with,0.4114447976293037
effective,0.35436564185310027
antidepressant,0.28922990632729495
treatment.,0.32885717461347014
Apoptosis,0.2994380250647445
that,0.17813980279846023
proceeds,0.19231490503115686
via,0.202664349660666
the,0.17831694070504778
mitochondrial,0.16928890895517018
pathway,0.22934589877052738
involves,0.25738826177926893
mitochondrial,0.19099775672421593
outer,0.17518533232232708
membrane,0.21757496040846916
permeabilization,0.2553871656330669
"(MOMP),",0.14525685220998227
responsible,0.32242266748214743
for,0.33851960652379937
the,0.355590903515729
release,0.34468497249468594
of,0.36277309066774593
cytochrome,0.3538991212809488
c,0.3691658511963747
and,0.32643222447066705
other,0.2854278077592915
proteins,0.23300261277579787
of,0.3815576804534985
the,0.3272655881567167
mitochondrial,0.22021740627029077
intermembrane,0.3293596972748306
space.,0.33212993891974274
This,0.12117986870517107
essential,0.10095381093807969
step,0.1283251821894184
is,0.051264938241026355
controlled,0.05585440177618229
and,0.07377290782408782
mediated,0.07219554876475658
by,0.04918213338906895
proteins,0.04358034160252576
of,0.05027072446768537
the,0.057249987777135865
Bcl-2,0.1379232956639745
family.,0.057498265883646954
The,0.13961930186211724
proapoptotic,0.17782177076781988
proteins,0.1905652215486151
Bax,0.24877512841373928
and,0.22936674801085583
Bak,0.2439439646266807
are,0.1747973119899189
required,0.20390150145405608
for,0.22427369773832379
"MOMP,",0.192506839410864
while,0.20326253215208193
the,0.15059449248391057
antiapoptotic,0.21826054503098924
Bcl-2,0.27842851766218507
"proteins,",0.20275165491411243
including,0.14900586857441958
"Bcl-2,",0.3051708764027858
"Bcl-xL,",0.32725856753652083
"Mcl-1,",0.36102070522102114
and,0.11192251189148185
"others,",0.11740399200326808
prevent,0.16346834334978233
MOMP.,0.2399266454491708
Different,0.0799610256054648
proapoptotic,0.12817293935913557
BH3-only,0.41806268576532835
proteins,0.4013968117772293
act,0.453874626141393
to,0.4543682195308766
interfere,0.4478178664457597
with,0.45061281865679825
the,0.47657219964358094
function,0.4682942091641512
of,0.43158578176439055
the,0.4039413346214229
antiapoptotic,0.45796660922536014
Bcl-2,0.41837116202777413
members,0.3777565002208143
and/or,0.5425444020139731
activate,0.4529728584759174
Bax,0.4208403112962964
and,0.4433838395332441
Bak.,0.3893067921799914
"Here,",0.13151229852202062
we,0.13010866595148166
discuss,0.0608252178830952
an,0.04972182872844605
emerging,0.040568114331332006
"view,",0.04561842235703254
proposed,0.04437991116609261
by,0.056322054203919475
Certo,0.09732275532561965
et,0.05524522968258954
al.,0.04261674251911157
in,0.05584717278201719
this,0.06821935190596787
issue,0.046521268484732335
of,0.08908498653203752
Cancer,0.08658065918774834
"Cell,",0.08545302215921514
on,0.042229610553005704
how,0.06163731750716183
these,0.08375574551182714
interactions,0.10876792560764845
result,0.07359924414408903
in,0.08472644667569079
MOMP,0.11267412147873802
and,0.08556357827569834
apoptosis.,0.09884327391567678
The,0.011914244476794405
RNA-guided,0.005291762579343499
DNA,0.009373111080656145
endonuclease,0.007090480547804529
Cas9,0.012295359344843814
is,0.005569625060766798
a,0.005721872828153192
powerful,0.004360613792064845
tool,0.003800177416550787
for,0.00422473948487685
genome,0.003418968320752413
editing.,0.003238342724208409
Little,0.003301574798870811
is,0.0019563613778901955
known,0.002424214201989567
about,0.002489307083833415
the,0.002219675904129974
kinetics,0.0021010002548019807
and,0.003045553139185099
fidelity,0.0022048166196415985
of,0.002922493658421539
the,0.0042265472776916325
double-strand,0.0029991043649670542
break,0.004192237996631483
(DSB),0.002445999776710568
repair,0.003975215880583116
process,0.00368506386217188
that,0.0040490291658925835
follows,0.003493866114619859
a,0.004786537980850735
Cas9,0.014489253584098897
cutting,0.004154622817192931
event,0.006651142353515822
in,0.004063633877330105
living,0.0025803138059638324
cells.,0.00366622631859848
"Here,",0.004437287940596772
we,0.006501084422634027
developed,0.0030205517070577646
a,0.0026691234810543103
strategy,0.0016510778327003223
to,0.0017404628917205168
measure,0.0022518440654657962
the,0.0016624856343398812
kinetics,0.0015482785652267065
of,0.0020064741691813727
DSB,0.003940839014850239
repair,0.003112510028444684
for,0.002084402025937298
single,0.0018407974668892314
loci,0.0019513968485684943
in,0.002224849283141511
human,0.0029582262270639237
cells.,0.0021502011834911685
Quantitative,0.009469481607714537
modeling,0.01527376372947459
of,0.014157247766805034
repaired,0.018597243482699054
DNA,0.02409862645958201
in,0.015105445635433796
time,0.014102593603452646
series,0.011052261767338744
after,0.02032833366313278
Cas9,0.04447802434299893
activation,0.035558290537915746
reveals,0.017008262573575267
variable,0.010029115573078472
and,0.03107146827863502
often,0.011590452204027714
slow,0.009806931931705789
repair,0.017850763538311963
"rates,",0.008788844683569146
with,0.0168534212019504
half-life,0.013268536154533557
times,0.019729917658426792
up,0.022064548624732224
to,0.01773428895902017
∼10,0.032840378681097286
hr.,0.010032643235483103
"Furthermore,",0.06802240897857849
repair,0.10104594002487277
of,0.0873258131244231
the,0.06925997473810834
DSBs,0.081274368399474
tends,0.09075013312510875
to,0.12968212723240793
be,0.14669410516793116
error,0.0707112488255516
prone.,0.09886760856000015
Both,0.19460448536111516
classical,0.17861027043590408
and,0.19616144738385827
microhomology-mediated,0.11280962116382444
end,0.15264632016823076
joining,0.1411342437170158
pathways,0.1650338780150678
contribute,0.12820511301502255
to,0.12785715111962317
the,0.15654049164739897
erroneous,0.10814690540670027
repair.,0.13343362480446766
Estimation,0.15933536679197
of,0.10286769663984781
their,0.12819554679452624
individual,0.13293931922079852
rate,0.15237480167667716
constants,0.1210101281564182
indicates,0.19239234475921882
that,0.2228473524867033
the,0.1357612755066919
balance,0.19456302869546319
between,0.13302542226360947
these,0.17653087866883774
two,0.16454120636251726
pathways,0.21775358793799904
changes,0.19638689047228883
over,0.2784692312767762
time,0.19225392743289682
and,0.3297921895757424
can,0.20271781995769586
be,0.19960423731329338
altered,0.17718185418680496
by,0.2710653113576982
additional,0.24859138131794523
ionizing,0.20545743460424715
radiation.,0.24233881481555417
Our,0.17634206995312546
approach,0.12248923403988393
provides,0.06528109463506918
quantitative,0.061366905905311776
insights,0.06386072126122998
into,0.060176807646536774
DSB,0.13038240997936715
repair,0.11511514765682429
kinetics,0.04720222151248707
and,0.0403626212553121
fidelity,0.04988834382559125
in,0.05044572357602425
single,0.032384648076522034
loci,0.03756016844869061
and,0.1771543443723957
indicates,0.13085613546194116
that,0.14418788203999658
Cas9-induced,0.23497470863973519
DSBs,0.18846238747012584
are,0.09855952170799842
repaired,0.09721751400962858
in,0.1352957892143946
an,0.10809764113363057
unusual,0.06749592274430681
manner.,0.115777364231327
Application,0.00304442912151706
of,0.0027923350832220425
stem,0.0024121063759928703
cell,0.005415997995566146
biology,0.003048905209378918
to,0.002579511945446734
breast,0.007774821458513529
cancer,0.006208371106862441
research,0.0030931513173946463
has,0.001353454503567152
been,0.0015570041486108904
limited,0.0014995899341673092
by,0.0018619603411109214
the,0.0015004230320400478
lack,0.0013661998297457452
of,0.001535609883058396
simple,0.0013756043691747497
methods,0.001711728136057407
for,0.002036177919059544
identification,0.001720465620558667
and,0.0016990283809023348
isolation,0.0014621708690501617
of,0.0019222494869683305
normal,0.0021473685726542385
and,0.002367992626365469
malignant,0.001640838666392355
stem,0.0031114168390887274
cells.,0.0040538816384225055
Utilizing,0.09381375479717038
in,0.07698102672572907
vitro,0.10141047742873195
and,0.042141733332241256
in,0.0448911908483536
vivo,0.04915129822014441
experimental,0.08236196005508473
"systems,",0.08529605222438244
we,0.26785602108318685
show,0.3625731781057565
that,0.40927002229131515
normal,0.36494425965988697
and,0.4277981082433193
cancer,0.22693542104439593
human,0.3286883017886769
mammary,0.23514422422144607
epithelial,0.3481301462438259
cells,0.3280070917799686
with,0.4051315914638295
increased,0.3158338261015722
aldehyde,0.2672800932387396
dehydrogenase,0.29611091683894525
activity,0.2643287314633129
(ALDH),0.19506158722355876
have,0.315930643148852
stem/progenitor,0.24003175949230124
properties.,0.25035924890054406
These,0.06370084387712747
cells,0.028314654986434214
contain,0.02024296740425082
the,0.019126711387080084
subpopulation,0.016010335607138475
of,0.02365347366801746
normal,0.017841734930459038
breast,0.02746194983499909
epithelium,0.024601551446972014
with,0.016861812032362374
the,0.015872771034995348
broadest,0.008262127511293873
lineage,0.012987172432839329
differentiation,0.018759212130169154
potential,0.017300905792814757
and,0.02381926308611925
greatest,0.01110896183278386
growth,0.020532443477304593
capacity,0.020798591963195636
in,0.015506812203784817
a,0.010161748073536514
xenotransplant,0.009021236461930201
model.,0.012221411294359932
In,0.5239865437464748
breast,0.41488739504846445
"carcinomas,",0.38231323523514954
high,0.3480572610340749
ALDH,0.3940983658440779
activity,0.3992991573079158
identifies,0.44363613149521147
the,0.3465328305068068
tumorigenic,0.22319779332961337
cell,0.28842718207216217
"fraction,",0.2671004482000978
capable,0.3263982296506192
of,0.4021348180075624
self-renewal,0.29436893526324853
and,0.3741028730031452
of,0.4461746758947093
generating,0.2669832412437834
tumors,0.20161062249137193
that,0.20452424615218873
recapitulate,0.19796817394640498
the,0.2358557670879911
heterogeneity,0.15457318572302142
of,0.158453113232142
the,0.16659663880538395
parental,0.21535974216381162
tumor.,0.167427958564923
In,0.7309984032496777
a,0.6491864764538368
series,0.636892054083603
of,0.6174238715485062
577,0.5256018932988923
breast,0.6156639797702014
"carcinomas,",0.6138652162054966
expression,0.6466276171957536
of,0.7059892512044558
ALDH1,0.6796528584607631
detected,0.7210800044790782
by,0.7266214690194885
immunostaining,0.6997977778770489
correlated,0.6785572069241255
with,0.6638503697019154
poor,0.6325605295924385
prognosis.,0.6452093199828545
These,0.041912779425217636
findings,0.027163340107562294
offer,0.017190584333784995
an,0.015486277210611622
important,0.01815180635703304
new,0.010497262940736725
tool,0.012027001175008628
for,0.012304700508963078
the,0.010247941716884987
study,0.009385454292218483
of,0.01352335779246982
normal,0.013882688514171062
and,0.010450528687220158
malignant,0.008925760358768062
breast,0.024005290787789485
stem,0.010087898350301917
cells,0.014073088285072
and,0.04290556206053955
facilitate,0.014040184534722316
the,0.009264196217092253
clinical,0.009467422177817902
application,0.008892515393523513
of,0.009643254116194872
stem,0.007777396831610545
cell,0.012416113210733278
concepts.,0.010779812089353087
BACKGROUND,0.35172572803568836
Screening,0.8485045686369201
for,0.7885033814282143
cervical,0.8453400543710273
cancer,0.8233296474583371
based,0.8466695810365595
on,0.8326491480364014
testing,0.8651578993483973
for,0.826453134208433
human,0.88186597970561
papillomavirus,0.8018402461531661
(HPV),0.8763004248972742
increases,0.9292004650852063
the,0.9247070345379544
sensitivity,0.9332118926545562
of,0.9433189880869499
detection,0.9387427303254523
of,0.9412281461258176
high-grade,0.9386168251625532
(grade,0.9257885832478007
2,0.9429024232871949
or,0.868019896780854
3),0.9362248588799196
cervical,0.9454436579583625
intraepithelial,0.9471305093637108
"neoplasia,",0.935604014037069
but,0.8518719965342914
whether,0.1557874810990256
this,0.890091166790156
gain,0.8998873588161526
represents,0.856161235117033
overdiagnosis,0.9002253084714006
or,0.8266841603652897
protection,0.890135544931238
against,0.8857278534280204
future,0.8824507759355689
high-grade,0.8825879786325872
cervical,0.8909503061162203
epithelial,0.850546276577712
neoplasia,0.850476086841478
or,0.38319722267554723
cervical,0.8086107300086325
cancer,0.8624163805024425
is,0.03363844120363296
unknown.,0.03445245057173723
METHODS,0.027803509644766033
In,0.016291189249133177
a,0.011425168661711777
population-based,0.005299647168971336
screening,0.006325423411739778
program,0.00700564270785517
in,0.009364375122089706
"Sweden,",0.015393113687148645
"12,527",0.004466891210551978
women,0.00717279913185165
32,0.004038766110823714
to,0.004909869745576574
38,0.0054343851960216415
years,0.00428415011027862
of,0.004582013879954198
age,0.004238121520748615
were,0.005740810708884189
randomly,0.0031756196222173477
assigned,0.002954406040758763
at,0.004592070543176137
a,0.00588702497748416
1:1,0.007982094722692765
ratio,0.005762543588090018
to,0.006751253782697952
have,0.018190682465689143
an,0.003072581727828446
HPV,0.0031437063546464047
test,0.0036003548529383853
plus,0.003727029830010501
a,0.002474222612047321
Papanicolaou,0.004656483389991833
(Pap),0.0030210098131695337
test,0.0028052714729111584
(intervention,0.0020158006671234722
group),0.0021936727467276856
or,0.0031596100587083244
a,0.002228495193217601
Pap,0.004383667323723473
test,0.003123777781780871
alone,0.002630028663643561
(control,0.0023982836331388397
group).,0.0028455881243616326
Women,0.010507076776616702
with,0.010283769632317216
a,0.009734290880750077
positive,0.009184192819159552
HPV,0.01088799842350743
test,0.0168629246639524
and,0.01858725296651022
a,0.009097082020082739
normal,0.017919304072164202
Pap,0.013646361563056946
test,0.012088805846227443
result,0.01915884012372028
were,0.012235306407755199
offered,0.009021684072651606
a,0.007985640959640179
second,0.009555892060650377
HPV,0.010215327318578493
test,0.010026900166115366
at,0.007772009749826641
least,0.008068230516037273
1,0.0120474454763428
year,0.0064779560147105765
"later,",0.010335405086688081
and,0.02408653770626733
those,0.006667430889561081
who,0.005886886843084186
were,0.005667885423232372
found,0.004997663387538957
to,0.0067276364956504325
be,0.006755019899177607
persistently,0.004400566206303282
infected,0.007858056055762426
with,0.009155670039320286
the,0.0065649146939868565
same,0.0048659832515078934
high-risk,0.003963866315755944
type,0.008948922396043744
of,0.005557377571149762
HPV,0.01089363582946203
were,0.007713497464584025
then,0.006662441397569946
offered,0.0054519656727081145
colposcopy,0.0045779204334169534
with,0.004467580414707239
cervical,0.004539027419721959
biopsy.,0.004483357075313838
A,0.008069905996747487
similar,0.005681335278179182
number,0.009225737469516897
of,0.005785958580977254
double-blinded,0.001983605004337641
Pap,0.005094402961201573
smears,0.0031797506296220674
and,0.0046156803987816835
colposcopies,0.002844911017679175
with,0.004319087350117185
biopsy,0.002730052729129449
were,0.004140990072819665
performed,0.0029831394751020303
in,0.004022171573366806
randomly,0.0017506191975232256
selected,0.0023615736661292412
women,0.004018907394969382
in,0.005417773161186381
the,0.00398613964041308
control,0.007628884733669037
group.,0.0011846136307719292
Comprehensive,0.0005939032764072531
registry,0.00083776701777096
data,0.0007359467243572977
were,0.0008875181988745971
used,0.0007916818483791489
to,0.0008762365149806203
follow,0.0009391382238180968
the,0.0008365226135441748
women,0.0007970809827901441
for,0.0007670065725023674
a,0.0009360903727981451
mean,0.0007554221898460409
of,0.0012599116825934714
4.1,0.0011053818187025167
years.,0.001031019220523187
The,0.0014535672187071663
relative,0.0013448014222184699
rates,0.001051320604431292
of,0.002216360191192748
grade,0.0014702683759414755
2,0.0027759599497617746
or,0.0028102660406615102
3,0.002589432089084277
cervical,0.0019466829743525656
intraepithelial,0.001575720627506967
neoplasia,0.0015302036992649972
or,0.0018541330636923604
cancer,0.0010748426730707995
detected,0.0008574099200941133
at,0.0016102063491173527
enrollment,0.0009939334773448106
and,0.0014317015963998942
at,0.0014056928142421631
subsequent,0.0011947800902840108
screening,0.0012329826528531451
examinations,0.0009802237505261403
were,0.0012667701389593368
calculated.,0.0008861083483111107
RESULTS,0.3163331972666644
At,0.28353026733473163
"enrollment,",0.0912589264632468
the,0.15335371145194743
proportion,0.17549855164867223
of,0.16330164798574986
women,0.18939764268616177
in,0.09654906046711337
the,0.10730743787513422
intervention,0.24299144144393636
group,0.19934882640558083
who,0.17627301257109607
were,0.08469822770471538
found,0.14339639855848618
to,0.17230555849273615
have,0.26280386682025325
lesions,0.36915164770514475
of,0.3319058530117077
grade,0.2526108607085926
2,0.21053215307510975
or,0.1564785888550311
3,0.1779508047770433
cervical,0.33224494275646843
intraepithelial,0.35048954037832714
neoplasia,0.33010156455503903
or,0.3098565179858262
cancer,0.2903816059371544
was,0.20122164792894795
51%,0.38443826350094606
greater,0.3350948856647754
(95%,0.3456646031794547
confidence,0.3344345278808961
interval,0.3725322487526248
"[CI],",0.21754148269657153
13,0.3038171774698379
to,0.29607083446899907
102),0.23404896254735677
than,0.3714654736430215
the,0.2096139490199974
proportion,0.20771556745568526
of,0.2094744288688836
women,0.21298268467266382
in,0.11538528498194621
the,0.07960517538096623
control,0.1402120812099976
group,0.14126200109156314
who,0.13683149071850892
were,0.060801809689556105
found,0.09808322527336372
to,0.01979784383408003
have,0.009636919398261548
such,0.02531204647144015
lesions.,0.021423301400040545
At,0.007550341980252316
subsequent,0.005158416647025582
screening,0.0053904329348019725
"examinations,",0.006951727186910133
the,0.010318207025962641
proportion,0.009801129363805377
of,0.012431489864270152
women,0.012770701155962733
in,0.008674661285102974
the,0.009050428298139509
intervention,0.016766436433166634
group,0.011709011703289668
who,0.012538584055824226
were,0.006783137198816403
found,0.011402965917280612
to,0.014317675421601114
have,0.01277939109085949
grade,0.01596352383245021
2,0.02479162270123722
or,0.024577782614634586
3,0.024619542345794852
lesions,0.021935574844909947
or,0.039099323100596925
cancer,0.017060475578333106
was,0.017718899606588127
42%,0.02682745434599585
less,0.024857417154407355
(95%,0.017427829946318914
"CI,",0.0678095265500765
4,0.044666645299471355
to,0.03858687958838832
64),0.017377915749237128
and,0.022301729151567473
the,0.01482684204167936
proportion,0.014494669365241636
with,0.0243177448239867
grade,0.015032462561127781
3,0.0321012252618199
lesions,0.029222084195528217
or,0.04074998885242126
cancer,0.024714111061910043
was,0.020017973007292293
47%,0.06923429723810733
less,0.017452377837662368
(95%,0.02007982307599601
"CI,",0.05157699817797674
2,0.03539053131109636
to,0.0439163176279581
71),0.02296436727752532
than,0.02893372848922
the,0.015356380386609404
proportions,0.010238454391608899
of,0.01149118860030951
control,0.012541397574024737
women,0.012048658666482318
who,0.0076878859264068325
were,0.005485834252072065
found,0.005403204911739073
to,0.008586687000667635
have,0.006920234830003097
such,0.011083388693988202
lesions.,0.011670891925857756
Women,0.004675682663595849
with,0.003092000968277007
persistent,0.003193134889694686
HPV,0.005025724746642501
infection,0.003771940222357263
remained,0.00399313814946886
at,0.002908351705978416
high,0.0024021125130631047
risk,0.0026543619314978195
for,0.004963722769323896
grade,0.003056782673480986
2,0.00464606690565141
or,0.0035348362555881084
3,0.0039643398245056685
lesions,0.002821672775984603
or,0.003996228695224533
cancer,0.0016775846623562198
after,0.0037542552076979285
referral,0.003400321932380518
for,0.00301750828188979
colposcopy.,0.002377006274463653
CONCLUSIONS,0.6549023873246009
The,0.32097184520037936
addition,0.30732888962683164
of,0.323581232302121
an,0.3040709868932858
HPV,0.8348622293198619
test,0.8235836207193827
to,0.8427924082862739
the,0.8331469482934868
Pap,0.7540894019473785
test,0.8417879285440963
to,0.8350582390778365
screen,0.8675551883737664
women,0.8370053124850055
in,0.8208395099166353
their,0.862487781529782
mid-30s,0.8867484445900715
for,0.901744108141544
cervical,0.9131992127131578
cancer,0.8802963928155226
reduces,0.9084632598996298
the,0.8966589666494521
incidence,0.9001891975020333
of,0.9109047781661377
grade,0.9162632625018405
2,0.9337770527724965
or,0.8777380713174784
3,0.9334704370423937
cervical,0.9276409388046504
intraepithelial,0.9351838957778276
neoplasia,0.9193177941473315
or,0.8954547943099932
cancer,0.8722232432570104
detected,0.8947294919334889
by,0.845267318682437
subsequent,0.8773086789142773
screening,0.7882752774536206
examinations.,0.8373136431232003
(ClinicalTrials.gov,0.0982993794898568
"number,",0.010290396437623401
NCT00479375,0.00936129467899559
[ClinicalTrials.gov].).,0.01669117256792012
Fibrosis,0.0296945369545478
is,0.015976926100015006
a,0.014810508893920332
pathological,0.006884892307351731
result,0.014988508625887057
of,0.01896264004313583
a,0.018017042303919133
dysfunctional,0.012526513375938374
repair,0.016641365945211803
response,0.015903503358317743
to,0.014737079049337949
tissue,0.016352521997631746
injury,0.014838094984769021
and,0.018011325419399062
occurs,0.014368882349651255
in,0.0179085116291205
a,0.011224964599987473
number,0.008233560711356678
of,0.010765751513424807
"organs,",0.012777219563809507
including,0.008904917349840143
the,0.021576094696874583
lungs1.,0.022732556548873736
Cellular,0.07102489586107813
metabolism,0.08651429776899879
regulates,0.05699209992887141
tissue,0.04832090512503427
repair,0.0659026140564915
and,0.05655063440899581
remodelling,0.047517823242616004
responses,0.04758664568957071
to,0.03853229539412524
injury2-4.,0.04078767553658046
AMPK,0.03128324594632396
is,0.024013925337877644
a,0.030810308685468975
critical,0.022023920328329043
sensor,0.0161393158070425
of,0.025583519582124865
cellular,0.013450689466778921
bioenergetics,0.015231568216253611
and,0.025083636514806038
controls,0.008443117599305291
the,0.007033794967885625
switch,0.01724749704464431
from,0.011420973961744733
anabolic,0.006691904733649059
to,0.006595770854920912
catabolic,0.004759686025378353
metabolism5.,0.017962510396307058
"However,",0.002064245373262643
the,0.00210625889325388
role,0.002833106146098644
of,0.0033672373272503903
AMPK,0.012446798867575356
in,0.0023956742194489017
fibrosis,0.0029924497074659473
is,0.0014776502713903356
not,0.0016343945203838534
well,0.001549277334320958
understood.,0.0019548815818996317
"Here,",0.5549371567865924
we,0.6383305422623639
demonstrate,0.5976363345892669
that,0.652290090251588
in,0.6198163434620995
humans,0.4773933498788621
with,0.5195125436623753
idiopathic,0.44792806731181467
pulmonary,0.452118134149171
fibrosis,0.4390903153859631
(IPF),0.42454280536715966
and,0.5487113598636386
in,0.34041711647356876
an,0.15803650985048634
experimental,0.10165282924567248
mouse,0.1808219668459028
model,0.17123657217548122
of,0.11380898774690144
lung,0.22749547181299043
"fibrosis,",0.193192453645811
AMPK,0.3870670268087969
activity,0.3150687469529959
is,0.1796731913435563
lower,0.2835104709459325
in,0.3073546859662951
fibrotic,0.3770085737341518
regions,0.3499828807830428
associated,0.3045454393039036
with,0.2700326994507459
metabolically,0.33402471381050597
active,0.3590517486544709
and,0.2907182947846887
apoptosis-resistant,0.4246291363002464
myofibroblasts.,0.3496905008459902
Pharmacological,0.7292281064853244
activation,0.7788225609178836
of,0.7956572666446688
AMPK,0.7410929142685491
in,0.8041652389971575
myofibroblasts,0.7340937972626052
from,0.7695984044041413
lungs,0.7314357040028616
of,0.7442017914296364
humans,0.6465752954320736
with,0.8135502665127861
IPF,0.6934587133567892
display,0.7663393053185519
lower,0.7844613506206015
fibrotic,0.731410869360494
"activity,",0.7163417321888721
along,0.8362703396128821
with,0.8258680158401218
enhanced,0.7910559368831701
mitochondrial,0.7425941245509751
biogenesis,0.7876771626146186
and,0.8226000167663898
normalization,0.7799999270802331
of,0.720829898091303
sensitivity,0.6773310967930716
to,0.6788040228156562
apoptosis.,0.7564207587935011
In,0.587365548863789
a,0.4912255478226103
bleomycin,0.3257586906371139
model,0.46021452427628873
of,0.3858559633596123
lung,0.40717918388970037
fibrosis,0.4225988121449522
in,0.41042379356866193
"mice,",0.4308756522912561
metformin,0.49238965857700906
therapeutically,0.6352088372570686
accelerates,0.6240243108135769
the,0.569042238408244
resolution,0.4973585257648454
of,0.45857482080808026
well-established,0.44450189647630045
fibrosis,0.592739403770413
in,0.6975651341034839
an,0.7321038661484671
AMPK-dependent,0.6970264970398176
manner.,0.7150293993380875
These,0.8016392763813278
studies,0.8875771472450382
implicate,0.919439730454535
deficient,0.9272581910783484
AMPK,0.881723527415584
activation,0.9137083916907592
in,0.9188574323573622
"non-resolving,",0.9172362843416062
pathologic,0.9506157732757209
fibrotic,0.9130259643212584
"processes,",0.9094108011235204
and,0.9154496505233544
support,0.9201786725959997
a,0.9228618528685159
role,0.9105698054959563
for,0.9157200324801664
metformin,0.866559627752867
(or,0.9010249483960132
other,0.8972119697452438
AMPK,0.8523401026633423
activators),0.9184538021642908
to,0.9216310307533608
reverse,0.9218446746812348
established,0.8896061021496783
fibrosis,0.8998678540561615
by,0.9420081596921729
facilitating,0.9455838958760006
deactivation,0.9260111464086049
and,0.9165542495364654
apoptosis,0.9350379322499904
of,0.8963918424321284
myofibroblasts.,0.8932772542424177
The,0.014878905916687897
Hippo,0.021149250061425904
pathway,0.02066790791301225
controls,0.012505831694945471
organ,0.01099778875158181
size,0.012654817253237397
and,0.011168236004554803
tissue,0.013115539233448275
"homeostasis,",0.01028216575528006
with,0.00954598421032855
deregulation,0.005767552068604663
leading,0.013004264456034111
to,0.0099164667395122
cancer.,0.005913872874360165
The,0.08369472887991085
core,0.08783964829959359
Hippo,0.11103869316567166
components,0.1258520338648441
in,0.1010049292290772
mammals,0.09036157018546352
are,0.08556825133216897
composed,0.10438821287143969
of,0.135156079336828
the,0.13010124544608956
upstream,0.14524444966004896
serine/threonine,0.14784818236452757
kinases,0.10955650957343108
"Mst1/2,",0.21792196954438928
MAPK4Ks,0.22782599623466118
and,0.1497760530480417
Lats1/2.,0.24908422128825394
Inactivation,0.038202283054246305
of,0.05361627334407191
these,0.0556804153212417
upstream,0.04873768990781822
kinases,0.048074284715253275
leads,0.059528631007839145
to,0.1258112596489759
"dephosphorylation,",0.02764025284275237
"stabilization,",0.02113817218329837
nuclear,0.027684308517810396
translocation,0.022808012942214267
and,0.06765541723353222
thus,0.04961097839718873
activation,0.03974023348742052
of,0.036978471480858956
the,0.04095957543805272
major,0.03582558409050338
functional,0.027523930202879424
transducers,0.02711226597629913
of,0.034150452847404686
the,0.029971492061558254
Hippo,0.04222417215548987
"pathway,",0.04037853578816499
YAP,0.04103403525265716
and,0.03307253406330341
its,0.04134445364729022
paralogue,0.0242704478657106
TAZ.,0.04296823609053579
YAP/TAZ,0.3919253775354155
are,0.4640457913983684
transcription,0.5954728349750106
co-activators,0.5994423116889296
that,0.4917065881092519
regulate,0.5081103407974821
gene,0.11545171994380372
expression,0.1112267284554157
primarily,0.09960162317150795
through,0.11375681220388888
interaction,0.09681827453837318
with,0.08778180726596568
the,0.10151366922703618
TEA,0.09846924198049362
domain,0.12573134380381443
DNA-binding,0.09298385797108707
family,0.09135258127738881
of,0.047561798872613456
transcription,0.07359618402009778
factors,0.0495043054632188
(TEAD).,0.05303315744588681
The,0.02106672462529816
current,0.022577949235730754
paradigm,0.020466193063482702
for,0.021038456350157404
regulation,0.05002198264110301
of,0.02520357802896455
this,0.037844150803000944
pathway,0.06822150397433556
centres,0.02251713319418679
on,0.04995718879757616
phosphorylation-dependent,0.09562205886007927
nucleocytoplasmic,0.14930984441969747
shuttling,0.11425444142275745
of,0.17459038782754727
YAP/TAZ,0.1954538832704503
through,0.14691209312786788
a,0.06052454346647019
complex,0.027798186927142497
network,0.04265719853212264
of,0.04663813012998004
upstream,0.09901105387576405
components.,0.09806287414694989
"However,",0.005863393786596382
unlike,0.00850503196074796
other,0.008621231281551624
transcription,0.009643693579359878
"factors,",0.008795185976777357
such,0.0060569278428923646
as,0.008491861168446743
"SMAD,",0.010504848604058788
"NF-κB,",0.015383018988956502
NFAT,0.009375741413847893
and,0.007102609720485481
"STAT,",0.005066857835871023
the,0.0058180892664479325
regulation,0.010568798119614456
of,0.009743883832470008
TEAD,0.008622945190677437
nucleocytoplasmic,0.008057264455079228
shuttling,0.009108970391466137
has,0.0033430537969417655
been,0.0031445335711622257
largely,0.003222747012408482
overlooked.,0.0033817487685033226
In,0.5281603538959653
the,0.4373734101047881
present,0.3498087969708306
"study,",0.4045236697880082
we,0.5912771169055299
show,0.5801807714541366
that,0.6217103552209425
environmental,0.47617288400959074
stress,0.47164852100458593
promotes,0.5422837171620436
TEAD,0.42552113095722943
cytoplasmic,0.40370746642340305
translocation,0.39989686204179997
via,0.48380854067334633
p38,0.4138281860826065
MAPK,0.3949429670314576
in,0.48533243312193264
a,0.4863736004518307
Hippo-independent,0.5522581240508809
manner.,0.4219212571504106
"Importantly,",0.7840653520870391
stress-induced,0.734625681215015
TEAD,0.7346663491282999
inhibition,0.8717773517744908
predominates,0.8538464685305398
YAP-activating,0.7327789449549391
signals,0.8475411750372437
and,0.8749600908967891
selectively,0.8762389092804755
suppresses,0.8552377231959917
YAP-driven,0.7468006633737735
cancer,0.7440133288123885
cell,0.8143141145378743
growth.,0.846344726234609
Our,0.3495009443619014
data,0.3428117012415817
reveal,0.2894967209659282
a,0.2452894738011967
mechanism,0.2729686494267634
governing,0.24824754044230046
TEAD,0.30288130231801574
nucleocytoplasmic,0.26089450083409677
shuttling,0.321545475566916
and,0.3459224502088638
show,0.3821686467483821
that,0.3756908251869423
TEAD,0.362272937062826
localization,0.36670377748280936
is,0.2999440423400261
a,0.34750640325726073
critical,0.35361375240831355
determinant,0.3182207704632296
of,0.34203288650017416
Hippo,0.4681474974082607
signalling,0.4365750603617895
output.,0.3906755722425621
